RESULT_COUNT: 2321,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
BMY,BMY:US,BBG000DQLV23,Roche (RHHBY) Reports Sales Numbers for First 9 Months,2017-10-20 23:59:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8nW7N42diis/roche-rhhby-reports-sales-numbers-for-first-9-months-cm863000,Roche Holding AG s RHHBY reported sales of CHF39 4 billion in the first nine months of 2017 up 5 from the year ago period Roche s stock has gained 7 2 year to date compared with industry s gain of 23 8 The company reports results under two divisions Pharmaceuticals
BMY,BMY:US,BBG000DQLV23,Cancer Treatment Update: Second Gene Therapy Receives Approval,2017-10-20 21:28:09 +0000,https://finance.yahoo.com/news/cancer-treatment-second-gene-therapy-212809708.html?.tsrc=rss,"The FDA approved Gilead&apos;s Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs."
BMY,BMY:US,BBG000DQLV23,Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?,2017-10-20 17:05:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g2f7Jhzk9O0/glaxo-gsk-q3-earnings-will-it-deliver-a-beat-yet-again-cm862664,We expect GlaxoSmithKline plc GSK to beat expectations when it reports third quarter 2017 results on Oct 25 before the market opens Last quarter the company delivered a positive earnings surprise of 2 94 Glaxo s shares are up 6 7 this year so far underperforming the 20 5
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling",2017-10-20 15:14:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-gagVZGWJ0M/pharma-stock-roundup-beat-raise-quarter-from-jj-allergan-hit-by-restasis-ruling-cm862525,Johnson amp Johnson JNJ kicked off third quarter earnings season for the pharmaceutical sector on a strong note with the company beating on both earnings and revenues While focus remained on J amp J s strong earnings results companies like Allergan AGN were also in the news regarding
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling",2017-10-20 12:47:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-beat-raise-124712930.html?.tsrc=rss,Johnson & Johnson&apos;s (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Present New Data Advancing Research Across Serious Liver Diseases at The Liver Meeting® 2017,2017-10-20 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-present-data-105900161.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced that new data across serious liver diseases, including nonalcoholic steatohepatitis and hepatocellular carcinoma , will be presented at The Liver Meeting® 2017 in Washington, DC, October 20 – 24, 2017."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers To Present Data Across Serious Liver Diseases - Quick Facts,2017-10-20 08:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TrH5-tNo1tY/bristolmyers-to-present-data-across-serious-liver-diseases--quick-facts-20171020-00422,Bristol-Myers To Present Data Across Serious Liver Diseases - Quick Facts
BMY,BMY:US,BBG000DQLV23,In The Spotlight: UniQure,2017-10-20 06:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Rx6U2_iYz0c/in-the-spotlight-uniqure-20171020-00213,In The Spotlight: UniQure
BMY,BMY:US,BBG000DQLV23,"PPH, AZN, MYL, BMY: ETF Outflow Alert",2017-10-19 16:44:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yMXb5Z1K7zg/pph-azn-myl-bmy-etf-outflow-alert-cm862017,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Pharmaceutical ETF Symbol PPH where we have detected an approximate 23 1 million dollar outflow that s a 7 9 decrease week over week from 5 088 138 00
BMY,BMY:US,BBG000DQLV23,What to Expect from Big Pharmas After J&J's Solid Q3 Results?,2017-10-18 22:52:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e4YHAAqtt4s/what-to-expect-from-big-pharmas-after-jjs-solid-q3-results-cm861641,Johnson amp Johnson JNJ was the first large cap pharma stock to report its earnings results for this season on Oct 17 J amp J beat the Zacks Consensus Estimate for both earnings and revenues in the third quarter and also raised its 2017 sales and profit outlook Shares of J amp J were up
BMY,BMY:US,BBG000DQLV23,What to Expect from Big Pharmas After J&J&apos;s Solid Q3 Results?,2017-10-18 20:21:08 +0000,https://finance.yahoo.com/news/expect-big-pharmas-j-j-202108992.html?.tsrc=rss,"Large-cap pharmas are expected to report encouraging third-quarter results, following J&J&apos;s earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter."
BMY,BMY:US,BBG000DQLV23,Johnson & Johnson Posts Solid Q3 Numbers Led By Ramp Up In Oncology Drugs,2017-10-18 18:19:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/npnvZ8Q0_ro/johnson-johnson-posts-solid-q3-numbers-led-by-ramp-up-in-oncology-drugs-cm861520,Johnson amp Johnson s 160 JNJ stock increased by over 3 following its Q3 2017 earnings announcement effectively adding 13 billion in market cap The results were largely in line with expectations with a ramp up in key oncology drug sales benefits from the Actelion acquisition
BMY,BMY:US,BBG000DQLV23,Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?,2017-10-18 15:55:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xEoN8X6b7Z8/biogen-biib-q3-earnings-will-it-deliver-a-beat-again-cm861331,We expect Biogen Inc BIIB a well known name in the multiple sclerosis MS market to beat expectations when it reports third quarter 2017 results on Oct 24 before the market opens Last quarter the company delivered a positive earnings surprise of 15 60 Biogen s shares have risen 21
BMY,BMY:US,BBG000DQLV23,Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?,2017-10-18 13:54:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5bnIzrtRjhE/eli-lilly-lly-to-report-q3-earnings-whats-in-store-cm861192,Eli Lilly and Company LLY will report third quarter 2017 results on Oct 24 before the market opens Last quarter the company delivered a positive earnings surprise of 6 73 Lilly s shares have risen 17 this year so far while the industry recorded an increase of 18 2 Lilly
BMY,BMY:US,BBG000DQLV23,Inside Bristol-Myers Squibb’s Performance in 3Q17,2017-10-18 13:12:39 +0000,http://finance.yahoo.com/r/5243c288-ef2f-39f2-9abb-e8681ad10a43/inside-bristol-myers-squibbs-performance-in-3q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb (BMY) has a portfolio that includes cardiovascular, oncology, neuroscience, immuno-science, and virology drugs."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. : BMY-US: Dividend Analysis : October 06th, 2017 (record date) : By the numbers : October 18, 2017",2017-10-18 13:10:06 +0000,http://finance.yahoo.com/r/3c9d2d39-9699-326c-ae35-a8a174fc17c4/bristol-myers-squibb-co-bmy-us-dividend-analysis-october-06th-2017-record-date-by-the-numbers-october-18-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Our analysis is based on comparing Bristol-Myers Squibb Co. with the following peers – Eli Lilly and Company, Merck & Co., Inc., Pfizer Inc., Sanofi Sponsored ADR, Novartis AG Sponsored ADR, Astrazeneca PLC Sponsored ADR, AbbVie, Inc., Johnson & Johnson, Celgene Corporation and Amgen Inc. (LLY-US, MRK-US, PFE-US, SNY-US, NVS-US, AZN-US, ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-10-18 12:00:49 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120049604.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,This hot trade is about to get even hotter: Trader,2017-10-17 21:00:00 +0000,https://finance.yahoo.com/video/hot-trade-even-hotter-trader-210000526.html?.tsrc=rss,The “Fast Money” traders discuss the health care sector seeing a pop and where it could go from here.
BMY,BMY:US,BBG000DQLV23,US Pharma Mergers and Acquisitions in 3Q17,2017-10-17 19:56:05 +0000,http://finance.yahoo.com/r/c93e3466-34cb-3371-9d5d-db590d7da5fa/us-pharma-mergers-and-acquisitions-in-3q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Calendar 3Q17 saw several major mergers and acquisitions in the US pharmaceutical industry.
BMY,BMY:US,BBG000DQLV23,FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx,2017-10-17 14:55:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZZXqkk2SHBQ/fda-grants-priority-review-for-exelixis-rcc-drug-cabomteyx-cm860718,Exelixis Inc EXEL announced that the FDA has granted priority review to its supplemental New Drug Application sNDA for Cabomteyx The sNDA seeks approval of Cabometyx for patients with previously untreated advanced renal cell carcinoma RCC The FDA determined the sNDA to be
BMY,BMY:US,BBG000DQLV23,3 Drug Stocks Hitting 52-Week Highs: Are They Buys?,2017-10-17 14:54:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/onVhgahUM5c/3-drug-stocks-hitting-52-week-highs-are-they-buys-cm860683,October has often been a scary month for stocks That isn t the case so far this year though And it s especially not true for three drug stocks Biogen NASDAQ BIIB Halozyme Therapeutics NASDAQ HALO and Ionis Pharmaceuticals NASDAQ IONS stocks have all
BMY,BMY:US,BBG000DQLV23,3 Dividend Healthcare Stocks,2017-10-17 14:00:00 +0000,https://finance.yahoo.com/news/3-dividend-healthcare-stocks-140000927.html?.tsrc=rss,"If you&apos;re on the hunt for outstanding healthcare dividend stocks, Allergan, Bristol-Myers Squibb, and McKesson need to be on your radar."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Gets Priority Review for Opdivo Label Expansion,2017-10-17 13:49:01 +0000,https://finance.yahoo.com/news/bristol-myers-gets-priority-review-134901753.html?.tsrc=rss,Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.
BMY,BMY:US,BBG000DQLV23,"Hartford Financial Management Inc. Buys DowDuPont Inc, SPDR Gold Trust, iShares National Muni ...",2017-10-17 12:15:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OSIhoQB71gQ/hartford-financial-management-inc-buys-dowdupont-inc-spdr-gold-trust-ishares-national-muni-cm860449,Hartford Financial Management Inc New Purchases DWDP GLD MUB SPY IWF VTI CBU TCP SEP IWM Added Positions WMB RSP CMCSA PGX PAA V APC MSFT RYH XLF Reduced Positions CI DIS AAPL FOXA RGC CI PG VNQ QCOM XOM Sold Out DD
BMY,BMY:US,BBG000DQLV23,"ANIK Expands Horizons, FENC Hits Study Goals, IMDZ Abuzz, One More For Opdivo",2017-10-17 01:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qW-POLLbrWk/anik-expands-horizons-fenc-hits-study-goals-imdz-abuzz-one-more-for-opdivo-20171017-00037,"ANIK Expands Horizons, FENC Hits Study Goals, IMDZ Abuzz, One More For Opdivo"
BMY,BMY:US,BBG000DQLV23,"HIIQ In Good Health, BOLD Awaits ASPIRO Data, CELESTIAL Lights Up EXEL",2017-10-16 21:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4hhrQ3h8PGQ/hiiq-in-good-health-bold-awaits-aspiro-data-celestial-lights-up-exel-20171016-01420,"HIIQ In Good Health, BOLD Awaits ASPIRO Data, CELESTIAL Lights Up EXEL"
BMY,BMY:US,BBG000DQLV23,"Exelixis Rockets To 17-Year High On Kidney, Liver Cancer News",2017-10-16 21:18:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ajMdKto9Ixo/exelixis-rockets-to-17-year-high-on-kidney-liver-cancer-news-cm860060,Exelixis EXEL popped early Monday after its drug Cabometyx proved effective in treating patients with a form of liver cancer known as hepatocellular carcinoma 160 prompting officials to end the Phase 3 trial early ibd display video id 2368152 width 50 float
BMY,BMY:US,BBG000DQLV23,U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review,2017-10-16 20:15:00 +0000,https://finance.yahoo.com/news/u-food-drug-administration-fda-201500278.html?.tsrc=rss,Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration has accepted for priority review its supplemental Biologics License Application for Opdivo to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.
BMY,BMY:US,BBG000DQLV23,"Noteworthy Monday Option Activity: FCX, BMY, BIIB",2017-10-16 19:15:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c7NsuLbCZ7Y/noteworthy-monday-option-activity-fcx-bmy-biib-cm860263,Looking at options trading activity among components of the S amp P 500 index there is noteworthy activity today in Freeport McMoran Copper amp Gold Symbol FCX where a total volume of 75 338 contracts has been traded thus far today a contract volume which is representative
BMY,BMY:US,BBG000DQLV23,What Goes Up….Is Bristol-Myers a $48 Stock?,2017-10-16 14:44:00 +0000,http://finance.yahoo.com/r/80ca04a3-ddf5-34c5-9c89-badd9c800987/what-goes-up-is-bristol-myers-a-48-stock-1508165057?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Is it time to get cautious on Bristol-Myers Squibb (BMY).  The drug maker’s share price is falling today after Jefferies analyst Jeffrey Holford  downgraded the stock from a Buy to a Hold, and shaved his 12-month price target by a dollar to $71 a share.  Sure, Holford sees Bristol-Myers as a leading player in the immuno-oncology market and believes that the Street may be underestimating the potential for some of its drugs, namely the diverse set of indications it is pursuing for the cancer drug cocktail composed of Opdivo and Yervoy."
BMY,BMY:US,BBG000DQLV23,"Morning Movers: Nordstrom Tumbles, Adobe Drops, Bristol-Myers Slips",2017-10-16 13:23:00 +0000,http://finance.yahoo.com/r/bee2657c-763c-3cb3-a4a8-07f29a76cb99/morning-movers-nordstrom-tumbles-adobe-drops-bristol-myers-slips-1508160218?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Stocks look set for a higher open this morning after the Dow and S&P closed just below new highs last week. S&P 500 futures have ticked up 0.1%, while Dow Jones Industrial Average futures have advanced ..."
BMY,BMY:US,BBG000DQLV23,Incyte Cancer Treatment Uses Patients' Immune System To Fight Disease,2017-10-16 13:17:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sONgkph384Q/incyte-cancer-treatment-uses-patients-immune-system-to-fight-disease-cm859976,Among the biotech companies chasing next generation cancer treatments that work with patients own immune systems Incyte INCY stands out with a treatment analysts say could prove to be a blockbuster ibd display video id 2326965 width 50 float left autostart true
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Gets a Boost,2017-10-16 11:53:00 +0000,http://finance.yahoo.com/r/c71b9899-66d1-37d8-84a1-e47a489f2ded/bristol-myers-gets-a-boost-1508154828?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb (BMY: NYSE) Guggenheim Securities ($65.11, Oct. 12, 2017) We are raising our price target for Bristol-Myers Squibb to $75 from $68.  Our ..."
BMY,BMY:US,BBG000DQLV23,Corporate News Blog - Bristol-Myers Squibb's Opdivo to be Available for Head and Neck Cancer Patients in UK,2017-10-16 11:20:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-bristol-myers-112000497.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / October 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Bristol-Myers Squibb Co. (NYSE: BMY ), following which we have ..."
BMY,BMY:US,BBG000DQLV23,"Opdivo Alone or Combined with Yervoy Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden, in Exploratory Analysis from Phase 1/2 Study CheckMate -032",2017-10-16 07:15:00 +0000,https://finance.yahoo.com/news/opdivo-alone-combined-yervoy-shows-071500920.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced data evaluating Opdivo and Opdivo plus Yervoy in previously treated small cell lung cancer patients whose tumors were evaluable for tumor mutation burden , from the Phase 1/2 CheckMate -032 trial."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers: Opdivo Shows Encouraging Response, Survival Rates - Quick Facts",2017-10-16 03:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5g_LcxsDJmk/bristolmyers-opdivo-shows-encouraging-response-survival-rates--quick-facts-20171016-00132,"Bristol-Myers: Opdivo Shows Encouraging Response, Survival Rates - Quick Facts"
BMY,BMY:US,BBG000DQLV23,Riding High: Agilent Technologies,2017-10-16 01:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HohXbtLKPXE/riding-high-agilent-technologies-20171016-00036,Riding High: Agilent Technologies
BMY,BMY:US,BBG000DQLV23,"Exane Asset Management Buys AT&T Inc, Verizon Communications Inc, CNH Industrial NV, Sells ...",2017-10-14 12:15:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qw87DRM0U6I/exane-asset-management-buys-att-inc-verizon-communications-inc-cnh-industrial-nv-sells-cm859800,Exane Asset Management New Purchases CNHI CF UNVR BMRN MRK TWX KITE BA DDC NXTM Added Positions T VZ LBTYA GILD QGEN ASH OLN BIIB SNI BCR Reduced Positions MON GCP FTI BMY DB UBS TSU ALXN TMO PCAR Sold Out CELG AXTA WFC
BMY,BMY:US,BBG000DQLV23,5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings,2017-10-13 20:14:08 +0000,https://finance.yahoo.com/news/5-large-cap-drug-stocks-201408113.html?.tsrc=rss,The pharma/biotech sector has a number of things going in its favor.
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study",2017-10-13 14:23:02 +0000,https://finance.yahoo.com/news/bristol-myers-bmy-target-extend-142302507.html?.tsrc=rss,"Bristol-Myers Squibb (BMY) extended its strategic partnership with TARGET PharmaSolutions, Inc. for NASH study."
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback",2017-10-13 14:20:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o-6IHur8DDQ/pharma-stock-roundup-pfizer-mulls-options-for-consumer-healthcare-llys-pipeline-setback-cm859307,Companies like Pfizer PFE Merck MRK and Eli Lilly LLY were in the news this week while Pfizer is mulling strategic options for its Consumer Healthcare business Merck said that it will not file its CETP inhibitor Recap of the Week s Most Important Stories Pfizer to
BMY,BMY:US,BBG000DQLV23,Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap,2017-10-13 11:13:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gduBJOOCbhE/why-high-flying-aurinia-pharmaceuticals-stock-could-still-be-dirt-cheap-cm859205,If 2017 ended today Aurinia Pharmaceuticals NASDAQ AUPH would rank as one of the biggest winners of the year among biopharmaceutical stocks Aurinia s share price has more than tripled so far this year Is Aurinia overpriced after such tremendous gains Some might think so
BMY,BMY:US,BBG000DQLV23,Non-Alcoholic Steatohepatitis 2017 Progress Update,2017-10-13 01:12:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ib7V2EqL_pM/non-alcoholic-steatohepatitis-2017-progress-update-cm859149,Big time investors of late have been investing a substantial portion of their R amp D sources for the treatment of Non Alcoholic Steatohepatitis NASH The market for NASH is poised to witness rapid growth unlike other lucrative but saturated markets like cancer A chronic liver disease NASH
BMY,BMY:US,BBG000DQLV23,Cramer's lightning round: Zagg's got good swag,2017-10-12 23:01:00 +0000,https://finance.yahoo.com/video/cramers-lightning-round-zaggs-got-230100265.html?.tsrc=rss,"Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a consumer electronics play."
BMY,BMY:US,BBG000DQLV23,Seattle Genetics Inks Clinical Collaborations for Cancer Drug,2017-10-12 16:17:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-UoXM68OHDA/seattle-genetics-inks-clinical-collaborations-for-cancer-drug-cm858802,Seattle Genetics Inc SGEN announced two clinical collaborations to evaluate SGN LIV1A in triple negative breast cancer TNBC SGN LIV1A is an antibody drug conjugate ADC that being developed for the treatment of metastatic breast cancer in patients whose tumors express the LIV 1
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH,2017-10-12 13:00:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-bmy-extends-130000359.html?.tsrc=rss,"CHAPEL HILL, N.C , Oct. 12, 2017 /PRNewswire/ -- TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Bristol-Myers Squibb (BMY) has extended its strategic partnership ..."
BMY,BMY:US,BBG000DQLV23,5 Game-Changing Cancer Drug Innovations Being Developed Right Now,2017-10-12 11:13:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wHSNlY8m4nY/5-game-changing-cancer-drug-innovations-being-developed-right-now-cm858560,Image source Getty Images The emperor of all maladies the king of terrors 160 This phrase was used by a 19th century surgeon to describe cancer More than a century later the description unfortunately still applies Oncologist 160 Siddhartha Mukherjee even used the first
BMY,BMY:US,BBG000DQLV23,The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September,2017-10-09 15:34:00 +0000,http://finance.yahoo.com/r/ca389dcd-d0f0-34a9-8622-ddb2589b680f/the-1-event-that-sent-newlink-genetics-corporation.aspx?yptr=yahoo&.tsrc=rss,New data on NewLink&apos;s lead drug puts some pep in this clinical-stage drug developers&apos; step.
BMY,BMY:US,BBG000DQLV23,"Investors Are Scooping Up Shares of Apple, Ditching Bristol Myers and Pfizer",2017-10-09 14:35:00 +0000,http://finance.yahoo.com/r/719ce611-33cf-3472-ac0a-7f957d447230/investors-are-scooping-up-shares-of-apple-ditching-bristol-myers-and-pfizer.html?puc=yahoov&cm_ven=YAHOOV&yptr=yahoo&.tsrc=rss,"Investors rolled into shares of Apple in September, according to TD Ameritrade, but took profits on shares of Bristol-Myers and Pfizer shares."
BMY,BMY:US,BBG000DQLV23,Is Bristol-Myers Squibb Company’s (BMY) ROE Of 30.51% Sustainable?,2017-10-09 13:19:20 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-131920594.html?.tsrc=rss,"Bristol-Myers Squibb Company (NYSE:BMY) delivered an ROE of 30.51% over the past 12 months, which is an impressive feat relative to its industry average of 18.27% during the same period.Read More..."
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-10-09 12:01:23 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120123742.html?.tsrc=rss,"This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY.  Over the last one-month, outflows of investor capital in ETFs holding BMY totaled $5.51 billion."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicine",2017-10-09 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-appoints-saurabh-105900220.html?.tsrc=rss,"Bristol-Myers Squibb Company announced that it has appointed scientific and business thought-leader, Saurabh Saha, M.D., Ph.D., as senior vice president and global head of translational medicine in the company’s R&D organization, effective today."
BMY,BMY:US,BBG000DQLV23,Better Buy: Celgene Corporation vs. Bristol-Myers Squibb,2017-10-07 15:51:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2mXehf43ALo/better-buy-celgene-corporation-vs-bristol-myers-squibb-cm856670,By most metrics Celgene Corporation NASDAQ CELG is smaller than Bristol Myers Squibb NYSE BMY Celgene has fewer employees lower revenue and lower earnings than BMS does In one key way though Celgene is the bigger drugmaker Its market cap is greater by several
BMY,BMY:US,BBG000DQLV23,Better Buy: Celgene Corporation vs. Bristol-Myers Squibb,2017-10-07 14:34:00 +0000,http://finance.yahoo.com/r/3be6f34a-2d78-3bd2-9fc2-1c63fce47401/better-buy-celgene-corporation-vs-bristol-myers-sq.aspx?yptr=yahoo&.tsrc=rss,Two of the biggest pharma stocks with two of the most successful cancer drugs. But which is the better pick for investors?
BMY,BMY:US,BBG000DQLV23,Here's What's Has Happened in the HCV Space Lately,2017-10-06 21:42:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0N3PCfuwV5k/heres-whats-has-happened-in-the-hcv-space-lately-cm856488,Hepatitis C is an infectious disease caused by the hepatitis C virus HCV that primarily affects the liver Gilead Sciences Inc GILD markets blockbuster HCV drugs Sovaldi and Harvoni while other well known names in this market are AbbVie Inc s ABBV Viekira Pak Bristol Myers BMY
BMY,BMY:US,BBG000DQLV23,"Missing Link: Long Capital One, Bristol-Myers",2017-10-06 16:38:00 +0000,https://finance.yahoo.com/video/missing-long-capital-one-bristol-163800826.html?.tsrc=rss,"&quot;Fast Money Halftime Report&quot; trader Stephanie Link talks her new portfolio adds, Capital One and Bristol-Myers."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Won't Be Left Behind in This Bull Market -- Jim Cramer,2017-10-06 16:26:00 +0000,http://finance.yahoo.com/r/7b4904aa-e7c6-38fa-8b51-e7ecf6f6a35b/bristol-myers-squibb-still-hot.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb continues to trade higher and no one's going to leave the stock behind in this kind of market, Jim Cramer says."
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-10-06 12:01:18 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120118573.html?.tsrc=rss,"This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY.  Over the last one-month, outflows of investor capital in ETFs holding BMY totaled $1.93 billion."
BMY,BMY:US,BBG000DQLV23,AbbVie (ABBV) Stock Up Almost 17% in One Month: Here's Why,2017-10-05 16:51:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/snoBDjGkfno/abbvie-abbv-stock-up-almost-17-in-one-month-heres-why-cm855856,AbbVie Inc ABBV shares have gained an impressive 16 7 in the past month comparing favorably with a gain of 4 5 recorded by the industry The share price surge was supported by a series of positive news for the company in the past few weeks Last week AbbVie announced the
BMY,BMY:US,BBG000DQLV23,"The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September",2017-10-05 14:37:00 +0000,http://finance.yahoo.com/r/c97280b3-dbf2-39de-876a-9072bf6b6b31/the-2-surprising-reasons-exelixis-inc-lost-17-in-s.aspx?yptr=yahoo&.tsrc=rss,"Despite a poor showing last month, the outlook for Exelixis&apos; lead drug remains positive."
BMY,BMY:US,BBG000DQLV23,"Stillwater Investment Management, LLC Buys DowDuPont Inc, Bristol-Myers Squibb Company",2017-10-04 21:38:01 +0000,https://finance.yahoo.com/news/stillwater-investment-management-llc-buys-213801266.html?.tsrc=rss,"Stillwater, MN, based Investment company Stillwater Investment Management, LLC buys DowDuPont Inc, Bristol-Myers Squibb Company during the 3-months ended 2017-09-30, according to the most recent filings ..."
BMY,BMY:US,BBG000DQLV23,Why These Biotechs Are Leading The Group Near A 21-Month High,2017-10-04 20:47:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tK5nDHbzrYg/why-these-biotechs-are-leading-the-group-near-a-21-month-high-cm855432,Biotech stocks narrowed in on a 21 month high Wednesday with big rises coming from the likes of Intercept Pharmaceuticals ICPT Amicus Therapeutics FOLD and Exelixis EXEL on positive drug and partnership news ibd display video id 2326965 width
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for October 05, 2017",2017-10-04 13:21:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n0qnPsGunXE/bristol-myers-squibb-company-bmy-ex-dividend-date-scheduled-for-october-05-2017-cm855059,Bristol Myers Squibb Company BMY will begin trading ex dividend on October 05 2017 A cash dividend payment of 0 39 per share is scheduled to be paid on November 01 2017 Shareholders who purchased BMY prior to the ex dividend date are eligible for the cash dividend payment This marks
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-10-04 12:00:47 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120047531.html?.tsrc=rss,"This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY.  Over the last one-month, outflows of investor capital in ETFs holding BMY totaled $1.07 billion."
BMY,BMY:US,BBG000DQLV23,"Caregivers Wish Liver Cancer Received Greater Public Awareness in the U.S., New Survey Reveals",2017-10-04 10:59:00 +0000,https://finance.yahoo.com/news/caregivers-wish-liver-cancer-received-105900315.html?.tsrc=rss,"Bristol-Myers Squibb Company , in collaboration with Blue Faery: The Adrienne Wilson Liver Cancer Association, a leading liver cancer patient advocacy organization, today announced the findings from a new survey exploring the experiences of caregivers of people living with early or advanced stage liver cancer in the U.S."
BMY,BMY:US,BBG000DQLV23,"Ex-Dividend Reminder: Bristol-Myers Squibb, Kite Realty Group Trust and DCT Industrial Trust",2017-10-03 16:57:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dscVRNkQPY4/ex-dividend-reminder-bristol-myers-squibb-kite-realty-group-trust-and-dct-industrial-trust-cm854663,Looking at the universe of stocks we cover at Dividend Channel on 10 5 17 Bristol Myers Squibb Co Symbol BMY Kite Realty Group Trust Symbol KRG and DCT Industrial Trust Inc Symbol DCT will all trade ex dividend for their respective upcoming dividends Bristol Myers Squibb Co
BMY,BMY:US,BBG000DQLV23,Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs?,2017-10-03 14:58:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/StPiVWyC5rs/will-gilead-abbvie-benefit-from-mercks-decision-to-drop-two-hcv-programs-cm854557,Late last week Merck MRK announced its decision to discontinue the development of a couple of candidates in its hepatitis C virus HCV program MK 3682B grazoprevir ruzasvir uprifosbuvir and MK 3682C ruzasvir uprifosbuvir The company s decision was based on a review of available
BMY,BMY:US,BBG000DQLV23,Seattle Genetics' Adcetris Gets Breakthrough Therapy Status,2017-10-03 14:57:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8N3b6n3Bcec/seattle-genetics-adcetris-gets-breakthrough-therapy-status-cm854532,Seattle Genetics Inc SGEN announced that the FDA has granted Breakthrough Therapy Designation status to its lymphoma drug Adcetris as frontline treatment for advanced classical Hodgkin lymphoma The company recently completed a phase III study ECHELON 1 on the drug for this
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Named Top Dividend Stock With Insider Buying and 2.45% Yield (BMY),2017-10-02 21:46:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rWkeLfSu2tQ/bristol-myers-squibb-named-top-dividend-stock-with-insider-buying-and-245-yield-bmy-cm854216,In this series we look through the most recent Dividend Channel DividendRank report and then we cherry pick only those companies that have experienced insider buying within the past six months The officers and directors of a company tend to have a unique insider s view of the business
BMY,BMY:US,BBG000DQLV23,Merck's Keytruda Continues To Roll With Another FDA Approval,2017-10-02 18:48:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wt3hU7DPyRw/mercks-keytruda-continues-to-roll-with-another-fda-approval-cm854145,Merck s 160 MRK Keytruda was recently approved by the U S FDA for gastric cancer Keytruda has been on a strong run in 2017 with a series of approvals Keytruda already had approval for melanoma metastatic non small cell lung cancer head and neck cancer Hodgkin s lymphoma and
BMY,BMY:US,BBG000DQLV23,1 Great Biotech Stock You Have Never Heard Of,2017-09-29 17:36:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9f1c3XvF4p8/1-great-biotech-stock-you-have-never-heard-of-cm853199,About 90 of drug candidates that enter clinical trials never make it to market That brutal fact makes the small cap biotech sector a tough place for investors to put their money to work However one way investors can increase their odds of success is to watch where big
BMY,BMY:US,BBG000DQLV23,"VYM, PFE, BMY, CB: ETF Outflow Alert",2017-09-29 16:35:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YyG_d6mqO6E/vym-pfe-bmy-cb-etf-outflow-alert-cm853162,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard High Dividend Yield ETF Symbol VYM where we have detected an approximate 85 0 million dollar outflow that s a 0 4 decrease week over week
BMY,BMY:US,BBG000DQLV23,Must-Know Changes to Bristol-Myers Squibb’s Valuation,2017-09-29 14:40:15 +0000,http://finance.yahoo.com/r/5291550d-982b-3297-9fe7-e6b51ab4ffff/must-know-changes-to-bristol-myers-squibbs-valuation?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb (BMY), a US pharmaceutical company, includes innovative products from its Cardiovascular, Immunoscience, Neuroscience, Oncology, and Virology franchises."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Immunoscience Products,2017-09-29 13:11:07 +0000,http://finance.yahoo.com/r/f9aa9c55-eb9d-3b17-bbb9-875e36cebcef/bristol-myers-squibbs-immunoscience-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb’s (BMY) Immunoscience franchise includes Orencia, which is a fusion protein used for the treatment of rheumatoid arthritis and aligned problems."
BMY,BMY:US,BBG000DQLV23,UNC lands $1.7M grant from Bristol-Myers Squibb,2017-09-29 12:35:08 +0000,http://finance.yahoo.com/r/1fc2cfea-d60f-3831-9f77-b5f38bb83acb/unc-lands-1-7m-grant-from-bristol-myers-squibb.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"The UNC School of Medicine has landed a $1.7 million grant from the Bristol-Myers Squibb Foundation – aimed at improving care and education for patients with atrial fibrillation (Afib), or an irregular heartbeat that can lead to stroke and heart failure, among other complications.  The three-year grant will be used by cardiologist Dr. Anil Gehi to further a care model he launched back in 2015.  According to UNC, Gehi's work has reduced hospitalizations for Afib patients in the emergency room by upward of 30 percentage points in year one."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Cardiovascular Portfolio,2017-09-29 11:40:03 +0000,http://finance.yahoo.com/r/92f7e119-8c43-3a69-94a9-f347929e2c1c/bristol-myers-squibbs-cardiovascular-portfolio?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb’s (BMY) cardiovascular portfolio includes the blockbuster drug Eliquis, developed in alliance with Pfizer (PFE)."
BMY,BMY:US,BBG000DQLV23,Tax reform could spark a wave of biopharma M&A,2017-09-28 21:27:00 +0000,https://finance.yahoo.com/video/tax-reform-could-spark-wave-212700721.html?.tsrc=rss,CNBC's Meg Tirrell discusses the failed attempts at Pfizer trying to acquire two companies in the past but how the Republican tax reform plan could change that. The “Fast Money” traders weigh in.
BMY,BMY:US,BBG000DQLV23,Biotech Stocks To Watch And Pharma Industry News,2017-09-28 19:42:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aOlKlN8WoQc/biotech-stocks-to-watch-and-pharma-industry-news-cm852776,One minute Dow Jones industrial average component Merck MRK might be doing battle with fellow drugmaker Bristol Myers Squibb BMY over drugs that can ward off cancer The next biotech giants like Amgen AMGN and Sanofi SNY are
BMY,BMY:US,BBG000DQLV23,"Noteworthy Thursday Option Activity: GILD, BMY, XOM",2017-09-28 19:41:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J71u00-_R6U/noteworthy-thursday-option-activity-gild-bmy-xom-cm852759,Among the underlying components of the S amp P 500 index we saw noteworthy options trading volume today in Gilead Sciences Inc Symbol GILD where a total of 71 221 contracts have traded so far representing approximately 7 1 million underlying shares That amounts to about 60 8 of GILD
BMY,BMY:US,BBG000DQLV23,Bulls dial into this stock,2017-09-28 17:36:00 +0000,https://finance.yahoo.com/video/bulls-dial-stock-173600727.html?.tsrc=rss,&quot;Halftime Report&quot; traders Jon and Pete Najarian spot unusual activity in shares of Blackberry and Bristol-Myers.
BMY,BMY:US,BBG000DQLV23,Strategy To YieldBoost Bristol-Myers Squibb Co. From 2.5% To 7.2% Using Options,2017-09-28 16:43:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9EkIqcXk5Ow/strategy-to-yieldboost-bristol-myers-squibb-co-from-25-to-72-using-options-cm852660,Shareholders of Bristol Myers Squibb Co Symbol BMY looking to boost their income beyond the stock s 2 5 annualized dividend yield can sell the June 2018 covered call at the 70 strike and collect the premium based on the 2 10 bid which annualizes to an additional 4 7 rate of return
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Virology Portfolio,2017-09-28 14:41:00 +0000,http://finance.yahoo.com/r/beca1240-9212-34f5-8e29-4d9613efeca2/bristol-myers-squibbs-virology-portfolio?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb’s (BMY) virology portfolio includes products for the treatment of chronic virus infections like Hepatitis B virus infections, Hepatitis C virus (or HCV) infections, and HIV infections...."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Opdivo and Recent Developments,2017-09-28 13:10:27 +0000,http://finance.yahoo.com/r/499cd157-6a64-3d0c-b05b-21f77cdfcb16/bristol-myers-squibbs-opdivo-and-recent-developments?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb’s (BMY) Opdivo is part of the company’s alliance with Ono Pharmaceuticals. Opdivo was the largest revenue-contributing drug for the company in 2Q17.
BMY,BMY:US,BBG000DQLV23,Analyzing Bristol-Myers Squibb’s Oncology Portfolio,2017-09-28 11:42:46 +0000,http://finance.yahoo.com/r/5d5094b0-0da2-3210-8c0d-e1369106b92e/analyzing-bristol-myers-squibbs-oncology-portfolio?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb’s (BMY) oncology portfolio includes its Empliciti, Opdivo, Sprycel, and Yervoy products."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Growing Quarterly Revenues,2017-09-27 21:37:34 +0000,http://finance.yahoo.com/r/048e3814-700b-3f1f-9885-17b2c4d02a1c/bristol-myers-squibbs-growing-quarterly-revenues?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb (BMY) reported revenues of $5.14 billion in 2Q17—5.6% growth from revenues of $4.87 billion in 2Q16.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb: Advancing Research Across Thoracic Cancers with New Data at IASLC 18th World Conference on Lung Cancer,2017-09-27 21:00:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-advancing-research-210000345.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced the presentation of 28 abstracts for Opdivo , alone and in combination with Yervoy , targeted therapy or chemotherapy, at the International Association for the Study of Lung Cancer  18th World Conference on Lung Cancer in Yokohama, Japan, from October 15-18."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Important Recent Developments,2017-09-27 19:48:45 +0000,http://finance.yahoo.com/r/7dd75d16-fa5a-3697-b216-eb4914c19039/bristol-myers-squibbs-important-recent-developments?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Headquartered in New York City, Bristol-Myers Squibb (BMY) is a US pharmaceutical company that includes products from its Cardiovascular, Immunoscience, Neuroscience, Oncology, and Virology franchises...."
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-09-27 12:01:18 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120125396.html?.tsrc=rss,"This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY.  Over the last one-month, outflows of investor capital in ETFs holding BMY totaled $3.29 billion."
BMY,BMY:US,BBG000DQLV23,What Happened to Allergan’s Valuation after 2Q17?,2017-09-27 11:37:12 +0000,http://finance.yahoo.com/r/08cec61f-6888-3ef7-a419-b673d64a59e6/what-happened-to-allergans-valuation-after-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Of the 21 analysts tracking Allergan stock, 14 recommend a “buy,” and seven analysts recommend a “hold.” None recommends a “sell.”"
BMY,BMY:US,BBG000DQLV23,Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal,2017-09-26 16:56:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8FRxrYNAo-g/infinity-bristol-myers-adds-tnbc-patients-to-clinical-deal-cm851181,Infinity Pharmaceuticals Inc INFI announced that it has expanded its existing clinical collaboration with Bristol Myers Squibb BMY for evaluating IPI 549 in combination with 160 latter s checkpoint inhibitor Opdivo The collaboration will include patients with triple negative breast
BMY,BMY:US,BBG000DQLV23,"Gilead Sciences: New Market, Same Problem?",2017-09-26 16:51:00 +0000,http://finance.yahoo.com/r/7330ca3f-19a0-39ae-b2bc-7911db79fc79/gilead-sciences-new-market-same-problem-1506444713?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Yesterday, Gilead Sciences (GILD) announced that China's Food and Drug Administration had approved Sovaldi for the treatment of hepatitis C. But will Gilead run into the same problems in China that it has in the U.S.?  It sure looks that way, says Maxim analyst Gabrielle Zhou and team.  Remember, Gilead's hepatitis-C treatments were huge blockbusters for the company--until AbbVie (ABBV) and other competitors had their treatments approved, and forced prices lower."
BMY,BMY:US,BBG000DQLV23,Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal,2017-09-26 14:24:02 +0000,https://finance.yahoo.com/news/infinity-bristol-myers-adds-tnbc-142402318.html?.tsrc=rss,Infinity (INFI) expanded its existing clinical collaboration with Bristol-Myers Squibb for evaluating IPI-549 in combination with Opdivo to include patients with triple negative breast cancer.
BMY,BMY:US,BBG000DQLV23,3 Reasons to Buy the Dip With Exelixis,2017-09-26 13:54:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5e3WC7Biph0/3-reasons-to-buy-the-dip-with-exelixis-cm850884,In just two days Exelixis NASDAQ EXEL has lost over 15 of its market cap The tumble for the once hot biotech stock started last week with a downgrade of the stock by an analyst at Leerink Partners It wasn t over anything Exelixis did analyst Mike Schmidt said the biotech
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: J&J Drug Gets CRL, Label Expansion for Merck and BMY Drugs",2017-09-26 12:50:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IavOpd2pqmg/pharma-stock-roundup-jj-drug-gets-crl-label-expansion-for-merck-and-bmy-drugs-cm850815,Key highlights in the pharma sector include a complete response letter CRL from the FDA for Johnson amp Johnson s JNJ investigational rheumatoid arthritis RA treatment and FDA approval for Merck s MRK and Bristol Myers Squibb s BMY cancer drugs Recap of the Week s Most
BMY,BMY:US,BBG000DQLV23,"Biotech Stock Roundup: Amgen Reiterates 2017 Outlook, Intercept Hit by Ocaliva Safety Issues",2017-09-26 12:25:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-amgen-reiterates-122512208.html?.tsrc=rss,Key highlights this week include Amgen&apos;s (AMGN) update regarding Hurricane Maria and safety issues concerning Intercept&apos;s Ocaliva.
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-09-26 12:01:18 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120118295.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: J&J Drug Gets CRL, Label Expansion for Merck and BMY Drugs",2017-09-26 10:52:10 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-j-j-105210392.html?.tsrc=rss,"Industry heavyweights like Johnson & Johnson (JNJ), Merck and Bristol-Myers were in the news related to regulatory updates."
BMY,BMY:US,BBG000DQLV23,"FDA Rejects IPCI's Painkiller, GNCA Bleeds On Herpes Vaccine News, PRQR Abuzz",2017-09-26 01:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8P16qBLV6z4/fda-rejects-ipcis-painkiller-gnca-bleeds-on-herpes-vaccine-news-prqr-abuzz-20170926-00037,"FDA Rejects IPCI's Painkiller, GNCA Bleeds On Herpes Vaccine News, PRQR Abuzz"
BMY,BMY:US,BBG000DQLV23,Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer,2017-09-25 16:51:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uykP3mWgkS0/abbviebristol-myers-inks-deal-to-develop-therapeutic-cancer-cm850446,AbbVie ABBV and Bristol Myers Squibb Company BMY entered into a deal to evaluate the combination of AbbVie s investigational antibody drug conjugate ABBV 399 and Bristol Myers Squibb s immune oncology drug Opdivo nivolumab in c Met overexpressing non small cell lung cancer
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Opdivo Gets Approval for Liver Cancer,2017-09-25 14:52:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P5enUOzxSXY/bristol-myers-bmy-opdivo-gets-approval-for-liver-cancer-cm850329,Bristol Myers Squibb Company BMY announced that the FDA has approved immuno oncology drug Opdivo for intravenous use for patients with hepatocellular carcinoma HCC who have been previously treated with 160 Nexavar The approval for this indication was granted under accelerated approval
BMY,BMY:US,BBG000DQLV23,Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer,2017-09-25 14:49:02 +0000,https://finance.yahoo.com/news/abbvie-bristol-myers-inks-deal-144902944.html?.tsrc=rss,AbbVie (ABBV) and Bristol-Myers Squibb entered into a deal to evaluate the combination of ABBV-399 and Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Opdivo Gets Approval for Liver Cancer,2017-09-25 12:35:12 +0000,https://finance.yahoo.com/news/bristol-myers-bmy-opdivo-gets-123512253.html?.tsrc=rss,Bristol-Myers Squibb Company (BMY) announced that the FDA has approved immuno-oncology drug Opdivo for liver cancer.
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-09-25 12:01:24 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120124012.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,"Infinity Pharma, Bristol-Myers Collaborate; Expands IPI-549 Study",2017-09-25 08:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/350Tv0amiDo/infinity-pharma-bristolmyers-collaborate-expands-ipi549-study-20170925-00545,"Infinity Pharma, Bristol-Myers Collaborate; Expands IPI-549 Study"
BMY,BMY:US,BBG000DQLV23,"Opdivo, Keytruda Back In The News, FDA Snubs AGN, EARS Catches Eyes",2017-09-24 22:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6nJFlMBC3uc/opdivo-keytruda-back-in-the-news-fda-snubs-agn-ears-catches-eyes-20170924-00100,"Opdivo, Keytruda Back In The News, FDA Snubs AGN, EARS Catches Eyes"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib,2017-09-22 22:10:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-opdivo-nivolumab-221000386.html?.tsrc=rss,Bristol-Myers Squibb Company today announced the U.S. Food and Drug Administration has approved Opdivo injection for intravenous use for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update",2017-09-22 14:40:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aD0-fF1ZJ_8/pharma-stock-roundup-pfizer-files-suit-against-jj-supernus-hit-by-study-update-cm849533,Key highlights this week include a lawsuit filed by Pfizer PFE accusing Johnson amp Johnson JNJ of adopting exclusionary contracts and other anticompetitive practices to prevent biosimilar uptake Meanwhile companies like GlaxoSmithKline GSK and Supernus Pharmaceuticals SUPN were in the
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-09-22 12:00:54 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120054752.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,These 3 Stocks Are Priced for Perfection. Can They Deliver?,2017-09-22 11:37:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZVbgQ3BViVI/these-3-stocks-are-priced-for-perfection-can-they-deliver-cm849421,You expect a top ranked football team to play well every game You expect the Kentucky Derby winner to place in the Preakness Stakes And you expect a stock with a high valuation to generate strong sales and earnings growth every quarter Three healthcare stocks are especially priced
BMY,BMY:US,BBG000DQLV23,AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors,2017-09-22 11:00:00 +0000,https://finance.yahoo.com/news/abbvie-bristol-myers-squibb-announce-110000183.html?.tsrc=rss,"NORTH CHICAGO, Ill. and NEW YORK , Sept. 22, 2017 /PRNewswire/ --  AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination ..."
BMY,BMY:US,BBG000DQLV23,"Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy",2017-09-22 09:00:00 +0000,https://finance.yahoo.com/news/japan-ministry-health-labor-welfare-090000008.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced that the Japanese Ministry of Health, Labor and Welfare has approved Opdivo for the treatment of unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Reports Approval Of Opdivo For Recurrent Gastric Cancer In Japan,2017-09-22 05:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MM_4T02oQqA/bristolmyers-reports-approval-of-opdivo-for-recurrent-gastric-cancer-in-japan-20170922-00123,Bristol-Myers Reports Approval Of Opdivo For Recurrent Gastric Cancer In Japan
BMY,BMY:US,BBG000DQLV23,"VYM, JPM, WFC, BMY: Large Inflows Detected at ETF",2017-09-21 19:39:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kn2bsoWylog/vym-jpm-wfc-bmy-large-inflows-detected-at-etf-cm849229,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard High Dividend Yield ETF Symbol VYM where we have detected an approximate 196 0 million dollar inflow that s a 1 0 increase week over week
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-09-21 12:00:43 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120043684.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,New Global Report Finds Majority of People at High Risk of Stroke Not Being Screened for Common Risk Factors,2017-09-21 10:59:00 +0000,https://finance.yahoo.com/news/global-report-finds-majority-people-105900069.html?.tsrc=rss,"New research released today by The Economist Intelligence Unit , a division of The Economist and a leader in global business intelligence, revealed that on average, more than 75 percent of people aged 65 and older worldwide are not being screened for atrial fibrillation and other common stroke risk factors during routine primary care examinations, even though this population is at high risk for stroke...."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference,2017-09-21 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-part-leerink-105900266.html?.tsrc=rss,"Bristol-Myers Squibb Company will take part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference on Thursday, September 28, 2017, in New York. Thomas Lynch, chief scientific officer, will answer questions about the company at 11:00 a.m."
BMY,BMY:US,BBG000DQLV23,2 Important Dates for Big Pharma,2017-09-20 19:50:01 +0000,https://finance.yahoo.com/news/2-important-dates-big-pharma-195001453.html?.tsrc=rss,Big PDUFA dates to watch for at the end of September
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-09-20 12:00:47 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120047636.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,Roche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA,2017-09-18 23:35:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dzquLKTQSBE/roches-rhhby-tecentriq-studies-put-on-partial-hold-by-fda-cm847443,Roche Holdings AG RHHBY announced that the FDA has put a partial clinical hold on a phase Ib and phase I II b trials evaluating Tecentriq due to safety issues A partial hold was put due to emerging safety data from clinical trials evaluating Merck amp Co MRK Keytruda in combination
BMY,BMY:US,BBG000DQLV23,Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear,2017-09-18 18:35:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NuJmqgpNcOU/buy-bristol-myers-squibb-co-bmy-stock-with-no-fear-cm847333,InvestorPlace Stock Market News Stock Advice amp Trading Tips Bristol Myers Squibb Co NYSE BMY stock has had a tumultuous 12 month period In January it fell 20 but luckily for the bulls it recovered all of it within five weeks Since then and after several 8 moves
BMY,BMY:US,BBG000DQLV23,The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017,2017-09-18 15:40:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8PpY7-1gudA/the-top-cancer-immunotherapies-expected-to-reach-1-billion-in-sales-in-2017-cm847095,There is perhaps no scarier word in the English language than cancer More than 15 5 million Americans who were alive as of Jan 1 2016 have had cancer at some point in their lives according to the American Cancer Society and it s expected to lead to 600 920 deaths
BMY,BMY:US,BBG000DQLV23,Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear,2017-09-18 14:19:26 +0000,https://finance.yahoo.com/news/buy-bristol-myers-squibb-co-141926484.html?.tsrc=rss,"Bristol-Myers Squibb Co (NYSE:BMY) stock has had a tumultuous 12-month period. In January, it fell 20% but luckily for the bulls it recovered all of it within five weeks. Since then and after several +/-8% moves, BMY is up 12% in 52 weeks which is decent but still underwhelming relative to the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) as a whole.Source: A 4 via Flickr"
BMY,BMY:US,BBG000DQLV23,The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017,2017-09-18 13:42:00 +0000,http://finance.yahoo.com/r/57820e44-f3d3-3613-a469-d0209b667aae/the-top-cancer-immunotherapies-expected-to-reach-1.aspx?yptr=yahoo&.tsrc=rss,These next-generation medicines are quickly becoming the foundation for advanced cancer treatments.
BMY,BMY:US,BBG000DQLV23,Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb,2017-09-17 12:35:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hyVCSBL6LQA/better-buy-pfizer-inc-vs-bristol-myers-squibb-cm846781,You can call them frenemies Pfizer NYSE PFE and Bristol Myers Squibb NYSE BMY are friends when it comes to blockbuster blood thinner Eliquis But the two big pharma companies are enemies in the oncology and immunology arenas How do these collaborators and
BMY,BMY:US,BBG000DQLV23,Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb,2017-09-17 11:03:00 +0000,http://finance.yahoo.com/r/7e793b44-1a64-36e8-a706-b91b8fb0a997/better-buy-pfizer-inc-vs-bristol-myers-squibb.aspx?yptr=yahoo&.tsrc=rss,It&apos;s a tough decision between these two big pharma stocks.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Stock Still a Beast?,2017-09-17 11:02:00 +0000,http://finance.yahoo.com/r/a7a34776-b2e8-3121-b584-7a626de8330c/bristol-myers-squibb.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The drug-maker's stock just keeps going higher. What is the next move?
BMY,BMY:US,BBG000DQLV23,"Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?",2017-09-16 16:35:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u53HUED6s14/halozyme-inovalon-and-teva-soared-this-week-can-they-go-higher-cm846722,Many healthcare stocks muddled along over the past week That wasn t the case though for three stocks of companies operating in very different parts of the healthcare spectrum Shares of Halozyme Therapeutics NASDAQ HALO Inovalon Holdings NASDAQ INOV and
BMY,BMY:US,BBG000DQLV23,"Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?",2017-09-16 14:47:00 +0000,http://finance.yahoo.com/r/1d856052-bb96-3c0c-98c3-8d02fbb0dc0c/halozyme-inovalon-and-teva-soared-this-week-can-th.aspx?yptr=yahoo&.tsrc=rss,Prospects for two of this week&apos;s big healthcare winners look great. But it&apos;s a different story for one of them.
BMY,BMY:US,BBG000DQLV23,Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?,2017-09-16 13:35:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oRiw8QvF4ew/which-of-these-5-will-be-the-best-selling-drug-worldwide-in-2020-cm846701,The global pharmaceutical industry is a giant in case you didn t already know it According to a 2016 report from the International Trade Administration ITA global sales of pharmaceuticals are expected to climb from roughly 1 trillion in 2015 to 1 3 trillion by 2020 representing
BMY,BMY:US,BBG000DQLV23,"Notable Friday Option Activity: IDCC, BMY, TCS",2017-09-15 20:36:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iHilunGZmqk/notable-friday-option-activity-idcc-bmy-tcs-cm846516,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Interdigital Inc Symbol IDCC where a total volume of 1 822 contracts has been traded thus far today a contract volume which is representative of approximately 182
BMY,BMY:US,BBG000DQLV23,Oncology Space in Focus this Week on ESMO Presentations,2017-09-15 16:38:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vXpy5Y27IW8/oncology-space-in-focus-this-week-on-esmo-presentations-cm846326,Cancer capable of striking fear in even the strongest of hearts is a malignancy characterized by uncontrolled growth of abnormal cells which if not treated can lead to death According to the American Cancer Society there are more than 100 types of cancers the deadliest among them
BMY,BMY:US,BBG000DQLV23,"Halozyme Up After Cancer Deal, Markets Down",2017-09-15 16:34:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y3qo6gjDYmU/halozyme-up-after-cancer-deal-markets-down-cm846403,U S stock market indexes opened lower on Thursday Futures for the Dow Jones Industrial Average declined 3 points to 22 109 The Standard amp Poor s 500 index futures lost 2 points to 2 493 and futures for the Nasdaq 100 index declined 7 points to 6 002 The dollar index is down 0 06 at 92
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE,2017-09-15 15:42:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oaOk_jZRM3U/bristol-myers-bmy-collaborates-with-halozyme-for-enhanze-cm846293,Bristol Myers Squibb Company BMY recently entered into a collaboration and license agreement with Halozyme Therapeutics Inc HALO Per the agreement Bristol Myers will use Halozyme s ENHANZE drug delivery technology This will facilitate subcutaneous administration of Bristol
BMY,BMY:US,BBG000DQLV23,Time to Adjust as Bristol-Myers Squibb Continues Its Climb,2017-09-15 15:41:00 +0000,http://finance.yahoo.com/r/93c9123a-96b9-37a8-b12f-4bf41166a781/time-adjust-bristol-myers-squibb-continues-its-climb?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,It just keeps going higher.
BMY,BMY:US,BBG000DQLV23,Oncology Space in Focus this Week on ESMO Presentations,2017-09-15 14:55:02 +0000,https://finance.yahoo.com/news/oncology-space-focus-week-esmo-145502098.html?.tsrc=rss,There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca&apos;s lung cancer study data was positive and so was Bristol-Myers&apos;s melanoma candidate.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE,2017-09-15 13:34:01 +0000,https://finance.yahoo.com/news/bristol-myers-bmy-collaborates-halozyme-133401259.html?.tsrc=rss,"Bristol-Myers Squibb Company (BMY) enters into a collaboration and license agreement with Halozyme Therapeutics, Inc. (HALO)."
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO",2017-09-15 12:38:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nEtZLBtU3oM/pharma-stock-roundup-achillion-slumps-on-end-of-hcv-deal-teva-gets-a-new-ceo-cm846148,Several important developments were reported this week with key highlights including the termination of a hepatitis C virus deal the approval of the first cancer biosimilar in the United States and the presentation of data by companies like Pfizer PFE and Bristol Myers Squibb BMY among
BMY,BMY:US,BBG000DQLV23,Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?,2017-09-15 11:37:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rdOxPWtmZx8/who-will-win-the-kidney-cancer-battle-between-bristol-myers-squibb-and-exelixis-cm846124,A head to head competition for market share in the renal cell carcinoma RCC market appears to be about to intensify In one corner is Bristol Myers Squibb NYSE BMY With a market cap of over 100 billion and a history dating back to 1887 the big pharma has a lot of muscle to
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO",2017-09-15 10:52:10 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-achillion-slumps-105210457.html?.tsrc=rss,Key highlights this week include Teva&apos;s (TEVA) CEO announcement and the FDA approval of the first cancer biosimilar.
BMY,BMY:US,BBG000DQLV23,Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?,2017-09-15 10:04:00 +0000,http://finance.yahoo.com/r/c5d8f8ee-4ea5-3c8a-b59b-0d3c3bf68279/who-will-win-the-kidney-cancer-battle-between-bris.aspx?yptr=yahoo&.tsrc=rss,The answer might surprise you.
BMY,BMY:US,BBG000DQLV23,HALO Just Got Brighter - What Other Pharma Stocks Made News This Week?,2017-09-15 02:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x8i9EL_bHw8/halo-just-got-brighter--what-other-pharma-stocks-made-news-this-week-20170915-00044,HALO Just Got Brighter - What Other Pharma Stocks Made News This Week?
BMY,BMY:US,BBG000DQLV23,"Why Halozyme Therapeutics, Tenet Healthcare, and AMC Entertainment Holdings Jumped Today",2017-09-14 22:35:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pyT7ntegiLs/why-halozyme-therapeutics-tenet-healthcare-and-amc-entertainment-holdings-jumped-today-cm846004,The stock market was once again mixed on Thursday with the Dow Jones Industrials gaining ground to set a record high for the third session in a row even as other major benchmarks lagged behind Market participants turned their attention to the interest rate arena today weighing
BMY,BMY:US,BBG000DQLV23,"Close Update: Dow Closes At Record High, While S&P 500 Stays Negative on Inflation Data, Geopolitics",2017-09-14 21:15:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/txVMrXxrdKQ/close-update-dow-closes-at-record-high-while-sp-500-stays-negative-on-inflation-data-geopolitics-cm845992,Fueled by gains in component stocks Boeing BA and United Technologies UTX the Dow Jones Industrial Average closed at a record high with a fifth consecutive higher close while the S amp P 500 and Nasdaq were weighed down by strong inflation data soft Chinese manufacturing data and
BMY,BMY:US,BBG000DQLV23,"Daily Dividend Report: INTC, CSCO, BMY, ABT, KR, KRC, NFG, MFA",2017-09-14 20:35:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UK4bSBGHI-E/daily-dividend-report-intc-csco-bmy-abt-kr-krc-nfg-mfa-cm845932,Intel has declared a quarterly dividend of 0 2725 per share 1 09 per share on an annual basis on the company s common stock The dividend will be payable on Dec 1 2017 to stockholders of record on Nov 7 2017 Cisco CSCO declared a quarterly dividend of 0 29 per common share
BMY,BMY:US,BBG000DQLV23,"Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale",2017-09-14 20:35:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qfs_wrIDo2M/exelixis-inc-and-bristol-myers-squibb-co-gear-up-for-round-2-of-the-kidney-cancer-drug-battle-royale-cm845933,Take your seats investors The battle in first line advanced renal cell carcinoma the most common type of kidney cancer is about to begin In one corner weighing in at a market cap of 8 billion there s Exelixis NASDAQ EXEL and its tyrosine 160 kinase inhibitor
BMY,BMY:US,BBG000DQLV23,"This Small Cap Biotech Soars On Deals With Bristol-Myers, Roche",2017-09-14 20:20:18 +0000,http://finance.yahoo.com/r/34a3e7bb-8bdc-3ad3-8012-586aee24df46/bristol-myers-squibb-teams-with-small-cap-halozyme-in-cancer-immuno-oncology-drugs?src=A00220&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb is teaming up with Halozyme to test its immuno-oncology drugs as injections using the small cap firm&apos;s technology.
BMY,BMY:US,BBG000DQLV23,Halozyme to license drug delivery tech to Bristol-Myers a...,2017-09-14 19:43:00 +0000,https://finance.yahoo.com/video/halozyme-license-drug-delivery-tech-194300108.html?.tsrc=rss,Halozyme CEO Dr. Helen Torley speaks with CNBC's Meg Tirrell about the company using technology that makes it easier for patients to take medicine.
BMY,BMY:US,BBG000DQLV23,"Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale",2017-09-14 19:19:00 +0000,http://finance.yahoo.com/r/ef330264-d576-3c33-8519-fc4154094353/exelixis-inc-and-bristol-myers-squibb-co-gear-up-f.aspx?yptr=yahoo&.tsrc=rss,"Ironically, round three could have the companies fighting on the same side."
BMY,BMY:US,BBG000DQLV23,"Here's Why Halozyme Therapeutics, Inc. Is Soaring Today",2017-09-14 17:38:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l05rMtscnQ4/heres-why-halozyme-therapeutics-inc-is-soaring-today-cm845849,What happened Shares of Halozyme Therapeutics NASDAQ HALO a small cap biotech focused on creating products that help other drugs work more effectively rose by 16 as of 10 45 a m EDT on Thursday Investors can thank a trio of positive news announcements including two
BMY,BMY:US,BBG000DQLV23,Midday Update: Market Averages Mixed After Inflation Data Surprises to the Upside,2017-09-14 17:15:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1NRZVyyRL6s/midday-update-market-averages-mixed-after-inflation-data-surprises-to-the-upside-cm845869,The Dow Jones Industrial Average has erased earlier losses and moved into the plus column on gains in component stocks Boeing BA and United Technologies UTX while the S amp P 500 and Nasdaq continue to languish in negative territory weighed by losses in the technology and
BMY,BMY:US,BBG000DQLV23,"Here&apos;s Why Halozyme Therapeutics, Inc. Is Soaring Today",2017-09-14 15:45:00 +0000,http://finance.yahoo.com/r/d8b5953b-768c-3033-9317-cac620de7ce6/why-halozyme-therapeutics-inc-is-soaring-today.aspx?yptr=yahoo&.tsrc=rss,Shareholders can look at a trio of positive updates for today&apos;s big jump.
BMY,BMY:US,BBG000DQLV23,"Futures Pull-Back as Inflation Perks Up, Chinese Economy Slows",2017-09-14 13:37:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_gJLESCizhU/futures-pull-back-as-inflation-perks-up-chinese-economy-slows-cm845577,U S stock futures added to their earlier losses on the back of inflation data that indicated a measurable improvement in consumer prices The consumer price index increased by a greater than expected 0 4 in August while the core index was up 0 2 both of which could give the Federal
BMY,BMY:US,BBG000DQLV23,Health Care Sector Update for 09/14/2017: HALO,2017-09-14 13:37:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ss0GOav20sU/health-care-sector-update-for-09142017-halo-cm845576,Top Health care stocks Top Health care stocks JNJ flatJNJ flat PFE 0 2 PFE 0 2 ABT flatABT flat MRK 0 8 MRK 0 8 AMGN flatAMGN flat Health care shares were mainly unchanged in pre market trade on ThursdayHealth care shares were mainly unchanged in pre market trade on Thursday
BMY,BMY:US,BBG000DQLV23,"Halozyme to license drug delivery tech to Roche, Bristol-Myers",2017-09-14 12:00:58 +0000,https://finance.yahoo.com/news/halozyme-license-drug-delivery-tech-120058631.html?.tsrc=rss,"U.S. drugmaker Halozyme Therapeutics Inc  said on Thursday it would license its drug delivery  technology to Bristol-Myers Squibb Co and Swiss  drugmaker Roche in separate collaborations.  Shares of Halozyme rose 12.7 percent to $14.85 in premarket  trading after the company also raised its 2017 revenue forecast  as a result of the deals.  Halozyme will receive $105 million upfront from  Bristol-Myers, while Roche will pay $30 million upfront for  Halozyme's Enhanze technology that helps quicken the  administration of injectable drugs."
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-09-14 12:00:44 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120044180.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take,2017-09-14 12:00:00 +0000,http://finance.yahoo.com/r/3121d9c1-42c9-3f66-8da4-8af8c37e4d91/bristol-to-pay-halozyme-105-million-to-make-new-cancer-drugs-easier-to-take?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb will pay Halozyme $105 million for the right to use the smaller company's technology to develop easier-to-use versions of its best-selling cancer immunotherapy Opdivo, as well as as many as 11 other drugs in the larger company's research pipeline."
BMY,BMY:US,BBG000DQLV23,Halozyme's stock soars after Bristol-Myers license deal,2017-09-14 11:18:07 +0000,http://finance.yahoo.com/r/3a104c60-47e2-3a34-82b2-f44a0b044c95/Story.aspx?guid=9C294356-1197-4C3D-B292-D1E4AC612FF9&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Shares of Halozyme Therapeutics Inc. rocketed 13% in premarket trade Thursday, after the biotechnology company announced a license agreement with Bristol-Myers Squibb Co. , to develop subcutaneously administered ..."
BMY,BMY:US,BBG000DQLV23,Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers,2017-09-14 11:00:00 +0000,http://finance.yahoo.com/r/ee13ddbd-2f5e-364d-947d-897126906c20/immuno-oncology-deal-with-bristol-myers-could-boost-halozyme.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Pharma giant aims to develop cancer drug delivery technology. Halozyme shares are up more than 16% in pre-market trading.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology,2017-09-14 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-halozyme-enter-105900615.html?.tsrc=rss,"Bristol-Myers Squibb Company and Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement to develop subcutaneously administered Bristol-Myers Squibb immuno-oncology medicines using Halozyme’s ENHANZE® drug-delivery technology."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Partners With Halozyme; Gains Access To ENHANZE Technology,2017-09-14 07:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3gmVclnHuYY/bristolmyers-partners-with-halozyme-gains-access-to-enhanze-technology-20170914-00336,Bristol-Myers Partners With Halozyme; Gains Access To ENHANZE Technology
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces Dividend,2017-09-13 20:30:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-announces-dividend-203000848.html?.tsrc=rss,The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of thirty-nine cents per share on the $.10 par value Common Stock of the corporation.
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Names Karen Vousden, Ph.D. to Board of Directors",2017-09-13 20:15:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-names-karen-201500249.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced that its Board of Directors has elected Karen Vousden, Ph.D., to the Board, effective January 1, 2018. Dr. Vousden will serve as a member of the Science and Technology Committee of the Board of Directors."
BMY,BMY:US,BBG000DQLV23,Nektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate,2017-09-13 17:35:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ds8n9EB9KLM/nektar-nktr-starts-propel-combo-study-for-cancer-candidate-cm845217,Nektar Therapeutics NKTR announced initiation of phase I II PROPEL study to evaluate efficacy and safety of its lead immuno oncology candidate NKTR 214 in combination with Roche s RHHBY Tecentriq atezolizumab and Merck s MRK Keytruda pembrolizumab Notably the checkpoint
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Stock May Be Fully Valued,2017-09-13 17:35:00 +0000,http://finance.yahoo.com/r/d5833fda-db75-3eb5-ae0e-b21d8c3b9c0e/bristol-myers-stock-may-be-fully-valued-1505324153?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb (BMY:NYSE)  By Hilliard Lyons ($62.72, Sept. 12, 2017) With Bristol-Myers Squibb approaching our previously published two-year price target of $65, we believe shares are appropriately valued and are downgrading the stock to Neutral from Long-term Buy.  Investors should note Checkmate-227 will likely result in volatility for Bristol-Myers (BMY) stock.  As such, we remain comfortable with investors holding Bristol-Myers shares."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Reports Positive Results from Melanoma Study,2017-09-12 21:36:09 +0000,https://finance.yahoo.com/news/bristol-myers-reports-positive-results-213609426.html?.tsrc=rss,"Bristol-Myers Squibb Company (BMY) announced encouraging results from a phase III study, CheckMate -238, on Opdivo."
BMY,BMY:US,BBG000DQLV23,"Here's Why Advaxis, Inc. Stock Is Getting Pummeled Today",2017-09-12 18:36:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tGzTvBhMIiY/heres-why-advaxis-inc-stock-is-getting-pummeled-today-cm844513,What happened Shares of Advaxis Inc NASDAQ ADXS a clinical stage biotech developing novel cancer immunotherapies are sinking after the company provided a business update along with a third quarter earnings report after the bell yesterday Investors weren t impressed with
BMY,BMY:US,BBG000DQLV23,"Company News For Sep 12, 2017",2017-09-12 16:39:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t60zBhtaJgc/company-news-for-sep-12-2017-cm844435,Shares of Teva Pharmaceutical Industries Ltd TEVA surged 19 4 after the company announced Kare Schultz as its new chief executive officer Bristol Myers Squibb Co s BMY shares increased 0 2 after the company reported positive results from studies conducted on its
BMY,BMY:US,BBG000DQLV23,iShares Core Dividend Growth ETF Experiences Big Inflow,2017-09-12 16:37:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x0f8l8L2Urg/ishares-core-dividend-growth-etf-experiences-big-inflow-cm844418,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Core Dividend Growth ETF Symbol DGRO where we have detected an approximate 45 0 million dollar inflow that s a 2 2 increase week over week
BMY,BMY:US,BBG000DQLV23,"Company News For Sep 12, 2017",2017-09-12 14:17:02 +0000,https://finance.yahoo.com/news/company-news-sep-12-2017-141702659.html?.tsrc=rss,"Companies in the news are: TEVA,BMY,EFX,FB"
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-09-12 12:00:47 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120047170.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,"Here's Why Idera Pharmaceuticals, Inc. Is Surging Today",2017-09-11 17:36:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gkLpY-b7jDc/heres-why-idera-pharmaceuticals-inc-is-surging-today-cm843860,What happened Shares of Idera Pharmaceuticals Inc NASDAQ IDRA a clinical stage biotech advancing novel therapies for skin related diseases are getting a bump after the company presented trial results at the annual European Society for Medical Oncology conference on Sunday
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-09-11 14:05:46 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120045859.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,Cancer immunotherapy proves itself in earlier-stage disease,2017-09-11 09:32:20 +0000,https://finance.yahoo.com/news/cancer-immunotherapy-proves-itself-earlier-093220840.html?.tsrc=rss,"Cancer doctors are widening the  net for immunotherapy, a hot new class of drugs that enlist the  body's defences in the fight against tumours.  The latest research shared with 23,000 experts at Europe's  top oncology meeting shows how medicines that have already  delivered durable benefits in metastatic disease can also work  well at an earlier stage.  The findings promise to expand the market for established  immuno-oncology (I-O) drugs from companies like Merck,  Bristol-Myers Squibb and Roche, while opening up  a window for relative latecomers such as AstraZeneca."
BMY,BMY:US,BBG000DQLV23,"New Hope For AZN's Old Drug, More About BMY's Opdivo, IMDZ On Watch",2017-09-11 00:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YSrwGw-FWiI/new-hope-for-azns-old-drug-more-about-bmys-opdivo-imdz-on-watch-20170911-00011,"New Hope For AZN's Old Drug, More About BMY's Opdivo, IMDZ On Watch"
BMY,BMY:US,BBG000DQLV23,Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Study,2017-09-10 22:11:00 +0000,https://finance.yahoo.com/news/opdivo-nivolumab-demonstrates-superior-recurrence-221100523.html?.tsrc=rss,Bristol-Myers Squibb Company announced today that treatment with Opdivo 3 mg/kg resulted in a significant improvement in recurrence-free survival compared to Yervoy 10 mg/kg in patients with stage IIIb/c or stage IV melanoma following complete surgical resection.
BMY,BMY:US,BBG000DQLV23,"After melanoma surgery, Bristol's Opdivo offers new care standard",2017-09-10 22:05:00 +0000,https://finance.yahoo.com/news/melanoma-surgery-bristols-opdivo-offers-220500760.html?.tsrc=rss,"Bristol-Myers Squibb's  immunotherapy drug Opdivo is a better and safer option than its  older medicine Yervoy for treating melanoma patients who have  had surgery to remove disease, researchers reported on Monday.  The finding represents an advance for so-called PDx drugs in  treating cancer at an earlier stage, before it has spread around  the body.  At present, the use of such drugs, which help the  immune system fight tumours, is confined to metastatic disease."
BMY,BMY:US,BBG000DQLV23,Bristol's drug cocktail cuts kidney cancer death risk 37 pct,2017-09-10 17:00:38 +0000,https://finance.yahoo.com/news/bristols-drug-cocktail-cuts-kidney-170038246.html?.tsrc=rss,"A combination of two  Bristol-Myers Squibb immunotherapy drugs cut the risk of  death by 37 percent in a key group of kidney cancer patients,  data from a closely watched clinical trial showed on Sunday.  In August, Bristol-Myers reported Opdivo and Yervoy failed  to significantly outperform standard care in checking cancer  progression, although there was a trend towards benefit.  The latest result is important for doctors and investors  alike, not only because it opens up a new option for treating  kidney cancer but also because it helps validate the idea of  combining two different kinds of immunotherapy."
BMY,BMY:US,BBG000DQLV23,Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma in Phase 3 CheckMate -214 Trial,2017-09-10 15:55:00 +0000,https://finance.yahoo.com/news/opdivo-plus-yervoy-combination-demonstrated-155500582.html?.tsrc=rss,"Bristol-Myers Squibb Company announced today results from the Phase 3 CheckMate -214 trial evaluating Opdivo plus Yervoy versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma , including data on key subgroups."
BMY,BMY:US,BBG000DQLV23,Bristol kidney cancer drug cut death risk 37 pct in key patients,2017-09-10 15:55:00 +0000,https://finance.yahoo.com/news/bristol-kidney-cancer-drug-cut-155500705.html?.tsrc=rss,"A combination of two  Bristol-Myers Squibb immunotherapy drugs cut the risk of  death by 37 percent in a key group of kidney cancer patients,  data from a closely watched clinical trial showed on Sunday.  The result is important for doctors and investors alike, not  only because it opens up a new option for treating kidney cancer  but also because it helps validate the idea of combining two  different kinds of immunotherapy.  Opdivo works by blocking the activity of a protein called  PD-1, while Yervoy tackles another called CTLA-4."
BMY,BMY:US,BBG000DQLV23,"Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors",2017-09-10 12:50:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SW5oi9U9BBE/why-exelixis-inc-could-be-a-gold-mine-for-growth-investors-cm843374,Exelixis NASDAQ EXEL was one of the top biotech stocks of 2016 It s also one of the best biotech stocks so far this year However Exelixis shares have pulled back in recent days primarily due to Bristol Myers Squibb s NYSE BMY announcement that it was halting
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Announces Results From The Phase 3 CheckMate,2017-09-10 12:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PyWDPndf_14/bristolmyers-announces-results-from-the-phase-3-checkmate-20170910-00026,Bristol-Myers Announces Results From The Phase 3 CheckMate
BMY,BMY:US,BBG000DQLV23,3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?,2017-09-09 15:50:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OxOK_C3cycc/3-biotech-stocks-that-skyrocketed-this-week-can-they-go-higher-cm843317,Every biotech company goes into a clinical study with great hopes and often great fears as well There s no guarantee that all will go well All the time and money poured into an experimental drug can go down the drain with bad results But good results mean an entirely different
BMY,BMY:US,BBG000DQLV23,Exelixis Recovers From Bristol-Inspired Pitfall In Kidney Cancer,2017-09-08 19:22:42 +0000,http://finance.yahoo.com/r/11b37dc4-dd13-3797-a422-9138423f29e7/exelixis-recovers-from-bristol-inspired-pitfall-in-kidney-cancer?src=A00220&yptr=yahoo&.tsrc=rss,Exelixis recovered Friday from a pitfall earlier in the week on updated guidelines for kidney cancer treatment.
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers' Opdivo Study Meets Early Success, Stock Up",2017-09-08 15:55:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SVbtogYJDoM/bristol-myers-opdivo-study-meets-early-success-stock-up-cm842946,Shares of Bristol Myers Squibb Company BMY gained about 5 after the company ended its phase III combination study CheckMate 214 earlier than expected after it met its co primary endpoint The phase III study evaluated Opdivo plus Yervoy in patients with previously untreated advanced
BMY,BMY:US,BBG000DQLV23,"2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August",2017-09-08 15:54:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VrMH7AIeGws/2-big-reasons-exelixis-inc-added-626-million-to-its-market-cap-in-august-cm842952,What happened Shares of Exelixis NASDAQ EXEL a biotech company primarily focused on developing drugs to treat cancer rallied more than 2 per share during the month of August according to data from S amp P Global Market Intelligence adding 626 million to
BMY,BMY:US,BBG000DQLV23,"2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August",2017-09-08 14:34:00 +0000,http://finance.yahoo.com/r/124805ac-4f3f-32c5-aa2d-c0f4b8ed8d4b/2-big-reasons-exelixis-inc-added-626-million-to-it.aspx?yptr=yahoo&.tsrc=rss,Cabometyx remains the key to a higher valuation.
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-09-08 14:21:37 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-142137504.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' (BMY) Opdivo's Myeloma Studies Put on Hold,2017-09-08 13:54:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YyNYAqFlZGQ/bristol-myers-bmy-opdivos-myeloma-studies-put-on-hold-cm842885,Bristol Myers Squibb Company BMY announced that the FDA put a partial clinical hold on three clinical trials CA209602 CheckMate 602 CA209039 CheckMate 039 and CA204142 The trials are investigating Opdivo based combinations in patients with relapsed or refractory multiple myeloma The
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018",2017-09-08 13:54:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gWEYvBsFK_k/pharma-stock-roundup-lilly-to-cut-jobs-streamline-operations-nvs-ceo-to-step-down-in-2018-cm842878,There were quite a few important developments this week with Eli Lilly and Company LLY announcing that it is streamlining its operations and cutting down its workforce as it focuses on developing new medicines and improving its cost structure Meanwhile Novartis NVS announced that its CEO
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers&apos; Opdivo Study Meets Early Success, Stock Up",2017-09-08 13:45:01 +0000,https://finance.yahoo.com/news/bristol-myers-apos-opdivo-study-134501899.html?.tsrc=rss,Bristol-Myers&apos; (BMY) phase III study evaluating Opdivo plus Yervoy successfully met its co-primary endpoints and thus was stopped earlier than expected.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers&apos; (BMY) Opdivo&apos;s Myeloma Studies Put on Hold,2017-09-08 12:20:12 +0000,https://finance.yahoo.com/news/bristol-myers-apos-bmy-opdivo-122012471.html?.tsrc=rss,"Bristol-Myers Squibb Company (BMY) announced that the FDA put a partial clinical hold on three clinical trials, investigating Opdivo-based combinations in patients with relapsed or refractory multiple myeloma."
BMY,BMY:US,BBG000DQLV23,Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock,2017-09-08 11:51:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zKuAyp3NiX0/good-news-for-opdivo-shows-why-you-shouldnt-give-up-on-bristol-myers-squibb-stock-cm842738,Bristol Myers Squibb NYSE BMY investors might have been just a bit worried on Wednesday After all the U S Food and Drug Administration FDA had just placed a partial clinical hold on three clinical trials for Opdivo in combination with other drugs in treating multiple
BMY,BMY:US,BBG000DQLV23,Good News for Opdivo Shows Why You Shouldn&apos;t Give Up on Bristol-Myers Squibb Stock,2017-09-08 10:08:00 +0000,http://finance.yahoo.com/r/5cb1860f-309b-3f80-aa0e-b0e87141fa74/good-news-for-opdivo-shows-why-you-shouldnt-give-u.aspx?yptr=yahoo&.tsrc=rss,An early halt to a late-stage study of Opdivo points to the potential for Bristol-Myers Squibb in the years ahead.
BMY,BMY:US,BBG000DQLV23,Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer,2017-09-08 09:30:00 +0000,https://finance.yahoo.com/news/two-pivotal-opdivo-nivolumab-trials-093000124.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced three-year overall survival data from CheckMate -017 and CheckMate -057, two pivotal Phase 3 randomized studies evaluating Opdivo versus docetaxel in patients with previously treated metastatic non-small cell lung cancer ."
BMY,BMY:US,BBG000DQLV23,Stocks Flashing Renewed Technical Strength: Bristol-Myers Squibb,2017-09-08 07:00:00 +0000,http://finance.yahoo.com/r/fc51eb20-ccb7-3ea6-9669-abc636170539/stocks-flashing-renewed-technical-strength-bristol-myers-squibb?src=A00220&yptr=yahoo&.tsrc=rss,A Relative Strength Rating upgrade for Bristol-Myers Squibb shows improving technical performance.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers: Phase 3 Data Reinforce Sustained Survival Benefit Of Opdivo,2017-09-08 05:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r1ACvbinZv4/bristolmyers-phase-3-data-reinforce-sustained-survival-benefit-of-opdivo-20170908-00141,Bristol-Myers: Phase 3 Data Reinforce Sustained Survival Benefit Of Opdivo
BMY,BMY:US,BBG000DQLV23,3 Stocks Soaring Today,2017-09-07 22:10:19 +0000,https://finance.yahoo.com/news/3-stocks-soaring-today-221019584.html?.tsrc=rss,Big moves on positive news
BMY,BMY:US,BBG000DQLV23,Why Clovis Oncology Fell 7.1% in August,2017-09-07 21:52:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L-aYpYURTjk/why-clovis-oncology-fell-71-in-august-cm842619,What happened Shares of Clovis Oncology NASDAQ CLVS a commercial stage biotech focused on cancer fell more than 7 in August according to data from S amp P Global Market Intelligence The decline was owed to the company sharing good and bad news with investors during in
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Completes Previously Announced Acquisition of IFM Therapeutics,2017-09-07 20:30:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-completes-previously-203000397.html?.tsrc=rss,Bristol-Myers Squibb Company today announced that it has completed the previously announced planned acquisition of IFM Therapeutics.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb: And Just Like That…,2017-09-07 18:00:00 +0000,http://finance.yahoo.com/r/4c368ccd-949e-30a5-9ccd-c61e05ae7f75/bristol-myers-squibb-and-just-like-that-1504807240?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,Shares of Bristol-Myers Squibb (BMY) have jumped to a new 52-week high today after reporting that a study looking at a combination of two drugs in the treatment of renal-cell cancer worked well enough ...
BMY,BMY:US,BBG000DQLV23,FDA widens holds on immunotherapy combination blood cancer trials,2017-09-07 17:07:26 +0000,https://finance.yahoo.com/news/fda-puts-celgenes-multiple-cancer-122706745.html?.tsrc=rss,"U.S. health regulators stopped five blood  cancer trials testing AstraZeneca Plc's immunotherapy  Imfinzi in combination with Celgene Corp medicines from  accepting new patients  and halted another study entirely, the  companies said on Thursday.  The Food and Drug Administration's decisions stem from  safety concerns uncovered in similar blood cancer trials of  Merck & Co Inc's rival Keytruda medicine in combination  with widely used multiple myeloma drugs that Celgene sells."
BMY,BMY:US,BBG000DQLV23,AbbVie Submits NDA for Endometriosis Candidate to the FDA,2017-09-07 16:54:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J_4ps9YXxWQ/abbvie-submits-nda-for-endometriosis-candidate-to-the-fda-cm842394,AbbVie Inc ABBV and partner Neurocrine Biosciences announced that the new drug application NDA for their pipeline candidate elagolix has been submitted to the FDA AbbVie is looking to get elagolix approved as an oral medicine for the management of pain associated with endometriosis
BMY,BMY:US,BBG000DQLV23,"Notable Thursday Option Activity: FEYE, TWOU, BMY",2017-09-07 16:53:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vcdfS6a16lM/notable-thursday-option-activity-feye-twou-bmy-cm842374,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in FireEye Inc Symbol FEYE where a total of 27 201 contracts have traded so far representing approximately 2 7 million underlying shares That amounts to about 73 of FEYE s
BMY,BMY:US,BBG000DQLV23,Stocks Close Roughly Flat Following Lackluster Session - U.S. Commentary,2017-09-07 16:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4vHzKR1idZ8/stocks-close-roughly-flat-following-lackluster-session--us-commentary-20170907-01440,Stocks Close Roughly Flat Following Lackluster Session - U.S. Commentary
BMY,BMY:US,BBG000DQLV23,"S&P 500 Movers: LEG, MA",2017-09-07 15:54:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yHw0FfgQUOk/sp-500-movers-leg-ma-cm842292,In early trading on Thursday shares of Mastercard topped the list of the day s best performing components of the S amp P 500 index trading up 3 3 Year to date Mastercard registers a 32 9 gain And the worst performing S amp P 500 component thus far on the day is Leggett amp
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers kidney cancer drug meets early success, study stopped",2017-09-07 12:58:47 +0000,https://finance.yahoo.com/news/bristol-myers-kidney-cancer-drug-115343614.html?.tsrc=rss,"Bristol-Myers Squibb Co said on  Thursday the success of its combination therapy to improve  overall survival in kidney cancer patients helped it end the  trial early, despite having reported mixed results on other main  goals earlier.  The drugmaker said a combination of Opdivo and Yervoy, its  two main drugs, showed superior overall survival rates in  previously untreated patients with advanced or metastatic renal  cell carcinoma, than those given a standard-of-care drug.  Last month, Bristol-Myers said the combination treatment had  failed to improve progression-free survival in patients, but had  succeeded in reducing the size of their tumors."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb says late-stage cancer drug combination study met endpoints and will be stopped early,2017-09-07 11:23:08 +0000,http://finance.yahoo.com/r/232f1590-1b5d-3d63-93b7-70c28fa781fc/Story.aspx?guid=481C6454-0FF0-4362-B3F5-F08552FAD388&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb Co. said early Thursday that a late-stage clinical trial for cancer drugs Opdivo and Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma showed ...
BMY,BMY:US,BBG000DQLV23,Bristol-Myers kidney cancer drug meets main goal of late-stage trial,2017-09-07 11:22:23 +0000,https://finance.yahoo.com/news/bristol-myers-kidney-cancer-drug-112223183.html?.tsrc=rss,"Bristol-Myers Squibb Co said on  Thursday its combination drug to treat a type of kidney cancer  met one of the main goals of overall survival in a late-stage  study.  The trial was testing a combination of Opdivo and Yervoy,  Bristol-Myers' top drugs, in previously untreated patients with  advanced or metastatic renal cell carcinoma.  Last month, the company said the combination treatment had  failed to improve progression-free survival in patients in the  same late-stage trial, but had met one of the other main goals."
BMY,BMY:US,BBG000DQLV23,CheckMate -214 Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma,2017-09-07 10:59:00 +0000,https://finance.yahoo.com/news/checkmate-214-study-evaluating-opdivo-105900824.html?.tsrc=rss,"Bristol-Myers Squibb Company announced today that a Phase 3 study evaluating Opdivo plus Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma met its co-primary endpoint, demonstrating superior overall survival compared to sunitinib in intermediate- and poor-risk patients."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Announce Results for Third Quarter 2017 on October 26,2017-09-07 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-announce-results-105900638.html?.tsrc=rss,"Bristol-Myers Squibb Company will announce results for the third quarter of 2017 on Thursday, October 26, 2017. During a conference call at 10:30 a.m. EDT on October 26, company executives will review financial information and will address inquiries from investors and analysts."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb (BMY) Has Risen To A New High On Phase 3 Study News,2017-09-07 10:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cbz7eXxiQio/bristolmyers-squibb-bmy-has-risen-to-a-new-high-on-phase-3-study-news-20170907-00940,Bristol-Myers Squibb (BMY) Has Risen To A New High On Phase 3 Study News
BMY,BMY:US,BBG000DQLV23,Bristol-Myers: Phase 3 Study Of Opdivo Plus Yervoy Met Co-primary Endpoint,2017-09-07 07:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T2TIIsnJcug/bristolmyers-phase-3-study-of-opdivo-plus-yervoy-met-coprimary-endpoint-20170907-00422,Bristol-Myers: Phase 3 Study Of Opdivo Plus Yervoy Met Co-primary Endpoint
BMY,BMY:US,BBG000DQLV23,Bristol-Myers says FDA places partial hold on Opdivo myeloma trials,2017-09-06 22:17:14 +0000,https://finance.yahoo.com/news/bristol-myers-says-fda-places-221714804.html?.tsrc=rss,"The U.S. Food and Drug Administration has  placed a partial hold on three clinical trials testing  Bristol-Myers Squibb's immunotherapy Opdivo in  combination with other medicines for multiple myeloma due to  risks seen in similar studies involving a rival drug, the  company said on Wednesday.  Patients with relapsed multiple myeloma taking part in the  trials who were experiencing clinical benefit will be allowed to  continue treatment, but no new patients will be enrolled for  now, Bristol Myers said.  The FDA in July placed a hold on three Merck & Co  multiple myeloma trials testing its Keytruda along with other  standard medicines for the blood cancer following reports of  more deaths in patients who received Keytruda than in the  control arms of the studies."
BMY,BMY:US,BBG000DQLV23,4 Drug Stocks Worth a Look on Promising Cancer Pipeline,2017-09-06 16:55:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KlT1ZASm774/4-drug-stocks-worth-a-look-on-promising-cancer-pipeline-cm841764,Cancer is the second most common cause of death in the U S preceded only by heart disease The traditional cancer treatments include surgery radiation and chemotherapy However immunotherapy gene therapy and other new novel therapies are being developed to improve supplement or
BMY,BMY:US,BBG000DQLV23,Merck & Co snaps up 3 yr-old German biotech firm for up to $550 mln,2017-09-06 13:57:58 +0000,https://finance.yahoo.com/news/merck-co-snaps-3-yr-135758889.html?.tsrc=rss,"U.S. pharma group Merck & Co  has acquired 3-1/2 year old German biotech start-up  Rigontec for up to 464 million euros ($554 million), adding a  new approach to its development of drugs that spur the immune  system to attack tumours.  Merck, maker of promising cancer immunotherapy Keytruda,  agreed to pay 115 million euros upfront for the Munich-based  firm and up to 349 million euros on top, depending on regulatory  and commercial achievements, the two companies said in a  statement on Wednesday.  Rigontec just started testing its most advanced compound  RGT100 on humans in May, banking on a mechanism of action called  RIG-I which is designed to trigger a long-term response of the  innate immune system, the body's first line of defense against  infections."
BMY,BMY:US,BBG000DQLV23,7 Medical Conditions That Will Be Lining Big Pharma's Pockets by 2020,2017-09-06 11:50:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_PMPntqAH_g/7-medical-conditions-that-will-be-lining-big-pharmas-pockets-by-2020-cm841383,Image source Getty Images Imagine a stack of dollar bills reaching from the ground to more than 95 000 miles into the sky nearly four tenths of the way to the moon That stack would total 1 4 trillion 160 It s a staggering number It s also how much will be spent worldwide
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Employees Ride Across the U.S. to Raise Money to Support Cancer Research by Stand Up To Cancer,2017-09-06 11:00:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-employees-ride-110000839.html?.tsrc=rss,"The first of seven teams of Bristol-Myers Squibb employees mounted their bikes in Cannon Beach, OR, today to kick off the 2017 Coast 2 Coast 4 Cancer Ride. Ninety-three novice riders will bike a total of nearly 2,800 miles during the 21-day mission to raise money and awareness for Stand Up To Cancer’s innovative cancer research programs that bring together collaborative teams of scientific researchers ..."
BMY,BMY:US,BBG000DQLV23,IBD Rating Upgrades: Bristol-Myers Squibb Flashes Improved Relative Price Strength,2017-09-06 07:00:00 +0000,http://finance.yahoo.com/r/38a9b193-b986-3ff7-847e-841b8324737e/ibd-rating-upgrades-bristol-myers-squibb-flashes-improved-relative-price-strength?src=A00220&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb shows improving price performance, earning an upgrade to its IBD Relative Strength Rating"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference,2017-09-05 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-part-morgan-105900564.html?.tsrc=rss,"Bristol-Myers Squibb Company will take part in the Morgan Stanley 2017 Global Health Care Conference on Monday, September 11, 2017, in New York. Giovanni Caforio, M.D., chairman and chief executive officer will make formal remarks about the company and answer questions at 2:15 p.m."
BMY,BMY:US,BBG000DQLV23,Key FDA Regulatory Events to Watch Out for in Sep 2017,2017-09-04 13:50:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ytCH56SlVIQ/key-fda-regulatory-events-to-watch-out-for-in-sep-2017-cm840710,The FDA which approved 22 novel drugs last year has given its approval to 31 drugs so far in 2017 including five in August Key approvals this year include Gilead s Vosevi hepatitis C virus Puma s Nerlynx to reduce the risk of breast cancer returning J amp J s Tremfya moderate to
BMY,BMY:US,BBG000DQLV23,Key FDA Regulatory Events to Watch Out for in Sep 2017,2017-09-04 12:05:12 +0000,https://finance.yahoo.com/news/key-fda-regulatory-events-watch-120512052.html?.tsrc=rss,Will the FDA follow the recommendation of its advisory panel and give its nod to Amgen (AMGN) and Mylan&apos;s biosimilars?
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-09-04 12:01:20 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120120288.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-09-02 12:06:10 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120610239.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda,2017-09-01 23:48:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g0_TUDGoc5w/incyte-incy-reports-positive-data-on-epacadostatkeytruda-cm840524,Incyte Corporation INCY announced that the European Society for Medical Oncology ESMO published an abstract containing new and updated data from the ongoing phase I II ECHO 202 trial on epacadostat The ECHO 202 study NCT02178722 is evaluating the safety and efficacy of Incyte s
BMY,BMY:US,BBG000DQLV23,Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda,2017-09-01 21:32:09 +0000,https://finance.yahoo.com/news/incyte-incy-reports-positive-data-213209189.html?.tsrc=rss,Incyte Corporation (INCY) announced new and updated data from the ongoing phase I/II ECHO-202 trial on pipeline candidate epacadostat with Keytruda.
BMY,BMY:US,BBG000DQLV23,Top Buys by Directors: Samuels II's $335.6K Bet on BMY,2017-09-01 18:51:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mivbJrc9VNY/top-buys-by-directors-samuels-iis-3356k-bet-on-bmy-cm840419,The directors of a company tend to have a unique inside view into the business so when directors make major buys investors are wise to take notice Presumably the only reason a director of a company would choose to take their hard earned cash and use it to buy stock in the open market is
BMY,BMY:US,BBG000DQLV23,BMY Crosses Above Average Analyst Target,2017-09-01 13:51:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1nu7kGQr4ig/bmy-crosses-above-average-analyst-target-cm840119,In recent trading shares of Bristol Myers Squibb Co Symbol BMY have crossed above the average analyst 12 month target price of 60 25 changing hands for 60 48 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-09-01 12:01:28 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120128476.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,Eli Lilly’s Valuations after Its 2Q17 Earnings,2017-08-31 19:02:29 +0000,http://finance.yahoo.com/r/3c187d36-78e5-35ef-a953-453f81dbec46/eli-lillys-valuations-after-its-2q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly (LLY) surpassed Wall Street estimates in 2Q17, reporting earnings per share of $1.11 on revenues of ~$5.8 billion. Analysts estimated that the company would report EPS of $1.05 on revenues of ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Is Primed for an Upside Breakout,2017-08-31 13:28:00 +0000,http://finance.yahoo.com/r/9c634384-e208-3594-b4c5-b5707ae46b26/bristol-myers-squibb-primed-upside-breakout?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Prices have test $60 several times, but this looks like the real deal."
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-08-31 12:01:25 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120125359.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Immunoscience Products in 2Q17,2017-08-31 11:36:56 +0000,http://finance.yahoo.com/r/f5a82096-de57-3709-b3c7-770ce68b03d3/bristol-myers-squibbs-immunoscience-products-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Orencia revenues rose to $650.0 million in 2Q17, a 10.0% rise compared to $593 million in 2Q16."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Data at ESMO 2017 Demonstrate Company’s Innovative Research Approach to Treating Cancer from All Angles,2017-08-30 22:05:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-data-esmo-220500385.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced more than 60 presentations, including seven late-breaking abstracts, from its Oncology portfolio will be featured at the European Society for Medical Oncology 2017 Congress in Madrid, Spain, September 8-12."
BMY,BMY:US,BBG000DQLV23,5 Greatest Health-Care Stocks of All Time,2017-08-30 20:48:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wWPnuDfM0Qc/5-greatest-health-care-stocks-of-all-time-cm839395,Health care stocks have always benefited from the powerful demographic forces of steady population growth and longer life expectancy Indeed the population of the U S has more than tripled over the past 100 years And the average American can expect to live to the age of 79 up from 51
BMY,BMY:US,BBG000DQLV23,"Griffin Asset Management, Inc. Buys NextEra Energy Inc, Exxon Mobil Corp, Bristol-Myers Squibb ...",2017-08-30 16:48:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1asrB1ft9rk/griffin-asset-management-inc-buys-nextera-energy-inc-exxon-mobil-corp-bristol-myers-squibb-cm839271,Griffin Asset Management Inc New Purchases DTE AJG NJR DUK SRE PPL SCG WGL PNC AEP Added Positions NEE XOM BMY D CVX VZ JPM T AAPL WMT Reduced Positions JNJ MSFT BAX SYY PEP GE BRK A MMM DD PG Sold Out AIG ESRX COST
BMY,BMY:US,BBG000DQLV23,Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe,2017-08-30 15:54:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uq0Y531Kt1M/pfizers-snda-for-bosulif-accepted-in-the-us-and-europe-cm839183,Pfizer Inc PFE and partner Avillion announced that a supplemental New Drug Application sNDA for Bosulif has been accepted and granted priority review by the FDA We remind investors that Bosulif is currently approved for the treatment of chronic accelerated or blast phase
BMY,BMY:US,BBG000DQLV23,Merck: Heartbreak Over A Cholesterol Drug,2017-08-30 15:46:00 +0000,http://finance.yahoo.com/r/c7945d4c-67f3-3280-aac8-18b2e25cb635/merck-heartbreak-over-a-cholesterol-drug-1504108016?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Is it still a good time to buy Merck & Co. (MRK)?  In fact, Merck appears poised to become the leader in the new market for immuno-cancer therapies that use the body’s own defense system to battle malignant cells.  Thanks to underwhelming results from a big study of its experimental cholesterol drug anacetrapib, Merck’s fortunes seem more attached than ever to those cancer drugs."
BMY,BMY:US,BBG000DQLV23,Performance of Bristol-Myers Squibb’s Eliquis in 2Q17,2017-08-30 14:37:00 +0000,http://finance.yahoo.com/r/2ba2e173-2b96-3f3a-a54e-e5c8915a6b1a/performance-of-bristol-myers-squibbs-eliquis-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol Myers Squibb’s (BMY) cardiovascular portfolio includes the blockbuster drug Eliquis.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Virology Products in 2Q17,2017-08-30 13:08:10 +0000,http://finance.yahoo.com/r/5dc6d6b9-c2ba-3845-9fb1-1882aba1e337/bristol-myers-squibbs-virology-products-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb’s (BMY) virology products portfolio includes products for the treatment of chronic virus infections.
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-08-30 12:01:12 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120112638.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,Performance of Bristol-Myers Squibb’s Opdivo in 2Q17,2017-08-30 11:37:19 +0000,http://finance.yahoo.com/r/8917c476-d9b5-39d2-9823-ff93a532ca03/performance-of-bristol-myers-squibbs-opdivo-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol Myers Squibb’s (BMY) Opdivo reported revenues of $1.2 billion during 2Q17, a rise of 42.0% compared to $840.0 million in 2Q16."
BMY,BMY:US,BBG000DQLV23,Here's Why AVEO Pharmaceuticals Lost as Much as 19% Today,2017-08-29 21:50:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eRHDwylcE-4/heres-why-aveo-pharmaceuticals-lost-as-much-as-19-today-cm838840,What happened Shares of biopharma AVEO Pharmaceuticals NASDAQ AVEO sank 19 Tuesday after investors had more time to digest Monday s news That was the company announced that the drug Fotivda gained marketing approval in the European Union for treating advanced renal
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Oncology Products in 2Q17,2017-08-29 20:35:56 +0000,http://finance.yahoo.com/r/eacd7f7b-2afb-386f-89cb-32da328fc3ed/bristol-myers-squibbs-oncology-products-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb (BMY) reported a rise in sales for oncology drugs Opdivo, Empliciti, Sprycel, and Yervoy in 2Q17."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Revenues in 2Q17,2017-08-29 19:05:43 +0000,http://finance.yahoo.com/r/2ad0c627-b10a-3453-9834-40cd89df70df/bristol-myers-squibbs-revenues-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb (BMY) surpassed Wall Street analysts’ estimate for 2Q17 revenues, reporting $5.14 billion compared to the estimate of $5.09 billion."
BMY,BMY:US,BBG000DQLV23,Pfizer Presents Encouraging Eliquis Results in NVAF Patients,2017-08-29 17:51:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u_CNTXBbgbw/pfizer-presents-encouraging-eliquis-results-in-nvaf-patients-cm838728,Pfizer Inc PFE and partner Bristol Myers Squibb Company BMY presented findings from a phase IV study on Eliquis which demonstrated the oral anticoagulation s potential in achieving and maintaining normal heart rhythm cardioversion The study EMANATE compared Eliquis with standard of
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Valuation after 2Q17 Earnings,2017-08-29 17:12:58 +0000,http://finance.yahoo.com/r/6187a854-9ad1-3969-b977-291393c7d80a/bristol-myers-squibbs-valuation-after-2q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb (BMY) met Wall Street analysts’ estimate for EPS at $0.74. It also surpassed the estimates for revenues.
BMY,BMY:US,BBG000DQLV23,Pfizer Presents Encouraging Eliquis Results in NVAF Patients,2017-08-29 15:45:03 +0000,https://finance.yahoo.com/news/pfizer-presents-encouraging-eliquis-results-154503751.html?.tsrc=rss,Pfizer (PFE) and partner Bristol-Myers presented data on Eliquis which showed the potential of the drug in reducing stroke and systemic embolism in NVAF patients undergoing cardioversion.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Pfizer Alliance Announce Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Elderly Patients with Non-Valvular Atrial Fibrillation,2017-08-29 12:21:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-pfizer-alliance-122100205.html?.tsrc=rss,"Bristol-Myers Squibb Company and Pfizer Inc. today announced findings from a real-world data analysis of the U.S. Humana database, in which treatment with Eliquis® was associated with a significantly lower risk of stroke/systemic embolism and lower rates of major bleeding compared to warfarin in patients aged 65 years and older with non-valvular atrial fibrillation ."
BMY,BMY:US,BBG000DQLV23,Biotech Stocks Facing FDA Decision In September,2017-08-29 08:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eLoYmPQkXWM/biotech-stocks-facing-fda-decision-in-september-20170829-00502,Biotech Stocks Facing FDA Decision In September
BMY,BMY:US,BBG000DQLV23,"KMDA Slips On AAT Therapy Concerns, ETRM Gains Weight, LJPC On Watch",2017-08-29 04:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f4dzkIsGmGE/kmda-slips-on-aat-therapy-concerns-etrm-gains-weight-ljpc-on-watch-20170829-00154,"KMDA Slips On AAT Therapy Concerns, ETRM Gains Weight, LJPC On Watch"
BMY,BMY:US,BBG000DQLV23,"KMDA Slips On AAT Therapy Concerns, ETRM Gains Weight, LJPC On Watch",2017-08-29 04:56:00 +0000,,"KMDA Slips On AAT Therapy Concerns, ETRM Gains Weight, LJPC On Watch"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Daiichi Sankyo to test Opdivo combo for cancers",2017-08-28 21:06:46 +0000,https://finance.yahoo.com/news/bristol-myers-daiichi-sankyo-test-210646349.html?.tsrc=rss,"Bristol-Myers Squibb Co and  Daiichi Sankyo said they were evaluating a combination  of Bristol-Myers' immuno-oncology drug, Opdivo, with the  Japanese company's experimental drug in patients with breast and  bladder cancers.  Opdivo belongs to a new class of medicines called PD-1  checkpoint inhibitors, which work by taking the brakes off the  immune system.  The combination therapy involves Daiichi Sankyo's DS-8201,  which delivers chemotherapy directly to target cancer cells."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Daiichi Sankyo to test combo therapy for breast, bladder cancers",2017-08-28 20:40:01 +0000,https://finance.yahoo.com/news/bristol-myers-daiichi-sankyo-test-204001069.html?.tsrc=rss,"Bristol-Myers Squibb Co and Daiichi Sankyo said they would collaborate on a clinical trial to evaluate a combination of Bristol-Myers' immuno-oncology drug, Opdivo, with the Japanese company's experimental ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers,2017-08-28 20:01:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-daiichi-sankyo-200100381.html?.tsrc=rss,"Bristol-Myers Squibb Company and Daiichi Sankyo Company, Limited today announced a collaborative clinical trial to evaluate the combination of Bristol-Myers Squibb’s immunotherapy Opdivo and Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 in HER2-expressing metastatic breast and urothelial cancers."
BMY,BMY:US,BBG000DQLV23,A Look at Johnson & Johnson’s Post-2Q17 Valuation,2017-08-28 18:59:09 +0000,http://finance.yahoo.com/r/6d6410be-034a-38e1-a1b0-341a26fef7ac/a-look-at-johnson-johnsons-post-2q17-valuation?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Pfizer Present Investigational Eliquis® (apixaban) Data for Patients with Non-Valvular Atrial Fibrillation (NVAF) Undergoing Cardioversion,2017-08-28 09:00:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-pfizer-present-090000880.html?.tsrc=rss,"Bristol-Myers Squibb Company and Pfizer Inc. today presented findings from EMANATE , a Phase 4 clinical trial, during a late-breaking hot line presentation at the ESC Congress 2017, organized by the European Society of Cardiology, in Barcelona, Spain."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Pfizer Present Observational Real-World Data Analysis on the Effectiveness and Safety of Eliquis® (apixaban) Compared to Warfarin in Select High-Risk Patients with Non-Valvular Atrial Fibrillation,2017-08-28 06:30:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-pfizer-present-063000339.html?.tsrc=rss,Bristol-Myers Squibb Company and Pfizer Inc. today announced results from an analysis of real-world data pooled from four large U.S. insurance claims databases.
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Pfizer Report Investigational Eliquis Data - Quick Facts",2017-08-28 05:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DoJufwLqaZo/bristolmyers-pfizer-report-investigational-eliquis-data--quick-facts-20170828-00124,"Bristol-Myers, Pfizer Report Investigational Eliquis Data - Quick Facts"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers: Eliquis Shows Lower Risk Of Stroke In NVAF Patient Subgroups,2017-08-28 02:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WVwj-8orcAw/bristolmyers-eliquis-shows-lower-risk-of-stroke-in-nvaf-patient-subgroups-20170828-00061,Bristol-Myers: Eliquis Shows Lower Risk Of Stroke In NVAF Patient Subgroups
BMY,BMY:US,BBG000DQLV23,Can Buying Exelixis Stock Still Make You Rich?,2017-08-27 20:48:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pSpoif0i4-k/can-buying-exelixis-stock-still-make-you-rich-cm837666,What were you doing on Friday Jan 2 2015 It s OK if you don t remember I certainly can t But there were some investors who did something on that date who probably recall it with a smile Anyone who bought shares of Exelixis NASDAQ EXEL at the beginning of 2015 and held on
BMY,BMY:US,BBG000DQLV23,Can Buying Exelixis Stock Still Make You Rich?,2017-08-27 19:04:00 +0000,http://finance.yahoo.com/r/99743af0-beda-3b65-83a4-c68d64345767/can-buying-exelixis-stock-still-make-you-rich.aspx?yptr=yahoo&.tsrc=rss,The potential for Cabometyx -- and the potential for an acquisition -- could drive Exelixis stock a lot higher.
BMY,BMY:US,BBG000DQLV23,3 Blue-Chip Stocks to Buy Before They Get Hot,2017-08-26 00:39:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Oomh5xo_kYU/3-blue-chip-stocks-to-buy-before-they-get-hot-cm837503,InvestorPlace Stock Market News Stock Advice amp Trading Tips The market has been following the typical seasonality trends to a T this year as the S amp P 500 Index and other major indices are experiencing selling pressure despite trading near all time highs Source
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug",2017-08-25 13:47:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-8O4vBBSNiU/pharma-stock-roundup-roche-drug-gets-priority-review-eu-nod-for-novartis-drug-cm836996,Key news this week include priority review for Roche s RHHBY experimental hemophilia A drug and EU approval for Novartis NVS advanced breast cancer drug Meanwhile deals involving companies like AstraZeneca plc AZN and Eli Lilly and Company LLY were also announced this week Recap of
BMY,BMY:US,BBG000DQLV23,Celldex Ends Phase II Enrollment for Breast Cancer Candidate,2017-08-24 23:38:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4HG3oDa0x-4/celldex-ends-phase-ii-enrollment-for-breast-cancer-candidate-cm836870,Celldex Therapeutics Inc CLDX announced completion of enrollment in a phase IIb study METRIC evaluating lead pipeline candidate glembatumumab vedotin for treating patients with metastatic triple negative breast cancers Shares of Celldex have underperformed the industry year to date
BMY,BMY:US,BBG000DQLV23,Celldex Ends Phase II Enrollment for Breast Cancer Candidate,2017-08-24 21:42:09 +0000,https://finance.yahoo.com/news/celldex-ends-phase-ii-enrollment-214209606.html?.tsrc=rss,"Celldex (CLDX) announces completion of enrollment in METRIC, a phase IIb study, evaluating glembatumumab vedotin for breast cancer treatment."
BMY,BMY:US,BBG000DQLV23,Here's Why Clovis Stock Is Up Almost 60% So Far in 2017,2017-08-23 22:37:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ktsBJoVZK2E/heres-why-clovis-stock-is-up-almost-60-so-far-in-2017-cm836233,Shares of Clovis Oncology Inc CLVS have witnessed a continuous upside this year Shares of this small biotech company are up 62 3 so far this year outperforming the 7 2 increase registered by the industry 160 during this period Let s analyze the factors that have driven the rally so
BMY,BMY:US,BBG000DQLV23,"Noteworthy ETF Inflows: VUG, BMY, NVDA, AGN",2017-08-23 19:39:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lp3t7cb3Q8Q/noteworthy-etf-inflows-vug-bmy-nvda-agn-cm836160,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Growth ETF Symbol VUG where we have detected an approximate 48 8 million dollar inflow that s a 0 2 increase week over week in outstanding units
BMY,BMY:US,BBG000DQLV23,30 Great Stocks of All Time,2017-08-23 19:37:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RLMg7vOIajU/30-great-stocks-of-all-time-cm836173,A finance professor made a startling discovery about the stock market Over a 90 year span 96 of all stocks collectively performed no better than risk free 1 month Treasury bills After analyzing the lifetime returns of 25 782 common stocks Hendrik Bessembinder determined that just 1
BMY,BMY:US,BBG000DQLV23,Why Intra-Cellular Therapies Is Skyrocketing Today,2017-08-23 17:38:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6_NnjmRG0jw/why-intra-cellular-therapies-is-skyrocketing-today-cm836041,What happened Intra Cellular Therapies NASDAQ ITCI 160 a clinical stage biopharma focused on diseases of the central nervous system rose more than 26 as of 11 35 a m EDT Wednesday The big jump came in response to the company sharing some upbeat regulatory news related
BMY,BMY:US,BBG000DQLV23,Incyte Had These Key Collaborations and Developments in 2Q17,2017-08-23 15:53:09 +0000,http://finance.yahoo.com/r/d44557c7-fd8b-305b-a230-e06f99622b1d/incyte-had-these-key-collaborations-and-developments-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Incyte (INCY) distributes its key drug, Jakafi, through its own network of specialty pharmacy providers and wholesalers in US markets."
BMY,BMY:US,BBG000DQLV23,"Gainers & Losers Of Aug.22: OVID, SNNA, BPMC, ABIO, TOCA...",2017-08-22 22:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fHsap0GIE8w/gainers--losers-of-aug22-ovid-snna-bpmc-abio-toca-20170822-01145,"Gainers & Losers Of Aug.22: OVID, SNNA, BPMC, ABIO, TOCA..."
BMY,BMY:US,BBG000DQLV23,What's Next for Bristol-Myers Squibb After Its Opdivo Setback?,2017-08-22 21:39:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RQM3Xio_2iA/whats-next-for-bristol-myers-squibb-after-its-opdivo-setback-cm835640,The signs were definitely there for a disappointment from Bristol Myers Squibb NYSE BMY Several weeks ago AstraZeneca NYSE AZN reported its checkpoint inhibitor Imfinzi failed to improve progression free survival in a late stage study targeting lung cancer There
BMY,BMY:US,BBG000DQLV23,What&apos;s Next for Bristol-Myers Squibb After Its Opdivo Setback?,2017-08-22 19:47:00 +0000,http://finance.yahoo.com/r/5794cafa-6879-3d7d-a241-59789f1d48ca/whats-next-for-bristol-myers-squibb-after-its-opdi.aspx?yptr=yahoo&.tsrc=rss,Mixed results for a study with Opdivo in treating first-line kidney cancer give reasons for concern. But how worried should investors really be?
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-08-22 12:00:54 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120054134.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17,2017-08-22 11:36:25 +0000,http://finance.yahoo.com/r/cc22cf1a-dd9b-33e6-ba22-acdceeae0039/eliquis-and-sprycel-could-boost-bmys-revenue-growth-in-2h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. : BMY-US: Dividend Analysis : July 07th, 2017 (record date) : By the numbers : August 21, 2017",2017-08-21 18:25:29 +0000,http://finance.yahoo.com/r/12da970f-a16e-394f-a47c-047f26adfa5f/bristol-myers-squibb-co-bmy-us-dividend-analysis-july-07th-2017-record-date-by-the-numbers-august-21-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Our analysis is based on comparing Bristol-Myers Squibb Co. with the following peers – Eli Lilly and Company, Merck & Co., Inc., Pfizer Inc., Sanofi Sponsored ADR, Novartis AG Sponsored ADR, Astrazeneca PLC Sponsored ADR, AbbVie, Inc., Johnson & Johnson, Celgene Corporation and Amgen Inc. (LLY-US, MRK-US, PFE-US, SNY-US, NVS-US, AZN-US, ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,Orencia Could Witness Robust Growth in 2017,2017-08-21 14:36:33 +0000,http://finance.yahoo.com/r/b975cd52-3646-3491-b5b8-1d4bdf98054a/orencia-could-witness-robust-growth-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Orencia contributed around 13% of Bristol-Myers Squibb’s net revenues."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Yervoy Is Expected to See Steady Growth,2017-08-21 13:06:48 +0000,http://finance.yahoo.com/r/f49bdd70-438f-3dfd-a728-a09d28e37544/bristol-myers-squibbs-yervoy-is-expected-to-see-steady-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In the Phase 3 CheckMate-214 trial, 41.6% patients on Opdivo and Yervoy combination therapy achieved the objective response rate (or ORR) compared to 26.5% patients who were on sunitinib."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Opdivo Could Be a Long-Term Growth Driver,2017-08-21 11:36:54 +0000,http://finance.yahoo.com/r/ce3250b1-8acd-3278-b94f-e06d95334e87/bristol-myers-squibbs-opdivo-could-be-a-long-term-growth-driver?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In June 2017, Bristol-Myers Squibb presented the clinical trial data of its Phase 1/2 ECHO-204 trial."
BMY,BMY:US,BBG000DQLV23,Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada,2017-08-18 16:42:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j25SDp5PjE0/gilead-gild-hcv-drug-vosevi-receives-approval-in-canada-cm834035,Gilead Sciences Inc GILD announced that Health Canada has granted a Notice of Compliance for its single tablet regimen Vosevi sofosbuvir 400 mg velpatasvir 100 mg voxilaprevir 100 mg for the treatment of chronic hepatitis C virus HCV infection Vosevi has been approved for the
BMY,BMY:US,BBG000DQLV23,Opdivo Could Drive Bristol-Myers Squibb’s Revenue Growth in 2017,2017-08-18 14:38:09 +0000,http://finance.yahoo.com/r/c64989ee-5d48-3ff0-817c-46e32c859820/opdivo-could-drive-bristol-myers-squibbs-revenue-growth-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Bristol-Myers Squibb’s (BMY) Opdivo generated revenues of around $1.2 billion, which reflected ~45% growth on a year-over-year basis."
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo",2017-08-18 13:42:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QJF6KhgQNco/pharma-stock-roundup-multiple-sclerosis-drug-prices-in-focus-mixed-data-on-bmys-opdivo-cm833799,Pharmaceutical stocks were in the limelight this week with Merck s MRK CEO Ken Frazier resigning from President Donald Trump s manufacturing council The sector was also in the news with an investigation being launched into the rising prices of multiple sclerosis MS drugs Recap of
BMY,BMY:US,BBG000DQLV23,Chart in Focus: Bristol-Myers Squibb’s Performance in 2Q17,2017-08-18 13:08:31 +0000,http://finance.yahoo.com/r/752e395a-75a1-32e4-8624-793b7b466436/chart-in-focus-bristol-myers-squibbs-performance-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Bristol-Myers Squibb reported diluted earnings per share (or EPS) of $0.56 compared to $0.69 in 2Q16."
BMY,BMY:US,BBG000DQLV23,Analysts’ Recommendations for Bristol-Myers Squibb in August 2017,2017-08-18 11:39:11 +0000,http://finance.yahoo.com/r/62ccc48c-e2ea-3300-9a0b-da4feab35f38/analysts-recommendations-for-bristol-myers-squibb-in-august-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts ..."
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY&apos;s Opdivo",2017-08-18 11:09:11 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-multiple-sclerosis-110911289.html?.tsrc=rss,"Key highlights this week in the pharmaceutical sector include the launch of a drug pricing probe, a resignation from the President&apos;s manufacturing council and data on Bristol-Myers&apos; (BMY) Opdivo."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation (NVAF) and Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) at ESC Congress 2017,2017-08-18 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-pfizer-highlight-105900576.html?.tsrc=rss,"Bristol-Myers Squibb Company and Pfizer Inc. today announced that 15 abstracts have been accepted for presentation at the ESC Congress 2017, organized by the European Society of Cardiology, on August 26-30 in Barcelona, Spain."
BMY,BMY:US,BBG000DQLV23,Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx,2017-08-17 23:38:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y9_Gf8HnLpY/exelixis-submits-snda-for-kidney-cancer-drug-cabometyx-cm833643,Exelixis Inc EXEL announced that it has completed the submission of a supplemental New Drug Application sNDA to the FDA for Cabometyx tablets for patients with previously untreated advanced renal cell carcinoma RCC The sNDA submission was based on positive results from phase II
BMY,BMY:US,BBG000DQLV23,Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx,2017-08-17 21:59:09 +0000,https://finance.yahoo.com/news/exelixis-submits-snda-kidney-cancer-215909367.html?.tsrc=rss,"Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer."
BMY,BMY:US,BBG000DQLV23,FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa,2017-08-17 16:39:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sIIqu04cmSo/fda-accepts-portolas-ptla-bla-resubmission-for-andexxa-cm833384,Portola Pharmaceuticals Inc PTLA recently announced that the FDA has accepted its resubmitted biologics license application BLA for the reversal agent for Factor Xa inhibitors AndexXa Andexanet Alfa A decision from the U S regulatory body is expected on Feb 2 2018 AndexXa has
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Can Overcome Market's Pessimism,2017-08-16 19:31:00 +0000,http://finance.yahoo.com/r/f28d9a0b-092c-3fea-ba9e-e62ff78ebe41/bristol-myers-can-overcome-markets-pessimism-1502911914?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Despite all the takeover rumors and blockbuster drug sales, it’s been a disappointing year for Bristol-Myers Squibb.  Shares of the drugmaker, down 2.5% this year, haven’t recovered from the drubbing they took last year when its key cancer drug Opdivo failed in a big lung cancer study.  Late Tuesday, the woes continued when Bristol-Myers (BMY) delivered mixed results from a late-stage study testing Opdivo and an older drug, Yervoy, for patients newly diagnosed with advanced or metastatic kidney cancer."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214,2017-08-16 16:37:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_3Irn9-X_Sc/bristol-myers-opdivo-fails-kidney-cancer-trial-checkmate-214-cm832869,Bristol Myers Squibb Company BMY announced disappointing top line results from the CheckMate 214 trial The study investigated immuno oncology drug Opdivo nivolumab in combination with Yervoy ipilimumab versus Pfizer Inc s PFE Sutent in intermediate and poor risk patients
BMY,BMY:US,BBG000DQLV23,Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive',2017-08-16 15:59:22 +0000,https://finance.yahoo.com/news/market-reaction-bristol-myers-mixed-155922437.html?.tsrc=rss,Credit Suisse termed the market reaction to Bristol-Myers Squibb Co (NYSE: BMY )'s CM-214 data as overly pessimistic. The comment was based on the 3-percent pullback in the company's shares in after-hours ...
BMY,BMY:US,BBG000DQLV23,"S&P 500 Movers: AMD, FCX",2017-08-16 15:35:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/umtieRifpiY/sp-500-movers-amd-fcx-cm832754,In early trading on Wednesday shares of Freeport McMoran Copper amp Gold FCX topped the list of the day s best performing components of the S amp P 500 index trading up 4 6 Year to date Freeport McMoran Copper amp Gold registers a 10 8 gain And the worst performing S amp P
BMY,BMY:US,BBG000DQLV23,Cramer: Investors Can't Get Enough of Bristol-Myers Despite Latest Drug Setback,2017-08-16 14:53:00 +0000,http://finance.yahoo.com/r/3e465a38-52f8-3954-b2fc-3e45aff1e770/jim-cramer-investors-want-to-own-bristol-myers-despite-setback.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Despite a Phase 3 stumble, BMY stock is holding up."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214,2017-08-16 14:03:02 +0000,https://finance.yahoo.com/news/bristol-myers-opdivo-fails-kidney-140302116.html?.tsrc=rss,Bristol-Myers Squibb Company (BMY) announced disappointing top-line results from the CheckMate-214 trial on Opdivo in renal cell carcinoma.
BMY,BMY:US,BBG000DQLV23,Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis,2017-08-16 13:45:00 +0000,http://finance.yahoo.com/r/c215e62a-fbc5-34af-9d33-ce30a659cc34/biotech-movers-disappointment-for-bristol-myers-kidney-cancer-combo-boosts-exel.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Stock Falls as Kidney Cancer Drug Fails,2017-08-16 13:30:00 +0000,http://finance.yahoo.com/r/879fd04b-2da9-38ba-93e3-926c0b050ad1/bristol-myers-squibb-stock-falls-as-kidney-cancer-drug-fails.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Late stage trials failed to show significant statistical efficacy.
BMY,BMY:US,BBG000DQLV23,"Stocks to Watch: Target, Apple, Amazon, Urban Outfitters, Bristol-Myers",2017-08-16 13:25:49 +0000,http://finance.yahoo.com/r/bd038672-5a11-3516-a60c-2515a36c0578/stocks-to-watch-target-apple-amazon-urban-outfitters-bristol-myers-1502889948?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Among the companies with shares expected to trade actively in Wednesday's session are Target Corp., Apple Inc., Amazon.com Inc., Urban Outfitters Inc. and Bristol-Myers Squibb Co."
BMY,BMY:US,BBG000DQLV23,"ALXN's Strengthening Patents, FOLD's Fabry Drug Approved In OZ, VBIV Surges",2017-08-16 02:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UPeOCxT4xeY/alxns-strengthening-patents-folds-fabry-drug-approved-in-oz-vbiv-surges-20170816-00044,"ALXN's Strengthening Patents, FOLD's Fabry Drug Approved In OZ, VBIV Surges"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers falls on kidney cancer drug trial results,2017-08-15 20:56:00 +0000,https://finance.yahoo.com/video/bristol-myers-falls-kidney-cancer-205600218.html?.tsrc=rss,"CNBC's Meg Tirrell reports on Bristol-Myers falling after its kidney cancer drug trial results. Also, more on Merck's CEO's decision to leave the President's manufacturing council."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb shares slip as kidney cancer drug trial falls short of goal,2017-08-15 20:55:20 +0000,http://finance.yahoo.com/r/76678a96-c235-3e2b-bde3-b2cbf51c5089/Story.aspx?guid=53FF6A1A-0B06-42B3-9403-127640BE5F8A&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb Co. shares declined in the extended session Tuesday after the drugmaker said one of the endpoints of a kidney cancer drug study was not met. Bristol-Myers Squibb shares fell 2.5% to ...
BMY,BMY:US,BBG000DQLV23,Bristol-Myers kidney cancer drug fails late-stage trial,2017-08-15 20:51:58 +0000,https://finance.yahoo.com/news/bristol-myers-kidney-cancer-drug-205158607.html?.tsrc=rss,"Bristol-Myers Squibb Co said on Tuesday its combination drug to treat previously untreated patients with advanced or metastatic renal cell carcinoma, a type of kidney cancer, failed to meet one of the ..."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Announces Topline Results from CheckMate -214, a Phase 3 Study of Opdivo in Combination with Yervoy in Intermediate and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",2017-08-15 20:30:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-announces-topline-203000992.html?.tsrc=rss,Bristol-Myers Squibb Company announced topline results today from the CheckMate -214 trial investigating Opdivo in combination with Yervoy versus sunitinib in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma.
BMY,BMY:US,BBG000DQLV23,"3 Big Stock Charts for Tuesday: Bristol-Myers Squibb Co (BMY), United Parcel Service, Inc. (UPS) and Intuit Inc. (INTU)",2017-08-15 19:34:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5N_HVYOFt_Y/3-big-stock-charts-for-tuesday-bristol-myers-squibb-co-bmy-united-parcel-service-inc-ups-and-intuit-inc-intu-cm832420,InvestorPlace Stock Market News Stock Advice amp Trading Tips Monday s surge in the market may have been the boost in the arm that was needed as we have been seeing a number of stocks that have been slipping into technically challenging situations We often watch these
BMY,BMY:US,BBG000DQLV23,"IWV, PCLN, BMY, GS: ETF Outflow Alert",2017-08-15 16:37:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A6L8-BZF3wg/iwv-pcln-bmy-gs-etf-outflow-alert-cm832287,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 3000 ETF Symbol IWV where we have detected an approximate 43 7 million dollar outflow that s a 0 6 decrease week over week from 53 350 000
BMY,BMY:US,BBG000DQLV23,"Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses",2017-08-15 15:42:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XKIdC7gfMzg/clovis-clvs-focuses-on-label-expansion-rubraca-impresses-cm832221,We issued an updated research report on Boulder CO based Clovis Oncology Inc CLVS on Aug 14 Rubraca has shown impressive growth trend in 2017 on the back of the company s commercialization efforts Rubraca sales doubled sequentially in the second quarter Rubraca sales were 14 6 million
BMY,BMY:US,BBG000DQLV23,"3 Big Stock Charts for Tuesday: Bristol-Myers Squibb Co (BMY), United Parcel Service, Inc. (UPS) and Intuit Inc. (INTU)",2017-08-15 15:17:01 +0000,https://finance.yahoo.com/news/3-big-stock-charts-tuesday-151701235.html?.tsrc=rss,"Each of these stocks pierced their respective top Bollinger Bands yesterday, which put them on most technical trader’s radar.  Like much of the Pharmaceutical sector, Bristol-Myers Squibb shares have been volatile, trading with little trend.  BMY stock broke its top Bollinger Band yesterday, signaling that more volatility is on the way."
BMY,BMY:US,BBG000DQLV23,What Trump has done to lower the ‘RIPOFF DRUG PRICES’ he’s decrying,2017-08-14 18:20:36 +0000,https://finance.yahoo.com/news/trump-done-lower-ripoff-drug-prices-hes-decrying-182036675.html?.tsrc=rss,"Trump has decried these price hikes since the campaign.  President Donald Trump blasted Merck CEO Kenneth C. Frazier on Monday morning after Frazier announced he was leaving the President’s manufacturing council following Trump’s equivocal response to the neo-Nazi and white nationalist rally in Charlottesville, Virginia.  In March, Democratic Representatives Elijah Cummings (MD) and Peter Welch (VT) met with Trump to discuss their bill that would help lower prescription drug prices by allowing regulated drug importation and Medicare’s ability to negotiate wholesale prices for wholesale drugs, instead of retail prices."
BMY,BMY:US,BBG000DQLV23,Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review,2017-08-14 15:39:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0_c_yQ9lSVk/gilead-gild-nda-for-hiv-combo-regimen-gets-priority-review-cm831680,Gilead Sciences Inc GILD announced that the FDA has granted priority review for the company s New Drug Application NDA for an investigational fixed dose combination of bictegravir 50mg BIC a novel investigational integrase strand transfer inhibitor INSTI and emtricitabine
BMY,BMY:US,BBG000DQLV23,3 Beaten-Up Biotech Stocks: Are They Bargains?,2017-08-14 15:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/m1-ab5q1E8k/3-beaten-up-biotech-stocks-are-they-bargains-cm831691,The iShares Nasdaq Biotechnology Index has tacked on a healthy gain of around 15 so far this year without any help from Celldex Therapeutics Inc NASDAQ CLDX Agenus Inc NASDAQ AGEN or Progenics Pharmaceuticals Inc NASDAQ PGNX All three of these
BMY,BMY:US,BBG000DQLV23,Edited Transcript of BMY earnings conference call or presentation 27-Jul-17 2:30pm GMT,2017-08-13 07:46:04 +0000,https://finance.yahoo.com/news/edited-transcript-bmy-earnings-conference-023253906.html?.tsrc=rss,Q2 2017 Bristol-Myers Squibb Co Earnings Call
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-08-12 12:01:00 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120100498.html?.tsrc=rss,"BMY credit default swap spreads are near their highest levels of the last 3 years, which indicates the market&apos;s more negative perception of the company&apos;s credit worthiness.  Please send all inquiries related to the report to score@ihsmarkit.com."
BMY,BMY:US,BBG000DQLV23,"ETFs with exposure to Bristol-Myers Squibb Co. : August 11, 2017",2017-08-11 21:02:20 +0000,http://finance.yahoo.com/r/418abc5c-81a0-317f-8b5a-27a5c7019b10/etfs-with-exposure-to-bristol-myers-squibb-co-august-11-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Bristol-Myers Squibb Co. Here are 5 ETFs with the largest exposure to BMY-US. Comparing the performance and risk of Bristol-Myers Squibb Co. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,Pfizer’s Valuation after 2Q17 Earnings,2017-08-11 19:59:09 +0000,http://finance.yahoo.com/r/278f9d57-73ba-3f43-89ae-52dab407cb1b/pfizers-valuation-after-2q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. It reported a 2% decline in revenues, to $12.89 billion in 2Q17 from $13.15 billion in 2Q16."
BMY,BMY:US,BBG000DQLV23,"Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag",2017-08-11 19:35:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xitXTGiEMAc/nektars-nktr-shares-fall-post-wider-q2-loss-revenues-lag-cm831095,Nektar Therapeutics NKTR shares have declined almost 9 since Aug 8 after the company reported second quarter results The biotech reported a wider than expected loss while sales missed estimates Nektar s second quarter 2017 loss of 39 cents per share was wider than the Zacks
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure",2017-08-11 13:40:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/upgHNSRuF5Y/pharma-stock-roundup-mylan-misses-perrigo-tops-in-q2-zynerba-plunges-on-study-failure-cm830794,Second quarter earnings season is drawing to a close with most major companies having reported results This week companies like Endo Mylan MYL Novo Nordisk and Perrigo PRGO presented their second quarter results Recap of the Week s Most Important Stories A Look at Q2
BMY,BMY:US,BBG000DQLV23,Luspatercept: Opportunity for Celgene’s Long-Term Growth?,2017-08-11 13:06:04 +0000,http://finance.yahoo.com/r/1273d6bf-e79c-3769-aaf6-35adf89dc808/luspatercept-opportunity-celgenes-long-term-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Celgene and Acceleron are conducting the Phase 3 MEDALIST trial to evaluate the safety and efficacy of luspatercept in individuals with ring sideroblasts.
BMY,BMY:US,BBG000DQLV23,See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.,2017-08-11 12:01:07 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120106335.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected,2017-08-10 16:39:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bpHpOAvffF4/aveo-pharmaceuticals-aveo-q2-loss-narrower-than-expected-cm830306,AVEO Pharmaceuticals Inc AVEO reported second quarter 2017 adjusted loss of 8 cents per share excluding change in fair value of warrant liability narrower than the Zacks Consensus Estimate of 10 cents as well as the year ago loss of 11 cents However reported loss for the quarter was
BMY,BMY:US,BBG000DQLV23,IHS Markit Score Update: Drop in demand for ETFs holding Bristol-Myers Squibb Co is a negative sign for its shares,2017-08-10 12:01:09 +0000,https://finance.yahoo.com/news/ihs-markit-score-drop-demand-120109199.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,How Celgene’s Pomalyst Is Positioned after 2Q17,2017-08-10 11:37:33 +0000,http://finance.yahoo.com/r/b2f9a0f6-f27a-3127-82e7-ffe47cfa044f/celgenes-pomalyst-positioned-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Celgene’s (CELG) Pomalyst generated revenues of ~$391 million, which reflected ~23% growth on a year-over-year basis."
BMY,BMY:US,BBG000DQLV23,How Celgene Performed in 2Q17,2017-08-09 18:36:00 +0000,http://finance.yahoo.com/r/4590d37d-74d8-37e8-96cf-f78c29b8283f/celgene-performed-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Celgene updated its adjusted diluted EPS from $7.15–$7.30 to $7.25–$7.35 and its adjusted operating margin from about 57.0%–57.5%.
BMY,BMY:US,BBG000DQLV23,Pfizer: Some Near Term Challenges May Mute Positive Triggers,2017-08-09 17:05:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M5c_Ex_3_SE/pfizer-some-near-term-challenges-may-mute-positive-triggers-cm829615,The impact of Pfizer s PFE second quarter results on the company s stock was barely noticeable and this has almost become a norm The company s stock has remained largely rangebound for the last five years despite Pfizer showing a rebound in revenue This is likely because the market
BMY,BMY:US,BBG000DQLV23,"Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up",2017-08-09 16:38:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bXDhaBoqbxY/celldex-cldx-q2-loss-narrows-revenues-beat-shares-up-cm829529,Celldex Therapeutics Inc CLDX incurred second quarter 2017 loss of 23 cents per share which was narrower than the Zacks Consensus Estimate of a loss of 25 cents as well as the year ago loss of 32 cents per share Lower costs and higher revenues led to the narrower loss in the quarter
BMY,BMY:US,BBG000DQLV23,"Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts",2017-08-09 16:36:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_t0ubY-u81o/exelixis-inc-continued-its-winning-ways-and-rose-10-in-july-thanks-to-these-3-catalysts-cm829504,What happened Shares of Exelixis NASDAQ EXEL a biotechnology company focused on the development of drugs to treat various types of cancer moved steadily higher by a cool 10 in July according to data from S amp P Global Market Intelligence A confluence of
BMY,BMY:US,BBG000DQLV23,"Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts",2017-08-09 15:18:00 +0000,http://finance.yahoo.com/r/6854002c-942f-3c13-8418-c2dfada2ab73/exelixis-inc-continued-its-winning-ways-and-rose-1.aspx?yptr=yahoo&.tsrc=rss,Can nothing slow down this biotech rocket?
BMY,BMY:US,BBG000DQLV23,"Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up",2017-08-09 14:48:02 +0000,https://finance.yahoo.com/news/celldex-cldx-q2-loss-narrows-144802162.html?.tsrc=rss,"Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q2 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday."
BMY,BMY:US,BBG000DQLV23,Why BeiGene Soared 56.6% In July,2017-08-09 13:37:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7u-8spsdnHo/why-beigene-soared-566-in-july-cm829254,What happened After inking a collaboration agreement with biotech powerhouse Celgene NASDAQ CELG shares in BeiGene Ltd NASDAQ BGNE rocketed 56 6 higher last month 160 according to S amp P Global Market Intelligence So what Celgene
BMY,BMY:US,BBG000DQLV23,"Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum",2017-08-09 13:37:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NH_xzl8GXgA/celldex-therapeutics-inc-finishes-second-quarter-with-plenty-of-cash-and-clinical-momentum-cm829252,Investors view quarterly updates from clinical stage biotechs in a much different way from how they view those of other companies When Celldex Therapeutics NASDAQ CLDX reported its first quarter results earlier this year the focus wasn t on its revenue but instead on
BMY,BMY:US,BBG000DQLV23,IHS Markit Score Update: Decline in perceived credit worthiness is a negative sign for Bristol-Myers Squibb Co shares,2017-08-09 12:01:07 +0000,https://finance.yahoo.com/news/ihs-markit-score-decline-perceived-120107357.html?.tsrc=rss,Bristol-Myers Squibb Co NYSE:BMY
BMY,BMY:US,BBG000DQLV23,Retail names soar on earnings,2017-08-08 17:43:00 +0000,https://finance.yahoo.com/video/retail-names-soar-earnings-174300159.html?.tsrc=rss,The &quot;Halftime Report&quot; traders take investors through some of the day's biggest movers.
BMY,BMY:US,BBG000DQLV23,"Horizon Pharma (HZNP) Q2 Earnings & Sales Top, Raises View",2017-08-08 16:41:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JDki0exwMhU/horizon-pharma-hznp-q2-earnings-sales-top-raises-view-cm828874,Horizon Pharma plc HZNP topped both earnings and sales estimate in second quarter 2017 The company also raised its sales guidance for 2017 The company s shares moved up 4 72 on better than expected second quarter results and increased guidance However Horizon Pharma s stock is
BMY,BMY:US,BBG000DQLV23,Q2 Earnings Fail to Impress Pharma ETF,2017-08-07 15:42:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7wKlBEenEnM/q2-earnings-fail-to-impress-pharma-etf-cm828073,Total earnings for 83 3 of the total healthcare market capitalization are up 6 on revenue growth of 4 1 Though earnings growth is weak compared with many other sectors earnings and revenue beat ratios of 85 and 70 respectively are particularly encouraging In fact healthcare is
BMY,BMY:US,BBG000DQLV23,Q2 Earnings Fail to Impress Pharma ETF,2017-08-07 13:45:01 +0000,https://finance.yahoo.com/news/q2-earnings-fail-impress-pharma-134501496.html?.tsrc=rss,The string of earnings beat failed to boost pharma ETFs.
BMY,BMY:US,BBG000DQLV23,Weekly Top Insider Buys Highlight for the Week of August 4,2017-08-07 11:33:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DK70ws7CESU/weekly-top-insider-buys-highlight-for-the-week-of-august-4-cm827893,The largest Insider Buys this week were for AbbVie Inc ABBV Bristol Myers Squibb Company BMY General Motors Co GM and Kinder Morgan Inc KMI The largest Insider Buys this week were for AbbVie Inc ABBV Bristol Myers Squibb Company BMY General Motors Co
BMY,BMY:US,BBG000DQLV23,"AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games",2017-08-06 14:37:52 +0000,http://finance.yahoo.com/r/a0bf935a-d38c-3c21-9bba-535183973ce5/Story.aspx?guid=962545D0-7917-11E7-8BAC-51224A647843&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"On paper, the newly-approved hepatitis C drug Mavyret is a positive steal."
BMY,BMY:US,BBG000DQLV23,"10 Reasons Cancer Drugs Usually Cost $100,000 or More a Year",2017-08-06 13:59:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G7UiuJ_f7LU/10-reasons-cancer-drugs-usually-cost-100000-or-more-a-year-cm827779,If you ve picked up a prescription from your local pharmacy recently you probably don t need me to tell you that prescription drug prices have handily outpaced wage growth and the rate of inflation in the U S for some time now Cancer drug prices are headed into the
BMY,BMY:US,BBG000DQLV23,"10 Reasons Cancer Drugs Usually Cost $100,000 or More a Year",2017-08-06 12:21:00 +0000,http://finance.yahoo.com/r/729ad781-dfcc-3562-a404-9cb43c33b1e4/10-reasons-cancer-drugs-usually-cost-100000-or-mor.aspx?yptr=yahoo&.tsrc=rss,Don&apos;t expect cancer drug inflation to slow anytime soon.
BMY,BMY:US,BBG000DQLV23,[$$] Atlas Venture Scores Hat Trick of Early-Stage Biotech Exits,2017-08-04 23:40:45 +0000,http://finance.yahoo.com/r/a5490d98-86c7-3c1a-86b5-0297ec5670f2/atlas-venture-scores-hat-trick-of-early-stage-biotech-exits-1501890043?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"For the third time since early 2016, Atlas Venture has sold a young biotechnology company in a blockbuster deal."
BMY,BMY:US,BBG000DQLV23,Celgene vs. Gilead Sciences: Who Reported Better Earnings?,2017-08-04 23:00:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FeKwT2zbOYg/celgene-vs-gilead-sciences-who-reported-better-earnings-cm827602,Celgene Corp NASDAQ CELG and Gilead Sciences NASDAQ GILD reported second quarter earnings that were better than industry watchers forecasts but these two giants circumstances are very different While Celgene is racking up substantial growth for its top selling
BMY,BMY:US,BBG000DQLV23,"Infinity (INFI) Q2 Loss Wider than Expected, View Intact",2017-08-04 23:00:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gDQoadMunmk/infinity-infi-q2-loss-wider-than-expected-view-intact-cm827601,Infinity Pharmaceuticals Inc INFI reported a loss of 34 cents per share in second quarter 2017 wider than the Zacks Consensus Estimate loss of 22 cents The company had reported a loss of 12 cents in the year ago quarter Infinity Pharmaceuticals Inc Price Consensus and
BMY,BMY:US,BBG000DQLV23,"Exelixis, Inc. Grows Revenue, Eyes Treating More Patients",2017-08-04 20:00:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q8IrOzACAYE/exelixis-inc-grows-revenue-eyes-treating-more-patients-cm827473,Sales of Exelixis NASDAQ EXEL kidney cancer drug Cabometyx continued to grow at a torrid pace in the second quarter allowing the company to post another profitable quarter Exelixis results The raw numbers
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals",2017-08-04 12:47:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-mixed-2q-124712684.html?.tsrc=rss,Pfizer&apos;s (PFE) results were mixed while Teva had a dismal quarter with the company missing estimates as well as cutting its outlook and guidance.
BMY,BMY:US,BBG000DQLV23,"Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales",2017-08-03 23:01:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4Edc4AFmYYQ/exelixis-exel-q2-earnings-sales-beat-on-cabometyx-sales-cm826925,Exelixis Inc EXEL reported impressive results for the second quarter on the back of increased Cabometyx sales The company posted second quarter 2017 earnings of 8 cents beating the Zacks Consensus Estimate of 3 cents Notably the company had reported a loss of 15 cents per share in
BMY,BMY:US,BBG000DQLV23,"Aduro (ADRO) Q2 Loss Narrower than Expected, Revenues Top",2017-08-03 22:01:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KhdF8sm34cg/aduro-adro-q2-loss-narrower-than-expected-revenues-top-cm826878,Aduro BioTech Inc ADRO reported second quarter 2017 loss of 27 cents per share narrower than the Zacks Consensus Estimate of a loss of 36 cents However the company reported earnings of 3 cents per share a year ago Quarterly revenues plunged 84 9 year over year to 5 9 million
BMY,BMY:US,BBG000DQLV23,Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline,2017-08-03 21:14:54 +0000,https://finance.yahoo.com/news/bristol-myers-buy-ifm-therapeutics-211454992.html?.tsrc=rss,"Bristol-Myers Squibb Co said it  would buy privately held IFM Therapeutics for an upfront payment  of $300 million, as the drugmaker looks to bolster its cancer  portfolio after losing ground to Merck & Co's rival  treatment Keytruda.  The acquisition of IFM, whose backers include Novartis, will  give Bristol-Myers access to the company's preclinical cancer  programs.  IFM investors are also eligible to additional contingent  payments of up to $1.01 billion upon the achievement of certain  milestones, the companies said on Thursday."
BMY,BMY:US,BBG000DQLV23,3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance,2017-08-03 21:01:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/25XNDWK8t5s/3-reasons-to-still-buy-exelixis-stock-after-its-strong-q2-performance-cm826819,Any way you look at Exelixis NASDAQ EXEL just reported an impressive second quarter performance The biotech posted its second quarter of profitability with earnings topping Wall Street expectations Revenue for Cabometyx soared Exelixis even emerged from the period without
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers to buy IFM Therapeutics for $300 million, and potential contingent payments",2017-08-03 20:14:51 +0000,http://finance.yahoo.com/r/1a4f370e-df51-3ee1-aebd-7456e540674d/Story.aspx?guid=27FAC7E7-1C42-4168-A3F0-1C7A2E3AAC83&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb Co. announced Thursday a deal to buy privately-held biotechnology company IFM Therapeutics for $300 million, and contingent payments of up to $1.01 billion. The acquisition gives Bristol-Myers ..."
BMY,BMY:US,BBG000DQLV23,Innately Innovative: IFM Therapeutics Acquired By BMS,2017-08-03 20:03:00 +0000,http://finance.yahoo.com/r/2e68f1e0-eb97-3eb6-9f00-f599f3ce04a0/innately-innovative-ifm-therapeutics-acquired-by-bms?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Today BMS announced the acquisition of IFM Therapeutics, an emerging biotech focused on modulating core innate immune pathways to treat cancer and autoimmune disease."
BMY,BMY:US,BBG000DQLV23,Pharma giant Bristol-Myers Squibb just made another big bet on cancer immunotherapy,2017-08-03 20:00:30 +0000,https://finance.yahoo.com/news/pharma-giant-bristol-myers-squibb-200030100.html?.tsrc=rss,"Bristol-Myers Squibb, a company known for its cancer immunotherapy drugs, just acquired..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity,2017-08-03 20:00:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-acquire-ifm-200000328.html?.tsrc=rss,"Bristol-Myers Squibb Company and IFM Therapeutics announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders...."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb To Acquire IFM Therapeutics - Quick Facts,2017-08-03 16:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w7rYtfMi6s4/bristolmyers-squibb-to-acquire-ifm-therapeutics--quick-facts-20170803-02090,Bristol-Myers Squibb To Acquire IFM Therapeutics - Quick Facts
BMY,BMY:US,BBG000DQLV23,"Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses",2017-08-03 16:05:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M_HqQX5lLzA/clovis-clvs-q2-loss-wider-than-expected-rubraca-impresses-cm826555,Clovis Oncology Inc CLVS reported second quarter 2017 loss of 1 29 per share which was narrower than the year ago loss of 2 07 per share The reported loss was however wider than the Zacks Consensus Estimate of a loss of 1 27 Clovis PARP inhibitor Rubraca rucaparib
BMY,BMY:US,BBG000DQLV23,"Forget BMY's Q2 Earnings, Watch Out For Opdivo Trials Going Forward",2017-08-02 19:06:00 +0000,http://finance.yahoo.com/r/9357ff19-9cf0-3282-b3c5-402ed2428621/forget-bmys-q2-earnings-watch-out-for-opdivo-trials-going-forward?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Opdivo and Eliquis were the usual suspects driving Bristol-Myers Squibb‘s growth in Q2 2017. There were no real surprises, but the recent Mystic trial results from AstraZeneca put Opdivo’s current trials under more scrutiny, and that’s what we expect the market to track going forward."
BMY,BMY:US,BBG000DQLV23,"Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong",2017-08-02 16:58:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e_mI3CYOJII/incyte-incy-q2-loss-wider-than-expected-jakafi-strong-cm825857,Shares of Incyte Corporation INCY were down 3 4 after the company reported a loss in the second quarter of 2017 Incyte reported a loss of 6 cents a penny wider than the Zacks Consensus Estimate of a loss of 5 cents Incyte had reported earnings of 18 cents per share in the year
BMY,BMY:US,BBG000DQLV23,"The Zacks Analyst Blog Highlights: Procter & Gamble, Altria, Bristol-Myers, ConocoPhillips and Electronic Arts",2017-08-02 16:57:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4msd5jOgsNc/the-zacks-analyst-blog-highlights-procter-gamble-altria-bristol-myers-conocophillips-and-electronic-arts-cm825822,For Immediate Release Chicago IL August 02 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the
BMY,BMY:US,BBG000DQLV23,"The Zacks Analyst Blog Highlights: Procter & Gamble, Altria, Bristol-Myers, ConocoPhillips and Electronic Arts",2017-08-02 15:12:03 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-procter-151203418.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Procter & Gamble, Altria, Bristol-Myers, ConocoPhillips and Electronic Arts"
BMY,BMY:US,BBG000DQLV23,What's in the Cards for Celldex (CLDX) this Earnings Season?,2017-08-02 14:58:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LQa1v-n6hFY/whats-in-the-cards-for-celldex-cldx-this-earnings-season-cm825634,Celldex Therapeutics Inc CLDX is scheduled to report second quarter 2017 results on Aug 8 after market close Celldex s performance has been encouraging as it delivered positive surprise in three of the trailing four quarters and met estimates in one delivering an average positive surprise
BMY,BMY:US,BBG000DQLV23,What&apos;s in the Cards for Celldex (CLDX) this Earnings Season?,2017-08-02 13:20:01 +0000,https://finance.yahoo.com/news/apos-cards-celldex-cldx-earnings-132001374.html?.tsrc=rss,"With no approved product in Celldex Therapeutics&apos;s (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results."
BMY,BMY:US,BBG000DQLV23,How BMY Is Valued following Its 2Q17 Earnings,2017-08-02 11:37:01 +0000,http://finance.yahoo.com/r/024deee5-cd23-3f8c-8c34-d96b3e1e2b0f/how-bmy-is-valued-following-its-2q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb (BMY) met Wall Street analysts’ consensus estimate for earnings per share (or EPS) in 2Q17, reporting EPS of $0.74."
BMY,BMY:US,BBG000DQLV23,Eli Lilly’s Valuation after 2Q17 Earnings Release,2017-08-02 11:35:56 +0000,http://finance.yahoo.com/r/692b92c6-c691-3256-a106-cddd80d7e3ab/eli-lillys-valuation-after-2q17-earnings-release?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"For 2Q17, Eli Lilly (LLY) surpassed analysts’ EPS estimate of $1.05 and reported EPS of $1.11. Analysts are estimating EPS of $1.03 for 3Q17."
BMY,BMY:US,BBG000DQLV23,Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo,2017-08-02 02:54:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YuMZH5KuTe4/mercks-keytruda-plays-catch-up-to-bristol-myers-opdivo-cm825400,Merck amp Co NYSE MRK and Bristol Myers Squibb NYSE BMY are engaged in a battle of sorts The two won FDA approval for new non small cell lung cancer therapies in 2015 that work similarly and ever since they ve been elbowing at one another for market share So
BMY,BMY:US,BBG000DQLV23,"FDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount",2017-08-02 02:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NKjz_8xnheE/fda-nod-for-agios-idhifa-bmy-expands-opdivo-use-ocul-reduces-headcount-20170802-00079,"FDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount"
BMY,BMY:US,BBG000DQLV23,Merck&apos;s Keytruda Plays Catch-Up to Bristol-Myers&apos; Opdivo,2017-08-02 01:31:00 +0000,http://finance.yahoo.com/r/a23bc434-d63b-3eab-8975-0a40bdd49704/mercks-keytruda-plays-catch-up-to-bristol-myers-op.aspx?yptr=yahoo&.tsrc=rss,The two biopharma giants PD-1 inhibitors are facing off against each other in cancer indications that are worth billions of dollars in annual sales.
BMY,BMY:US,BBG000DQLV23,"Top Stock Reports for Procter & Gamble, Altria & Bristol-Myers",2017-08-01 22:26:10 +0000,https://finance.yahoo.com/news/top-stock-reports-procter-gamble-222610393.html?.tsrc=rss,"Top Stock Reports for Procter & Gamble, Altria & Bristol-Myers"
BMY,BMY:US,BBG000DQLV23,12 Numbers in Pfizer's Q2 Update More Important Than Its Revenue Decline,2017-08-01 20:55:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ws_MTe_-aK0/12-numbers-in-pfizers-q2-update-more-important-than-its-revenue-decline-cm825276,Pfizer NYSE PFE announced its second quarter results before the market opened on Tuesday And investors yawned at least for the most part Many of the headlines about the big drugmaker s quarterly performance centered on Pfizer s year over year revenue decline The
BMY,BMY:US,BBG000DQLV23,Pfizer delays major M&A as it awaits U.S. tax reform clarity,2017-08-01 17:35:49 +0000,https://finance.yahoo.com/news/pfizer-revenue-misses-lower-prevnar-111832898.html?.tsrc=rss,"Pfizer Inc's chief executive said  on Tuesday he would prefer to wait for clarity on U.S. tax  reform before engaging in any big deals in order to get a better  understanding of any potential acquisition target's value.  The largest U.S. drugmaker has been under increasing  pressure from investors and Wall Street to pull off a large deal  to help reignite growth.  ""There are short-term events in the marketplace, such as tax  reform, that may change asset values."
BMY,BMY:US,BBG000DQLV23,Biotech Stocks Seen Fueled by Next M&A Wave,2017-08-01 15:35:00 +0000,http://finance.yahoo.com/r/f9c13cea-d744-3f49-9fd9-ea47c4ea0574/biotech-stocks-seen-fueled-next-ma-wave?partner=YahooSA&yptr=yahoo&.tsrc=rss,The biotech sector needs mergers to happen to jumpstart the group's dismal revenue growth.
BMY,BMY:US,BBG000DQLV23,"Lucas Capital Management Buys General Electric Co, Western Gas Equity Partners LP, Cabot Oil ...",2017-08-01 14:54:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7i-yHQtL424/lucas-capital-management-buys-general-electric-co-western-gas-equity-partners-lp-cabot-oil-cm824959,Lucas Capital Management New Purchases COG CLR VOX CXO HESM Y XLK AR KMI QEP Added Positions GE WGP EFA VET BMY IBB AMZN XOM APC BGS Reduced Positions SBR OXY BSM DMLP MPLX NBL SHLX PBT HES NDRO Sold Out APA GILD MRO
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s 2Q17 Earnings: Orencia and Other Brands,2017-08-01 14:39:24 +0000,http://finance.yahoo.com/r/724ca9b9-7e95-3e3d-9ffa-45c3e1ace020/bristol-myers-squibbs-2q17-earnings-orencia-and-other-brands?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb's (BMY) immunoscience business is represented by the drug Orencia. Let's take a look at Orencia's revenue over the last few quarters.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s 2Q17 Earnings: Eliquis,2017-08-01 13:10:41 +0000,http://finance.yahoo.com/r/02367625-190c-399b-95a5-96176eca0ce4/bristol-myers-squibbs-2q17-earnings-eliquis?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb’s (BMY) cardiovascular portfolio includes the blockbuster drug Eliquis. Let's take a closer look at Eliquis's revenue over the last few quarters.
BMY,BMY:US,BBG000DQLV23,Key FDA Events to Watch Out for in Aug 2017,2017-08-01 12:57:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fYPlKUCJw4M/key-fda-events-to-watch-out-for-in-aug-2017-cm824807,The FDA which approved 22 treatments last year has given its approval to 26 drugs so far in 2017 including 3 in July Key approvals this year include Gilead s Vosevi hepatitis C virus Puma s Nerlynx to reduce the risk of breast cancer returning J amp J s Tremfya moderate to severe
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s 2Q17 Earnings: Virology Products,2017-08-01 11:41:10 +0000,http://finance.yahoo.com/r/82f78ed7-4f7c-31e8-8614-de4e0b8498c1/bristol-myers-squibbs-2q17-earnings-virology-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb's (BMY) virology portfolio includes drugs for the treatment of chronic viral diseases and infections such as hepatitis B, hepatitis C, and HIV."
BMY,BMY:US,BBG000DQLV23,Key FDA Events to Watch Out for in Aug 2017,2017-08-01 11:29:11 +0000,https://finance.yahoo.com/news/key-fda-events-watch-aug-112911630.html?.tsrc=rss,Will the FDA follow the recommendation of its advisory panel and give its nod to Dynavax&apos;s (DVAX) hepatitis B vaccine?
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin, and Irinotecan",2017-08-01 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-receives-fda-105900100.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced the U.S. Food and Drug Administration has approved Opdivo injection for intravenous use for the treatment of adult and pediatric patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.2 Approval for this indication ..."
BMY,BMY:US,BBG000DQLV23,Why Clovis Oncology Tumbled 13.5% Today,2017-07-31 22:55:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eCqBA0PT3zY/why-clovis-oncology-tumbled-135-today-cm824587,What happened After disclosing that it s entered into a pact with Bristol Myers Squibb NYSE BMY 160 on its cancer fighting drug Rubraca shares in Clovis Oncology NASDAQ CLVS lost 13 5 of their value Monday So what While teaming up with biopharma
BMY,BMY:US,BBG000DQLV23,"Gainers & Losers Of July 31: SBBP, AKCA, ACRX, ICPT, ZYNE...",2017-07-31 22:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DnLgQw23eVk/gainers--losers-of-july-31-sbbp-akca-acrx-icpt-zyne-20170731-01572,"Gainers & Losers Of July 31: SBBP, AKCA, ACRX, ICPT, ZYNE..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s 2Q17 Earnings: Opdivo,2017-07-31 22:05:43 +0000,http://finance.yahoo.com/r/8e3600d2-815f-3606-b6f9-c0aaf53b6320/bristol-myers-squibbs-2q17-earnings-opdivo?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb’s (BMY) blockbuster drug Opdivo reported revenue of $1.2 billion in 2Q17, a 42% rise compared to $840 million in 2Q16."
BMY,BMY:US,BBG000DQLV23,"Why Clovis Oncology, Gulfport Energy, and Hertz Global Holdings Slumped Today",2017-07-31 21:55:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pfViNAWAa9A/why-clovis-oncology-gulfport-energy-and-hertz-global-holdings-slumped-today-cm824558,The stock market saw a lot of indecision on Monday as major benchmarks moved in different directions The Nasdaq Composite was weaker than most of its peers but the Dow Jones Industrials jumped to another record high and made investors start thinking about the rapidly
BMY,BMY:US,BBG000DQLV23,"Pfizer Inc. (PFE) Stock Isn’t the Sexiest, But it’s Worth Checking Out",2017-07-31 20:56:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/li-AiVxSQu4/pfizer-inc-pfe-stock-isnt-the-sexiest-but-its-worth-checking-out-cm824577,InvestorPlace Stock Market News Stock Advice amp Trading Tips Pfizer Inc NYSE PFE isn t the sexiest stock in the market but that doesn t mean investors shouldn t be interested PFE stock is up more than 2 in 2017 but down nearly 10 over the past year Now may be as good
BMY,BMY:US,BBG000DQLV23,Why Clovis Oncology Tumbled 13.5% Today,2017-07-31 20:51:00 +0000,http://finance.yahoo.com/r/d99f0825-7c5f-38dd-a674-c2b5764f1e81/why-clovis-oncology-tumbled-135-today.aspx?yptr=yahoo&.tsrc=rss,News of a collaboration with Bristol-Myers Squibb dashed some of investor&apos;s hopes that Clovis Oncology could get acquired.
BMY,BMY:US,BBG000DQLV23,Examining Bristol-Myers Squibb’s Oncology Portfolio’s 2Q17,2017-07-31 20:36:04 +0000,http://finance.yahoo.com/r/358defc5-028f-3e61-9729-b14dd8f577f7/examining-bristol-myers-squibbs-oncology-portfolios-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"The key products in Bristol-Myers Squibb's (BMY) oncology portfolio include Empliciti, Opdivo, Sprycel, and Yervoy. Let's take a closer look at these drugs and their performances."
BMY,BMY:US,BBG000DQLV23,"Why Clovis Oncology, Gulfport Energy, and Hertz Global Holdings Slumped Today",2017-07-31 20:30:00 +0000,http://finance.yahoo.com/r/f35c4809-a195-3d7b-9fe5-66ef822e4c03/why-clovis-oncology-gulfport-energy-and-hertz-glob.aspx?yptr=yahoo&.tsrc=rss,These stocks fell to start the week. Find out why.
BMY,BMY:US,BBG000DQLV23,"How Dow&apos;s Merck Is Benefiting On The Backs On AstraZeneca, Bristol",2017-07-31 20:15:34 +0000,http://finance.yahoo.com/r/6ec29e1a-ee1b-3335-9ea7-71bd0e2db4b3/how-dows-merck-is-benefiting-on-the-backs-on-astrazeneca-bristol?src=A00220&yptr=yahoo&.tsrc=rss,Dow&apos;s Merck is benefiting on the backs of AstraZeneca and Bristol-Myers Squibb.
BMY,BMY:US,BBG000DQLV23,"Why Clovis, Regeneron Are Leading A Biotech Deluge Today",2017-07-31 20:11:39 +0000,http://finance.yahoo.com/r/aec2deb0-3e6d-32d5-801a-9b12278142a8/why-clovis-regeneron-are-leading-a-biotech-deluge-today?src=A00220&yptr=yahoo&.tsrc=rss,Clovis and Regeneron were among some of the biggest biotech stock losers on news related to clinical partnerships.
BMY,BMY:US,BBG000DQLV23,"A Beat From Qiagen NV, but Only Half a Raise",2017-07-31 18:55:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VsieCSFnkQ0/a-beat-from-qiagen-nv-but-only-half-a-raise-cm824448,It was another solid quarter 160 for Qiagen NASDAQ QGEN as the maker of diagnostic and scientific products continues to post decent revenue growth while getting more efficient which drives income to grow even faster QIAsymphony Image source Qiagen
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Reports Growth in 2Q17,2017-07-31 18:38:10 +0000,http://finance.yahoo.com/r/d74ee8f3-44e7-3383-a2f4-42ba36d4e26a/bristol-myers-squibb-reports-growth-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb’s top line rose nearly 6% to ~$5.1 billion in 2Q17 due to operational growth of 7% in its revenue.
BMY,BMY:US,BBG000DQLV23,Clovis Sell-Off May Be Overdone,2017-07-31 17:45:00 +0000,http://finance.yahoo.com/r/7757bc4b-9fb9-392f-b6d2-b6e6177df909/clovis-pops-on-bristol-myers-partnership-intercept-dives-on-weak-earnings-biotech-movers.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31."
BMY,BMY:US,BBG000DQLV23,Midday Update: Boeing Lifts Dow to Fifth Straight Gain,2017-07-31 17:34:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y7Agql-YXd4/midday-update-boeing-lifts-dow-to-fifth-straight-gain-cm824423,Led higher by continued strength in shares of Boeing BA and sizable gains in the financial sector the Dow Jones Industrial Average was trading higher for a fifth consecutive day The S amp P 500 however was straddling the flatline while the Nasdaq lingered in negative territory for a
BMY,BMY:US,BBG000DQLV23,"A Beat From Qiagen NV, but Only Half a Raise",2017-07-31 16:49:00 +0000,http://finance.yahoo.com/r/ab141cb2-97de-36b2-9644-e0d2fb7048b1/a-beat-from-qiagen-nv-but-only-half-a-raise.aspx?yptr=yahoo&.tsrc=rss,"After a solid quarter, management raises 2017 revenue guidance but leaves earnings guidance intact."
BMY,BMY:US,BBG000DQLV23,"Pfizer Inc. (PFE) Stock Isn’t the Sexiest, But it’s Worth Checking Out",2017-07-31 16:20:38 +0000,https://finance.yahoo.com/news/pfizer-inc-pfe-stock-isn-162038282.html?.tsrc=rss,"Pfizer Inc. (NYSE:PFE) isn’t the sexiest stock in the market, but that doesn’t mean investors shouldn’t be interested.  PFE stock is up more than 2% in 2017, but down nearly 10% over the past year.  Pfizer is probably best known for Viagra, but it’s got other brands, too, such as Eliquis, Lipitor and Celebrex, among others."
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More",2017-07-31 13:58:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6oRUXJ7Xm1g/pharma-stock-roundup-q2-earnings-results-from-merck-lilly-bristol-myers-more-cm824039,Last week several pharma majors reported second quarter results Meanwhile important study data was released by Merck MRK and AstraZeneca AZN Recap of the Week s Most Important Stories A Look at Q2 Earnings Results Big pharma companies like Merck Lilly LLY Glaxo
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More",2017-07-31 12:06:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-q2-earnings-120612184.html?.tsrc=rss,Companies like AstraZeneca (AZN) and Lilly saw their shares fall after the release of second quarter results.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers and Clovis will partner for cancer combination trials,2017-07-31 11:10:39 +0000,http://finance.yahoo.com/r/63f9101f-bf39-3719-882b-852b2c7668bd/Story.aspx?guid=7485744B-0807-4306-942D-7982FBC80127&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb Co. and Clovis Oncology Inc. plan to work together to test a combination of Bristol-Myers' drug Opdivo and Clovis' drug Rubraca in cancer clinical trials. Shares of Clovis were up ...
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types,2017-07-31 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-clovis-oncology-105900413.html?.tsrc=rss,"Bristol-Myers Squibb Company and Clovis Oncology, Inc. announced the companies have entered into a clinical collaboration agreement to evaluate the combina"
BMY,BMY:US,BBG000DQLV23,Biotech Stocks Facing FDA Decision In August,2017-07-31 01:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T6SiGP_nfTo/biotech-stocks-facing-fda-decision-in-august-20170731-00044,Biotech Stocks Facing FDA Decision In August
BMY,BMY:US,BBG000DQLV23,What's Next for AstraZeneca and Its Dividend?,2017-07-29 15:57:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JMuXBPs8nwU/whats-next-for-astrazeneca-and-its-dividend-cm823811,Just over three summers ago AstraZeneca plc NYSE AZN CEO Pascal Soriot convinced shareholders to reject a generous buyout offer from Pfizer with promises that drugs in its pipeline would deliver even greater returns While the company has had some success since then
BMY,BMY:US,BBG000DQLV23,"Noteworthy Friday Option Activity: QUAD, RLGY, BMY",2017-07-28 20:58:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uR-5_SbYlx4/noteworthy-friday-option-activity-quad-rlgy-bmy-cm823626,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Quad Graphics Inc Symbol QUAD where a total of 1 275 contracts have traded so far representing approximately 127 500 underlying shares That amounts to about 77 8 of QUAD s
BMY,BMY:US,BBG000DQLV23,Roche Continues Steady Growth,2017-07-28 19:02:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UDr-Oh_pOtM/roche-continues-steady-growth-cm823554,Roche s 160 RHHBY recently released Q2 2017 earnings emphasize its research centric robust business model which has kept its results afloat despite competitive concerns We believe that Roche s mix of defensive and aggressive strategies positions it well as the pharma industry undergoes
BMY,BMY:US,BBG000DQLV23,Roche's (RHHBY) Sales Grow Y/Y in 1H17 on New Drug Launches,2017-07-28 17:03:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lUeqF9aPDKs/roches-rhhby-sales-grow-yy-in-1h17-on-new-drug-launches-cm823451,Roche Holding AG s RHHBY reported sales of CHF26 3 billion in the first half of 2017 up 5 from the year ago period Core earnings came in at CHF8 23 per share up 6 from the first half of 2016 Shares of Roche have performed better than the Zacks classified industry in the year
BMY,BMY:US,BBG000DQLV23,Seattle Genetics (SGEN) Q2 Loss Narrower than Expected,2017-07-28 16:59:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dKt87_okxfg/seattle-genetics-sgen-q2-loss-narrower-than-expected-cm823353,Seattle Genetics Inc SGEN reported a loss of 39 cents per share for the second quarter of 2017 narrower than the Zacks Consensus Estimate of a loss of 43 cents but wider than the year ago loss of 23 cents per share Revenues came in at 108 2 million up 13 4 year over year primarily on
BMY,BMY:US,BBG000DQLV23,"Company News For July 28, 2017",2017-07-28 16:04:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qP3JRBOToTU/company-news-for-july-28-2017-cm823228,160 160 160 160 160 160 160 160 Shares of Procter amp Gamble Co PG increased 1 6 after it posted net sales of 16 08 billion surpassing the Zacks Consensus Estimate of 16 00 billion 160 160 160 160 160 160 160 160 Mastercard Inc MA posted revenues
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. :BMY-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017",2017-07-28 16:02:27 +0000,http://finance.yahoo.com/r/61f73f20-fff6-3dc8-8b52-81f8036d5ee1/bristol-myers-squibb-co-bmy-us-earnings-analysis-q2-2017-by-the-numbers-july-28-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Bristol-Myers Squibb Co. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Bristol-Myers Squibb Co. – Eli Lilly and Company, Novartis AG Sponsored ADR, Johnson & Johnson and Amgen Inc. (LLY-US, NVS-US, JNJ-US and AMGN-US) that have also reported for ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,"Company News For July 28, 2017",2017-07-28 14:11:02 +0000,https://finance.yahoo.com/news/company-news-july-28-2017-141102379.html?.tsrc=rss,"Companies In The News Are: PG,MA,BMY,BUD"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : BMY-US : July 28, 2017",2017-07-28 13:46:49 +0000,http://finance.yahoo.com/r/3d827ca3-95d8-36e8-ae68-6283fc09553f/bristol-myers-squibb-co-breached-its-50-day-moving-average-in-a-bearish-manner-bmy-us-july-28-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Bristol-Myers Squibb Co.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,Featured Company News - The European Commission Approves Bristol-Myers Squibb's ORENCIA(R) for the Treatment of Active Psoriatic Arthritis,2017-07-28 11:10:00 +0000,https://finance.yahoo.com/news/featured-company-news-european-commission-111000737.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / July 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Bristol-Myers Squibb Co. (NYSE: BMY ) (""BMY""), following ..."
BMY,BMY:US,BBG000DQLV23,[$$] AstraZeneca Shocker Reminds Investors Miracle Drugs Are No Remedy for Risk,2017-07-28 06:03:39 +0000,http://finance.yahoo.com/r/64672c4f-7c2a-31a3-8fbf-4486caea0038/astrazeneca-shocker-reminds-investors-miracle-drugs-are-no-remedy-for-risk-1501164740?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,Chasing exciting new developments in medicine can be a very expensive endeavor. Such is the takeaway from AstraZeneca’s announcement that a hotly anticipated clinical trial didn’t meet expectations.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers beats Street 2Q forecasts,2017-07-28 05:24:38 +0000,https://finance.yahoo.com/news/bristol-myers-beats-street-2q-113006116.html?.tsrc=rss,"The New York-based company said it had net income of 56 cents per share. Earnings, adjusted for non-recurring costs, came to 74 cents per share. The results beat Wall Street expectations. The average estimate ..."
BMY,BMY:US,BBG000DQLV23,Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial,2017-07-28 02:58:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o5IpSFfXNhQ/mighty-astrazeneca-takes-a-lickin-on-failed-mystic-trial-cm822958,When AstraZeneca NYSE AZN spurned overtures from Pfizer NYSE PFE to combine in one of the biggest merger deals of all time it told investors not to worry It had plenty of irons in the fire that could fuel significant increases in sales profit and share price
BMY,BMY:US,BBG000DQLV23,Why Bristol-Myers Squibb Co (BMY) Shares Are Sinking Today,2017-07-27 20:59:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T5hn-xlHuTc/why-bristol-myers-squibb-co-bmy-shares-are-sinking-today-cm822890,InvestorPlace Stock Market News Stock Advice amp Trading Tips Bristol Myers Squibb Co NYSE BMY stock took a hit today 160 after 160 AstraZeneca plc ADR NYSE AZN reported a failed drug test Source A 4 via Flickr AstraZeneca plc ADR s failed test was
BMY,BMY:US,BBG000DQLV23,"Why AstraZeneca plc (ADR) (AZN), Advanced Micro Devices, Inc. (AMD) and Spirit Airlines Incorporated (SAVE) Are 3 of Today’s Worst Stocks",2017-07-27 20:18:52 +0000,https://finance.yahoo.com/news/why-astrazeneca-plc-adr-azn-201852202.html?.tsrc=rss,"You could have owners Advanced Micro Devices, Inc. (NASDAQ:AMD), Spirit Airlines Incorporated (NASDAQ:SAVE) or AstraZeneca plc (ADR) (NYSE:AZN).  Realistically speaking, the 14.9% setback AstraZeneca shares suffered today was likely overdone."
BMY,BMY:US,BBG000DQLV23,"With Cancer Rival's Immuno-oncology Flop, Bristol-Myers Looks Less Enticing for Suitors Too",2017-07-27 20:10:00 +0000,http://finance.yahoo.com/r/03f4fa5e-5ece-3836-af49-3641ee8f9925/with-cancer-rival-s-immuno-oncology-flop-bristol-myers-looks-less-enticing-for-suitors-too.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"The results from a clinical trial of AstraZeneca's lung cancer treatment increase uncertainty about Bristol-Myers' immuno-oncology franchise, according to BMO analyst Alex Arfaei."
BMY,BMY:US,BBG000DQLV23,"Thursday Sector Laggards: Healthcare, Technology & Communications",2017-07-27 19:57:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nSDo-1gaSKA/thursday-sector-laggards-healthcare-technology-communications-cm822790,The worst performing sector as of midday Thursday is the Healthcare sector showing a 1 0 loss Within that group Vertex Pharmaceuticals Inc Symbol VRTX and Bristol Myers Squibb Co Symbol BMY are two of the day s laggards showing a loss of 5 6 and 3 5 respectively Among
BMY,BMY:US,BBG000DQLV23,AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers,2017-07-27 19:12:00 +0000,http://finance.yahoo.com/r/cb44c44c-e6c4-3952-9ab4-d3b604b5ee2a/astrazeneca-shares-plunge-the-most-in-8-years-after-key-cancer-drug-failure.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Shares lost more than 16% in London trading
BMY,BMY:US,BBG000DQLV23,"Gilead Sciences, Inc. (GILD) Stock Has Tremendous Potential Even Post-Rally",2017-07-27 19:00:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/azk3h1DpzOY/gilead-sciences-inc-gild-stock-has-tremendous-potential-even-post-rally-cm822813,InvestorPlace Stock Market News Stock Advice amp Trading Tips For the past few months Gilead Sciences Inc NASDAQ GILD could not fulfill the technical upside promise It threatened several times to stop its slide but failed But then on June 16 it finally set a low that
BMY,BMY:US,BBG000DQLV23,Did the Checkpoint Inhibitor Bubble Just Burst?,2017-07-27 18:59:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5pwEoVuLcoY/did-the-checkpoint-inhibitor-bubble-just-burst-cm822753,What happened Shares of Agenus NASDAQ AGEN a small cap cancer immunotherapy company were down by almost 16 at 1 20 p m Thursday as a result of AstraZeneca s NYSE AZN Mystic trial 160 missing its primary endpoint for progression free survival in non small
BMY,BMY:US,BBG000DQLV23,Did the Checkpoint Inhibitor Bubble Just Burst?,2017-07-27 17:26:00 +0000,http://finance.yahoo.com/r/4c976d0e-f363-3442-a749-d8a9691643fe/did-the-checkpoint-inhibitor-bubble-just-burst.aspx?yptr=yahoo&.tsrc=rss,A failure in AstraZeneca&apos;s Mystic immuno-oncology drug trial sent shares of fellow cancer-fighters Agenus and Bristol-Myers Squibb tumbling Thursday.
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View",2017-07-27 17:03:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eax5alrMsx0/bristol-myers-bmy-beats-on-q2-earnings-tweaks-2017-view-cm822587,Bristol Myers Squibb Company s BMY second quarter 2017 earnings of 74 cents per share beat the Zacks Consensus Estimate of 73 cents and increased 7 from the year ago period Bristol Myers Squibb Company Price Consensus and EPS Surprise Bristol Myers
BMY,BMY:US,BBG000DQLV23,Why Bristol-Myers Squibb Co (BMY) Shares Are Sinking Today,2017-07-27 16:45:13 +0000,https://finance.yahoo.com/news/why-bristol-myers-squibb-co-164513643.html?.tsrc=rss,AstraZeneca plc (ADR)’s failed test was for lung cancer drug Imfinzi.  The reason that this matters to BMY stock is because it has a similar drug in testing. Bristol-Myers Squibb Co is testing a combination of Opdivo and Yervoy. Credit Suisse analysts warn that the similarity between the two drug tests may tamper expectations for BMY’s efforts.  The bad news for BMY stock came at the same time that it released its earnings report for the second quarter of 2017.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers shares slump after failed AstraZeneca drug trial,2017-07-27 16:43:43 +0000,https://finance.yahoo.com/news/bristol-myers-shares-fall-failed-123628299.html?.tsrc=rss,"Bristol-Myers Squibb Co shares  fell 4 percent on Thursday as investors bet that a failed  cancer-drug trial at AstraZeneca Plc would have negative  implications for Bristol-Myers' similar immunotherapy treatment  regimen.  AstraZeneca's Mystic study, released Thursday, looked at a  combination of immune system-boosting drugs to treat non-small  cell lung cancer (NSCLC).  Bristol-Myers is studying a similar combination of its two  top drugs in the same therapy class, Opdivo and Yervoy."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View",2017-07-27 15:07:03 +0000,https://finance.yahoo.com/news/bristol-myers-bmy-beats-q2-150703411.html?.tsrc=rss,"Bristol-Myers (BMY) reports encouraging second-quarter results, beating both earnings and sales estimates."
BMY,BMY:US,BBG000DQLV23,"AstraZeneca Beats, But Stock Dives On Drug Failure; 4 More Report",2017-07-27 14:27:26 +0000,http://finance.yahoo.com/r/fbf729ae-b2bc-30e8-b2c0-0076ed74d9bd/astrazeneca-beats-but-stock-dives-on-mystic-failure-3-more-drug-giants-report?src=A00220&yptr=yahoo&.tsrc=rss,"AstraZeneca topped profit views, but shares crashed on an immuno-oncology setback. Roche also beat."
BMY,BMY:US,BBG000DQLV23,[$$] AstraZeneca Shocker Reminds Investors Miracle Drugs Are No Remedy for Risk,2017-07-27 14:12:23 +0000,http://finance.yahoo.com/r/64672c4f-7c2a-31a3-8fbf-4486caea0038/astrazeneca-shocker-reminds-investors-miracle-drugs-are-no-remedy-for-risk-1501164740?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Chasing exciting new developments in medicine can be a very expensive endeavor. Such is the takeaway from AstraZeneca’s announcement that a hotly anticipated clinical trial didn’t meet expectations.
BMY,BMY:US,BBG000DQLV23,"Gilead Sciences, Inc. (GILD) Stock Has Tremendous Potential Even Post-Rally",2017-07-27 14:07:29 +0000,https://finance.yahoo.com/news/gilead-sciences-inc-gild-stock-140729807.html?.tsrc=rss,"For the past few months, Gilead Sciences, Inc. (NASDAQ:GILD) could not fulfill the technical upside promise.  Last night, GILD report earnings and the stock is spiking toward $76.  Click to Enlarge Coming into the earnings, sentiment had also shifted in favor of better days to come from GILD stock, and I am one who likes to trade with the market sentiment."
BMY,BMY:US,BBG000DQLV23,Why Bristol-Myers is Tanking,2017-07-27 13:55:00 +0000,http://finance.yahoo.com/r/6c881313-c249-3c35-aee4-0698d2592f24/why-bristol-myers-is-tanking-1501163722?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Bristol-Myers Squibb (BMY) are sinking this morning despite meeting earnings forecasts and raising the low-end of its full-year range.  Bristol-Myers reported a profit of 74 cents a share, in line with analyst forecasts, on sales of $5.1 billion, ever so slightly higher than expectations for $5.09 billion.  Bristol also said it would earn between $2.90 and $3.00 in 2017, up from a range of $2.85 to $3.00."
BMY,BMY:US,BBG000DQLV23,"Health Care Sector Update for 07/27/2017: JNJ, PFE, ABT, MRK, AMGN, BMY, EW, VAR",2017-07-27 13:37:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q2eeKD4kEYA/health-care-sector-update-for-07272017-jnj-pfe-abt-mrk-amgn-bmy-ew-var-cm822335,Top Health Care Stocks Top Health Care Stocks JNJ 0 6 JNJ 0 6 PFE flatPFE flat ABT 0 2 ABT 0 2 MRK 4 MRK 4 AMGN 2 8 AMGN 2 8 Health care shares were mixed in pre market trade Thursday Health care shares were mixed in pre market trade Thursday In sector news Bristol
BMY,BMY:US,BBG000DQLV23,AstraZeneca shares take historic tumble on failed lung cancer study,2017-07-27 13:12:17 +0000,https://finance.yahoo.com/news/astrazeneca-shares-historic-tumble-failed-131217026.html?.tsrc=rss,AstraZeneca shares fell 15 percent after disappointing results for a lung cancer treatment in highly anticipated clinical trial.
BMY,BMY:US,BBG000DQLV23,AstraZeneca shares take historic tumble on failed lung cancer study,2017-07-27 13:12:17 +0000,http://finance.yahoo.com/r/3d831fc8-e3a1-3128-aaee-9cc1265efce6/104613924?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104613924&yptr=yahoo&.tsrc=rss,AstraZeneca shares fell 15 percent after disappointing results for a lung cancer treatment in highly anticipated clinical trial.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Q2 Earnings Beats Estimates,2017-07-27 13:01:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8f-fLsfzyuU/bristol-myers-bmy-q2-earnings-beats-estimates-cm822220,Bristol Myers Squibb Company BMY is a New York based major producer and distributor of pharmaceuticals and other healthcare related products The company s key oncology products include Opdivo Sprycel Yervoy and the recently launched Empliciti Other than oncology the company is focused
BMY,BMY:US,BBG000DQLV23,"Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up",2017-07-27 13:00:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IhX_01R-Ga0/gilead-gild-tops-q2-earnings-revenue-estimates-stock-up-cm822274,Gilead Sciences Inc s GILD reported results for the second quarter wherein both earnings and revenues surpassed expectations Second quarter 2017 earnings including the impact of stock based compensation expenses of 2 51 per share beat the Zacks Consensus Estimate of 2 11
BMY,BMY:US,BBG000DQLV23,"Pre-Market Most Active for Jul 27, 2017 :  TWTR, AZN, FB, BTI, SIRI, BMY, CMCSA, MRK, NOK, SHOR, QQQ, TLT",2017-07-27 12:56:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EuZICV6RobM/pre-market-most-active-for-jul-27-2017-twtr-azn-fb-bti-siri-bmy-cmcsa-mrk-nok-shor-qqq-tlt-cm822235,The NASDAQ 100 Pre Market Indicator is up 50 37 to 6 001 1 The total Pre Market volume is currently 15 649 936 shares traded The following are the most active stocks for the pre market session Twitter Inc TWTR is 2 03 at 17 58 with 4 940 383 shares traded
BMY,BMY:US,BBG000DQLV23,"AstraZeneca’s late-stage trial failure sends its shares down 16% and Bristol-Myers, Merck stocks seesawing",2017-07-27 12:43:14 +0000,http://finance.yahoo.com/r/4b5ef644-ce8c-3d7b-a781-0d16ed994def/Story.aspx?guid=3C2799A6-72C4-11E7-9E70-77DD8B13BB6F&siteid=yhoof2&yptr=yahoo&.tsrc=rss,The three pharmaceutical companies are competing to be leaders in treating lung cancer.
BMY,BMY:US,BBG000DQLV23,Investor Network: Bristol-Myers Squibb Company to Host Earnings Call,2017-07-27 12:40:00 +0000,https://finance.yahoo.com/news/investor-network-bristol-myers-squibb-124000477.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / July 27, 2017 / Bristol-Myers Squibb Company (NYSE: BMY ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, July 27, 2017 at 10:30 ..."
BMY,BMY:US,BBG000DQLV23,"Morning Movers: Bristol-Myers Sinks, Barrick Climbs, Alexion Soars",2017-07-27 12:29:00 +0000,http://finance.yahoo.com/r/7e8c2156-466d-3e78-8bb7-c2578d59baef/morning-movers-bristol-myers-sinks-barrick-climbs-alexion-soars-1501158563?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Stocks look set for a higher open one day after the Federal Reserve left interest rates unchanged. S&P 500 futures have advanced 0.2%, while Dow Jones Industrial Average futures have ticked up 0.1%. Nasdaq ..."
BMY,BMY:US,BBG000DQLV23,AstraZeneca sinks on failed lung cancer study,2017-07-27 11:34:00 +0000,https://finance.yahoo.com/video/astrazeneca-sinks-failed-lung-cancer-113400485.html?.tsrc=rss,CNBC's Meg Tirrell reports shares of the pharmaceutical giant are having a bad day after the company's experimental lung cancer drug failed to pass a major test.
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers reports Q2 profit match, revenue beat",2017-07-27 11:22:22 +0000,http://finance.yahoo.com/r/a9a3d08e-ef0d-32ec-b2c4-82d83efa4efe/Story.aspx?guid=9FA2DC2F-9B62-4F3F-B4EA-25DFE25DA7D6&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb Co. reported a second-quarter profit match and revenue beat on Thursday, but shares plummeted 6.2% in premarket trade on news of rival AstraZeneca's late-stage clinical trial failure, ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Q2 Earnings Beats Estimates,2017-07-27 11:15:11 +0000,https://finance.yahoo.com/news/bristol-myers-bmy-q2-earnings-111511801.html?.tsrc=rss,Bristol-Myers (BMY) reports second-quarter results beating both earnings and sales estimates.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Reports Second Quarter Financial Results,2017-07-27 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-reports-second-105900663.html?.tsrc=rss,"Bristol-Myers Squibb Company today reported results for the second quarter of 2017 which were highlighted by strong sales for key products Opdivo and Eliquis and regulatory approvals for Opdivo, the Daklinza and Sunvepra regimen and Orencia."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers quarterly sales meet Wall Street estimates,2017-07-27 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-quarterly-sales-meet-105900025.html?.tsrc=rss,"Bristol-Myers Squibb Co posted a lower second-quarter net profit on Thursday as research and development costs increased, but sales of its key cancer immunotherapies continued to rise, meeting Wall Street ..."
BMY,BMY:US,BBG000DQLV23,"Earnings Reaction History: Bristol Myers Squibb Co, 45.5% Follow-Through Indicator, 2.5% Sensitive",2017-07-27 10:57:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9LFNGBg5NME/earnings-reaction-history-bristol-myers-squibb-co-455-follow-through-indicator-25-sensitive-cm822171,Expected Earnings Release 07 27 2017 PremarketExpected Earnings Release 07 27 2017 Premarket Avg Extended Hours Dollar Volume 7 836 863Avg Extended Hours Dollar Volume 7 836 863 Bristol Myers Squibb Co BMY is due to issue its quarterly earnings report in the upcoming extended
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Q2 17 Earnings Conference Call At 10:30 AM ET,2017-07-27 09:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jn429s_ijPM/bristolmyers-squibb-q2-17-earnings-conference-call-at-1030-am-et-20170727-01167,Bristol-Myers Squibb Q2 17 Earnings Conference Call At 10:30 AM ET
BMY,BMY:US,BBG000DQLV23,Cancer drug war heats up as Big Pharma squares off against Genentech,2017-07-27 01:23:44 +0000,http://finance.yahoo.com/r/d928f391-1e5b-3fc3-a5a5-7a759686a823/genentech-cancer-immunotherapy-bms-bmy-pd-1-pd-l1.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Drug giant Bristol-Myers Squibb Co. filed suit Wednesday against biotech pioneer Genentech Inc., saying the South San Francisco company infringed patents in developing a potential blockbuster cancer immunotherapy drug.  Bristol-Myers Squibb (BMY) seeks unspecified damages in the suit, filed in U.S. District Court in Delaware.  At stake are sales of potentially billions of dollars worth of cancer drugs."
BMY,BMY:US,BBG000DQLV23,Biogen Inc Wants to Be the &quot;Fastest-Growing Large-Cap Biotech Company&quot;,2017-07-26 21:58:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BDeXT9wEtSc/biogen-inc-wants-to-be-the-fastest-growing-large-cap-biotech-company-cm822075,Biogen NASDAQ BIIB started 160 the biotech earnings season off with a bang generating enough revenue for the company to have confidence to increase its revenue guidance for the year Earnings weren t nearly as hot but Biogen has a good excuse one time investments in the company
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s 2Q17 Estimates: Expect Growth!,2017-07-26 20:35:43 +0000,http://finance.yahoo.com/r/67c9d89f-77b5-3ea1-af3c-ad97fcab41c9/bristol-myers-squibbs-2q17-estimates-expect-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb (BMY) is expected to report a rise of ~4.4% in its earnings to $5.1 billion for 2Q17 on July 27, 2017."
BMY,BMY:US,BBG000DQLV23,"Pre-Market Earnings Report for July 27, 2017 :  PG, CMCSA, VZ, MO, MA, CELG, CHTR, BMY, DOW, UPS, AMT, COP",2017-07-26 20:16:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p7T0mmWMir0/pre-market-earnings-report-for-july-27-2017-pg-cmcsa-vz-mo-ma-celg-chtr-bmy-dow-ups-amt-cop-cm822036,The following companies are expected to report earnings prior to market open on 07 27 2017 Visit our Earnings Calendar for a full list of expected earnings releases Procter amp Gamble Company PG is reporting for the quarter ending June 30 2017 The
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s 2Q17 Earnings: Analysts’ Estimates,2017-07-26 18:38:53 +0000,http://finance.yahoo.com/r/a4f0a142-3983-361f-b033-3dd555d9e46f/bristol-myers-squibbs-2q17-earnings-analysts-estimates?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Headquartered in New York City, Bristol-Myers Squibb (BMY) is a leading American pharmaceutical company."
BMY,BMY:US,BBG000DQLV23,AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?,2017-07-26 16:04:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/We_3LvdX5JU/aveo-pharmaceuticals-aveo-q2-earnings-whats-in-store-cm821682,AVEO Pharmaceuticals Inc AVEO is expected to report second quarter 2017 results next week In the last reported quarter AVEO delivered a positive surprise of 7 69 Let s see how things are shaping up for this quarter AVEO s share price movement shows that the stock has
BMY,BMY:US,BBG000DQLV23,"VOO, MDT, GILD, BMY: Large Outflows Detected at ETF",2017-07-26 15:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HclNiSQ9EWs/voo-mdt-gild-bmy-large-outflows-detected-at-etf-cm821640,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard S amp P 500 ETF Symbol VOO where we have detected an approximate 254 1 million dollar outflow that s a 0 4 decrease week over week from 316 434
BMY,BMY:US,BBG000DQLV23,"Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN",2017-07-26 15:03:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gcMbigB7vzo/biotech-stocks-jul27-q2-earnings-roster-bmy-celg-alxn-cm821738,The second quarter earnings season is off to a strong start As of July 25 approximately 128 S amp P 500 companies or 36 1 of the index s total membership have reported results 160 A deep look into the results show that earnings for the companies reported so far are up 7 year over year
BMY,BMY:US,BBG000DQLV23,These 2 Pharma Giants May Be on Pfizer's M&A Radar Right Now,2017-07-26 13:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X04rQfJPW80/these-2-pharma-giants-may-be-on-pfizers-ma-radar-right-now-cm821381,Despite overcoming a whopping 23 billion in branded patent expirations over the course of 2011 to 2016 and returning to growth on an operational basis Wall Street thinks Pfizer NYSE PFE still has a lot more to work to do The basic issue is that Pfizer is barreling toward
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s ORENCIA® (abatacept) Receives Second European Commission Approval in Less than a Year – New Approval for Treatment of Active Psoriatic Arthritis (PsA)1,2017-07-26 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-orencia-abatacept-105900587.html?.tsrc=rss,Bristol-Myers Squibb Company announced today that the European Commission has approved ORENCIA alone or in combination with methotrexate for the treatment of activ
BMY,BMY:US,BBG000DQLV23,The Startling History Behind Merck's New Cancer Blockbuster,2017-07-26 06:15:00 +0000,http://finance.yahoo.com/r/d74e1e4f-30c1-371e-a780-221ef012547c/the-startling-history-behind-mercks-new-cancer-blockbuster?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"The success of Merck’s blockbuster cancer drug pembrolizumab (Keytruda) was anything but inevitable. It was discovered accidentally, weathered two company acquisitions, and nearly out-licensed for next to nothing -- before it was developed in one of the most aggressive pharma programs in history."
BMY,BMY:US,BBG000DQLV23,U.S. Food and Drug Administration Accepts Bristol-Myers Squibb’s Applications for Opdivo (nivolumab) Four-Week Dosing Schedule Across All Approved Indications,2017-07-24 20:15:00 +0000,https://finance.yahoo.com/news/u-food-drug-administration-accepts-201500835.html?.tsrc=rss,Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Applications to update Opdivo dosing to include 480 mg infused over 30 minutes every four weeks for all currently approved monotherapy indications.
BMY,BMY:US,BBG000DQLV23,Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers,2017-07-24 19:29:49 +0000,https://finance.yahoo.com/news/ahead-earnings-why-buying-merck-192949530.html?.tsrc=rss,"Pharmaceutical giants Bristol-Myers Squibb Co (NYSE: BMY ) and Merck & Co., Inc. (NYSE: MRK ) both release their second quarter earnings reports this week. According to BMO Capital, investors should be ..."
BMY,BMY:US,BBG000DQLV23,Novartis in 2Q17: Performance of Innovative Medicines,2017-07-24 18:35:43 +0000,http://finance.yahoo.com/r/39086da0-2137-31af-ae6a-94ae7bfecfe0/novartis-in-2q17-performance-of-innovative-medicines?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,The overall contribution of the Innovative Medicines segment was ~67.6% at $8.28 billion for 2Q17.
BMY,BMY:US,BBG000DQLV23,What's in the Cards for Exelixis (EXEL) in Q2 Earnings?,2017-07-24 17:09:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tPDyd3kQAmk/whats-in-the-cards-for-exelixis-exel-in-q2-earnings-cm820318,Exelixis Inc EXEL is scheduled to report second quarter 2017 results on Aug 2 after the market closes Exelixis track record is outstanding The company has surpassed expectations in all the four trailing quarters with an average positive earnings surprise of 512 1
BMY,BMY:US,BBG000DQLV23,Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs,2017-07-24 16:10:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZANGpJtUFzw/surprise-in-store-for-healthcare-in-q2-buy-top-ranked-etfs-cm820210,Despite the hurdles in Trump s plans to repeal and replace Obamacare healthcare is the second best performing sector this year lagging technology The optimism comes especially from encouraging industry trends and hopes of a favorable policy environment The Trump administration plans to
BMY,BMY:US,BBG000DQLV23,Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs,2017-07-24 14:11:02 +0000,https://finance.yahoo.com/news/surprise-store-healthcare-q2-buy-141102443.html?.tsrc=rss,"Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs."
BMY,BMY:US,BBG000DQLV23,U.S. Food and Drug Administration Expands Approval of Yervoy® (ipilimumab) to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma,2017-07-24 10:59:00 +0000,https://finance.yahoo.com/news/u-food-drug-administration-expands-105900774.html?.tsrc=rss,Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has expanded the indication for Yervoy® injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Reports Expanded Approval For Yervoy - Quick Facts,2017-07-24 07:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BFa-bUJhzo4/bristolmyers-squibb-reports-expanded-approval-for-yervoy--quick-facts-20170724-00384,Bristol-Myers Squibb Reports Expanded Approval For Yervoy - Quick Facts
BMY,BMY:US,BBG000DQLV23,"Noteworthy Friday Option Activity: BMY, COST, UAA",2017-07-21 20:02:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mQTY1FSDGqQ/noteworthy-friday-option-activity-bmy-cost-uaa-cm819533,Among the underlying components of the S amp P 500 index we saw noteworthy options trading volume today in Bristol Myers Squibb Co Symbol BMY where a total of 30 687 contracts have traded so far representing approximately 3 1 million underlying shares That amounts to about 49 3 of BMY
BMY,BMY:US,BBG000DQLV23,What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings?,2017-07-21 17:08:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ml7WPn97Riw/whats-in-the-offing-for-bristol-myers-bmy-in-q2-earnings-cm819391,Bristol Myers Squibb Company BMY is scheduled to report first quarter 2017 results on Jul 27 before the opening bell Last quarter the company beat earnings estimates by 16 7 Bristol Myers Squibb Company Price and EPS Surprise Bristol Myers Squibb Company Price and
BMY,BMY:US,BBG000DQLV23,What&apos;s in the Offing for Bristol-Myers (BMY) in Q2 Earnings?,2017-07-21 15:23:03 +0000,https://finance.yahoo.com/news/apos-offing-bristol-myers-bmy-152303937.html?.tsrc=rss,"Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%."
BMY,BMY:US,BBG000DQLV23,3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now?,2017-07-21 03:02:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PcU5QIOFpvk/3-hottest-biotech-stocks-of-2017-are-they-still-buys-now-cm819044,Biotechnology s top performing stocks this year have already given investors envy inspiring returns but there s reason to believe that Calithera Biosciences NASDAQ CALA Aurinia Pharmaceuticals NASDAQ AUPH and Esperion Therapeutics NASDAQ ESPR could still go
BMY,BMY:US,BBG000DQLV23,Amazon Snags Former Box Executive of Health In Pursuit of the Medical Industry,2017-07-20 19:54:00 +0000,http://finance.yahoo.com/r/6ade9931-857e-31ce-8594-3f3563882d77/amazon-snags-former-box-exec-of-health-in-pursuit-of-the-medical-industry.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Amazon has been reinforcing its HIPAA-compliant offerings so that health-care providers and insurers can save and transfer customer data.
BMY,BMY:US,BBG000DQLV23,"Exane Asset Management Buys Monsanto Co, Biogen Inc, Qiagen NV, Sells Citigroup Inc, W R Grace, ...",2017-07-20 10:02:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o47GE0W7INw/exane-asset-management-buys-monsanto-co-biogen-inc-qiagen-nv-sells-citigroup-inc-w-r-grace-cm818454,Exane Asset Management New Purchases MON BIIB BAC ALXN OLN NXPI LBTYA WOOF MBLY VWR Added Positions QGEN ASH FTI GILD DB BMY PCAR DBVT SU HAL Reduced Positions C UBS WFC TSU APD HES TMUS AXTA APC CLR Sold Out GRA WLK
BMY,BMY:US,BBG000DQLV23,Gilead's HCV Portfolio Receives a Boost With Vosevi Approval,2017-07-19 16:06:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xykBXjyUaNE/gileads-hcv-portfolio-receives-a-boost-with-vosevi-approval-cm818109,Gilead Sciences Inc GILD announced that the FDA has approved Vosevi Sovaldi velpatasvir 100 mg voxilaprevir 100 mg tablets The drug is a single tablet regimen STR for the re treatment of chronic hepatitis C virus HCV infection in adults with genotype 1 2 3 4 5 or 6
BMY,BMY:US,BBG000DQLV23,"Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics",2017-07-19 12:03:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DAq2yLLqSiI/better-buy-celldex-therapeutics-inc-vs-juno-therapeutics-cm817864,Celldex Therapeutics NASDAQ CLDX and Juno Therapeutics NASDAQ JUNO are both once promising clinical stage biotechs that have fallen on extremely hard times of late Over the past two and half years for example these former stars have each lost a staggering amount of
BMY,BMY:US,BBG000DQLV23,"How Risky Is Organovo Holdings, Inc.?",2017-07-18 21:04:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xIVbZrgL-wk/how-risky-is-organovo-holdings-inc-cm817740,You probably won t be shocked to learn that Organovo Holdings Inc NASDAQ ONVO has historically been a risky stock After all the share price of the 3D bioprinting company dropped nearly 36 in 2014 and 66 in 2015 and it s down 23 so far this year Over the last three and
BMY,BMY:US,BBG000DQLV23,"UPRO, BMY, ABT, GS: ETF Outflow Alert",2017-07-18 16:03:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lpFKN2-i-xw/upro-bmy-abt-gs-etf-outflow-alert-cm817505,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the ProShares UltraPro S amp P500 Symbol UPRO where we have detected an approximate 32 5 million dollar outflow that s a 3 5 decrease week over week
BMY,BMY:US,BBG000DQLV23,Quintiles IMS: A Novel Way To Invest In Biopharma,2017-07-17 22:49:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wZ878-6rxjY/quintiles-ims-a-novel-way-to-invest-in-biopharma-cm817177,By In Sickness and Wealth ByIn Sickness and Wealth Photo credit istockphoto com Photo credit Photo credit istockphoto comistockphoto com By David Lerman amp Jodie Warner By David Lerman amp Jodie WarnerBy David Lerman Jodie Warner
BMY,BMY:US,BBG000DQLV23,How Bristol-Meyers Squibb Has Benefited from Intangible Assets,2017-07-17 15:26:54 +0000,http://finance.yahoo.com/r/8e730d71-3e24-3f9c-9a0f-9f9008707a54/bristol-meyers-benefited-intangible-assets?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Meyers Squibb considers its people to be its competitive advantage, and it plans to build long-term, sustainable growth through innovation."
BMY,BMY:US,BBG000DQLV23,MannKind Names Steven Binder CFO,2017-07-17 09:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T13Sw3-Lw6c/mannkind-names-steven-binder-cfo-20170717-00623,MannKind Names Steven Binder CFO
BMY,BMY:US,BBG000DQLV23,"3 Stocks That Turned $1,000 Into at Least $2,017 in 12 Months",2017-07-15 11:45:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aqMrzpHwZCs/3-stocks-that-turned-1000-into-at-least-2017-in-12-months-cm816473,Although there is some truth in the saying that it takes money to make money that doesn t mean investors can t start small and reap big rewards With little more than 1 000 in your account you can turn what seems to be a tiny grubstake into a weighty retirement nest egg Let s look
BMY,BMY:US,BBG000DQLV23,Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain?,2017-07-15 00:46:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d8QigSQVFPc/down-148-is-celldex-therapeutics-stock-an-incredible-bargain-cm816443,What happened Despite a widespread rally across the biotech landscape last month the struggling clinical stage cancer company Celldex Therapeutics NASDAQ CLDX 160 still managed to shed 14 8 of its value in June 160 according to S amp P Global Market Intelligence
BMY,BMY:US,BBG000DQLV23,Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain?,2017-07-14 23:01:00 +0000,http://finance.yahoo.com/r/7b5db167-3002-3458-825d-a982798b5323/down-148-is-celldex-therapeutics-stock-an-incredib.aspx?yptr=yahoo&.tsrc=rss,Celldex&apos;s clinical updates at ASCO failed to impress investors.
BMY,BMY:US,BBG000DQLV23,AstraZeneca Pops On Report CEO Won&apos;t Jump Ship For Teva Pharma,2017-07-14 20:42:44 +0000,http://finance.yahoo.com/r/b83e77ee-8157-3b71-8794-e33da1b0ffac/astrazeneca-pops-on-report-ceo-wont-jump-ship-for-teva-pharma?src=A00220&yptr=yahoo&.tsrc=rss,"AstraZeneca stock rallied Friday on reports CEO Pascal Soriot will remain on board, defying rumors he would leave to take the top job at Teva Pharmaceutical."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : BMY-US : July 14, 2017",2017-07-14 13:10:12 +0000,http://finance.yahoo.com/r/5ffa3c02-4aaa-3b61-b2b1-d6fecffb3bf0/bristol-myers-squibb-co-breached-its-50-day-moving-average-in-a-bearish-manner-bmy-us-july-14-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Bristol-Myers Squibb Co.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,What Allergan’s Valuation as of July 13 Tells Us,2017-07-14 11:40:11 +0000,http://finance.yahoo.com/r/96c0385a-c5b0-39cc-9bbf-5a5641d2578f/what-allergans-valuation-as-of-july-13-tells-us?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"For 2Q17, Wall Street analysts estimate AGN's EPS (earnings per share) to come in at $3.93, which would be a 17.5% growth over 2Q16."
BMY,BMY:US,BBG000DQLV23,Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?,2017-07-14 00:45:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W3RpU-720zY/why-are-shares-of-exelixis-exel-up-77-so-far-in-2017-cm815934,Shares of Exelixis Inc EXEL have gained almost 4 68 on Aug 12 The company s shares have rallied a whopping 77 this year so far outperforming the 7 8 increase registered by the Zacks categorized Medical Biomedical and Genetics industry during this period Here we analyze the
BMY,BMY:US,BBG000DQLV23,Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?,2017-07-13 22:11:10 +0000,https://finance.yahoo.com/news/why-shares-exelixis-exel-77-221110564.html?.tsrc=rss,"Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company&apos;s shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period."
BMY,BMY:US,BBG000DQLV23,BMY Crosses Below Key Moving Average Level,2017-07-13 16:47:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CQ3NBAxwNa0/bmy-crosses-below-key-moving-average-level-cm815660,In trading on Thursday shares of Bristol Myers Squibb Co Symbol BMY crossed below their 200 day moving average of 54 70 changing hands as low as 54 22 per share Bristol Myers Squibb Co shares are currently trading down about 1 1 on the day The chart below shows the one year
BMY,BMY:US,BBG000DQLV23,"Gainers & Losers Of July 12: CALA, TRVN, GEMP, ALDR, INSY...",2017-07-12 22:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J0mW0CsSDfQ/gainers--losers-of-july-12-cala-trvn-gemp-aldr-insy-20170712-01296,"Gainers & Losers Of July 12: CALA, TRVN, GEMP, ALDR, INSY..."
BMY,BMY:US,BBG000DQLV23,3 Dividend Stocks That Thrive in Market Crashes,2017-07-12 22:17:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bZ2LKsAQTRU/3-dividend-stocks-that-thrive-in-market-crashes-cm815301,Stock market crashes can take a toll on just about any stock portfolio but investors might come out of a market crash a bit better off if they add Wal Mart Stores NYSE WMT Johnson amp Johnson NYSE JNJ and Bristol Myers Squibb NYSE BMY to their holdings
BMY,BMY:US,BBG000DQLV23,3 Dividend Stocks That Thrive in Market Crashes,2017-07-12 20:11:00 +0000,http://finance.yahoo.com/r/f6b3bbd4-916a-32b9-938c-2ddcce31c163/3-dividend-stocks-that-thrive-in-market-crashes.aspx?yptr=yahoo&.tsrc=rss,"Sales at Johnson & Johnson, Wal-Mart, and Bristol-Myers Squibb could outperform their peers in a market crash, and that could help investors beat the market."
BMY,BMY:US,BBG000DQLV23,3 Top Healthcare Stocks to Buy Today,2017-07-11 22:45:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W5NF9vljQoI/3-top-healthcare-stocks-to-buy-today-cm814762,The healthcare sector is riddled with companies that are long on potential but short on profits For that reason it makes sense to be extremely picky about which stocks you choose to buy So which healthcare stocks do we think are worth the risk right now We asked that very question
BMY,BMY:US,BBG000DQLV23,Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx,2017-07-11 22:44:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1E9pc97kLoM/exelixis-bristol-myers-initiate-trial-on-opdivo-cabometyx-cm814746,Exelixis Inc EXEL and Bristol Myers Squibb Company BMY announced that they have initiated a phase III trial CheckMate 9ER The trial will evaluate Bristol Myers immuno oncology drug Opdivo in combination with Exelixis Cabometyx or Opdivo and Yervoy in combination with Cabometyx
BMY,BMY:US,BBG000DQLV23,3 Dividend Stocks in Healthcare,2017-07-11 21:46:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fgQeau4PhcA/3-dividend-stocks-in-healthcare-cm814734,No one gets to choose when they get sick That s a big reason the demand for healthcare tends to remain stable even during periods of economic stress For income investors this means some healthcare 160 stocks can be looked upon as reliable dividend payers But which healthcare
BMY,BMY:US,BBG000DQLV23,3 Top Healthcare Stocks to Buy Today,2017-07-11 21:15:00 +0000,http://finance.yahoo.com/r/3b847fe7-9095-3865-bc7c-3fa1e1dd5fcf/3-top-healthcare-stocks-to-buy-today.aspx?yptr=yahoo&.tsrc=rss,"Here&apos;s why our healthcare experts think that Bristol-Myers Squibb, Celgene, and Mazor Robotics are all great buys right now."
BMY,BMY:US,BBG000DQLV23,Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx,2017-07-11 20:44:08 +0000,https://finance.yahoo.com/news/exelixis-bristol-myers-initiate-trial-204408859.html?.tsrc=rss,"Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb on the Street: Analyst Recommendations in July 2017,2017-07-11 14:36:14 +0000,http://finance.yahoo.com/r/0891f87f-7a1a-3092-a5f3-fcf0c9992c2e/bristol-myers-squibb-on-the-street-analyst-recommendations-in-july-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb's strong clinical pipeline is one of its primary strengths for long-term growth potential. In 2016, BMY invested $4.9 billion in R&D."
BMY,BMY:US,BBG000DQLV23,Behind Bristol-Myer Squibb’s Virology Franchise Prospects,2017-07-11 13:06:12 +0000,http://finance.yahoo.com/r/e4b6d079-eec1-3c8f-8069-186a4894c237/behind-bristol-myer-squibbs-virology-franchise-prospects?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, Bristol-Myers Squibb’s (BMY) hepatitis C franchise reported revenues of ~$1.6 billion, which represents a ~2% YoY fall."
BMY,BMY:US,BBG000DQLV23,Why Bristol-Myers Squibb’s Empliciti Matters in 2017,2017-07-11 11:36:01 +0000,http://finance.yahoo.com/r/495bced2-5452-3367-824a-2d7a3c587abf/why-bristol-myers-squibbs-empliciti-matters-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, Bristol-Myers Squibb’s (BMY) Empliciti reported revenues of ~$133 million. The US accounted for ~89% of Empliciti’s total revenues."
BMY,BMY:US,BBG000DQLV23,"ARNA Heartened By Phase II Trial, BMY To Face FDA In Nov., Concert Back In Play",2017-07-11 01:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e5EnfJPEo4I/arna-heartened-by-phase-ii-trial-bmy-to-face-fda-in-nov-concert-back-in-play-20170711-00039,"ARNA Heartened By Phase II Trial, BMY To Face FDA In Nov., Concert Back In Play"
BMY,BMY:US,BBG000DQLV23,These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now,2017-07-10 21:47:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gUAoYLFTik8/these-5-cancer-drugs-will-be-the-biggest-winners-5-years-from-now-cm814090,Five years fly by quickly In 2022 the landscape for cancer drugs will be different from today but with some familiar players Pharmaceutical market analysis firm EvaluatePharma recently published its report looking at what the biopharmaceutical world might look like five years
BMY,BMY:US,BBG000DQLV23,These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now,2017-07-10 20:22:00 +0000,http://finance.yahoo.com/r/0ca6ce6f-5816-30f6-be9e-60b7a94bc2be/these-5-cancer-drugs-will-be-the-biggest-winners-5.aspx?yptr=yahoo&.tsrc=rss,Five cancer drugs that are already successful will become even bigger winners by 2022.
BMY,BMY:US,BBG000DQLV23,How Bristol-Myers Squibb Stock Has Performed in 2Q17,2017-07-10 14:37:23 +0000,http://finance.yahoo.com/r/f8e984c7-edbf-3a2b-aa01-4c33d8812413/how-bristol-myers-squibb-stock-has-performed-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Headquartered in New York City, Bristol-Myers Squibb (BMY) is an American pharmaceutical company that develops innovative medicines in various therapeutic areas, including cardiovascular, neuroscience, ..."
BMY,BMY:US,BBG000DQLV23,Inside BMY’s Yervoy: What the Revenue Trends Tell Us,2017-07-10 14:36:22 +0000,http://finance.yahoo.com/r/ba786eb5-2703-3434-9822-132620b9a69d/inside-bmys-yervoy-what-the-revenue-trends-tell-us?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, Bristol-Myers Squibb’s (BMY) Yervoy reported revenues of ~$1.1 billion, which represents a ~6% YoY rise."
BMY,BMY:US,BBG000DQLV23,A Look at Merck and Co.’s Performance in 2Q17,2017-07-10 13:08:32 +0000,http://finance.yahoo.com/r/11796645-f22a-3b75-a3a1-1bd0c6235856/a-look-at-merck-and-co-s-performance-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Headquartered in New Jersey, Merck and Co. (MRK) is one of the oldest and largest pharmaceutical companies by revenue. It does business as Merck Sharp & Dohme outside the United…"
BMY,BMY:US,BBG000DQLV23,What Sprycel Could Mean for Bristol-Myers Squibb,2017-07-10 13:06:27 +0000,http://finance.yahoo.com/r/9f493802-455a-3ac2-9652-7c6d858b1ec2/what-sprycel-could-mean-for-bristol-myers-squibb?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, Bristol-Myer Squibb’s (BMY) Sprycel reported revenues of ~$1.8 billion, which represents a ~13% YoY rise."
BMY,BMY:US,BBG000DQLV23,"Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",2017-07-10 12:00:00 +0000,https://finance.yahoo.com/news/exelixis-bristol-myers-squibb-initiate-120000837.html?.tsrc=rss,"Exelixis, Inc. and Bristol-Myers Squibb Company today announced the initiation of the phase 3 CheckMate 9ER trial to evaluate Opdivo® in combination with CABOMETYX™ tablets, a small molecule inhibitor of receptor tyrosine kinases, or Opdivo and Yervoy® in combination with CABOMETYX versus sunitinib in patients with previously untreated, advanced or metastatic renal cell carcinoma ."
BMY,BMY:US,BBG000DQLV23,U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Sprycel (dasatinib) in Children with Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia,2017-07-10 10:58:00 +0000,https://finance.yahoo.com/news/u-food-drug-administration-accepts-105800542.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application to include an indication for Sprycel to treat children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia , as well as a powder for oral suspension formulation of Sprycel."
BMY,BMY:US,BBG000DQLV23,FDA Accepts For Priority Review Bristol-Myers' SNDA For Sprycel For Children,2017-07-10 07:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZgBft8s2hiE/fda-accepts-for-priority-review-bristolmyers-snda-for-sprycel-for-children-20170710-00309,FDA Accepts For Priority Review Bristol-Myers' SNDA For Sprycel For Children
BMY,BMY:US,BBG000DQLV23,What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers,2017-07-10 01:20:00 +0000,http://finance.yahoo.com/r/c3ad822f-a27c-3c09-a37d-7c3fbfe96835/fda-puts-three-merck-studies-on-hold-what-it-means-for-other-drug-makers.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The FDA has placed a clinical hold on three combination studies of Merck's Keytruda in multiple myeloma.
BMY,BMY:US,BBG000DQLV23,Bristol Myers Vies to Be King of Immune-Boosting Cancer Drugs with New Trial Update,2017-07-10 00:38:00 +0000,http://finance.yahoo.com/r/6e0b97a2-867b-39ea-b34e-c90d26fb79b5/bristol-myers-vies-to-be-king-of-immuno-boosting-cancer-drugs-with-new-trial-update.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The trial's success props open doors for exploring new uses for Opdivo's treatment in immunotherapy.
BMY,BMY:US,BBG000DQLV23,Is Amgen Making a Mistake?,2017-07-07 17:58:00 +0000,http://finance.yahoo.com/r/ecd2e7db-ad0a-3824-988a-a6a0cd05caf2/is-amgen-making-a-mistake-1499450322?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Yesterday, Celgene (CELG) bought the rights to an anti-cancer treatment from Beigene, making it the latest company to bet big on what's known as a PD-1 inhibitor.  Bristol-Myers Squibb (BMY) and Merck (MRK) are the leaders in this field but it's Amgen (AMGN) that's notably absent.  Thus, for companies who have decided to invest heavily in the I/O space like Celgene, Regeneron Pharmaceuticals (REGN) (and others), it makes more sense to own both components of a combination rather than give much of the value away to the PD(L)1 owner."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Gets FDA Nod for Orencia's Label Expansion,2017-07-07 15:51:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iFDGcYsWCE8/bristol-myers-gets-fda-nod-for-orencias-label-expansion-cm813048,Bristol Myers Squibb Company BMY announced that the FDA has approved Orencia for the treatment of adults with active psoriatic arthritis PsA The approval was based on results from two randomized double blind placebo controlled trials Per the data from the trials Orencia improved
BMY,BMY:US,BBG000DQLV23,This Biotech Finds Its Stride With Kidney Cancer Treatment,2017-07-07 14:46:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/De3-HLLEvYs/this-biotech-finds-its-stride-with-kidney-cancer-treatment-cm812918,Exelixis EXEL is on a hot streak The South San Francisco based biotech 160 has notched 160 a series of achievements in recent months posting first time operating profit confirming the effectiveness of its breakout compound for treating kidney cancer and retiring
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: MRK's Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook",2017-07-07 13:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2RgckUoZQQ8/pharma-stock-roundup-mrks-keytruda-mm-combo-studies-on-clinical-hold-bayer-to-revise-outlook-cm812971,Merck s MRK Keytruda has hit a stumbling block with the FDA placing three combination studies on clinical hold Meanwhile Bayer BAYRY said that it will be revising its outlook when it reports second quarter results later this month to reflect inventory issues associated with the Crop
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Gets FDA Nod for Orencia&apos;s Label Expansion,2017-07-07 13:16:01 +0000,https://finance.yahoo.com/news/bristol-myers-gets-fda-nod-131601916.html?.tsrc=rss,Bristol-Myers Squibb Company (BMY) announced that the FDA has approved Orencia for treatment of adults with active psoriatic arthritis (PsA).
BMY,BMY:US,BBG000DQLV23,How BMY’s Opdivo Is Expected to Perform in 2017,2017-07-07 13:09:29 +0000,http://finance.yahoo.com/r/32ef5861-6a97-39d5-a190-2402b77ee1d6/how-bmys-opdivo-is-expected-to-perform-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, Bristol-Myers Squibb’s (BMY) Opdivo reported revenues of ~$3.8 billion. The drug accounted for ~20% of BMY's total revenues in 2016."
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: MRK&apos;s Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook",2017-07-07 12:25:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-mrk-apos-122512550.html?.tsrc=rss,3 studies on Merck&apos;s (MRK) Keytruda have been put on clinical hold while Bayer said that it expects to revise its 2017 outlook when it reports Q2 results.
BMY,BMY:US,BBG000DQLV23,How Bristol-Myers Squibb Is Expected to Perform in 2017,2017-07-07 11:40:44 +0000,http://finance.yahoo.com/r/6559f2f8-16a0-3196-b9a3-a6febe642b6a/how-bristol-myers-squibb-is-expected-to-perform-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, Bristol-Myers Squibb reported revenues of ~$19.4 billion, which was ~17% higher YoY. In 2016, the US accounted for ~55% of BMY's revenue share."
BMY,BMY:US,BBG000DQLV23,"BMY's Orencia Scores Another FDA Nod, Janssen Ends Deal With CAPR, PBYI On Track",2017-07-07 01:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/grM11UAzP9M/bmys-orencia-scores-another-fda-nod-janssen-ends-deal-with-capr-pbyi-on-track-20170707-00017,"BMY's Orencia Scores Another FDA Nod, Janssen Ends Deal With CAPR, PBYI On Track"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Opdivo Superior to Yervoy in Melanoma Study,2017-07-06 20:45:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pdD4wFbda1M/bristol-myers-opdivo-superior-to-yervoy-in-melanoma-study-cm812657,Bristol Myers Squibb Company BMY announced that a phase III study CheckMate 238 evaluating Opdivo 3 mg kg versus Yervoy 10 mg kg met its primary endpoint at a planned interim analysis The study evaluated patients with stage IIIb c or stage IV melanoma who are at high risk of
BMY,BMY:US,BBG000DQLV23,Bristol-Myers&apos; Opdivo Superior to Yervoy in Melanoma Study,2017-07-06 18:22:06 +0000,https://finance.yahoo.com/news/bristol-myers-apos-opdivo-superior-182206439.html?.tsrc=rss,"Bristol-Myers Squibb Company (BMY) announced that a phase III study, CheckMate-238, evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg met its primary endpoint at a planned interim analysis."
BMY,BMY:US,BBG000DQLV23,"Company News for July 06, 2017",2017-07-06 16:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NTwm3GKMLhE/company-news-for-july-06-2017-cm812458,160 160 160 Shares of O Reilly Automotive Inc ORLY tanked 41 6 after the company s same store sales grew 1 7 during second quarter well below its projections of 3 to 5 growth 160 160 160 Bristol Myers Squibb Co s BMY shares rose 0 8 after the company declared
BMY,BMY:US,BBG000DQLV23,"Company News for July 06, 2017",2017-07-06 14:52:02 +0000,https://finance.yahoo.com/news/company-news-july-06-2017-145202792.html?.tsrc=rss,"Companies in the News are: ORLY,BMY,MORE,PRPO"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis (PsA) in Adults,2017-07-06 11:30:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-orencia-abatacept-113000074.html?.tsrc=rss,Bristol-Myers Squibb Company announced today the U.S. Food and Drug Administration has approved ORENCIA for the treatment of adults with active Psoriatic Arthritis
BMY,BMY:US,BBG000DQLV23,7 Stocks to Buy in July,2017-07-05 23:43:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Me-KJxBafM0/7-stocks-to-buy-in-july-cm812147,InvestorPlace Stock Market News Stock Advice amp Trading Tips With Independence Day behind us traders are looking ahead to what July will bring to Wall Street Washington remains preoccupied with the healthcare reform effort moving through the Senate The Federal Reserve is
BMY,BMY:US,BBG000DQLV23,Bristol Beats Itself In Cancer Test; Can It Conquer Dow&apos;s Merck?,2017-07-05 20:15:34 +0000,http://finance.yahoo.com/r/81ffd12e-f2b1-31a9-81a0-e1e9346f5bdc/bristol-beats-itself-in-cancer-test-can-it-conquer-dows-merck?src=A00220&yptr=yahoo&.tsrc=rss,"Bristol could add $1 billion in sales after a study showed its Opdivo was better than another of its drugs, Yervoy, in treating melanoma."
BMY,BMY:US,BBG000DQLV23,"Bank on Gilead Sciences, Inc. (GILD) Stock Getting Its Mojo Back",2017-07-05 14:20:24 +0000,https://finance.yahoo.com/news/bank-gilead-sciences-inc-gild-142024734.html?.tsrc=rss,"For the past 12 months Gilead Sciences, Inc. (NASDAQ:GILD) could have served as the poster-child for a falling knife to avoid.  Finally, GILD stock was able to participate in the biotech sector bounce that happened in June."
BMY,BMY:US,BBG000DQLV23,"Early movers: VNTV, CAB, PFE, AAPL, INTC, WMT, DIS, BMY & more",2017-07-05 11:59:39 +0000,http://finance.yahoo.com/r/9737cb8c-7071-36c3-942c-4397b6bf0cc3/104567901?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104567901&yptr=yahoo&.tsrc=rss,These are the stocks posting the largest moves before the bell.
BMY,BMY:US,BBG000DQLV23,"Early movers: VNTV, CAB, PFE, AAPL, INTC, WMT, DIS, BMY & more",2017-07-05 11:59:39 +0000,https://finance.yahoo.com/news/early-movers-vntv-cab-pfe-115939411.html?.tsrc=rss,These are the stocks posting the largest moves before the bell.
BMY,BMY:US,BBG000DQLV23,Tech set to extend losses as stock market focuses on Fed minutes,2017-07-05 11:38:21 +0000,http://finance.yahoo.com/r/c808c2a0-68fd-35a7-aa40-13c935b613db/Story.aspx?guid=A21A5722-6157-11E7-A449-2CBA60BED3C2&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Shares of technology companies on Wednesday look ready to extend declines to a fourth straight session, with investors returning from Fourth of July celebrations focused on coming Federal Reserve minutes...."
BMY,BMY:US,BBG000DQLV23,Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint,2017-07-05 10:15:00 +0000,https://finance.yahoo.com/news/phase-3-study-evaluating-safety-101500049.html?.tsrc=rss,"Bristol-Myers Squibb Company announced today that a Phase 3 study evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection met its primary endpoint at a planned interim analysis, demonstrating superior recurrence-free survival  in patients receiving Opdivo compared to Yervoy."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Phase 3 Study Of Opdivo Vs Yervoy Meets Primary Goal,2017-07-05 06:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/icK1RxbvXMA/bristolmyers-phase-3-study-of-opdivo-vs-yervoy-meets-primary-goal-20170705-00218,Bristol-Myers Phase 3 Study Of Opdivo Vs Yervoy Meets Primary Goal
BMY,BMY:US,BBG000DQLV23,16 Stock Picks With Staying Power,2017-07-04 12:43:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0z3Snbfe3Fg/16-stock-picks-with-staying-power-cm811530,Call him Ishmael On New Year s Eve 1948 he is born at Mercy Medical Center in Des Moines Ishmael s parents scrape together a pre nest egg of 3 000 out of savings and gifts from relatives They invest the money in a mutual fund called Lexington Corporate Leaders which has a
BMY,BMY:US,BBG000DQLV23,10 Biotech Stocks With Game-Changing Dates in Q3,2017-07-03 21:43:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e5HMV4M6h8Q/10-biotech-stocks-with-game-changing-dates-in-q3-cm811459,InvestorPlace Stock Market News Stock Advice amp Trading Tips For some investors they ve created small fortunes For others they ve brought nothing but misery For all investors though there s no denying the fact that biotech stocks have kept things interesting if only because they
BMY,BMY:US,BBG000DQLV23,3 Top High-Yield Pharmaceutical Stocks to Buy Now,2017-07-03 19:43:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6oRA351SpMo/3-top-high-yield-pharmaceutical-stocks-to-buy-now-cm811338,Stocks that sport unusually high dividend yields compared to their peers often do so because an underlying problem with their business has cut into their value Still high yielders can on occasion represent fantastic bargains for risk tolerant investors Big pharma
BMY,BMY:US,BBG000DQLV23,"Ex-Dividend Reminder: Bristol-Myers Squibb, Medtronic and Global Net Lease",2017-07-03 15:48:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GIpVGJNzNJQ/ex-dividend-reminder-bristol-myers-squibb-medtronic-and-global-net-lease-cm811191,Looking at the universe of stocks we cover at Dividend Channel on 7 5 17 Bristol Myers Squibb Co Symbol BMY Medtronic PLC Symbol MDT and Global Net Lease Inc Symbol GNL will all trade ex dividend for their respective upcoming dividends Bristol Myers Squibb Co will pay
BMY,BMY:US,BBG000DQLV23,"Notable Monday Option Activity: TWX, FC, BMY",2017-07-03 15:45:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5YPX23vXbRM/notable-monday-option-activity-twx-fc-bmy-cm811295,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Time Warner Inc Symbol TWX where a total of 83 573 contracts have traded so far representing approximately 8 4 million underlying shares That amounts to about 235 4 of TWX s
BMY,BMY:US,BBG000DQLV23,Finding Value in Biotech?,2017-07-03 14:14:00 +0000,http://finance.yahoo.com/r/d634d985-bc32-34a9-a642-02f4d895aef6/finding-value-in-biotech-1499091291?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Biotech stocks are often considered among the faster-growing stocks in the market. But a number of them--Amgen (AMGN) Biogen (BIIB), and Gilead Sciences (GILD), for instance--are part of the Russell 1000 ..."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for July 05, 2017",2017-07-03 13:14:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dy_0dQnsy1o/bristol-myers-squibb-company-bmy-ex-dividend-date-scheduled-for-july-05-2017-cm811075,Bristol Myers Squibb Company BMY will begin trading ex dividend on July 05 2017 A cash dividend payment of 0 39 per share is scheduled to be paid on August 01 2017 Shareholders who purchased BMY prior to the ex dividend date are eligible for the cash dividend payment This marks the
BMY,BMY:US,BBG000DQLV23,"Early movers: TSLA, GSK, LVS, WYNN, CAT, GS, BMY & more",2017-07-03 12:08:08 +0000,http://finance.yahoo.com/r/6e4efc03-e6fb-3e0f-81c0-9a60371be417/104565061?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104565061&yptr=yahoo&.tsrc=rss,These are the stocks posting the largest moves before the bell.
BMY,BMY:US,BBG000DQLV23,"Barron's Picks And Pans: Bristol-Myers, Texas Instruments, Altaba And More",2017-07-02 21:01:53 +0000,https://finance.yahoo.com/news/barrons-picks-pans-bristol-myers-210153685.html?.tsrc=rss,This weekend's Barron's offers a look at a big pharma stock that acts like a big tech one. Other featured articles discuss an old-school chip stock poised to reward investors and who the players may be ...
BMY,BMY:US,BBG000DQLV23,Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb,2017-07-02 15:36:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AbfLFJAhdZg/better-buy-glaxosmithkline-plc-vs-bristol-myers-squibb-cm810952,Big pharma stocks are arguably set to shine now that the threat of hard caps 160 on drug prices is off the table Global prescription drug sales after all are forecast to grow at a healthy 6 5 per year for the next five years running according to EvaluatePharma Keeping
BMY,BMY:US,BBG000DQLV23,"A New Class of Cancer Drugs Could Wipe Out Your Life Savings, Even if You're Enrolled in Medicare",2017-07-02 15:36:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q1CXGsDc8zg/a-new-class-of-cancer-drugs-could-wipe-out-your-life-savings-even-if-youre-enrolled-in-medicare-cm810950,No one ever said retirement was going to be easy As more and more Americans have marched toward the proverbial finish line we re seeing on a greater scale that many are unprepared for the rising costs of being retired According to the Social Security Administration 61 of
BMY,BMY:US,BBG000DQLV23,Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb,2017-07-02 13:47:00 +0000,http://finance.yahoo.com/r/a4f91118-090e-35e4-859e-0e0ccd2435c6/better-buy-glaxosmithkline-plc-vs-bristol-myers-sq.aspx?yptr=yahoo&.tsrc=rss,Is GlaxoSmithKline or Bristol-Myers Squibb the better big pharma stock to buy right now?
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Could Return 40% in Two to Three Years,2017-07-01 06:21:00 +0000,http://finance.yahoo.com/r/a1323251-be47-3d95-8ff6-77264e2bdf4d/bristol-myers-could-return-40-in-two-to-three-years-1498890109?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Of course, as a drug company, Bristol-Myers (BMY) isn’t grouped with the tech sector.  The stock has taken a beating in the past year due to a disappointing lung-cancer trial and a related setback involving Opdivo, the company’s key IO product.  The stock could return 25% to 40% in the next two to three years as Opdivo use grows and Bristol’s pipeline yields marketable products."
BMY,BMY:US,BBG000DQLV23,Beauty of Weakness; Uncertainty Remains: Rev Shark's Best Blog,2017-07-01 01:00:00 +0000,http://finance.yahoo.com/r/f5670848-fd44-3921-8f28-95a972156d43/on-not-talking-about-the-market-darth-vader-meet-amazon-jim-cramer-s-best-blog.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Guest James 'Rev Shark' DePorre discusses the beauty of weakness and also mentions that uncertainty remains.
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises",2017-06-30 13:06:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7zucFpzGRNM/pharma-stock-roundup-sanofi-ra-drug-gets-eu-nod-merck-cetp-inhibitor-surprises-cm810414,This week s highlights include positive data on Merck s MRK CETP inhibitor while Sanofi SNY gained EU approval for its rheumatoid arthritis RA drug which has blockbuster potential Recap of the Week s Most Important Stories Merck s CETP Inhibitor Meets Endpoint in REVEAL
BMY,BMY:US,BBG000DQLV23,Is It Too Late to Buy Portola Pharmaceuticals Stock?,2017-06-29 22:03:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5Ibp8W6ORvU/is-it-too-late-to-buy-portola-pharmaceuticals-stock-cm810244,Portola Pharmaceuticals NASDAQ PTLA is enjoying the best year ever at least in terms of stock performance After losing more than half of its market cap last year the biotech s share price is up more than 140 so far in 2017 There has been nothing but good news for Portola
BMY,BMY:US,BBG000DQLV23,"M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks",2017-06-29 22:02:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gIpEven5cMk/mas-rich-pipelines-catalyst-rich-2017-to-drive-pharma-stocks-cm810261,Although pharma and biotech stocks are facing challenges in the form of increasing focus on the high prices of drugs a changing competitive scenario and mixed results the sector s fundamentals remain strong innovation mergers and acquisitions M amp As product approvals and positive
BMY,BMY:US,BBG000DQLV23,Strategy To YieldBoost Bristol-Myers Squibb Co. From 2.8% To 5.9% Using Options,2017-06-29 19:04:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BeN5sJPLuP4/strategy-to-yieldboost-bristol-myers-squibb-co-from-28-to-59-using-options-cm810169,Shareholders of Bristol Myers Squibb Co Symbol BMY looking to boost their income beyond the stock s 2 8 annualized dividend yield can sell the September 2018 covered call at the 65 strike and collect the premium based on the 2 12 bid which annualizes to an additional 3 1 rate of
BMY,BMY:US,BBG000DQLV23,Risks To Consider As J&J's Stock Inches Up,2017-06-29 16:03:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RAyzSQqWpvg/risks-to-consider-as-jjs-stock-inches-up-cm810035,Johnson amp Johnson s 160 JNJ market price 160 fell 3 in a single day following its Q1 2017 earnings announcement which is a rare occurrence for the generally steady stock However the stock price has 160 rebounded by nearly 160 12 in the last 2 5 months effectively adding
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb a Top 25 Dividend Giant With 2.80% Yield (BMY),2017-06-29 13:04:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bzuap_4YRGM/bristol-myers-squibb-a-top-25-dividend-giant-with-280-yield-bmy-cm809743,Bristol Myers Squibb Co Symbol BMY has been named as a Top 25 Dividend Giant by ETF Channel with a whopping 8 07B worth of stock held by ETFs and above average DividendRank statistics including a strong 2 80 yield according to the most recent Dividend Channel
BMY,BMY:US,BBG000DQLV23,Where to find value in health-care stocks ahead of Senate...,2017-06-28 16:39:00 +0000,https://finance.yahoo.com/video/where-value-health-care-stocks-163900033.html?.tsrc=rss,CNBC's Landon Dowdy reports on the health care sector moves ahead of the Senate health-care bill vote. The “Fast Money Halftime Report” traders weigh in.
BMY,BMY:US,BBG000DQLV23,Modern Family Star Eric Stonestreet Challenges Americans to Support the Cancer Community and Learn about Immuno-Oncology Research Through Ready. Raise. Rise.,2017-06-28 10:59:00 +0000,https://finance.yahoo.com/news/modern-family-star-eric-stonestreet-105900732.html?.tsrc=rss,"Eric Stonestreet of television’s hit comedy “Modern Family” and new reality competition series, “The Toy Box,” is once again lending his star power to the Ready. Raise. Rise. campaign, challenging people across the country to show their support for the cancer community and spread the word about immuno-oncology – a rapidly evolving area of cancer research that aims to offer renewed hope and the potential ..."
BMY,BMY:US,BBG000DQLV23,Gilead's (GILD) HCV Drug Application Accepted in the EU,2017-06-27 15:53:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s92YtOxU6zI/gileads-gild-hcv-drug-application-accepted-in-the-eu-cm808796,Gilead Sciences Inc GILD announced that the Committee for Medicinal Products for Human Use CHMP has adopted a positive opinion on the company s Marketing Authorization Application MAA for Vosevi following an accelerated assessment procedure Vosevi is an experimental once daily
BMY,BMY:US,BBG000DQLV23,A Closer Look At Bristol-Myers Squibb's Oncology Business,2017-06-27 15:22:00 +0000,http://finance.yahoo.com/r/17bce3c3-a1b4-3066-8654-7a482407d336/a-closer-look-at-bristol-myers-squibbs-oncology-business?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Cancer drugs (oncology business) account for nearly 60% of Bristol-Myers Squibb's valuation, according to our estimates. Empirically and fundamentally speaking, the stock’s performance is highly tied to clinical trial results and the uptake of the company’s new cancer drugs."
BMY,BMY:US,BBG000DQLV23,AVEO's Kidney Cancer Candidate Gets CHMP Recommendation,2017-06-27 14:54:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YreC2kI--0M/aveos-kidney-cancer-candidate-gets-chmp-recommendation-cm808839,AVEO Pharmaceuticals Inc AVEO announced on Friday that the Committee for Medicinal Products for Human Use CHMP has recommended the approval of its lead candidate Fotivda tivozanib for the treatment of advanced renal cell carcinoma RCC We note that the European Commission
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti,2017-06-27 14:01:02 +0000,https://finance.yahoo.com/news/bristol-myers-reports-data-immuno-140102912.html?.tsrc=rss,"Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti."
BMY,BMY:US,BBG000DQLV23,2 Pharma Buyout Targets That May Surprise You,2017-06-27 13:52:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4X3eYqqERa8/2-pharma-buyout-targets-that-may-surprise-you-cm808514,Mergers and acquisitions can be extremely profitable for pharmaceutical investors A little over a year ago for instance Jazz Pharmaceuticals swooped in to buy Celator Pharmaceuticals 160 in a cash deal valued at 1 5 billion representing a stunning 73 windfall for Celator
BMY,BMY:US,BBG000DQLV23,Three Little-Noticed Wins for Corporations at the Supreme Court,2017-06-27 13:00:06 +0000,http://finance.yahoo.com/r/bfd65893-301a-3121-9f70-04cc17c4bf85/three-little-noticed-wins-for-corporations-at-the-supreme-court?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Some class-action plaintiffs will have to find less-friendly courts for their lawsuits.
BMY,BMY:US,BBG000DQLV23,"Beware Of Tidy Success Narratives -- In Pharma, And In Life",2017-06-27 04:35:00 +0000,http://finance.yahoo.com/r/c6bf3700-f486-3a9c-adff-71fd99d2f62f/beware-of-tidy-success-narratives-in-pharma-and-in-life?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"“If your idea succeeds, everybody says you’re persistent,” pioneering Harvard surgeon Folkman said. “If it doesn’t, you’re obstinate.”"
BMY,BMY:US,BBG000DQLV23,After health care gains eight percent in one quarter,2017-06-26 14:24:00 +0000,https://finance.yahoo.com/video/health-care-gains-eight-percent-142400664.html?.tsrc=rss,"According to Kensho, health care gains 8% in one quarter with Merck, Bristol-Myers and Pfizer as some of its outperformers."
BMY,BMY:US,BBG000DQLV23,InPlay from Briefing.com,2017-06-26 06:57:35 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
BMY,BMY:US,BBG000DQLV23,3 Stocks That Could Double Your Money,2017-06-24 16:49:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Tjo-32X9Do8/3-stocks-that-could-double-your-money-cm807771,Nearly any stock could double your money You just might have to wait a long time potentially even decades For investors who don t want to wait that long and have a high tolerance for risk there are several stocks that could double in a much shorter time frame Celldex
BMY,BMY:US,BBG000DQLV23,Four-Year Follow-up with Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) in Patients with Advanced Multiple Myeloma Shows Long-term Efficacy in ELOQUENT-2 Trial,2017-06-24 14:00:00 +0000,https://finance.yahoo.com/news/four-empliciti-elotuzumab-plus-lenalidomide-140000363.html?.tsrc=rss,"Bristol-Myers Squibb Company presented four-year follow-up data from the Phase 3 ELOQUENT-2 study in which Empliciti plus lenalidomide/dexamethasone continued to demonstrate efficacy in patients with relapsed/refractory multiple myeloma , compared to patients treated with lenalidomide/dexamethasone alone."
BMY,BMY:US,BBG000DQLV23,Portola Pharmaceuticals' FDA Nod Could Spark M&A Interest,2017-06-24 13:51:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dgzi__jOhkk/portola-pharmaceuticals-fda-nod-could-spark-ma-interest-cm807751,Portola Pharmaceuticals NASDAQ PTLA 160 investors who stuck with it after stumbles caused share prices to crash last year are feeling a bit better about their position today On Friday the Food and Drug Administration approved the company s first drug 160 Bevyxxa and
BMY,BMY:US,BBG000DQLV23,Portola Pharmaceuticals&apos; FDA Nod Could Spark M&A Interest,2017-06-24 12:03:00 +0000,http://finance.yahoo.com/r/f4d78d7a-5352-35d8-800c-2acfc9b9fea7/portola-pharmaceuticals-fda-nod-could-spark-ma-int.aspx?yptr=yahoo&.tsrc=rss,"The FDA has approved its first commercial medicine, and because it could reshape a big indication, the company may have just gotten a lot more interesting to suitors."
BMY,BMY:US,BBG000DQLV23,"After Hours Most Active for Jun 23, 2017 :  EXEL, EBAY, AVP, FNB, GRPN, BGCP, NRZ, CVS, MU, ESV, BMY, AAPL",2017-06-23 20:59:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BgumOuwTx-4/after-hours-most-active-for-jun-23-2017-exel-ebay-avp-fnb-grpn-bgcp-nrz-cvs-mu-esv-bmy-aapl-cm807652,The NASDAQ 100 After Hours Indicator is up 17 to 5 803 28 The total After hours volume is currently 712 465 360 shares traded The following are the most active stocks for the after hours session Exelixis Inc EXEL is 0 0047 at 23 78 with 16 395 951 shares traded
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod",2017-06-23 13:55:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f-piJqMQvYk/pharma-stock-roundup-nvs-scores-with-positive-data-shire-adhd-drug-gets-fda-nod-cm807285,This week s highlights include positive data from Novartis NVS while the FDA approved a couple of attention deficit hyperactive disorder ADHD drugs Recap of the Week s Most Important Stories Novartis Eye Drug Hits Endpoints CANTOS Data Impresses Novartis experimental
BMY,BMY:US,BBG000DQLV23,Changes in Bristol-Myers Squibb’s Profitability 1Q17,2017-06-22 11:36:18 +0000,http://finance.yahoo.com/r/5f1bcdec-0ebe-3a78-acc3-98bf08bbd966/changes-bristol-myers-squibbs-profitability-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers reported a net profit of ~$1.57 billion in 1Q17—compared to $1.19 billion in 1Q16. Analysts expect a net profit of $1.18 billion during 2Q16.
BMY,BMY:US,BBG000DQLV23,7 Healthcare Stocks to Buy Now,2017-06-21 22:19:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PCltdn2YVU4/7-healthcare-stocks-to-buy-now-cm806577,InvestorPlace Stock Market News Stock Advice amp Trading Tips With the benefit of perfect hindsight the middle of 2015 represented a high tide in healthcare investing Source Shutterstock While the sector overall has recovered this year the Health Care SPDR ETF NYSEARCA
BMY,BMY:US,BBG000DQLV23,AVEO Reaches Enrollment Target in Pivotal Tivozanib Study,2017-06-21 17:24:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iyfxKyGEXPg/aveo-reaches-enrollment-target-in-pivotal-tivozanib-study-cm806395,AVEO Pharmaceuticals Inc AVEO announced that the phase III study TIVO 3 evaluating tivozanib in patients with refractory advanced renal cell carcinoma RCC has reached its enrollment target of 322 patients two months earlier than the targeted timeline Top line data from the study
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Reported Revenue Growth in 1Q17,2017-06-21 14:37:47 +0000,http://finance.yahoo.com/r/0917ff25-fa3e-392e-97c7-4f47b923c469/bristol-myers-squibb-reported-revenue-growth-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb (BMY) reported 12% growth in its top line to ~$4.93 billion during 1Q17 due to 13% operational growth in its revenues
BMY,BMY:US,BBG000DQLV23,S&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017,2017-06-21 14:00:00 +0000,https://finance.yahoo.com/news/p-500-buybacks-fall-17-140000215.html?.tsrc=rss,"- Q1 2017 repurchases is 1.6% less than Q4 2016 and 17.5% less than Q1 2016 - EPS support via share count reduction significantly declines - Cash reserves set new record NEW YORK , June 21, 2017 /PRNewswire/ ..."
BMY,BMY:US,BBG000DQLV23,Analyzing Bristol-Myers Squibb’s Valuation on June 20,2017-06-21 13:08:03 +0000,http://finance.yahoo.com/r/d9d97336-5d2a-3ba7-8378-48387cccb598/analyzing-bristol-myers-squibbs-valuation-june-20?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"As of June 20, 2017, Bristol-Myers Squibb was trading at a forward PE multiple of ~18.0x—compared to the industry average of 16.0x."
BMY,BMY:US,BBG000DQLV23,Adcetris-Opdivo Combination for Classical Hodgkin Lymphoma,2017-06-21 11:36:50 +0000,http://finance.yahoo.com/r/d00231af-7efc-366e-ad31-959952a81077/adcetris-opdivo-combination-classical-hodgkin-lymphoma?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb and Seattle Genetics are evaluating the Adcetris-Opdivo combination to treat patients with relapsed classical Hodgkin Lymphoma.
BMY,BMY:US,BBG000DQLV23,U.S. Supreme Court ruling threatens massive talc litigation against J&J,2017-06-21 11:00:00 +0000,https://finance.yahoo.com/news/u-supreme-court-ruling-threatens-110000317.html?.tsrc=rss,"Johnson & Johnson is seizing  upon a U.S. Supreme Court ruling from Monday limiting where  injury lawsuits can be filed to fight off claims it failed to  warn women that talcum powder could cause ovarian cancer.  New Jersey-based J&J has been battling a series of lawsuits  over its talc-based products, including Johnson's Baby Powder,  brought by around 5,950 women and their families.  The company  denies any link between talc and cancer."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces the Expiration of its Cash Tender Offer,2017-06-21 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-announces-expiration-105900385.html?.tsrc=rss,"Bristol-Myers Squibb Company announced today the expiration, as of 5:00 p.m., New York City time, on June 20, 2017, of its previously announced cash tender offer for any and all of certain of its outstanding debt securities."
BMY,BMY:US,BBG000DQLV23,U.S. Supreme Court ruling threatens massive talc litigation against J&J,2017-06-21 01:45:22 +0000,https://finance.yahoo.com/news/u-supreme-court-ruling-threatens-014522084.html?.tsrc=rss,"Johnson & Johnson is seizing  upon a U.S. Supreme Court ruling from Monday limiting where  injury lawsuits can be filed to fight off claims it failed to  warn women that talcum powder could cause ovarian cancer.  New Jersey-based J&J has been battling a series of lawsuits  over its talc-based products, including Johnson's Baby Powder,  brought by around 5,950 women and their families.  The company  denies any link between talc and cancer."
BMY,BMY:US,BBG000DQLV23,Exelixis's Cabometyx Positive for First-Line Kidney Cancer,2017-06-20 23:19:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hViLhjShXlw/exelixiss-cabometyx-positive-for-first-line-kidney-cancer-cm805981,Exelixis Inc EXEL announced results from an analysis of the data from the phase II trial CABOSUN The study compared Cabometyx to Pfizer s PFE Sutent in the first line treatment of intermediate or poor risk advanced renal cell carcinoma RCC patients We note that Cabometyx tablets
BMY,BMY:US,BBG000DQLV23,U.S. Supreme Court ruling threatens massive talc litigation against J&J,2017-06-20 23:13:40 +0000,https://finance.yahoo.com/news/u-supreme-court-ruling-threatens-231340752.html?.tsrc=rss,"Johnson & Johnson is seizing  upon a U.S. Supreme Court ruling from Monday limiting where  injury lawsuits can be filed to fight off claims it failed to  warn women that talcum powder could cause ovarian cancer.  New Jersey-based J&J has been battling a series of lawsuits  over its talc-based products, including Johnson's Baby Powder,  brought by around 5,950 women and their families.  The company  denies any link between talc and cancer."
BMY,BMY:US,BBG000DQLV23,Why Pomalyst Could See Significant Revenue Growth in 2017,2017-06-20 22:05:43 +0000,http://finance.yahoo.com/r/95f53564-2f92-3041-a6c3-84b674b0f87a/why-pomalyst-could-see-significant-revenue-growth-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, Celgene’s (CELG) Pomalyst crossed the $1 billion sales mark."
BMY,BMY:US,BBG000DQLV23,Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada,2017-06-20 21:20:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o91wj7k3cXk/gileads-gild-hbv-drug-vemlidy-receives-approval-in-canada-cm805929,Gilead Sciences Inc GILD announced that hepatitis B virus HBV drug Vemlidy has been approved in Canada Health Canada granted a Notice of Compliance NOC for Vemlidy 25mg tablets a once daily treatment for adults with chronic HBV infection with compensated liver disease The approval
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Any and All of Certain of its Outstanding Debt Securities,2017-06-20 19:40:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-announces-pricing-194000200.html?.tsrc=rss,Bristol-Myers Squibb Company announced today the pricing terms of its previously announced cash tender offer for any and all of certain of its outstanding debt securities.
BMY,BMY:US,BBG000DQLV23,Updates on the Adcetris and Opdivo Combination,2017-06-20 19:36:10 +0000,http://finance.yahoo.com/r/d1dfdee6-b40d-3a1a-8523-e64daa81bf20/updates-adcetris-opdivo-combination?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb and Seattle Genetics are evaluating a combination of Opdivo with Adcetris to treat refractory or relapsed classical Hodgkin Lymphoma.
BMY,BMY:US,BBG000DQLV23,Data from the Checkmate-205 Study Evaluating Opdivo,2017-06-20 18:06:03 +0000,http://finance.yahoo.com/r/2b3e90bf-caa5-3a7f-ba70-5813caf12681/data-checkmate-205-study-evaluating-opdivo?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Follow-up data were released from the Checkmate-205 study. It evaluated long-term effects of PD-1 inhibitors in patients with classical Hodgkin Lymphoma.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Is Poised for a Breakout,2017-06-20 16:15:00 +0000,http://finance.yahoo.com/r/78058eb1-febe-3097-9811-7348b8deee6f/bristol-myers-squibb-is-poised-for-a-breakout.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Shares of BMY finished Monday at new June highs and are now set up well for an upside breakout.
BMY,BMY:US,BBG000DQLV23,"SK Biotek to Acquire Manufacturing Facility in Swords, Ireland",2017-06-20 16:09:22 +0000,http://finance.yahoo.com/r/4ab79852-7609-3be9-8365-438128dae7cc/sk-biotek-co-ltd-acquire-manufacturing-facility-swords-ireland?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In its press release on June 16, 2017, Bristol-Myers Squibb (BMY) announced that it entered into a definitive purchase agreement with SK Biotek."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb a Top Socially Responsible Dividend Stock With 2.8% Yield (BMY),2017-06-20 13:22:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hevXj_Eh9UI/bristol-myers-squibb-a-top-socially-responsible-dividend-stock-with-28-yield-bmy-cm805455,Bristol Myers Squibb Co Symbol BMY has been named a Top Socially Responsible Dividend Stock by Dividend Channel signifying a stock with above average DividendRank statistics including a strong 2 8 yield as well as being recognized by prominent asset managers as being a
BMY,BMY:US,BBG000DQLV23,5 Most Profitable Big Pharma Stocks on the Market Right Now,2017-06-20 13:21:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MukY_YPYtXs/5-most-profitable-big-pharma-stocks-on-the-market-right-now-cm805467,It s no secret that many big pharma companies are highly profitable In fact the industry s gigantic profits have attracted plenty of negative attention from politicians and the press For investors though stocks for businesses that are very profitable are a great thing Five
BMY,BMY:US,BBG000DQLV23,5 Most Profitable Big Pharma Stocks on the Market Right Now,2017-06-20 11:27:00 +0000,http://finance.yahoo.com/r/003646c7-280d-3ef3-b660-d57cff7b2db6/5-most-profitable-big-pharma-stocks-on-the-market.aspx?yptr=yahoo&.tsrc=rss,"Looking for big pharma stocks with big-time profit margins? Check out Gilead Sciences, Amgen, Novartis, Biogen, and Bristol-Myers Squibb."
BMY,BMY:US,BBG000DQLV23,Top 10 Holdings of Our Ultimate Stock-Pickers' Index,2017-06-20 10:00:00 +0000,http://finance.yahoo.com/r/55c4c01e-9679-31be-9037-79029020ade3/article.aspx?id=812931&SR=Yahoo&yptr=yahoo&.tsrc=rss,"While Healthcare names continue to present opportunities, our lists revealed names from other sectors that may be compelling."
BMY,BMY:US,BBG000DQLV23,"AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade",2017-06-20 02:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mVef7veM52A/amgns-xgeva-to-face-fda-in-feb-double-treat-for-lpcn-sgen-drops-cascade-20170620-00069,"AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade"
BMY,BMY:US,BBG000DQLV23,[$$] Supreme Court Further Limits Plaintiffs' Venue Shopping,2017-06-19 23:02:33 +0000,http://finance.yahoo.com/r/c1456d24-1a6a-363d-90f1-ec8e3b14ee07/supreme-court-further-curbs-plaintiffs-venue-shopping-with-bristol-myers-ruling-1497913350?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,The Supreme Court dealt a blow to consumer plaintiffs by limiting where lawsuits against companies with business in multiple states can be heard.
BMY,BMY:US,BBG000DQLV23,U.S. Supreme Court again limits where companies can be sued,2017-06-19 22:11:42 +0000,https://finance.yahoo.com/news/supreme-court-again-limits-where-185005220.html?.tsrc=rss,"The Supreme Court on Monday slapped limits on where injury lawsuits may be filed for the second time in three weeks, again siding with businesses that want to prevent plaintiffs from ""shopping"" for friendly courts for their cases.  In an 8-1 ruling, the justices overturned a lower court's decision that had allowed hundreds of out-of-state patients who took Bristol-Myers Squibb Co's (BMY.N) blood-thinning medication Plavix to sue the company in California.  State courts cannot hear claims against companies that are not based in the state when the alleged injuries did not occur there, the justices ruled."
BMY,BMY:US,BBG000DQLV23,U.S. Supreme Court again limits where companies can be sued,2017-06-19 22:10:47 +0000,https://finance.yahoo.com/news/u-supreme-court-again-limits-161509913.html?.tsrc=rss,"The Supreme Court on Monday  slapped limits on where injury lawsuits may be filed for the  second time in three weeks, again siding with businesses that  want to prevent plaintiffs from ""shopping"" for friendly courts  for their cases.  In an 8-1 ruling, the justices overturned a lower court's  decision that had allowed hundreds of out-of-state patients who  took Bristol-Myers Squibb Co's blood-thinning medication  Plavix to sue the company in California.  State courts cannot hear claims against companies that are  not based in the state when the alleged injuries did not occur  there, the justices ruled."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205,2017-06-19 17:20:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZeoxO2hx_y8/bristol-myers-opdivo-positive-in-phase-ii-study-checkmate-205-cm805171,Bristol Myers Squibb Company BMY announced an extended follow up data on immuno oncology drug Opdivo The data from ongoing phase II study CheckMate 205 evaluated adult patients with classical Hodgkin lymphoma cHL who have failed autologous stem cell transplant ASCT irrespective
BMY,BMY:US,BBG000DQLV23,"Noteworthy ETF Outflows: SSO, V, KO, BMY",2017-06-19 16:21:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D7Fvsp0zuXQ/noteworthy-etf-outflows-sso-v-ko-bmy-cm805114,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the ProShares Ultra S amp P500 Symbol SSO where we have detected an approximate 22 6 million dollar outflow that s a 1 2 decrease week over week from 20 900
BMY,BMY:US,BBG000DQLV23,The Amount You Pay for Cancer Drugs May Double -- Here's Why,2017-06-19 15:23:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SqfZKPcm2DY/the-amount-you-pay-for-cancer-drugs-may-double-heres-why-cm805035,Chances are that you need little or no reminder about how expensive prescription drug costs are these days If you ve been to the pharmacy at any point over the past couple of years you know Cancer drug prices could soar According to findings from AARP the aggregate cost
BMY,BMY:US,BBG000DQLV23,High court sides with drugmaker in Plavix lawsuit,2017-06-19 14:56:59 +0000,https://finance.yahoo.com/news/high-court-sides-drugmaker-plavix-145659327.html?.tsrc=rss,The Supreme Court says hundreds of out-state-residents can't sue drugmaker Bristol-Myers Squibb Co. in California state court over adverse reactions to the blood thinner Plavix. The justices ruled 8-1 ...
BMY,BMY:US,BBG000DQLV23,High court sides with drugmaker in Plavix lawsuit,2017-06-19 14:56:59 +0000,http://finance.yahoo.com/r/8c57c50e-8c0f-3278-8721-cb6b7823bc4b/high-court-sides-drugmaker-plavix-145659327.html?.tsrc=rss,WASHINGTON (AP) — The Supreme Court says hundreds of out-state-residents can't sue drugmaker Bristol-Myers Squibb Co. in California state court over adverse reactions to the blood thinner Plavix.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205,2017-06-19 14:52:02 +0000,https://finance.yahoo.com/news/bristol-myers-opdivo-positive-phase-145202920.html?.tsrc=rss,Bristol-Myers Squibb Company (BMY) announced an extended follow-up data on immuno-oncology drug Opdivo.
BMY,BMY:US,BBG000DQLV23,U.S. Supreme Court limits where companies can be sued,2017-06-19 14:49:09 +0000,https://finance.yahoo.com/news/u-supreme-court-limits-where-144909987.html?.tsrc=rss,"The U.S. Supreme Court on  Monday tightened rules on where injury lawsuits may be filed,  handing a victory to corporations by undercutting the ability of  plaintiffs to bring claims in friendly courts in a case  involving litigation over the Bristol-Myers Squibb Co  blood-thinning medication Plavix.  State courts cannot  hear claims against companies that are not based in the state  when the alleged injuries did not occur there, the justices  ruled.  The court last month reached a similar conclusion in a  separate case involving out-of-state injury claims against  Texas-based BNSF Railway Co."
BMY,BMY:US,BBG000DQLV23,J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use,2017-06-19 14:24:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6JmUlFmh5KI/jj-immunotherapy-darzalex-okd-for-expanded-combination-use-cm804934,Johnson amp Johnson JNJ announced that its immunotherapy Darzalex has been approved for use in combination with Celgene Corporation s CELG multiple myeloma drug Pomalyst pomalidomide and dexamethasone The combination has been approved for the treatment of patients with multiple myeloma
BMY,BMY:US,BBG000DQLV23,Companies Get New Suit Limits as Supreme Court Backs Bristol-Myers,2017-06-19 14:12:07 +0000,https://finance.yahoo.com/news/companies-suit-limits-supreme-court-141207774.html?.tsrc=rss,"The U.S. Supreme Court gave companies a new tool to defeat some lawsuits, siding with Bristol-Myers Squibb Co. in a bid to limit a consumer lawsuit in California over its Plavix blood thinner."
BMY,BMY:US,BBG000DQLV23,A Surprising Disappointment Derails NewLink Genetics -- What's Next?,2017-06-19 13:22:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-AeuWMSWqmU/a-surprising-disappointment-derails-newlink-genetics-whats-next-cm804898,Roche Holdings NASDAQOTH RHHBY surprisingly cut ties with NewLink Genetics NASDAQ NLNK 160 on GDC 0919 last week and that decision puts NewLink Genetics further back behind Incyte Corporation in the race 160 to develop a new class of cancer fighting
BMY,BMY:US,BBG000DQLV23,Corporate News Blog - Bristol-Myers Squibb Announces Sale of Swords Plant; Set to Expand its Biologics Portfolio,2017-06-19 12:15:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-bristol-myers-121500716.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / June 19, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Bristol-Myers Squibb Co. (NYSE: BMY ). The Company announced on ..."
BMY,BMY:US,BBG000DQLV23,Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon,2017-06-19 08:42:00 +0000,http://finance.yahoo.com/r/6fb4f336-998a-3cb9-837f-a1e4d8bf7356/novartis-secures-european-approval-for-biosimilar-cancer-treatment-rixathon.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche's Rituxan that generated $7.5 billion in 2016 sales."
BMY,BMY:US,BBG000DQLV23,3 Top Healthcare Stocks You Haven't Thought Of,2017-06-18 14:20:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PO-KVAeTWcc/3-top-healthcare-stocks-you-havent-thought-of-cm804795,The best performing healthcare stocks typically receive little to no fanfare until after they ve already made a monstrous move upward 160 Many 160 fly under the radar before reaching a major value creating event such as a pivotal clinical or regulatory catalyst With this theme
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused",2017-06-16 14:11:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kzkrRPbC_Dg/pharma-stock-roundup-jj-lilly-present-data-merck-keytruda-study-enrolment-paused-cm804262,This week s highlights include data from companies like Johnson amp Johnson JNJ and Lilly LLY while Merck MRK paused new enrolment in a couple of studies being conducted with Keytruda Recap of the Week s Most Important Stories J amp J Presents Data on Invokana Simponi Aria
BMY,BMY:US,BBG000DQLV23,3 Dividend Stocks in Healthcare,2017-06-16 14:10:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GtNVYqGiDqk/3-dividend-stocks-in-healthcare-cm804267,The healthcare sector can be an enormously profitable area to hunt for dividend stocks Top healthcare companies after all often sport ginormous free cash flows and sustainable levels of growth Based on this insight we turned to our contributors to ask them which
BMY,BMY:US,BBG000DQLV23,Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed Classical Hodgkin Lymphoma,2017-06-16 10:58:00 +0000,https://finance.yahoo.com/news/extended-data-evaluating-opdivo-nivolumab-105800406.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced extended follow-up data in which Opdivo demonstrated responses in adult patients with relapsed or progressed classical Hodgkin lymphoma after autologous stem cell transplant , irrespective of brentuximab vedotin therapy history."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb to Sell Manufacturing Facility in Swords, Ireland to SK Biotek Co., Ltd.",2017-06-16 08:35:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-sell-manufacturing-083500839.html?.tsrc=rss,"Bristol-Myers Squibb Company and SK Biotek Co., Ltd. today announced the companies have signed a definitive purchase agreement to sell Bristol-Myers Squibb’s small molecule active pharmaceutical ingredient manufacturing facility in Swords, Ireland, to SK Biotek, a wholly-owned subsidiary of SK Holdings, based in Seoul, South Korea."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Reports Opdivo Follow-Up Data - Quick Facts,2017-06-16 07:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g0cJTMToDYw/bristolmyers-reports-opdivo-followup-data--quick-facts-20170616-00187,Bristol-Myers Reports Opdivo Follow-Up Data - Quick Facts
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers To Sell Manufacturing Facility In Swords, Ireland - Quick Facts",2017-06-16 05:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eZ-fbd-fcxQ/bristolmyers-to-sell-manufacturing-facility-in-swords-ireland--quick-facts-20170616-00107,"Bristol-Myers To Sell Manufacturing Facility In Swords, Ireland - Quick Facts"
BMY,BMY:US,BBG000DQLV23,Is the Market Wrong About Bristol-Myers Squibb?,2017-06-15 21:08:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AweYDWaPSdE/is-the-market-wrong-about-bristol-myers-squibb-cm804079,Bristol Myers Squibb BMS NYSE BMY might be the pharmaceutical company equivalent of the late comedian Rodney Dangerfield Dangerfield s money line during his career was I don t get no respect BMS executives and shareholders could be saying the same thing these days The stock
BMY,BMY:US,BBG000DQLV23,Is the Market Wrong About Bristol-Myers Squibb?,2017-06-15 19:21:00 +0000,http://finance.yahoo.com/r/8594715d-308d-36db-a609-559e6539a60f/is-the-market-wrong-about-bristol-myers-squibb.aspx?yptr=yahoo&.tsrc=rss,There&apos;s a lot of negativity about Bristol-Myers Squibb&apos;s prospects. Is it too negative?
BMY,BMY:US,BBG000DQLV23,"ETFs with exposure to Bristol-Myers Squibb Co. : June 15, 2017",2017-06-15 17:19:11 +0000,http://finance.yahoo.com/r/eb16080a-6835-3d94-bc2a-3491b4df1f7f/etfs-with-exposure-to-bristol-myers-squibb-co-june-15-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Bristol-Myers Squibb Co. Here are 5 ETFs with the largest exposure to BMY-US. Comparing the performance and risk of Bristol-Myers Squibb Co. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,Why Most Stocks Are Stinkers (and What You Can Do About It),2017-06-15 12:06:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EoOcCXn-xWI/why-most-stocks-are-stinkers-and-what-you-can-do-about-it-cm803667,Most stocks lose money How can that be As almost all investors know large company stocks have returned on average an annualized 10 1 since 1926 But a fascinating new academic paper finds that virtually all of those profits can be attributed to fewer than 4 of all stocks Most stocks
BMY,BMY:US,BBG000DQLV23,Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed Hodgkin Lymphoma at the International Conference on Malignant Lymphoma,2017-06-15 10:58:00 +0000,https://finance.yahoo.com/news/seattle-genetics-bristol-myers-squibb-105800129.html?.tsrc=rss,"Seattle Genetics, Inc. and Bristol-Myers Squibb Company today highlighted an updated interim analysis from the ongoing phase 1/2 clinical trial evaluating ADCETRIS and Opdivo in relapsed or refractory classical Hodgkin lymphoma at the International Conference on Malignant Lymphoma in Lugano, Switzerland."
BMY,BMY:US,BBG000DQLV23,"Daily Dividend Report: CAT, MSFT, TGT, BMY, JCI",2017-06-14 18:06:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KlveOOrRTS8/daily-dividend-report-cat-msft-tgt-bmy-jci-cm803420,The board of directors of Caterpillar voted today to increase the quarterly cash dividend by one cent to seventy eight cents 0 78 per share of common stock payable August 19 2017 to shareholders of record at the close of business on July 20 2017 Caterpillar has paid higher dividends to
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. – Value Analysis (NYSE:BMY) : June 14, 2017",2017-06-14 17:59:30 +0000,http://finance.yahoo.com/r/c3a223fe-44fd-3bfc-9a51-98e5a84c0854/bristol-myers-squibb-co-value-analysis-nysebmy-june-14-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Bristol-Myers Squibb Co. a score of 72. Our analysis is based on comparing Bristol-Myers Squibb Co. with the following peers – Eli Lilly and Company, Merck & Co., Inc., Pfizer Inc., Sanofi Sponsored ADR, Novartis AG Sponsored ADR, Astrazeneca PLC Sponsored ADR, AbbVie, Inc., Johnson & Johnson, ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces Cash Tender Offer For Any and All of Certain of Its Outstanding Debt Securities,2017-06-14 12:40:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-announces-cash-124000909.html?.tsrc=rss,"Bristol-Myers Squibb Company announced today that it has commenced a cash tender offer for any and all of its 5.875% Notes due 2036, 6.125% Notes due 2038 and 6.875% Debentures due 2097 ."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb To Present At Goldman Sachs Conference; Webcast At 1:00 PM,2017-06-14 12:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/De2VUfxAjU4/bristolmyers-squibb-to-present-at-goldman-sachs-conference-webcast-at-100-pm-20170614-00838,Bristol-Myers Squibb To Present At Goldman Sachs Conference; Webcast At 1:00 PM
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease at the Annual European Congress of Rheumatology (EULAR 2017)",2017-06-14 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-present-research-105900251.html?.tsrc=rss,"Bristol-Myers Squibb Company today confirmed that 23 abstracts related to ORENCIA® , including new data on the role of biomarkers and MRI in RA patient identification and treatment, will be presented at the Annual European Congress of Rheumatology , June 14-17 in Madrid, Spain."
BMY,BMY:US,BBG000DQLV23,Exelixis Initiates Cabozantinib-Tecentriq Combination Trial,2017-06-13 23:27:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/61L82vUyd4U/exelixis-initiates-cabozantinib-tecentriq-combination-trial-cm802995,Exelixis Inc EXEL announced that it initiated the dose escalation stage of a phase Ib trial of cabozantinib in combination with Roche s RHHBY Tecentriq The drug will be evaluated in patients suffering from locally advanced or metastatic urothelial carcinoma UC or renal cell carcinoma
BMY,BMY:US,BBG000DQLV23,Exelixis Initiates Cabozantinib-Tecentriq Combination Trial,2017-06-13 21:32:09 +0000,https://finance.yahoo.com/news/exelixis-initiates-cabozantinib-tecentriq-combination-213209427.html?.tsrc=rss,"Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche&apos;s (RHHBY) Tecentriq."
BMY,BMY:US,BBG000DQLV23,Merck's Keytruda Hit With Safety Snag,2017-06-13 21:28:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sQhfxRhZASA/mercks-keytruda-hit-with-safety-snag-cm802965,Merck amp Co s NYSE MRK cancer fighting drug Keytruda has been on a roll lately delivering top notch efficacy and winning FDA approval for use across a host of cancer indications The company s winning streak however could be in jeopardy On Monday management
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces Dividend,2017-06-13 20:05:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-announces-dividend-200500913.html?.tsrc=rss,The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of thirty-nine cents per share on the $.10 par value Common Stock of the corporation.
BMY,BMY:US,BBG000DQLV23,Will Bristol-Myers Share Merck's Woe?,2017-06-13 15:51:00 +0000,http://finance.yahoo.com/r/32371b42-4287-39e7-8b50-4ac68b510ed7/will-bristol-myers-share-mercks-woe-1497369066?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"As we reported earlier, Merck’s (MRK) blockbuster cancer drug Keytruda hit a bit of a speed bump today when the drug maker announce it was pausing enrollment in two late-stage studies testing the medication on multiple myeloma to investigate increased reports of deaths in the groups using the drug.  Evercore ISI analyst Umer Raffat asked the question, has Bristol-Myers Squibb (BMY) seen a similar imbalance?  The two drug makers are in a pitched battle for dominance in the immuno-oncology market."
BMY,BMY:US,BBG000DQLV23,Merck: A Speed Bump For Keytruda?,2017-06-13 13:18:00 +0000,http://finance.yahoo.com/r/3a9481fa-28e1-3b22-9b71-281369492229/merck-a-speed-bump-for-keytruda-1497359892?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,Shares of Merck (MRK) are falling today after the drug maker announced late Monday that it was hitting the brakes on two late-stage studies involving the use of its immuno-cancer drug Keytruda as a treatment for multiple myeloma.  Merck is investigating increased reports of deaths in the groups using the drug.  Evercore ISI analyst  Umer Raffat has the details.
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. breached its 50 day moving average in a Bullish Manner : BMY-US : June 13, 2017",2017-06-13 12:27:18 +0000,http://finance.yahoo.com/r/bd0a234a-f382-333e-b56d-18e3a1e4d507/bristol-myers-squibb-co-breached-its-50-day-moving-average-in-a-bullish-manner-bmy-us-june-13-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Bristol-Myers Squibb Co.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Announce Results for Second Quarter 2017 on July 27,2017-06-12 14:00:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-announce-results-140000189.html?.tsrc=rss,"Bristol-Myers Squibb Company will announce results for the second quarter of 2017 on Thursday, July 27, 2017. During a conference call at 10:30 a.m. EDT on July 27, company executives will review financial information and will address inquiries from investors and analysts."
BMY,BMY:US,BBG000DQLV23,What Traders Can Learn From Professional Horse Betting,2017-06-10 14:26:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OryLqWeD8hg/what-traders-can-learn-from-professional-horse-betting-cm801601,Thegreek com a horse racing blog discusses the seven deadly sins losing horse bettors commit Repeat these sins in your trading and you ll suffer the same fate as the losers at the track Thegreek com a horse racing blog discusses the seven deadly sins losing horse bettors commit
BMY,BMY:US,BBG000DQLV23,"Sector Gamma As Buys Bristol-Myers Squibb Company, Perrigo Co PLC, Abbott Laboratories, Sells ...",2017-06-10 10:26:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3QS2pCW3_AU/sector-gamma-as-buys-bristol-myers-squibb-company-perrigo-co-plc-abbott-laboratories-sells-cm801567,Sector Gamma As New Purchases PRGO LH LXRX Added Positions BMY ABT ANTM GILD SHPG BAX BSX IPXL Reduced Positions UTHR VRTX MASI IART OMI CI MNTA IRWD Sold Out MRK EXEL ALXN New Purchases PRGO LH LXRX
BMY,BMY:US,BBG000DQLV23,3 Dividend Stocks for Shrewd Investors,2017-06-09 16:29:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FITuHNJALY0/3-dividend-stocks-for-shrewd-investors-cm801231,LCI Industries NYSE LCII Bristol Myers Squibb NYSE BMY and Boeing NYSE BA are three dividend paying stocks that shrewd investors might want to add to their portfolios All three companies have proven they know how to grow their businesses through thick and thin
BMY,BMY:US,BBG000DQLV23,PowerShares Dynamic Pharmaceuticals Portfolio Experiences Big Outflow,2017-06-09 16:27:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q-kPk1L9HvY/powershares-dynamic-pharmaceuticals-portfolio-experiences-big-outflow-cm801254,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the PowerShares Dynamic Pharmaceuticals Portfolio Symbol PJP where we have detected an approximate 113 8 million dollar outflow that s a 13 5 decrease week
BMY,BMY:US,BBG000DQLV23,3 Dividend Stocks for Shrewd Investors,2017-06-09 15:09:00 +0000,http://finance.yahoo.com/r/bb4ea747-03ec-36d0-9e32-93a2d2c9cbc2/3-dividend-stocks-for-shrewd-investors.aspx?yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb, LCI Industries, and Boeing are shrewd companies that smart investors might want to add to their portfolios soon."
BMY,BMY:US,BBG000DQLV23,7 Reasons Why Prescription Drug Prices Are Extremely Expensive,2017-06-09 11:28:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D3tBCPPcZXw/7-reasons-why-prescription-drug-prices-are-extremely-expensive-cm800997,Image source Getty Images Spending on prescription drugs increased by 3 8 in 2016 according 160 to pharmacy benefit manager Express Scripts While that s slower growth than the 5 2 year over year increase experienced in 2015 spending is still headed in the wrong
BMY,BMY:US,BBG000DQLV23,Cancer Setback Leaves Bristol-Myers Vulnerable to Takeover,2017-06-09 09:00:00 +0000,http://finance.yahoo.com/r/79290f81-09a4-30f7-8a8e-e76f8fa38ec6/cancer-setback-leaves-bristol-myers-vulnerable-to-possible-sale?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"At a Chicago convention jammed with thousands of doctors in 2015, a buzz of excitement rippled through the hall as a researcher revealed data showing that a Bristol-Myers Squibb Co. drug cocktail had remarkable ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces Availability of New ORENCIA® (abatacept) Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA),2017-06-08 11:30:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-announces-availability-113000110.html?.tsrc=rss,"Bristol-Myers Squibb Company announced today the availability of a new FDA-approved subcutaneous ORENCIA administration option for use in patients 2 years of age and older with moderately to severely active polyarticular Juvenile Idiopathic Arthritis .1 The new prefilled syringe offers physicians, patients, and caregivers of these patients the option of ORENCIA treatment that can be administered at ..."
BMY,BMY:US,BBG000DQLV23,ASCO Was A Bust For Biotech,2017-06-07 16:56:00 +0000,http://finance.yahoo.com/r/178aa1da-6eb2-3749-8f4f-e84b484ddea4/asco-was-a-bust-for-biotech-1496854582?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The American Society of Clinical Oncology meeting is one of the most closely watched medical conferences of the year.  The Wall Street Journal’s “Heard on the Street” columnist Charley Grant noted today that this year’s conference, which ended Tuesday, passed “without much of a stir, at least from an investor point of view.” In short, while some individual stocks rose and fell sharply, the broader S&P Biotechnology Select Industry Index essentially hasn’t moved through Tuesday."
BMY,BMY:US,BBG000DQLV23,An Unprecedented FDA Approval Bodes Well for this Drug Stock,2017-06-07 12:00:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rtn2p382O1U/an-unprecedented-fda-approval-bodes-well-for-this-drug-stock-cm799710,Pharmaceutical giant Merck NYSE MRK has been on a roll recently with anti cancer drug Keytruda winning approval for multiple manifestations of the disease An approval for one particular indication last month continues the good news for the drug and has broader implications for
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part in Goldman Sachs 38th Annual Global Healthcare Conference,2017-06-07 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-part-goldman-105900150.html?.tsrc=rss,"Bristol-Myers Squibb Company will take part in Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, 2017, in Rancho Palos Verdes, CA. Thomas Lynch, chief scientific officer, will answer questions about the company at 1 p.m."
BMY,BMY:US,BBG000DQLV23,"Novartis, Bristol-Myers Collaborate for Opdivo Combination",2017-06-07 00:16:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d8OUTMPlgXQ/novartis-bristol-myers-collaborate-for-opdivo-combination-cm799724,Novartis AG NVS announced that it has entered into clinical research collaboration with Bristol Myers Squibb Company BMY Per the terms of the agreement Bristol Myers will investigate the safety tolerability and efficacy of Novartis s Mekinist in combination with its own Opdivo
BMY,BMY:US,BBG000DQLV23,"Bristol Myers, Novartis to Explore Potential Treatment for Metastatic Colorectal Cancer",2017-06-06 22:17:00 +0000,http://finance.yahoo.com/r/160739d8-7c1f-39ad-b306-700b6b5e1475/bristol-myers-novartis-to-explore-potential-treatment-for-metastatic-colorectal-cancer.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Bristol-Myers will conduct the study and both companies will evaluate the findings.
BMY,BMY:US,BBG000DQLV23,"Novartis, Bristol-Myers Collaborate for Opdivo Combination",2017-06-06 22:12:10 +0000,https://finance.yahoo.com/news/novartis-bristol-myers-collaborate-opdivo-221210611.html?.tsrc=rss,Novartis AG (NVS) and Bristol-Myers Squibb Company (BMY) collaborate for Opdivo combination therapies.
BMY,BMY:US,BBG000DQLV23,"Gainers & Losers Of June 6: VTL, EGLT, AMRI, AGLE, CRVS...",2017-06-06 21:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K3VHQ4BgSNM/gainers--losers-of-june-6-vtl-eglt-amri-agle-crvs-20170606-01380,"Gainers & Losers Of June 6: VTL, EGLT, AMRI, AGLE, CRVS..."
BMY,BMY:US,BBG000DQLV23,BMY Crosses Above 3% Yield Territory,2017-06-06 20:18:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JBZVAQInk8I/bmy-crosses-above-3-yield-territory-cm799613,Looking at the universe of stocks we cover at Dividend Channel in trading on Tuesday shares of Bristol Myers Squibb Co Symbol BMY were yielding above the 3 mark based on its quarterly dividend annualized to 1 56 with the stock changing hands as low as 51 68 on the day Dividends
BMY,BMY:US,BBG000DQLV23,"Health Care Sector Update for 06/06/2017: JNJ, PFE, ABT, MRK, AMGN, CTIC, PTCT, CLDX",2017-06-06 16:36:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x9zvWTNRaKw/health-care-sector-update-for-06062017-jnj-pfe-abt-mrk-amgn-ctic-ptct-cldx-cm799509,Top Health Care stocks Top Health Care stocks JNJ 0 5 JNJ 0 5 PFE 0 8 PFE 0 8 ABT 0 1 ABT 0 1 MRK 0 3 MRK 0 3 AMGN 0 2 AMGN 0 2 Health care shares were mostly lower in mid day trade Tuesday Health care shares were mostly lower in mid day trade Tuesday In health
BMY,BMY:US,BBG000DQLV23,Incyte Provides Updated Data on Cancer Combination Therapies,2017-06-06 15:05:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fQa-Qoi6wi8/incyte-provides-updated-data-on-cancer-combination-therapies-cm799315,Incyte Corporation INCY along with partner Bristol Myers Squibb Company BMY announced updated data from phase I II study ECHO 204 evaluating Incyte s epacadostat in combination with the latter s immune oncology drug Opdivo for the treatment of squamous cell carcinoma of the head and
BMY,BMY:US,BBG000DQLV23,Incyte Provides Updated Data on Cancer Combination Therapies,2017-06-06 13:09:01 +0000,https://finance.yahoo.com/news/incyte-provides-updated-data-cancer-130901158.html?.tsrc=rss,"Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of the head and neck and melanoma."
BMY,BMY:US,BBG000DQLV23,[$$] Is Bristol-Myers Falling Behind?,2017-06-06 11:25:00 +0000,http://finance.yahoo.com/r/1ffd55f4-2f4d-31de-9c8b-812ba63734f7/is-bristol-myers-falling-behind-1496748331?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb (BMY: NYSE) By Guggenheim Securities ($54.97, June 5, 2017) Bristol-Myers Squibb is moving very fast but the perception today among investors is that competitors have caught up with ..."
BMY,BMY:US,BBG000DQLV23,[$$] F-Star Strikes Drug Deal With Merck KGaA Valued as Much as $1.1 Billion,2017-06-05 23:44:50 +0000,http://finance.yahoo.com/r/ace4cb7f-7e79-3911-942e-0238b46c6f24/f-star-strikes-drug-deal-with-merck-kgaa-valued-as-much-as-1-1-billion-1496706286?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,U.K. biotechnology startup F-star has struck a cancer-drug deal with Merck KGaA that could be worth more than 1 billion euros ($1.1 billion).
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo,2017-06-05 23:01:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yTj6QAVOWsE/bristol-myers-presents-data-on-immuno-oncology-drug-opdivo-cm799033,Bristol Myers Squibb Company BMY announced that the European Commission EC has approved immuno oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma mUC in adults after failure of prior platinum containing therapy Opdivo is approved
BMY,BMY:US,BBG000DQLV23,Why Array BioPharma Inc. Sank 13.5% in May,2017-06-05 23:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F7mJU9O6csI/why-array-biopharma-inc-sank-135-in-may-cm799029,What happened Shares of Array BioPharma NASDAQ ARRY a clinical stage biotech focused on cancer dropped 13 in May according to data from S amp P Global Market Intelligence The big drop has this Fool scratching his head given all the positive announcements made during
BMY,BMY:US,BBG000DQLV23,"Novartis, Bristol-Myers To Evaluate Treatments In Metastatic Colorectal Cancer",2017-06-05 21:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cC8p26fxQhE/novartis-bristolmyers-to-evaluate-treatments-in-metastatic-colorectal-cancer-20170605-01301,"Novartis, Bristol-Myers To Evaluate Treatments In Metastatic Colorectal Cancer"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo,2017-06-05 20:29:08 +0000,https://finance.yahoo.com/news/bristol-myers-presents-data-immuno-202908298.html?.tsrc=rss,Bristol-Myers BMY announced that the EC has approved immuno-oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces New Collaboration to Evaluate Combination Therapy in Colorectal Cancer,2017-06-05 20:05:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-announces-collaboration-200500939.html?.tsrc=rss,"Bristol-Myers Squibb Company announced today it has entered into a clinical research collaboration with Novartis to investigate the safety, tolerability and efficacy of Opdivo and Opdivo + Yervoy regimen in combination with Mekinist® , as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair ."
BMY,BMY:US,BBG000DQLV23,Amgen (AMGN) Presents Positive Clinical Data on Cancer Drugs,2017-06-05 19:00:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wTYOISxRRM0/amgen-amgn-presents-positive-clinical-data-on-cancer-drugs-cm798903,Amgen Inc AMGN presented encouraging results from a phase III study evaluating its marketed drug Xgeva denosumab for an expanded indication at the American Society of Clinical Oncology ASCO The company is looking to expand Xgeva s label for treating patients with multiple myeloma
BMY,BMY:US,BBG000DQLV23,Incyte Announces Data on Enzyme Inhibitor with Keytruda,2017-06-05 18:02:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hoXeb8E6q20/incyte-announces-data-on-enzyme-inhibitor-with-keytruda-cm798856,Incyte Corporation INCY and Merck amp Co MRK announced an updated data from the advanced non small cell lung cancer NSCLC patient cohort of the ongoing phase I II ECHO 202 study The study was evaluating Incyte s selective IDO1 enzyme inhibitor epacadostat in combination with Merck
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb: Value Or Value Trap?,2017-06-05 17:59:00 +0000,http://finance.yahoo.com/r/809b5d29-8e2e-348c-b9e4-a4c2b426b460/bristol-myers-squibb-value-or-value-trap-1496685553?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,It doesn’t look like this year’s ASCO is shaping up well for Bristol-Myers Squibb (BMY).  The stock price has fallen 4.6% in recent market action following a slew of drug trial updates at the annual meeting of cancer researchers.  A lack of clarity of how Opdivo can fare as a first-line treatment for lung cancer.
BMY,BMY:US,BBG000DQLV23,Incyte Announces Data on Enzyme Inhibitor with Keytruda,2017-06-05 15:29:03 +0000,https://finance.yahoo.com/news/incyte-announces-data-enzyme-inhibitor-152903908.html?.tsrc=rss,Incyte Corporation (INCY) and Merck & Co. (MRK) announced an updated data from the advanced non-small cell lung cancer patient cohort of the ongoing phase I/II ECHO-202 study.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb CEO: Critical that treatments reach ...,2017-06-05 14:33:00 +0000,https://finance.yahoo.com/video/bristol-myers-squibb-ceo-critical-143300148.html?.tsrc=rss,"Bristol-Myers Squibb CEO Giovanni Caforio speaks to CNBC's Meg Tirrell at the American Society of Clinical Oncology conference, about drug pricing, the company's development and M&A in the space."
BMY,BMY:US,BBG000DQLV23,QIAGEN & Bristol-Myers Squibb Partner on Cancer Research,2017-06-05 14:28:02 +0000,https://finance.yahoo.com/news/qiagen-bristol-myers-squibb-partner-142802603.html?.tsrc=rss,QIAGEN N.V. (QGEN) has made significant advancement in the field of cancer research through the use of its revolutionary next-generation sequencing (NGS) technology.
BMY,BMY:US,BBG000DQLV23,Why Regeneron Is Quickly Becoming My Top Biotech Stock Pick,2017-06-05 14:03:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DsDmn2dopZY/why-regeneron-is-quickly-becoming-my-top-biotech-stock-pick-cm798565,Regeneron Pharmaceuticals NASDAQ REGN 160 investors have lost a lot of money since 2015 However shares are making back ground after key FDA drug approvals and a number of intriguing drugs in its pipeline have me thinking that there s more room left in this stock to run
BMY,BMY:US,BBG000DQLV23,Here's the Best Dividend Stock in Big Pharma,2017-06-05 14:03:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YspTbm6EHi0/heres-the-best-dividend-stock-in-big-pharma-cm798559,Not long ago I labeled Bristol Myers Squibb Co NYSE BMY Eli Lilly and Co NYSE LLY Johnson amp Johnson NYSE JNJ and Pfizer Inc NYSE PFE the best dividend stocks in pharmaceuticals 160 I still believe all four have what it takes to boost
BMY,BMY:US,BBG000DQLV23,Here&apos;s the Best Dividend Stock in Big Pharma,2017-06-05 12:47:00 +0000,http://finance.yahoo.com/r/eca3cdc4-958c-36c8-9ba8-9e9a91956ff7/heres-the-best-dividend-stock-in-big-pharma.aspx?yptr=yahoo&.tsrc=rss,Pharmaceutical industry stocks are famous for fast-growing dividends -- and infamous for cutting them when conditions change.
BMY,BMY:US,BBG000DQLV23,InPlay from Briefing.com,2017-06-05 11:53:54 +0000,https://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
BMY,BMY:US,BBG000DQLV23,Encouraging Disease Control Rates Observed with Nivolumab Alone or in Combination with Ipilimumab in Refractory or Relapsing Malignant Pleural Mesothelioma Patients: Results from IFCT-1501 MAPS-2 Trial,2017-06-05 11:30:00 +0000,https://finance.yahoo.com/news/encouraging-disease-control-rates-observed-113000200.html?.tsrc=rss,The French Cooperative Thoracic Intergroup and Bristol-Myers Squibb Company announced today results from the IFCT-1501 MAPS-2 trial evaluating the safety and efficacy of nivolumab or nivolumab combined with ipilimumab for previously treated unresectable malignant pleural mesothelioma patients.
BMY,BMY:US,BBG000DQLV23,Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer,2017-06-05 11:30:00 +0000,https://finance.yahoo.com/news/clinical-trial-data-combination-epacadostat-113000741.html?.tsrc=rss,"Incyte Corporation and Bristol-Myers Squibb Company today announced updated data from the ongoing Phase 1/2 ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, in combination with Opdivo® , Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, in multiple advanced solid tumors."
BMY,BMY:US,BBG000DQLV23,3 Dividend Stocks Perfect for Retirement,2017-06-05 11:21:00 +0000,http://finance.yahoo.com/r/823d4fc2-d174-3471-9f18-7f719534f5f0/3-dividend-stocks-perfect-for-retirement.aspx?yptr=yahoo&.tsrc=rss,"Our contributors think retirees may want to check out Bristol-Myers Squibb, Target, and Seagate Technology."
BMY,BMY:US,BBG000DQLV23,"Early, Durable Responses Seen with Sprycel (dasatinib) in First- and Second-Line Treatment of Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML)",2017-06-05 11:15:00 +0000,https://finance.yahoo.com/news/early-durable-responses-seen-sprycel-111500634.html?.tsrc=rss,Bristol-Myers Squibb Company today announced the first presentation of data from two cohorts of the Phase 2 CA180-226 clinical trial evaluating Sprycel in imatinib-resistant or -intolerant and newly diagnosed pediatric patients with chronic phase chronic myeloid leukemia.
BMY,BMY:US,BBG000DQLV23,[$$] Plenty Can Go Right for Bristol-Myers,2017-06-05 04:13:44 +0000,http://finance.yahoo.com/r/f10c974c-5053-3637-8f7d-c5fd6326a39f/plenty-can-go-right-for-bristol-myers-1496415744?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,Last year’s cancer drug darling is this year’s value stock.
BMY,BMY:US,BBG000DQLV23,New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in Resected High-Risk Melanoma Patients Presented at ASCO,2017-06-04 12:30:00 +0000,https://finance.yahoo.com/news/data-evaluating-safety-preliminary-relapse-123000490.html?.tsrc=rss,Bristol-Myers Squibb Company today announced results of an interim descriptive analysis from an ongoing National Cancer Institute Phase 3 randomized study evaluating Yervoy 3 mg/kg and Yervoy 10 mg/kg in patients with stage III or resectable stage IV melanoma who are at high risk of recurrence following complete surgical resection.
BMY,BMY:US,BBG000DQLV23,First Presentation of Efficacy Data from CheckMate -204 Evaluating the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) Demonstrates Anti-tumor Activity in Advanced Melanoma Patients with Brain Metastases,2017-06-04 12:00:00 +0000,https://finance.yahoo.com/news/first-presentation-efficacy-data-checkmate-120000110.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced efficacy and safety data from CheckMate -204, the first Phase 2 study to evaluate Opdivo plus Yervoy as a potential treatment for patients with melanoma metastatic to the brain."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies,2017-06-03 17:00:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-qiagen-sign-170000115.html?.tsrc=rss,Bristol-Myers Squibb Company and QIAGEN have signed an agreement to explore the use of next-generation sequencing technology to develop gene expression profiles as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology therapies in cancer treatment.
BMY,BMY:US,BBG000DQLV23,Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrated Promising Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer in Phase 2 CheckMate -142 Study,2017-06-03 13:00:00 +0000,https://finance.yahoo.com/news/opdivo-nivolumab-combination-yervoy-ipilimumab-130000562.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced interim data from CheckMate -142, a Phase 2, multi-cohort trial evaluating Opdivo monotherapy or in combination with Yervoy for the treatment of patients with DNA mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer ."
BMY,BMY:US,BBG000DQLV23,Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy,2017-06-03 12:00:00 +0000,https://finance.yahoo.com/news/anti-lag-3-bms-986016-120000156.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced proof-of-concept data showing preliminary efficacy for BMS-986016, an investigational anti-lymphocyte-activation gene 3 therapy in combination with Opdivo in patients with advanced melanoma previously treated with anti-PD-1/PD-L1 therapy ."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Breaks Above 200-Day Moving Average - Bullish for BMY,2017-06-02 21:30:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D2LvTPV_akk/bristol-myers-squibb-breaks-above-200-day-moving-average-bullish-for-bmy-cm798228,In trading on Friday shares of Bristol Myers Squibb Co Symbol BMY crossed above their 200 day moving average of 55 05 changing hands as high as 55 16 per share Bristol Myers Squibb Co shares are currently trading up about 1 1 on the day The chart below shows the one year performance
BMY,BMY:US,BBG000DQLV23,"After Hours Most Active for Jun 2, 2017 :  QQQ, BAC, SGU, CTSH, INFO, MYL, CSCO, FCX, JHG, ODP, BMY, PHM",2017-06-02 21:01:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/txto1hK4giY/after-hours-most-active-for-jun-2-2017-qqq-bac-sgu-ctsh-info-myl-csco-fcx-jhg-odp-bmy-phm-cm798259,The NASDAQ 100 After Hours Indicator is down 1 37 to 5 880 09 The total After hours volume is currently 41 255 971 shares traded The following are the most active stocks for the after hours session PowerShares QQQ Trust Series 1 QQQ is 0 03 at 143 49 with 1 944
BMY,BMY:US,BBG000DQLV23,European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platinum-Containing Therapy,2017-06-02 21:00:00 +0000,https://finance.yahoo.com/news/european-commission-approves-bristol-myers-210000237.html?.tsrc=rss,Bristol-Myers Squibb Company announced today that the European Commission has approved Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.
BMY,BMY:US,BBG000DQLV23,Dow&apos;s Merck Beats Out Rival Bristol In Melanoma Study,2017-06-02 20:18:44 +0000,http://finance.yahoo.com/r/8236ecdf-391c-383f-978a-9822e7a87278/dow-component-merck-quashes-rival-bristol-in-a-3-year-melanoma-study?src=A00220&yptr=yahoo&.tsrc=rss,Merck&apos;s Keytruda outperformed an immuno-oncological counterpart from Bristol in a three-year study of patients with advanced melanoma.
BMY,BMY:US,BBG000DQLV23,Bristol Drug Shows Promise In Treatment Of Cervical Cancer,2017-06-02 20:10:09 +0000,http://finance.yahoo.com/r/06cf9cc3-bd7c-385a-ad53-a135cffd9f26/how-one-drugmaker-is-dominating-cervical-cancer-this-week?src=A00220&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb&apos;s immuno-oncology drug Opdivo showed promise in a trial of 19 patients with advanced cervical cancer.
BMY,BMY:US,BBG000DQLV23,Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU,2017-06-02 17:31:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ga407wuWx7s/pfizers-kidney-cancer-drug-gets-acceptance-in-the-us-eu-cm798076,Pfizer Inc PFE announced encouraging news with the FDA and the European Medicines Agency EMA accepting the company s regulatory submission for label expansion of its cancer drug Sutent sunitinib The company is looking to expand Sutent s label for adjuvant treatment of adult patients
BMY,BMY:US,BBG000DQLV23,Stocks to watch during ASCO,2017-06-02 16:49:00 +0000,https://finance.yahoo.com/video/stocks-watch-during-asco-164900354.html?.tsrc=rss,"CNBC's Meg Tirrell reports on what stocks to watch during ASCO, the biggest cancer research conference in Chicago. The “Fast Money Halftime Report” traders weigh in."
BMY,BMY:US,BBG000DQLV23,[$$] Plenty Can Go Right for Bristol-Myers,2017-06-02 15:35:03 +0000,http://finance.yahoo.com/r/f10c974c-5053-3637-8f7d-c5fd6326a39f/plenty-can-go-right-for-bristol-myers-1496415744?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Last year’s cancer drug darling is this year’s value stock.
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY's Deals & More",2017-06-02 14:36:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zyOvflCjBeA/pharma-stock-roundup-positive-data-from-lilly-teva-bmys-deals-more-cm797951,This week there were quite a few regulatory and pipeline updates with Lilly LLY reporting positive results on its cancer drug Cyramza while the FDA expanded the label of Merck s MRK HIV drug Isentress Recap of the Week s Most Important Stories Lilly s Cyramza Hits Primary
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. breached its 50 day moving average in a Bullish Manner : BMY-US : June 2, 2017",2017-06-02 12:43:04 +0000,http://finance.yahoo.com/r/9e16107a-7224-3733-9ff4-cd91d0a3d098/bristol-myers-squibb-co-breached-its-50-day-moving-average-in-a-bullish-manner-bmy-us-june-2-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Bristol-Myers Squibb Co.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY&apos;s Deals & More",2017-06-02 12:12:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-positive-data-121212412.html?.tsrc=rss,Lilly (LLY) posted positive data on Cyramza while Teva&apos;s migraine drug delivered positive results in a late-stage study.
BMY,BMY:US,BBG000DQLV23,Merck reports positive results for late-stage trial comparing its Keytruda against Bristol-Myers' Yervoy,2017-06-02 11:49:19 +0000,http://finance.yahoo.com/r/fa8498ff-4fd4-30cf-962d-945e3008dcd2/Story.aspx?guid=EAE602AA-1A4E-49D4-AFDD-7225B2D4DD37&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Merck & Co. Inc. said premarket Friday that a late-stage clinical trial comparing its cancer drug Keytruda to Bristol-Myers Squibb's  cancer drug Yervoy found patients on Keytruda had better results. ...
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb reports data from phase 1/2 trial for cancers associated with HPV,2017-06-02 11:18:50 +0000,http://finance.yahoo.com/r/60fe5446-646d-3f79-829c-e5f8bf2136b9/Story.aspx?guid=4F4A2FC5-2FCE-4FDE-BCC2-E1A93E81999E&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb Co. reported results from a phase 1/2 clinical trial looking at the company's blockbuster cancer drug Opdivo in patients with human papillomavirus (HPV)-associated cancers premarket ...
BMY,BMY:US,BBG000DQLV23,"Opdivo (nivolumab) Data in Patients with Advanced Cervical, Vaginal and Vulvar Cancers from Phase 1/2 CheckMate -358 Presented at ASCO",2017-06-02 10:59:00 +0000,https://finance.yahoo.com/news/opdivo-nivolumab-data-patients-advanced-105900575.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced the first disclosure of data from a cohort of the Phase 1/2 CheckMate -358 study evaluating Opdivo for the treatment of patients with advanced cervical, vaginal and vulvar cancers, all associated with infection by the human papillomavirus ."
BMY,BMY:US,BBG000DQLV23,Cancer drug prices could double or triple thanks to this popular but unproven drug trend,2017-06-02 10:56:45 +0000,http://finance.yahoo.com/r/b2261002-4768-3d36-a970-820d72301dbc/Story.aspx?guid=15FFEA12-4623-11E7-980C-8D853B065349&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"There are nearly 800 immuno-oncology combination trials today, up from around 200 in 2015."
BMY,BMY:US,BBG000DQLV23,Cancer drug prices could double or triple thanks to this popular but unproven drug trend,2017-06-02 10:56:45 +0000,https://finance.yahoo.com/news/cancer-drug-prices-could-double-105645725.html?.tsrc=rss,"There are nearly 800 immuno-oncology combination trials today, up from around 200 in 2015."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Seattle Genetics Expand Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and ADCETRIS® (Brentuximab Vedotin) in Pivotal Phase 3 Clinical Trial in Relapsed Hodgkin Lymphoma,2017-06-02 10:00:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-seattle-genetics-100000534.html?.tsrc=rss,"Bristol-Myers Squibb Company and Seattle Genetics, Inc. announced that the companies have entered into a collaboration agreement to evaluate the combination of Bristol-Myers Squibb’s immunotherapy Opdivo and Seattle Genetics’ antibody-drug conjugate ADCETRIS in a pivotal phase 3 clinical trial."
BMY,BMY:US,BBG000DQLV23,Wall Street Aims High At Opening,2017-06-02 07:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EkbyDPGNCAc/wall-street-aims-high-at-opening-20170602-00237,Wall Street Aims High At Opening
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Reports Opdivo Data, Shows Overall Response Rate Of 26.3%",2017-06-02 07:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GOLEiuFFREM/bristolmyers-reports-opdivo-data-shows-overall-response-rate-of-263-20170602-00236,"Bristol-Myers Reports Opdivo Data, Shows Overall Response Rate Of 26.3%"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers & Seattle Genetics To Evaluate Combination Of Opdivo And ADCETRIS,2017-06-02 06:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pu3lkbYQBlE/bristolmyers--seattle-genetics-to-evaluate-combination-of-opdivo-and-adcetris-20170602-00174,Bristol-Myers & Seattle Genetics To Evaluate Combination Of Opdivo And ADCETRIS
BMY,BMY:US,BBG000DQLV23,"Notable ETF Inflow Detected - PJP, AKRX, BMY, BAX",2017-06-01 16:33:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8_hPny_ZLvY/notable-etf-inflow-detected-pjp-akrx-bmy-bax-cm797496,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the PowerShares Dynamic Pharmaceuticals Portfolio Symbol PJP where we have detected an approximate 93 9 million dollar inflow that s a 12 9 increase week over
BMY,BMY:US,BBG000DQLV23,Why Is Bristol-Myers (BMY) Down 3.1% Since the Last Earnings Report?,2017-06-01 13:35:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dmoc-kCfupE/why-is-bristol-myers-bmy-down-31-since-the-last-earnings-report-cm797274,A month has gone by since the last earnings report for Bristol Myers Squibb Company BMY Shares have lost about 3 1 in that time frame underperforming the market Will the recent negative trend continue leading up to the stock s next earnings release or is it due for a breakout Before
BMY,BMY:US,BBG000DQLV23,"Blog Coverage: Array BioPharma and Bristol-Myers Squibb Partner to Investigate Combinations of Binimetinib, Opdivo, and Yervoy in Colorectal Cancer Patients",2017-06-01 12:15:00 +0000,https://finance.yahoo.com/news/blog-coverage-array-biopharma-bristol-121500346.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / June 1, 2017 / Active Wall St. blog coverage looks at the headline from Array BioPharma Inc. (NASDAQ: ARRY ) and Bristol-Myers Squibb Co. (NYSE: BMY ) as both companies announced ..."
BMY,BMY:US,BBG000DQLV23,Why Is Bristol-Myers (BMY) Down 3.1% Since the Last Earnings Report?,2017-06-01 11:01:11 +0000,https://finance.yahoo.com/news/why-bristol-myers-bmy-down-110111483.html?.tsrc=rss,Bristol-Myers (BMY) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Partners Array to Investigate Cancer Candidate,2017-05-31 17:33:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_wnmpJUOHDI/bristol-myers-partners-array-to-investigate-cancer-candidate-cm796955,Bristol Myers Squibb Company BMY and Array BioPharma ARRY entered into a clinical research collaboration to investigate the safety tolerability and efficacy of Array s binimetinib in combination with Bristol Myers Squibb s Opdivo nivolumab and Opdivo Yervoy ipilimumab regimen 160
BMY,BMY:US,BBG000DQLV23,Novartis CEO sees no need for big takeover,2017-05-31 15:44:54 +0000,https://finance.yahoo.com/news/novartis-warns-u-price-pressure-061656152.html?.tsrc=rss,"Novartis does not need a  big acquisition to kick-start growth, Chief Executive Joe  Jimenez told investors on Wednesday, playing down suggestions he  could use proceeds from a slew of asset sales for a significant  takeover.  Amid speculation Novartis might use proceeds to buy  AstraZeneca or Bristol-Myers Squibb to fill  holes in its cancer drug portfolio, Jimenez said he remained  focused on smaller purchases of up to $5 billion to bolster his  pipeline.  ""Obviously, there's been a lot of speculation because that  would be a lot of capital,"" Jimenez said at an event at  Novartis's research campus in Boston."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Partners Array to Investigate Cancer Candidate,2017-05-31 15:13:03 +0000,https://finance.yahoo.com/news/bristol-myers-partners-array-investigate-151303590.html?.tsrc=rss,"Bristol-Myers Squibb Company (BMY) and Array BioPharma (ARRY) entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array&apos;s binimetinib in combination with the former&apos;s Opdivo and Opdivo + Yervoy regimen."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Hookup Boosts Array BioPharma,2017-05-30 22:20:00 +0000,http://finance.yahoo.com/r/108e2294-4a2d-3e8e-bbe1-cea652cc1a4e/bristol-myers-hookup-boosts-array-biopharma.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Arrary reacquired MEK inhibitor in 2015 as part of FTC settlement with Novartis.
BMY,BMY:US,BBG000DQLV23,"Array BioPharma, Bristol-Myers Squibb to collaborate on cancer drug research",2017-05-30 20:14:25 +0000,http://finance.yahoo.com/r/eafc7427-b9a0-372f-a20d-db941a725516/array-biopharma-bristol-myers-squibb-to.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Array BioPharma and pharmaceutical giant Bristol-Myers Squibb will test the effectiveness of Array’s drug binimetinib in combination with a Bristol-Myers’ immunotherapy drug as a treatment for some kinds of colorectal cancer.  The research partnership, announced Tuesday, is the second announced this month by Boulder-based Array BioPharma Inc. (ARRY) for testing binimetinib as part of a treatment for colorectal cancer cases with metastatic tumors.  The new pact with New York City-based Bristol-Myers Squibb will have both companies supporting early-phase clinical trials testing binimetinib in combination with Bristol-Myers cancer drug Opdivo and added as a third drug used in combination with Opdivo and Yervoy."
BMY,BMY:US,BBG000DQLV23,Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration,2017-05-30 13:29:00 +0000,http://finance.yahoo.com/r/b29d834b-7687-35ad-88dd-539b3df20949/biotech-movers-array-shares-rise-on-bristol-myers-collaboration.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday."
BMY,BMY:US,BBG000DQLV23,Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo (nivolumab) in Metastatic Cervical Cancer,2017-05-30 10:59:00 +0000,https://finance.yahoo.com/news/advaxis-bristol-myers-squibb-announce-105900949.html?.tsrc=rss,"Advaxis, Inc. and Bristol-Myers Squibb today announced a clinical development collaboration to evaluate ADXS-DUAL, an investigational immunotherapy targeting HPV-associated cancers, and Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, Opdivo , as a potential combination treatment option for women with metastatic cervical cancer."
BMY,BMY:US,BBG000DQLV23,Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration,2017-05-30 10:59:00 +0000,https://finance.yahoo.com/news/array-biopharma-bristol-myers-squibb-105900638.html?.tsrc=rss,"BOULDER, Colo. and NEW YORK, May 30, 2017 /PRNewswire/ --  Array BioPharma (Nasdaq: ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical research ..."
BMY,BMY:US,BBG000DQLV23,How Two Biotechs Fell On Cancer Partnerships With Bristol-Myers,2017-05-30 09:17:00 +0000,http://finance.yahoo.com/r/8f0075c4-8c0e-3b53-abc6-099ece5296bc/how-these-biotechs-split-on-cancer-partnerships-with-bristol-myers?src=A00220&yptr=yahoo&.tsrc=rss,Array and Advaxis shares tumbled more than 3% in action Tuesday after the firms announced partnerships with Bristol.
BMY,BMY:US,BBG000DQLV23,"Array BioPharma, Bristol-Myers Squibb Announce Strategic Collaboration",2017-05-30 07:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AsazgK3NuVg/array-biopharma-bristolmyers-squibb-announce-strategic-collaboration-20170530-00298,"Array BioPharma, Bristol-Myers Squibb Announce Strategic Collaboration"
BMY,BMY:US,BBG000DQLV23,Better Buy: Celgene Corporation vs. Bristol-Myers Squibb,2017-05-28 12:30:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nh-UPvD6ifI/better-buy-celgene-corporation-vs-bristol-myers-squibb-cm795743,Investors haven t been too enamored with Celgene NASDAQ CELG and Bristol Myers Squibb NYSE BMY lately Both have super successful cancer drugs and are making plenty of money However neither stock has performed very well so far in 2017 Which of these two drug stocks is
BMY,BMY:US,BBG000DQLV23,Better Buy: Celgene Corporation vs. Bristol-Myers Squibb,2017-05-28 11:27:00 +0000,http://finance.yahoo.com/r/857c7062-f0f3-3302-a102-76e25435e570/better-buy-celgene-corporation-vs-bristol-myers-sq.aspx?yptr=yahoo&.tsrc=rss,It&apos;s Celgene versus Bristol-Myers Squibb in a head-to-head matchup. Which drug stock wins as the better pick for long-term investors?
BMY,BMY:US,BBG000DQLV23,Celldex's Immuno-Oncology Pipeline Continues to Impress,2017-05-26 15:36:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7SEv5Ovh8Sw/celldexs-immuno-oncology-pipeline-continues-to-impress-cm795268,On May 25 we issued an updated research report on Hampton NJ based Celldex Therapeutics Inc CLDX Celldex is a development stage biopharmaceutical company focused on the development and commercialization of immunotherapy technologies and other cancer targeting biologics So far this
BMY,BMY:US,BBG000DQLV23,Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer,2017-05-26 15:36:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vsyv3bnPbkk/merck-mrk-buys-rights-to-anti-tau-antibody-for-alzheimer-cm795236,Merck amp Co Inc MRK announced that it has bought exclusive worldwide license from Teijin Pharma for the development manufacture and commercialization of an investigational preclinical anti tau antibody Merck sees potential in the development and commercialization of the candidate for
BMY,BMY:US,BBG000DQLV23,CORRECTING and REPLACING Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights,2017-05-26 13:47:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-hold-investor-105900929.html?.tsrc=rss,Please replace the release with the following corrected version due to multiple revisions.
BMY,BMY:US,BBG000DQLV23,Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer,2017-05-26 13:42:01 +0000,https://finance.yahoo.com/news/merck-mrk-buys-rights-anti-134201797.html?.tsrc=rss,"Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody."
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data",2017-05-26 13:34:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QKdPN0FpI-w/pharma-stock-roundup-label-expansion-for-merck-drug-aerie-up-on-eye-data-cm795202,This week there were quite a few regulatory updates with Merck MRK getting FDA approval for yet another indication for Keytruda while Bristol Myers BMY got priority review for a regulatory application for Opdivo Recap of the Week s Most Important Stories Aerie Soars on Positive
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data",2017-05-26 12:08:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-label-expansion-120812582.html?.tsrc=rss,Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.
BMY,BMY:US,BBG000DQLV23,Nplate and Vectibix Could Contribute to Amgen’s Revenue Growth in 2017,2017-05-26 11:36:00 +0000,http://finance.yahoo.com/r/e54bf33a-9942-387f-acf5-5e2620967142/nplate-and-vectibix-could-contribute-to-amgens-revenue-growth-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1Q17, Amgen’s (AMGN) Nplate generated revenues of ~$154 million, which reflected a year-over-year growth rate of 9%."
BMY,BMY:US,BBG000DQLV23,"After Hours Most Active for May 25, 2017 :  HPE, KO, OZRK, JNPR, MSFT, XOM, DFS, ALXN, BMY, CTSH, JD, CMCSA",2017-05-25 21:00:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5s4Yx8Fxtu4/after-hours-most-active-for-may-25-2017-hpe-ko-ozrk-jnpr-msft-xom-dfs-alxn-bmy-ctsh-jd-cmcsa-cm794882,The NASDAQ 100 After Hours Indicator is up 2 57 to 5 780 94 The total After hours volume is currently 39 306 456 shares traded The following are the most active stocks for the after hours session Hewlett Packard Enterprise Company HPE is 0 0112 at 18 85 with 5 301
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer,2017-05-25 16:30:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mvQA9-vCfd8/bristol-myers-opdivo-gets-priority-review-for-liver-cancer-cm794596,Bristol Myers Squibb Company BMY announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application sBLA for the label expansion of Opdivo nivolumab to patients with hepatocellular carcinoma HCC after prior Nexavar therapy
BMY,BMY:US,BBG000DQLV23,Bristol-Myers&apos; Opdivo Gets Priority Review for Liver Cancer,2017-05-25 14:42:02 +0000,https://finance.yahoo.com/news/bristol-myers-apos-opdivo-gets-144202352.html?.tsrc=rss,Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients with hepatocellular carcinoma (HCC).
BMY,BMY:US,BBG000DQLV23,Getting Struck Twice: Acquisitions And Spinouts In Biotech,2017-05-25 11:55:00 +0000,http://finance.yahoo.com/r/3fcc16e5-984d-3844-ab1e-bd229d08ebd4/getting-struck-twice-acquisitions-spinouts-in-biotech?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Biotech M&A deals are often driven by the buyer's interest in the lead asset in the biotech's portfolio. In order to capture the full value, spinouts of the secondary assets following an acquisition can be solution. Here are several recent examples."
BMY,BMY:US,BBG000DQLV23,U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated Hepatocellular Carcinoma,2017-05-24 15:15:00 +0000,https://finance.yahoo.com/news/u-food-drug-administration-accepts-151500987.html?.tsrc=rss,Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted a supplemental Biologics License Application that seeks to extend the use of Opdivo  to patients with hepatocellular carcinoma after prior sorafenib therapy.
BMY,BMY:US,BBG000DQLV23,Performance of Merck’s Diabetes Portfolio in 1Q17,2017-05-24 14:36:50 +0000,http://finance.yahoo.com/r/5b41dfb4-0fd3-3c3f-8287-3b385fc11d87/performance-of-mercks-diabetes-portfolio-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Combined sales for Januvia and Janumet were ~$1.3 billion for 1Q17, a ~5.0% fall from $1.4 billion in 1Q16."
BMY,BMY:US,BBG000DQLV23,The 7 Best “Comeback” Stocks to Buy for a Huge Second Half,2017-05-24 00:12:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jvOvRj8Mf5U/the-7-best-comeback-stocks-to-buy-for-a-huge-second-half-cm793646,InvestorPlace Stock Market News Stock Advice amp Trading Tips There s been a number of stocks that have stumbled over the past year Yet despite their struggles there are attractive components to some of these names Source Shutterstock Put simply these are comeback stocks Two
BMY,BMY:US,BBG000DQLV23,"With Stock Returns Of Over 205% in the Last Year, This Fund Is Proof That Hedge Funds Aren’t Going Anywhere",2017-05-23 20:27:45 +0000,http://finance.yahoo.com/r/1df25683-8167-3e9f-9ad7-fbd058d33c0d/with-stock-returns-of-over-205-in-the-last-year-this-fund-is-proof-that-hedge-funds-arent-going-anywhere-582137?yptr=yahoo&.tsrc=rss,"If someone is looking for convincing arguments about the wildly publicized doom of the hedge fund business, they don’t need to look far beyond the 2017 list of the highest paid hedge fund managers compiled by Institutional Investors’ Alpha. According to the coveted magazine, 2016 was the year when the top-25 earning hedge fund managers […]"
BMY,BMY:US,BBG000DQLV23,Household Debt Is Enslaving Americans,2017-05-23 13:11:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IIAjNkY2T9o/household-debt-is-enslaving-americans-cm793135,Consumer debt in America is rising at an alarming pace The average household has thousands in credit card debt alone followed by thousands in student loan debt and thousands more in auto loans Add a mortgage on top of that and the sum seems insurmountable to many households Consumer debt
BMY,BMY:US,BBG000DQLV23,"3 Big Stock Charts for Monday: Bristol-Myers Squibb Co (BMY), Pfizer Inc. (PFE) and Amgen, Inc. (AMGN)",2017-05-22 21:12:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LCW1kvwSPio/3-big-stock-charts-for-monday-bristol-myers-squibb-co-bmy-pfizer-inc-pfe-and-amgen-inc-amgn-cm792945,InvestorPlace Stock Market News Stock Advice amp Trading Tips Stocks are ready to continue last week s recovery as traders continue to look for opportunities to buy the short term dip caused by the political headlines from last week While there are some deals to be had
BMY,BMY:US,BBG000DQLV23,Catch Bristol-Myers Squibb Co (BMY) Stock With Confidence,2017-05-22 18:13:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jgh2LmdKb1Q/catch-bristol-myers-squibb-co-bmy-stock-with-confidence-cm792864,InvestorPlace Stock Market News Stock Advice amp Trading Tips Bristol Myers Squibb Co NYSE BMY stock has had a rough 12 month period down over 30 within that tine range Compare that with the 10 performance of the iShares Nasdaq Biotechnology Index ETF NASDAQ
BMY,BMY:US,BBG000DQLV23,Blog Coverage: Bristol-Myers Squibs Received EMA Validation of Sprycel for the Treatment in Children with Chronic Myelogenous Leukemia,2017-05-22 12:15:00 +0000,https://finance.yahoo.com/news/blog-coverage-bristol-myers-squibs-121500015.html?.tsrc=rss,"Upcoming AWS Coverage on GW Pharmaceuticals Post-Earnings Results LONDON, UK / ACCESSWIRE / May 22, 2017 / Active Wall St. blog coverage looks at the headline from Bristol-Myers Squibb Co. (NYSE: BMY ) ..."
BMY,BMY:US,BBG000DQLV23,What Orencia Meant to BMY in 1Q17,2017-05-22 11:36:08 +0000,http://finance.yahoo.com/r/f738dc6c-40db-36f2-989e-0cfaf42dccfa/what-orencia-meant-to-bmy-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb's (BMY) oncology and cardiovascular products were among the most prioritized brands in the company's total portfolio in 1Q17.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb To Present At UBS Global Conference; Webcast At 10:00 AM ET,2017-05-22 09:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6uX5eI3O1MY/bristolmyers-squibb-to-present-at-ubs-global-conference-webcast-at-1000-am-et-20170522-00609,Bristol-Myers Squibb To Present At UBS Global Conference; Webcast At 10:00 AM ET
BMY,BMY:US,BBG000DQLV23,"New Research Reports for Britol-Myers, Pricline & Phillips 66",2017-05-20 05:11:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vHysrsD9WZE/new-research-reports-for-britol-myers-pricline-phillips-66-cm792218,Friday May 19 2017 The Zacks Research Daily presents the best research output of our analyst team Today s publication features new research reports on 16 major stocks including Bristol Myers BMY Priceline PCLN and Phillips 66 PSX These research reports have been hand picked from
BMY,BMY:US,BBG000DQLV23,"New Research Reports for Britol-Myers, Pricline & Phillips 66",2017-05-19 21:48:09 +0000,https://finance.yahoo.com/news/research-reports-britol-myers-pricline-214809043.html?.tsrc=rss,"New Research Reports for Britol-Myers, Pricline & Phillips 66"
BMY,BMY:US,BBG000DQLV23,Top 5 Buys of Market-Beating Investors at Primecap Management,2017-05-19 21:24:00 +0000,https://finance.yahoo.com/news/top-5-buys-market-trouncing-215448929.html?.tsrc=rss,Quiet managers have beat benchmark over long and short term
BMY,BMY:US,BBG000DQLV23,"Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase",2017-05-19 15:17:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y91peI6pB8g/merck-kgaa-mkgaf-q1-earnings-fall-yy-revenues-increase-cm791861,Merck KGaA MKGAF reported first quarter 2017 earnings of 1 28 per American Depositary Share 14 7 lower than the year ago figure of 1 50 Net sales in the reported quarter came in at 4 1 billion 3 86 billion up 5 3 Organic sales growth of 3 1 was driven by the Healthcare and
BMY,BMY:US,BBG000DQLV23,Behind BMY’s Cardiovascular Performance in 1Q17,2017-05-19 14:36:51 +0000,http://finance.yahoo.com/r/d64fb7c1-a626-375a-aedb-9f391653b685/behind-bmys-cardiovascular-performance-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eliquis is a new blockbuster drug in Bristol-Myers Squibb’s portfolio, and its sales rose ~50% to $1.1 billion in 1Q17."
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More",2017-05-19 13:15:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7Syp6ebPPDY/pharma-stock-roundup-jjs-pharma-pipeline-update-shires-hae-data-more-cm791797,This week industry bellwether J amp J JNJ provided an update on its pharmaceutical products pipeline at a meeting and said it expects to launch or file for approval for more than 10 new blockbuster products by 2021 Meanwhile Shire s SHPG shares were up 4 3 on pipeline data Recap of
BMY,BMY:US,BBG000DQLV23,Revisiting Bristol-Myers Squibb’s Virology in 1Q17,2017-05-19 13:06:46 +0000,http://finance.yahoo.com/r/05663bd3-37e5-34a6-8e0b-3e23bfa04bbf/revisiting-bristol-myers-squibbs-virology-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Daklinza and Sunvepra are the two drugs in BMY's Hepatitis C franchise. Revenues from these drugs fell to $162 million in 1Q17.
BMY,BMY:US,BBG000DQLV23,European Medicines Agency Validates Application for Bristol-Myers Squibb’s Sprycel (dasatinib) in Children with Chronic Myelogenous Leukemia,2017-05-19 12:13:00 +0000,https://finance.yahoo.com/news/european-medicines-agency-validates-application-121300892.html?.tsrc=rss,Bristol-Myers Squibb Company today announced that the European Medicines Agency validated its grouped Type II variation/Extension of Application for Sprycel to treat children and adolescents aged 1 year to 18 years with chronic phase Philadelphia chromosome positive chronic myelogenous leukemia and to include the powder for oral suspension.
BMY,BMY:US,BBG000DQLV23,What Happened to Bristol-Myers Squibb’s Opdivo in 1Q17?,2017-05-19 11:36:57 +0000,http://finance.yahoo.com/r/9e8c8537-2b4d-38f5-809b-2e6fa5540b7a/what-happened-to-bristol-myers-squibbs-opdivo-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb’s (BMY) latest drug Opdivo was the seventh drug to be approved by the FDA for the treatment of melanoma.
BMY,BMY:US,BBG000DQLV23,EMA Validates Application For Bristol-Myers' Sprycel In Children With CML,2017-05-19 08:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2VCKIaMikLs/ema-validates-application-for-bristolmyers-sprycel-in-children-with-cml-20170519-00334,EMA Validates Application For Bristol-Myers' Sprycel In Children With CML
BMY,BMY:US,BBG000DQLV23,Incyte (INCY) Announces Positive Data on Enzyme Inhibitor,2017-05-19 00:11:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/m1PCYdOSFtg/incyte-incy-announces-positive-data-on-enzyme-inhibitor-cm791628,Incyte Corporation INCY recently announced that new data was published online from the ongoing trial ECHO 202 by the American Society of Clinical Oncology ASCO in advance of its annual meeting in Chicago IL June 2 6 2017 The trial is evaluating Incyte s selective IDO1 enzyme
BMY,BMY:US,BBG000DQLV23,The Hot Stock: Incyte Climbs,2017-05-18 20:50:00 +0000,http://finance.yahoo.com/r/7ac84036-0dc3-393f-a883-66e46341ed2e/the-hot-stock-incyte-climbs-1495140657?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Incyte (INCY) lead the S&P 500 higher, rising almost 7% as clinical trial data boosted confidence about its experimental cancer drugs. At $128.80 a share, the stock climbed 6.89%, making the ..."
BMY,BMY:US,BBG000DQLV23,Understanding Bristol-Myers Squibb’s Oncology Performance in 1Q17,2017-05-18 14:37:45 +0000,http://finance.yahoo.com/r/18097216-052b-3b4b-b63f-a17ab3803db9/understanding-bristol-myers-squibbs-oncology-performance-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Opdivo reported ~60% growth in revenues to just over $1.1 billion in 1Q17, as compared to $704 million in 1Q16."
BMY,BMY:US,BBG000DQLV23,Biotech Movers: Fast Track Designation Sends Sage Shares Higher,2017-05-18 13:57:00 +0000,http://finance.yahoo.com/r/f865659b-e02c-3f61-838c-1aaecd8f71e9/biotech-movers-fast-track-designation-sends-sage-shares-higher.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday."
BMY,BMY:US,BBG000DQLV23,Behind Bristol-Myers Squibb’s 1Q17 Performance,2017-05-18 13:07:43 +0000,http://finance.yahoo.com/r/48f366cc-5d01-300b-8b55-b0e1344f2299/behind-bristol-myers-squibbs-1q17-performance?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb’s (BMY) top line rose 12% to ~$4.93 billion in 1Q17, driven by an operational growth of 13% in revenues."
BMY,BMY:US,BBG000DQLV23,Inside Bristol-Myers Squibb’s Valuation after the 1Q17 Earnings,2017-05-18 11:37:47 +0000,http://finance.yahoo.com/r/e3aa8374-ec7c-3034-b989-c0d363357eb2/inside-bristol-myers-squibbs-valuation-after-the-1q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb’s top line rose 12% to ~$4.9 billion in 1Q17, driven by an operational growth of 13% in revenues."
BMY,BMY:US,BBG000DQLV23,What to watch at ASCO cancer conference,2017-05-18 10:21:00 +0000,https://finance.yahoo.com/video/watch-asco-cancer-conference-102100102.html?.tsrc=rss,CNBC's Meg Tirrell reports on the major names making waves in cancer research ahead of the American Society of Clinical Oncology conference.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017,2017-05-17 21:00:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-research-showcases-210000527.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced that more than 80 presentations, including 16 oral presentations and seven poster discussions, highlighting data from Company-sponsored studies, collaborations and investigator-sponsored research evaluating its oncology compounds across 20 types of cancer, will be featured at the American Society of Clinical Oncology Annual Meeting 2017 in Chicago from June ..."
BMY,BMY:US,BBG000DQLV23,Eli Lilly: Worries Ahead In Patent Fight,2017-05-17 16:39:00 +0000,http://finance.yahoo.com/r/ad3fe1db-7d9b-3d32-97cd-77f760dd6edc/eli-lilly-but-investors-may-under-appreciate-the-downside-risk-the-company-faces-from-the-ipr-patent-challenge-on-the-cancer-drug-alimta-for-which-a-decision-is-expected-between-now-and-june-3-worries-ahead-in-patent-fight-1495039189?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Bernstein Research warns that Eli Lilly (LLY) could be in for a bumpy ride.  Tim Anderson and his team remain bullish on the stock, with an Outperform rating and a $88 price target, which implies a 12% upside from the $78.68 a share it fetches today.  In a worst-case scenario, Alimta could face generics in 2017, even though it won an earlier appeals court ruling on a more ""traditional"" patent challenge."
BMY,BMY:US,BBG000DQLV23,"Vanguard Health Care Fund Buys Abbott Laboratories, Tesaro Inc, Teva Pharmaceutical Industries, ...",2017-05-17 13:14:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bX4cvX8yJQg/vanguard-health-care-fund-buys-abbott-laboratories-tesaro-inc-teva-pharmaceutical-industries-cm790414,Vanguard Health Care Fund New Purchases TSRO CNC PTHN HUM Added Positions ABT REGN TEVA BMY IONS CTEC GEN EVHC APN ACHC Reduced Positions INCY AGN AMGN AET MRK Q UNH HCA MDT BSX Sold Out STJ INOV BIVV New Purchases
BMY,BMY:US,BBG000DQLV23,Biogen (BIIB) Buys Stroke Candidate Cirara for $120M,2017-05-16 21:16:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xCEMajf_3ew/biogen-biib-buys-stroke-candidate-cirara-for-120m-cm790187,Biogen Inc BIIB announced the acquisition of New York based private pharma company Remedy Pharmaceuticals phase III candidate Cirara for an upfront payment of 120 million Cirara is being evaluated for the treatment of large hemispheric stroke LHI Shares were up almost 1 5 on Monday
BMY,BMY:US,BBG000DQLV23,"Noteworthy Tuesday Option Activity: RXN, BMY, TPX",2017-05-16 21:16:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7OSBAyKu4Nc/noteworthy-tuesday-option-activity-rxn-bmy-tpx-cm790194,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Rexnord Corp Symbol RXN where a total of 2 815 contracts have traded so far representing approximately 281 500 underlying shares That amounts to about 42 5 of RXN s average
BMY,BMY:US,BBG000DQLV23,Cramer: Carl Icahn Was Right to Sell Apple at $95,2017-05-16 16:30:00 +0000,http://finance.yahoo.com/r/74b4dc76-fec7-3020-ad46-c9c2cf0bbef7/cramer-carl-icahn-was-right-sell-apple-95?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"What's right for a hedge fund manager sitting on a big gain, isn't necessarily right for you."
BMY,BMY:US,BBG000DQLV23,Eli Lilly: Has This Bloom Begun To Wilt?,2017-05-16 16:17:00 +0000,http://finance.yahoo.com/r/55cd360a-9ebc-3b18-869a-ffe0b69e3995/eli-lilly-has-this-bloom-begun-to-wilt-1494951434?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,Shares of U.S. drug maker Eli Lilly & Co. (LLY) fell to a three-month low after Goldman Sachs pulled the stock off its closely-followed Conviction Buy List. Don’t panic. It isn’t as if Goldman analyst ...
BMY,BMY:US,BBG000DQLV23,"VYM, BMY, GILD, QCOM: ETF Inflow Alert",2017-05-16 16:16:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0eP0jcnV7is/vym-bmy-gild-qcom-etf-inflow-alert-cm789972,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard High Dividend Yield ETF Symbol VYM where we have detected an approximate 56 4 million dollar inflow that s a 0 3 increase week over week
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part in UBS Global Healthcare Conference,2017-05-16 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-part-ubs-105900581.html?.tsrc=rss,"Bristol-Myers Squibb Company will take part in the UBS Global Healthcare Conference on Monday, May 22, 2017, in New York. Murdo Gordon, executive vice president, head of Commercial, will answer questions about the company at 10 a.m."
BMY,BMY:US,BBG000DQLV23,AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study,2017-05-15 16:17:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q7aNIyTkoLk/astrazeneca-imfinzi-positive-in-phase-iii-lung-cancer-study-cm789259,AstraZeneca PLC AZN recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate Imfinzi durvalumab The candidate is meant for the sequential treatment of patients with locally advanced unresectable stage III non small cell lung cancer NSCLC
BMY,BMY:US,BBG000DQLV23,Retired? 3 Stocks You Should Consider Buying,2017-05-15 11:49:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/az-q5-DDz9o/retired-3-stocks-you-should-consider-buying-cm789018,If you re retired you ll want to be especially picky about where you put your money Some investment alternatives that might be fine for your children might not be so great for you Ideally you d be best off with stocks of companies with solid business models dependable dividends
BMY,BMY:US,BBG000DQLV23,Agilent Announces Expanded Use For PD-L1 IHC 28-8 PharmDx Diagnostic In Europe,2017-05-15 04:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QKqP2WyZ7WY/agilent-announces-expanded-use-for-pdl1-ihc-288-pharmdx-diagnostic-in-europe-20170515-00145,Agilent Announces Expanded Use For PD-L1 IHC 28-8 PharmDx Diagnostic In Europe
BMY,BMY:US,BBG000DQLV23,Retired? 3 Stocks You Should Consider Buying,2017-05-14 19:03:00 +0000,http://finance.yahoo.com/r/ed958c30-2912-3186-af53-ae4d8026e63d/retired-3-stocks-you-should-consider-buying.aspx?yptr=yahoo&.tsrc=rss,"Why Bristol-Myers Squibb, Iron Mountain, and Wells Fargo look like solid stocks for retirees."
BMY,BMY:US,BBG000DQLV23,Johnson & Johnson Analyst Day,2017-05-12 21:00:00 +0000,https://finance.yahoo.com/video/johnson-johnson-analyst-day-210023669.html?.tsrc=rss,"Johnson & Johnson hosts its annual presentation for investors from the company's headquarters in New Brunswick, NJ.  J&J CEO Alex Gorsky will give the keynote address in the morning followed by other J&J executives with new product announcements and vision for the company."
BMY,BMY:US,BBG000DQLV23,Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1,2017-05-11 16:05:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zhhMLA5GmyM/nektar-therapeutics-nktr-loss-wider-than-expected-in-q1-cm787907,Nektar Therapeutics NKTR reported first quarter 2017 loss of 42 cents per share wider than the Zacks Consensus Estimate of a loss of 40 cents The reported loss was also significantly wider than the year ago loss of 14 cents per share The company s shares gained 8 15 following the release
BMY,BMY:US,BBG000DQLV23,"Here's What The FDA Approval Of Keytruda Means For Merck, And For Bristol-Myers",2017-05-11 15:52:15 +0000,http://finance.yahoo.com/news/heres-fda-approval-keytruda-means-155215425.html?.tsrc=rss,"This week, the FDA granted approval for Merck & Co., Inc. (NYSE: MRK )’s Keyruda for chemotherapy combination treatment of frontline lung cancer. While the approval was far from a surprise, it may be enough ..."
BMY,BMY:US,BBG000DQLV23,Merck: Seal of Approval?,2017-05-11 15:20:00 +0000,http://finance.yahoo.com/r/e7176f89-530d-3b1b-9f6f-c689618e1877/merck-seal-of-approval-1494516052?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Merck (MRK) are gaining today after the FDA expanded the use of Keytruda to patients with advanced lung cancer when combined with chemotherapy, even when a high level of a key protein is missing. ..."
BMY,BMY:US,BBG000DQLV23,Human Antibody Discovery: Of Mice And Phage,2017-05-11 10:55:00 +0000,http://finance.yahoo.com/r/919d10ba-2965-3229-9390-1f4e7298ed8d/human-antibody-discovery-of-mice-and-phage?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Human antibody discovery has come a long way in the last two decades, with contributions from transgenic mice and phage display. Author reviews the data on their success, speculates of why the former has outperformed, closing with thoughts on the future of antibody discovery"
BMY,BMY:US,BBG000DQLV23,"Why Roche&apos;s Cancer Failure Might Tank Bristol, Pfizer — But Not Merck",2017-05-10 23:43:31 +0000,http://finance.yahoo.com/r/d8438ad3-d1d8-3c30-8d08-9f6fe97f0e23/why-roches-cancer-failure-might-tank-bristol-pfizer-but-not-merck?src=A00220&yptr=yahoo&.tsrc=rss,The failure of Roche&apos;s Tecentriq in a late-stage bladder cancer trial could bode badly for Bristol and Pfizer while boosting Merck.
BMY,BMY:US,BBG000DQLV23,The Not-So-Subtle Reason Behind Nektar Therapeutics' 10% Pop,2017-05-10 23:02:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dOY6yOQtVH4/the-not-so-subtle-reason-behind-nektar-therapeutics-10-pop-cm787555,What happened Shares of Nektar Therapeutics NASDAQ NKTR a biotech company that develops and licenses specialized medicines in the fields of cancer chronic pain and autoimmune diseases surged higher by as much as 10 after releasing its first quarter earnings results
BMY,BMY:US,BBG000DQLV23,"Gainers & Losers Of May 10: CUR, TEAR, PRTO, CXRX, DERM...",2017-05-10 22:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VoFUIUbQ_DM/gainers--losers-of-may-10-cur-tear-prto-cxrx-derm-20170510-01922,"Gainers & Losers Of May 10: CUR, TEAR, PRTO, CXRX, DERM..."
BMY,BMY:US,BBG000DQLV23,U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer,2017-05-10 22:12:38 +0000,http://finance.yahoo.com/news/u-fda-approves-merck-immunotherapy-215525456.html?.tsrc=rss,"Merck & Co said on Wednesday U.S.  health regulators  approved its Keytruda in combination with  chemotherapy for previously untreated advanced lung cancer,  solidifying the drugmaker's lead position in the field of  medicines that help the immune system fight cancer.  Lung cancer is by far the largest oncology market and the  approval significantly expands the number of patients available  for Keytruda therapy.  Merck shares were up 3.2 percent at $65.99 in extended  trading."
BMY,BMY:US,BBG000DQLV23,Here's Why Calithera Biosciences Stock Gained as Much as 16.4% Today,2017-05-10 21:03:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lkxCCdfFAl4/heres-why-calithera-biosciences-stock-gained-as-much-as-164-today-cm787486,What happened Shares of clinical stage biopharma Calithera Biosciences NASDAQ CALA rose over 16 today after the company announced first quarter 2017 financial results after the market closed yesterday The pre revenue company had little to report other than a strong cash
BMY,BMY:US,BBG000DQLV23,Here&apos;s Why Calithera Biosciences Stock Gained as Much as 16.4% Today,2017-05-10 19:13:01 +0000,http://finance.yahoo.com/r/8089a1aa-94ad-3839-a603-5312606cf57d/heres-why-calithera-biosciences-stock-gained-as-mu.aspx?yptr=yahoo&.tsrc=rss,An expanded collaboration with Bristol-Myers Squibb and an update on first-quarter 2017 financials had investors cheering.
BMY,BMY:US,BBG000DQLV23,"Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up",2017-05-10 16:02:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XSU4vVa13b4/celldex-cldx-q1-loss-in-line-revenues-beat-shares-up-cm787312,Celldex Therapeutics Inc CLDX posted first quarter 2017 loss of 28 cents per share which was in line with the Zacks Consensus Estimate but wider than the year ago loss of 160 35 cents per share Total revenue in the quarter rose 15 3 year over year to 1 5 million beating
BMY,BMY:US,BBG000DQLV23,"Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up",2017-05-10 14:30:02 +0000,http://finance.yahoo.com/news/celldex-cldx-q1-loss-line-143002570.html?.tsrc=rss,"Celldex Therapeutics, Inc. (CLDX) posted first-quarter 2017 loss of 28 cents per share, which was in line with the Zacks Consensus Estimate"
BMY,BMY:US,BBG000DQLV23,3 Stocks That Could Double Your Investment,2017-05-10 14:03:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kjs2RA5w_XA/3-stocks-that-could-double-your-investment-cm787023,There are plenty of underlying factors that could drive a stock to double but predicting which stock will double is hard and getting the timing right is next to impossible The best investors can do is buy stocks that have the potential to do well in the future and hold on
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. breached its 50 day moving average in a Bullish Manner : BMY-US : May 10, 2017",2017-05-10 12:19:17 +0000,http://finance.yahoo.com/r/aa29c645-ad6f-3588-9c60-476e33be22a8/bristol-myers-squibb-co-breached-its-50-day-moving-average-in-a-bullish-manner-bmy-us-may-10-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Bristol-Myers Squibb Co.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma,2017-05-10 10:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-calithera-biosciences-105900495.html?.tsrc=rss,"Bristol-Myers Squibb Company and Calithera Biosciences, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced the companies have expanded their existing collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Calithera’s ..."
BMY,BMY:US,BBG000DQLV23,Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers,2017-05-10 09:50:00 +0000,http://finance.yahoo.com/r/29e68794-b42c-3506-be7f-b15c9839c40d/roche-s-loss-in-bladder-cancer-lifts-astrazeneca-and-could-boost-bristol-myers.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Roche, the Swiss drugmaker, was let down by Tecentriq in clinical trials providing scope for Astra to close the gap and a possible boost for Bristol on Wednesday"
BMY,BMY:US,BBG000DQLV23,"Celldex Therapeutics, Inc.'s Collaboration with Bristol-Myers Squibb Key in First-Quarter Update",2017-05-09 23:02:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DTzWrVPGY0c/celldex-therapeutics-incs-collaboration-with-bristol-myers-squibb-key-in-first-quarter-update-cm786885,Financial contributions from a big partner helped Celldex Therapeutics NASDAQ CLDX the last time it reported quarterly results back in March Bristol Myers Squibb NYSE BMY provided a boost for Celldex in its fourth quarter and full year 2016 results Celldex announced
BMY,BMY:US,BBG000DQLV23,"Celldex Therapeutics, Inc.&apos;s Collaboration with Bristol-Myers Squibb Key in First-Quarter Update",2017-05-09 21:41:00 +0000,http://finance.yahoo.com/r/38612fc2-7996-3f5b-a5ed-c2988cb2607b/celldex-therapeutics-collaboration-with-bristol-my.aspx?yptr=yahoo&.tsrc=rss,The clinical-stage biotech reports higher quarterly revenue thanks to its combination studies with Bristol-Myers Squibb.
BMY,BMY:US,BBG000DQLV23,"Noteworthy Tuesday Option Activity: MDLZ, JWN, BMY",2017-05-09 21:03:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z0m7hg5DqOE/noteworthy-tuesday-option-activity-mdlz-jwn-bmy-cm786833,Among the underlying components of the S amp P 500 index we saw noteworthy options trading volume today in Mondelez International Inc Symbol MDLZ where a total of 30 624 contracts have traded so far representing approximately 3 1 million underlying shares That amounts to about 44 6
BMY,BMY:US,BBG000DQLV23,"Blackhill Capital Inc Buys Kinder Morgan Inc, Sunoco Logistics Partners LP, Energy Transfer ...",2017-05-09 17:01:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9O4ax4nhpZg/blackhill-capital-inc-buys-kinder-morgan-inc-sunoco-logistics-partners-lp-energy-transfer-cm786639,Blackhill Capital Inc New Purchases SUN 4ETA Added Positions KMI BMY BRK B EEQ WPZ PRSS Reduced Positions WSM MJN PFE JNJ ESRX TCP AAPL DIS BAX ZBH Sold Out ETP ETP MMM HON SHPG UTX SBUX RTN ROK COL New Purchases
BMY,BMY:US,BBG000DQLV23,"Buy &apos;repatriation stocks&apos; because that is sure to make the cut in the final tax bill, UBS says",2017-05-09 17:00:23 +0000,http://finance.yahoo.com/news/buy-apos-repatriation-stocks-apos-170023714.html?.tsrc=rss,"One highly anticipated piece of tax reform should support stocks in two industries, UBS analysts say."
BMY,BMY:US,BBG000DQLV23,"Buy 'repatriation stocks' because that is sure to make the cut in the final tax bill, UBS says",2017-05-09 17:00:23 +0000,http://finance.yahoo.com/r/fcdc1f25-79b0-305f-a4ca-b66765419f02/104455472?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104455472&yptr=yahoo&.tsrc=rss,"One highly anticipated piece of tax reform should support stocks in two industries, UBS analysts say."
BMY,BMY:US,BBG000DQLV23,Celldex Reports Updated 2017 Guidance - Quick Facts,2017-05-09 16:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7UJbylG3VjA/celldex-reports-updated-2017-guidance--quick-facts-20170509-01882,Celldex Reports Updated 2017 Guidance - Quick Facts
BMY,BMY:US,BBG000DQLV23,"Incyte (INCY) Q1 Loss Narrower than Expected, Revenues Beat",2017-05-08 21:01:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E9GXrJIoBuI/incyte-incy-q1-loss-narrower-than-expected-revenues-beat-cm786131,Incyte Corporation INCY reported first quarter 2017 loss of 96 cents a penny narrower than the Zacks Consensus Estimate of a loss of 97 cents Incyte had reported earnings of 12 cents per share in the year ago quarter Quarterly revenues were 384 1 million up 45 8 year over year and
BMY,BMY:US,BBG000DQLV23,ProShares UltraPro S&P500 Experiences Big Outflow,2017-05-08 16:02:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zU8btZDO0LQ/proshares-ultrapro-sp500-experiences-big-outflow-cm785894,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the ProShares UltraPro S amp P500 Symbol UPRO where we have detected an approximate 30 2 million dollar outflow that s a 3 3 decrease week over week
BMY,BMY:US,BBG000DQLV23,J&J: What's In Store At Next Week's Analyst Meeting,2017-05-08 13:34:00 +0000,http://finance.yahoo.com/r/226b7c4c-3ef1-320c-8f8d-069fd79070e0/j-j-whats-in-store-at-next-weeks-analyst-meeting-1494250482?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The biggest source of revenue for Johnson & Johnson (JNJ) is its famed pharmaceutical business.  It alone generated 46% of the company’s 2016 revenue, and has been a key driver of top line growth over the past few years.  Wells Fargo analyst Larry Biegelsen notes that the unit’s revenue growth is set to slow into the low single digits in the face of several headwinds -- or at least that’s what J&J’s 2017 guidance has implied."
BMY,BMY:US,BBG000DQLV23,Near-Term Events Cast Shadow Of Uncertainty On Bristol-Myers,2017-05-06 13:03:02 +0000,http://finance.yahoo.com/news/near-term-events-cast-shadow-130302284.html?.tsrc=rss,"BMO Capital Markets earlier this week downgraded shares of Bristol-Myers Squibb Co (NYSE: BMY ), citing strong near-term headwinds and the lower odds of a takeout. Near-Term Headwinds Analyst Alex Arfaei ..."
BMY,BMY:US,BBG000DQLV23,AVEO Pharmaceuticals (AVEO) Q1 Loss Narrower Than Expected,2017-05-05 22:26:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xj53nelCGZA/aveo-pharmaceuticals-aveo-q1-loss-narrower-than-expected-cm785320,AVEO Pharmaceuticals Inc AVEO reported a first quarter 2017 loss of 12 cents per share narrower than the Zacks Consensus Estimate as well as year ago loss of 13 cents Shares of the company fell more than 3 on Thursday However AVEO s share price movement shows that the stock
BMY,BMY:US,BBG000DQLV23,Vanguard Sector Funds,2017-05-04 19:13:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0ttRCI5xeuQ/vanguard-sector-funds-cm784531,InvestorPlace Stock Market News Stock Advice amp Trading Tips The list of Vanguard sector funds is relatively short but each of the funds provide focused 160 coverage to specialty areas of the market at a low cost to investors Sector funds can be smart additions to
BMY,BMY:US,BBG000DQLV23,"FVD, DPK: Big ETF Outflows",2017-05-04 16:14:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TXAplyk2ixU/fvd-dpk-big-etf-outflows-cm784266,Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel the biggest outflow was seen in the First Trust Value Line Dividend Index Fund where 3 800 000 units were destroyed or a 3 1 decrease week over week Among the largest underlying components
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers &apos;Too Risky&apos; To Acquire As Merck, Roche Pile On Pressure",2017-05-03 20:31:58 +0000,http://finance.yahoo.com/r/04b8ec2c-5917-3bac-8b82-52541ae31f33/bristol-myers-too-risky-to-acquire-as-merck-roche-pile-on-pressure?src=A00220&yptr=yahoo&.tsrc=rss,"Bristol-Myers is too risky to acquire as Merck and Roche pile on the pressure in immuno-oncology, an analyst argued Wednesday."
BMY,BMY:US,BBG000DQLV23,"Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates",2017-05-03 19:52:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KxIw2viu4ls/gilead-gild-beats-on-q1-earnings-revenues-miss-estimates-cm783712,Gilead Sciences Inc s GILD first quarter 2017 earnings including the impact of stock based compensation expenses of 2 20 per share beat the Zacks Consensus Estimate of 2 18 However earnings were down from 2 98 in the year ago quarter Moreover total revenue in the reported quarter
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Stock Falls Following Ratings Cut at BMO,2017-05-03 18:52:00 +0000,http://finance.yahoo.com/r/2e4821da-c1e4-3248-8bad-a78918c191af/bristol-myers-stock-falls-following-ratings-cut-at-bmo.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,BMO cut the company to 'Underperform.'
BMY,BMY:US,BBG000DQLV23,Bristol-Myers: Going Stag to the Ball?,2017-05-03 14:33:00 +0000,http://finance.yahoo.com/r/b14b4c1f-eaba-38e4-987f-4883fde11706/bristol-myers-going-stag-to-the-ball-1493822038?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"When Bristol-Myers Squibb (BMY) tumbled last year following disappointing drug trial data, analysts were quick to talk up a potential acquisition, naming companies like Pfizer (PFE), Gilead Sciences (GILD) ..."
BMY,BMY:US,BBG000DQLV23,"Analysts' Actions -- Anadarko, FireEye, Bristol-Myers, Twilio and More",2017-05-03 13:12:00 +0000,http://finance.yahoo.com/news/analysts-actions-anadarko-fireeye-bristol-131200015.html?.tsrc=rss,"Here are Wednesday's top research calls, including downgrades for Anadarko Petroleum, Twilio and Bristol-Myers Squibb, and an upgrade for FireEye."
BMY,BMY:US,BBG000DQLV23,"Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus",2017-05-02 22:27:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J__3lkUeK2E/exelixis-exel-posts-earnings-in-q1-cabometyx-in-focus-cm783071,Exelixis Inc EXEL posted first quarter 2017 earnings of 5 cents compared with a loss of 26 cents per share in the year ago quarter The Zacks Consensus Estimate was a loss of 1 cent Net revenue came in at 80 9 million significantly up from 15 4 million in the prior year quarter
BMY,BMY:US,BBG000DQLV23,Gilead Topples On Consensus-Lagging Q1 As Hepatitis C Drug Sales Plummet,2017-05-02 21:31:30 +0000,http://finance.yahoo.com/r/bc91b16e-6db9-3b99-8d0b-152d55ad37e0/gilead-stock-topples-on-consensus-lagging-q1-sales-earnings?src=A00220&yptr=yahoo&.tsrc=rss,"Gilead Sciences[ticker symb=GILD] stock toppled late Tuesday after the No. 3 biotech reported first-quarter sales and earnings that lagged Wall Street and said it had another quarter of declining revenue from its blockbuster hepatitis C drugs. Overall sales fell 17% year over year to $6.5 billion for the quarter ended March 31, missing views for $6.62 billion. Adjusted income of $2.23..."
BMY,BMY:US,BBG000DQLV23,"Whoa, an Operating Profit for Exelixis, Inc.",2017-05-02 21:29:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8al41ykMgG4/whoa-an-operating-profit-for-exelixis-inc-cm783047,Exelixis NASDAQ EXEL reported first quarter earnings posting something many biotechs never achieve profitability on an operating basis Exelixis results The raw numbers Metric Q1 2017
BMY,BMY:US,BBG000DQLV23,"After Hours Most Active for May 2, 2017 :  TWLO, AAPL, V, GE, OCLR, BMY, NBL, INTC, MSFT, SYF, ARRY, MU",2017-05-02 20:56:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z10_laMuoEQ/after-hours-most-active-for-may-2-2017-twlo-aapl-v-ge-oclr-bmy-nbl-intc-msft-syf-arry-mu-cm783059,The NASDAQ 100 After Hours Indicator is down 14 98 to 5 629 09 The total After hours volume is currently 41 884 707 shares traded The following are the most active stocks for the after hours session Twilio Inc TWLO is 10 06 at 23 88 with 3 312 317 shares
BMY,BMY:US,BBG000DQLV23,5 Things Exelixis Inc. Management Said After the Q1 Earnings Blowout That You'll Want to Know,2017-05-02 18:29:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ci8qP1NwDLI/5-things-exelixis-inc-management-said-after-the-q1-earnings-blowout-that-youll-want-to-know-cm782908,Exelixis Inc NASDAQ EXEL just reported the best quarter the company has had Ever 160 The biotech beat analysts revenue estimates It beat analysts earnings estimates As you might imagine Exelixis executives were quite upbeat in the company s first quarter results
BMY,BMY:US,BBG000DQLV23,Celldex Therapeutics (CLDX) Q1 Earnings: What's in Store?,2017-05-02 17:28:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xxdeqjYD2BU/celldex-therapeutics-cldx-q1-earnings-whats-in-store-cm782838,Celldex Therapeutics Inc CLDX is expected to report first quarter 2017 results on May 4 Celldex s performance has been encouraging with a three quarter average positive surprise of 8 06 In the last reported quarter the company recorded a positive surprise of 11 76 Celldex
BMY,BMY:US,BBG000DQLV23,5 Things Exelixis Inc. Management Said After the Q1 Earnings Blowout That You&apos;ll Want to Know,2017-05-02 16:24:00 +0000,http://finance.yahoo.com/r/0dffe24a-ffde-34f3-ab50-ba8c2fdb683c/5-things-exelixis-inc-management-said-that-youll-w.aspx?yptr=yahoo&.tsrc=rss,Exelixis announced great results for Q1. Here&apos;s what management said afterwards.
BMY,BMY:US,BBG000DQLV23,"ETFs with exposure to Bristol-Myers Squibb Co. : May 1, 2017",2017-05-01 19:42:12 +0000,http://finance.yahoo.com/r/c9988436-c40d-359f-9687-1b9966c7a673/etfs-with-exposure-to-bristol-myers-squibb-co-may-1-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Bristol-Myers Squibb Co. Here are 5 ETFs with the largest exposure to BMY-US. Comparing the performance and risk of Bristol-Myers Squibb Co. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,"Seattle Genetics, Inc. Earnings: Solid Quarter, but Investors Wait",2017-05-01 19:27:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/za3SgQcp6yw/seattle-genetics-inc-earnings-solid-quarter-but-investors-wait-cm782198,Seattle Genetics NASDAQ SGEN reported solid first quarter earnings on Thursday but the potential expansion of Adcetris into treating patients in other cancer settings and the development of the rest of the biotech s pipeline are what investors are mainly focused on Seattle
BMY,BMY:US,BBG000DQLV23,"Health Care Sector Update for 05/01/2017: ITCI,AMPE,AEZS",2017-05-01 17:46:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uMfWwDVhl2I/health-care-sector-update-for-05012017-itciampeaezs-cm782158,Top Health Care StocksTop Health Care Stocks JNJ 0 32 JNJ 0 32 PFE 0 29 PFE 0 29 MRK 0 37 MRK 0 37 ABT 0 22 ABT 0 22 AMGN 0 14 AMGN 0 14 Health care stocks were edging higher Monday with the NYSE Health Care Index rising about 0 2 while shares of health care companies in
BMY,BMY:US,BBG000DQLV23,Is Merck a Great Pick for Your Dividend Portfolio?,2017-05-01 17:30:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9x-k8n4fzBo/is-merck-a-great-pick-for-your-dividend-portfolio-cm782122,Keeping a portion of your portfolio dedicated to stocks of solid dividend paying companies is a wise strategy for building wealth for the long term while maintaining some relative safety Stocks of large pharmaceutical companies come into favor in times of economic uncertainty because
BMY,BMY:US,BBG000DQLV23,"Drug Stocks Q1 Earnings Slated for May 2: MRK, PFE & GILD",2017-05-01 15:31:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/53GFHnUIF8Q/drug-stocks-q1-earnings-slated-for-may-2-mrk-pfe-gild-cm781951,The Q1 earnings season is in full swing with financial results from 288 S amp P 500 members or 63 8 of the index already out as of Apr 28 2017 according to the latest Earnings Preview report Total earnings for these index members jumped 13 7 from the year ago quarter driven by 8
BMY,BMY:US,BBG000DQLV23,Edited Transcript of BMY earnings conference call or presentation 27-Apr-17 2:30pm GMT,2017-05-01 12:05:57 +0000,http://finance.yahoo.com/news/edited-transcript-bmy-earnings-conference-124553394.html?.tsrc=rss,Q1 2017 Bristol-Myers Squibb Co Earnings Call
BMY,BMY:US,BBG000DQLV23,[$$] China Approves Bristol-Myers Squibb’s Dual-Drug Hepatitis C Treatment,2017-05-01 04:10:12 +0000,http://finance.yahoo.com/r/71400220-6d9d-3b82-8583-f51a6504b232/china-approves-bristol-myers-squibbs-dual-drug-hepatitis-c-treatment-1493381392?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,"China’s drug regulator approved Bristol-Myers Squibb’s all-oral treatment for hepatitis C, which will be the first therapy of its kind for the liver disease to be sold in the country, giving the U.S. company ..."
BMY,BMY:US,BBG000DQLV23,2 Beaten-Up Dividend Stocks: Are They Bargains?,2017-04-29 18:07:00 +0000,http://finance.yahoo.com/r/596a18d4-cd37-3e97-a36b-277a169f74fa/2-beaten-up-dividend-stocks-are-they-bargains.aspx?yptr=yahoo&.tsrc=rss,"Shares of Signet Jewelers Ltd. and Bristol-Myers Squibb have had a rough year. Has the market gone too far, or are these value stocks actually value traps?"
BMY,BMY:US,BBG000DQLV23,5 Things Bristol-Myers Squibb's Management Wants You to Know,2017-04-29 12:26:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DuXc4S3g2rc/5-things-bristol-myers-squibbs-management-wants-you-to-know-cm781597,Bristol Myers Squibb NYSE BMY blew past all expectations when it reported first quarter results on Thursday Wall Street estimated earnings of 0 74 per share on revenue of 4 72 billion The drugmaker delivered first quarter adjusted earnings of 0 84 per share with revenue of 4
BMY,BMY:US,BBG000DQLV23,5 Things Bristol-Myers Squibb&apos;s Management Wants You to Know,2017-04-29 10:42:00 +0000,http://finance.yahoo.com/r/a4f10c0a-b2cc-3e52-b642-9d18bbc0d2a6/5-things-bristol-myers-squibbs-management-wants-yo.aspx?yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb knocked it out of the park with its Q1 earnings.
BMY,BMY:US,BBG000DQLV23,"Roche Earnings: Story Remains The Same, All Eyes On New Drugs",2017-04-28 22:58:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MJ4UxI6pe7A/roche-earnings-story-remains-the-same-all-eyes-on-new-drugs-cm781534,Roche 160 RHHBY recently announced its Q1 2017 earnings The results were in line with our expectation and there was no significant movement in the stock In essence Roche s story remains the same We stated in our pre earnings note that we expect Roche s diagnostics division to
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Squibb Passes on Buyout Option for F-star Alpha,2017-04-28 21:42:57 +0000,http://finance.yahoo.com/r/fea7fe11-73d8-35b7-8c67-a9a2e622ab7d/bristol-myers-squibb-passes-on-buyout-option-for-f-star-alpha-1493415774?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb Co. has passed on an option to acquire F-star Alpha Ltd. that it had gained through a $475 million agreement with the venture-backed drug company.
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Beats Gilead, Merck To Key Approvals In China, Europe",2017-04-28 20:38:33 +0000,http://finance.yahoo.com/r/7e910bd4-0c12-3b59-b642-5a2f5db9f60f/bristol-myers-beats-gilead-merck-to-key-approvals-in-china-europe?src=A00220&yptr=yahoo&.tsrc=rss,Bristol-Myers grabbed a pair of wins Friday after China approved its hepatitis C regimen and Europe blessed immuno-oncology drug Opdivo in head-and-neck cancer.
BMY,BMY:US,BBG000DQLV23,"Despite Worries, Bristol-Myers' Opdivo Keeps Racking Up Sales",2017-04-28 20:27:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WM4SkV5V4jc/despite-worries-bristol-myers-opdivo-keeps-racking-up-sales-cm781409,Shares in Bristol Myers Squibb NYSE BMY tumbled over worry that Opdivo s sales would slow following a failure in a key cancer drug trial last year However Bristol Myers first quarter financial results show that demand for Opdivo remains strong despite the setback and that
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb: Strong Earnings Could Warrant Higher Dividend Growth Ahead,2017-04-28 19:59:18 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-strong-earnings-195918014.html?.tsrc=rss,Analyzing the biopharmaceutical company's quarterly results
BMY,BMY:US,BBG000DQLV23,InPlay from Briefing.com,2017-04-28 19:57:48 +0000,http://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
BMY,BMY:US,BBG000DQLV23,"Despite Worries, Bristol-Myers&apos; Opdivo Keeps Racking Up Sales",2017-04-28 19:21:00 +0000,http://finance.yahoo.com/r/12b88436-5738-3cc4-9769-198ed52ff372/despite-worries-bristol-myers-opdivo-keeps-racking.aspx?yptr=yahoo&.tsrc=rss,"If you&apos;re not buying Bristol-Myers because of last year&apos;s Opdivo trial failure, you ought to reconsider."
BMY,BMY:US,BBG000DQLV23,European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Squamous Cell Cancer of the Head and Neck in Adults Progressing On or After Platinum-based Therapy,2017-04-28 18:38:00 +0000,http://finance.yahoo.com/news/european-commission-approves-bristol-myers-183800867.html?.tsrc=rss,Bristol-Myers Squibb Company today announced that the European Commission has approved Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy.
BMY,BMY:US,BBG000DQLV23,[$$] China Approves Bristol-Myers Dual-Drug Hepatitis C Treatment,2017-04-28 15:43:46 +0000,http://finance.yahoo.com/r/71400220-6d9d-3b82-8583-f51a6504b232/china-approves-bristol-myers-squibbs-dual-drug-hepatitis-c-treatment-1493381392?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"China’s drug regulator approved Bristol-Myers Squibb’s all-oral treatment for hepatitis C, which will be the first therapy of its kind for the liver disease to be sold in the country, giving the U.S. company ..."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. :BMY-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017",2017-04-28 15:16:38 +0000,http://finance.yahoo.com/r/8599ecba-2d2b-36a5-a94d-9a411b9f32fa/bristol-myers-squibb-co-bmy-us-earnings-analysis-q1-2017-by-the-numbers-april-28-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Bristol-Myers Squibb Co. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Bristol-Myers Squibb Co. – Eli Lilly and Company, Novartis AG Sponsored ADR, Johnson & Johnson and Amgen Inc. (LLY-US, NVS-US, JNJ-US and AMGN-US) that have also reported for ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More",2017-04-28 14:31:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hbwmZ5eBk3Y/pharma-stock-roundup-lilly-bristol-myers-novartis-q1-earnings-more-cm780993,Earnings season for the pharma sector started in full flow this week with companies like Lilly LLY Novartis NVS Bristol Myers BMY Roche AstraZeneca Glaxo GSK and Sanofi SNY reporting results So far it looks like a mixed quarter for the sector Recap of the Week s Most
BMY,BMY:US,BBG000DQLV23,"Company News for April 28, 2017",2017-04-28 14:09:02 +0000,http://finance.yahoo.com/news/company-news-april-28-2017-140902219.html?.tsrc=rss,"Companies in the News are: F,LUV,UNP,BMY"
BMY,BMY:US,BBG000DQLV23,Health Care Sector Update for 04/28/2017: BMY,2017-04-28 13:46:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z0tft7_mz60/health-care-sector-update-for-04282017-bmy-cm781006,Top Health care stocks Top Health care stocks JNJ 0 1 JNJ 0 1 PFE 0 1 PFE 0 1 ABT flatABT flat MRK flatMRK flat AMGN 0 1 AMGN 0 1 Health care shares were mixed in pre market trade on Friday Health care shares were mixed in pre market trade on Friday In health care stocks
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More",2017-04-28 12:41:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-lilly-bristol-124112594.html?.tsrc=rss,Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. breached its 50 day moving average in a Bullish Manner : BMY-US : April 28, 2017",2017-04-28 12:23:00 +0000,http://finance.yahoo.com/r/369237b8-cb98-3e65-860a-036bb439e29f/bristol-myers-squibb-co-breached-its-50-day-moving-average-in-a-bullish-manner-bmy-us-april-28-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Bristol-Myers Squibb Co.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers wins approval in China for oral treatment for chronic hepatitis C virus,2017-04-28 12:21:04 +0000,http://finance.yahoo.com/r/fcc793fe-4557-3d86-bdb7-43fbe72deed1/Story.aspx?guid=5D676394-155B-4D44-96D7-92EA41D68508&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Shares of Bristol-Myers Squibb Co. said Friday it has won approval from the China Food and Drug Administration for its oral treatment for chronic hepatitis C virus. The drug company said Daklinza in combination ...
BMY,BMY:US,BBG000DQLV23,"China FDA Approves Country’s First All-Oral Regimen for Chronic Hepatitis C, Daklinza® (daclatasvir) in Combination with Sunvepra® (asunaprevir)",2017-04-28 11:19:00 +0000,http://finance.yahoo.com/news/china-fda-approves-country-first-111900958.html?.tsrc=rss,"Bristol-Myers Squibb Company announced today that the China Food and Drug Administration has approved a direct-acting antiviral regimen comprised of Daklinza® and Sunvepra® , for the treatment of treatment-naive or -experienced patients, with or without compensated cirrhosis, infected with genotype 1b chronic hepatitis C virus ."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers: China FDA Oks Daklinza, Sunvepra Combination For HCV",2017-04-28 07:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/auP52UFMm9E/bristolmyers-china-fda-oks-daklinza-sunvepra-combination-for-hcv-20170428-00474,"Bristol-Myers: China FDA Oks Daklinza, Sunvepra Combination For HCV"
BMY,BMY:US,BBG000DQLV23,Oil's 'false tell' could set off domino effect,2017-04-27 23:42:00 +0000,http://finance.yahoo.com/video/oils-false-tell-could-set-234200168.html?.tsrc=rss,Jim Cramer says oil prices bottoming could have an effect on investors' stock picks.
BMY,BMY:US,BBG000DQLV23,"Cramer: When Oil Falls, These Dominoes Get Hit",2017-04-27 23:01:00 +0000,http://finance.yahoo.com/r/07bfcdf8-3f74-3aa3-8edf-e4d3f167c804/cramer-when-oil-falls-these-dominoes-get-hit?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,It doesn't look like Washington will be much help.
BMY,BMY:US,BBG000DQLV23,Cramer: How oil's 'false tell' could set off a market-cha...,2017-04-27 22:37:00 +0000,http://finance.yahoo.com/video/cramer-oils-false-tell-could-223700164.html?.tsrc=rss,Jim Cramer says oil prices bottoming could have an effect on investors' stock picks.
BMY,BMY:US,BBG000DQLV23,Cramer: How oil&apos;s &apos;false tell&apos; could set off a market-changing domino effect,2017-04-27 22:11:48 +0000,http://finance.yahoo.com/news/cramer-oil-apos-apos-false-221148658.html?.tsrc=rss,Jim Cramer says oil prices bottoming could have an effect on investors&apos; stock picks.
BMY,BMY:US,BBG000DQLV23,Cramer: How oil's 'false tell' could set off a market-changing domino effect,2017-04-27 22:11:48 +0000,http://finance.yahoo.com/r/5f0dd354-9014-3c53-9b3a-a438fd337428/104432405?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104432405&yptr=yahoo&.tsrc=rss,Jim Cramer says oil prices bottoming could have an effect on investors' stock picks.
BMY,BMY:US,BBG000DQLV23,Strong Sales for Opdivo and Eliquis Drive Bristol-Myers' Solid Q1,2017-04-27 21:08:00 +0000,http://finance.yahoo.com/r/80649d1f-d3f2-3119-81f1-2cf445cd4214/strong-sales-for-opdivo-and-eliquis-drive-bristol-myers-solid-q1.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Sales of cancer drug Opdivo were up 60% year-over-year, while sales of blood thinner Eliquis grew 50%."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Stock Pops On Street-Crushing Q1 Revenue, Profits",2017-04-27 21:02:53 +0000,http://finance.yahoo.com/r/5e624863-0930-36f3-9701-2d7f17fd61bf/bristol-myers-stock-pops-on-street-crushing-q1-revenue-profits?src=A00220&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb&apos;s Merck-rivaling immuno-oncology drug, Opdivo, grew 60% in the first quarter, helping the drugmaker to smash Wall Street&apos;s expectations."
BMY,BMY:US,BBG000DQLV23,"AbbVie Flirts With Buy Point After Q1 Earnings, Sales Top",2017-04-27 20:48:42 +0000,http://finance.yahoo.com/r/16693180-f10d-3670-a61e-760fac0fa42e/abbvie-crushes-q1-sales-earnings-views?src=A00220&yptr=yahoo&.tsrc=rss,AbbVie reported better-than-expected earnings and revenue early Thursday. Shares of the drugmaker traded around a buy point.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers: Not Dead Yet?,2017-04-27 19:05:00 +0000,http://finance.yahoo.com/r/a717316d-6787-38cc-98dc-965155ab2eab/bristol-myers-not-dead-yet-1493319923?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Remember when Bristol-Myers Squibb tumbled in August after announcing that a late-stage trial for the use of Opdivo in lung cancer failed to meet its primary endpoint?  Well, Bristol is starting to make back some of those losses after releasing better-than-expected earnings today.  Despite the good news, Bernstein's Tim Anderson notes the difficulty in predicting the future for Bristol-Myers' cancer drugs: While the focus by investors remains on [immuno-oncology, or IO,] BMY is working to broaden the focus, calling out other non-IO approaches it is engaged in like fibrosis, CV medicine, immunology (pipeline still pre-phase 3 in these areas)."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Stock Pops On Street-Crushing Q1 Revenue, Profits",2017-04-27 19:00:53 +0000,http://finance.yahoo.com/r/c01568ee-9f92-3082-b1d9-2dcd12a3174e/bristol-myers-stock-pops-on-street-crushing-q1-revenue-profits-branch?src=A00220&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb&apos;s Merck-rivaling immuno-oncology drug, Opdivo, grew 60% in the first quarter, helping the drugmaker to smash Wall Street&apos;s expectations."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View",2017-04-27 17:31:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UvB3_DUBab0/bristol-myers-bmy-beats-on-q1-earnings-ups-2017-view-cm780504,Bristol Myers Squibb Company s BMY first quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14 from the year ago period We note that the bottom line was boosted by an 18 cent contribution from the patent infringement litigation settlement
BMY,BMY:US,BBG000DQLV23,A Refreshing Voice At Bristol-Myers Squibb,2017-04-27 17:02:00 +0000,http://finance.yahoo.com/r/3f28889e-1194-324e-929d-c1e4aed67da9/a-refreshing-voice-at-bristol-myers-squibb?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,Bristol beat earnings forecasts -- and showed off its new R&D boss.
BMY,BMY:US,BBG000DQLV23,Biopharma earnings bonanza,2017-04-27 16:07:00 +0000,http://finance.yahoo.com/video/biopharma-earnings-bonanza-160700524.html?.tsrc=rss,"CNBC's Meg Tirrell reports on the moves in the biotech sector following earnings from Amgen, Bristol-Myers and more. The &quot;Fast Money Halftime Report&quot; traders weigh in."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View",2017-04-27 15:01:03 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-beats-q1-150103081.html?.tsrc=rss,Bristol-Myers Squibb Company&apos;s (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo",2017-04-27 14:34:53 +0000,http://finance.yahoo.com/news/bristol-myers-beats-wall-st-143453385.html?.tsrc=rss,"Bristol-Myers Squibb Co  on Thursday reported higher-than-expected quarterly  earnings, helped by increased sales of cancer drugs Opdivo and  Yervoy and blood thinner Eliquis.  The U.S. drugmaker, which has faced increasing competition  for blockbuster Opdivo as well as pressure from activist  investors, also raised its full-year earnings outlook, reversing  a cut it made in January.  Opdivo sales jumped 60 percent in the first quarter, while  Eliquis gained 50 percent and Yervoy rose 25 percent."
BMY,BMY:US,BBG000DQLV23,US STOCKS-Wall St little changed with eyes on earnings,2017-04-27 13:53:52 +0000,http://finance.yahoo.com/news/us-stocks-wall-st-little-135352695.html?.tsrc=rss,"U.S. stocks were little changed on  Thursday amid a flood of quarterly earnings reports, while  investors assessed President Donald Trump's tax reform plan.  ""Yesterday, you saw some selling but it didn't develop into  an outright heavy pressure day,"" said Robert Pavlik, chief  market strategist at Boston Private Wealth.  At 9:38 a.m. ET (1338 GMT), the Dow Jones Industrial Average  was up 11.43 points, or 0.05 percent, at 20,986.52, the  S&P 500 was up 0.14 points, or 0.01 percent, at 2,387.59  and the Nasdaq Composite was up 6.55 points, or 0.11  percent, at 6,031.78."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part in Deutsche Bank Annual Health Care Conference,2017-04-27 12:00:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-part-deutsche-120000175.html?.tsrc=rss,"Bristol-Myers Squibb Company will take part in the 42nd Annual Deutsche Bank Health Care Conference on Thursday, May 4, 2017, in Boston. Charles Bancroft executive vice president, head of Global Business Operations, will answer questions about the company at 11:20 a.m."
BMY,BMY:US,BBG000DQLV23,Analysts’ Ratings and Recommendations for Bristol-Myers Squibb,2017-04-27 11:36:57 +0000,http://finance.yahoo.com/r/3681f3ad-e64c-3d82-9d5d-817c50f9555c/analysts-ratings-and-recommendations-for-bristol-myers-squibb?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Wall Street analysts’ expect Bristol-Myers Squibb’s (BMY) top line to rise 8.0% to ~$4.7 billion in 1Q17. They also expect its earnings per share (or EPS) to be $0.74 for 1Q17.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers tops Street 1Q forecasts,2017-04-27 11:28:24 +0000,http://finance.yahoo.com/news/bristol-myers-tops-street-1q-112824501.html?.tsrc=rss,"The New York-based company said it had profit of 94 cents per share. Earnings, adjusted for non-recurring gains, were 84 cents per share. The results beat Wall Street expectations. The average estimate ..."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb stock surges 3% after first-quarter profit, revenue beats",2017-04-27 11:09:38 +0000,http://finance.yahoo.com/r/8b42c8d8-e1ef-36be-a71f-6e33ce73f27b/Story.aspx?guid=E298CD1B-97F9-4455-B3B4-71B86DFB0C9C&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb Co. shares surged 3.2% in premarket trade Thursday after the company reported first-quarter profit and revenue beats. Earnings for the latest quarter rose to $1.57 billion, or 94 cents ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Optimism on Cancer Drug Give Rare Sense of Relief,2017-04-27 11:01:24 +0000,http://finance.yahoo.com/r/4760b72f-0d6c-3b1f-b8d1-319430bf7cb4/bristol-myers-s-strong-cancer-results-may-ease-concerns-for-now?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb Co.’s blockbuster cancer drug Opdivo held its ground against competing products in the first quarter, a relief for investors concerned about the prospects of a drug that’s faced roadblocks ..."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers beats Wall St estimates, helped by Cancer drug Opdivo",2017-04-27 10:59:47 +0000,http://finance.yahoo.com/news/bristol-myers-beats-wall-st-105947832.html?.tsrc=rss,"Bristol-Myers Squibb Co  on Thursday posted better-than-expected first-quarter  earnings, helped by growth from cancer drugs Opdivo and Yervoy  and blood thinner Eliquis.  The U.S. drugmaker, which has faced increasing competition  for blockbuster Opdivo as well as pressure from activist  investors, also raised its expectations for its full-year  earnings, reversing a cut to its outlook it made in the previous  quarter.  Opdivo sales rose 60 percent in the quarter, while Eliquis  and Yervoy sales rose 50 percent and 25 percent, respectively."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Reports First Quarter Financial Results,2017-04-27 10:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-reports-first-105900655.html?.tsrc=rss,"Bristol-Myers Squibb Company today reported results for the first quarter of 2017, which were highlighted by strong sales for key products Opdivo and Eliquis, regulatory approval for Opdivo in advanced bladder cancer in the U.S., positive opinions from the Committee for Medicinal Products for Human Use for advanced bladder and head and neck cancers in Europe, and strategic transactions in oncology ..."
BMY,BMY:US,BBG000DQLV23,Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids,2017-04-27 10:35:00 +0000,http://finance.yahoo.com/r/3a691b3d-e2e6-3147-9326-c0d47e838a6d/market-recon-the-tax-reform-is-just-ordinary-negotiation-on-steroids.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Nobody shows their hand in negotiations. Why should government? This new tax plan must go to Congress.
BMY,BMY:US,BBG000DQLV23,"Earnings Reaction History: Bristol Myers Squibb Co, 41.7% Follow-Through Indicator, 2.2% Sensitive",2017-04-27 10:25:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pLBe6e-2Jnk/earnings-reaction-history-bristol-myers-squibb-co-417-follow-through-indicator-22-sensitive-cm780044,Expected Earnings Release 04 27 2017 PremarketExpected Earnings Release 04 27 2017 Premarket Avg Extended Hours Dollar Volume 6 703 671Avg Extended Hours Dollar Volume 6 703 671 Bristol Myers Squibb Co BMY is due to issue its quarterly earnings report in the upcoming extended
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Q1 17 Earnings Conference Call At 10:30 AM ET,2017-04-27 09:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bsUpHki5yxs/bristolmyers-q1-17-earnings-conference-call-at-1030-am-et-20170427-00867,Bristol-Myers Q1 17 Earnings Conference Call At 10:30 AM ET
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Co. Reveals 13% Rise In Q1 Bottom Line,2017-04-27 07:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kPB4efBctTE/bristolmyers-squibb-co-reveals-13-rise-in-q1-bottom-line-20170427-00685,Bristol-Myers Squibb Co. Reveals 13% Rise In Q1 Bottom Line
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Q1 Profit Rises; Lifts 2017 Profit View,2017-04-27 07:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZjYHwIzc38k/bristolmyers-squibb-q1-profit-rises-lifts-2017-profit-view-20170427-00616,Bristol-Myers Squibb Q1 Profit Rises; Lifts 2017 Profit View
BMY,BMY:US,BBG000DQLV23,Roche Should Remain Resilient And Grow Moderately In Q1,2017-04-26 20:46:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7ZtDzjSlD7U/roche-should-remain-resilient-and-grow-moderately-in-q1-cm779779,Roche 160 RHHBY will announce its Q1 2017 results on April 27 We expect Roche s diagnostics division to see mid single digit growth driven by expansion 160 in international markets including China and focus on high throughput laboratories with new products in the Cobas family We
BMY,BMY:US,BBG000DQLV23,Biogen Inc. Earnings: New Drug Sparks Life,2017-04-26 20:44:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Eeo4tNXG9JM/biogen-inc-earnings-new-drug-sparks-life-cm779825,Biogen NASDAQ BIIB reported first quarter earnings on Tuesday resulting in investors excited about the potential for Spinraza its new spinal muscular atrophy drug developed with Ionis Pharmaceuticals NASDAQ IONS but tolerating ho hum sales growth of its multiple
BMY,BMY:US,BBG000DQLV23,"Pre-Market Earnings Report for April 27, 2017 :  CMCSA, ABBV, CELG, UNP, BMY, DOW, UPS, AMT, SPG, RTN, F, CME",2017-04-26 20:12:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p6Q_D9qSseE/pre-market-earnings-report-for-april-27-2017-cmcsa-abbv-celg-unp-bmy-dow-ups-amt-spg-rtn-f-cme-cm779833,The following companies are expected to report earnings prior to market open on 04 27 2017 Visit our Earnings Calendar for a full list of expected earnings releases Comcast Corporation CMCSA is reporting for the quarter ending March 31 2017 The cable
BMY,BMY:US,BBG000DQLV23,"Crossvault Capital Management LLC Buys Expedia, JPMorgan Chase, Lockheed Martin, Sells ...",2017-04-26 19:03:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8S-49H8H2Q0/crossvault-capital-management-llc-buys-expedia-jpmorgan-chase-lockheed-martin-sells-cm779805,Crossvault Capital Management LLC New Purchases EXPE JPM GD Added Positions LMT GOOGL ROK PNC IBM SPLK HON BA NKE AMZN Reduced Positions PFE GE KR UNH WBA XOM JNJ WMT KO SO Sold Out QCOM DUK PPL CNP PNW New Purchases
BMY,BMY:US,BBG000DQLV23,A Look at Bristol-Myers Squibb’s Other Segments in 1Q17,2017-04-26 14:37:52 +0000,http://finance.yahoo.com/r/d3d61295-5dba-3121-9040-1aa9a633794e/a-look-at-bristol-myers-squibbs-other-segments-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb’s (BMY) other segments include the Neuroscience segment, the Cardiovascular segment, and the Immuno-Science segment."
BMY,BMY:US,BBG000DQLV23,"Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY",2017-04-26 14:08:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J5LPdt37ifM/pharma-stocks-q1-earnings-roster-for-apr-27-celg-abbv-bmy-cm779340,Things are certainly looking up as we get into the thick of the Q1 earnings season By the end of this week approximately half of the S amp P 500 Index would be reporting making the picture clearer As of Apr 21 95 S amp P 500 members accounting for 24 9 of the index s total
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s 1Q17 Estimates: Virology Segment,2017-04-26 13:09:06 +0000,http://finance.yahoo.com/r/eaaa3aa8-6dc3-37fc-b4b6-0805295ebeec/bristol-myers-squibbs-1q17-estimates-virology-segment?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,The Virology segment is Bristol-Myers Squibb’s (BMY) second-largest revenue contributor. The segment contributes ~25% of the company's total revenue.
BMY,BMY:US,BBG000DQLV23,"Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY",2017-04-26 12:04:12 +0000,http://finance.yahoo.com/news/pharma-stocks-q1-earnings-roster-120412931.html?.tsrc=rss,"Celgene, AbbVie and Bristol-Myers Squibb are expected to report earnings on Apr 27."
BMY,BMY:US,BBG000DQLV23,A Look at Bristol-Myers Squibb’s Oncology Segment in 1Q17,2017-04-26 11:37:24 +0000,http://finance.yahoo.com/r/d76fccf5-71c0-3652-8ea0-59ca5106f17a/a-look-at-bristol-myers-squibbs-oncology-segment-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Given the strong performance of Opdivo, the Oncology segment has emerged as the largest revenue contributor for Bristol-Myers Squibb (BMY) during the last few quarters."
BMY,BMY:US,BBG000DQLV23,"Moody's: Outlook for global pharmaceuticals industry stable on low earnings growth, new product launches",2017-04-26 08:21:05 +0000,http://finance.yahoo.com/r/86ca4cfc-6403-3b5d-9abf-78f0a98d7b5a/viewresearchdoc.aspx?docid=PR_365746&WT.mc_id=AM~WWFob29fRmluYW5jZV9TQl9SYXRpbmcgTmV3c19BbGxfRW5n~20170426_PR_365746&yptr=yahoo&.tsrc=rss,"Announcement: Moody's: Outlook for global pharmaceuticals industry stable on low earnings growth, new product launches. Global Credit Research- 26 Apr 2017. New York, April 26, 2017-- The outlook for the ..."
BMY,BMY:US,BBG000DQLV23,"[$$] Aquinnah Pharmaceuticals Taps Pfizer, AbbVie for $10 Million",2017-04-26 02:07:01 +0000,http://finance.yahoo.com/r/c95183f3-79f9-3e49-b065-de8aa98679d5/aquinnah-pharmaceuticals-taps-pfizer-abbvie-for-10-million-1493172418?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,A trio of pharmaceutical companies is financing an effort by Aquinnah Pharmaceuticals Inc. to use a new approach to tackling neurological diseases that have long frustrated drugmakers.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s 1Q17 Estimates: Expect Growth!,2017-04-25 22:06:03 +0000,http://finance.yahoo.com/r/7dc4d22c-7d65-307d-8410-a6fa23a3e244/bristol-myers-squibbs-1q17-estimates-expect-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb (BMY) is expected to report a rise of ~8% to $4.7 billion in its 1Q17 earnings on April 27, 2017."
BMY,BMY:US,BBG000DQLV23,Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?,2017-04-25 22:05:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c7aLBH0RhJw/exelixis-exel-q1-earnings-will-the-stock-disappoint-cm779088,Exelixis Inc EXEL is scheduled to report first quarter 2017 results on May 1 after the market close The company surpassed expectations thrice in the four trailing quarters and missed the same once with an average positive earnings surprise of 360 11 Exelixis share price has
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store?,2017-04-25 21:07:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ov5tohhQTkE/bristol-myers-bmy-to-post-q1-earnings-whats-in-store-cm779051,Bristol Myers Squibb Company BMY is scheduled to report first quarter 2017 results on Apr 27 before the opening bell Last quarter the company missed earnings estimates by 4 55 Bristol Myers stock lost 24 2 in the past year underperforming the Zacks classified Large Cap
BMY,BMY:US,BBG000DQLV23,What Analysts Expect of Bristol-Myers Squibb’s 1Q17 Earnings,2017-04-25 20:28:42 +0000,http://finance.yahoo.com/r/a08b2418-5f29-3383-a8ec-67cea7cf9ca3/what-analysts-expect-of-bristol-myers-squibbs-1q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb is set to release its 1Q17 earnings on April 27, 2017. Analysts expect EPS (earnings per share) of $0.74 and revenue of $4.7 billion for the company in 1Q17."
BMY,BMY:US,BBG000DQLV23,U.S. Supreme Court may limit where companies can be sued,2017-04-25 19:46:46 +0000,http://finance.yahoo.com/news/u-supreme-court-may-limit-194646204.html?.tsrc=rss,"The U.S. Supreme Court on Tuesday appeared poised to clamp down on where corporations can be sued, a potential setback for plaintiffs' lawyers who strive to bring cases in courts and locales they consider friendly.  The nine justices in two separate cases heard appeals of lower court rulings allowing out-of-state injury lawsuits against drug maker Bristol-Myers Squibb Co(BMY.N) and BNSF Railway Co(BNISF.UL).  Companies and plaintiffs are engaged in a fight over where lawsuits seeking financial compensation for injuries should be filed."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) to Post Q1 Earnings: What&apos;s in Store?,2017-04-25 18:46:06 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-post-q1-184606635.html?.tsrc=rss,"Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell."
BMY,BMY:US,BBG000DQLV23,Chill Pill: Eli Lilly Cuts Guidance with Earnings,2017-04-25 17:00:00 +0000,http://finance.yahoo.com/r/ce30bef7-115c-3462-9d78-b9c57915a070/chill-pill-eli-lilly-cuts-guidance-earnings?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Lilly trimmed its full-year GAAP EPS guidance, dragging shares lower today."
BMY,BMY:US,BBG000DQLV23,U.S. Supreme Court may limit where companies can be sued,2017-04-25 16:14:29 +0000,http://finance.yahoo.com/news/u-supreme-court-may-limit-161429208.html?.tsrc=rss,"U.S. Supreme Court justices  on Tuesday signaled a willingness to place limits on where  corporations can be sued in a dispute involving drug maker  Bristol-Myers Squibb Co, a potential setback to  plaintiffs' lawyers who try to bring suits in friendly courts.  The justices heard arguments in Bristol-Myers' appeal of a  California Supreme Court ruling allowing that state's courts to  hear claims related to its blood-thinning medication Plavix even  though most plaintiffs do not live in the state and the company  is not based there.  The justices on Monday also were set to hear a similar  appeal by Texas-based BNSF Railway Co of a 2015  Montana Supreme Court ruling allowing out-of-state residents to  sue there over injuries that happened anywhere in BNSF's  nationwide network."
BMY,BMY:US,BBG000DQLV23,3 Reasons Pfizer Is a Better Dividend Stock Than Bristol-Myers Squibb,2017-04-25 14:06:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ePttkD5qVqs/3-reasons-pfizer-is-a-better-dividend-stock-than-bristol-myers-squibb-cm778482,Big pharma stocks have been popular among investors seeking solid dividends for a long time And for good reason Large drugmakers historically have generated such tremendous cash flow and earnings that they have been able to reward shareholders with juicy dividends Bristol
BMY,BMY:US,BBG000DQLV23,3 Reasons Pfizer Is a Better Dividend Stock Than Bristol-Myers Squibb,2017-04-25 12:04:00 +0000,http://finance.yahoo.com/r/2ff76473-dd59-32ee-9387-277a404078f3/3-reasons-pfizer-is-a-better-dividend-stock-than-b.aspx?yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb might have fast-growing cancer drug Opdivo, but here&apos;s why Pfizer is the better dividend stock."
BMY,BMY:US,BBG000DQLV23,America&apos;s 12 Most Charitable Companies,2017-04-25 10:05:00 +0000,http://finance.yahoo.com/r/61aa756c-4b02-3bf5-b3cb-ac17adbd591e/americas-12-most-charitable-companies.aspx?yptr=yahoo&.tsrc=rss,"These healthcare, bank, and tech companies are leading the way in investing in global change."
BMY,BMY:US,BBG000DQLV23,Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer,2017-04-25 05:30:00 +0000,http://finance.yahoo.com/news/transgene-bristol-myers-squibb-announce-053000038.html?.tsrc=rss,"Bristol-Myers Squibb Company and Transgene today announced a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene’s investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo + standard chemotherapy as a first-line treatment for advanced non-squamous non-small cell lung cancer in patients whose tumors have low or undetectable ..."
BMY,BMY:US,BBG000DQLV23,Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer,2017-04-25 05:30:00 +0000,http://finance.yahoo.com/news/transgene-bristol-myers-squibb-announce-053000647.html?.tsrc=rss,Regulatory News:
BMY,BMY:US,BBG000DQLV23,NASH: The next untapped pharma market gives investors many options,2017-04-24 17:52:43 +0000,http://finance.yahoo.com/news/nash-next-untapped-pharma-market-175243627.html?.tsrc=rss,"Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver ..."
BMY,BMY:US,BBG000DQLV23,Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?,2017-04-24 16:07:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mJQtgnHo7q8/is-pain-ahead-for-healthcare-etfs-after-weak-jnj-q1-cm777840,The hot healthcare sector has made a nice comeback this year on cheap valuation robust earnings results encouraging industry trends and a slew of positive actions taken by the President despite the collapse of the healthcare bill read Best ETFs amp Stocks from Top Sectors of Q1
BMY,BMY:US,BBG000DQLV23,3 Key Factors to Look Out for in Biogen's Q1 Results,2017-04-24 15:07:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3dEaTYIH2ds/3-key-factors-to-look-out-for-in-biogens-q1-results-cm777766,This week earnings season for the pharma and biotech sector will start in earnest with several major companies scheduled to report results Biotech major Biogen Inc BIIB is one of the companies that will be reporting results tomorrow A look at Biogen s earnings track record shows
BMY,BMY:US,BBG000DQLV23,3 Key Factors to Look Out for in Biogen&apos;s Q1 Results,2017-04-24 13:06:01 +0000,http://finance.yahoo.com/news/3-key-factors-look-biogen-130601603.html?.tsrc=rss,"With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue."
BMY,BMY:US,BBG000DQLV23,NASH: The next untapped pharma market gives investors many options,2017-04-24 11:00:00 +0000,http://finance.yahoo.com/news/nash-next-untapped-pharma-market-110000335.html?.tsrc=rss,"Large drugmakers with piles of cash are  on the hunt for promising medicines being developed by small  companies to treat NASH, a progressive fatty liver disease  poised to become the leading cause of liver transplants by 2020.  With intense competition and pricing pressure eroding sales  of medicines for diabetes, rheumatoid arthritis and other  lucrative disease categories, and an already crowded field for  developmental cancer drugs, big pharma sees NASH as an enormous  new market for future profit that will accelerate a wave of deal  making.  Bristol-Myers Squibb also confirmed it is looking  for additional assets to enhance its internally-developed NASH  drugs."
BMY,BMY:US,BBG000DQLV23,NASH: The next untapped pharma market gives investors many options,2017-04-24 05:00:00 +0000,http://finance.yahoo.com/news/nash-next-untapped-pharma-market-050000478.html?.tsrc=rss,"Large drugmakers with piles of cash are  on the hunt for promising medicines being developed by small  companies to treat NASH, a progressive fatty liver disease  poised to become the leading cause of liver transplants by 2020.  With intense competition and pricing pressure eroding sales  of medicines for diabetes, rheumatoid arthritis and other  lucrative disease categories, and an already crowded field for  developmental cancer drugs, big pharma sees NASH as an enormous  new market for future profit that will accelerate a wave of deal  making.  Bristol-Myers Squibb also confirmed it is looking  for additional assets to enhance its internally-developed NASH  drugs."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial",2017-04-22 05:01:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-bms-986036-050100126.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced data from a Phase 2 study of BMS-986036, an investigational pegylated analogue of human fibroblast growth factor 21 , a key regulator of metabolism, in patients with biopsy-confirmed nonalcoholic steatohepatitis ."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers NASH drug reduces liver fat in midstage study,2017-04-22 05:00:00 +0000,http://finance.yahoo.com/news/bristol-myers-nash-drug-reduces-050000538.html?.tsrc=rss,"Bristol-Myers Squibb Co said  its lead experimental drug for nonalcoholic steatohepatitis, or  NASH, significantly reduced liver fat versus placebo, according  to data from a mid-stage trial presented at a medical meeting on  Saturday.  NASH, a progressive fatty liver disease tied to obesity and  diabetes, afflicts about 5 percent of the population and is  poised to become the leading cause of liver transplants.  The 16-week, 74-patient trial tested the  subcutaneously-injected drug, BMS-986036, at two dosing regimens  versus placebo in adults whose NASH was confirmed by liver  biopsy."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer",2017-04-21 18:06:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-receives-positive-180600779.html?.tsrc=rss,Bristol-Myers Squibb Company announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.
BMY,BMY:US,BBG000DQLV23,10 Reasons Merck Could Be the World's Most Perfect Stock,2017-04-21 14:06:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sPZncLj4bhk/10-reasons-merck-could-be-the-worlds-most-perfect-stock-cm776940,The average investor has more than 5 000 publicly traded stocks on reputable U S exchanges to choose from With that much hay in the barn finding that needle can be quite difficult But if you re looking for the world s most perfect stock perhaps your search might
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL",2017-04-21 13:05:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Lhqx_1cDwZE/pharma-stock-roundup-jj-slips-on-mixed-q1-lilly-hit-by-fda-crl-cm776874,Johnson amp Johnson JNJ kicked off the first quarter earnings season for the pharma sector this week Meanwhile Lilly LLY was also in the news with the company receiving a complete response letter CRL for its experimental rheumatoid arthritis RA treatment baricitinib Recap of
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL",2017-04-21 11:12:11 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-j-j-111211147.html?.tsrc=rss,Key highlights from the pharma sector include J&J&apos;s (JNJ) first quarter results and a CRL for Lilly&apos;s RA drug.
BMY,BMY:US,BBG000DQLV23,Is Bristol-Myers Prepping To Outdo Itself In Immuno-Oncology?,2017-04-20 20:32:36 +0000,http://finance.yahoo.com/r/2248dc5a-0423-390a-acc1-b75df6347ca6/is-bristol-myers-prepping-to-outdo-itself-in-immuno-oncology?src=A00220&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb and Cytomx could be working on a less potent version of Yervoy and have data as early as 2018, an analyst said Thursday."
BMY,BMY:US,BBG000DQLV23,"Here's Why the Best Is Yet to Come for Exelixis, Inc.",2017-04-20 20:03:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GjYbrRouUCE/heres-why-the-best-is-yet-to-come-for-exelixis-inc-cm776657,Exelixis NASDAQ EXEL has been on a tear over the last year nearly quadrupling EXEL data by YCharts While much of the growth in Exelixis stock price has to do with the better than expected launch of Cabometyx in kidney cancer the
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Co: Buy the Dip?,2017-04-20 16:04:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BRvkgIz74YY/bristol-myers-squibb-co-buy-the-dip-cm776435,Shares of Bristol Myers Squibb NYSE BMY have slipped about 30 since the company announced a surprising setback for its lead growth driver Opdivo last August More recent missteps in skin and brain cancer trials have analysts scrambling to adjust their peak sales targets for
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Co: Buy the Dip?,2017-04-20 14:47:00 +0000,http://finance.yahoo.com/r/fe6e15fa-8ccf-3f55-ac1d-4d4b5638cc84/bristol-myers-squibb-co-buy-the-dip.aspx?yptr=yahoo&.tsrc=rss,The reaction to Opdivo’s recent shortcomings seem overblown. Is Bristol-Myers Squibb stock a buy right now?
BMY,BMY:US,BBG000DQLV23,Is J&J's Pharma Sales Slowdown a Warning for Other Players?,2017-04-19 22:03:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NtH_GlPPegE/is-jjs-pharma-sales-slowdown-a-warning-for-other-players-cm776123,Johnson amp Johnson JNJ reported mixed first quarter 2017 earnings results on Tuesday While earnings beat the Zacks Consensus Estimate sales missed due to a slowdown in pharmaceutical product sales For the first quarter J amp J s earnings of 1 83 per share beat the Zacks
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers &apos;Holding Up Better,&apos; But Dow&apos;s Merck Still Gouging Share",2017-04-19 21:03:23 +0000,http://finance.yahoo.com/r/177304e0-097f-3386-93de-7ca012724cc6/bristol-holding-up-better-but-dows-merck-still-gouging-share?src=A00220&yptr=yahoo&.tsrc=rss,"Merck&apos;s Keytruda continued to swipe share from Bristol&apos;s immuno-oncology drugs, but Bristol is &quot;holding up better than expected.&quot;"
BMY,BMY:US,BBG000DQLV23,"Noteworthy Wednesday Option Activity: BMY, UNP, HAL",2017-04-19 20:04:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9baBQpxSPrE/noteworthy-wednesday-option-activity-bmy-unp-hal-cm776030,Looking at options trading activity among components of the S amp P 500 index there is noteworthy activity today in Bristol Myers Squibb Co Symbol BMY where a total volume of 39 462 contracts has been traded thus far today a contract volume which is representative of approximately 3
BMY,BMY:US,BBG000DQLV23,The 4 Best Dividend Stocks in Pharmaceuticals,2017-04-18 17:06:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/epOvHju2R5A/the-4-best-dividend-stocks-in-pharmaceuticals-cm775334,If you re looking for steadily growing income the pharmaceutical industry boasts plenty of dividend paying stocks Not all of them are created equal though and plenty of investors in this space have seen their payouts frozen or slashed in recent years as their leading products
BMY,BMY:US,BBG000DQLV23,Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion,2017-04-18 17:05:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bz0nLnR3ECk/roches-rhhby-cancer-drug-gets-fda-nod-for-label-expansion-cm775341,Roche Holding AG s RHHBY unit Genentech announced that its drug Tecentriq atezolizumab has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma mUC a form of bladder 160 cancer who are unable to receive initial
BMY,BMY:US,BBG000DQLV23,"The Zacks Analyst Blog Highlights: Alphabet, Amgen, Lowe's, Bristol-Myers and Priceline",2017-04-18 15:06:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uevlLJeR_HA/the-zacks-analyst-blog-highlights-alphabet-amgen-lowes-bristol-myers-and-priceline-cm775277,For Immediate Release Chicago IL April 18 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BMY,BMY:US,BBG000DQLV23,"Exelixis, Inc.: Time to Move On?",2017-04-18 15:06:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zuNe1jxruAM/exelixis-inc-time-to-move-on-cm775044,Exelixis NASDAQ EXEL is without question one of the hottest biotech stocks around Shares have nearly quintupled in value over the last 12 months So far in 2017 Exelixis stock is up more than 40 But this tremendous success now raises questions about how much farther
BMY,BMY:US,BBG000DQLV23,Bristol-Myers and Nordic Ink Biomarker Collaboration Deal,2017-04-18 15:04:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wlQYLxuerIg/bristol-myers-and-nordic-ink-biomarker-collaboration-deal-cm775248,Bristol Myers Squibb Company BMY recently announced that it has inked a collaboration agreement with Nordic Bioscience a Danish company specializing in biomarker technologies The partnership will focus on developing translational biomarkers and diagnostics for the evaluation of non
BMY,BMY:US,BBG000DQLV23,The 4 Best Dividend Stocks in Pharmaceuticals,2017-04-18 15:04:00 +0000,http://finance.yahoo.com/r/c46662c2-0dbb-3e46-b8d2-7d7376f59b9f/the-4-best-dividend-stocks-in-pharmaceuticals.aspx?yptr=yahoo&.tsrc=rss,Find out how these pharma stocks could boost your dividend growth portfolio’s performance.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers and Nordic Ink Biomarker Collaboration Deal,2017-04-18 14:08:02 +0000,http://finance.yahoo.com/news/bristol-myers-nordic-ink-biomarker-140802424.html?.tsrc=rss,"Bristol-Myers Squibb Company (BMY) recently announced that it has inked a collaboration agreement with Nordic Bioscience, a Danish company specializing in biomarker technologies."
BMY,BMY:US,BBG000DQLV23,"Exelixis, Inc.: Time to Move On?",2017-04-18 12:22:00 +0000,http://finance.yahoo.com/r/544bdbf3-fefa-384a-a321-24c122dc6615/exelixis-inc-time-to-move-on.aspx?yptr=yahoo&.tsrc=rss,Exelixis stock has soared to all-time highs. But will the biotech&apos;s share price soon reach a plateau?
BMY,BMY:US,BBG000DQLV23,Blog Coverage Bristol-Myers and Nordic Announce an Agreement for Development of Fibrosis Biomarker Technology,2017-04-18 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-bristol-myers-nordic-121500616.html?.tsrc=rss,"Upcoming AWS Coverage on GlaxoSmithKline LONDON, UK / ACCESSWIRE / April 18, 2017 / Active Wall St. blog coverage looks at the headline from Bristol-Myers Squibb Co. (NYSE: BMY ) (""BMS"") as the ..."
BMY,BMY:US,BBG000DQLV23,"Top Research Reports for Alphabet, Amgen & Lowe's",2017-04-17 23:56:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F-viGTrzmd8/top-research-reports-for-alphabet-amgen-lowes-cm774954,Monday April 17 2017 Today s Research Daily features new research reports on 16 major stocks including Alphabet GOOGL Amgen AMGN and Lowe s LOW Alphabet shares led the Zacks Tech sector at the start of the year but have lagged since the weaker than expected quarterly report
BMY,BMY:US,BBG000DQLV23,"Top Research Reports for Alphabet, Amgen & Lowe&apos;s",2017-04-17 20:43:08 +0000,http://finance.yahoo.com/news/top-research-reports-alphabet-amgen-204308135.html?.tsrc=rss,"Top Research Reports for Alphabet, Amgen & Lowe&apos;s"
BMY,BMY:US,BBG000DQLV23,5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates,2017-04-17 18:53:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j9W4NfDGcZU/5-major-drug-stocks-likely-to-beat-q1-earnings-estimates-cm774773,Pharma and biotech stocks had a difficult 2016 fraught with headwinds mainly related to drug pricing issues Though the drug pricing issues still persist the industry has nonetheless picked up backed by strong results FDA approvals success of new products and significant contributions
BMY,BMY:US,BBG000DQLV23,Why Shares of Portola Pharmaceuticals Are Up Over 60% in 2017,2017-04-17 14:58:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-AcK9AKShWE/why-shares-of-portola-pharmaceuticals-are-up-over-60-in-2017-cm774581,2017 has been a great year for investors of Portola Pharmaceuticals NASDAQ PTLA with shares up almost 70 year to date The reason for the run A combination one two punch of an FDA resubmission combined with a priority review has led to a substantial rise in the stock So can
BMY,BMY:US,BBG000DQLV23,Biogen to License Alzheimer Candidate from Bristol-Myers,2017-04-17 13:37:01 +0000,http://finance.yahoo.com/news/biogen-license-alzheimer-candidate-bristol-133701144.html?.tsrc=rss,"Biogen Inc. (BIIB) recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb&apos;s (BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Nordic Bioscience Announce Collaboration for Fibrosis Biomarker Technology,2017-04-17 10:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-nordic-bioscience-105900454.html?.tsrc=rss,"Bristol-Myers Squibb Company and Nordic Bioscience, a Danish company specializing in biomarker technologies, today announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including Non-alcoholic steatohepatitis ."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Nordic Bioscience To Develop Fibrosis Biomarker Technology",2017-04-17 07:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VbARz2b2Gfc/bristolmyers-nordic-bioscience-to-develop-fibrosis-biomarker-technology-20170417-00148,"Bristol-Myers, Nordic Bioscience To Develop Fibrosis Biomarker Technology"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. : BMY-US: Dividend Analysis : April 07th, 2017 (record date) : By the numbers : April 14, 2017",2017-04-14 15:40:46 +0000,http://finance.yahoo.com/r/5204c742-86fb-3779-8163-ccdd4fe2eb1e/bristol-myers-squibb-co-bmy-us-dividend-analysis-april-07th-2017-record-date-by-the-numbers-april-14-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Our analysis is based on comparing Bristol-Myers Squibb Co. with the following peers – Eli Lilly and Company, Merck & Co., Inc., Pfizer Inc., Sanofi Sponsored ADR, Novartis AG Sponsored ADR, Astrazeneca PLC Sponsored ADR, AbbVie, Inc., Johnson & Johnson, Celgene Corporation and Amgen Inc. (LLY-US, MRK-US, PFE-US, SNY-US, NVS-US, AZN-US, ... Read more
<b>(Read more...)</b>"
BMY,BMY:US,BBG000DQLV23,AbbVie Inc.: The Bear Case From a Bull,2017-04-14 13:56:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rgkKq6Yd2N0/abbvie-inc-the-bear-case-from-a-bull-cm774208,It s not hard to find reasons to like AbbVie NYSE ABBV stock There s the impressive revenue and earnings growth And of course who wouldn t like the biotech s high dividend yield I have a positive view about AbbVie and even own the stock However I also recognize that
BMY,BMY:US,BBG000DQLV23,Could Bristol&apos;s Drug Help Biogen Take AbbVie In Alzheimer&apos;s?,2017-04-13 20:40:07 +0000,http://finance.yahoo.com/r/ed6cad67-1e28-35ff-bb51-82f8dac19d03/could-bristols-drug-help-biogen-take-abbvie-in-alzheimers?src=A00220A&yptr=yahoo&.tsrc=rss,Biogen is licensing Bristol&apos;s palsy drug with a $2 billion market opportunity and the potential to pivot into Alzheimer&apos;s.
BMY,BMY:US,BBG000DQLV23,J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat?,2017-04-13 16:57:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S72ixqilwjg/jj-jnj-to-kick-off-pharma-q1-earnings-will-it-beat-cm773890,We expect Johnson amp Johnson JNJ a healthcare bellwether to beat expectations when it reports first quarter 2017 results on Apr 18 before the opening bell Last quarter the company reported a positive earnings surprise of 1 28 J amp J s share price is up 8 8 so far this
BMY,BMY:US,BBG000DQLV23,Morgan Stanley Ups Incyte Target to $150,2017-04-13 16:01:00 +0000,http://finance.yahoo.com/r/edc4754b-0466-3f53-9c98-03527e062784/morgan-stanley-ups-incyte-target-to-150?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Analystand his team reiterated an Overweight rating on the stock and raised their price target by $20, to $150.  Berens writes that he sees the company’s cancer drug epacadostat is a best-in-class treatment, and could be expanded to more tumor uses over time.  More detail from the note:   Following data presented last week at the American Association for Cancer Research (AACR) conference in Washington DC, we increasingly believe epacadostat possesses superior efficacy and safety relative to other IDO competitors, resulting in a best-in-class profile."
BMY,BMY:US,BBG000DQLV23,Biogen pays $300M to Bristol-Myers for another potential Alzheimer's drug,2017-04-13 14:20:11 +0000,http://finance.yahoo.com/r/b521f09f-f0df-3a61-bc03-4e8422dfc877/biogen-pays-300m-to-bristol-myers-for-another.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Biogen is beefing up its Alzheimer’s pipeline, agreeing to pay $300 million to license an experimental drug from Bristol-Myers Squibb that the Cambridge biotech plans to quickly push into mid-stage studies.  Biogen (BIIB) said Thursday that it will give New York-based Bristol-Myers Squibb (BMY) an upfront payment of $300 million, plus up to $410 million in additional milestone payments and royalties in exchange for full rights to BMS-986168.  The drug targets a type of protein, called tau, that forms deposits in the brain linked to Alzheimer’s disease."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers to license two drugs to Biogen, Roche",2017-04-13 12:29:25 +0000,http://finance.yahoo.com/news/bristol-myers-license-two-drugs-115641596.html?.tsrc=rss,"Bristol-Myers Squibb Co said on  Thursday it would license two of its drugs to Biogen Inc  and Roche Holding AG for an upfront fee of $470  million.  Bristol will license its experimental neurodegenerative  disorder drug, BMS-986168, to Biogen as a treatment for  progressive supranuclear palsy, which is characterized by brain  cell damage."
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops",2017-04-13 11:36:11 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-merck-gets-113611773.html?.tsrc=rss,Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers to get $470 million upfront for license deals with Biogen and Roche,2017-04-13 11:11:31 +0000,http://finance.yahoo.com/r/8b10fcdf-9246-32b7-b5d1-abefe001e485/Story.aspx?guid=B543BBBA-425E-483C-9AA2-2813639E94BB&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb Co. said Thursday it entered into license deals with Biogen Inc. and Roche, in which it will receive a combined $470 million in upfront payments and up to $615 million in potential ..."
BMY,BMY:US,BBG000DQLV23,Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb,2017-04-13 11:00:00 +0000,http://finance.yahoo.com/news/biogen-licenses-phase-2-anti-110000184.html?.tsrc=rss,"Biogen  today announced an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer’s disease and progressive supranuclear palsy , from Bristol-Myers Squibb ."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Enters into Separate Agreements with Biogen and Roche to License Anti-eTau and Anti-Myostatin Compounds, Respectively",2017-04-13 10:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-enters-separate-105900455.html?.tsrc=rss,"Bristol-Myers Squibb Company  today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy , to Biogen , and BMS-986089, an anti-myostatin adnectin in development for Duchenne Muscular Dystrophy , to Roche."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers To Get $470 Mln Upfront From Licensing Deals With Biogen, Roche",2017-04-13 07:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4mbND805XYM/bristolmyers-to-get-470-mln-upfront-from-licensing-deals-with-biogen-roche-20170413-00286,"Bristol-Myers To Get $470 Mln Upfront From Licensing Deals With Biogen, Roche"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo,2017-04-12 22:40:10 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-collaborates-apexigen-224010280.html?.tsrc=rss,"Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc."
BMY,BMY:US,BBG000DQLV23,"VOO, BMY, GILD, AGN: Large Inflows Detected at ETF",2017-04-12 16:56:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e0YtG5ww43E/voo-bmy-gild-agn-large-inflows-detected-at-etf-cm773342,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard S amp P 500 ETF Symbol VOO where we have detected an approximate 71 5 million dollar inflow that s a 0 1 increase week over week in outstanding
BMY,BMY:US,BBG000DQLV23,[$$] Incyte: Why This Biotech Beauty Can Stay Hot,2017-04-12 12:08:00 +0000,http://finance.yahoo.com/r/24f062fb-7bfd-372d-ad50-944ccbefa50a/incyte-why-this-biotech-beauty-can-stay-hot-1491998918?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"In the burgeoning market for drugs that use the body’s immune system to fight cancer, Incyte is the belle of the ball. Shares of Incyte (ticker: INCY) have jumped 76% in the past year. And with revenue ..."
BMY,BMY:US,BBG000DQLV23,3 Big Drugmakers Most Likely to Buy Incyte,2017-04-11 19:03:00 +0000,http://finance.yahoo.com/r/5a0eeaab-7a39-3ad2-ae55-194954159cb3/3-big-drugmakers-most-likely-to-buy-incyte.aspx?yptr=yahoo&.tsrc=rss,"Incyte could find itself in the crosshairs of Gilead Sciences, Amgen, and/or Bristol-Myers Squibb."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors",2017-04-11 10:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-apexigen-inc-105900994.html?.tsrc=rss,"Bristol-Myers Squibb Company and Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer with an emphasis on new Immuno-Oncology agents, today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Apexigen’s APX005M in patients with advanced solid tumors...."
BMY,BMY:US,BBG000DQLV23,UK cost agency turns down Bristol drug for head and neck cancer,2017-04-10 23:01:00 +0000,http://finance.yahoo.com/news/uk-cost-agency-turns-down-230100961.html?.tsrc=rss,"Britain's healthcare  cost-effectiveness watchdog NICE said on Tuesday that  Bristol-Myers Squibb's immunotherapy drug Opdivo was not  worth using on the state health service for treating head and  neck cancer due to its high price.  The draft decision from the National Institute for Health  and Care Excellence (NICE) is the latest example of an expensive  new cancer drug being spurned by the watchdog over cost issues.  Paul Workman, Chief Executive of the Institute of Cancer  Research, said the decision would deny patients ""a genuine  breakthrough treatment"" and he urged NICE and Bristol to work  together to reach an agreement on price."
BMY,BMY:US,BBG000DQLV23,AbbVie's Elagolix Meets Primary Endpoint in Phase II Study,2017-04-10 16:55:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fo3PwiBWt88/abbvies-elagolix-meets-primary-endpoint-in-phase-ii-study-cm772211,AbbVie Inc ABBV along with Neurocrine Biosciences Inc NBIX announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids The data from the study were presented at the
BMY,BMY:US,BBG000DQLV23,Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549,2017-04-10 15:58:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C7gad6SeO50/infinity-pharmaceuticals-focuses-on-lead-candidate-ipi-549-cm772184,We issued an updated report on Infinity Pharmaceuticals Inc INFI on Apr 7 Infinity s share price shows that the company has outperformed the Zacks classified Medical Drugs industry year to date The stock rose 79 3 compared with the industry s gain of 0 2 The company is
BMY,BMY:US,BBG000DQLV23,Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549,2017-04-10 13:29:01 +0000,http://finance.yahoo.com/news/infinity-pharmaceuticals-focuses-lead-candidate-132901146.html?.tsrc=rss,"We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7."
BMY,BMY:US,BBG000DQLV23,How Bristol-Myers Squibb Stock Performed in 1Q17,2017-04-07 19:05:49 +0000,http://finance.yahoo.com/r/0b13d544-8877-3655-9a3f-69350b0008b6/how-bristol-myers-squibb-stock-performed-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb’s stock price fell ~11.7% in 1Q17. On April 6, 2017, the stock's price had risen 9.2% year-to-date (or YTD)."
BMY,BMY:US,BBG000DQLV23,PeptiDream Reports Discovery Collaboration Agreement With Janssen,2017-04-07 08:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SrmFn_WDhzc/peptidream-reports-discovery-collaboration-agreement-with-janssen-20170407-00325,PeptiDream Reports Discovery Collaboration Agreement With Janssen
BMY,BMY:US,BBG000DQLV23,3 Top Big Pharma Stocks to Buy Now,2017-04-06 16:56:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4D-Vxrb4z5g/3-top-big-pharma-stocks-to-buy-now-cm770900,Despite the ongoing political storm over U S prescription drug prices major drug manufacturers or Big Pharma remain on balance an attractive group of equities for long term investors The fact of the matter is that major pricing reforms aren t even on the political radar
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA,2017-04-06 15:57:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dsrzArqjvrs/bristol-myers-bmy-sbla-for-opdivo-accepted-by-the-fda-cm770778,Bristol Myers Squibb Company BMY recently announced that the FDA has accepted the company s supplemental Biologics License Application sBLA for the label expansion of immune oncology drug Opdivo The company is looking to expand Opdivo s label for the treatment of patients with mismatch
BMY,BMY:US,BBG000DQLV23,Bristol-Myers&apos; (BMY) sBLA For Opdivo Accepted by the FDA,2017-04-06 13:57:01 +0000,http://finance.yahoo.com/news/bristol-myers-apos-bmy-sbla-135701660.html?.tsrc=rss,Bristol-Myers Squibb Company (BMY) recently announced that the FDA has accepted the company&apos;s supplemental Biologics License Application (sBLA) for the label expansion of immune-oncology drug Opdivo.
BMY,BMY:US,BBG000DQLV23,"Step Aside, Merck And Bristol: These Are Your Future Rivals In Cancer Drugs",2017-04-05 18:38:01 +0000,http://finance.yahoo.com/r/499021d3-5c5e-3e2a-8f82-4b807a24e7ad/step-aside-merck-and-bristol-these-are-your-future-rivals-in-cancer?src=A00220A&yptr=yahoo&.tsrc=rss,"Bristol, Roche and Merck tend to grab immuno-oncology headlines, but a conference highlighted competitors waiting in the wings."
BMY,BMY:US,BBG000DQLV23,The Mutual Fund That Is a Top 10 Guru,2017-04-05 18:09:41 +0000,http://finance.yahoo.com/news/mutual-fund-top-10-guru-180941099.html?.tsrc=rss,"With an average annual return of 10.2% over the past 10 years, Vanguard ranks 6th on the GuruFocus Score Board"
BMY,BMY:US,BBG000DQLV23,5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now,2017-04-05 15:27:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sZRcWR8_Pe8/5-reasons-to-invest-in-eli-lilly-lly-stock-right-now-cm770127,Indianapolis IN based Eli Lilly and Company LLY is a global healthcare company which enjoys presence across a wide range of therapeutic areas including neuroscience oncology endocrinology immunology and cardiovascular which are all high growth areas and represent significant
BMY,BMY:US,BBG000DQLV23,"INNL To Be Acquired, ELGX Seeks Funds, Opdivo At FDA Altar Again, NLNK Abuzz",2017-04-05 02:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VS2wOGG0bXo/innl-to-be-acquired-elgx-seeks-funds-opdivo-at-fda-altar-again-nlnk-abuzz-20170405-00066,"INNL To Be Acquired, ELGX Seeks Funds, Opdivo At FDA Altar Again, NLNK Abuzz"
BMY,BMY:US,BBG000DQLV23,"Bristol Keeps Up With Merck In Cancer, But Incyte Is True Winner: Analyst",2017-04-04 20:48:13 +0000,http://finance.yahoo.com/r/5c840af5-5302-3881-be6c-0f66572001fb/bristol-keeps-up-with-merck-in-cancer-but-incyte-is-true-winner-analyst?src=A00220A&yptr=yahoo&.tsrc=rss,Bristol is keeping pace with Merck after announcing a partnership with Incyte.
BMY,BMY:US,BBG000DQLV23,U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer,2017-04-04 20:15:00 +0000,http://finance.yahoo.com/news/u-food-drug-administration-accepts-201500008.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted a supplemental Biologics License Application that seeks to extend the use of Opdivo to patients with mismatch repair deficient or microsatellite instability high metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo,2017-04-04 18:24:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7SXQo5CfGPs/bristol-myers-announces-data-on-immuno-oncology-drug-opdivo-cm769704,Bristol Myers Squibb Company BMY recently announced encouraging data from various trials on Opdivo The company announced first report of five year overall survival OS data from the phase I dose ranging study CA209 003 The study evaluated Opdivo in patients with previously treated
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo,2017-04-04 16:01:04 +0000,http://finance.yahoo.com/news/bristol-myers-announces-data-immuno-160104490.html?.tsrc=rss,Bristol-Myers Squibb Company (BMY) recently announced encouraging data from various trials on Opdivo.
BMY,BMY:US,BBG000DQLV23,Incyte Is Smart to Date Around,2017-04-04 15:17:39 +0000,http://finance.yahoo.com/r/bd606f81-bd46-3d7d-9050-610f393f0693/incyte-immune-oncology-approach-smartly-dating-around?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,It's leveraging a competitive market to get the most for its IO drug.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Opdivo Fails In Glioblastoma Study,2017-04-04 14:49:00 +0000,http://finance.yahoo.com/r/a1580921-963b-3743-84a0-b574b9da9fb6/bristolmyers-opdivo-fails-glioblastoma-study-bmy?partner=YahooSA&yptr=yahoo&.tsrc=rss,Brain cancer drug Opdivo failed to improve survival in a late-stage study when compared to bevacizumab.
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Melanoma Drug Combo Succeeds,2017-04-04 13:22:00 +0000,http://finance.yahoo.com/r/ed5a41ff-a2c7-3c7a-ad41-8fcf603430b1/bristolmyers-melanoma-drug-combo-succeeds-bmy?partner=YahooSA&yptr=yahoo&.tsrc=rss,Opdivo alone and as a combo (with Yervoy) significantly improved survival in melanoma patients.
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for April 05, 2017",2017-04-04 13:16:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OjFnpfmZGl0/bristol-myers-squibb-company-bmy-ex-dividend-date-scheduled-for-april-05-2017-cm769451,Bristol Myers Squibb Company BMY will begin trading ex dividend on April 05 2017 A cash dividend payment of 0 39 per share is scheduled to be paid on May 01 2017 Shareholders who purchased BMY prior to the ex dividend date are eligible for the cash dividend payment This represents
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers (BMY), Incyte to Advance Clinical Program",2017-04-03 23:35:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N882ucFp4Ps/bristol-myers-bmy-incyte-to-advance-clinical-program-cm769303,Bristol Myers Squibb Company BMY and Incyte Corporation INCY recently announced that the companies will advance their clinical development program The clinical development program evaluates the combination of Incyte s investigational oral selective IDO1 enzyme inhibitor epacadostat with
BMY,BMY:US,BBG000DQLV23,"FDA Nod For TEVA, Cheers For PRTK, SRNE Hits Goal, SNY Launches Kids Toothpaste",2017-04-03 23:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2lMh_CDwmvU/fda-nod-for-teva-cheers-for-prtk-srne-hits-goal-sny-launches-kids-toothpaste-20170403-01547,"FDA Nod For TEVA, Cheers For PRTK, SRNE Hits Goal, SNY Launches Kids Toothpaste"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers (BMY), Incyte to Advance Clinical Program",2017-04-03 21:05:09 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-incyte-advance-210509124.html?.tsrc=rss,Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers (BMY), Incyte to Advance Clinical Program",2017-04-03 21:05:09 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-incyte-advance-210509124.html,"Bristol-Myers (BMY), Incyte to Advance Clinical Program"
BMY,BMY:US,BBG000DQLV23,The Hot Stock: Incyte Jumps 3.6%,2017-04-03 21:02:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/04/03/the-hot-stock-incyte-jumps-3-6/?mod=yahoobarrons&ru=yahoo,The Hot Stock: Incyte Jumps 3.6%
BMY,BMY:US,BBG000DQLV23,The Hot Stock: Incyte Jumps 3.6%,2017-04-03 21:02:00 +0000,http://finance.yahoo.com/r/4286a40f-b904-3b84-85ac-fb885ada1f4d/the-hot-stock-incyte-jumps-3-6?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"One trading day after tumbling to the bottom of the S&P 500 following an expanded partnership with Merck (MRK), Incyte (INCY) soared to the top of the popular benchmark after announcing that its cancer ..."
BMY,BMY:US,BBG000DQLV23,Bristol 'Can't Afford To Lose' To Dow Stock Merck In Immuno-Oncology,2017-04-03 20:20:46 +0000,http://www.investors.com/news/technology/bristol-hurdles-key-cancer-obstacle-with-melanoma-combo/?src=A00220A,Bristol 'Can't Afford To Lose' To Dow Stock Merck In Immuno-Oncology
BMY,BMY:US,BBG000DQLV23,Bristol &apos;Can&apos;t Afford To Lose&apos; To Dow Stock Merck In Immuno-Oncology,2017-04-03 20:20:46 +0000,http://finance.yahoo.com/r/0d4745eb-6c89-329e-8657-b2f7d43c9ea9/bristol-hurdles-key-cancer-obstacle-with-melanoma-combo?src=A00220A&yptr=yahoo&.tsrc=rss,Bristol stock popped early Monday after the drugmaker&apos;s immuno-oncology combination significantly improved overall survival in melanoma patients.
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers May Be Hedging on IO,2017-04-03 19:33:00 +0000,http://finance.yahoo.com/r/813e6d0a-7d33-30e6-8a78-d9a0faf3a7f7/bristol-myers-may-be-hedging-on-io-1491248030?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Guggenheim Securities Bristol-Myers Squibb and Incyte announced plans to initiate Phase 3 registrational trials with Incyte’s IDO inhibitor, epacadostat, and Bristol-Myers’ Opdivo (anti-PD-1) in first-line ..."
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers May Be Hedging on IO,2017-04-03 19:33:00 +0000,http://www.barrons.com/articles/bristol-myers-may-be-hedging-on-io-1491248030?mod=yahoobarrons&ru=yahoo,[$$] Bristol-Myers May Be Hedging on IO
BMY,BMY:US,BBG000DQLV23,iShares Russell 1000 Growth ETF Experiences Big Inflow,2017-04-03 16:37:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7OscVVkXiPM/ishares-russell-1000-growth-etf-experiences-big-inflow-cm769110,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 1000 Growth ETF Symbol IWF where we have detected an approximate 108 1 million dollar inflow that s a 0 3 increase week over week
BMY,BMY:US,BBG000DQLV23,"Ex-Dividend Reminder: Morningstar, American Eagle Outfitters and Bristol-Myers Squibb",2017-04-03 15:37:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vPIy4BmEKuw/ex-dividend-reminder-morningstar-american-eagle-outfitters-and-bristol-myers-squibb-cm768995,Looking at the universe of stocks we cover at Dividend Channel on 4 5 17 Morningstar Inc Symbol MORN American Eagle Outfitters Inc Symbol AEO and Bristol Myers Squibb Co Symbol BMY will all trade ex dividend for their respective upcoming dividends Morningstar Inc will pay
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb says cancer drug combination 'significantly' improved survival in late-stage melanoma trial,2017-04-03 15:07:05 +0000,http://finance.yahoo.com/r/da67655c-e058-3d47-99d7-497136a4832d/Story.aspx?guid=B5CFF9DC-0FA7-4D92-8F56-31D420C828A5&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Bristol-Myers Sqibb Co. said Monday morning that the combination of its two cancer drugs showed the best survival rates in melanoma patients in a late-stage clinical trial. The combination of the drugs ...
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb says cancer drug combination 'significantly' improved survival in late-stage melanoma trial,2017-04-03 15:07:05 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=B5CFF9DC-0FA7-4D92-8F56-31D420C828A5&siteid=yhoof2,Bristol-Myers Squibb says cancer drug combination 'significantly' improved survival in late-stage melanoma trial
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme",2017-04-03 14:47:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-announces-results-144700694.html,"[Business Wire] - Bristol-Myers Squibb Company today announced that CheckMate -143, a randomized Phase 3 clinical trial evaluating the efficacy and safety of Opdivo in patients with first recurrence of glioblastoma multiforme , did not meet its primary endpoint of improved overall survival over bevacizumab monotherapy."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme",2017-04-03 14:47:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-announces-results-144700694.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced that CheckMate -143, a randomized Phase 3 clinical trial evaluating the efficacy and safety of Opdivo in patients with first recurrence of glioblastoma multiforme , did not meet its primary endpoint of improved overall survival over bevacizumab monotherapy."
BMY,BMY:US,BBG000DQLV23,3 Stocks the Smartest Investors are Buying Right Now,2017-04-03 13:38:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2eA5J_nm95k/3-stocks-the-smartest-investors-are-buying-right-now-cm768902,Although it s never a particularly good strategy to blindly follow other investors the activity of elite investors like Carl Icahn and Warren Buffet which is reported quarterly can provide worthwhile investing ideas Armed with this insight we asked three of our contributors
BMY,BMY:US,BBG000DQLV23,8:32 am Bristol-Myers announces the first report of five-year overall survival data from the Phase 1 dose-ranging study CA209-003 evaluating Opdivo in patients with previously treated advanced non-small cell lung cancer at the 2017 AACR Mee,2017-04-03 12:32:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#bmy,8:32 am Bristol-Myers announces the first report of five-year overall survival data from the Phase 1 dose-ranging study CA209-003 evaluating Opdivo in patients with previously treated advanced non-small cell lung cancer at the 2017 AACR Mee
BMY,BMY:US,BBG000DQLV23,Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) and Opdivo Monotherapy Significantly Improved Overall Survival Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma,2017-04-03 12:30:00 +0000,http://finance.yahoo.com/news/opdivo-nivolumab-combination-yervoy-ipilimumab-123000440.html,"[Business Wire] - Bristol-Myers Squibb Company today announced the first overall survival data from the Phase 3 CheckMate -067 clinical trial. With a minimum follow-up of 28 months, the median OS had not yet been reached in either of the two Opdivo treatment groups and was 20 months for the Yervoy monotherapy group ."
BMY,BMY:US,BBG000DQLV23,Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) and Opdivo Monotherapy Significantly Improved Overall Survival Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma,2017-04-03 12:30:00 +0000,http://finance.yahoo.com/news/opdivo-nivolumab-combination-yervoy-ipilimumab-123000440.html?.tsrc=rss,"Bristol-Myers Squibb Company today announced the first overall survival data from the Phase 3 CheckMate -067 clinical trial. With a minimum follow-up of 28 months, the median OS had not yet been reached in either of the two Opdivo treatment groups and was 20 months for the Yervoy monotherapy group ."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers immunotherapy combination extends survival in melanoma,2017-04-03 12:30:00 +0000,http://finance.yahoo.com/news/bristol-myers-immunotherapy-combination-extends-123000147.html?.tsrc=rss,"Patients with advanced melanoma who  received Bristol-Myers Squibb's immunotherapies Opdivo  and Yervoy had improved overall survival compared with those on  Yervoy alone, with 64 percent on the combination therapy still  alive after two years, according to data released on Monday.  The combination therapy won approval to treat the deadliest  form of skin cancer based on its ability to delay disease  worsening, known as progression-free survival, with the  condition that it ultimately helps patients live longer.  Data presented at the American Association for Cancer  Research meeting in Washington for the first time demonstrated  that overall survival benefit."
BMY,BMY:US,BBG000DQLV23,"Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), in Phase 1 Study CA209-003",2017-04-03 12:30:00 +0000,http://finance.yahoo.com/news/five-survival-observed-opdivo-nivolumab-123000619.html?.tsrc=rss,Bristol-Myers Squibb Company today announced the first report of five-year overall survival data from the Phase 1 dose-ranging study CA209-003 evaluating Opdivo in patients with previously treated advanced non-small cell lung cancer .
BMY,BMY:US,BBG000DQLV23,Bristol-Myers immunotherapy combination extends survival in melanoma,2017-04-03 12:30:00 +0000,http://finance.yahoo.com/news/bristol-myers-immunotherapy-combination-extends-123000147.html,Bristol-Myers immunotherapy combination extends survival in melanoma
BMY,BMY:US,BBG000DQLV23,"Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), in Phase 1 Study CA209-003",2017-04-03 12:30:00 +0000,http://finance.yahoo.com/news/five-survival-observed-opdivo-nivolumab-123000619.html,[Business Wire] - Bristol-Myers Squibb Company today announced the first report of five-year overall survival data from the Phase 1 dose-ranging study CA209-003 evaluating Opdivo in patients with previously treated advanced non-small cell lung cancer .
BMY,BMY:US,BBG000DQLV23,3 Stocks the Smartest Investors are Buying Right Now,2017-04-03 12:21:00 +0000,https://www.fool.com/investing/2017/04/03/3-stocks-the-smartest-investors-are-buying-right-n.aspx,3 Stocks the Smartest Investors are Buying Right Now
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Says CheckMate -143 Fails To Meet Primary Endpoint,2017-04-03 11:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mwRQfzcgm9I/bristolmyers-says-checkmate-143-fails-to-meet-primary-endpoint-20170403-00913,Bristol-Myers Says CheckMate -143 Fails To Meet Primary Endpoint
BMY,BMY:US,BBG000DQLV23,[$$] Merck's Keytruda cancer drug records sales surge,2017-04-03 10:05:29 +0000,"http://www.ft.com/cms/s/86c84d7a-1621-11e7-80f4-13e067d5072c,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[$$] Merck's Keytruda cancer drug records sales surge
BMY,BMY:US,BBG000DQLV23,The cost of cancer: new drugs show success at a steep price,2017-04-03 06:00:00 +0000,http://uk.finance.yahoo.com/news/cost-cancer-drugs-show-success-060000160.html,"[Reuters - UK Focus] - Newer cancer drugs that enlist the body's immune system are improving the odds of survival, but competition between them is not reining in prices that can now top $250,000 a year. The drugs' success for patients is the result of big bets in cancer therapy made by Bristol-Myers Squibb Co, Merck (Jakarta: 28586808.JK - news) & Co Inc and Roche Holding AG (IOB: 0QOK.IL - news) , among others in big pharma. The industry's pipeline of cancer drugs expanded by 63 percent between 2005 and 2015, according to the QuintilesIMS Institute, and a good number are reaching the market."
BMY,BMY:US,BBG000DQLV23,"Setback For ACOR In Ampyra Suit, EARS Put On Notice, STDY On Steady Rise",2017-04-03 00:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5jI90mHkdz0/setback-for-acor-in-ampyra-suit-ears-put-on-notice-stdy-on-steady-rise-20170403-00002,"Setback For ACOR In Ampyra Suit, EARS Put On Notice, STDY On Steady Rise"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Trades Ex-Dividend Wednesday,2017-04-02 13:40:00 +0000,http://www.investopedia.com/news/bristolmyers-squibb-trades-exdividend-wednesday-bmy/?partner=YahooSA,Bristol-Myers Squibb Trades Ex-Dividend Wednesday
BMY,BMY:US,BBG000DQLV23,5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them,2017-04-02 13:36:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r9wOg8-QRto/5-deadliest-diseases-in-the-us-and-the-top-drugs-potentially-on-the-way-to-treat-them-cm768774,Just five diseases caused the deaths of roughly 1 6 million Americans in 2015 the most recent year for which the Centers for Disease Control and Prevention CDC has statistics Many more patients suffer from the diseases Promising drugs could be on the way to treat these
BMY,BMY:US,BBG000DQLV23,5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them,2017-04-02 11:23:00 +0000,https://www.fool.com/investing/2017/04/02/5-deadliest-diseases-in-the-us-and-the-top-drugs-p.aspx,5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials,2017-04-02 10:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-incyte-advance-105900259.html,"[Business Wire] - Bristol-Myers Squibb Company and Incyte Corporation today announced the companies have agreed to advance their clinical development program evaluating the combination of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with Opdivo , Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, into phase 3 registrational studies in first-line non-small cell lung cancer across ..."
BMY,BMY:US,BBG000DQLV23,Will Bristol Prove This Longtime Theory In Cancer Defense?,2017-03-31 20:23:44 +0000,http://www.investors.com/news/technology/will-bristol-prove-this-longtime-theory-in-cancer-defense/?src=A00220A,Will Bristol Prove This Longtime Theory In Cancer Defense?
BMY,BMY:US,BBG000DQLV23,"Friday Sector Laggards: Healthcare, Services",2017-03-31 19:59:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-W3EKNcLK5U/friday-sector-laggards-healthcare-services-cm768514,In afternoon trading on Friday Healthcare stocks are the worst performing sector showing a 0 3 loss Within that group Incyte Corporation Symbol INCY and Bristol Myers Squibb Co Symbol BMY are two large stocks that are lagging showing a loss of 3 0 and 2 1 respectively
BMY,BMY:US,BBG000DQLV23,"Merck, Incyte Expand Cancer Collaboration",2017-03-31 16:48:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/31/merck-incyte-expand-cancer-collaboration/?mod=yahoobarrons&ru=yahoo,"Merck, Incyte Expand Cancer Collaboration"
BMY,BMY:US,BBG000DQLV23,Exploring Eli Lilly’s Oncology Franchise in 2016,2017-03-31 14:36:14 +0000,http://marketrealist.com/2017/03/exploring-eli-lillys-oncology-franchise-in-2016/?utm_source=yahoo&utm_medium=feed,Exploring Eli Lilly’s Oncology Franchise in 2016
BMY,BMY:US,BBG000DQLV23,Should Investors Worry About Bristol-Myers Squibb's Recent Setbacks?,2017-03-30 21:00:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NdOuAmNijvM/should-investors-worry-about-bristol-myers-squibbs-recent-setbacks-cm767981,A year ago large cap drugmaker Bristol Myers Squibb NYSE BMY was in the extraordinary position of having what many considered the best immuno oncology franchise in the industry But in the last few months some major setbacks for the company s flagship drug Opdivo have
BMY,BMY:US,BBG000DQLV23,Should Investors Worry About Bristol-Myers Squibb's Recent Setbacks?,2017-03-30 19:26:00 +0000,https://www.fool.com/investing/2017/03/30/should-investors-worry-about-bristol-myers-squibbs.aspx,Should Investors Worry About Bristol-Myers Squibb's Recent Setbacks?
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine’s Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents,2017-03-30 10:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-enters-collaboration-105900895.html,[Business Wire] - Bristol-Myers Squibb Company and Foundation Medicine today announced a collaboration that leverages Foundation Medicine’s comprehensive genomic profiling and molecular information solutions to identify predictive biomarkers such as Tumor Mutational Burden and Microsatellite Instability in patients enrolled across clinical trials investigating Bristol-Myers Squibb’s cancer immunotherapies.
BMY,BMY:US,BBG000DQLV23,Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage,2017-03-29 23:59:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NN4nyuX3MVc/athersys-athx-stock-rallies-as-william-blair-initiates-coverage-cm767530,Shares of Athersys Inc ATHX surged significantly in the post market trading on Mar 28 after research firm William Blair initiated a coverage on the stock with an outperform rating Share Price Movement Shares of the Athersys have performed better than the Zacks
BMY,BMY:US,BBG000DQLV23,Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage,2017-03-29 21:18:00 +0000,http://www.investopedia.com/partner/zacks/athersys-athx-stock-rallies-william-blair-initiates-coverage/?partner=YahooSA,Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage
BMY,BMY:US,BBG000DQLV23,U.S. FDA nominee moves to untangle potential conflicts of interest,2017-03-29 21:02:45 +0000,http://uk.finance.yahoo.com/news/u-fda-nominee-moves-untangle-210245072.html,"[Reuters - UK Focus] - Dr. Scott Gottlieb, President Donald Trump's nominee to lead the U.S. Food and Drug Administration, has outlined measures he would take to untangle his ties to the pharmaceutical industry if confirmed by the Senate. In an ethics disclosure form filed with the Department of Health and Human Services on Tuesday, Gottlieb said he would resign from multiple corporate boards including GlaxoSmithKline (Amsterdam: GO8.AS - news) Plc and consulting positions. Gottlieb's financial ties to the healthcare industry are extensive."
BMY,BMY:US,BBG000DQLV23,YieldBoost BMY From 2.8% To 6.6% Using Options,2017-03-29 18:58:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B6GJKTRZdgg/yieldboost-bmy-from-28-to-66-using-options-cm767387,Shareholders of Bristol Myers Squibb Co Symbol BMY looking to boost their income beyond the stock s 2 8 annualized dividend yield can sell the January 2018 covered call at the 65 strike and collect the premium based on the 1 77 bid which annualizes to an additional 3 9 rate of
BMY,BMY:US,BBG000DQLV23,The Most Undervalued Sectors in the Market Today,2017-03-29 18:01:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_Wo3D9jsTrc/the-most-undervalued-sectors-in-the-market-today-cm767367,One of the primary goals of any investor should be to beat the returns of the broader market a difficult task considering the S amp P 500 s average annual return of around 10 And it stands to reason that looking for undervalued stocks or those trading for less than they re
BMY,BMY:US,BBG000DQLV23,U.S. FDA nominee moves to untangle potential conflicts of interest,2017-03-29 16:10:35 +0000,http://uk.finance.yahoo.com/news/u-fda-nominee-moves-untangle-161035220.html,"[Reuters - UK Focus] - Dr. Scott Gottlieb, President Donald Trump's nominee to lead the U.S. Food and Drug Administration, has outlined measures he would take to untangle his ties to the pharmaceutical industry if confirmed by the Senate. In an ethics disclosure form filed with the Department of Health and Human Services on Tuesday, Gottlieb said he would resign from multiple corporate boards including GlaxoSmithKline (Amsterdam: GO8.AS - news) Plc and consulting positions. Gottlieb's financial ties to the healthcare industry are extensive."
BMY,BMY:US,BBG000DQLV23,What Wall Street Analysts Recommend for Merck,2017-03-29 11:36:09 +0000,http://marketrealist.com/2017/03/what-wall-street-analysts-recommend-for-merck/?utm_source=yahoo&utm_medium=feed,What Wall Street Analysts Recommend for Merck
BMY,BMY:US,BBG000DQLV23,[$$] FDA Nominee Scott Gottlieb Plans Recusals From Decisions on Many Drug Firms,2017-03-29 04:21:53 +0000,https://www.wsj.com/articles/fda-nominee-plans-recusals-from-decisions-on-many-drug-firms-1490760063?ru=yahoo?mod=yahoo_itp,[$$] FDA Nominee Scott Gottlieb Plans Recusals From Decisions on Many Drug Firms
BMY,BMY:US,BBG000DQLV23,[$$] FDA Nominee Plans Recusals From Decisions on Many Drug Firms,2017-03-29 04:01:10 +0000,https://www.wsj.com/articles/fda-nominee-plans-recusals-from-decisions-on-many-drug-firms-1490760063?mod=yahoo_hs,[$$] FDA Nominee Plans Recusals From Decisions on Many Drug Firms
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion,2017-03-28 22:59:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TphS-Z4F54w/bristol-myers-bmy-opdivo-gets-positive-chmp-opinion-cm766948,Bristol Myers Squibb Company BMY announced that the Committee for Medicinal Products for Human Use CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck SCCHN in adults progressing on or after platinum
BMY,BMY:US,BBG000DQLV23,Cramer's lightning round: Stick with this 'terrific' defense play,2017-03-28 22:51:16 +0000,http://www.cnbc.com/id/104369203?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104369203,Cramer's lightning round: Stick with this 'terrific' defense play
BMY,BMY:US,BBG000DQLV23,Could Real-World Studies Boost These 3 Big Pharma Stocks' Prospects?,2017-03-28 21:00:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_eS98D7qMGo/could-real-world-studies-boost-these-3-big-pharma-stocks-prospects-cm766869,Pharmaceutical companies rely primarily on rigorous randomized clinical trials to demonstrate efficacy and safety for their prescription drugs However data from real world usage of drugs has become a bigger factor in helping to convince physicians and patients to go with one
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion,2017-03-28 20:55:08 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-opdivo-gets-205508911.html,Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion
BMY,BMY:US,BBG000DQLV23,Could Real-World Studies Boost These 3 Big Pharma Stocks' Prospects?,2017-03-28 19:42:00 +0000,https://www.fool.com/investing/2017/03/28/could-real-world-studies-boost-these-3-big-pharma.aspx,Could Real-World Studies Boost These 3 Big Pharma Stocks' Prospects?
BMY,BMY:US,BBG000DQLV23,What Analysts Recommend for Novartis in 2017,2017-03-28 18:45:44 +0000,http://marketrealist.com/2017/03/analysts-recommendations-novartis-2017/?utm_source=yahoo&utm_medium=feed,What Analysts Recommend for Novartis in 2017
BMY,BMY:US,BBG000DQLV23,Why Clovis' Advantage Might Squash Tesaro In Ovarian Cancer,2017-03-28 16:18:53 +0000,http://www.investors.com/news/technology/why-clovis-advantage-might-squash-tesaro-in-ovarian-cancer/?src=A00220A,Why Clovis' Advantage Might Squash Tesaro In Ovarian Cancer
BMY,BMY:US,BBG000DQLV23,[$$] Could Pfizer Make Cash Bid for Bristol-Myers?,2017-03-28 15:31:00 +0000,http://www.barrons.com/articles/could-pfizer-make-cash-bid-for-bristol-myers-1490715108?mod=yahoobarrons&ru=yahoo,[$$] Could Pfizer Make Cash Bid for Bristol-Myers?
BMY,BMY:US,BBG000DQLV23,"Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute Announce Collaboration to Accelerate Immuno-Oncology Research",2017-03-28 10:59:00 +0000,http://finance.yahoo.com/news/parker-institute-cancer-immunotherapy-bristol-105900413.html,"[Business Wire] - The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company and the Cancer Research Institute today announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology studies across the Parker Institute and CRI networks."
BMY,BMY:US,BBG000DQLV23,"PICI, Bristol-Myers, CRI Collaborate To Accelerate Immuno-Oncology Research",2017-03-28 07:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5GiGw2Klf2I/pici-bristolmyers-cri-collaborate-to-accelerate-immunooncology-research-20170328-00367,"PICI, Bristol-Myers, CRI Collaborate To Accelerate Immuno-Oncology Research"
BMY,BMY:US,BBG000DQLV23,"Warren, Democrats Write Icahn About Advising Trump",2017-03-27 23:00:00 +0000,https://www.thestreet.com/story/14061344/1/warren-democrats-write-icahn-about-advising-trump.html?puc=yahoo&cm_ven=YAHOO,"Warren, Democrats Write Icahn About Advising Trump"
BMY,BMY:US,BBG000DQLV23,3 Top Cancer Drug Stocks to Buy in 2017,2017-03-27 22:00:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qj-329w4NDM/3-top-cancer-drug-stocks-to-buy-in-2017-cm766215,Some of the best performing biopharma stocks in recent years belong to companies developing cancer drugs and it looks as if this trend is going to continue throughout 2017 and into the foreseeable future Estimated global spending for oncology medicines is expected to grow from
BMY,BMY:US,BBG000DQLV23,3 Top Cancer Drug Stocks to Buy in 2017,2017-03-27 20:29:00 +0000,https://www.fool.com/investing/2017/03/27/3-top-cancer-drug-stocks-to-buy-in-2017.aspx,3 Top Cancer Drug Stocks to Buy in 2017
BMY,BMY:US,BBG000DQLV23,Can Pfizer Boost Its Value By $5 Billion By Taking Over Bristol?,2017-03-27 20:13:27 +0000,http://www.investors.com/news/technology/this-drugmaker-could-boost-its-value-by-5-billion-in-a-bristol-takeover/?src=A00220A,Can Pfizer Boost Its Value By $5 Billion By Taking Over Bristol?
BMY,BMY:US,BBG000DQLV23,"Senators press Icahn on White House influence, business conflicts",2017-03-27 19:20:58 +0000,http://finance.yahoo.com/news/senators-press-icahn-white-house-192058186.html,"[Reuters] - Several Democratic senators pressed billionaire investor Carl Icahn on Monday to clarify his role as an adviser to President Donald Trump, saying his position in the administration raised ""alarming"" questions about potential conflicts of interest with his stakes in the biofuels and pharmaceutical industries. The senators, led by Sheldon Whitehouse of Rhode Island, sent a letter to Icahn pointing out that, as a Trump adviser on regulation, he has made policy proposals that benefit his own investments - which range from an oil refinery to an nutritional supplement manufacturer. ""We write because we are increasingly concerned about the role you are playing in the Trump Administration and the possibility that you are breaking federal conflict of interest laws,"" the seven senators wrote in the letter, seen by Reuters."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb's Motivation Behind CytomX Deal,2017-03-27 18:29:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GwWO2psr20Q/bristol-myers-squibbs-motivation-behind-cytomx-deal-cm766125,Bristol Myers Squibb 160 BMY recently extended its collaboration with U S biotech firm CytomX The two companies entered the original contract in 2014 when Bristol Myers Squibb endorsed CytomX s probody platform and made a bet on four oncology candidates Under the new
BMY,BMY:US,BBG000DQLV23,Pfizer Stock Rises on Bristol-Myers Takeover Talk,2017-03-27 16:55:00 +0000,http://www.investopedia.com/news/pfizer-bristolmyers-takeover-talk-pfe-bmy/?partner=YahooSA,Pfizer Stock Rises on Bristol-Myers Takeover Talk
BMY,BMY:US,BBG000DQLV23,New budget test puts UK on front line in global drug price fight,2017-03-27 14:34:13 +0000,http://sg.finance.yahoo.com/news/budget-test-puts-uk-front-143413425.html,New budget test puts UK on front line in global drug price fight
BMY,BMY:US,BBG000DQLV23,Bristol-Myers: Maybe a Pfizer Acquisition Could Makes Sense After All?,2017-03-27 14:22:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/27/bristol-myers-maybe-a-pfizer-acquisition-could-makes-sense-after-all/?mod=yahoobarrons&ru=yahoo,Bristol-Myers: Maybe a Pfizer Acquisition Could Makes Sense After All?
BMY,BMY:US,BBG000DQLV23,Chinese drug approval boosts AstraZeneca's lung cancer hopes,2017-03-27 07:20:52 +0000,http://uk.finance.yahoo.com/news/chinese-drug-approval-boosts-astrazenecas-072052931.html,"[Reuters - UK Focus] - AstraZeneca (NYSE: AZN - news) has won approval for its lung cancer pill Tagrisso in China, a key market for the potential blockbuster medicine. Tagrisso is designed to help cancer patients with certain genetic mutations that are very common in China and the regulatory green light boosts the British drugmaker's prospects in a key therapy area."
BMY,BMY:US,BBG000DQLV23,"XENE Loses Face As Acne Trial Flops, NBRV Awaits LEAP Data, Opdivo Scores A Nod",2017-03-26 23:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zUDYgWU4b8M/xene-loses-face-as-acne-trial-flops-nbrv-awaits-leap-data-opdivo-scores-a-nod-20170326-00096,"XENE Loses Face As Acne Trial Flops, NBRV Awaits LEAP Data, Opdivo Scores A Nod"
BMY,BMY:US,BBG000DQLV23,3 Stocks That Could Double Your Money,2017-03-25 17:58:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uAvQeR-W3fU/3-stocks-that-could-double-your-money-cm765613,Could you double your money in the next 12 months According to Wall Street you potentially can Analysts think the share prices could soar by at least 100 by a year from now for three biotech stocks Celldex Therapeutics NASDAQ CLDX Idera Pharmaceuticals NASDAQ
BMY,BMY:US,BBG000DQLV23,"IWF, BA, CELG, BMY: ETF Inflow Alert",2017-03-24 16:59:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SUzt-aMUWvg/iwf-ba-celg-bmy-etf-inflow-alert-cm765297,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 1000 Growth ETF Symbol IWF where we have detected an approximate 107 4 million dollar inflow that s a 0 3 increase week over week
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Opdivo Gets CHMP Nod for Head, Neck Cancer",2017-03-24 16:59:00 +0000,http://www.investopedia.com/news/bristolmyers-opdivo-gets-chmp-nod-head-neck-cancer-bmy/?partner=YahooSA,"Bristol-Myers Opdivo Gets CHMP Nod for Head, Neck Cancer"
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved",2017-03-24 14:01:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_-mL-5KBKeU/pharma-stock-roundup-is-sanofi-buying-flexion-pfizer-merck-kgaa-drug-approved-cm765118,Shortly after the release of the Budget Blueprint for 2018 which could require companies to shell out higher fees for regulatory reviews as well as a reduction of 5 8 billion in the National Institutes of Health s NIH spending the President continued to focus on drug prices at a meeting
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer of the Head and Neck in Adults Progressing on or After Platinum-based Therapy,2017-03-24 12:31:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-receives-positive-123100680.html,[Business Wire] - Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use has recommended the approval of Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy.
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved",2017-03-24 11:47:11 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-sanofi-buying-114711173.html,"Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved"
BMY,BMY:US,BBG000DQLV23,Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment,2017-03-24 10:46:00 +0000,https://www.thestreet.com/story/14058246/1/merck-kgaa-shares-spike-after-fda-approves-skin-cancer-treatment.html?puc=yahoo&cm_ven=YAHOO,Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment
BMY,BMY:US,BBG000DQLV23,Could Nektar Therapeutics Be Worth More?,2017-03-23 21:59:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xlUa59EXaqs/could-nektar-therapeutics-be-worth-more-cm764917,Nektar Therapeutics NASDAQ NKTR is an intriguing commercial stage biotech company that s just reported positive late stage trial results for its pain busting drug NKTR 181 However shares have jumped on the news and the company s market cap has swollen to more than 3 billion
BMY,BMY:US,BBG000DQLV23,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers",2017-03-23 20:32:58 +0000,http://biz.yahoo.com/e/170323/bmy8-k.html,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers"
BMY,BMY:US,BBG000DQLV23,"RARE's Seizure Study Fails, HTGM Soars After-hours, NTEC Awaits Data In Q3",2017-03-23 02:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gD7xSV5lZ-0/rares-seizure-study-fails-htgm-soars-afterhours-ntec-awaits-data-in-q3-20170323-00042,"RARE's Seizure Study Fails, HTGM Soars After-hours, NTEC Awaits Data In Q3"
BMY,BMY:US,BBG000DQLV23,Dow's Merck Swipes Immuno-Oncology Share From Heavyweight Rivals,2017-03-22 20:34:16 +0000,http://www.investors.com/news/technology/dow-leader-merck-swipes-immuno-oncology-share-from-this-heavyweight-rival/?src=A00220A,Dow's Merck Swipes Immuno-Oncology Share From Heavyweight Rivals
BMY,BMY:US,BBG000DQLV23,Making Sense Of Roche's Recent Settlement With Mylan And Aphinity Trial,2017-03-22 19:58:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oeWoFrIJWQs/making-sense-of-roches-recent-settlement-with-mylan-and-aphinity-trial-cm764301,Roche s RHHBY stock rallied by nearly 7 earlier this month when the company announced the results from its much awaited Aphinity trial which tested the combination of Herceptin and Perjeta for after surgery breast cancer The 160 results were positive and put the recent settlement
BMY,BMY:US,BBG000DQLV23,"Biotech giant plans $25M Tampa investment, 450 jobs",2017-03-22 18:55:09 +0000,http://www.bizjournals.com/tampabay/news/2017/03/22/biotech-giant-plans-25m-tampa-investment-450-jobs.html?ana=yahoo,"Biotech giant plans $25M Tampa investment, 450 jobs"
BMY,BMY:US,BBG000DQLV23,Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017,2017-03-22 14:37:51 +0000,http://marketrealist.com/2017/03/durvalumab-tagrisso-may-boost-astrazenecas-revenues-2017/?utm_source=yahoo&utm_medium=feed,Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017
BMY,BMY:US,BBG000DQLV23,Infinity Pharma Focuses on Cancer Drug: Competition Looms,2017-03-21 21:07:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h7FVmtEhtjk/infinity-pharma-focuses-on-cancer-drug-competition-looms-cm763747,We issued an updated research report on Infinity Pharmaceuticals Inc INFI on Mar 20 2017 Infinity s share price has increased considerably by 148 9 year to date while the Zacks classified Medical Drugs industry gained 4 7 The company is currently focused on the development of
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and CytomX Therapeutics Extend Deal,2017-03-21 17:06:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eXWhTqw75tk/bristol-myers-squibb-and-cytomx-therapeutics-extend-deal-cm763542,Bristol Myers Squibb Company BMY and CytomX Therapeutics Inc CTMX announced an expansion of their 2014 strategic collaboration to discover novel therapies The collaboration will include up to eight additional targets using CytomX s proprietary Probody platform Bristol Myers Squibb s
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and CytomX Therapeutics Extend Deal,2017-03-21 15:26:03 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-cytomx-therapeutics-152603585.html,Bristol-Myers Squibb and CytomX Therapeutics Extend Deal
BMY,BMY:US,BBG000DQLV23,6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017,2017-03-21 15:11:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q2AQHxA2koE/6-reasons-to-invest-in-glaxosmithkline-gsk-stock-in-2017-cm763381,GlaxoSmithKline plc GSK one of the largest health care companies reshaped its business following Mar 2015 completion of the three part inter conditional transaction with Novartis AG NVS Under the deal Glaxo sold oncology assets to Novartis and acquired Novartis Vaccines
BMY,BMY:US,BBG000DQLV23,ONCYF: Oncolytic Viruses Emerging as Effective Cancer Treatment,2017-03-21 15:00:00 +0000,http://finance.yahoo.com/news/oncyf-oncolytic-viruses-emerging-effective-150000642.html,ONCYF: Oncolytic Viruses Emerging as Effective Cancer Treatment
BMY,BMY:US,BBG000DQLV23,6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017,2017-03-21 13:18:01 +0000,http://finance.yahoo.com/news/6-reasons-invest-glaxosmithkline-gsk-131801097.html,6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
BMY,BMY:US,BBG000DQLV23,"Gainers & Losers Of Mar.20.: ESPR, NKTR, CTMX, CERU, GNMX...",2017-03-20 22:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cL0Np-7P7A4/gainers--losers-of-mar20-espr-nktr-ctmx-ceru-gnmx-20170320-01219,"Gainers & Losers Of Mar.20.: ESPR, NKTR, CTMX, CERU, GNMX..."
BMY,BMY:US,BBG000DQLV23,Close Update: Wall Street Struggles to Find Direction With Fed Speakers in Focus,2017-03-20 20:46:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x05ilbT_wmk/close-update-wall-street-struggles-to-find-direction-with-fed-speakers-in-focus-cm763154,The main US markets struggled to find direction on Monday with the Nasdaq Composite touching a record high on an intraday basis before pulling back The Dow Jones Industrial Average and the S amp P 500 fluctuated between gains and losses as oil prices retreated and amid a busy week of
BMY,BMY:US,BBG000DQLV23,"Health Care Sector Update for 03/20/2017: CTMX,BMY,ESPR,CERU,NVS",2017-03-20 20:26:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xN4_-O665ng/health-care-sector-update-for-03202017-ctmxbmyesprcerunvs-cm763125,Top Health Care StocksTop Health Care Stocks JNJ 0 11 JNJ 0 11 PFE 0 25 PFE 0 25 MRK 0 44 MRK 0 44 ABT 0 30 ABT 0 30 AMGN 0 38 AMGN 0 38 Health care stocks saw their losses widen slightly this afternoon with the NYSE Health Care Index declining 0 1 while shares of health
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Partner Hits 18-Month High On Immuno-Oncology Deal,2017-03-20 20:10:13 +0000,http://www.investors.com/news/technology/bristol-myers-partner-rockets-to-18-month-high-on-immuno-oncology-deal/?src=A00220A,Bristol-Myers Partner Hits 18-Month High On Immuno-Oncology Deal
BMY,BMY:US,BBG000DQLV23,Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide,2017-03-20 19:56:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c9VmtdgUYTc/mid-afternoon-market-update-cytomx-therapeutics-climbs-following-bristol-myers-squibb-partnership-medgenics-shares-slide-cm763123,Toward the end of trading Monday the Dow traded down 0 01 percent to 20 912 59 while the NASDAQ declined 0 04 percent to 5 898 64 The S amp P also fell dropping 0 19 percent to 2 373 85 Leading and Lagging Sectors Monday afternoon the non cyclical consumer goods amp
BMY,BMY:US,BBG000DQLV23,3 Top Stocks on Sale This Spring,2017-03-20 18:45:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UhHrjkit1W8/3-top-stocks-on-sale-this-spring-cm762862,The leaves are blooming and optimism is riding high for Wall Street and investors as we ready to head into a new season After beginning 2016 with a whimper stocks have vaulted higher with a bang since the new year began Through March 14 the iconic Dow Jones Industrial Average
BMY,BMY:US,BBG000DQLV23,"Here’s Why Wells Fargo, eBay, CytomX Therapeutics, Dominion Diamond, and More Are Trending",2017-03-20 18:26:45 +0000,http://www.insidermonkey.com/blog/heres-why-wells-fargo-ebay-cytomx-therapeutics-dominion-diamond-and-more-are-trending-567704/,"Here’s Why Wells Fargo, eBay, CytomX Therapeutics, Dominion Diamond, and More Are Trending"
BMY,BMY:US,BBG000DQLV23,Mid-Day Market Update: Nektar Surges After Positive Results From NKTR-181 Study; Cerulean Pharma Shares Drop,2017-03-20 17:26:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IkB-Wegs8AQ/mid-day-market-update-nektar-surges-after-positive-results-from-nktr-181-study-cerulean-pharma-shares-drop-cm763064,Midway through trading Monday the Dow traded up 0 16 percent to 20 947 67 while the NASDAQ climbed 0 11 percent to 5 907 59 However the S amp P fell 0 03 percent to 2 377 54 Leading and Lagging Sectors Monday morning the telecommunications services sector proved to be a source
BMY,BMY:US,BBG000DQLV23,"Midday Update: Dow Pushes Into Positive Territory, Nasdaq Sets Record High",2017-03-20 17:26:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SY8SQDnnq1A/midday-update-dow-pushes-into-positive-territory-nasdaq-sets-record-high-cm763051,Propped up by gains in component stocks Apple AAPL and Caterpillar CAT along with technical support the Dow Jones Industrial Average clawed its way into positive territory at midday on Monday erasing early losses tied to fears of protectionist trade policies within the Group of 20
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, CytomX Extend Cancer Drug Pact",2017-03-20 16:52:00 +0000,http://www.investopedia.com/news/bristolmyers-cytomx-extend-cancer-pact-bmyctmx/?partner=YahooSA,"Bristol-Myers, CytomX Extend Cancer Drug Pact"
BMY,BMY:US,BBG000DQLV23,A small drug company that's trying to make cancer treatments safer just received a $3.8 billion endorsement,2017-03-20 15:10:17 +0000,http://finance.yahoo.com/news/small-drug-company-thats-trying-151017319.html,A small drug company that's trying to make cancer treatments safer just received a $3.8 billion endorsement
BMY,BMY:US,BBG000DQLV23,Monday’s Top Biopharma Movers,2017-03-20 14:55:24 +0000,http://finance.yahoo.com/news/monday-top-biopharma-movers-145524604.html,Monday’s Top Biopharma Movers
BMY,BMY:US,BBG000DQLV23,Stocks Edge Lower At The Open; Sprouts Up Again On Merger Talk,2017-03-20 13:38:05 +0000,http://www.investors.com/market-trend/stock-market-today/indexes-quiet-cytomx-soars-on-expanded-bristol-myers-pact/?src=A00220A,Stocks Edge Lower At The Open; Sprouts Up Again On Merger Talk
BMY,BMY:US,BBG000DQLV23,CytomX Soars on Bristol-Myers Partnership,2017-03-20 13:21:00 +0000,https://www.thestreet.com/story/14051044/1/cytomx-soars-on-bristol-myers-partnership.html?puc=yahoo&cm_ven=YAHOO,CytomX Soars on Bristol-Myers Partnership
BMY,BMY:US,BBG000DQLV23,3 Top Stocks on Sale This Spring,2017-03-20 13:08:00 +0000,https://www.fool.com/investing/2017/03/20/3-top-stocks-on-sale-this-spring.aspx,3 Top Stocks on Sale This Spring
BMY,BMY:US,BBG000DQLV23,Changes in Bristol-Myers Squibb’s Profitability in 2016,2017-03-20 13:06:37 +0000,http://marketrealist.com/2017/03/changes-in-bristol-myers-squibbs-profitability-in-2016/?utm_source=yahoo&utm_medium=feed,Changes in Bristol-Myers Squibb’s Profitability in 2016
BMY,BMY:US,BBG000DQLV23,"How BMY’s Neuroscience, Immunoscience Segments Performed in 2016",2017-03-20 11:36:14 +0000,http://marketrealist.com/2017/03/how-bmys-neuroscience-immunoscience-segments-performed-in-2016/?utm_source=yahoo&utm_medium=feed,"How BMY’s Neuroscience, Immunoscience Segments Performed in 2016"
BMY,BMY:US,BBG000DQLV23,CytomX's stock rockets after expanding Bristol-Myers collaboration,2017-03-20 11:18:26 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=5EBEFE24-E600-4292-96D8-4EAF9D6979F0&siteid=yhoof2,CytomX's stock rockets after expanding Bristol-Myers collaboration
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™ Therapeutics for the Treatment of Cancer and Other Diseases,2017-03-20 10:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-cytomx-therapeutics-105900764.html,"[Business Wire] - Bristol-Myers Squibb Company and CytomX Therapeutics, Inc. , a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today announced an expansion of their 2014 strategic collaboration to discover novel therapies that will include up to eight additional targets using CytomX’s proprietary Probody platform."
BMY,BMY:US,BBG000DQLV23,CytomX Therapeutics (CTMX) Has Jumped To A 10-Month High On Bristol-Myers Deal,2017-03-20 09:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2WgQhWckRxY/cytomx-therapeutics-ctmx-has-jumped-to-a-10month-high-on-bristolmyers-deal-20170320-00638,CytomX Therapeutics (CTMX) Has Jumped To A 10-Month High On Bristol-Myers Deal
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, CytomX Extend Deal To Find Probody Therapeutics To Treat Cancer",2017-03-20 07:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nBzPEwFDSjs/bristolmyers-cytomx-extend-deal-to-find-probody-therapeutics-to-treat-cancer-20170320-00254,"Bristol-Myers, CytomX Extend Deal To Find Probody Therapeutics To Treat Cancer"
BMY,BMY:US,BBG000DQLV23,European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade,2017-03-20 07:00:00 +0000,https://www.thestreet.com/story/14050477/1/european-stocks-set-for-mixed-open-dollar-slumps-in-quiet-asia-trade.html?puc=yahoo&cm_ven=YAHOO,European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade
BMY,BMY:US,BBG000DQLV23,"Dow, S&P 500 Decline as Health Care Losses Counter Gains",2017-03-17 20:22:00 +0000,https://www.thestreet.com/story/14049576/1/dow-s-amp-p-500-decline-as-health-care-losses-counter-gains.html?puc=yahoo&cm_ven=YAHOO,"Dow, S&P 500 Decline as Health Care Losses Counter Gains"
BMY,BMY:US,BBG000DQLV23,Fired U.S. Attorney Preet Bharara Was Investigating HHS Chief Tom Price - Report,2017-03-17 20:03:00 +0000,https://www.thestreet.com/story/14049570/1/fired-u-s-attorney-preet-bharara-was-investigating-hhs-chief-tom-price-report.html?puc=yahoo&cm_ven=YAHOO,Fired U.S. Attorney Preet Bharara Was Investigating HHS Chief Tom Price - Report
BMY,BMY:US,BBG000DQLV23,Broad Gains Overshadow Health Care Losses to Boost Wall Street,2017-03-17 18:41:00 +0000,https://www.thestreet.com/story/14049133/1/stocks-creep-lower-as-health-care-selloff-extends-into-day-2.html?puc=yahoo&cm_ven=YAHOO,Broad Gains Overshadow Health Care Losses to Boost Wall Street
BMY,BMY:US,BBG000DQLV23,3 Best Pharmaceutical Stocks for Long-Term Investors,2017-03-17 17:06:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lDJ97jD08NA/3-best-pharmaceutical-stocks-for-long-term-investors-cm762299,People needed prescription drugs 20 years ago They need them now They ll need them 20 years from now too Those three statements sum up the argument for long term investors to buy pharmaceutical stocks Three of The Motley Fool s healthcare contributors weighed in on
BMY,BMY:US,BBG000DQLV23,3 Best Pharmaceutical Stocks for Long-Term Investors,2017-03-17 16:03:00 +0000,https://www.fool.com/investing/2017/03/17/3-best-pharmaceutical-stocks-for-long-term-investo.aspx,3 Best Pharmaceutical Stocks for Long-Term Investors
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation,2017-03-17 15:15:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-pfizer-present-151500688.html,[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial fibrillation who were treated with direct oral anticoagulants versus warfarin.
BMY,BMY:US,BBG000DQLV23,What Cardiovascular Drug Eliquis’s 2016 Looked Like,2017-03-17 14:37:05 +0000,http://marketrealist.com/2017/03/what-cardiovascular-drug-eliquiss-2016-looked-like/?utm_source=yahoo&utm_medium=feed,What Cardiovascular Drug Eliquis’s 2016 Looked Like
BMY,BMY:US,BBG000DQLV23,How BMY’s Virology Segment Performed in 2016,2017-03-17 13:06:35 +0000,http://marketrealist.com/2017/03/how-bmys-virology-segment-performed-in-2016/?utm_source=yahoo&utm_medium=feed,How BMY’s Virology Segment Performed in 2016
BMY,BMY:US,BBG000DQLV23,A Look at Opdivo’s Performance in 2016,2017-03-17 11:38:01 +0000,http://marketrealist.com/2017/03/a-look-at-opdivos-performance-in-2016/?utm_source=yahoo&utm_medium=feed,A Look at Opdivo’s Performance in 2016
BMY,BMY:US,BBG000DQLV23,How Bristol-Myers Squibb’s Oncology Segment Performed in 2016,2017-03-16 20:35:43 +0000,http://marketrealist.com/2017/03/how-bristol-myers-squibbs-oncology-segment-performed-in-2016/?utm_source=yahoo&utm_medium=feed,How Bristol-Myers Squibb’s Oncology Segment Performed in 2016
BMY,BMY:US,BBG000DQLV23,Analyzing Bristol-Myers Squibb’s 2016 Performance,2017-03-16 19:05:43 +0000,http://marketrealist.com/2017/03/analyzing-bristol-myers-squibbs-2016-performance/?utm_source=yahoo&utm_medium=feed,Analyzing Bristol-Myers Squibb’s 2016 Performance
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Valuation Compared to Its Peers’,2017-03-16 17:21:10 +0000,http://marketrealist.com/2017/03/bristol-myers-squibbs-valuation-compared-to-its-peers-2/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb’s Valuation Compared to Its Peers’
BMY,BMY:US,BBG000DQLV23,"IWF, CELG, BMY, GILD: ETF Inflow Alert",2017-03-16 16:05:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1bXK1LPIimU/iwf-celg-bmy-gild-etf-inflow-alert-cm761641,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 1000 Growth ETF Symbol IWF where we have detected an approximate 165 9 million dollar inflow that s a 0 5 increase week over week
BMY,BMY:US,BBG000DQLV23,3 Active Vanguard Funds That You Can’t Ignore,2017-03-15 23:05:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xFUVznMCaYo/3-active-vanguard-funds-that-you-cant-ignore-cm761420,InvestorPlace Stock Market News Stock Advice amp Trading Tips When most investors hear the name Vanguard funds they think of indexing After all Vanguard founder John Bogle created the idea of passive investing when he launched Vanguard 500 Index 160 Fund 160
BMY,BMY:US,BBG000DQLV23,Merck Could Be Nearing This Rival With Another Keytruda Approval,2017-03-15 20:25:08 +0000,http://www.investors.com/news/technology/merck-could-be-nearing-this-rival-with-another-keytruda-approval/?src=A00220A,Merck Could Be Nearing This Rival With Another Keytruda Approval
BMY,BMY:US,BBG000DQLV23,Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat,2017-03-15 17:08:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FVU6-mXn7RA/celldex-cldx-shares-up-as-q4-loss-narrows-sales-beat-cm761209,Celldex Therapeutics Inc CLDX posted fourth quarter 2016 loss of 30 cents per share narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year ago loss of 33 cents Total revenue in the fourth quarter of 2016 rose 5 6 year over year to 1 9 million beating the
BMY,BMY:US,BBG000DQLV23,Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat,2017-03-15 14:55:02 +0000,http://finance.yahoo.com/news/celldex-cldx-shares-q4-loss-145502653.html,Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. :BMY-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017",2017-03-15 13:32:57 +0000,http://www.capitalcube.com/blog/index.php/bristol-myers-squibb-co-bmy-us-earnings-analysis-q4-2016-by-the-numbers-march-15-2017/,"Bristol-Myers Squibb Co. :BMY-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017"
BMY,BMY:US,BBG000DQLV23,Johnson & Johnson’s Major Developments,2017-03-15 11:36:28 +0000,http://marketrealist.com/2017/03/johnson-johnsons-major-developments/?utm_source=yahoo&utm_medium=feed,Johnson & Johnson’s Major Developments
BMY,BMY:US,BBG000DQLV23,Bristol-Myers To Participate In Barclays Health Care Conference At 8:30 AM ET,2017-03-15 07:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VOzxQMo21fI/bristolmyers-to-participate-in-barclays-health-care-conference-at-830-am-et-20170315-00321,Bristol-Myers To Participate In Barclays Health Care Conference At 8:30 AM ET
BMY,BMY:US,BBG000DQLV23,"Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies Progressing",2017-03-15 00:07:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hGUz466v4QI/celldex-therapeutics-inc-ends-q4-with-plenty-of-cash-and-several-key-studies-progressing-cm760844,It s been an up and down ride for Celldex Therapeutics NASDAQ CLDX shareholders since the biotech reported the late stage failure for Rintega Celldex refocused on the rest of its pipeline after the major disappointment early last year The company announced its fourth quarter
BMY,BMY:US,BBG000DQLV23,"Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies Progressing",2017-03-14 22:23:00 +0000,http://www.fool.com/investing/2017/03/14/celldex-therapeutics-inc-ends-q4-with-plenty-of-ca.aspx,"Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies Progressing"
BMY,BMY:US,BBG000DQLV23,Why Lantheus Holdings Inc. Got Smacked Down Today,2017-03-14 19:06:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/urthqwI03jI/why-lantheus-holdings-inc-got-smacked-down-today-cm760697,What happened Lantheus Holdings NASDAQ LNTH is down 12 at 12 38 p m EDT after announcing that an existing shareholder plans to sell 3 million shares So what Unlike a secondary offering where a company sells new shares Lantheus Holdings won t get any cash for the sale
BMY,BMY:US,BBG000DQLV23,"The 3 Most Important Numbers for Exelixis, Inc.",2017-03-14 13:07:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jVK6gC-YaAk/the-3-most-important-numbers-for-exelixis-inc-cm760331,Exelixis NASDAQ EXEL boasts several numbers that make its shareholders smile The biotech s stock has soared more than 430 over the past 12 months Its most promising drug Cabometyx has quickly captured around 20 of the market share as a second line treatment for kidney cancer
BMY,BMY:US,BBG000DQLV23,Why Did the Healthcare Sector Fall on March 13?,2017-03-14 11:39:11 +0000,http://marketrealist.com/2017/03/healthcare-sector-decline-march-13/?utm_source=yahoo&utm_medium=feed,Why Did the Healthcare Sector Fall on March 13?
BMY,BMY:US,BBG000DQLV23,"The 3 Most Important Numbers for Exelixis, Inc.",2017-03-14 11:23:00 +0000,http://www.fool.com/investing/2017/03/14/the-3-most-important-numbers-for-exelixis.aspx,"The 3 Most Important Numbers for Exelixis, Inc."
BMY,BMY:US,BBG000DQLV23,"APRI On Track, Stellar Bio Shines, FDA Nod For NVS, Study Results Heat Up HTBX",2017-03-14 02:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f4325_ZIm5A/apri-on-track-stellar-bio-shines-fda-nod-for-nvs-study-results-heat-up-htbx-20170314-00045,"APRI On Track, Stellar Bio Shines, FDA Nod For NVS, Study Results Heat Up HTBX"
BMY,BMY:US,BBG000DQLV23,US STOCKS-Wall St dips as drug stocks drag; Fed meeting in focus,2017-03-13 17:09:16 +0000,http://finance.yahoo.com/news/us-stocks-wall-st-dips-170916849.html,US STOCKS-Wall St dips as drug stocks drag; Fed meeting in focus
BMY,BMY:US,BBG000DQLV23,There's tremendous churn beneath the surface of the seemingly calm stock market,2017-03-13 17:05:35 +0000,http://finance.yahoo.com/news/the-stock-market-looks-calm-but-theres-major-churn-under-the-surface-170535687.html,There's tremendous churn beneath the surface of the seemingly calm stock market
BMY,BMY:US,BBG000DQLV23,3 Big Pharma Stocks To Buy in Your 401(k),2017-03-12 17:10:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ucYpBWwPwMQ/3-big-pharma-stocks-to-buy-in-your-401k-cm759733,A larger longer living population is going to drive demand for medicine higher and if so then adding top pharmaceuticals stocks Pfizer Inc NYSE PFE Bristol Myers Squibb NYSE BMY and Johnson amp Johnson NYSE JNJ to your 401 k could be smart All three of
BMY,BMY:US,BBG000DQLV23,3 Big Pharma Stocks To Buy in Your 401(k),2017-03-12 15:41:00 +0000,http://www.fool.com/investing/2017/03/12/3-big-pharma-stocks-to-buy-in-your-401k.aspx,3 Big Pharma Stocks To Buy in Your 401(k)
BMY,BMY:US,BBG000DQLV23,Top Stocks Billionaires Are Buying Now,2017-03-11 00:13:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DaQk5cC8pB0/top-stocks-billionaires-are-buying-now-cm759401,Keeping tabs on what iconic billionaire investors George Soros Warren Buffett and Carl Icahn are doing with their money can help you find new money making ideas What have Soros Buffett and Icahn been buying lately According to reports Celgene Corp NASDAQ CELG Apple
BMY,BMY:US,BBG000DQLV23,Top Stocks Billionaires Are Buying Now,2017-03-10 21:41:00 +0000,http://www.fool.com/investing/2017/03/10/top-stocks-billionaires-are-buying-now.aspx,Top Stocks Billionaires Are Buying Now
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Announce Results for First Quarter 2017 on April 27,2017-03-10 15:20:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-announce-results-152000628.html,"[Business Wire] - Bristol-Myers Squibb Company will announce results for the first quarter of 2017 on Thursday, April 27, 2017. During a conference call at 10:30 a.m. EDT on April 27, company executives will review financial information and will address inquiries from investors and analysts."
BMY,BMY:US,BBG000DQLV23,"Billionaire Barry Rosenstein’s Top Q4 Moves: Alphabet (GOOG), Bristol-Myers (BMY), More",2017-03-09 16:21:39 +0000,http://www.insidermonkey.com/blog/billionaire-barry-rosensteins-top-q4-moves-alphabet-goog-bristol-myers-bmy-more-560762/,"Billionaire Barry Rosenstein’s Top Q4 Moves: Alphabet (GOOG), Bristol-Myers (BMY), More"
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Squibb Names New R&D Chief,2017-03-09 05:52:55 +0000,https://www.wsj.com/articles/bristol-myers-squibb-names-new-r-d-chief-1488991068?ru=yahoo?mod=yahoo_itp,[$$] Bristol-Myers Squibb Names New R&D Chief
BMY,BMY:US,BBG000DQLV23,PRESS DIGEST - Wall Street Journal - March 9,2017-03-09 05:18:18 +0000,http://finance.yahoo.com/news/press-digest-wall-street-journal-051818726.html,[Reuters] - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - A leading contender to purchase Time Inc dropped out of the ...
BMY,BMY:US,BBG000DQLV23,Buy Bristol-Myers Squibb Co (BMY) Stock Without Fear,2017-03-08 23:12:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7nEujPxmtsw/buy-bristol-myers-squibb-co-bmy-stock-without-fear-cm758227,InvestorPlace Stock Market News Stock Advice amp Trading Tips The biotech and healthcare sectors were the political punching bags of the 2016 U S elections And now President Trump s rhetoric of lower drug prices continues the turmoil in pharmaceutical stocks As a result the
BMY,BMY:US,BBG000DQLV23,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib",2017-03-08 21:37:50 +0000,http://biz.yahoo.com/e/170308/bmy8-k.html,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib"
BMY,BMY:US,BBG000DQLV23,This Pharma Firm Is Beating The Pack In Getting Drugs To Market,2017-03-08 21:22:43 +0000,http://www.investors.com/news/technology/this-small-drugmaker-is-routing-pfizer-merck-bristol-in-rd-bang/?src=A00220A,This Pharma Firm Is Beating The Pack In Getting Drugs To Market
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer",2017-03-08 17:24:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-appoints-dr-172400002.html,"[Business Wire] - Bristol-Myers Squibb Company today announced that it has appointed Dr. Thomas J. Lynch, Jr., 56, executive vice president and chief scientific officer, effective March 16, 2017."
BMY,BMY:US,BBG000DQLV23,Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs,2017-03-08 17:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eMS5F9JVygY/trump-tweet-on-drug-pricing-hits-biotech-and-pharma-etfs-cm757946,The pharma and biotech industry has been hit badly by concerns over high drug prices in the past few years The initial panic was triggered in September 2015 when the Democratic presidential candidate Hillary Clinton tweeted about price gouging and laid out a proposal for combating
BMY,BMY:US,BBG000DQLV23,5 Stocks Insiders Are Loading Up On,2017-03-08 16:57:00 +0000,https://www.thestreet.com/story/14032322/1/5-stocks-insiders-are-loading-up-on.html?puc=yahoo&cm_ven=YAHOO,5 Stocks Insiders Are Loading Up On
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Squibb Names New R&D Chief,2017-03-08 16:37:53 +0000,https://www.wsj.com/articles/bristol-myers-squibb-names-new-r-d-chief-1488991068?mod=yahoo_hs,[$$] Bristol-Myers Squibb Names New R&D Chief
BMY,BMY:US,BBG000DQLV23,Forget the Distractions: Bristol-Myers Squibb Is a Bargain,2017-03-08 14:13:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d0xsatyXJW8/forget-the-distractions-bristol-myers-squibb-is-a-bargain-cm757714,What will Carl Icahn do Will Bristol Myers Squibb NYSE BMY be acquired How will Opdivo fare against Merck s NYSE MRK Keytruda There are plenty of unanswered questions swirling around about Bristol Myers Squibb BMS these days But as I listened to the company s CEO
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part in Barclays Global Health Care Conference,2017-03-08 14:00:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-part-barclays-140000720.html,"[Business Wire] - Bristol-Myers Squibb Company will present at Barclays Global Health Care Conference on Wednesday, March 15, 2017, in Miami. Charles Bancroft, executive vice president and chief financial officer, will answer questions about the company at 8:30 a.m."
BMY,BMY:US,BBG000DQLV23,Forget the Distractions: Bristol-Myers Squibb Is a Bargain,2017-03-08 13:04:00 +0000,http://www.fool.com/investing/2017/03/08/forget-the-distractions-bristol-myers-squibb-is-a.aspx,Forget the Distractions: Bristol-Myers Squibb Is a Bargain
BMY,BMY:US,BBG000DQLV23,Race Tightens for Next Wave of Cancer Drugs,2017-03-08 05:32:06 +0000,https://www.wsj.com/articles/race-tightens-for-next-wave-of-cancer-drugs-1488796210?ru=yahoo?mod=yahoo_itp,Race Tightens for Next Wave of Cancer Drugs
BMY,BMY:US,BBG000DQLV23,"Celldex Therapeutics, Inc. Is Feeling Some Pressure Today -- Here's Why",2017-03-07 23:14:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/11o6MhXiuRA/celldex-therapeutics-inc-is-feeling-some-pressure-today-heres-why-cm757603,What happened Shares of Celldex Therapeutics Inc NASDAQ CLDX 160 a clinical stage biotech developing targeted cancer therapies were down about 10 as of 2 45 p m EST on Tuesday despite a lack of significant news For biotechs without any approved drugs to sell
BMY,BMY:US,BBG000DQLV23,"Noteworthy Tuesday Option Activity: BMY, KRO, AFSI",2017-03-07 22:12:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OSmdVoPxd78/noteworthy-tuesday-option-activity-bmy-kro-afsi-cm757525,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Bristol Myers Squibb Co Symbol BMY where a total volume of 90 278 contracts has been traded thus far today a contract volume which is representative of approximately 9
BMY,BMY:US,BBG000DQLV23,"Psst! Want To Turbocharge Your Retirement Account? Check Out American Funds' Buys, Sells",2017-03-07 21:13:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xRIsRMIkRrI/psst-want-to-turbocharge-your-retirement-account-check-out-american-funds-buys-sells-cm757532,Looking for some ideas for your portfolio Want to boost the octane in your retirement account Then check out how American Funds and Fidelity Investments 160 the second and third largest mutual fund complexes after Vanguard as of Dec 31 according to Morningstar Inc were
BMY,BMY:US,BBG000DQLV23,Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?,2017-03-07 17:16:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DE_1MfwK0Vc/catalyst-pharma-cprx-whats-in-store-in-q4-earnings-cm757312,Catalyst Pharmaceuticals Inc CPRX is expected to report fourth quarter 2016 results this month Last quarter the company recorded a positive earnings surprise of 16 67 The company beat expectations in all of the last four quarters with average positive earnings surprise of 10
BMY,BMY:US,BBG000DQLV23,Repros (RPRX) Q4 Earnings: What's in Store for the Stock?,2017-03-07 17:15:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cDlpJrfqGJ8/repros-rprx-q4-earnings-whats-in-store-for-the-stock-cm757305,Repros Therapeutics Inc RPRX is expected to report fourth quarter 2016 results this month Let s see how things are shaping up for this quarter Repros Therapeutics share price decreased 8 3 year to date while the Zacks classified Medical Biomed Genetics industry gained 10
BMY,BMY:US,BBG000DQLV23,The Big Reason Bristol-Myers Squibb Company Stock Exploded 15% Higher in February,2017-03-07 17:15:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ay2-ryyMcoM/the-big-reason-bristol-myers-squibb-company-stock-exploded-15-higher-in-february-cm757276,What happened Shares of Bristol Myers Squibb NYSE BMY a U S drug giant that s primarily focused on oncology cardiovascular and immunoscience therapies catapulted higher by 15 during February according to data from S amp P Global Market Intelligence The jump
BMY,BMY:US,BBG000DQLV23,Is Portola Pharmaceuticals Balance Sheet Safe?,2017-03-07 16:14:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VVXHhkI5dqI/is-portola-pharmaceuticals-balance-sheet-safe-cm757227,Portola Pharmaceuticals NASDAQ PTLA 160 could have two commercial stage drugs on the market next year but turning them into top sellers will require a lot of money Is Portola Pharmaceuticals balance sheet flush enough with cash to get its drugs across the finish line What
BMY,BMY:US,BBG000DQLV23,The Big Reason Bristol-Myers Squibb Company Stock Exploded 15% Higher in February,2017-03-07 16:03:00 +0000,http://www.fool.com/investing/2017/03/07/the-big-reason-bristol-myers-squibb-company-explod.aspx,The Big Reason Bristol-Myers Squibb Company Stock Exploded 15% Higher in February
BMY,BMY:US,BBG000DQLV23,What Illumina's and Bristol-Myers Squibb's Latest GRAIL Moves Mean for Investors,2017-03-07 15:15:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JGY-iArxJUw/what-illuminas-and-bristol-myers-squibbs-latest-grail-moves-mean-for-investors-cm757169,There was a step forward and a step backward last week related to GRAIL the company seeking to develop a simple DNA blood test to detect most forms of cancer early enough to be effectively treated The step backward came from Illumina NASDAQ ILMN GRAIL s primary founder
BMY,BMY:US,BBG000DQLV23,"3 Factors That Drove Exelixis, Inc. Higher By 19% in February",2017-03-07 15:14:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y8pYbLDWL6s/3-factors-that-drove-exelixis-inc-higher-by-19-in-february-cm757149,What happened Shares of Exelixis NASDAQ EXEL a biopharmaceutical company focused on the development of medicines for the treatment of cancer surged 19 in February according to data from S amp P Global Market Intelligence While Exelixis stock has been on fire for
BMY,BMY:US,BBG000DQLV23,Is Portola Pharmaceuticals Balance Sheet Safe?,2017-03-07 14:21:00 +0000,http://www.fool.com/investing/2017/03/07/is-portola-pharmaceuticals-balance-sheet-safe.aspx,Is Portola Pharmaceuticals Balance Sheet Safe?
BMY,BMY:US,BBG000DQLV23,What Illumina's and Bristol-Myers Squibb's Latest GRAIL Moves Mean for Investors,2017-03-07 13:21:00 +0000,http://www.fool.com/investing/2017/03/07/what-illuminas-and-bristol-myers-squibbs-latest-gr.aspx,What Illumina's and Bristol-Myers Squibb's Latest GRAIL Moves Mean for Investors
BMY,BMY:US,BBG000DQLV23,AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?,2017-03-07 01:12:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7OfUNYPZkB8/aveo-pharmaceuticals-aveo-q4-earnings-whats-in-store-cm756933,AVEO Pharmaceuticals Inc AVEO is expected to report fourth quarter 2016 results this month The company has an impressive track record for the last four reported quarters having beaten estimates on three occasions and meeting expectations in one with an average positive surprise of 17 56
BMY,BMY:US,BBG000DQLV23,AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?,2017-03-06 23:32:11 +0000,http://finance.yahoo.com/news/aveo-pharmaceuticals-aveo-q4-earnings-233211952.html,AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?
BMY,BMY:US,BBG000DQLV23,"Psst! Want To Turbocharge Your Retirement Account? Check Out American Funds' Buys, Sells",2017-03-06 20:12:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UkFsugl9KCY/psst-want-to-turbocharge-your-retirement-account-check-out-american-funds-buys-sells-cm756811,Looking for some ideas for your portfolio Want to boost the octane in your retirement account Then check out how American Funds and Fidelity Investments 160 the second and third largest mutual fund complexes after Vanguard as of Dec 31 according to Morningstar Inc were
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb: Don't Get Your Hopes Up,2017-03-06 18:29:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/06/bristol-myers-squibb-dont-get-your-hopes-up/?mod=yahoobarrons&ru=yahoo,Bristol-Myers Squibb: Don't Get Your Hopes Up
BMY,BMY:US,BBG000DQLV23,Race Tightens for Next Wave of Cancer Drugs,2017-03-06 17:23:06 +0000,https://www.wsj.com/articles/race-tightens-for-next-wave-of-cancer-drugs-1488796210?mod=yahoo_hs,Race Tightens for Next Wave of Cancer Drugs
BMY,BMY:US,BBG000DQLV23,"IWB, BA, CELG, BMY: ETF Outflow Alert",2017-03-06 17:14:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U7rn5zWUsy8/iwb-ba-celg-bmy-etf-outflow-alert-cm756661,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 1000 ETF Symbol IWB where we have detected an approximate 79 7 million dollar outflow that s a 0 4 decrease week over week from 135 000 000
BMY,BMY:US,BBG000DQLV23,Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?,2017-03-06 16:18:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2lf1UbtqDS0/celldex-therapeutics-cldx-q4-earnings-whats-in-store-cm756607,Celldex Therapeutics Inc CLDX is expected to report fourth quarter 2016 results on Mar 4 after market close Celldex s performance has been encouraging with a three quarter average positive surprise of 5 12 In the last reported quarter the company recorded a positive surprise of 9
BMY,BMY:US,BBG000DQLV23,What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?,2017-03-06 16:17:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k5aEl1tkxCw/whats-in-store-for-merck-kgaa-mkgaf-in-q4-earnings-cm756581,Merck KGaA MKGAF is scheduled to report fourth quarter 2016 earnings results on Mar 9 The company reports results under three business sectors Healthcare Life Science and Performance Materials Strong performance at Life Science which was the catalyst behind sales growth in the last
BMY,BMY:US,BBG000DQLV23,Japan Joins Trump in Drug Price War Crimping Pharma Profits,2017-03-06 15:00:00 +0000,https://www.bloomberg.com/news/articles/2017-03-06/japan-joins-trump-in-drug-price-war-crimping-big-pharma-profits?cmpid=yhoo.headline,Japan Joins Trump in Drug Price War Crimping Pharma Profits
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session,2017-03-06 13:30:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-pfizer-present-133000652.html,"[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced that eight abstracts have been accepted for presentation at the American College of Cardiology 66th Annual Scientific Session, taking place March 17-19 in Washington, D.C."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers To Present At Cowen & Company Conference; Webcast At 2:00 PM ET,2017-03-06 12:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NJ-Rv2bLjgI/bristolmyers-to-present-at-cowen--company-conference-webcast-at-200-pm-et-20170306-00987,Bristol-Myers To Present At Cowen & Company Conference; Webcast At 2:00 PM ET
BMY,BMY:US,BBG000DQLV23,"Insider Buying Steady as Market Again Hits All-Time Highs: Arconic, Murphy’s USA, Bristol-Myers, Avon and More",2017-03-05 15:20:23 +0000,http://finance.yahoo.com/news/insider-buying-steady-market-again-152023048.html,"Insider Buying Steady as Market Again Hits All-Time Highs: Arconic, Murphy’s USA, Bristol-Myers, Avon and More"
BMY,BMY:US,BBG000DQLV23,Weekly Top Insider Buys Highlight for the Week of March 3,2017-03-05 00:20:14 +0000,http://finance.yahoo.com/news/weekly-top-insider-buys-highlight-002014680.html,Weekly Top Insider Buys Highlight for the Week of March 3
BMY,BMY:US,BBG000DQLV23,"Daily Dividend Report: SUI, BIG, VZ, DEI, BMY",2017-03-03 19:12:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S1u0QonNVds/daily-dividend-report-sui-big-vz-dei-bmy-cm756104,Sun Communities a real estate investment trust that owns and operates or has an interest in manufactured housing and recreational vehicle communities today announced its Board of Directors declared a quarterly distribution of 0 67 per share of common stock for the first quarter of 2017
BMY,BMY:US,BBG000DQLV23,Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4,2017-03-03 16:13:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lTJlpRMdzL8/nektar-therapeutics-nktr-loss-wider-than-expected-in-q4-cm755933,Nektar Therapeutics NKTR reported loss of 28 cents per share in the fourth quarter of 2016 wider than the Zacks Consensus Estimate of loss of 26 cents The reported loss was however narrower than the year ago loss of 40 cents per share The company s shares gained 13 7 following the
BMY,BMY:US,BBG000DQLV23,Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4,2017-03-03 14:32:02 +0000,http://finance.yahoo.com/news/nektar-therapeutics-nktr-loss-wider-143202285.html,Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4
BMY,BMY:US,BBG000DQLV23,"Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4",2017-03-03 14:13:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/groCUYoEh94/aduro-adro-loss-wider-than-expected-sales-miss-in-q4-cm755880,Aduro BioTech Inc ADRO reported fourth quarter 2016 loss of 44 cents per share wider than the Zacks Consensus Estimate of a loss of 38 cents The company had reported earnings of 4 cents per share in the year ago quarter So far this year Aduro s shares underperformed the Zacks
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug",2017-03-03 13:33:01 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-mylan-endo-133301707.html,"Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces Dividend,2017-03-02 21:34:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-announces-dividend-213400223.html,[Business Wire] - The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of thirty-nine cents per share on the $.10 par value Common Stock of the corporation.
BMY,BMY:US,BBG000DQLV23,"Thursday 3/2 Insider Buying Report: BMY, MUSA",2017-03-02 17:14:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ilAGfzcLUnk/thursday-32-insider-buying-report-bmy-musa-cm755480,Bargain hunters are wise to pay careful attention to insider buying because although there are many various reasons for an insider to sell a stock presumably the only reason they would use their hard earned dollars to make a purchase is that they expect to make money Today we look at
BMY,BMY:US,BBG000DQLV23,"Director at Giant Drugmaker Buys New Stake Amid Takeover Speculations and Activist Pressure, Plus Other Insider Trading",2017-03-02 14:29:43 +0000,http://www.insidermonkey.com/blog/director-at-giant-drugmaker-buys-new-stake-amid-takeover-speculations-and-activist-pressure-plus-other-insider-trading-563201/,"Director at Giant Drugmaker Buys New Stake Amid Takeover Speculations and Activist Pressure, Plus Other Insider Trading"
BMY,BMY:US,BBG000DQLV23,Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?,2017-03-02 01:12:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xVea_hJVif8/aerie-pharmaceuticals-aeri-q4-earnings-what-to-expect-cm755162,Aerie Pharmaceuticals Inc AERI is expected to report fourth quarter 2016 results on Mar 7 Last quarter the company recorded a negative earnings surprise of 15 71 In fact Aerie s performance over the last four quarters has been disappointing The company reported a wider than expected
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR 2017,2017-03-01 23:20:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-present-data-232000868.html,"[Business Wire] - Bristol-Myers Squibb Company today announced that new clinical data will be presented at the American Association for Cancer Research Annual Meeting 2017 in Washington, D.C., from April 1-5."
BMY,BMY:US,BBG000DQLV23,Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?,2017-03-01 22:42:10 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-aeri-q4-earnings-224210249.html,Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?
BMY,BMY:US,BBG000DQLV23,Drugs stocks shrug off Trump warning,2017-03-01 22:15:00 +0000,http://finance.yahoo.com/video/drugs-stocks-shrug-off-trump-221500115.html,Drugs stocks shrug off Trump warning
BMY,BMY:US,BBG000DQLV23,Jana Partners' Largest 4th-Quarter Buys,2017-03-01 19:46:05 +0000,http://finance.yahoo.com/news/jana-partners-largest-4th-quarter-194605921.html,Jana Partners' Largest 4th-Quarter Buys
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. : BMY-US: Dividend Analysis : January 06th, 2017 (record date) : By the numbers : March 1, 2017",2017-03-01 19:37:49 +0000,http://www.capitalcube.com/blog/index.php/bristol-myers-squibb-co-bmy-us-dividend-analysis-january-06th-2017-record-date-by-the-numbers-march-1-2017/,"Bristol-Myers Squibb Co. : BMY-US: Dividend Analysis : January 06th, 2017 (record date) : By the numbers : March 1, 2017"
BMY,BMY:US,BBG000DQLV23,"Exelixis, Inc. Turns a Profit, but Don't Get Too Excited",2017-03-01 17:14:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9Ygqk3Rho9I/exelixis-inc-turns-a-profit-but-dont-get-too-excited-cm754867,Exelixis NASDAQ EXEL reported fourth quarter earnings on Monday showing solid growth in sales of Cabometyx The biotech reported a profit for the quarter but there were some extenuating circumstances that helped push Exelixis into the black Exelixis results The raw
BMY,BMY:US,BBG000DQLV23,"Exelixis, Inc. Turns a Profit, but Don't Get Too Excited",2017-03-01 15:40:00 +0000,http://www.fool.com/investing/2017/03/01/exelixis-inc-turns-a-profit-but-dont-get-too-excit.aspx,"Exelixis, Inc. Turns a Profit, but Don't Get Too Excited"
BMY,BMY:US,BBG000DQLV23,[$$] Cancer Test Makers Raise Nearly $1 Billion,2017-03-01 15:04:59 +0000,https://www.wsj.com/articles/cancer-test-makers-raise-nearly-1-billion-1488380695?mod=yahoo_hs,[$$] Cancer Test Makers Raise Nearly $1 Billion
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Expands Focus on Precision Medicine with Investment and Planned Collaboration with GRAIL on Blood-Based Cancer Screening,2017-03-01 13:10:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-expands-focus-131000879.html,"[Business Wire] - Bristol-Myers Squibb Company announced today its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is to detect cancer early when it potentially can be cured."
BMY,BMY:US,BBG000DQLV23,Carl Icahn Takes Aim at Bristol-Myers Squibb,2017-03-01 13:06:00 +0000,http://www.fool.com/investing/2017/03/01/carl-icahn-takes-aim-at-bristol-myers-squibb.aspx,Carl Icahn Takes Aim at Bristol-Myers Squibb
BMY,BMY:US,BBG000DQLV23,AstraZeneca’s New Products May Offer 2017 Growth Opportunities,2017-03-01 12:37:46 +0000,http://marketrealist.com/2017/02/new-product-launches-may-offer-solid-growth-opportunity-astrazeneca-2017/?utm_source=yahoo&utm_medium=feed,AstraZeneca’s New Products May Offer 2017 Growth Opportunities
BMY,BMY:US,BBG000DQLV23,Short Sellers Pile On Pfizer After Buyout Rumors,2017-03-01 11:54:50 +0000,http://finance.yahoo.com/news/short-sellers-pile-pfizer-buyout-115450624.html,Short Sellers Pile On Pfizer After Buyout Rumors
BMY,BMY:US,BBG000DQLV23,[$$] OrbiMed Logs Two Decades of Novel Attacks on Cancer,2017-03-01 00:14:33 +0000,https://www.wsj.com/articles/vc-profile-orbimed-funds-novel-attacks-on-cancer-1488205956?mod=yahoo_hs,[$$] OrbiMed Logs Two Decades of Novel Attacks on Cancer
BMY,BMY:US,BBG000DQLV23,"Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y",2017-02-28 18:51:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qq2jtT2nnwA/exelixis-exel-reports-q4-earnings-revenues-beat-yy-cm754310,Exelixis Inc EXEL posted fourth quarter 2016 earnings of 12 cents compared with a loss of 18 cents per share in the year ago quarter Earnings surpassed Zacks Consensus Estimate of a loss of 1 cent Net revenue came in at 77 6 million significantly up from 9 9 million in the prior
BMY,BMY:US,BBG000DQLV23,Eli Lilly & Co.’s Valuation after Its 4Q16 Earnings Report,2017-02-28 15:35:48 +0000,http://marketrealist.com/2017/02/eli-lilly-co-s-valuation-after-its-4q16-earnings-report/?utm_source=yahoo&utm_medium=feed,Eli Lilly & Co.’s Valuation after Its 4Q16 Earnings Report
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Is Focused on Creating Shareholder Value in 2017,2017-02-28 14:07:43 +0000,http://marketrealist.com/2017/02/bristol-myers-squibb-focused-creating-shareholder-value-2017/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb Is Focused on Creating Shareholder Value in 2017
BMY,BMY:US,BBG000DQLV23,Merck Expected to Witness Rise in Its Net Profit Margin in 2017,2017-02-28 12:39:02 +0000,http://marketrealist.com/2017/02/merck-expected-witness-robust-rise-net-profit-margins-2017/?utm_source=yahoo&utm_medium=feed,Merck Expected to Witness Rise in Its Net Profit Margin in 2017
BMY,BMY:US,BBG000DQLV23,Immuno-Oncology Is Still a Key Growth Driver for BMY in 2017,2017-02-28 12:38:09 +0000,http://marketrealist.com/2017/02/immuno-oncology-continues-key-growth-driver-bristol-myers-squibb-2017/?utm_source=yahoo&utm_medium=feed,Immuno-Oncology Is Still a Key Growth Driver for BMY in 2017
BMY,BMY:US,BBG000DQLV23,BMY Is Expected to See a Small Rise in Its 2017 Net Profit Margin,2017-02-27 22:05:48 +0000,http://marketrealist.com/2017/02/bristol-myers-squibb-expected-witness-marginal-rise-net-profit-margins-2017/?utm_source=yahoo&utm_medium=feed,BMY Is Expected to See a Small Rise in Its 2017 Net Profit Margin
BMY,BMY:US,BBG000DQLV23,"Exelixis Rockets On Bristol, Roche I-O Ties Following Merck-Incyte Team",2017-02-27 21:34:10 +0000,http://www.investors.com/news/technology/exelixis-rockets-on-bristol-roche-i-o-ties-following-merck-incyte-team/,"Exelixis Rockets On Bristol, Roche I-O Ties Following Merck-Incyte Team"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Expects Modest Revenue Growth in 2017,2017-02-27 20:35:55 +0000,http://marketrealist.com/2017/02/bristol-myers-squibb-expected-modest-growth-revenues-2017/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb Expects Modest Revenue Growth in 2017
BMY,BMY:US,BBG000DQLV23,Cramer: Money's Being Thrown at Almost Everything in the Market,2017-02-27 19:30:00 +0000,https://www.thestreet.com/story/14017446/1/cramer-money-s-being-thrown-at-almost-everything-in-the-market.html?puc=yahoo&cm_ven=YAHOO,Cramer: Money's Being Thrown at Almost Everything in the Market
BMY,BMY:US,BBG000DQLV23,Analysts’ Recommendations for Bristol-Myers Squibb in 2017,2017-02-27 18:54:40 +0000,http://marketrealist.com/2017/02/analyst-recommendations-bristol-myers-squibb-2017/?utm_source=yahoo&utm_medium=feed,Analysts’ Recommendations for Bristol-Myers Squibb in 2017
BMY,BMY:US,BBG000DQLV23,Why You Shouldn't Look Down On Your Depressed Colleagues,2017-02-27 18:22:00 +0000,http://www.forbes.com/sites/simonconstable/2017/02/27/why-you-shouldnt-look-down-on-your-depressed-colleagues/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Why You Shouldn't Look Down On Your Depressed Colleagues
BMY,BMY:US,BBG000DQLV23,Billionaire Julian Robertson Bets Big on Technology Sector With These Stocks,2017-02-27 16:46:00 +0000,http://www.insidermonkey.com/blog/billionaire-julian-robertson-bets-big-on-technology-sector-with-these-stocks-560558/,Billionaire Julian Robertson Bets Big on Technology Sector With These Stocks
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part in Cowen and Company 37th Annual Global Health Care Conference,2017-02-27 14:30:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-part-cowen-143000050.html,"[Business Wire] - Bristol-Myers Squibb Company will present at the Cowen and Company 37th Annual Global Health Care Conference on Monday, March 6, 2017, in Boston. Giovanni Caforio, chief executive officer, will make a formal presentation about the company at 2:00 p.m."
BMY,BMY:US,BBG000DQLV23,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2017-02-27 14:25:33 +0000,http://biz.yahoo.com/e/170227/bmy8-k.html,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BMY,BMY:US,BBG000DQLV23,Pfizer’s Innovative Health and Essential Health in 4Q16,2017-02-27 12:38:10 +0000,http://marketrealist.com/2017/02/pfizers-innovative-health-and-essential-health-in-4q16/?utm_source=yahoo&utm_medium=feed,Pfizer’s Innovative Health and Essential Health in 4Q16
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Expands International Immuno-Oncology Network (II-ON) With Addition of Columbia University Medical Center and Peter MacCallum Cancer Centre,2017-02-27 11:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-expands-international-115900124.html,"[Business Wire] - Bristol-Myers Squibb Company today announced that Columbia University Medical Center and Peter MacCallum Cancer Centre have joined the International Immuno-Oncology Network , a global peer-to-peer collaboration between Bristol-Myers Squibb and academia that aims to advance Immuno-Oncology science and translational medicine to improve patient outcomes."
BMY,BMY:US,BBG000DQLV23,Exelixis and Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma,2017-02-27 11:59:00 +0000,http://finance.yahoo.com/news/exelixis-bristol-myers-squibb-enter-115900280.html,"[Business Wire] - Exelixis, Inc. and Bristol-Myers Squibb Company today announced the companies have entered into a clinical development collaboration to evaluate CABOMETYX™ , Exelixis’ small molecule inhibitor of receptor tyrosine kinases, with Opdivo , Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, either alone or in combination with Yervoy ."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Up 20.5% Since Earnings Report: Can It Continue?,2017-02-27 11:50:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l0h5hYlUyYQ/bristol-myers-bmy-up-205-since-earnings-report-can-it-continue-cm753367,It has been about a month since the last earnings report for Bristol Myers Squibb Company BMY Shares have added about 20 5 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a pullback
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Up 20.5% Since Earnings Report: Can It Continue?,2017-02-27 09:09:09 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-20-5-090909080.html,Bristol-Myers (BMY) Up 20.5% Since Earnings Report: Can It Continue?
BMY,BMY:US,BBG000DQLV23,"IBM, Apple, Amazon: Doug Kass' Views",2017-02-27 06:00:00 +0000,https://www.thestreet.com/story/14015982/1/ibm-apple-amazon-doug-kass-views.html?puc=yahoo&cm_ven=YAHOO,"IBM, Apple, Amazon: Doug Kass' Views"
BMY,BMY:US,BBG000DQLV23,Billionaire Carl Icahn Is Reportedly Buying Bristol-Myers Squibb Stock -- Should You?,2017-02-26 17:49:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VIo-0U4gksg/billionaire-carl-icahn-is-reportedly-buying-bristol-myers-squibb-stock-should-you-cm753292,Carl Icahn didn t amass a net worth of an estimated 16 6 billion by making dumb moves 160 So when Dow Jones reported that the billionaire bought a stake in Bristol Myers Squibb NYSE BMY it captured the attention of the investment community What potential does Icahn see
BMY,BMY:US,BBG000DQLV23,Billionaire Carl Icahn Is Reportedly Buying Bristol-Myers Squibb Stock -- Should You?,2017-02-26 16:56:25 +0000,http://www.fool.com/investing/2017/02/26/billionaire-carl-icahn-is-buying-bristol-myers-squ.aspx,Billionaire Carl Icahn Is Reportedly Buying Bristol-Myers Squibb Stock -- Should You?
BMY,BMY:US,BBG000DQLV23,Cramer: I'll Give You the Key to the Rally,2017-02-25 00:01:00 +0000,http://realmoney.thestreet.com/articles/02/24/2017/cramer-ill-give-you-key-rally?puc=yahoo&cm_ven=YAHOO,Cramer: I'll Give You the Key to the Rally
BMY,BMY:US,BBG000DQLV23,"Gainers & Losers Of The Day: CEMP, IPCI, OREX, RNVA, ARGS...",2017-02-24 21:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q5MCTUpROhs/gainers--losers-of-the-day-cemp-ipci-orex-rnva-args-20170224-01164,"Gainers & Losers Of The Day: CEMP, IPCI, OREX, RNVA, ARGS..."
BMY,BMY:US,BBG000DQLV23,"Health Care Sector Update for 02/24/2017: IPCI,BMY,CEMP,MGLN",2017-02-24 21:09:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M6c0xaktjko/health-care-sector-update-for-02242017-ipcibmycempmgln-cm753046,Top Health Care StocksTop Health Care Stocks JNJ 1 25 JNJ 1 25 PFE 0 29 PFE 0 29 MRK 0 08 MRK 0 08 ABT 0 02 ABT 0 02 AMGN 0 03 AMGN 0 03 Health care stocks were edging higher just before tonight s closing bell with the NYSE Health Care Index rising less than 0 1 while shares
BMY,BMY:US,BBG000DQLV23,BRISTOL MYERS SQUIBB CO Financials,2017-02-24 18:04:07 +0000,http://finance.yahoo.com/q/is?s=bmy,BRISTOL MYERS SQUIBB CO Financials
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs",2017-02-24 14:54:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IzbzaW6L2ls/pharma-stock-roundup-is-bmy-the-next-acquisition-target-priority-review-for-pfe-novartis-drugs-cm752604,This week focus remained on Bristol Myers BMY with the company making additions to its Board and billionaire activist investor Carl Icahn reportedly acquiring a stake in the company Recap of the Week s Most Important Stories Is Bristol Myers the Next Takeover Target According
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs",2017-02-24 12:27:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-bmy-next-122712720.html,"Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs"
BMY,BMY:US,BBG000DQLV23,"Final Trade: ORCL, AN & more",2017-02-23 22:59:00 +0000,http://finance.yahoo.com/video/final-trade-orcl-more-225900407.html,"Final Trade: ORCL, AN & more"
BMY,BMY:US,BBG000DQLV23,"Merck, Roche Gouge Bristol's I-O Share After Lung Cancer Approvals",2017-02-23 21:15:28 +0000,http://www.investors.com/news/technology/merck-roche-gouge-bristols-i-o-share-after-lung-cancer-approvals/,"Merck, Roche Gouge Bristol's I-O Share After Lung Cancer Approvals"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Co (BMY) To Sell Senior Notes As Formidable Activist Investor Shows Interest,2017-02-23 19:25:57 +0000,http://www.insidermonkey.com/blog/bristol-myers-squibb-co-bmy-to-sell-senior-notes-as-formidable-activist-investor-shows-interest-561940/,Bristol-Myers Squibb Co (BMY) To Sell Senior Notes As Formidable Activist Investor Shows Interest
BMY,BMY:US,BBG000DQLV23,iShares Global 100 ETF Experiences Big Outflow,2017-02-23 17:53:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jCKFbjkmKv8/ishares-global-100-etf-experiences-big-outflow-cm752187,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Global 100 ETF Symbol IOO where we have detected an approximate 24 1 million dollar outflow that s a 1 5 decrease week over week from 20 100 000
BMY,BMY:US,BBG000DQLV23,"Company News for February 23, 2017",2017-02-23 16:49:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NYcDfjdxjjY/company-news-for-february-23-2017-cm751975,Shares of Toll Brothers Inc TOL increased 6 1 after contracts rose in its five other markets with company saying that there was an acceleration in contracts from November to December to January Shares of First Solar Inc FSLR tanked 8 3 after the solar panel maker
BMY,BMY:US,BBG000DQLV23,"Company News for February 23, 2017",2017-02-23 15:10:03 +0000,http://finance.yahoo.com/news/company-news-february-23-2017-151003169.html,"Company News for February 23, 2017"
BMY,BMY:US,BBG000DQLV23,Januvia and Janumet: Merck & Co.’s Blockbuster Diabetes Products,2017-02-23 14:24:53 +0000,http://marketrealist.com/2017/02/januvia-and-janumet-mercks-blockbuster-diabetes-products-2/?utm_source=yahoo&utm_medium=feed,Januvia and Janumet: Merck & Co.’s Blockbuster Diabetes Products
BMY,BMY:US,BBG000DQLV23,Why Do Stocks' Fair Value Estimates Change?,2017-02-23 11:00:00 +0000,http://news.morningstar.com/articlenet/article.aspx?id=794288&SR=Yahoo,Why Do Stocks' Fair Value Estimates Change?
BMY,BMY:US,BBG000DQLV23,Carl Icahn’s Stake in Bristol-Myers Squibb Co (BMY) Fuels Takeover Talk,2017-02-23 08:49:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uVD8p0fXgoM/carl-icahns-stake-in-bristol-myers-squibb-co-bmy-fuels-takeover-talk-cm751733,InvestorPlace Stock Market News Stock Advice amp Trading Tips Bristol Myers Squibb Co NYSE BMY may be the next target for a takeover by Carl Icahn A new report claims that Carl Icahn has bought a stake in Bristol Myers Squibb Co The
BMY,BMY:US,BBG000DQLV23,Bristol Myers' Future Unsure as Carl Icahn Takes Stake,2017-02-23 00:50:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZAXWOG1XZ64/bristol-myers-future-unsure-as-carl-icahn-takes-stake-cm751699,Could Bristol Myers Squibb Company BMY soon be put on the market for sale as activist investor Carl Icahn takes interest in the company Though it is unclear how big of a portfolio Icahn has bought and Icahn s intention it is clear that the company is seeing growth after The Wall
BMY,BMY:US,BBG000DQLV23,Who Could Buy Bristol-Myers Squibb?,2017-02-23 00:50:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EhdxWGGKiSc/who-could-buy-bristol-myers-squibb-cm751696,Billionaire activist investor Carl Icahn has reportedly set his sights on Bristol Myers Squibb NYSE BMY a 90 billion market cap biopharma that s carving out an important leadership position in immuno oncology If past is prologue Icahn s about to start advocating for big
BMY,BMY:US,BBG000DQLV23,You'd be a fool to bet against the market now: Cramer,2017-02-23 00:34:00 +0000,http://finance.yahoo.com/video/youd-fool-bet-against-market-003400487.html,You'd be a fool to bet against the market now: Cramer
BMY,BMY:US,BBG000DQLV23,Cramer: Buyers for Bristol-Myers Are Few and Far Between,2017-02-23 00:01:00 +0000,http://realmoney.thestreet.com/articles/02/22/2017/cramer-buyers-bristol-myers-are-few-and-far-between?puc=yahoo&cm_ven=YAHOO,Cramer: Buyers for Bristol-Myers Are Few and Far Between
BMY,BMY:US,BBG000DQLV23,Cramer spells out why you would be a fool to bet against ...,2017-02-22 23:31:00 +0000,http://finance.yahoo.com/video/cramer-spells-why-fool-bet-233100022.html,Cramer spells out why you would be a fool to bet against ...
BMY,BMY:US,BBG000DQLV23,Who Could Buy Bristol-Myers Squibb?,2017-02-22 23:21:05 +0000,http://www.fool.com/investing/2017/02/22/who-could-buy-bristol-myers-squibb.aspx,Who Could Buy Bristol-Myers Squibb?
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes,2017-02-22 23:00:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-prices-1-230000339.html,"[Business Wire] - Bristol-Myers Squibb Company today announced that it has agreed to sell $1.5 billion of senior unsecured notes: $750 million in aggregate principal amount of 1.600% notes due 2019 and $750 million in aggregate principal amount of 3.250% notes due 2027, in an underwritten public offering."
BMY,BMY:US,BBG000DQLV23,Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?,2017-02-22 22:49:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DY5IzZNQ5QQ/exelixis-exel-q4-earnings-is-positive-surprise-in-store-cm751652,Exelixis Inc EXEL is scheduled to report fourth quarter 2016 results on Feb 27 after the market close Exelixis had a mixed track record over the last four quarters The company surpassed expectations thrice in the four trailing quarters and missed the same in the remaining with an
BMY,BMY:US,BBG000DQLV23,Bristol Myers' Future Unsure as Carl Icahn Takes Stake,2017-02-22 22:13:10 +0000,http://finance.yahoo.com/news/bristol-myers-future-unsure-carl-221310671.html,Bristol Myers' Future Unsure as Carl Icahn Takes Stake
BMY,BMY:US,BBG000DQLV23,Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?,2017-02-22 20:10:08 +0000,http://finance.yahoo.com/news/exelixis-exel-q4-earnings-positive-201008166.html,Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
BMY,BMY:US,BBG000DQLV23,S&P 500 Trades Lower as Fed Signals Move on Rates 'Fairly Soon',2017-02-22 20:01:00 +0000,https://www.thestreet.com/story/14011577/1/stocks-mostly-lower-in-wishy-washy-trading-ahead-of-fed-minutes.html?puc=yahoo&cm_ven=YAHOO,S&P 500 Trades Lower as Fed Signals Move on Rates 'Fairly Soon'
BMY,BMY:US,BBG000DQLV23,"Notable Wednesday Option Activity: DOW, BMY, GOOG",2017-02-22 19:49:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ESKsjOkOL5w/notable-wednesday-option-activity-dow-bmy-goog-cm751522,Looking at options trading activity among components of the S amp P 500 index there is noteworthy activity today in Dow Chemical Co Symbol DOW where a total volume of 38 164 contracts has been traded thus far today a contract volume which is representative of approximately 3 8
BMY,BMY:US,BBG000DQLV23,"Heart-Thumping, Game-Changing Ways We're Treating Cardiovascular Disease",2017-02-22 18:30:41 +0000,http://www.fool.com/investing/2017/02/22/heart-thumping-game-changing-ways-were-treating-ca.aspx,"Heart-Thumping, Game-Changing Ways We're Treating Cardiovascular Disease"
BMY,BMY:US,BBG000DQLV23,Midday Update: Dow Cautiously Pokes Into Positive Territory Ahead of FOMC Minutes,2017-02-22 18:29:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y7BkVa4zTCk/midday-update-dow-cautiously-pokes-into-positive-territory-ahead-of-fomc-minutes-cm751488,The Dow Jones Industrial Average set another record high as existing home sales rose to a 10 year high and shares of component stock DuPont DD rallied more than 4 on reports that the European Union is expected to approve its merger with Dow Chemical DOW The Dow Jones Industrial
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Squibb: grave dancing denied,2017-02-22 18:26:18 +0000,"http://www.ft.com/cms/s/09c21d4c-f91b-11e6-bd4e-68d53499ed71,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[$$] Bristol-Myers Squibb: grave dancing denied
BMY,BMY:US,BBG000DQLV23,"US STOCKS-S&P, Nasdaq dip ahead of Fed minutes; Dow hits record high",2017-02-22 18:04:44 +0000,http://finance.yahoo.com/news/us-stocks-p-nasdaq-dip-180444690.html,"US STOCKS-S&P, Nasdaq dip ahead of Fed minutes; Dow hits record high"
BMY,BMY:US,BBG000DQLV23,Carl Icahn Takes Stake in Bristol-Myers Squibb,2017-02-22 17:50:49 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=D9597A4A-564C-4E23-8484-1DA641A84C95&siteid=yhoof2,Carl Icahn Takes Stake in Bristol-Myers Squibb
BMY,BMY:US,BBG000DQLV23,This bullish stock signal has never been wrong — and it’s about to flash for 2017,2017-02-22 17:33:56 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=EA025B1E-F845-11E6-B75E-2961765E9140&siteid=yhoof2,This bullish stock signal has never been wrong — and it’s about to flash for 2017
BMY,BMY:US,BBG000DQLV23,"Carl Icahn just jumped into a $90 billion drug maker, and people are betting it'll be a takeover target",2017-02-22 17:29:04 +0000,http://finance.yahoo.com/news/carl-icahn-just-jumped-90-172904544.html,"Carl Icahn just jumped into a $90 billion drug maker, and people are betting it'll be a takeover target"
BMY,BMY:US,BBG000DQLV23,US STOCKS-Wall St slightly lower ahead of Fed minutes,2017-02-22 16:44:14 +0000,http://finance.yahoo.com/news/us-stocks-wall-st-slightly-164414710.html,US STOCKS-Wall St slightly lower ahead of Fed minutes
BMY,BMY:US,BBG000DQLV23,Dow Turns Positive in Wishy-Washy Trading Ahead of Fed Minutes,2017-02-22 15:57:00 +0000,https://www.thestreet.com/story/14011257/1/stocks-slip-as-wall-street-awaits-clarity-from-the-fed.html?puc=yahoo&cm_ven=YAHOO,Dow Turns Positive in Wishy-Washy Trading Ahead of Fed Minutes
BMY,BMY:US,BBG000DQLV23,Takeover speculation surrounds Bristol-Myers Squibb,2017-02-22 15:33:00 +0000,http://finance.yahoo.com/video/takeover-speculation-surrounds-bristol-myers-153300407.html,Takeover speculation surrounds Bristol-Myers Squibb
BMY,BMY:US,BBG000DQLV23,"Heart-Thumping, Game-Changing Ways We're Treating Cardiovascular Disease",2017-02-22 15:09:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-FsdV-rDAeQ/heart-thumping-game-changing-ways-were-treating-cardiovascular-disease-cm751104,A mgen Inc NASDAQ AMGN and Bristol Myers Squibb s NYSE BMY medicines 160 and a novel alternative to 160 heart surgery using 160 heart valves made by Edwards Lifesciences NYSE EW 160 are leading to big 160 changes in how doctors treat heart
BMY,BMY:US,BBG000DQLV23,"DISH tunes in solid profits, Toll builds on earnings & Carl Icahn eyes Bristol-Myers Squibb",2017-02-22 15:00:50 +0000,http://finance.yahoo.com/news/dish-tunes-in-for-solid-profits-toll-builds-an-earnings-report-carl-icahn-eyes-bristol-myers-squibb-150050730.html,"DISH tunes in solid profits, Toll builds on earnings & Carl Icahn eyes Bristol-Myers Squibb"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Company -- Moody's rates Bristol's notes A2; negative outlook,2017-02-22 14:30:03 +0000,http://www.moodys.com/page/viewresearchdoc.aspx?docid=PR_362455&WT.mc_id=AM~WWFob29fRmluYW5jZTQyX1NCX1JhdGluZyBOZXdzX0FsbF9Fbmc=~20170222_PR_362455,Bristol-Myers Squibb Company -- Moody's rates Bristol's notes A2; negative outlook
BMY,BMY:US,BBG000DQLV23,Merck & Co.’s Segment-Wise Revenues for 4Q16,2017-02-22 14:08:26 +0000,http://marketrealist.com/2017/02/merck-and-co-s-segment-wise-revenues-for-4q16/?utm_source=yahoo&utm_medium=feed,Merck & Co.’s Segment-Wise Revenues for 4Q16
BMY,BMY:US,BBG000DQLV23,Stock Futures Waver as Wall Street Awaits Clarity From the Fed,2017-02-22 13:55:00 +0000,https://www.thestreet.com/story/14009969/1/stock-futures-creep-lower-as-wall-street-awaits-clarity-from-the-fed.html?puc=yahoo&cm_ven=YAHOO,Stock Futures Waver as Wall Street Awaits Clarity From the Fed
BMY,BMY:US,BBG000DQLV23,Carl Icahn's Next Target: Bristol-Myers Squibb,2017-02-22 13:39:00 +0000,http://www.forbes.com/sites/adamsarhan/2017/02/22/carl-icahns-next-target-bristol-myers-squibb/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Carl Icahn's Next Target: Bristol-Myers Squibb
BMY,BMY:US,BBG000DQLV23,Fed minutes in focus,2017-02-22 13:07:33 +0000,http://finance.yahoo.com/news/fed-minutes-in-focus-130733520.html,Fed minutes in focus
BMY,BMY:US,BBG000DQLV23,Stock market set to lose grip on records as Fed minutes loom,2017-02-22 13:03:14 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=B2235D58-F8D4-11E6-BDE3-75B54C8A587F&siteid=yhoof2,"[at MarketWatch] - S. stocks futures traded slightly higher on Wednesday, with stocks set to hover at record levels, but investors will keep a close eye on what the minutes of the latest Fed meeting have to say about the ..."
BMY,BMY:US,BBG000DQLV23,Is Carl Icahn Targeting Bristol-Myers Squibb for a Takeover?,2017-02-22 12:32:00 +0000,http://www.investopedia.com/news/carl-icahn-targeting-bristolmyers-squibb-takeover-bmy/?partner=YahooSA,Is Carl Icahn Targeting Bristol-Myers Squibb for a Takeover?
BMY,BMY:US,BBG000DQLV23,"U.S. stocks on pause after record rally, with Fed minutes ahead",2017-02-22 10:36:48 +0000,http://finance.yahoo.com/news/u-stocks-pause-record-rally-103648668.html,"U.S. stocks on pause after record rally, with Fed minutes ahead"
BMY,BMY:US,BBG000DQLV23,Factor Xa's Win Billions of Dollars in Sales From Warfarin,2017-02-22 07:07:45 +0000,http://www.fool.com/investing/2017/02/21/factor-xas-win-billions-of-dollars-in-sales-from-w.aspx,Factor Xa's Win Billions of Dollars in Sales From Warfarin
BMY,BMY:US,BBG000DQLV23,Factor Xa's Win Billions of Dollars in Sales From Warfarin,2017-02-22 07:07:45 +0000,http://www.fool.com/investing/2017/02/21/factor-xas-win-billions-of-dollars-in-sales-from-w.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Factor Xa's Win Billions of Dollars in Sales From Warfarin
BMY,BMY:US,BBG000DQLV23,PRESS DIGEST - Wall Street Journal - Feb 22,2017-02-22 06:44:06 +0000,http://finance.yahoo.com/news/press-digest-wall-street-journal-064406345.html,[Reuters] - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - The same day Bristol-Myers Squibb Co shook up its board to ...
BMY,BMY:US,BBG000DQLV23,[$$] Carl Icahn Takes Stake in Bristol-Myers Squibb,2017-02-22 05:42:22 +0000,https://www.wsj.com/articles/carl-icahn-takes-stake-in-bristol-myers-squibb-1487710151?ru=yahoo?mod=yahoo_itp,"[at The Wall Street Journal] - The same day Bristol-Myers Squibb shook up its board to satisfy one activist investor, the drugmaker was faced with another: Carl Icahn, whose interest is fueling speculation the company could soon be ..."
BMY,BMY:US,BBG000DQLV23,Can Carl Icahn Save Bristol Myers Squibb?,2017-02-22 02:06:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I_zucA9shFQ/can-carl-icahn-save-bristol-myers-squibb-cm750980,Bristol Myers Squibb Company BMY experienced slight growth after Carl Icahn billionaire activist investor reportedly wants to take stake in the company Bristol Myers a global leader in biopharmaceutical hasn t been able to convince shareholders that its product can compete against
BMY,BMY:US,BBG000DQLV23,[$$] Carl Icahn Takes Stake in Bristol-Myers,2017-02-22 00:49:55 +0000,https://www.wsj.com/articles/carl-icahn-takes-stake-in-bristol-myers-squibb-1487710151?mod=yahoo_hs,[$$] Carl Icahn Takes Stake in Bristol-Myers
BMY,BMY:US,BBG000DQLV23,Can Carl Icahn Save Bristol Myers Squibb?,2017-02-21 23:59:11 +0000,http://finance.yahoo.com/news/carl-icahn-save-bristol-myers-235911863.html,Can Carl Icahn Save Bristol Myers Squibb?
BMY,BMY:US,BBG000DQLV23,Carl Icahn Reportedly Invests In Potential Takeout Target Bristol-Myers,2017-02-21 22:10:46 +0000,http://www.investors.com/news/technology/carl-icahn-reportedly-invests-in-potential-takeout-target-bristol-myers/,Carl Icahn Reportedly Invests In Potential Takeout Target Bristol-Myers
BMY,BMY:US,BBG000DQLV23,"Icahn buys Bristol-Myers shares, adding to activist pressure",2017-02-21 21:58:47 +0000,http://sg.finance.yahoo.com/news/bristol-myers-adds-three-directors-191358264.html,"Icahn buys Bristol-Myers shares, adding to activist pressure"
BMY,BMY:US,BBG000DQLV23,Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?,2017-02-21 21:48:20 +0000,http://finance.yahoo.com/news/icahn-takes-bristol-myers-stake-214820857.html,Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
BMY,BMY:US,BBG000DQLV23,Icahn Takes Stake In Bristol-Myers,2017-02-21 21:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fdjDuKJzLL0/icahn-takes-stake-in-bristolmyers-20170221-01935,Icahn Takes Stake In Bristol-Myers
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Rises After Report That Carl Icahn Owns Stake,2017-02-21 21:11:55 +0000,https://www.bloomberg.com/news/articles/2017-02-21/bristol-myers-rises-after-report-that-carl-icahn-owns-stake?cmpid=yhoo.headline,Bristol-Myers Rises After Report That Carl Icahn Owns Stake
BMY,BMY:US,BBG000DQLV23,Carl Icahn takes stake in Bristol Myers: WSJ,2017-02-21 21:00:38 +0000,http://finance.yahoo.com/news/carl-icahn-takes-stake-bristol-210038779.html,Carl Icahn takes stake in Bristol Myers: WSJ
BMY,BMY:US,BBG000DQLV23,Carl Icahn has reportedly taken a stake in Bristol-Myers and its shares are jumping,2017-02-21 20:51:52 +0000,http://finance.yahoo.com/news/carl-icahn-reportedly-taken-stake-205152164.html,Carl Icahn has reportedly taken a stake in Bristol-Myers and its shares are jumping
BMY,BMY:US,BBG000DQLV23,Icahn takes stake in Bristol-Myers: DJ,2017-02-21 20:46:00 +0000,http://finance.yahoo.com/video/icahn-takes-stake-bristol-myers-204600753.html,Icahn takes stake in Bristol-Myers: DJ
BMY,BMY:US,BBG000DQLV23,Icahn Purchases Stake in Bristol-Myers,2017-02-21 20:45:00 +0000,https://www.thestreet.com/story/14010133/1/icahn-purchases-stake-in-bristol-myers.html?puc=yahoo&cm_ven=YAHOO,Icahn Purchases Stake in Bristol-Myers
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Adds Three New Directors,2017-02-21 19:30:00 +0000,https://www.thestreet.com/story/14010012/1/bristol-meyers-adds-three-new-directors.html?puc=yahoo&cm_ven=YAHOO,Bristol-Myers Adds Three New Directors
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Buys Back Shares, Shuffles Board",2017-02-21 19:13:00 +0000,https://www.thestreet.com/story/14009889/1/bristol-myers-buys-back-shares-shuffles-board.html?puc=yahoo&cm_ven=YAHOO,"Bristol-Myers Buys Back Shares, Shuffles Board"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers adds 3 directors in agreement with JANA Partners,2017-02-21 19:03:35 +0000,http://finance.yahoo.com/news/bristol-myers-adds-3-directors-155624220.html,Bristol-Myers adds 3 directors in agreement with JANA Partners
BMY,BMY:US,BBG000DQLV23,Factor Xa's Win Billions of Dollars in Sales From Warfarin,2017-02-21 18:09:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LAwiGRpNWSA/factor-xas-win-billions-of-dollars-in-sales-from-warfarin-cm750728,Similar efficacy and a better safety profile are allowing a new type of anticoagulants known as factor Xa inhibitors to capture billions of dollars in sales away from warfarin a decades old drug that requires frequent testing dose adjustments and dietary changes Bristol Myers
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co (BMY), Merck & Co., Inc. (MRK), And Other Pharmaceutical Firms All Targeting I-O Segment",2017-02-21 16:10:11 +0000,http://www.insidermonkey.com/blog/bristol-myers-squibb-co-bmy-merck-co-inc-mrk-and-other-pharmaceutical-firms-all-targeting-i-o-segment-561053/,"Bristol-Myers Squibb Co (BMY), Merck & Co., Inc. (MRK), And Other Pharmaceutical Firms All Targeting I-O Segment"
BMY,BMY:US,BBG000DQLV23,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem",2017-02-21 13:18:15 +0000,http://biz.yahoo.com/e/170221/bmy8-k.html,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers adds three directors in deal with Jana Partners,2017-02-21 12:50:27 +0000,http://finance.yahoo.com/news/bristol-myers-adds-three-directors-125027867.html,Bristol-Myers adds three directors in deal with Jana Partners
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers announces $2 bln accelerated share buyback; adds former Bausch & Lomb CFO, others to board",2017-02-21 12:22:54 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=F5846BA1-E541-4A9E-ADD2-9D59F1FB15A8&siteid=yhoof2,"Bristol-Myers announces $2 bln accelerated share buyback; adds former Bausch & Lomb CFO, others to board"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Appoints Three New Independent Directors,2017-02-21 11:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-appoints-three-115900775.html,"[Business Wire] - Bristol-Myers Squibb Company announced today that it has appointed Robert J. Bertolini, Matthew W. Emmens and Theodore R. Samuels to its Board of Directors, effective immediately."
BMY,BMY:US,BBG000DQLV23,First Comprehensive Pediatric Hematology-Oncology Initiative Launched in Africa,2017-02-21 08:00:00 +0000,http://finance.yahoo.com/news/first-comprehensive-pediatric-hematology-oncology-080000267.html,"[Business Wire] - His Excellency the President Lieutenant General Dr. Seretse Khama Ian Khama of the Republic of Botswana, the Honorable Minister Dorcas Makgato of the Ministry of Health and Wellness, the Bristol-Myers Squibb Foundation, Texas Children’s Cancer and Hematology Centers and Baylor College of Medicine International Pediatric AIDS Initiative at Texas Children’s Hospital through public-private partnerships ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Plans $2 Bln Accelerated Share Buyback; Names 3 New Directors,2017-02-21 07:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MmeJgkmShOk/bristolmyers-plans-2-bln-accelerated-share-buyback-names-3-new-directors-20170221-00430,Bristol-Myers Plans $2 Bln Accelerated Share Buyback; Names 3 New Directors
BMY,BMY:US,BBG000DQLV23,"Merck, Bristol-Myers, Incyte Race For A Cure In $25 Billion I-O Market",2017-02-18 00:41:35 +0000,http://www.investors.com/news/technology/merck-bristol-myers-incyte-race-toward-a-cure-in-25-billion-i-o-market/,"Merck, Bristol-Myers, Incyte Race For A Cure In $25 Billion I-O Market"
BMY,BMY:US,BBG000DQLV23,These Are The First Immune-System Cancer Drugs OK'd By FDA,2017-02-18 00:34:26 +0000,http://www.investors.com/news/technology/immune-system-cancer-drugs-okd-by-fda/,These Are The First Immune-System Cancer Drugs OK'd By FDA
BMY,BMY:US,BBG000DQLV23,The Math Shows XLV Can Go To $81,2017-02-17 15:53:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fAvDfh8Ikk4/the-math-shows-xlv-can-go-to-81-cm749537,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ",2017-02-17 13:57:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YaFi7BW-HOE/pharma-stock-roundup-mercks-alzheimers-study-halted-allergan-to-buy-zeltiq-cm749492,Although companies like Teva Read more Teva Tops on Q4 Earnings Maintains 2017 Guidance and Shire reported fourth quarter results this week focus remained primarily on Merck s MRK announcement regarding its Alzheimer s disease candidate Recap of the Week s Most Important
BMY,BMY:US,BBG000DQLV23,"Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook",2017-02-17 09:43:30 +0000,http://sg.finance.yahoo.com/news/top-astrazeneca-shareholder-woodford-adds-094330618.html,"Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook"
BMY,BMY:US,BBG000DQLV23,"3 Big Stock Charts for Thursday: Bristol-Myers Squibb Co. (BMY), Cincinnati Financial Corporation (CINF) and Hasbro, Inc. (HAS)",2017-02-16 20:55:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TyzlAfqnV0M/3-big-stock-charts-for-thursday-bristol-myers-squibb-co-bmy-cincinnati-financial-corporation-cinf-and-hasbro-inc-has-cm749211,InvestorPlace Stock Market News Stock Advice amp Trading Tips There are some technically tired stocks out there that 160 appear ready to succumb to traders that may be growing eager to lock in short term profits Today s three big stock charts examines recent activity
BMY,BMY:US,BBG000DQLV23,"Thursday’s Vital Data: Apple Inc. (AAPL), Groupon Inc (GRPN) and Bristol-Myers Squibb Co (BMY)",2017-02-16 18:56:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QWUVmQrshbM/thursdays-vital-data-apple-inc-aapl-groupon-inc-grpn-and-bristol-myers-squibb-co-bmy-cm749139,InvestorPlace Stock Market News Stock Advice amp Trading Tips U S stock futures are feeling the heat this morning and Wall Street is set to take a breather following the longest record setting winning streak in nearly 25 years All three of the major market indices are up
BMY,BMY:US,BBG000DQLV23,"Go Short Netflix, Inc. (NFLX) Stock Before It Dives",2017-02-16 18:56:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/twUOBj7SrCM/go-short-netflix-inc-nflx-stock-before-it-dives-cm749138,InvestorPlace Stock Market News Stock Advice amp Trading Tips After an epic 50 rally of the late September lows at 95 shares of 160 Netflix Inc NASDAQ NFLX appear to have stalled out Major overhead resistance now looms and I expect NFLX stock
BMY,BMY:US,BBG000DQLV23,How Bristol-Myers Squibb and Pfizer Are Winning a Big Brawl in Blood Thinners,2017-02-16 17:55:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/coN6cS4qFbU/how-bristol-myers-squibb-and-pfizer-are-winning-a-big-brawl-in-blood-thinners-cm749029,Warfarin may have dominanted the 10 billion market for anticoagulants for the past 50 or so years but a new class of drugs that works in an entirely new way is quickly relegating warfarin s use to the dustbin Factor Xa inhibitors that keep blood clots from forming without
BMY,BMY:US,BBG000DQLV23,"Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook",2017-02-16 17:38:54 +0000,http://sg.finance.yahoo.com/news/top-astrazeneca-shareholder-woodford-adds-162858634.html,"Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook"
BMY,BMY:US,BBG000DQLV23,David Tepper Invests Heavily in Pharma in 4th Quarter,2017-02-16 17:06:55 +0000,http://finance.yahoo.com/news/david-tepper-invests-heavily-pharma-170655363.html,David Tepper Invests Heavily in Pharma in 4th Quarter
BMY,BMY:US,BBG000DQLV23,How Bristol-Myers Squibb and Pfizer Are Winning a Big Brawl in Blood Thinners,2017-02-16 16:41:06 +0000,http://www.fool.com/investing/2017/02/16/how-bristol-myers-squibb-and-pfizer-are-winning-a.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,How Bristol-Myers Squibb and Pfizer Are Winning a Big Brawl in Blood Thinners
BMY,BMY:US,BBG000DQLV23,3 Stocks We're Watching in the First Quarter,2017-02-16 00:34:16 +0000,http://www.fool.com/investing/2017/02/14/3-stocks-were-watching-in-the-first-quarter.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Stocks We're Watching in the First Quarter
BMY,BMY:US,BBG000DQLV23,Bristol-Myers: Don't Bet on a Pfizer Acquisition,2017-02-15 17:38:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/02/15/bristol-myers-dont-bet-on-a-pfizer-acquisition/?mod=yahoobarrons&ru=yahoo,Bristol-Myers: Don't Bet on a Pfizer Acquisition
BMY,BMY:US,BBG000DQLV23,"Notable ETF Outflow Detected - VONE, MCD, MDT, BMY",2017-02-15 16:54:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bB5Z6byTSLA/notable-etf-outflow-detected-vone-mcd-mdt-bmy-cm748329,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Russell 1000 ETF Symbol VONE where we have detected an approximate 56 4 million dollar outflow that s a 7 6 decrease week over week from 6 900 000
BMY,BMY:US,BBG000DQLV23,Merck: There's Only One Way to Outperform Now,2017-02-15 16:19:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/02/15/merck-theres-only-one-way-to-outperform-now/?mod=yahoobarrons&ru=yahoo,Merck: There's Only One Way to Outperform Now
BMY,BMY:US,BBG000DQLV23,Here Are The Major Moves Made By Bridgewater Associates Going Into 2017,2017-02-15 15:41:53 +0000,http://www.insidermonkey.com/blog/here-are-the-major-moves-made-by-bridgewater-associates-going-into-2017-558413/,Here Are The Major Moves Made By Bridgewater Associates Going Into 2017
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb To Present At Leerink Conference ; Webcast At 3:30 PM ET,2017-02-15 14:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wtLUL1MGE1Q/bristolmyers-squibb-to-present-at-leerink-conference--webcast-at-330-pm-et-20170215-01144,Bristol-Myers Squibb To Present At Leerink Conference ; Webcast At 3:30 PM ET
BMY,BMY:US,BBG000DQLV23,Markets Continue to Hit Record Highs: Today's Research Reports on Stocks to Watch Bristol-Myers Squibb and Himax Technologies,2017-02-15 14:30:00 +0000,http://finance.yahoo.com/news/markets-continue-hit-record-highs-143000492.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 15, 2017 / U.S. markets continued to rise off their record highs Tuesday after Federal Reserve Chairwoman hinted that the central bank could raise short-term interest ..."
BMY,BMY:US,BBG000DQLV23,3 Stocks We're Watching in the First Quarter,2017-02-14 23:19:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DU0HvftZRFE/3-stocks-were-watching-in-the-first-quarter-cm747964,The first quarter of 2017 is already chock full of weighty news events and potential catalysts that have investors collective heads spinning So while it may be tough to concentrate with so much going on our Foolish contributors think that Bristol Myers Squibb NYSE BMY
BMY,BMY:US,BBG000DQLV23,"Notable Tuesday Option Activity: BMY, GEO, TREE",2017-02-14 22:18:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YiO_2sEKF_U/notable-tuesday-option-activity-bmy-geo-tree-cm747936,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Bristol Myers Squibb Co Symbol BMY where a total volume of 107 434 contracts has been traded thus far today a contract volume which is representative of approximately 10
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb: Takeover Target?,2017-02-14 20:33:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/02/14/bristol-myers-squibb-takeover-target/?mod=yahoobarrons&ru=yahoo,Bristol-Myers Squibb: Takeover Target?
BMY,BMY:US,BBG000DQLV23,Baron Funds'  Fifth Avenue Growth Fund Comments on Bristol-Myers Squibb Company,2017-02-14 14:17:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QbdWsA0j03Y/baron-funds-fifth-avenue-growth-fund-comments-on-bristol-myers-squibb-company-cm747530,Bristol Myers Squibb Company BMY is a leading developer in Immuno Oncology the new wave of therapeutics aimed at displacing chemotherapeutics in cancer care with both improved efficacy measured via survival outcomes and safety profiles While the class as a whole represents a success
BMY,BMY:US,BBG000DQLV23,"Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb",2017-02-13 23:18:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mCtM39MPWUM/better-buy-exelixis-inc-vs-bristol-myers-squibb-cm747327,Two hot cancer drugs are being marketed by two very different companies Cabometyx is Exelixis NASDAQ EXEL crown jewel Opdivo is Bristol Myers Squibb s NYSE BMY rising star But Bristol Myers Squibb s stock is down over the last 12 months while Exelixis shares
BMY,BMY:US,BBG000DQLV23,"Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb",2017-02-13 22:17:17 +0000,http://www.fool.com/investing/2017/02/13/better-buy-exelixis-inc-vs-bristol-myers-squibb.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb"
BMY,BMY:US,BBG000DQLV23,"Tampa business leaders speak out on incentives, tourism marketing during Gov. Scott's visit (Video)",2017-02-13 21:12:00 +0000,http://www.bizjournals.com/tampabay/news/2017/02/13/tampa-business-leaders-speak-out-on-incentives.html?ana=yahoo,"Tampa business leaders speak out on incentives, tourism marketing during Gov. Scott's visit (Video)"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Company -- Moody's revises Bristol's outlook to negative; affirms A2/Prime-1,2017-02-13 19:31:05 +0000,http://www.moodys.com/page/viewresearchdoc.aspx?docid=PR_362082&WT.mc_id=AM~WWFob29fRmluYW5jZV9TQl9SYXRpbmcgTmV3c19BbGxfRW5n~20170213_PR_362082,Bristol-Myers Squibb Company -- Moody's revises Bristol's outlook to negative; affirms A2/Prime-1
BMY,BMY:US,BBG000DQLV23,Baron Funds' Fifth Avenue Growth Fund Comments on Bristol-Myers Squibb Company,2017-02-13 17:43:07 +0000,http://finance.yahoo.com/news/baron-funds-fifth-avenue-growth-174307083.html,Baron Funds' Fifth Avenue Growth Fund Comments on Bristol-Myers Squibb Company
BMY,BMY:US,BBG000DQLV23,Reckitt finalises deal to buy Mead Johnson for $16.6 bln,2017-02-10 15:55:06 +0000,http://uk.finance.yahoo.com/news/reckitt-benckiser-reaches-deal-buy-073736925.html,"[Reuters - UK Focus] - Reckitt Benckiser (Xetra: A0M1W6 - news) has agreed to buy U.S. baby formula maker Mead Johnson Nutrition for $16.6 billion, giving the British consumer goods company a new product line and expanding its presence in developing markets. Reckitt, the maker of Lysol cleaners, Durex condoms and Mucinex cold medicine, said on Friday it will pay $90 in cash for Mead Johnson shares, a 30 percent premium to their close on Wednesday last week, the day before Reckitt said it was in advanced talks with the maker of Enfamil baby formula."
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi",2017-02-10 14:20:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UTFQRQy9O5I/pharma-stock-roundup-allergan-gsk-top-4q-earnings-praluent-breather-for-sanofi-cm746062,Major pharma companies like Allergan AGN and GlaxoSmithKline GSK reported better than expected fourth quarter results this week Meanwhile French pharma giant Sanofi SNY got a breather in the PCSK9 inhibitor patent infringement lawsuit with a court allowing the company to continue selling
BMY,BMY:US,BBG000DQLV23,Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?,2017-02-10 13:35:53 +0000,http://finance.yahoo.com/news/short-sellers-doubting-trump-hiking-133553363.html,Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi",2017-02-10 11:44:11 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-allergan-gsk-114411776.html,"Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi"
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Squibb Stock in Bargain Bin,2017-02-09 23:44:00 +0000,http://www.barrons.com/articles/bristol-myers-squibb-stock-in-bargain-bin-1486683884?mod=yahoobarrons&ru=yahoo,[$$] Bristol-Myers Squibb Stock in Bargain Bin
BMY,BMY:US,BBG000DQLV23,[$$] Brakes on the pathway to treating cancer,2017-02-09 16:00:51 +0000,"http://www.ft.com/cms/s/24441526-ede0-11e6-ba01-119a44939bb6,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[$$] Brakes on the pathway to treating cancer
BMY,BMY:US,BBG000DQLV23,"Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints",2017-02-08 17:19:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qxXI2uJ8-2A/gilead-gild-beats-q4-earnings-sales-view-disappoints-cm744938,Gilead Sciences Inc s GILD fourth quarter 2016 earnings including the impact of stock based compensation expenses of 2 64 per share beat the Zacks Consensus Estimate of 2 31 However earnings were down from 3 27 in the year ago quarter Moreover total revenue in the reported
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part in Leerink 6th Annual Global Health Care Conference,2017-02-08 15:54:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-part-leerink-155400980.html,"[Business Wire] - Bristol-Myers Squibb Company will take part in the Leerink Annual Global Health Care Conference on Wednesday, February 15, 2017, in New York. Murdo Gordon, executive vice president and chief commercial officer, will answer questions about the company at 3:30 p.m."
BMY,BMY:US,BBG000DQLV23,Gilead Sciences & Bristol Myers: Two Wrongs Make a Right?,2017-02-08 15:17:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/02/08/gilead-sciences-bristol-myers-two-wrongs-make-a-right/?mod=yahoobarrons&ru=yahoo,Gilead Sciences & Bristol Myers: Two Wrongs Make a Right?
BMY,BMY:US,BBG000DQLV23,"FLXN Gets FDA Date, KTOV In Crosshairs, It''s A Thumbs Up For AMGN",2017-02-08 03:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bi4duK-uVLk/flxn-gets-fda-date-ktov-in-crosshairs-its-a-thumbs-up-for-amgn-20170208-00164,"FLXN Gets FDA Date, KTOV In Crosshairs, It''s A Thumbs Up For AMGN"
BMY,BMY:US,BBG000DQLV23,"Gainers & Losers Of The Day: EYES, SGNL, NEOT, DMTX, MBRX...",2017-02-07 23:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zcHPbgG0kvk/gainers--losers-of-the-day-eyes-sgnl-neot-dmtx-mbrx-20170207-01851,"Gainers & Losers Of The Day: EYES, SGNL, NEOT, DMTX, MBRX..."
BMY,BMY:US,BBG000DQLV23,Earnings No Longer a Headwind for Stocks,2017-02-07 21:19:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xdvk2kMO4SY/earnings-no-longer-a-headwind-for-stocks-cm744536,Tuesday February 7 2017 We feature the best research output of our analyst team in the Zacks Research Daily In today s write up we are featuring analyst reports on 16 major stocks including reports on Apple AAPL Visa V and AbbVie ABBV These stock research reports have been hand
BMY,BMY:US,BBG000DQLV23,"VYM, BMY, QCOM, TXN: ETF Outflow Alert",2017-02-07 17:18:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CFPg6rukUbg/vym-bmy-qcom-txn-etf-outflow-alert-cm744271,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard High Dividend Yield ETF Symbol VYM where we have detected an approximate 79 6 million dollar outflow that s a 0 5 decrease week over week
BMY,BMY:US,BBG000DQLV23,"3 Big Stock Charts for Monday: Bristol-Myers Squibb Co (BMY), Visa Inc (V) and Fiserv Inc (FISV)",2017-02-06 21:18:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WIX9OTspW14/3-big-stock-charts-for-monday-bristol-myers-squibb-co-bmy-visa-inc-v-and-fiserv-inc-fisv-cm743864,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Earnings season continues to provide both pre and post announcement trading opportunities from the charts Today s three 160 big stock charts look at charts for Bristol Myers Squibb
BMY,BMY:US,BBG000DQLV23,"Gainers & Losers Of The Day: PULM, AQB, GALE, PETX, KTOV...",2017-02-06 20:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0AU-NLkFUkg/gainers--losers-of-the-day-pulm-aqb-gale-petx-ktov-20170206-01406,"Gainers & Losers Of The Day: PULM, AQB, GALE, PETX, KTOV..."
BMY,BMY:US,BBG000DQLV23,Q4 Earnings Faring Well for Pharma ETFs,2017-02-06 17:19:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2oG8p1Qtx2o/q4-earnings-faring-well-for-pharma-etfs-cm743689,The Q4 earnings season is faring better than the last few years with not only earnings growth on track to reach the highest level in two years but also total earnings set to create a new quarterly record Most sectors are coming up with good results with healthcare being no exception The
BMY,BMY:US,BBG000DQLV23,Q4 Earnings Faring Well for Pharma ETFs,2017-02-06 14:55:02 +0000,http://finance.yahoo.com/news/q4-earnings-faring-well-pharma-145502433.html,Q4 Earnings Faring Well for Pharma ETFs
BMY,BMY:US,BBG000DQLV23,These 2 Factors Sent Bristol-Myers Squibb Co. Tumbling by 16% in January,2017-02-06 14:21:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZJvH6iuwxB8/these-2-factors-sent-bristol-myers-squibb-co-tumbling-by-16-in-january-cm743440,What happened Shares of global drug giant Bristol Myers Squibb NYSE BMY were hammered in January falling 16 according to data from S amp P Global Market Intelligence Once again the reason for the company s weak share price can be traced solely to blockbuster
BMY,BMY:US,BBG000DQLV23,"Portola, HealthCare Royalty Partners Ink $150 Million Deal",2017-02-06 14:18:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fuj7zzZeASg/portola-healthcare-royalty-partners-ink-150-million-deal-cm743499,Portola Pharmaceuticals Inc s PTLA shares were up 2 7 after the company announced that it has signed a royalty agreement with HealthCare Royalty Partners HCR a private investment firm for 150 million A look at Portola s share price movement over the past one year shows that
BMY,BMY:US,BBG000DQLV23,These 2 Factors Sent Bristol-Myers Squibb Co. Tumbling by 16% in January,2017-02-06 13:05:13 +0000,http://www.fool.com/investing/2017/02/06/these-2-factors-sent-bristol-myers-squibb-co-tumbl.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,These 2 Factors Sent Bristol-Myers Squibb Co. Tumbling by 16% in January
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Leukemia Drug Fails Mid-Stage Study,2017-02-06 12:47:00 +0000,http://www.investopedia.com/news/bristolmyers-innates-lirilumab-fails-trial-bmy/?partner=YahooSA,Bristol-Myers Leukemia Drug Fails Mid-Stage Study
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC,2017-02-04 00:56:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gsVauqDhe54/bristol-myers-injectable-opdivo-gets-fda-approval-for-muc-cm743202,Bristol Myers Squibb Company BMY announced that the FDA has approved an injectable form of immuno oncology drug Opdivo The drug will have an intravenous use in metastatic urothelial carcinoma mUC with a recommended dose of 240 mg Opdivo will be administered as an intravenous infusion over
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC,2017-02-03 22:28:10 +0000,http://finance.yahoo.com/news/bristol-myers-injectable-opdivo-gets-222810617.html,Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC
BMY,BMY:US,BBG000DQLV23,AstraZeneca Shrugs Off Bristol-Myers' Setback; Crushes Q4 Views,2017-02-03 21:29:11 +0000,http://www.investors.com/news/technology/astrazeneca-shrugs-off-bristol-myers-i-o-setback-crushes-q4-views/,AstraZeneca Shrugs Off Bristol-Myers' Setback; Crushes Q4 Views
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Opdivo Approved for Bladder Cancer,2017-02-03 18:03:00 +0000,http://www.investopedia.com/news/bristolmyers-opdivo-cleared-bladder-cancer-bmy/?partner=YahooSA,Bristol-Myers' Opdivo Approved for Bladder Cancer
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling",2017-02-03 13:33:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3s3hs5m8cow/pharma-stock-roundup-pfizer-merck-lly-report-results-teva-hit-by-copaxone-ruling-cm742674,Major pharma companies like Pfizer PFE Merck MRK and Lilly LLY reported fourth quarter results this week Meanwhile Teva TEVA was hit by an unfavorable ruling in the Copaxone patent infringement lawsuit Recap of the Week s Most Important Stories A Look at Earnings
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling",2017-02-03 11:54:11 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-pfizer-merck-115411134.html,"Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer",2017-02-02 21:15:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-receives-fda-211500753.html,"[Business Wire] - Bristol-Myers Squibb Company today announced the U.S. Food and Drug Administration has approved Opdivo injection, for intravenous use for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing ..."
BMY,BMY:US,BBG000DQLV23,U.S. FDA approves Bristol-Myers' Opdivo for bladder cancer,2017-02-02 20:13:45 +0000,http://finance.yahoo.com/news/u-fda-approves-bristol-myers-201345503.html,"[Reuters] - The U.S. Food and Drug Administration on Thursday expanded the use of Bristol-Myers Squibb Co's Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer. Opdivo, part of a new class of medicines designed to use the body's own immune system to fight cancer, is already approved to treat advanced melanoma, a form of lung cancer, kidney cancer, and Hodgkin lymphoma."
BMY,BMY:US,BBG000DQLV23,Lower Valuations Have Merck Looking 'Very Hard' at M&A Options,2017-02-02 17:58:00 +0000,https://www.thestreet.com/story/13976901/1/lower-valuations-have-merck-looking-very-hard-at-m-amp-a-options.html?puc=yahoo&cm_ven=YAHOO,Lower Valuations Have Merck Looking 'Very Hard' at M&A Options
BMY,BMY:US,BBG000DQLV23,"Roche (RHHBY) Beats on Earnings in 2016, Misses on Sales",2017-02-02 17:32:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w1_5i7iobuI/roche-rhhby-beats-on-earnings-in-2016-misses-on-sales-cm742259,Roche Holding AG s RHHBY core earnings came in at 1 84 per American Depositary Receipt ADR in 2016 beating the Zacks Consensus Estimate of 1 66 Revenues of 51 4 billion CHF50 6 billion missed the Zacks Consensus Estimate of 52 4 billion Shares of Roche have underperformed
BMY,BMY:US,BBG000DQLV23,"ETFs with exposure to Bristol-Myers Squibb Co. : February 2, 2017",2017-02-02 17:31:37 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-bristol-myers-squibb-co-february-2-2017/,"ETFs with exposure to Bristol-Myers Squibb Co. : February 2, 2017"
BMY,BMY:US,BBG000DQLV23,[$$] Merck hails rise in patient tests for immunotherapy drug Keytruda,2017-02-02 17:25:08 +0000,"http://www.ft.com/cms/s/d527b674-e960-11e6-967b-c88452263daf,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Merck & Co has seen a big jump in the number of lung cancer patients being tested to see if they would benefit from its immunotherapy drug Keytruda, and predicted sales would grow rapidly this year. The ..."
BMY,BMY:US,BBG000DQLV23,Reckitt Benckiser in talks to buy Mead Johnson for $16.7 bln,2017-02-02 16:09:40 +0000,http://uk.finance.yahoo.com/news/reckitt-benckiser-talks-buy-mead-004951021.html,Reckitt Benckiser in talks to buy Mead Johnson for $16.7 bln
BMY,BMY:US,BBG000DQLV23,Roche Bets on New Drugs to Boost Sales,2017-02-02 16:06:00 +0000,http://www.investopedia.com/news/roches-new-drugs-may-fuel-sales-growth-rhhby/?partner=YahooSA,Roche Bets on New Drugs to Boost Sales
BMY,BMY:US,BBG000DQLV23,Ignore Gilead Sciences Inc.: Here Are 2 Better Stocks,2017-02-02 15:35:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uOBVjTxW5s8/ignore-gilead-sciences-inc-here-are-2-better-stocks-cm742147,Because of the anemic outlook for its hepatitis C franchise and recent clinical setbacks Gilead Sciences NASDAQ GILD may not be the outright bargain that its rock bottom forward price to earnings ratio of about seven would seem to indicate In fact Pfizer NYSE PFE
BMY,BMY:US,BBG000DQLV23,Vanguard Health Care Fund Gains 5 New Stocks,2017-02-02 14:31:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RjDnJcyO3Io/vanguard-health-care-fund-gains-5-new-stocks-cm742075,The Vanguard Health Care Fund Trades Portfolio established five new holdings in the final quarter of 2016 The holdings are ConvaTec Group PLC LSE CTEC Ionis Pharmaceuticals Inc IONS Samsung BioLogics Co Ltd XKRX 207940 Shanghai Fosun Pharmaceutical Group Co
BMY,BMY:US,BBG000DQLV23,Dodge & Cox Comments on Bristol-Myers Squibb,2017-02-02 14:30:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UuB-nGs3Ifs/dodge-cox-comments-on-bristol-myers-squibb-cm742073,Once a diversified pharmaceutical company facing significant patent expirations a cliff Bristol Myers NYSE BMY has transitioned into a focused biopharmaceutical company that is positioned to grow Many of its competitors responded to their patent cliffs by expanding into other non
BMY,BMY:US,BBG000DQLV23,"Cancer Survivors Need More Efficient Integrated Long-Term Care and Stronger Policies Across Healthcare, Advocacy and the Workplace, New Research Concludes",2017-02-02 14:21:00 +0000,http://finance.yahoo.com/news/cancer-survivors-more-efficient-integrated-142100971.html,"[Business Wire] - As more patients are living longer with cancer, multi-stakeholder-driven changes are required to improve integrated, or coordinated, care that addresses the range of their long-term needs, according to a new Bristol-Myers Squibb-sponsored global research initiative developed by The Economist Intelligence Unit titled Global Cancer Survivorship: The Need for Integrated Care."
BMY,BMY:US,BBG000DQLV23,"Merck Posts In-Line 4Q Earnings, Issues Cautious 2017 Sales Outlook",2017-02-02 12:11:00 +0000,https://www.thestreet.com/story/13976015/1/merck-posts-in-line-4q-earnings-issues-cautious-2017-sales-outlook.html?puc=yahoo&cm_ven=YAHOO,"Merck Posts In-Line 4Q Earnings, Issues Cautious 2017 Sales Outlook"
BMY,BMY:US,BBG000DQLV23,3 Pharmaceutical Stocks With Bigger Dividends Than Johnson & Johnson,2017-02-02 12:00:48 +0000,http://www.fool.com/investing/2017/02/01/3-pharmaceutical-stocks-with-bigger-dividends-than.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Pharmaceutical Stocks With Bigger Dividends Than Johnson & Johnson
BMY,BMY:US,BBG000DQLV23,Reckitt Benckiser in talks to buy Mead Johnson for $16.7 billion,2017-02-02 11:50:27 +0000,http://sg.finance.yahoo.com/news/reckitt-benckiser-talks-buy-mead-010732891.html,Reckitt Benckiser in talks to buy Mead Johnson for $16.7 billion
BMY,BMY:US,BBG000DQLV23,3 Pharmaceutical Stocks With Bigger Dividends Than Johnson & Johnson,2017-02-01 22:33:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6lkQFKWZFOE/3-pharmaceutical-stocks-with-bigger-dividends-than-johnson-johnson-cm741862,If there were such a thing as the dividend stock hall of fame Johnson amp Johnson NYSE JNJ would be in it After all the company increased its dividend for a whopping 54 years in a row But if you re looking for high dividend yields there are better options Here are
BMY,BMY:US,BBG000DQLV23,Dodge & Cox Comments on Bristol-Myers Squibb,2017-02-01 17:46:29 +0000,http://finance.yahoo.com/news/dodge-cox-comments-bristol-myers-174629086.html,Dodge & Cox Comments on Bristol-Myers Squibb
BMY,BMY:US,BBG000DQLV23,Dodge & Cox's Stock Fund 4th Quarter Letter to Shareholders,2017-02-01 17:42:45 +0000,http://finance.yahoo.com/news/dodge-coxs-stock-fund-4th-172447384.html,Dodge & Cox's Stock Fund 4th Quarter Letter to Shareholders
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces European Patent Office Decision on Sprycel,2017-02-01 17:19:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-announces-european-171900298.html,"[Business Wire] - Bristol-Myers Squibb Company announced today that the European Patent Office upheld a decision with regard to European Patent No. 1169038 , the Composition of Matter patent covering dasatinib, the active ingredient in Sprycel."
BMY,BMY:US,BBG000DQLV23,Implied Volatility Surging for Bristol-Myers Squibb Co. (BMY) Stock Options,2017-02-01 15:36:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7_n7WIz7aHk/implied-volatility-surging-for-bristol-myers-squibb-co-bmy-stock-options-cm741495,Investors in Bristol Myers Squibb Company BMY need to pay close attention to the stock based on moves in the options market lately That is because the March 2nd 2017 42 50 Put had some of the highest implied volatility of all equity options today What is Implied Volatility
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Valuation Compared to Its Peers,2017-02-01 15:35:55 +0000,http://marketrealist.com/2017/01/bristol-myers-squibbs-valuation-compared-to-its-peers/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb’s Valuation Compared to Its Peers
BMY,BMY:US,BBG000DQLV23,Changes in Bristol-Myers Squibb’s 4Q16 Profitability,2017-02-01 14:06:20 +0000,http://marketrealist.com/2017/01/changes-in-bristol-myers-squibbs-4q16-profitability/?utm_source=yahoo&utm_medium=feed,Changes in Bristol-Myers Squibb’s 4Q16 Profitability
BMY,BMY:US,BBG000DQLV23,Implied Volatility Surging for Bristol-Myers Squibb Co. (BMY) Stock Options,2017-02-01 13:37:01 +0000,http://finance.yahoo.com/news/implied-volatility-surging-bristol-myers-133701019.html,Implied Volatility Surging for Bristol-Myers Squibb Co. (BMY) Stock Options
BMY,BMY:US,BBG000DQLV23,Imbruvica Expected to Drive AbbVie’s Revenue Growth,2017-02-01 12:38:06 +0000,http://marketrealist.com/2017/01/imbruvica-expected-drive-abbvies-revenue-growth-future-years/?utm_source=yahoo&utm_medium=feed,Imbruvica Expected to Drive AbbVie’s Revenue Growth
BMY,BMY:US,BBG000DQLV23,How Other Bristol-Myers Squibb Segments Are Doing,2017-02-01 12:36:29 +0000,http://marketrealist.com/2017/01/how-other-bristol-myers-squibb-segments-are-doing/?utm_source=yahoo&utm_medium=feed,How Other Bristol-Myers Squibb Segments Are Doing
BMY,BMY:US,BBG000DQLV23,Cramer warns pharma still not safe to own despite Trump’s...,2017-01-31 23:44:00 +0000,http://finance.yahoo.com/video/cramer-warns-pharma-still-not-234400420.html,Cramer warns pharma still not safe to own despite Trump’s...
BMY,BMY:US,BBG000DQLV23,Pfizer's 3 Fastest-Growing Drugs,2017-01-31 22:32:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QCId65D-kBM/pfizers-3-fastest-growing-drugs-cm741151,Pfizer Inc NYSE PFE is turning an important corner After years of declining sales due to patent expiration on its megablockbuster cholesterol drug Lipitor the company finally appears to be on a path back to reporting year over year growth Investments in mergers
BMY,BMY:US,BBG000DQLV23,Eliquis: Bristol-Myers Squibb’s Key Cardiovascular Drug,2017-01-31 15:36:51 +0000,http://marketrealist.com/2017/01/eliquis-bristol-myers-squibbs-key-cardiovascular-drug/?utm_source=yahoo&utm_medium=feed,Eliquis: Bristol-Myers Squibb’s Key Cardiovascular Drug
BMY,BMY:US,BBG000DQLV23,Merck Makes Nice With Bristol-Myers Squibb,2017-01-31 15:33:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pOagBzc_dM8/merck-makes-nice-with-bristol-myers-squibb-cm740726,After Bristol Myers Squibb NYSE BMY claimed Merck amp Co s NYSE MRK 160 cancer fighting Keytruda infringed upon patents protecting Opdivo Merck amp Co has agreed to pay Bristol Myers Squibb 625 million up front plus future royalties in exchange for a non
BMY,BMY:US,BBG000DQLV23,7 Top Stocks to Buy in February,2017-01-31 14:34:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QlAUDh3ms6w/7-top-stocks-to-buy-in-february-cm740653,With the Dow Jones Industrial Average 160 officially soaring above the 20 000 mark many investors are wondering if it s now too late to invest We Fools don t think it is so we asked a team of our top contributors to share some stocks they think can be safely purchased today Read
BMY,BMY:US,BBG000DQLV23,Merck Makes Nice With Bristol-Myers Squibb,2017-01-31 14:28:17 +0000,http://www.fool.com/investing/2017/01/31/merck-makes-nice-with-bristol-myers-squibb.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Merck Makes Nice With Bristol-Myers Squibb
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Virology Segment Is Facing Competition,2017-01-31 14:07:31 +0000,http://marketrealist.com/2017/01/bristol-myers-squibbs-virology-segment-is-facing-competition/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb’s Virology Segment Is Facing Competition
BMY,BMY:US,BBG000DQLV23,Opdivo: Bristol-Myers Squibb’s Blockbuster Oncology Drug,2017-01-31 12:37:56 +0000,http://marketrealist.com/2017/01/opdivo-bristol-myers-squibbs-blockbuster-oncology-drug/?utm_source=yahoo&utm_medium=feed,Opdivo: Bristol-Myers Squibb’s Blockbuster Oncology Drug
BMY,BMY:US,BBG000DQLV23,7 Top Stocks to Buy in February,2017-01-31 12:30:08 +0000,http://www.fool.com/investing/2017/01/31/7-top-stocks-to-buy-in-february.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,7 Top Stocks to Buy in February
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Strong Oncology Segment,2017-01-30 20:05:44 +0000,http://marketrealist.com/2017/01/bristol-myers-squibbs-strong-oncology-segment/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb’s Strong Oncology Segment
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Continued Growth in 4Q16,2017-01-30 18:35:57 +0000,http://marketrealist.com/2017/01/bristol-myers-squibb-continued-growth-in-4q16/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb Continued Growth in 4Q16
BMY,BMY:US,BBG000DQLV23,News! News! News! Here's What's Happened in Healthcare Last Week,2017-01-30 18:34:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6HjVjRzLAS8/news-news-news-heres-whats-happened-in-healthcare-last-week-cm740362,A big time patent settlement between Merck amp Co NYSE MRK and Bristol Myers Squibb NYSE BMY Johnson amp Johnson s NYSE JNJ fourth quarter earnings report and Aetna NYSE AET and Humana s NYSE HUM 37 billion merger bust were among the top stories
BMY,BMY:US,BBG000DQLV23,"UPRO, SBUX, BMY, TWX: ETF Outflow Alert",2017-01-30 17:34:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q1D5ezK3CUI/upro-sbux-bmy-twx-etf-outflow-alert-cm740253,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the ProShares UltraPro S amp P500 Symbol UPRO where we have detected an approximate 26 3 million dollar outflow that s a 3 4 decrease week over week
BMY,BMY:US,BBG000DQLV23,Assessing Bristol-Myers Post-Earnings Valuation,2017-01-30 17:15:00 +0000,http://www.investopedia.com/news/assessing-bristolmyers-postearnings-valuation-bmy-mrk/?partner=YahooSA,Assessing Bristol-Myers Post-Earnings Valuation
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb: 4Q16 Earnings Show Growth,2017-01-30 16:45:20 +0000,http://marketrealist.com/2017/01/bristol-myers-squibb-4q16-earnings-show-growth/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb: 4Q16 Earnings Show Growth
BMY,BMY:US,BBG000DQLV23,News! News! News! Here's What's Happened in Healthcare Last Week,2017-01-30 16:28:25 +0000,http://www.fool.com/investing/2017/01/30/news-news-news-heres-whats-happened-in-healthcare.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,News! News! News! Here's What's Happened in Healthcare Last Week
BMY,BMY:US,BBG000DQLV23,Gilead Sciences Plans to Focus on Its HCV Franchise in 2017,2017-01-30 15:36:44 +0000,http://marketrealist.com/2017/01/gilead-sciences-continues-focus-hcv-franchise-2017/?utm_source=yahoo&utm_medium=feed,Gilead Sciences Plans to Focus on Its HCV Franchise in 2017
BMY,BMY:US,BBG000DQLV23,What Are Analysts’ Future Estimates for Johnson & Johnson?,2017-01-30 15:35:59 +0000,http://marketrealist.com/2017/01/what-are-analysts-future-estimates-for-johnson-johnson/?utm_source=yahoo&utm_medium=feed,What Are Analysts’ Future Estimates for Johnson & Johnson?
BMY,BMY:US,BBG000DQLV23,3 Deeply Discounted Value Stocks on Sale This Winter,2017-01-30 15:34:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TSWlXcVvcmw/3-deeply-discounted-value-stocks-on-sale-this-winter-cm740101,Image source Getty Images The U S stock market has had its fair share of hiccups over the trailing 12 months but at the end of the day the scoreboard still reads green with the broad based S amp P 500 160 up better than 19 over the trailing year Unfortunately some
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. :BMY-US: Earnings Analysis: 2016 By the Numbers : January 30, 2017",2017-01-30 14:41:52 +0000,http://www.capitalcube.com/blog/index.php/bristol-myers-squibb-co-bmy-us-earnings-analysis-2016-by-the-numbers-january-30-2017/,"Bristol-Myers Squibb Co. :BMY-US: Earnings Analysis: 2016 By the Numbers : January 30, 2017"
BMY,BMY:US,BBG000DQLV23,3 Deeply Discounted Value Stocks on Sale This Winter,2017-01-30 13:36:07 +0000,http://www.fool.com/investing/2017/01/30/3-deeply-discounted-value-stocks-on-sale-this-wint.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Deeply Discounted Value Stocks on Sale This Winter
BMY,BMY:US,BBG000DQLV23,Drug Stocks Reporting Q4 Earnings on Jan 31: LLY and PFE,2017-01-30 13:33:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8OwP6JmTR8U/drug-stocks-reporting-q4-earnings-on-jan-31-lly-and-pfe-cm739957,As the Q4 earnings season picks up pace we believe this quarter is witnessing the highest growth momentum in the last eight quarters As of Jan 27 2017 170 S amp P 500 members accounting for 33 9 of the index s total market capitalization have reported results according to the
BMY,BMY:US,BBG000DQLV23,Here's the Best Dividend Stock in Big Pharma,2017-01-30 12:43:33 +0000,http://www.fool.com/investing/2017/01/29/heres-the-best-dividend-stock-in-big-pharma.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Here's the Best Dividend Stock in Big Pharma
BMY,BMY:US,BBG000DQLV23,Johnson & Johnson’s 4Q16 Earnings: Major Developments,2017-01-30 12:36:42 +0000,http://marketrealist.com/2017/01/johnson-johnsons-4q16-earnings-major-developments/?utm_source=yahoo&utm_medium=feed,Johnson & Johnson’s 4Q16 Earnings: Major Developments
BMY,BMY:US,BBG000DQLV23,Is Bristol-Meyers a Buy After 39% Price Decline?,2017-01-30 03:21:49 +0000,http://finance.yahoo.com/news/bristol-meyers-buy-39-price-023247708.html,Is Bristol-Meyers a Buy After 39% Price Decline?
BMY,BMY:US,BBG000DQLV23,Stocks Reach Their 3-Year Low Prices,2017-01-30 00:30:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LmN2sR9-Xvk/stocks-reach-their-3-year-low-prices-cm739915,Bristol Myers Squibb Company BMY reached 47 74 Bristol Myers Squibb Company BMY reached 47 74Bristol Myers Squibb Company BMY reached 47 74 The price of Bristol Myers Squibb Company shares have declined to 47 74 which is only 3 6 above the three year low
BMY,BMY:US,BBG000DQLV23,Here's the Best Dividend Stock in Big Pharma,2017-01-29 14:31:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lafqQ0VdCnY/heres-the-best-dividend-stock-in-big-pharma-cm739862,Many big pharma companies pay attractive dividends But which is the best big pharma dividend stock of all There s a strong case to be made that the distinction belongs to AbbVie NYSE ABBV Here s why Image source Getty Images Criteria What s the best way
BMY,BMY:US,BBG000DQLV23,Stocks Reach Their 3-Year Low Prices,2017-01-29 04:25:26 +0000,http://finance.yahoo.com/news/stocks-reach-3-low-prices-042526820.html,Stocks Reach Their 3-Year Low Prices
BMY,BMY:US,BBG000DQLV23,"[$$] Barron's Roundtable, Part 3: Digging Into the Details",2017-01-28 05:01:00 +0000,http://www.barrons.com/articles/barrons-2017-roundtable-part-3-17-picks-from-three-pros-1485582225?mod=yahoobarrons&ru=yahoo,"[$$] Barron's Roundtable, Part 3: Digging Into the Details"
BMY,BMY:US,BBG000DQLV23,2017 Small-Cap Biotech Watchlist: Takeaways for Investors,2017-01-27 22:33:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5-voNMzxd_8/2017-small-cap-biotech-watchlist-takeaways-for-investors-cm739688,Submitted by The Life Sciences Report as part of our contributors program Submitted bySubmitted by The Life Sciences ReportThe Life Sciences Report as part of ouras part of our contributorscontributors programprogram 2017 Small Cap Biotech Watchlist Takeaways
BMY,BMY:US,BBG000DQLV23,"Will Merck Let Incyte Go After AstraZeneca, Bristol, Roche Team-Ups Too?",2017-01-27 21:37:43 +0000,http://www.investors.com/news/technology/will-merck-let-incyte-go-after-astrazeneca-bristol-roche-team-ups-too/,"Will Merck Let Incyte Go After AstraZeneca, Bristol, Roche Team-Ups Too?"
BMY,BMY:US,BBG000DQLV23,3 Companies Putting the Squeeze on Bristol-Myers Squibb,2017-01-27 18:32:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b6lbWIuqhVU/3-companies-putting-the-squeeze-on-bristol-myers-squibb-cm739499,Most executives prefer to talk about their own companies instead of discussing rivals However Bristol Myers Squibb NYSE BMY CEO Giovanni Caforio and other officers spent a lot of time in the company s fourth quarter earnings call on Thursday talking about products made by
BMY,BMY:US,BBG000DQLV23,Sell Calls for Bristol-Myers to Limit Risk on Volatility,2017-01-27 18:07:00 +0000,https://www.thestreet.com/story/13969864/1/sell-calls-for-bristol-myers-to-limit-risk-on-volatility.html?puc=yahoo&cm_ven=YAHOO,Sell Calls for Bristol-Myers to Limit Risk on Volatility
BMY,BMY:US,BBG000DQLV23,Bristol-Myers: It's a 'Strategic Asset' Now,2017-01-27 17:25:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/01/27/bristol-myers-its-a-strategic-asset-now/?mod=yahoobarrons&ru=yahoo,Bristol-Myers: It's a 'Strategic Asset' Now
BMY,BMY:US,BBG000DQLV23,3 Companies Putting the Squeeze on Bristol-Myers Squibb,2017-01-27 17:13:24 +0000,http://www.fool.com/investing/2017/01/27/3-companies-putting-the-squeeze-on-bristol-myers-s.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Companies Putting the Squeeze on Bristol-Myers Squibb
BMY,BMY:US,BBG000DQLV23,"Stock Market News for January 27, 2017",2017-01-27 15:10:03 +0000,http://finance.yahoo.com/news/stock-market-news-january-27-151003453.html,"Stock Market News for January 27, 2017"
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint",2017-01-27 13:33:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kLuU7W2doGg/pharma-stock-roundup-jj-to-buy-actelion-bristol-myers-4q-results-disappoint-cm739155,Healthcare giant Johnson amp Johnson JNJ and Swiss company Actelion finally announced an agreement under which J amp J will acquire Actelion for about 30 billion Meanwhile companies like J amp J Read more J amp J Q4 Earnings Top Seeks Options for Diabetes Unit Novartis Read
BMY,BMY:US,BBG000DQLV23,Roche cancer drug taking bite out of Bristol's Opdivo,2017-01-27 11:08:22 +0000,http://finance.yahoo.com/news/roche-cancer-drug-taking-bite-110822821.html,Roche cancer drug taking bite out of Bristol's Opdivo
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint",2017-01-27 11:04:11 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-j-j-110411214.html,"Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint"
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Squibb: Make Lemonade From Lemons,2017-01-27 05:39:49 +0000,http://www.wsj.com/articles/bristol-myers-squibb-make-lemonade-from-lemons-1485449533?ru=yahoo?mod=yahoo_itp,[$$] Bristol-Myers Squibb: Make Lemonade From Lemons
BMY,BMY:US,BBG000DQLV23,"After Setback, Bristol-Myers Remains Committed to Developing Opdivo-Yervoy Combo",2017-01-26 23:18:00 +0000,https://www.thestreet.com/story/13967774/1/after-setback-bristol-myers-remains-committed-to-developing-opdivo-yervoy-combo.html?puc=yahoo&cm_ven=YAHOO,"After Setback, Bristol-Myers Remains Committed to Developing Opdivo-Yervoy Combo"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers (BMY) Misses on Q4 Earnings, Beats on Sales",2017-01-26 22:33:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D4IOHm32e_Y/bristol-myers-bmy-misses-on-q4-earnings-beats-on-sales-cm739045,Bristol Myers Squibb Company s BMY reported a mixed fourth quarter with earnings missing expectations while sales beating the same Shares declined around 2 in pre market trading In the past one year Bristol Myers share price was down 21 compared unfavorably with the 4 6
BMY,BMY:US,BBG000DQLV23,5 Things You Need to Know From Bristol-Myers Squibb's Q4 Update,2017-01-26 22:32:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_vyin68LjWQ/5-things-you-need-to-know-from-bristol-myers-squibbs-q4-update-cm738989,Bristol Myers Squibb NYSE BMY announced its fourth quarter and full year 2016 financial results before the market opened on Thursday The big drugmaker topped expectations in earlier quarters last year This time though Bristol Myers Squibb didn t report a positive surprise
BMY,BMY:US,BBG000DQLV23,"Noteworthy Thursday Option Activity: DKS, BMY, TSLA",2017-01-26 22:32:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7trZm2l0xq0/noteworthy-thursday-option-activity-dks-bmy-tsla-cm738999,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Dick s Sporting Goods Inc Symbol DKS where a total volume of 29 500 contracts has been traded thus far today a contract volume which is representative of approximately 3
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Topples On 2017 Guidance Cut Amid Merck I-O Competition,2017-01-26 21:57:37 +0000,http://www.investors.com/news/technology/bristol-myers-topples-on-2017-guidance-cut-amid-merck-i-o-competition/,Bristol-Myers Topples On 2017 Guidance Cut Amid Merck I-O Competition
BMY,BMY:US,BBG000DQLV23,Edited Transcript of BMY earnings conference call or presentation 26-Jan-17 3:30pm GMT,2017-01-26 21:55:50 +0000,http://finance.yahoo.com/news/edited-transcript-bmy-earnings-conference-215550899.html,Edited Transcript of BMY earnings conference call or presentation 26-Jan-17 3:30pm GMT
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Goes From Hunter to Target,2017-01-26 21:54:58 +0000,http://www.bloomberg.com/gadfly/articles/2017-01-26/bristol-myers-earnings-drugmaker-goes-from-hunter-to-target?cmpid=yhoo.headline,Bristol-Myers Goes From Hunter to Target
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Stock Falls on Q4 Earnings Miss,2017-01-26 21:32:00 +0000,http://www.investopedia.com/news/bristolmyers-stock-falls-q4-earnings-miss-bmy-mrk/?partner=YahooSA,Bristol-Myers Stock Falls on Q4 Earnings Miss
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Mattel Plunge into Thursday’s 52-Week Low Club",2017-01-26 21:04:55 +0000,http://finance.yahoo.com/news/bristol-myers-mattel-plunge-thursday-210455551.html,"Bristol-Myers, Mattel Plunge into Thursday’s 52-Week Low Club"
BMY,BMY:US,BBG000DQLV23,5 Things You Need to Know From Bristol-Myers Squibb's Q4 Update,2017-01-26 20:42:32 +0000,http://www.fool.com/investing/2017/01/26/5-things-you-need-to-know-from-bristol-myers-squib.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Things You Need to Know From Bristol-Myers Squibb's Q4 Update
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers (BMY) Misses on Q4 Earnings, Beats on Sales",2017-01-26 20:14:08 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-misses-q4-201408900.html,"Bristol-Myers (BMY) Misses on Q4 Earnings, Beats on Sales"
BMY,BMY:US,BBG000DQLV23,Dow Set for a Fresh Record as DuPont Provides a Bump,2017-01-26 19:31:00 +0000,https://www.thestreet.com/story/13968215/1/stocks-churn-as-wall-street-rally-runs-out-of-juice.html?puc=yahoo&cm_ven=YAHOO,Dow Set for a Fresh Record as DuPont Provides a Bump
BMY,BMY:US,BBG000DQLV23,Bristol-Myers cuts 2017 outlook amid Opdivo competition,2017-01-26 18:48:46 +0000,http://finance.yahoo.com/news/bristol-myers-cuts-2017-outlook-174730536.html,Bristol-Myers cuts 2017 outlook amid Opdivo competition
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Squibb Cuts Guidance on Cancer Drug Problems,2017-01-26 18:10:25 +0000,http://www.wsj.com/articles/bristol-myers-squibb-cuts-guidance-on-cancer-drug-problems-1485432039?mod=yahoo_hs,[$$] Bristol-Myers Squibb Cuts Guidance on Cancer Drug Problems
BMY,BMY:US,BBG000DQLV23,Manning & Napier's Top 3 New Holdings,2017-01-26 17:27:02 +0000,http://finance.yahoo.com/news/manning-napiers-top-3-holdings-172702735.html,Manning & Napier's Top 3 New Holdings
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Squibb: Make Lemonade From Lemons,2017-01-26 17:06:30 +0000,http://www.wsj.com/articles/bristol-myers-squibb-make-lemonade-from-lemons-1485449533?mod=yahoo_hs,[$$] Bristol-Myers Squibb: Make Lemonade From Lemons
BMY,BMY:US,BBG000DQLV23,Bristol-Myers: A Lot Not to Like,2017-01-26 16:39:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/01/26/bristol-myers-a-lot-not-to-like/?mod=yahoobarrons&ru=yahoo,Bristol-Myers: A Lot Not to Like
BMY,BMY:US,BBG000DQLV23,"The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb",2017-01-26 16:35:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rvepgBebphE/the-zacks-analyst-blog-highlights-johnson-johnson-biogen-celgene-and-bristol-myers-squibb-cm738687,For Immediate Release Chicago IL January 26 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BMY,BMY:US,BBG000DQLV23,Stocks Hold Mixed as Record-Breaking Rally Pauses,2017-01-26 16:29:00 +0000,https://www.thestreet.com/story/13967844/1/stocks-rise-as-indexes-trade-in-fresh-record-territory.html?puc=yahoo&cm_ven=YAHOO,Stocks Hold Mixed as Record-Breaking Rally Pauses
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Q4 Earnings Miss Estimates,2017-01-26 15:34:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sQ7ts0di2i4/bristol-myers-bmy-q4-earnings-miss-estimates-cm738588,New York based Bristol Myers Squibb Company BMY is a major producer and distributor of pharmaceuticals and other healthcare related products The company s key oncology products include Opdivo Sprycel Yervoy and the recently launched Empliciti Beyond oncology the company remains focused
BMY,BMY:US,BBG000DQLV23,52-Week Company Lows,2017-01-26 15:12:30 +0000,http://finance.yahoo.com/news/52-week-company-lows-151230921.html,52-Week Company Lows
BMY,BMY:US,BBG000DQLV23,"The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb",2017-01-26 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-johnson-143002915.html,"The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb"
BMY,BMY:US,BBG000DQLV23,What’s Driving Bristol-Myers Squibb’s Long-Term Growth?,2017-01-26 14:06:49 +0000,http://marketrealist.com/2017/01/diversification-strong-operating-model-may-drive-bristol-myers-squibbs-long-term-growth/?utm_source=yahoo&utm_medium=feed,What’s Driving Bristol-Myers Squibb’s Long-Term Growth?
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Just Took a Hatchet to Its Profit Outlook,2017-01-26 14:03:00 +0000,https://www.thestreet.com/story/13967450/1/bristol-myers-squibb-falls-as-it-cuts-2017-outlook.html?puc=yahoo&cm_ven=YAHOO,Bristol-Myers Squibb Just Took a Hatchet to Its Profit Outlook
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Q4 Earnings Miss Estimates,2017-01-26 13:52:01 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-q4-earnings-135201653.html,Bristol-Myers (BMY) Q4 Earnings Miss Estimates
BMY,BMY:US,BBG000DQLV23,"Pre-Market Most Active for Jan 26, 2017 :  MAT, FCAU, AVGR, YZC, VOD, F, ERIC, BMY, QQQ, BAC, USFD, EBAY",2017-01-26 13:51:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/83rH2MaI0Zw/pre-market-most-active-for-jan-26-2017-mat-fcau-avgr-yzc-vod-f-eric-bmy-qqq-bac-usfd-ebay-cm738528,The NASDAQ 100 Pre Market Indicator is up 6 18 to 5 157 65 The total Pre Market volume is currently 8 940 458 shares traded The following are the most active stocks for the pre market session Mattel Inc MAT is 4 46 at 27 10 with 770 984 shares traded As reported
BMY,BMY:US,BBG000DQLV23,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E",2017-01-26 13:36:28 +0000,http://biz.yahoo.com/e/170126/bmy8-k.html,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers misses 4Q profit forecasts,2017-01-26 12:55:44 +0000,http://sg.finance.yahoo.com/news/bristol-myers-misses-4q-profit-121847057.html,Bristol-Myers misses 4Q profit forecasts
BMY,BMY:US,BBG000DQLV23,Inside Bristol-Myers Squibb’s Core Immuno-Oncology Strategy,2017-01-26 12:37:38 +0000,http://marketrealist.com/2017/01/increased-focus-immuno-oncology-continues-core-strategy-bristol-myers-squibb-2017/?utm_source=yahoo&utm_medium=feed,Inside Bristol-Myers Squibb’s Core Immuno-Oncology Strategy
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb stock sinks 2.7% after fourth-quarter earnings miss and downbeat outlook,2017-01-26 12:19:21 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=C4A3CE19-3A04-44D7-A2BF-6963265E7831&siteid=yhoof2,Bristol-Myers Squibb stock sinks 2.7% after fourth-quarter earnings miss and downbeat outlook
BMY,BMY:US,BBG000DQLV23,Q4 2016 Bristol-Myers Squibb Co Earnings Release - Before Market Open,2017-01-26 12:07:07 +0000,http://biz.yahoo.com/research/earncal/20170126.html?t=bmy,Q4 2016 Bristol-Myers Squibb Co Earnings Release - Before Market Open
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Misses Estimates as Cancer, Virus Drug Sales Slow",2017-01-26 12:00:50 +0000,http://finance.yahoo.com/news/bristol-myers-misses-estimates-cancer-120050191.html,"Bristol-Myers Misses Estimates as Cancer, Virus Drug Sales Slow"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Misses Estimates as Cancer Drug’s Sales Slow,2017-01-26 12:00:50 +0000,http://www.bloomberg.com/news/articles/2017-01-26/bristol-myers-misses-estimates-as-cancer-virus-drug-sales-slow?cmpid=yhoo.headline,Bristol-Myers Misses Estimates as Cancer Drug’s Sales Slow
BMY,BMY:US,BBG000DQLV23,Bristol-Myers lowers 2017 earnings outlook,2017-01-26 12:00:00 +0000,http://finance.yahoo.com/news/bristol-myers-lowers-2017-earnings-120000747.html,Bristol-Myers lowers 2017 earnings outlook
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results,2017-01-26 11:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-reports-fourth-115900239.html,"[Business Wire] - Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2016, which were highlighted by strong sales for key products Opdivo and Eliquis, regulatory approvals for Opdivo in the U.S."
BMY,BMY:US,BBG000DQLV23,"Earnings Reaction History: Bristol Myers Squibb Co, 36.4% Follow-Through Indicator, 1.9% Sensitive",2017-01-26 11:31:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fc-bPY7L3o0/earnings-reaction-history-bristol-myers-squibb-co-364-follow-through-indicator-19-sensitive-cm738444,Expected Earnings Release 01 26 2017 PremarketExpected Earnings Release 01 26 2017 Premarket Avg Extended Hours Dollar Volume 5 201 928Avg Extended Hours Dollar Volume 5 201 928 Bristol Myers Squibb Co BMY is due to issue its quarterly earnings report in the upcoming extended
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Q4 16 Earnings Conference Call At 10:30 AM ET,2017-01-26 09:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C0ErC5n_WwA/bristolmyers-squibb-q4-16-earnings-conference-call-at-1030-am-et-20170126-00411,Bristol-Myers Squibb Q4 16 Earnings Conference Call At 10:30 AM ET
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Cuts FY17 Adj. EPS View Below Market - Quick Facts,2017-01-26 07:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TNvUs5LhYdg/bristolmyers-squibb-cuts-fy17-adj-eps-view-below-market--quick-facts-20170126-00458,Bristol-Myers Squibb Cuts FY17 Adj. EPS View Below Market - Quick Facts
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Co. Bottom Line Advances 64% In Q4,2017-01-26 07:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rMS8RFQ3SFI/bristolmyers-squibb-co-bottom-line-advances-64-in-q4-20170126-00417,Bristol-Myers Squibb Co. Bottom Line Advances 64% In Q4
BMY,BMY:US,BBG000DQLV23,European Shares Seen Higher At Open,2017-01-26 01:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O3ER5p_ip8U/european-shares-seen-higher-at-open-20170126-00035,European Shares Seen Higher At Open
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Gears Up for Earnings as Activist Investor Looms,2017-01-25 21:24:00 +0000,https://www.thestreet.com/story/13966732/1/bristol-myers-gears-up-for-earnings-as-activist-investor-looms.html?puc=yahoo&cm_ven=YAHOO,Bristol-Myers Gears Up for Earnings as Activist Investor Looms
BMY,BMY:US,BBG000DQLV23,"Pre-Market Earnings Report for January 26, 2017 :  CMCSA, CELG, BMY, DOW, BIIB, CAT, F, RTN, NOC, PX, AEP, LUV",2017-01-25 21:20:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8eFr0qivFZo/pre-market-earnings-report-for-january-26-2017-cmcsa-celg-bmy-dow-biib-cat-f-rtn-noc-px-aep-luv-cm738325,The following companies are expected to report earnings prior to market open on 01 26 2017 Visit our Earnings Calendar for a full list of expected earnings releases Comcast Corporation CMCSA is reporting for the quarter ending December 31 2016 The cable
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, DryShips Drop into Wednesday’s 52-Week Low Club",2017-01-25 21:04:19 +0000,http://finance.yahoo.com/news/bristol-myers-dryships-drop-wednesday-210419539.html,"Bristol-Myers, DryShips Drop into Wednesday’s 52-Week Low Club"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Profitability: Can Eliquis Do the Job in 2017?,2017-01-25 20:05:56 +0000,http://marketrealist.com/2017/01/oral-anticoagulant-eliquis-may-boost-bristol-myers-squibbs-profitability-2017/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb’s Profitability: Can Eliquis Do the Job in 2017?
BMY,BMY:US,BBG000DQLV23,Which Pharma Players Dominate The Lung Cancer Space?,2017-01-25 19:40:35 +0000,http://finance.yahoo.com/news/pharma-players-dominate-lung-cancer-194035343.html,Which Pharma Players Dominate The Lung Cancer Space?
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s 2017 Depends on This Portfolio,2017-01-25 18:35:55 +0000,http://marketrealist.com/2017/01/immuno-oncology-portfolio-continues-drive-bristol-myers-squibbs-performance-2017/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb’s 2017 Depends on This Portfolio
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb May Report Strong Revenue Performance for 2017,2017-01-25 16:51:15 +0000,http://marketrealist.com/2017/01/bristol-myers-squibb-may-report-strong-revenue-performance-2017/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb May Report Strong Revenue Performance for 2017
BMY,BMY:US,BBG000DQLV23,"Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY",2017-01-25 16:37:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iKm14iqHKm8/drug-stock-earnings-to-watch-on-jan-26-biib-celg-bmy-cm738039,Investors around the world are seeing a ray of hope as the fourth quarter earnings season kicked off on an encouraging note Both earnings and sales growth in Q4 are tracking above other recent periods and on track to reach the highest level in the last eight quarters With Q4
BMY,BMY:US,BBG000DQLV23,What to Expect From Major Health Care Stocks Reporting This Week,2017-01-25 16:25:15 +0000,http://finance.yahoo.com/news/expect-major-health-care-stocks-162515341.html,What to Expect From Major Health Care Stocks Reporting This Week
BMY,BMY:US,BBG000DQLV23,"Dow Closes Above 20,000 Amid Broad Based Strength - U.S. Commentary",2017-01-25 16:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y1upzy8dl5I/dow-closes-above-20000-amid-broad-based-strength--us-commentary-20170125-01236,"Dow Closes Above 20,000 Amid Broad Based Strength - U.S. Commentary"
BMY,BMY:US,BBG000DQLV23,"Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY",2017-01-25 14:08:02 +0000,http://finance.yahoo.com/news/drug-stock-earnings-watch-jan-140802252.html,"Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY"
BMY,BMY:US,BBG000DQLV23,Analyzing Bristol-Myers Squibb’s Other Segments in 4Q16,2017-01-25 14:06:35 +0000,http://marketrealist.com/2017/01/analyzing-bristol-myers-squibbs-other-segments-in-4q16/?utm_source=yahoo&utm_medium=feed,Analyzing Bristol-Myers Squibb’s Other Segments in 4Q16
BMY,BMY:US,BBG000DQLV23,How Did 4Q16 Treat Bristol-Myers Squibb’s Virology Segment?,2017-01-25 12:36:52 +0000,http://marketrealist.com/2017/01/how-did-4q16-treat-bristol-myers-squibbs-virology-segment/?utm_source=yahoo&utm_medium=feed,How Did 4Q16 Treat Bristol-Myers Squibb’s Virology Segment?
BMY,BMY:US,BBG000DQLV23,Roche Gouges Bristol-Myers' Q4 Lung Cancer Share Amid Merck Rivalry,2017-01-24 22:07:47 +0000,http://www.investors.com/news/technology/roche-gouges-bristol-myers-q4-lung-cancer-share-amid-merck-rivalry/,Roche Gouges Bristol-Myers' Q4 Lung Cancer Share Amid Merck Rivalry
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Earnings Preview: The Company Has To Reassure Investors,2017-01-24 22:01:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5Yeem7hJcgk/bristol-myers-squibb-earnings-preview-the-company-has-to-reassure-investors-cm737667,Bristol Myers Squibb 160 BMY will report its Q4 2016 and full year results on January 26th We expect strong performance from key drugs including Opdivo and Eliquis On the other hand Yervoy s sales are likely to decline and Hepatitis C franchise may feel the impact of growing
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co (BMY) To Share In Sales Of Merck & Co., Inc. (MRK) Keytruda Following Litigation Settlement",2017-01-24 17:32:02 +0000,http://www.insidermonkey.com/blog/bristol-myers-squibb-co-bmy-to-share-in-sales-of-merck-co-inc-mrk-keytruda-following-litigation-settlement-523250/,"Bristol-Myers Squibb Co (BMY) To Share In Sales Of Merck & Co., Inc. (MRK) Keytruda Following Litigation Settlement"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers: 'We See Increased Execution Risks',2017-01-24 17:00:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/01/24/bristol-myers-we-see-increased-execution-risks/?mod=yahoobarrons&ru=yahoo,Bristol-Myers: 'We See Increased Execution Risks'
BMY,BMY:US,BBG000DQLV23,How Bristol-Myers Squibb’s Oncology Drug Performed in 4Q16,2017-01-24 15:38:19 +0000,http://marketrealist.com/2017/01/how-bristol-myers-squibbs-oncology-drug-performed-in-4q16/?utm_source=yahoo&utm_medium=feed,How Bristol-Myers Squibb’s Oncology Drug Performed in 4Q16
BMY,BMY:US,BBG000DQLV23,Is It Finally OK to Buy Bristol-Myers Squibb?,2017-01-24 14:32:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uOkMIkQUev0/is-it-finally-ok-to-buy-bristol-myers-squibb-cm737156,After reporting disappointing news for its immunotherapy cancer drug Opdivo in lung cancer Bristol Myers Squibb s NYSE BMY shares have lost one third of their value Are they a bargain basement buy 160 Read on to learn more about the challenges and the opportunities facing
BMY,BMY:US,BBG000DQLV23,Exploring Bristol-Myers Squibb’s Oncology Segment in 4Q16,2017-01-24 14:07:16 +0000,http://marketrealist.com/2017/01/exploring-bristol-myers-squibbs-oncology-segment-in-4q16/?utm_source=yahoo&utm_medium=feed,Exploring Bristol-Myers Squibb’s Oncology Segment in 4Q16
BMY,BMY:US,BBG000DQLV23,Is It Finally OK to Buy Bristol-Myers Squibb?,2017-01-24 13:21:06 +0000,http://www.fool.com/investing/2017/01/24/is-it-finally-ok-to-buy-bristol-myers-squibb.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is It Finally OK to Buy Bristol-Myers Squibb?
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s 4Q16 Estimates: Expect Growth!,2017-01-24 12:38:33 +0000,http://marketrealist.com/2017/01/bristol-myers-squibbs-4q16-estimates-expect-growth/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb’s 4Q16 Estimates: Expect Growth!
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Settles Litigation with Merck for Keytruda,2017-01-24 00:31:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6vceqr6iQp4/bristol-myers-settles-litigation-with-merck-for-keytruda-cm737059,Bristol Myers Squibb Company BMY along with partner Ono Pharmaceutical Company Ltd announced that both the companies have signed a global patent license agreement with Merck amp Co Inc MRK to settle all patent infringement litigation related to Merck s anti PD 1 therapy Keytruda
BMY,BMY:US,BBG000DQLV23,Gilead (GILD) HCV Therapy Application Validated in Europe,2017-01-24 00:31:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LHRkN9bEDU4/gilead-gild-hcv-therapy-application-validated-in-europe-cm737057,Gilead Sciences Inc GILD announced that its Marketing Authorization Application MAA for 160 experimental direct acting antiviral DAA of once daily single tablet regimen STR of Sovaldi velpatasvir 100 mg and voxilaprevir 100 mg SOF VEL VOX for the treatment of chronic hepatitis
BMY,BMY:US,BBG000DQLV23,Bristol-Myers a takeout target?: 4 plays,2017-01-24 00:21:23 +0000,http://www.cnbc.com/id/104235786?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104235786,Bristol-Myers a takeout target?: 4 plays
BMY,BMY:US,BBG000DQLV23,Gilead (GILD) HCV Therapy Application Validated in Europe,2017-01-23 22:26:10 +0000,http://finance.yahoo.com/news/gilead-gild-hcv-therapy-application-222610318.html,Gilead (GILD) HCV Therapy Application Validated in Europe
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Settles Litigation with Merck for Keytruda,2017-01-23 22:22:10 +0000,http://finance.yahoo.com/news/bristol-myers-settles-litigation-merck-222210153.html,Bristol-Myers Settles Litigation with Merck for Keytruda
BMY,BMY:US,BBG000DQLV23,Bristol Myers a takeout target?,2017-01-23 22:18:00 +0000,http://finance.yahoo.com/video/bristol-myers-takeout-target-221800699.html,Bristol Myers a takeout target?
BMY,BMY:US,BBG000DQLV23,Bristol-Myers a takeout target? 4 trades,2017-01-23 22:00:00 +0000,http://finance.yahoo.com/video/bristol-myers-takeout-target-4-220000376.html,Bristol-Myers a takeout target? 4 trades
BMY,BMY:US,BBG000DQLV23,What’s Expected from Bristol-Myers Squibb’s 4Q16 Earnings?,2017-01-23 21:40:22 +0000,http://marketrealist.com/2017/01/whats-expected-from-bristol-myers-squibbs-4q16-earnings/?utm_source=yahoo&utm_medium=feed,What’s Expected from Bristol-Myers Squibb’s 4Q16 Earnings?
BMY,BMY:US,BBG000DQLV23,Could Merck's 'Meaningful' Keytruda Royalty Give Bristol-Myers A Leg Up?,2017-01-23 21:21:12 +0000,http://www.investors.com/news/technology/could-mercks-meaningful-keytruda-royalty-give-bristol-myers-a-leg-up/,Could Merck's 'Meaningful' Keytruda Royalty Give Bristol-Myers A Leg Up?
BMY,BMY:US,BBG000DQLV23,Here's the Price Where Fallen Angel Bristol-Myers Becomes an Attractive Takeover Target,2017-01-23 20:04:00 +0000,https://www.thestreet.com/story/13962537/1/bristol-myers-squibb-reiterated-buy-at-jefferies-analysts-respond.html?puc=yahoo&cm_ven=YAHOO,Here's the Price Where Fallen Angel Bristol-Myers Becomes an Attractive Takeover Target
BMY,BMY:US,BBG000DQLV23,Can Q4 Earnings Revitalize Healthcare ETFs?,2017-01-23 18:31:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CzcaOx8F4AI/can-q4-earnings-revitalize-healthcare-etfs-cm736826,The healthcare sector has long been a victim of concerns over increased regulatory scrutiny related to high drug prices While the worries cooled down after Trump s victory the biotech and pharma stocks were again troubled by the President s non friendly plan to lower drug prices read
BMY,BMY:US,BBG000DQLV23,What’s New with Johnson & Johnson?,2017-01-23 15:36:07 +0000,http://marketrealist.com/2017/01/whats-new-with-johnson-johnson/?utm_source=yahoo&utm_medium=feed,What’s New with Johnson & Johnson?
BMY,BMY:US,BBG000DQLV23,[video]Is It Time to Buy Beaten-Down Bristol-Myers Squibb Stock?,2017-01-23 13:07:00 +0000,https://www.thestreet.com/story/13961414/1/is-it-time-to-buy-beaten-down-bristol-myers-squibb-stock.html?puc=yahoo&cm_ven=YAHOO,[video]Is It Time to Buy Beaten-Down Bristol-Myers Squibb Stock?
BMY,BMY:US,BBG000DQLV23,"Why Rite Aid, Bristol-Myers Squibb, and TransDigm Group Slumped Today",2017-01-21 01:36:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vy4ZPleZ24k/why-rite-aid-bristol-myers-squibb-and-transdigm-group-slumped-today-cm736297,Friday was a positive day for the stock market The Dow Jones Industrials climbed by 95 points and there were similarly modest advances for the S amp P 500 and Nasdaq Composite The inauguration of the 45th president of the U S commanded the attention of many both on and off Wall
BMY,BMY:US,BBG000DQLV23,"Why Rite Aid, Bristol-Myers Squibb, and TransDigm Group Slumped Today",2017-01-20 23:52:00 +0000,http://www.fool.com/investing/2017/01/20/why-rite-aid-bristol-myers-squibb-and-transdigm-gr.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,"Why Rite Aid, Bristol-Myers Squibb, and TransDigm Group Slumped Today"
BMY,BMY:US,BBG000DQLV23,The Biggest Loser: Bristol-Myers Sinks 11%,2017-01-20 22:09:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/01/20/the-biggest-loser-bristol-myers-sinks-11/?mod=yahoobarrons&ru=yahoo,The Biggest Loser: Bristol-Myers Sinks 11%
BMY,BMY:US,BBG000DQLV23,"[$$] Merck Settles With Bristol-Meyers, Ono Over Cancer-Drug Patent",2017-01-20 21:55:01 +0000,http://www.wsj.com/articles/merck-settles-with-bristol-meyers-ono-over-cancer-drug-patent-1484948847?mod=yahoo_hs,"[$$] Merck Settles With Bristol-Meyers, Ono Over Cancer-Drug Patent"
BMY,BMY:US,BBG000DQLV23,"Biggest stock winners (including a fracking company) and losers on Donald Trump’s first day; Dow, S&P 500, Nasdaq all up",2017-01-20 21:54:57 +0000,http://www.bizjournals.com/phoenix/news/2017/01/20/biggest-stock-winners-including-a-fracking-company.html?ana=yahoo,"Biggest stock winners (including a fracking company) and losers on Donald Trump’s first day; Dow, S&P 500, Nasdaq all up"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers lung cancer delay slams shares, keeps Merck in lead",2017-01-20 21:53:18 +0000,http://finance.yahoo.com/news/bristol-myers-shares-fall-lung-171405197.html,"Bristol-Myers lung cancer delay slams shares, keeps Merck in lead"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers lung cancer delay slams shares, keeps Merck in lead",2017-01-20 21:52:10 +0000,http://uk.finance.yahoo.com/news/bristol-myers-lung-cancer-delay-215210382.html,"Bristol-Myers lung cancer delay slams shares, keeps Merck in lead"
BMY,BMY:US,BBG000DQLV23,Jim Cramer on Bristol-Myers' Opdivo/Yervoy Combo: 'That Story Was Taken Away From Us',2017-01-20 21:29:00 +0000,https://www.thestreet.com/story/13960960/1/jim-cramer-on-bristol-myers-opdivo-yervoy-combo-that-story-was-taken-away-from-us.html?puc=yahoo&cm_ven=YAHOO,Jim Cramer on Bristol-Myers' Opdivo/Yervoy Combo: 'That Story Was Taken Away From Us'
BMY,BMY:US,BBG000DQLV23,"Merck, Bristol-Myers agree to settle Keytruda patent suit",2017-01-20 21:23:47 +0000,http://finance.yahoo.com/news/merck-bristol-myers-agree-settle-212347549.html,"Merck, Bristol-Myers agree to settle Keytruda patent suit"
BMY,BMY:US,BBG000DQLV23,Merck will pay $625 million and royalties to settle Keytruda patent litigation with Bristol-Myers Squibb and Ono Pharma,2017-01-20 21:16:39 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=7F0FF6D0-00A1-44BF-908D-E789FF6C678D&siteid=yhoof2,Merck will pay $625 million and royalties to settle Keytruda patent litigation with Bristol-Myers Squibb and Ono Pharma
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Dives On Opdivo Setback, Will Get Keytruda Royalties",2017-01-20 21:15:17 +0000,http://www.investors.com/news/technology/bristol-myers-wont-seek-accelerated-opdivo-lung-cancer-ok/,"Bristol-Myers Dives On Opdivo Setback, Will Get Keytruda Royalties"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Target Sink into Friday’s 52-Week Low Club",2017-01-20 21:04:11 +0000,http://finance.yahoo.com/news/bristol-myers-target-sink-friday-210411944.html,"Bristol-Myers, Target Sink into Friday’s 52-Week Low Club"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and License Agreement with Merck to Resolve PD-1 Antibody Patent Litigation,2017-01-20 21:01:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-ono-pharmaceutical-210100587.html,"[Business Wire] - Bristol-Myers Squibb Company and Ono Pharmaceutical Company, Ltd. today announced the companies have signed a global patent license agreement with Merck & Co., Inc. to settle all patent-infringement litigation related to Merck’s PD-1 antibody Keytruda ."
BMY,BMY:US,BBG000DQLV23,"Why Merck & Co., Inc. (MRK) Stock Is Higher Today",2017-01-20 20:38:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LmlKx1Wq3sY/why-merck-co-inc-mrk-stock-is-higher-today-cm736195,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Merck amp Co Inc NYSE MRK stock is surging Friday as 160 a major competitor fell a step behind the pharmaceutical company Bristol Myers Squibb
BMY,BMY:US,BBG000DQLV23,Dow Industrials Take Lead As Trump Sworn In; Nvidia Sits Out Chip Rally,2017-01-20 20:23:48 +0000,http://www.investors.com/market-trend/stock-market-today/dow-industrials-take-lead-as-trump-sworn-in-nvidia-sits-out-chip-rally/,Dow Industrials Take Lead As Trump Sworn In; Nvidia Sits Out Chip Rally
BMY,BMY:US,BBG000DQLV23,Why Bristol-Myers Squibb Co Stock Is Slipping Today,2017-01-20 19:38:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MeZKm4wCgQo/why-bristol-myers-squibb-co-stock-is-slipping-today-cm736154,Image source Getty Images What happened Shares of Bristol Myers Squibb Co NYSE BMY a big pharma company trying to pivot toward oncology have fallen about 9 8 as of 11 50 a m EST Friday An announcement that it won t seek accelerated approval for a combination lung
BMY,BMY:US,BBG000DQLV23,Bristol's Opdivo Dependence Now Looks Dicey,2017-01-20 19:01:13 +0000,http://www.bloomberg.com/gadfly/articles/2017-01-20/bristol-opdivo-yervoy-lung-cancer-decision-risks-are-growing?cmpid=yhoo.headline,Bristol's Opdivo Dependence Now Looks Dicey
BMY,BMY:US,BBG000DQLV23,Stocks Fall Off Highs; Trump Sworn In As President,2017-01-20 18:31:48 +0000,http://www.investors.com/market-trend/stock-market-today/market-reverses-from-highs-as-donald-trump-sworn-in-as-president/,Stocks Fall Off Highs; Trump Sworn In As President
BMY,BMY:US,BBG000DQLV23,Mid-Day Market Update: Crude Oil Up 2.8%; Bristol-Myers Squibb Shares Slide After Opdivo Decision,2017-01-20 18:17:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xnrpjRnANNc/mid-day-market-update-crude-oil-up-28-bristol-myers-squibb-shares-slide-after-opdivo-decision-cm736135,Midway through trading Friday the Dow traded up 0 44 percent to 19 818 98 while the NASDAQ climbed 0 33 percent to 5 558 31 The S amp P also rose gaining 0 40 percent to 2 272 77 Leading and Lagging Sectors Non cyclical consumer goods amp services shares gained around 1 02
BMY,BMY:US,BBG000DQLV23,Why Bristol-Myers Squibb Co Stock Is Slipping Today,2017-01-20 17:51:39 +0000,http://www.fool.com/investing/2017/01/20/why-bristol-myers-squibb-co-stock-is-slipping-toda.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Bristol-Myers Squibb Co Stock Is Slipping Today
BMY,BMY:US,BBG000DQLV23,Go Long Bristol-Myers Squibb Co (BMY) Stock for Panic Profits!,2017-01-20 17:39:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q6QNgvIqG3Q/go-long-bristol-myers-squibb-co-bmy-stock-for-panic-profits-cm736127,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Last year was not friendly to pharmaceutical stocks This was evident as the iShares NASDAQ Biotechnology Index ETF NASDAQ IBB was a political rag doll that resulted
BMY,BMY:US,BBG000DQLV23,"ITOT, INTC, WMT, BMY: Large Inflows Detected at ETF",2017-01-20 17:38:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IJBYCqEKLRM/itot-intc-wmt-bmy-large-inflows-detected-at-etf-cm736075,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Core S amp P Total U S Stock Market ETF Symbol ITOT where we have detected an approximate 62 2 million dollar inflow that s a 1 0 increase week
BMY,BMY:US,BBG000DQLV23,Bristol-Myers shares drop after company says it will not seek fast-track drug approval,2017-01-20 17:32:22 +0000,http://www.cnbc.com/id/104231244?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104231244,Bristol-Myers shares drop after company says it will not seek fast-track drug approval
BMY,BMY:US,BBG000DQLV23,Bristol-Myers shares fall on lung cancer timeline setback,2017-01-20 17:20:45 +0000,http://sg.finance.yahoo.com/news/bristol-myers-shares-fall-lung-172045617.html,Bristol-Myers shares fall on lung cancer timeline setback
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb: There Goes Any Chance for Upside,2017-01-20 17:14:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/01/20/bristol-myers-squibb-there-goes-any-chance-for-upside/?mod=yahoobarrons&ru=yahoo,Bristol-Myers Squibb: There Goes Any Chance for Upside
BMY,BMY:US,BBG000DQLV23,"Ready to Trade Bristol-Myers Squibb, Bank of America, CSX? Here's What to Know",2017-01-20 16:48:00 +0000,https://www.thestreet.com/story/13960715/1/ready-to-trade-bristol-myers-squibb-bank-of-america-csx-here-s-what-to-know.html?puc=yahoo&cm_ven=YAHOO,"Ready to Trade Bristol-Myers Squibb, Bank of America, CSX? Here's What to Know"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy,2017-01-20 16:41:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qswLJbrlDck/bristol-myers-to-not-seek-accelerated-approval-for-opdivoyervoy-cm736031,Shares of Bristol Myers Squibb Company BMY fell 5 in afterhours trading on Jan 19 after the company disclosed that it will not seek an accelerated approval in the U S for a combination of its two immuno oncology treatments Opdivo plus Yervoy for first line lung cancer The company said
BMY,BMY:US,BBG000DQLV23,"S&P 500 Movers: BMY, SWKS",2017-01-20 16:39:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9WGzrrBhyfE/sp-500-movers-bmy-swks-cm735994,In early trading on Friday shares of Skyworks Solutions SWKS topped the list of the day s best performing components of the S amp P 500 index trading up 12 6 Year to date Skyworks Solutions registers a 18 3 gain And the worst performing S amp P 500 component thus far on the day
BMY,BMY:US,BBG000DQLV23,Nektar Therapeutics: An Undervalued Biopharmaceuticals Company With Plenty In The Pipeline,2017-01-20 16:38:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AedYyFhCAB4/nektar-therapeutics-an-undervalued-biopharmaceuticals-company-with-plenty-in-the-pipeline-cm736083,By Robert Lowy ByRobert Lowy Nektar Therapeutics Company Analysis and Recommendation Nektar Therapeutics Company Analysis and RecommendationNektar Therapeutics Company Analysis and Recommendation Date 01 17 2017 Date 01 17 201701 17 2017 Ticker
BMY,BMY:US,BBG000DQLV23,Mid-Morning Market Update: Markets Open Higher; General Electric Revenue Misses Views,2017-01-20 16:17:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s6rgAsMEsWI/mid-morning-market-update-markets-open-higher-general-electric-revenue-misses-views-cm736045,Following the market opening Friday the Dow traded up 0 42 percent to 19 814 86 while the NASDAQ climbed 0 55 percent to 5 570 54 The S amp P also rose gaining 0 50 percent to 2 275 00 Leading and Lagging Sectors Non cyclical consumer goods amp services shares gained around 1
BMY,BMY:US,BBG000DQLV23,Bristol-Myers’ tight-lipped pass on accelerated lung cancer drug approval leaves field wide open for Merck,2017-01-20 16:11:49 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=C726997C-DF16-11E6-AA31-16C7E0E52394&siteid=yhoof2,Bristol-Myers’ tight-lipped pass on accelerated lung cancer drug approval leaves field wide open for Merck
BMY,BMY:US,BBG000DQLV23,Stocks Up Nicely In Early Trade; Apple Shrugs Off China Trade Talk,2017-01-20 15:29:09 +0000,http://www.investors.com/market-trend/stock-market-today/stocks-up-nicely-in-early-trade-apple-shrugs-off-china-trade-talk/,Stocks Up Nicely In Early Trade; Apple Shrugs Off China Trade Talk
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers shares slide on immunotherapy setback,2017-01-20 15:17:11 +0000,"http://www.ft.com/cms/s/d79882c2-df19-11e6-9d7c-be108f1c1dce,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Bristol-Myers Squibb dashed hopes that it would quickly regain its lead in the fiercely-contested race to develop a new generation of immunotherapy cancer medicines, sending shares in the drugmaker down ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Remains Firmly Negative After Initial Decline,2017-01-20 14:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LzQf0wpYJ1M/bristolmyers-squibb-remains-firmly-negative-after-initial-decline-20170120-00737,Bristol-Myers Squibb Remains Firmly Negative After Initial Decline
BMY,BMY:US,BBG000DQLV23,Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy,2017-01-20 14:24:02 +0000,http://finance.yahoo.com/news/bristol-myers-not-seek-accelerated-142402703.html,Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy
BMY,BMY:US,BBG000DQLV23,Stock market set to take tepid step higher as Trump’s inauguration looms,2017-01-20 14:04:02 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=176DDA98-DEF0-11E6-AA31-16C7E0E52394&siteid=yhoof2,Stock market set to take tepid step higher as Trump’s inauguration looms
BMY,BMY:US,BBG000DQLV23,"Pre-Market Most Active for Jan 20, 2017 :  BMY, SGYP, PG, GE, BAC, MRK, FTI, QQQ, TVIX, AFAM, CSX, VOD",2017-01-20 13:57:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x5Sl5MY-LSw/pre-market-most-active-for-jan-20-2017-bmy-sgyp-pg-ge-bac-mrk-fti-qqq-tvix-afam-csx-vod-cm735871,The NASDAQ 100 Pre Market Indicator is up 8 69 to 5 059 86 The total Pre Market volume is currently 5 865 611 shares traded The following are the most active stocks for the pre market session Bristol Myers Squibb Company BMY is 4 06 at 51 43 with 1 661 206
BMY,BMY:US,BBG000DQLV23,Setback for Bristol-Myers on Lung Cancer Treatment Drugs,2017-01-20 13:55:00 +0000,http://www.thestreet.com/video/13960412/setback-for-bristol-myers-on-lung-cancer-treatment-drugs.html?puc=yahoov&cm_ven=YAHOOV,Setback for Bristol-Myers on Lung Cancer Treatment Drugs
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly",2017-01-20 13:17:00 +0000,https://www.thestreet.com/story/13960391/1/bristol-myers-squibb-where-art-thou-not-in-first-line-lung-cancer-immunotherapy-sadly.html?puc=yahoo&cm_ven=YAHOO,"Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb stock sinks 7.2% after it says it won't pursue accelerated approval for lung cancer combination treatment,2017-01-20 12:48:12 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=F99D667D-F6B2-4992-97E3-0BFC1DCA2BA5&siteid=yhoof2,Bristol-Myers Squibb stock sinks 7.2% after it says it won't pursue accelerated approval for lung cancer combination treatment
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb (BMY) Is Sinking After Opdivo Decision,2017-01-20 09:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JyVtPVShGWk/bristolmyers-squibb-bmy-is-sinking-after-opdivo-decision-20170120-00484,Bristol-Myers Squibb (BMY) Is Sinking After Opdivo Decision
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Falls Further Behind Merck in Lung Cancer Race,2017-01-20 00:33:41 +0000,http://www.bloomberg.com/news/articles/2017-01-20/bristol-myers-falls-further-behind-merck-in-lung-cancer-race?cmpid=yhoo.headline,Bristol-Myers Falls Further Behind Merck in Lung Cancer Race
BMY,BMY:US,BBG000DQLV23,Bristol-Myers won't seek accelerated Opdivo lung cancer approval,2017-01-19 23:49:22 +0000,http://finance.yahoo.com/news/bristol-myers-wont-seek-accelerated-234922692.html,"[Reuters] - Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for its combination of two immunotherapy drugs as an initial treatment for lung cancer. Bristol cited ""a review of data available at this time"" for the decision to hold off on filing for approval of the combination of its cancer drugs Opdivo and Yervoy. Merck last week said U.S. regulators had agreed to an accelerated review of its application to combine immune system-boosting drug Keytruda with chemotherapy as an initial therapy for advanced lung cancer."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer,2017-01-19 23:30:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-provides-regulatory-233000138.html,[Business Wire] - Bristol-Myers Squibb Company announced today that it has decided not to pursue an accelerated regulatory pathway for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S.
BMY,BMY:US,BBG000DQLV23,U.S. top court to hear Bristol-Myers out-of-state injury appeal,2017-01-19 20:08:13 +0000,http://finance.yahoo.com/news/u-top-court-hear-bristol-200813230.html,"[Reuters] - The U.S. Supreme Court on Thursday agreed to hear an appeal by pharmaceutical company Bristol-Myers Squibb Co in a dispute involving its blood-thinning medication Plavix that could limit where corporations can be sued, the second such case it has taken up in the past week. The justices will review a California Supreme Court decision allowing that state's courts to hear claims over Plavix even though the plaintiffs did not live in the state and the company is not based there. Last Friday, the justices said they would decide a similar appeal by Texas-based BNSF Railway Co of a 2015 Montana Supreme Court ruling allowing out-of-state residents to sue there over injuries that occurred anywhere in BNSF's nationwide network."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?,2017-01-19 15:41:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aC3UeT0E4C8/bristol-myers-bmy-q4-earnings-will-the-stock-disappoint-cm735331,Bristol Myers Squibb Company BMY is scheduled to report fourth quarter 2016 results on Jan 26 before the opening bell Last quarter the company posted a positive earnings surprise of 18 46 Bristol Myers has underperformed the Zacks classified Large Cap Pharmaceuticals industry in the
BMY,BMY:US,BBG000DQLV23,Opdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study,2017-01-19 14:00:00 +0000,http://finance.yahoo.com/news/opdivo-nivolumab-demonstrated-efficacy-improved-140000705.html,"[Business Wire] - Bristol-Myers Squibb Company announced today the results of ONO-4538-12 demonstrating Opdivo significantly reduced the risk of death by 37% in patients with previously treated advanced gastric cancer refractory to or intolerant of standard therapy, a condition without current standard-of-care treatments."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?,2017-01-19 13:39:01 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-q4-earnings-133901520.html,Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?
BMY,BMY:US,BBG000DQLV23,"The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway",2017-01-18 16:41:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7hpqY5f35Xg/the-zacks-analyst-blog-highlights-microsoft-biogen-home-depot-bristol-myers-and-berkshire-hathaway-cm734815,For Immediate Release Chicago IL January 18 2017 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the
BMY,BMY:US,BBG000DQLV23,AstraZeneca Offers Update on Immuno-Oncology Program,2017-01-18 14:41:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CzlJwETc79o/astrazeneca-offers-update-on-immuno-oncology-program-cm734754,AstraZeneca plc AZN provided an update on its late stage immuno oncology program for first line non small cell lung cancer NSCLC including amendments of the MYSTIC study expansion of the NEPTUNE study and initiation of the new PEARL study Shares of AstraZeneca have underperformed the
BMY,BMY:US,BBG000DQLV23,AstraZeneca Offers Update on Immuno-Oncology Program,2017-01-18 13:30:01 +0000,http://finance.yahoo.com/news/astrazeneca-offers-immuno-oncology-program-133001090.html,AstraZeneca Offers Update on Immuno-Oncology Program
BMY,BMY:US,BBG000DQLV23,Trump's health pick set to defend investments at U.S. Senate hearing,2017-01-18 11:00:01 +0000,http://finance.yahoo.com/news/trumps-health-pick-set-defend-110001339.html,"[Reuters] - President-elect Donald Trump's nominee for health secretary was expected to face hard questions from a U.S. Senate panel on Wednesday about his personal stock investments and proposals to dismantle Obamacare. Representative Tom Price, a Georgia orthopedic surgeon who has been in politics for more than 20 years, was chosen by fellow Republican Trump, who will become president on Friday, to head an agency that manages scores of healthcare programs. The Department of Health and Human Services runs the Medicare program for the elderly, Medicaid for the poor and President Barack Obama's Affordable Care Act, which was enacted in 2010 and brought health insurance coverage to millions of Americans who previously lacked it."
BMY,BMY:US,BBG000DQLV23,FDA Track Record Bodes Well For Merck Keytruda Plus Chemo: Leerink,2017-01-17 21:32:30 +0000,http://www.investors.com/news/technology/fda-track-record-bodes-well-for-merck-keytruda-plus-lilly-chemo-leerink/,FDA Track Record Bodes Well For Merck Keytruda Plus Chemo: Leerink
BMY,BMY:US,BBG000DQLV23,"Top Research Reports for Microsoft, Biogen & Home Depot",2017-01-17 19:37:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/otMzKqEe8dg/top-research-reports-for-microsoft-biogen-home-depot-cm734411,Tuesday January 17 2017 Today s Research Daily features new research reports on 16 major stocks including Microsoft MSFT Biogen BIIB and Home Depot HD Buy rated Microsoft shares lagged the Zacks Tech sector through the fall but have led the way over the last three months up 8
BMY,BMY:US,BBG000DQLV23,Why Bristol-Myers Squibb May Be a Merger Target Soon,2017-01-17 14:59:00 +0000,https://www.thestreet.com/story/13955786/1/why-bristol-myers-squibb-may-be-a-merger-target-soon.html?puc=yahoo&cm_ven=YAHOO,Why Bristol-Myers Squibb May Be a Merger Target Soon
BMY,BMY:US,BBG000DQLV23,These 5 Drug Patents Will Expire in 2017,2017-01-16 15:14:00 +0000,http://www.investopedia.com/news/5-drug-patents-expiring-2017-nvs-gsk-lly/?partner=YahooSA,These 5 Drug Patents Will Expire in 2017
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. – Value Analysis (NYSE:BMY) : January 13, 2017",2017-01-13 15:45:47 +0000,http://www.capitalcube.com/blog/index.php/bristol-myers-squibb-co-value-analysis-nysebmy-january-13-2017/,"Bristol-Myers Squibb Co. – Value Analysis (NYSE:BMY) : January 13, 2017"
BMY,BMY:US,BBG000DQLV23,"ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk",2017-01-13 14:40:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bIoRW1Pndw0/ariad-acquisition-by-takeda-bodes-well-competition-a-risk-cm733158,On Jan 13 we issued an updated report on ARIAD Pharmaceuticals Inc ARIA ARIAD s one month share price movement shows that the stock has significantly outperformed the Zacks classified Medical Drugs industry Specifically the company gained 89 2 during this period while the industry
BMY,BMY:US,BBG000DQLV23,Mylan’s Recent Commercial and Product Developments,2017-01-13 14:06:51 +0000,http://marketrealist.com/2017/01/mylans-recent-commercial-and-product-developments/?utm_source=yahoo&utm_medium=feed,Mylan’s Recent Commercial and Product Developments
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News",2017-01-13 13:39:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cwbyLAch2ws/pharma-stock-roundup-trump-targets-pharma-again-merck-up-on-keytruda-news-cm733130,The sector was once again slammed by president elect Donald Trump s comments this week regarding drug pricing and other issues Read more Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again The drug pricing issue in fact overshadowed guidance updates and pipeline news presented at
BMY,BMY:US,BBG000DQLV23,​Trump’s HHS nominee has promised to divest from these Mass. companies,2017-01-12 22:10:08 +0000,http://www.bizjournals.com/boston/news/2017/01/12/trump-s-hhs-nominee-has-promised-to-divest-from.html?ana=yahoo,​Trump’s HHS nominee has promised to divest from these Mass. companies
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Threatens Merck's 'Head Start' In Lung Cancer: Analyst,2017-01-12 21:04:11 +0000,http://www.investors.com/news/technology/bristol-myers-threatens-mercks-head-start-in-lung-cancer-analyst/,Bristol-Myers Threatens Merck's 'Head Start' In Lung Cancer: Analyst
BMY,BMY:US,BBG000DQLV23,Eli Lilly Rebounds On Chemo-Drug Patent Win Vs. Generic Teva,2017-01-12 19:00:57 +0000,http://www.investors.com/news/technology/eli-lilly-rebounds-on-chemo-drug-patent-win-vs-generic-teva/,Eli Lilly Rebounds On Chemo-Drug Patent Win Vs. Generic Teva
BMY,BMY:US,BBG000DQLV23,Trump Attacks Biotech & Pharma: ETFs Bleed,2017-01-12 16:57:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FXC6m2w_ZhQ/trump-attacks-biotech-pharma-etfs-bleed-cm732747,The pharma and biotech industry is a victim of concerns over increased regulatory scrutiny on high drug prices over the past two years The worries cooled down after Trump s victory and gave biotech stocks a shot in the arm But the trend has reversed again following Trump s first press
BMY,BMY:US,BBG000DQLV23,The Implied Analyst 12-Month Target For JKE,2017-01-12 14:58:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gu-w4NyB5f4/the-implied-analyst-12-month-target-for-jke-cm732585,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BMY,BMY:US,BBG000DQLV23,3 Charts Every Bristol-Myers Squibb Shareholder Needs to See,2017-01-12 14:55:04 +0000,http://www.fool.com/investing/2017/01/11/3-charts-every-bristol-myers-squibb-shareholder-ne.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Charts Every Bristol-Myers Squibb Shareholder Needs to See
BMY,BMY:US,BBG000DQLV23,Merck: News So Good Three Analysts Had to Upgrade It,2017-01-12 14:54:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/01/12/merck-news-so-good-three-analysts-had-to-upgrade-it/?mod=yahoobarrons&ru=yahoo,Merck: News So Good Three Analysts Had to Upgrade It
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : BMY-US : January 12, 2017",2017-01-12 12:57:19 +0000,http://www.capitalcube.com/blog/index.php/bristol-myers-squibb-co-breached-its-50-day-moving-average-in-a-bearish-manner-bmy-us-january-12-2017/,"Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : BMY-US : January 12, 2017"
BMY,BMY:US,BBG000DQLV23,Trump criticism leads to falling stock prices at these Tampa employers,2017-01-12 12:35:07 +0000,http://www.bizjournals.com/tampabay/news/2017/01/12/trump-criticism-leads-to-falling-stock-prices-at.html?ana=yahoo,Trump criticism leads to falling stock prices at these Tampa employers
BMY,BMY:US,BBG000DQLV23,"Pfizer Inc. (PFE), Lockheed Martin (LMT) Get “Trumped”",2017-01-11 22:56:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HXTdXbnchnU/pfizer-inc-pfe-lockheed-martin-lmt-get-trumped-cm732459,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips U S equities are suffering another bout of volatility on Wednesday after intense fireworks were seen at president elect Donald Trump s first press conference in months Issues such as Russian hacking of
BMY,BMY:US,BBG000DQLV23,Bristol-Myers and AstraZeneca Take Beatings,2017-01-11 21:33:00 +0000,https://www.thestreet.com/story/13950692/1/bristol-myers-astrazeneca-take-beating-in-wake-of-merck-s-latest-drug-approval.html?puc=yahoo&cm_ven=YAHOO,Bristol-Myers and AstraZeneca Take Beatings
BMY,BMY:US,BBG000DQLV23,Trump's Comments Slam Drug Stocks,2017-01-11 18:59:35 +0000,http://blogs.wsj.com/moneybeat/2017/01/11/trump-slams-drug-stocks-at-press-conference/?mod=yahoo_hs,Trump's Comments Slam Drug Stocks
BMY,BMY:US,BBG000DQLV23,2 Stocks For a Trump-ed Up Pharma Market,2017-01-11 18:03:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/01/11/2-stocks-for-a-trump-ed-up-pharma-market/?mod=yahoobarrons&ru=yahoo,2 Stocks For a Trump-ed Up Pharma Market
BMY,BMY:US,BBG000DQLV23,Merck Lung-Cancer Drug May Get OK For Large Patient Population,2017-01-11 17:28:32 +0000,http://www.investors.com/news/technology/merck-lung-cancer-drug-may-get-ok-for-large-patient-population/,Merck Lung-Cancer Drug May Get OK For Large Patient Population
BMY,BMY:US,BBG000DQLV23,Merck: One Giant Leap…,2017-01-11 15:29:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/01/11/merck-one-giant-leap/?mod=yahoobarrons&ru=yahoo,Merck: One Giant Leap…
BMY,BMY:US,BBG000DQLV23,"Merck boosts Dow, Amazon prime members get a new perk, ADM to buy pet food producer",2017-01-11 15:10:45 +0000,http://finance.yahoo.com/news/merck-boosts-dow-amazon-prime-members-get-a-new-perk-adm-to-buy-pet-food-producer-151045654.html,"Merck boosts Dow, Amazon prime members get a new perk, ADM to buy pet food producer"
BMY,BMY:US,BBG000DQLV23,3 Charts Every Bristol-Myers Squibb Shareholder Needs to See,2017-01-11 14:56:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xTOJHLaHfFc/3-charts-every-bristol-myers-squibb-shareholder-needs-to-see-cm732080,Bristol Myers Squibb NYSE BMY shareholders were understandably disappointed in August when results from a late stage study of Opdivo as a first line lung cancer treatment were announced Opdivo s failure in that study knocked more than 30 off Bristol Myers Squibb s market
BMY,BMY:US,BBG000DQLV23,Merck leapfrogs rivals in lung cancer drug combination race,2017-01-11 14:52:19 +0000,http://uk.finance.yahoo.com/news/merck-steals-march-rivals-lung-091115852.html,"[Reuters - UK Focus] - Merck & Co (Swiss: MRK-USD.SW - news) has pulled ahead of rivals in the race to combine immunotherapy with other drugs as a treatment for lung cancer, potentially giving it a major lift in the battle for the largest cancer market. U.S. regulators have agreed to a speedy review of Merck's application to combine its immune system-boosting drug Keytruda with chemotherapy as an initial therapy for advanced lung cancer, the U.S. drugmaker said."
BMY,BMY:US,BBG000DQLV23,Merck steals march on rivals in lung cancer drug combo race,2017-01-11 09:15:43 +0000,http://sg.finance.yahoo.com/news/merck-steals-march-rivals-lung-091543183.html,Merck steals march on rivals in lung cancer drug combo race
BMY,BMY:US,BBG000DQLV23,Roche Gets Priority Review for Immunotherapy Drug Tecentriq,2017-01-10 16:55:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bjcwcy3bgLg/roche-gets-priority-review-for-immunotherapy-drug-tecentriq-cm731699,Roche Holding AG s RHHBY Genentech announced that the FDA has accepted the company s supplemental Biologics License Application sBLA and granted Priority Review for cancer immunotherapy Tecentriq for the treatment of patients suffering from locally advanced or metastatic urothelial
BMY,BMY:US,BBG000DQLV23,Here's a Biotech IPO You'll Want to Watch,2017-01-10 13:23:50 +0000,http://www.fool.com/investing/2017/01/09/heres-a-biotech-ipo-youll-want-to-watch.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Here's a Biotech IPO You'll Want to Watch
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb To Present At J.P. Morgan Conference; Webcast At 12:30 PM,2017-01-10 11:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4LfS95p2UW8/bristolmyers-squibb-to-present-at-jp-morgan-conference-webcast-at-1230-pm-20170110-00724,Bristol-Myers Squibb To Present At J.P. Morgan Conference; Webcast At 12:30 PM
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study",2017-01-09 14:52:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EsOt2GXfvik/bristol-myers-genecentric-tie-up-for-opdivo-biomarker-study-cm730896,Bristol Myers Squibb Company BMY inked a biomarker research collaboration with GeneCentric Diagnostics Inc under which application of the latter s proprietary core technology Cancer Subtype Platform CSP will be explored for the identification of translational biomarkers for Bristol
BMY,BMY:US,BBG000DQLV23,Here's a Biotech IPO You'll Want to Watch,2017-01-09 14:52:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dRTxG2awj9A/heres-a-biotech-ipo-youll-want-to-watch-cm730931,You might be too busy to pay much attention to every tiny biotech that goes public There s one initial public offering IPO coming up though that I think you ll want to keep your eyes on Jounce Therapeutics filed a few days ago for an IPO in 2017 Any company that Celgene
BMY,BMY:US,BBG000DQLV23,2 Top Stocks in Biotech,2017-01-09 14:52:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IyhrE5lM7ns/2-top-stocks-in-biotech-cm730928,In 2016 the FDA approved less than half as many new drugs as the previous year An increasingly strict regulatory environment might not be great for investing in the broad based industry tracking iShares Nasdaq Biotechnology ETF NASDAQ IBB but it has made shares of
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study",2017-01-09 13:11:01 +0000,http://finance.yahoo.com/news/bristol-myers-genecentric-tie-opdivo-131101890.html,"Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study"
BMY,BMY:US,BBG000DQLV23,5 Tough Questions for Bristol-Myers Squibb's CEO,2017-01-08 12:25:05 +0000,http://www.fool.com/investing/2017/01/07/5-tough-questions-for-bristol-myers-squibbs-ceo.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Tough Questions for Bristol-Myers Squibb's CEO
BMY,BMY:US,BBG000DQLV23,5 Tough Questions for Bristol-Myers Squibb's CEO,2017-01-07 13:49:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E9sN6T3iygs/5-tough-questions-for-bristol-myers-squibbs-ceo-cm730684,Giovanni Caforio has been at the helm of Bristol Myers Squibb NYSE BMY for less than two years But he s gotten used to answering tough questions On Thursday morning the big drugmaker s CEO sat down for around 40 minutes responding to nonstop questions at the Goldman
BMY,BMY:US,BBG000DQLV23,Cramer's game plan: Banks will be in hog heaven next week,2017-01-06 23:16:23 +0000,http://www.cnbc.com/id/104204457?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104204457,Cramer's game plan: Banks will be in hog heaven next week
BMY,BMY:US,BBG000DQLV23,It Was CheckMate for Bristol-Myers Squibb Company in 2016,2017-01-06 17:40:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TXjScInokNA/it-was-checkmate-for-bristol-myers-squibb-company-in-2016-cm730455,Image source Getty Images What happened According to data from S amp P Global Market Intelligence shares of global drug giant Bristol Myers Squibb NYSE BMY tumbled 15 in 2016 160 meaning it underperformed the broad based S amp P 500 by nearly 25
BMY,BMY:US,BBG000DQLV23,"2 Big Reasons Merck & Co., Inc. Stock Surged 11% in 2016",2017-01-06 16:40:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AqQYh73zTsU/2-big-reasons-merck-co-inc-stock-surged-11-in-2016-cm730396,Image source Getty Images What happened Shares of Merck amp Co Inc NYSE MRK a U S based global drug behemoth climbed 11 higher in 2016 according to data from S amp P Global Market Intelligence slightly outpacing the 9 5 return of the S amp P 500
BMY,BMY:US,BBG000DQLV23,It Was CheckMate for Bristol-Myers Squibb Company in 2016,2017-01-06 16:01:12 +0000,http://www.fool.com/investing/2017/01/06/it-was-checkmate-for-bristol-myers-squibb-company.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,It Was CheckMate for Bristol-Myers Squibb Company in 2016
BMY,BMY:US,BBG000DQLV23,"2 Big Reasons Merck & Co., Inc. Stock Surged 11% in 2016",2017-01-06 14:42:08 +0000,http://www.fool.com/investing/2017/01/06/2-big-reasons-merck-co-inc-stock-surged-11-in-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"2 Big Reasons Merck & Co., Inc. Stock Surged 11% in 2016"
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View",2017-01-06 14:41:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CVGADu1vf3U/pharma-stock-roundup-pcsk9-inhibitor-praluent-in-news-allergans-preliminary-2017-view-cm730250,French pharma giant Sanofi SNY and partner Regeneron were hit by a court injunction blocking the sale of their PCSK9 inhibitor Praluent in the U S Meanwhile Allergan AGN provided a preliminary look at its expectations for 2017 Recap of the Week s Most Important Stories Sanofi
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, J&J Ink Immunotherapy Research Collaboration",2017-01-06 14:40:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WFlI3XUuJQs/bristol-myers-jj-ink-immunotherapy-research-collaboration-cm730346,Bristol Myers Squibb Company BMY announced a new clinical research collaboration with Johnson amp Johnson s JNJ Janssen Biotech Inc under which its immuno oncology drug Opdivo will be evaluated in combination with the latter s Darzalex in phase Ib phase II studies for multiple myeloma
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, J&J Ink Immunotherapy Research Collaboration",2017-01-06 13:17:01 +0000,http://finance.yahoo.com/news/bristol-myers-j-j-ink-131701835.html,"Bristol-Myers, J&J Ink Immunotherapy Research Collaboration"
BMY,BMY:US,BBG000DQLV23,Blog Coverage Five Prime Announced Extension of Collaboration Agreement by Bristol-Myers Squibb,2017-01-06 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-five-prime-announced-131500865.html,"[Accesswire] - LONDON, UK / ACCESSWIRE / January 6, 2017 / Active Wall St. blog coverage looks at the headline from clinical-stage biotechnology Company Five Prime Therapeutics, Inc. (NASDAQ: FPRX ) as the Company announced ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration,2017-01-06 12:55:07 +0000,http://www.publicnow.com/view/DD9EC695644AEBBCDEE720CBDF936ED194FF3B76,"[at noodls] - NEW YORK & DURHAM, N.C.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) andGeneCentric Diagnostics, Inc. today announced a biomarker research collaboration to explore whether the application ..."
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View",2017-01-06 12:24:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-pcsk9-inhibitor-122412444.html,"Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration,2017-01-06 11:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-genecentric-diagnostics-115900098.html,"[Business Wire] - Bristol-Myers Squibb Company and GeneCentric Diagnostics, Inc. today announced a biomarker research collaboration to explore whether the application of GeneCentric’s Cancer Subtype Platform might be able to identify translational biomarkers for Opdivo , which may help inform future clinical trials."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb To Explore Use Of GeneCentric's Cancer Subtyping Platform,2017-01-06 07:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aXtymQiS5cs/bristolmyers-squibb-to-explore-use-of-genecentrics-cancer-subtyping-platform-20170106-00127,Bristol-Myers Squibb To Explore Use Of GeneCentric's Cancer Subtyping Platform
BMY,BMY:US,BBG000DQLV23,"Final Trade: BMY, FXI & more",2017-01-05 22:59:00 +0000,http://finance.yahoo.com/video/final-trade-bmy-fxi-more-225900056.html,"Final Trade: BMY, FXI & more"
BMY,BMY:US,BBG000DQLV23,Crystal Ball Gazing: Biotech Predictions For 2017,2017-01-05 20:09:00 +0000,http://www.forbes.com/sites/brucebooth/2017/01/05/crystal-ball-gazing-biotech-predictions-for-2017/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Crystal Ball Gazing: Biotech Predictions For 2017
BMY,BMY:US,BBG000DQLV23,"Celldex Therapeutics, Inc.'s 3 Best Moves in 2016",2017-01-05 19:37:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9U-XQ-NhHjI/celldex-therapeutics-incs-3-best-moves-in-2016-cm730006,Although a surprising trial failure made 2016 a punishing year for Celldex Therapeutics NASDAQ CLDX investors the beaten up biotech took several wise steps that could set it up for success in 2017 and beyond Here s a look at three of the best moves this cancer therapy
BMY,BMY:US,BBG000DQLV23,"Notable ETF Inflow Detected - QUAL, KMB, MA, BMY",2017-01-05 17:39:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5UVY_0H6VnI/notable-etf-inflow-detected-qual-kmb-ma-bmy-cm729912,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Edge MSCI USA Quality Factor ETF Symbol QUAL where we have detected an approximate 129 5 million dollar inflow that s a 3 7 increase week over week
BMY,BMY:US,BBG000DQLV23,"Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio",2017-01-05 17:36:00 +0000,https://www.thestreet.com/story/13944072/1/senate-dems-d-c-watchdog-call-for-ethics-investigation-into-trump-hhs-pick-tom-price.html?puc=yahoo&cm_ven=YAHOO,"Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio"
BMY,BMY:US,BBG000DQLV23,"The 4 Building Blocks That Pushed Exelixis, Inc. Higher by 164% in 2016",2017-01-05 16:44:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8ZaocuxPYdk/the-4-building-blocks-that-pushed-exelixis-inc-higher-by-164-in-2016-cm729849,Image source Getty Images What happened Shares of Exelixis NASDAQ EXEL a mid cap biotech company primarily focused on developing therapies to treat cancer surged 164 during 2016 according to S amp P Global Market Intelligence There appear to be four key reasons
BMY,BMY:US,BBG000DQLV23,The Scariest Thing About Bristol-Myers Squibb's Dividend,2017-01-05 15:39:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zyD_rT9nc28/the-scariest-thing-about-bristol-myers-squibbs-dividend-cm729757,If there has been one thing to love about Bristol Myers Squibb NYSE BMY year in and year out it s been the big drugmaker s dividend With a current yield of 2 67 investors still have reason to show the love But there is something that might seem scary to some investors
BMY,BMY:US,BBG000DQLV23,"The 4 Building Blocks That Pushed Exelixis, Inc. Higher by 164% in 2016",2017-01-05 14:43:06 +0000,http://www.fool.com/investing/2017/01/05/the-4-building-blocks-that-pushed-exelixis-inc-hig.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"The 4 Building Blocks That Pushed Exelixis, Inc. Higher by 164% in 2016"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Extends Deal with Five Prime Therapeutics,2017-01-05 14:41:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3KBRsNDd-6E/bristol-myers-extends-deal-with-five-prime-therapeutics-cm729789,Bristol Myers Squibb Company BMY has exercised its option to extend the term of its existing research collaboration agreement with Five Prime Therapeutics Inc FPRX for the discovery development and commercialization of immuno oncology therapies focused on targets in three undisclosed
BMY,BMY:US,BBG000DQLV23,The Scariest Thing About Bristol-Myers Squibb's Dividend,2017-01-05 14:10:12 +0000,http://www.fool.com/investing/2017/01/05/the-scariest-thing-about-bristol-myers-squibbs-div.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The Scariest Thing About Bristol-Myers Squibb's Dividend
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Extends Deal with Five Prime Therapeutics,2017-01-05 13:13:01 +0000,http://finance.yahoo.com/news/bristol-myers-extends-deal-five-131301865.html,Bristol-Myers Extends Deal with Five Prime Therapeutics
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo (nivolumab) in Combination with Darzalex (daratumumab),2017-01-05 12:34:07 +0000,http://www.publicnow.com/view/E5A8AD8BAD5000E3E9E21B30203028BB29385B75,"[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate the combination of Bristol-Myers Squibb's ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo (nivolumab) in Combination with Darzalex (daratumumab),2017-01-05 11:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-announces-immunotherapy-115900416.html,"[Business Wire] - Bristol-Myers Squibb Company today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate the combination of Bristol-Myers Squibb’s Immuno-Oncology agent Opdivo and Janssen’s CD38-directed cytolytic antibody Darzalex in Phase 1b/2 clinical studies in multiple myeloma and solid tumors including non-small cell lung cancer, pancreatic cancer, colorectal cancer , triple ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb To Participate In Goldman Sachs CEO Unscripted At 9:30 AM,2017-01-05 08:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J6MLBcvkApo/bristolmyers-squibb-to-participate-in-goldman-sachs-ceo-unscripted-at-930-am-20170105-00519,Bristol-Myers Squibb To Participate In Goldman Sachs CEO Unscripted At 9:30 AM
BMY,BMY:US,BBG000DQLV23,"AEZS Disappoints, EVOK Gets New Lease Of Life, GNMX Calls For Attention",2017-01-05 00:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/47JUs3PW9eI/aezs-disappoints-evok-gets-new-lease-of-life-gnmx-calls-for-attention-20170105-00006,"AEZS Disappoints, EVOK Gets New Lease Of Life, GNMX Calls For Attention"
BMY,BMY:US,BBG000DQLV23,Deutsche Bank to pay $95 million to end U.S. tax fraud case,2017-01-04 22:16:56 +0000,http://sg.finance.yahoo.com/news/deutsche-bank-pay-95-million-211022716.html,Deutsche Bank to pay $95 million to end U.S. tax fraud case
BMY,BMY:US,BBG000DQLV23,Deutsche Bank to pay $95 mln to end U.S. tax fraud case,2017-01-04 22:16:00 +0000,http://finance.yahoo.com/news/deutsche-bank-pay-95-mln-221600850.html,"[Reuters] - Deutsche Bank AG agreed to pay $95 million to resolve a U.S. government lawsuit accusing the German bank of tax fraud for using ""insolvent"" shell companies to hide significant tax liabilities from the Internal Revenue Service in 2000. Under the accord described in papers filed on Wednesday with the federal court in Manhattan, Deutsche Bank also admitted to trying to stick the shell companies with the tax bill for its then-new stake in drugmaker Bristol-Myers Squibb Co. ""The government, through this action and settlement, has made Deutsche Bank admit to its actions designed to avoid taxes,"" U.S. Attorney Preet Bharara in Manhattan said in a statement."
BMY,BMY:US,BBG000DQLV23,Five Prime Therapeutics and Bristol-Myers Squibb Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways,2017-01-04 21:05:00 +0000,http://finance.yahoo.com/news/five-prime-therapeutics-bristol-myers-210500462.html,"[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Jan. 04, 2017-- Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, ..."
BMY,BMY:US,BBG000DQLV23,"Merck & Co., Inc. (MRK) Stock Is Defying the Bears!",2017-01-04 15:37:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6rcMFsYSN4U/merck-co-inc-mrk-stock-is-defying-the-bears-cm729154,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips The first trading day of 2017 was a mixed session Although the broader indices ended higher on the day underneath the surface things traded in a sloppy fashion Healthcare stocks lead
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Trades Ex-Dividend Wednesday,2017-01-04 14:01:00 +0000,http://www.investopedia.com/news/bristolmyers-trades-exdividend-wednesday-bmy/?partner=YahooSA,Bristol-Myers Trades Ex-Dividend Wednesday
BMY,BMY:US,BBG000DQLV23,4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017,2017-01-04 13:38:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5WHf6QhBzvY/4-reasons-why-pfizer-pfe-could-be-a-great-pick-in-2017-cm729081,Pfizer Inc PFE is one of the most prominent names in the pharmaceutical sector not just for its medicines and vaccines but also for its consumer healthcare products This New York based company is known for products like Prevnar Lyrica Lipitor and Celebrex among others Pfizer s
BMY,BMY:US,BBG000DQLV23,4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017,2017-01-04 11:25:11 +0000,http://finance.yahoo.com/news/4-reasons-why-pfizer-pfe-112511393.html,4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for January 04, 2017",2017-01-03 14:19:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UdIA7V8ApF8/bristol-myers-squibb-company-bmy-ex-dividend-date-scheduled-for-january-04-2017-cm728536,Bristol Myers Squibb Company BMY will begin trading ex dividend on January 04 2017 A cash dividend payment of 0 39 per share is scheduled to be paid on February 01 2017 Shareholders who purchased BMY prior to the ex dividend date are eligible for the cash dividend payment This
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference,2017-01-03 14:18:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-present-j-141800492.html,"[Business Wire] - Bristol-Myers Squibb Company will present at the J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017, in San Francisco. Giovanni Caforio, chief executive officer, will make a formal presentation about the company at 9:30 a.m."
BMY,BMY:US,BBG000DQLV23,3 Biggest Risks for Bristol-Myers Squibb in 2017,2017-01-01 17:57:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zznJgqHnMsU/3-biggest-risks-for-bristol-myers-squibb-in-2017-cm728280,From a financial standpoint 2016 was terrific for Bristol Myers Squibb NYSE BMY Revenue jumped more than 25 year over year in the first three quarters Earnings more than doubled Can the big drugmaker perform as well in 2017 Here are three of the biggest risks that Bristol
BMY,BMY:US,BBG000DQLV23,3 Biggest Risks for Bristol-Myers Squibb in 2017,2017-01-01 16:09:20 +0000,http://www.fool.com/investing/2017/01/01/3-biggest-risks-for-bristol-myers-squibb-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biggest Risks for Bristol-Myers Squibb in 2017
BMY,BMY:US,BBG000DQLV23,What Factors Are Contributing to Gilead Sciences’ Growth?,2016-12-30 23:05:28 +0000,http://marketrealist.com/2016/12/what-factors-are-contributing-to-gilead-sciences-growth/?utm_source=yahoo&utm_medium=feed,What Factors Are Contributing to Gilead Sciences’ Growth?
BMY,BMY:US,BBG000DQLV23,"ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong",2016-12-30 17:01:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iRoJFeP1ZcM/ariad-stock-beats-industry-in-2016-iclusig-sales-strong-cm727981,ARIAD Pharmaceuticals Inc ARIA remains focused on the discovery development and commercialization of breakthrough treatments for cancer This year was a tough one for the pharma sector which had to grapple with media and political focus on the high prices of drugs Shares of ARIAD
BMY,BMY:US,BBG000DQLV23,AbbVie's Humira and Imbruvica Drive Performance in 2016,2016-12-30 15:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lFdGUIrPtiM/abbvies-humira-and-imbruvica-drive-performance-in-2016-cm727887,North Chicago IL based AbbVie Inc ABBV came into existence on Jan 1 2013 after Abbott Laboratories ABT divested its pharmaceutical division AbbVie has a presence in the rheumatoid arthritis cancer psoriasis Crohn s disease HIV hepatitis C virus HCV testosterone thyroid
BMY,BMY:US,BBG000DQLV23,"ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong",2016-12-30 14:27:02 +0000,http://finance.yahoo.com/news/ariad-stock-beats-industry-2016-142702761.html,"ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong"
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded",2016-12-30 12:58:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yhNBqll0RdA/pharma-stock-roundup-cempra-plunges-to-52-week-low-shire-drug-label-expanded-cm727743,It was a relatively slow week for pharma stocks though a couple of companies suffered regulatory setbacks with the FDA issuing complete response letters CRLs for their regulatory applications Recap of the Week s Most Important Stories Cempra Plunges on CRL for
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top,2016-12-29 14:12:12 +0000,http://www.publicnow.com/view/0422DAE412E191B398DFD3F447A3DFFF89155EA1,"[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top on Thursday, January 5, 2017, in Boston, Massachusetts. ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top,2016-12-29 14:00:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-part-goldman-140000356.html,"[Business Wire] - Bristol-Myers Squibb Company will take part in the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top on Thursday, January 5, 2017, in Boston, Massachusetts. Giovanni Caforio, M.D., chief executive officer, will answer questions about the company at 9:30 a.m."
BMY,BMY:US,BBG000DQLV23,BMY a Top 25 Dividend Giant With $4.72B Held By ETFs,2016-12-29 13:58:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G1BsrmH_MB8/bmy-a-top-25-dividend-giant-with-472b-held-by-etfs-cm727265,Bristol Myers Squibb Co Symbol BMY has been named as a Top 25 Dividend Giant by ETF Channel with a stunning 4 72B worth of stock held by ETFs and above average DividendRank statistics including a strong 2 67 yield according to the most recent Dividend Channel
BMY,BMY:US,BBG000DQLV23,Will Keytruda’s Position Strengthen in the Lung Cancer Market?,2016-12-29 12:36:11 +0000,http://marketrealist.com/2016/12/increased-pd-l1-testing-expected-strengthen-keytrudas-position-lung-cancer-market/?utm_source=yahoo&utm_medium=feed,Will Keytruda’s Position Strengthen in the Lung Cancer Market?
BMY,BMY:US,BBG000DQLV23,"​Bristol-Myers, Tiffany among NYC companies lauded for environmental, social ‘values’",2016-12-29 07:00:08 +0000,http://www.bizjournals.com/newyork/news/2016/12/29/bristol-myers-tiffany-among-nyc-companies-lauded.html?ana=yahoo,"​Bristol-Myers, Tiffany among NYC companies lauded for environmental, social ‘values’"
BMY,BMY:US,BBG000DQLV23,"Agree To Purchase Bristol-Myers Squibb Co. At $30, Earn 2.7% Using Options",2016-12-28 18:00:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fxoaAM4WOMQ/agree-to-purchase-bristol-myers-squibb-co-at-30-earn-27-using-options-cm727049,Investors eyeing a purchase of Bristol Myers Squibb Co Symbol BMY shares but cautious about paying the going market price of 58 88 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the
BMY,BMY:US,BBG000DQLV23,"Noteworthy ETF Inflows: IWF, MA, BMY, CELG",2016-12-28 16:59:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NiS-DhVFSw8/noteworthy-etf-inflows-iwf-ma-bmy-celg-cm726962,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 1000 Growth ETF Symbol IWF where we have detected an approximate 196 7 million dollar inflow that s a 0 6 increase week over week
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb draws upside bet,2016-12-28 12:48:42 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-draws-upside-124842688.html,Bristol-Myers Squibb draws upside bet
BMY,BMY:US,BBG000DQLV23,"Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up",2016-12-27 16:01:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1I0Qa_PZBpg/portola-betrixaban-accepted-for-review-in-us-eu-stock-up-cm726398,Shares of Portola Pharmaceuticals Inc PTLA surged 33 8 after the company s new drug application for its oral once daily Factor Xa inhibitor anticoagulant betrixaban was accepted under priority review by the FDA Note that Portola is looking to get betrixaban approved for extended
BMY,BMY:US,BBG000DQLV23,"Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up",2016-12-27 14:07:02 +0000,http://finance.yahoo.com/news/portola-betrixaban-accepted-review-u-140702838.html,"Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up"
BMY,BMY:US,BBG000DQLV23,"If You're in Your 40s, Consider Buying These Stocks",2016-12-24 20:37:17 +0000,http://www.fool.com/investing/2016/12/23/if-youre-in-your-40s-consider-buying-these-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"If You're in Your 40s, Consider Buying These Stocks"
BMY,BMY:US,BBG000DQLV23,Why Portola Pharmaceuticals Inc Stock Surged Higher Today,2016-12-23 23:57:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UcIyicNfP6o/why-portola-pharmaceuticals-inc-stock-surged-higher-today-cm725903,Image source Getty Images What happened Shares of clinical stage anticoagulant specialist Portola Pharmaceuticals Inc NASDAQ PTLA 160 rose 33 5 at the end of Friday s session 160 Announcements that key regulatory agencies have officially accepted new drug applications
BMY,BMY:US,BBG000DQLV23,Why Portola Pharmaceuticals Inc Stock Surged Higher Today,2016-12-23 22:35:48 +0000,http://www.fool.com/investing/2016/12/23/why-portola-pharmaceuticals-is-up-27-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Portola Pharmaceuticals Inc Stock Surged Higher Today
BMY,BMY:US,BBG000DQLV23,"If You're in Your 40s, Consider Buying These Stocks",2016-12-23 21:56:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nNrG9qw4Uns/if-youre-in-your-40s-consider-buying-these-stocks-cm725863,Forty something investors shouldn t necessarily shy away from risk altogether but it is a good time to start pivoting toward more traditional large cap companies that pay dividends Keeping with this theme our Foolish contributors think that investors in their 40s may want to take a
BMY,BMY:US,BBG000DQLV23,"Gilead Sciences, Inc. (GILD) Is A Hail Mary: 3 Better Stocks To Consider",2016-12-23 19:32:32 +0000,http://www.insidermonkey.com/blog/gilead-sciences-inc-gild-is-a-hail-mary-3-better-stocks-to-consider-513001/,"Gilead Sciences, Inc. (GILD) Is A Hail Mary: 3 Better Stocks To Consider"
BMY,BMY:US,BBG000DQLV23,Something Strange Is Going On With Oral Insulin,2016-12-23 17:41:17 +0000,http://finance.yahoo.com/news/something-strange-going-oral-insulin-174117941.html,Something Strange Is Going On With Oral Insulin
BMY,BMY:US,BBG000DQLV23,Stock Exchange: Successful Trading Depends On Discipline And Focus,2016-12-23 13:58:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YK4m8PPOFAI/stock-exchange-successful-trading-depends-on-discipline-and-focus-cm725502,By Jeff Miller ByJeff Miller Last week s Stock Exchange was about how emotion and symbols affected technical analysis Could our charts help us when the picture displayed involved some psychological event like Dow 20K Last week sStock Exchange was about how emotion and symbols
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe",2016-12-23 12:58:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gu5pZXFat3c/pharma-stock-roundup-jj-back-in-talks-with-actelion-teva-settles-corruption-probe-cm725508,Several tuck in deals and licensing agreements were announced this week while healthcare giant Johnson amp Johnson JNJ is back in exclusive talks with Actelion regarding a possible deal Recap of the Week s Most Important Stories J amp J In Where Does that Leave Sanofi in
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe",2016-12-23 10:48:10 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-j-j-104810335.html,"Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo",2016-12-22 18:00:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nZlfScWZq1g/bristol-myers-calithera-team-up-for-opdivocb-839-combo-cm725212,Bristol Myers Squibb Company BMY announced a clinical trial collaboration with Calithera Biosciences Inc CALA under which Bristol Myers immuno oncology drug Opdivo will be evaluated in combination with Calithera s CB 839 in patients with clear cell renal cell carcinoma
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Opdivo May See Strong Demand in 2016,2016-12-22 15:37:53 +0000,http://marketrealist.com/2016/12/opdivo-may-continue-witness-strong-demand-2016/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb’s Opdivo May See Strong Demand in 2016
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo",2016-12-22 15:22:03 +0000,http://finance.yahoo.com/news/bristol-myers-calithera-team-opdivo-152203526.html,"Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo"
BMY,BMY:US,BBG000DQLV23,Positive Results from CheckMate-227 Trial May Boost Opdivo’s Position,2016-12-22 14:06:33 +0000,http://marketrealist.com/2016/12/positive-results-checkmate-227-trial-may-strengthen-opdivos-position-lung-cancer-segment/?utm_source=yahoo&utm_medium=feed,Positive Results from CheckMate-227 Trial May Boost Opdivo’s Position
BMY,BMY:US,BBG000DQLV23,Opdivo Is a Key Growth Driver for Bristol-Myers Squibb in 2016,2016-12-22 12:36:12 +0000,http://marketrealist.com/2016/12/opdivo-continues-key-growth-driver-bristol-myers-squibb-2016/?utm_source=yahoo&utm_medium=feed,Opdivo Is a Key Growth Driver for Bristol-Myers Squibb in 2016
BMY,BMY:US,BBG000DQLV23,[$$] Business Watch,2016-12-22 01:42:27 +0000,http://online.wsj.com/article/SB21496220223128894085604582511471609885742.html?ru=yahoo?mod=yahoo_itp,[$$] Business Watch
BMY,BMY:US,BBG000DQLV23,"CALA Surges On BMY Deal, OVAS Hands Pink Slips, MACK Halts Breast Cancer Study",2016-12-21 23:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LivsjpkbrEE/cala-surges-on-bmy-deal-ovas-hands-pink-slips-mack-halts-breast-cancer-study-20161221-00953,"CALA Surges On BMY Deal, OVAS Hands Pink Slips, MACK Halts Breast Cancer Study"
BMY,BMY:US,BBG000DQLV23,"Close Update: Wall Street Retreats From Record Highs Leaving Dow 20,000 For Another Day",2016-12-21 21:57:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tWtQComwl5Q/close-update-wall-street-retreats-from-record-highs-leaving-dow-20000-for-another-day-cm724823,The benchmark averages traded marginally lower Wednesday wedged in paper thin ranges for most of the day as light profit taking across most sectors tugged the Dow Jones Industrial Average and Nasdaq away from Tuesday s record highs and prevented the Dow from touching 20 000 for a
BMY,BMY:US,BBG000DQLV23,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib",2016-12-21 21:41:17 +0000,http://biz.yahoo.com/e/161221/bmy8-k.html,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib"
BMY,BMY:US,BBG000DQLV23,Mid-Afternoon Market Update: Crude Oil Down 1.5%; Merus Shares Spike Higher,2016-12-21 21:17:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZxMikSBvFPw/mid-afternoon-market-update-crude-oil-down-15-merus-shares-spike-higher-cm724821,Toward the end of trading Wednesday the Dow traded down 0 05 percent to 19 963 94 while the NASDAQ declined 0 08 percent to 5 479 51 The S amp P also fell dropping 0 10 percent to 2 268 60 Leading and Lagging Sectors Non cyclical consumer goods amp services shares gained
BMY,BMY:US,BBG000DQLV23,"Health Care Sector Update for 12/21/2016: CALA,BMY,MRUS,INCY,MACK",2016-12-21 19:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nnc5PN0cchk/health-care-sector-update-for-12212016-calabmymrusincymack-cm724760,Top Health Care StocksTop Health Care Stocks JNJ 0 28 JNJ 0 28 PFE 1 42 PFE 1 42 MRK 0 42 MRK 0 42 ABT 1 38 ABT 1 38 AMGN 0 82 AMGN 0 82 Health care stocks continued to weigh on the broader U S markets today but pared some of their earlier declines with the NYSE Health Care
BMY,BMY:US,BBG000DQLV23,Midday Update: Wall Street Retreats From Record Highs,2016-12-21 18:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IB9WOC-V1mY/midday-update-wall-street-retreats-from-record-highs-cm724723,The benchmark averages were slightly underwater midday on Wednesday as light profit taking pressure off Tuesday s record levels kept the Dow Jones Industrial Average from hitting the elusive 20 000 level for the seventh consecutive day Gains in the energy and materials sector on a
BMY,BMY:US,BBG000DQLV23,Mid-Morning Market Update: Markets Edge Lower; Finish Line Misses Q3 Expectations,2016-12-21 16:17:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dzrNNyMEXgg/mid-morning-market-update-markets-edge-lower-finish-line-misses-q3-expectations-cm724638,Following the market opening Wednesday the Dow traded down 0 07 percent to 19 960 55 while the NASDAQ declined 0 10 percent to 5 478 21 The S amp P also fell dropping 0 11 percent to 2 268 20 Leading and Lagging Sectors Non cyclical consumer goods amp services shares
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Names CEO as New Chairman,2016-12-21 16:02:19 +0000,http://www.wsj.com/articles/bristol-myers-names-ceo-giovanni-caforio-as-new-chairman-1482331695?mod=yahoo_hs,[$$] Bristol-Myers Names CEO as New Chairman
BMY,BMY:US,BBG000DQLV23,2016's Worst Clinical Failures,2016-12-21 15:59:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1Y3zSc1N59g/2016s-worst-clinical-failures-cm724489,It s been a depressing year for drugmakers and clinical trial failures made 2016 particularly upsetting Neurology has always been a difficult field but this one was unusually nerve wracking for Eli LIlly amp Co NYSE LLY and Biogen NASDAQ BIIB In their own
BMY,BMY:US,BBG000DQLV23,BMY’s Hepatitis C Franchise May See a Drop in Revenues in 2016,2016-12-21 15:37:29 +0000,http://marketrealist.com/2016/12/bristol-myers-squibbs-hepatitis-c-franchise-may-witness-drop-revenues-2016/?utm_source=yahoo&utm_medium=feed,BMY’s Hepatitis C Franchise May See a Drop in Revenues in 2016
BMY,BMY:US,BBG000DQLV23,Futures Mixed After Another Record-Setting Run for Dow and Nasdaq,2016-12-21 14:36:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BlpZO1DWv3I/futures-mixed-after-another-record-setting-run-for-dow-and-nasdaq-cm724467,Stock futures were trading flat to slightly lower with little buying interest for equities after the Dow Jones Industrial Average and Nasdaq both set new record highs on Tuesday and before the Christmas holiday Yesterday the Dow came withinm15 points of the elusive 20 000 level but drifted
BMY,BMY:US,BBG000DQLV23,Baraclude Faces Declining Revenues in 2016,2016-12-21 14:07:18 +0000,http://marketrealist.com/2016/12/baraclude-continues-face-decline-revenues-2016/?utm_source=yahoo&utm_medium=feed,Baraclude Faces Declining Revenues in 2016
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy",2016-12-21 13:49:01 +0000,http://finance.yahoo.com/news/bristol-myers-psioxus-ink-deal-134901467.html,"Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb CEO will serve as chairman, too",2016-12-21 13:40:57 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=E0F267A4-4A5E-49A4-AB9D-BB0038B3427C&siteid=yhoof2,"Bristol-Myers Squibb CEO will serve as chairman, too"
BMY,BMY:US,BBG000DQLV23,Giovanni Caforio Named Chairman of Bristol-Myers Squibb’s Board of Directors,2016-12-21 13:32:12 +0000,http://www.publicnow.com/view/0608874F7C2F24748F8E5AD62BF26AC598539E4F,"[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that the company's Board of Directors has appointed Giovanni Caforio, M.D. as chairman of the board, effective May 2, ..."
BMY,BMY:US,BBG000DQLV23,"Blog Coverage Bristol-Myers Squibb Signs Pre-clinical Stage, ""armed"" Virus Deal with PsiOxus",2016-12-21 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-bristol-myers-squibb-131500887.html,"[Accesswire] - Upcoming AWS Coverage on Impax Laboratories Post-Earnings Results LONDON, UK / ACCESSWIRE / December 21, 2016 / Active Wall St. blog coverage looks at the headline from Bristol-Myers Squibb Co. (NYSE: ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Plans to Strengthen Its Operating Model in 2017,2016-12-21 12:36:38 +0000,http://marketrealist.com/2016/12/bristol-myers-squibb-plans-strengthen-operating-model-2017/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb Plans to Strengthen Its Operating Model in 2017
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma,2016-12-21 12:22:14 +0000,http://www.publicnow.com/view/D3C432AC66C7F4E9149B4503B42ED229BAFFD841,"[at noodls] - NEW YORK & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Names CEO Giovanni Caforio as New Chairman,2016-12-21 10:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3EuQ2RD8nbA/bristolmyers-names-ceo-giovanni-caforio-as-new-chairman-20161221-00485,Bristol-Myers Names CEO Giovanni Caforio as New Chairman
BMY,BMY:US,BBG000DQLV23,Ono warns on profit after govt halves price of cancer drug Opdivo,2016-12-21 08:51:38 +0000,http://finance.yahoo.com/news/ono-warns-profit-govt-halves-085138278.html,Ono warns on profit after govt halves price of cancer drug Opdivo
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb: Caforio To Succeed Lamberto Andreotti As Chairman,2016-12-21 08:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lRyZgUdZqOg/bristolmyers-squibb-caforio-to-succeed-lamberto-andreotti-as-chairman-20161221-00350,Bristol-Myers Squibb: Caforio To Succeed Lamberto Andreotti As Chairman
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Calithera Biosciences Announce Clinical Trial Collaboration",2016-12-21 07:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jAhluPUvI2c/bristolmyers-calithera-biosciences-announce-clinical-trial-collaboration-20161221-00178,"Bristol-Myers, Calithera Biosciences Announce Clinical Trial Collaboration"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Expects Strong Revenue Growth in 2016,2016-12-20 22:31:27 +0000,http://marketrealist.com/2016/12/bristol-myers-squibb-expects-strong-revenue-growth-2016/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb Expects Strong Revenue Growth in 2016
BMY,BMY:US,BBG000DQLV23,[$$] Pharma Picks as Fundamentals Weaken,2016-12-20 16:19:00 +0000,http://www.barrons.com/articles/pharma-picks-as-fundamentals-weaken-1482250776?mod=yahoobarrons&ru=yahoo,[$$] Pharma Picks as Fundamentals Weaken
BMY,BMY:US,BBG000DQLV23,Exelixis Stock Is Up 203% in 2016 -- Is There Still More Upside Ahead?,2016-12-20 15:57:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3c-FhuqtssM/exelixis-stock-is-up-203-in-2016-is-there-still-more-upside-ahead-cm723879,While most of its biotechnology peers floundered in 2016 Cinderella stock Exelixis NASDAQ EXEL has treated investors to a stunning 200 gain so far this year Its lead drug Cabometyx also branded as Cometriq spent years generating lackluster sales as a rare thyroid
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Co (BMY) And Pfizer Inc. (PFE) Agree To $50 Million Loan To Portola Pharmaceuticals Inc (PTLA),2016-12-20 15:36:13 +0000,http://www.insidermonkey.com/blog/bristol-myers-squibb-co-bmy-and-pfizer-inc-pfe-agree-to-50-million-loan-to-portola-pharmaceuticals-inc-ptla-512239/,Bristol-Myers Squibb Co (BMY) And Pfizer Inc. (PFE) Agree To $50 Million Loan To Portola Pharmaceuticals Inc (PTLA)
BMY,BMY:US,BBG000DQLV23,"Health Care Sector Update for 12/20/2016: BMY, ACAD, JNJ, PFE, ABT, MRK, AMGN",2016-12-20 14:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FaAJRv6k-Kw/health-care-sector-update-for-12202016-bmy-acad-jnj-pfe-abt-mrk-amgn-cm723794,Top Health care stocks Top Health care stocks JNJ flatJNJ flat PFE 0 2 PFE 0 2 ABT flatABT flat MRK 0 2 MRK 0 2 AMGN 1 7 AMGN 1 7 Health care shares were mixed in pre market trade Tuesday Health care shares were mixed in pre market trade Tuesday In health care stocks
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Commits Up to $1 Billion for Virus 'Armed' to Fight Tumors,2016-12-20 14:14:00 +0000,https://www.thestreet.com/story/13932515/1/bristol-myers-commits-up-to-1b-for-virus-quot-armed-quot-to-fight-tumors.html?puc=yahoo&cm_ven=YAHOO,Bristol-Myers Commits Up to $1 Billion for Virus 'Armed' to Fight Tumors
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid Tumors",2016-12-20 12:02:12 +0000,http://www.publicnow.com/view/8B89B9EA0646E88C2B0BDF6243DC28DD8C170156,"[at noodls] - NEW YORK & OXFORD, United Kingdom--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an agreement granting Bristol-Myers Squibb exclusive ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Signs Exclusive License Deal For PsiOxus Therapeutics'' NG-348,2016-12-20 07:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jue5Wq3YcTg/bristolmyers-signs-exclusive-license-deal-for-psioxus-therapeutics-ng348-20161220-00202,Bristol-Myers Signs Exclusive License Deal For PsiOxus Therapeutics'' NG-348
BMY,BMY:US,BBG000DQLV23,"Close Update: Geopolitical Events Trim Early Gains; Dow Misses 20,000 For Fifth Day",2016-12-19 21:56:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fqDda3Vqi_c/close-update-geopolitical-events-trim-early-gains-dow-misses-20000-for-fifth-day-cm723609,Stocks closed modestly higher on Monday but off their session highs as geopolitical events spooked investors ahead of the holiday weekend The assassination of the Russian ambassador to Turkey followed by a vehicle attack on Berliners that killed nine people tugged the benchmark averages lower
BMY,BMY:US,BBG000DQLV23,Incyte Could Step Onto Auction Block With Strong Jakafi Sales: RBC,2016-12-19 21:14:27 +0000,http://www.investors.com/news/technology/incyte-could-step-onto-auction-block-with-strong-jakafi-sales-rbc/,Incyte Could Step Onto Auction Block With Strong Jakafi Sales: RBC
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Will Gain In Lung Cancer Square-Off Vs. Merck: Jefferies,2016-12-19 21:14:01 +0000,http://www.investors.com/news/technology/bristol-myers-win-in-2017-lung-cancer-square-off-vs-merck-jefferies/,Bristol-Myers Will Gain In Lung Cancer Square-Off Vs. Merck: Jefferies
BMY,BMY:US,BBG000DQLV23,"CLVS Gets FDA Nod, PBYI Leaves Big Board, LOXO Hits All-time High, CNAT On Watch",2016-12-19 20:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9I2-LeJFKKM/clvs-gets-fda-nod-pbyi-leaves-big-board-loxo-hits-alltime-high-cnat-on-watch-20161219-01000,"CLVS Gets FDA Nod, PBYI Leaves Big Board, LOXO Hits All-time High, CNAT On Watch"
BMY,BMY:US,BBG000DQLV23,"Why Jefferies Upgraded Bristol-Myers, Cut Merck",2016-12-19 19:06:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/19/why-jefferies-upgraded-bristol-myers-cut-merck/?mod=yahoobarrons&ru=yahoo,"Why Jefferies Upgraded Bristol-Myers, Cut Merck"
BMY,BMY:US,BBG000DQLV23,Midday Update: Stocks Hold Gains As Wall Street Waits For Reassurances From Yellen,2016-12-19 18:36:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w5J4NjSeD20/midday-update-stocks-hold-gains-as-wall-street-waits-for-reassurances-from-yellen-cm723485,The benchmark averages were holding onto modest gains midday Monday but are off their session highs following reports that the Russian ambassador to Turkey was killed in an attack tied to Russia s military involvement in the Syrian city of Aleppo The benchmark averages were holding onto
BMY,BMY:US,BBG000DQLV23,"The Juice is Nearly Loose for Bristol-Myers, Ritholtz's Brown Contends",2016-12-19 18:27:00 +0000,https://www.thestreet.com/story/13931423/1/the-juice-is-nearly-loose-for-bristol-myers-ritholtz-s-brown-contends.html?puc=yahoo&cm_ven=YAHOO,"The Juice is Nearly Loose for Bristol-Myers, Ritholtz's Brown Contends"
BMY,BMY:US,BBG000DQLV23,4 Stocks Insiders Are Loading Up On – and You Should Too,2016-12-19 17:58:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ht16CuG_i54/4-stocks-insiders-are-loading-up-on-and-you-should-too-cm723349,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips If you re cutting back on stocks because interest rates are rising you re making a mistake But don t just take my word for it after all I am a dyed in the wool dividend stock fan
BMY,BMY:US,BBG000DQLV23,"Noteworthy ETF Inflows: IWF, AAPL, AMZN, BMY",2016-12-19 17:57:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fw5nhd0SyMM/noteworthy-etf-inflows-iwf-aapl-amzn-bmy-cm723345,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 1000 Growth ETF Symbol IWF where we have detected an approximate 504 5 million dollar inflow that s a 1 6 increase week over week
BMY,BMY:US,BBG000DQLV23,"'I Didn't Buy This Call,' Jim Cramer Says of Merck Downgrade",2016-12-19 17:49:00 +0000,https://www.thestreet.com/story/13931373/1/i-didn-t-buy-this-call-jim-cramer-says-of-merck-downgrade.html?puc=yahoo&cm_ven=YAHOO,"'I Didn't Buy This Call,' Jim Cramer Says of Merck Downgrade"
BMY,BMY:US,BBG000DQLV23,Portola Pharma Wins on Pfizer and Bristol-Myers Loan Agreement,2016-12-19 17:20:55 +0000,http://finance.yahoo.com/news/portola-pharma-wins-pfizer-bristol-172055438.html,Portola Pharma Wins on Pfizer and Bristol-Myers Loan Agreement
BMY,BMY:US,BBG000DQLV23,The 12 Greatest Medical Breakthroughs of 2016,2016-12-19 16:51:28 +0000,http://www.fool.com/investing/2016/12/18/the-12-greatest-medical-breakthroughs-of-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The 12 Greatest Medical Breakthroughs of 2016
BMY,BMY:US,BBG000DQLV23,"Jefferies' Huge Pharma Pair Trade: Bristol-Myers Upgraded To Buy, Merck Downgraded To Sell",2016-12-19 14:09:24 +0000,http://finance.yahoo.com/news/jefferies-huge-pharma-pair-trade-140924012.html,"Jefferies' Huge Pharma Pair Trade: Bristol-Myers Upgraded To Buy, Merck Downgraded To Sell"
BMY,BMY:US,BBG000DQLV23,"Top Analysts Upgrades and Downgrades: Anadarko Petroleum, Bristol-Myers, Comcast, Disney, Merck and More",2016-12-19 13:55:29 +0000,http://247wallst.com/investing/2016/12/19/top-analysts-upgrades-and-downgrades-anadarko-petroleum-bristol-myers-comcast-disney-merck-and-more/,"Top Analysts Upgrades and Downgrades: Anadarko Petroleum, Bristol-Myers, Comcast, Disney, Merck and More"
BMY,BMY:US,BBG000DQLV23,Portola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa™ (andexanet alfa),2016-12-19 13:11:09 +0000,http://www.publicnow.com/view/D59C92548A8CF5B186820809D8F37AFE73441401,"[at noodls] - SOUTH SAN FRANCISCO, Calif., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc. (Nasdaq:PTLA) today announced it has signed a $50 million loan agreement with Bristol-Myers Squibb Company (NYSE:BMY) ..."
BMY,BMY:US,BBG000DQLV23,Portola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa™ (andexanet alfa),2016-12-19 13:00:00 +0000,http://finance.yahoo.com/news/portola-pharmaceuticals-enters-50-million-130000639.html,"[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Dec. 19, 2016-- Portola Pharmaceuticals Inc. ® today announced it has signed a $50 million loan agreement with Bristol-Myers Squibb Company and Pfizer Inc. that provides additional ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers upgraded by Jefferies,2016-12-19 11:45:48 +0000,http://finance.yahoo.com/q/ud?s=BMY,Bristol-Myers upgraded by Jefferies
BMY,BMY:US,BBG000DQLV23,Beximco Pharmaceuticals Gets U.S. Approval for Diabetes Control Drug,2016-12-19 04:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UGdiCk0RK6s/beximco-pharmaceuticals-gets-us-approval-for-diabetes-control-drug-20161219-00072,Beximco Pharmaceuticals Gets U.S. Approval for Diabetes Control Drug
BMY,BMY:US,BBG000DQLV23,The Most Expensive Drugs of 2016,2016-12-18 17:57:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_-tI5zo30LU/the-most-expensive-drugs-of-2016-cm722995,Prescription drug prices have gotten out of control for many Americans and many insurers Some drugs cost as much as premium sports cars Here are the five most expensive prescription drugs in 2016 as compiled by prescription drug comparison website GoodRx and which companies
BMY,BMY:US,BBG000DQLV23,The 12 Greatest Medical Breakthroughs of 2016,2016-12-18 17:56:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ww9xYozYefM/the-12-greatest-medical-breakthroughs-of-2016-cm722991,Image source Getty Images With less than two weeks to go before we turn the page on 2016 we can look back on another largely successful year for the healthcare industry The U S Food and Drug Administration has approved 19 novel drugs in 2016 to treat everything from psoriasis
BMY,BMY:US,BBG000DQLV23,White House Kills Plan for Drug Price Cap,2016-12-16 20:12:00 +0000,https://www.thestreet.com/story/13929151/1/white-house-kills-plan-for-drug-price-cap.html?puc=yahoo&cm_ven=YAHOO,White House Kills Plan for Drug Price Cap
BMY,BMY:US,BBG000DQLV23,"December Trades Bring Eggnog, Mistletoe -- and Some Coal",2016-12-16 16:38:00 +0000,http://realmoney.thestreet.com/articles/12/16/2016/december-trades-bring-eggnog-mistletoe-and-some-coal?puc=yahoo&cm_ven=YAHOO,"December Trades Bring Eggnog, Mistletoe -- and Some Coal"
BMY,BMY:US,BBG000DQLV23,"The Zacks Analyst Blog Highlights: Bristol-Myers, Shell, Facebook, Baker Hughes, Eli Lilly and Fifth Third Bancorp",2016-12-15 17:01:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ee1Mg5oPQ1g/the-zacks-analyst-blog-highlights-bristol-myers-shell-facebook-baker-hughes-eli-lilly-and-fifth-third-bancorp-cm722020,For Immediate Release Chicago IL December 15 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BMY,BMY:US,BBG000DQLV23,3 Top Big Pharma Stocks to Buy Now,2016-12-15 17:00:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yiSR7jBMlbs/3-top-big-pharma-stocks-to-buy-now-cm722000,A well rounded investment portfolio should arguably always include a couple of Big Pharma stocks These companies after all sport some of the highest profit margins and steady free cash flows and they often reward shareholder richly With this in mind I think investors may want
BMY,BMY:US,BBG000DQLV23,What Were Pfizer’s Major Achievements in 2016?,2016-12-15 15:05:28 +0000,http://marketrealist.com/2016/12/what-were-pfizers-major-achievements-in-2016/?utm_source=yahoo&utm_medium=feed,What Were Pfizer’s Major Achievements in 2016?
BMY,BMY:US,BBG000DQLV23,"Top Research Reports for Today: BMY, RDS.A, FB",2016-12-15 06:56:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pKT6bIo1-p8/top-research-reports-for-today-bmy-rdsa-fb-cm721689,Wednesday December 14 2016 Today s Research Daily features new research reports on 16 major stocks including Bristol Myers BMY Shell RDS A and Facebook FB Buy rated Bristol Myers shares have underperformed the broader market as well as the large cap pharma group this year though
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to shutter ZymoGenetics' Seattle Steam Plant facility,2016-12-14 22:35:06 +0000,http://www.bizjournals.com/seattle/blog/health-care-inc/2016/12/bristol-myers-squibb-to-shutter-zymogenetics.html?ana=yahoo,Bristol-Myers Squibb to shutter ZymoGenetics' Seattle Steam Plant facility
BMY,BMY:US,BBG000DQLV23,"Top Research Reports for Today: BMY, RDS.A, FB",2016-12-14 22:16:10 +0000,http://finance.yahoo.com/news/top-research-reports-today-bmy-221610646.html,"Top Research Reports for Today: BMY, RDS.A, FB"
BMY,BMY:US,BBG000DQLV23,Eli Lilly In 2017: Boom Or Bust?,2016-12-14 18:50:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/14/eli-lilly-in-2017-boom-or-bust/?mod=yahoobarrons&ru=yahoo,Eli Lilly In 2017: Boom Or Bust?
BMY,BMY:US,BBG000DQLV23,Bristol-Myers to boost Devens staff as part of R&D revamp,2016-12-13 19:05:05 +0000,http://www.bizjournals.com/boston/news/2016/12/13/bristol-myers-to-boost-devens-staff-as-part-of-r-d.html?ana=yahoo,Bristol-Myers to boost Devens staff as part of R&D revamp
BMY,BMY:US,BBG000DQLV23,"Organovo Holdings, Inc.'s Biggest Win in 2016",2016-12-13 17:22:04 +0000,http://www.fool.com/investing/2016/12/13/organovo-holdings-incs-biggest-win-in-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Organovo Holdings, Inc.'s Biggest Win in 2016"
BMY,BMY:US,BBG000DQLV23,"Organovo Holdings, Inc.'s Biggest Win in 2016",2016-12-13 17:00:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_gabpW50CGc/organovo-holdings-incs-biggest-win-in-2016-cm720856,This turned out to be great year for Organovo Holdings NASDAQ ONVO Shares of the 3D bioprinting company climbed over 30 during 2016 Organovo had several important developments during the year but what was the company s biggest win Image source Getty
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Strengthens Capabilities with Evolution of its U.S. Geographic Footprint,2016-12-13 14:30:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-strengthens-capabilities-143000279.html,"[Business Wire] - Bristol-Myers Squibb Company today announced important changes to its U.S. geographic footprint that will strengthen capabilities of the company's R&D hubs of world-class science and innovation in Central New Jersey, the San Francisco Bay Area and Cambridge, Massachusetts while further integrating biologics development with clinical manufacturing at key sites to foster greater speed and collaboration...."
BMY,BMY:US,BBG000DQLV23,"With Obamacare repealed, 1 in 4 adults could be uninsurable due to a pre-existing condition",2016-12-12 17:46:15 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=4D292502-C078-11E6-9CE4-1CAA3DBD2E2E&siteid=yhoof2,"With Obamacare repealed, 1 in 4 adults could be uninsurable due to a pre-existing condition"
BMY,BMY:US,BBG000DQLV23,"Stock Market News for December 12, 2016",2016-12-12 16:55:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rCj6C2HD40Y/stock-market-news-for-december-12-2016-cm720097,Benchmarks finished in the green on Friday as recently beaten down sector saw an impressive rebound Gains in sectors like consumer staples and healthcare led all the three key indexes to settle at record highs with the S amp P 500 reached its record high levels for third consecutive
BMY,BMY:US,BBG000DQLV23,"5 Trade Ideas for Monday: Bristol-Myers, eBay, IBM, Nasdaq and Och-Ziff",2016-12-11 19:39:16 +0000,http://finance.yahoo.com/tumblr/blog-5-trade-ideas-for-monday-bristol-myers-ebay-193922766.html,"5 Trade Ideas for Monday: Bristol-Myers, eBay, IBM, Nasdaq and Och-Ziff"
BMY,BMY:US,BBG000DQLV23,The 3 Fastest-Growing Drug Classes Over the Next 5 Years,2016-12-10 17:56:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E7I-p0kPH2U/the-3-fastest-growing-drug-classes-over-the-next-5-years-cm719760,Image source Getty Images If you ve picked up a prescription from the pharmacy recently you probably don t need any reminding that prescription drugs can be expensive In recent years drug prices have soared as biotech and pharmaceutical companies have focused their efforts
BMY,BMY:US,BBG000DQLV23,"Noteworthy Friday Option Activity: BMY, BREW, KO",2016-12-09 21:56:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ExD1rGYisEo/noteworthy-friday-option-activity-bmy-brew-ko-cm719586,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Bristol Myers Squibb Co Symbol BMY where a total of 44 113 contracts have traded so far representing approximately 4 4 million underlying shares That amounts to about 43 9 of BMY
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb to Announce Results for Fourth Quarter 2016 on January 26, 2017",2016-12-09 21:00:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-announce-results-210000772.html,"[Business Wire] - Bristol-Myers Squibb Company will announce results for the fourth quarter of 2016 on Thursday, January 26, 2017. During a conference call at 10:30 a.m. EST on January 26, company executives will review financial information and will address inquiries from investors and analysts."
BMY,BMY:US,BBG000DQLV23,"Daily Dividend Report: GE, BMY, ABT, ECL, EIX, VTR, CAG",2016-12-09 20:56:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eMtae7sPqpE/daily-dividend-report-ge-bmy-abt-ecl-eix-vtr-cag-cm719569,GE GE raised the Company s quarterly dividend 4 or 0 01 per outstanding share of the Company s common stock to 0 24 per outstanding share of the Company s common stock The Board declared that the dividend is payable January 25 2017 to shareowners of record at the close of business
BMY,BMY:US,BBG000DQLV23,"Friday's ETF Movers: PJP, GDXJ",2016-12-09 19:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KF1_0mrMkuA/fridays-etf-movers-pjp-gdxj-cm719512,In trading on Friday the PowerShares Dynamic Pharmaceuticals Portfolio ETF PJP is outperforming other ETFs up about 1 5 on the day Components of that ETF showing particular strength include shares of The Medicines MDCO up about 5 6 and shares of Bristol Myers Squibb BMY
BMY,BMY:US,BBG000DQLV23,"QUAL, PEG, BMY, SCHW: ETF Outflow Alert",2016-12-09 17:58:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wrcXqj_83eU/qual-peg-bmy-schw-etf-outflow-alert-cm719427,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Edge MSCI USA Quality Factor ETF Symbol QUAL where we have detected an approximate 69 3 million dollar outflow that s a 2 0 decrease week over
BMY,BMY:US,BBG000DQLV23,"Stocks Close Firmly Positive, Major Averages At New Highs - U.S. Commentary",2016-12-09 16:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KzCymGztzq4/stocks-close-firmly-positive-major-averages-at-new-highs--us-commentary-20161209-00576,"Stocks Close Firmly Positive, Major Averages At New Highs - U.S. Commentary"
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs",2016-12-09 14:59:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z4k6ihoe7Kw/pharma-stock-roundup-drug-pricing-heat-back-on-sector-endo-mylan-azn-to-cut-jobs-cm719273,Drug pricing is back in focus with President elect Donald Trump making it clear that he does not like price increases In an interview with TIME magazine which has named him 2016 Person of the Year Trump said that his intentions may have been misread by some stock analysts and that his
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Declares 39-Cent Cash Dividend,2016-12-09 13:40:00 +0000,http://www.investopedia.com/news/bristolmyers-declares-39cent-cash-dividend-bmy/?partner=YahooSA,Bristol-Myers Declares 39-Cent Cash Dividend
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs",2016-12-09 13:28:01 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-drug-pricing-132801721.html,"Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs"
BMY,BMY:US,BBG000DQLV23,Stocks Holding On To Gains In Mid-Day Trading - U.S. Commentary,2016-12-09 12:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j9bsGebM42g/stocks-holding-on-to-gains-in-midday-trading--us-commentary-20161209-00438,Stocks Holding On To Gains In Mid-Day Trading - U.S. Commentary
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb settles with Mass., other states over Abilify marketing",2016-12-09 02:50:08 +0000,http://www.bizjournals.com/boston/news/2016/12/08/bristol-myers-squibb-settles-with-mass-other.html?ana=yahoo,"Bristol-Myers Squibb settles with Mass., other states over Abilify marketing"
BMY,BMY:US,BBG000DQLV23,Official: Bristol-Myers Squibb to pay to settle allegations,2016-12-09 01:58:17 +0000,http://finance.yahoo.com/news/official-bristol-myers-squibb-pay-012850108.html,Official: Bristol-Myers Squibb to pay to settle allegations
BMY,BMY:US,BBG000DQLV23,Official: Bristol-Myers Squibb to pay to settle allegations,2016-12-09 01:58:05 +0000,http://sg.finance.yahoo.com/news/official-bristol-myers-squibb-pay-012850660.html,Official: Bristol-Myers Squibb to pay to settle allegations
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces Dividend Increase,2016-12-08 21:15:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-announces-dividend-211500227.html,"[Business Wire] - The Board of Directors of Bristol-Myers Squibb Company today declared an increase of 2.6% percent in the company’s quarterly dividend, beginning in the first quarter of 2017."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to pay $19.5 mln to settle off-label promotion case,2016-12-08 17:45:56 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-pay-19-174556124.html,"[Reuters] - Drugmaker Bristol-Myers Squibb Co will pay $19.5 million to resolve multi-state allegations that it improperly promoted a schizophrenia treatment for uses not approved by the U.S. government, New York Attorney General Eric Schneiderman said on Thursday. The company's agreement with 42 other states and the District of Columbia centers on charges that Bristol-Myers Squibb promoted its Abilify anti-psychotic drug for use in children and elderly patients with dementia and Alzheimer's disease. A company spokesman did not have an immediate comment on the settlement."
BMY,BMY:US,BBG000DQLV23,Bristol-Meyers Squibb to pay $19.5 mln to settle off-label promotion case,2016-12-08 17:00:02 +0000,http://finance.yahoo.com/news/bristol-meyers-squibb-pay-19-170002742.html,"[Reuters] - Drugmaker Bristol-Meyers Squibb Co will pay $19.5 million to resolve multi-state allegations that it improperly promoted a schizophrenia treatment for uses not approved by the U.S. government, New York Attorney General Eric Schneiderman said on Thursday. The company's agreement with 42 other states and the District of Columbia centers on charges that Bristol-Meyers Squibb promoted its Abilify anti-psychotic drug for use in children and elderly patients with dementia and Alzheimer's disease. A company spokesman did not have an immediate comment on the settlement."
BMY,BMY:US,BBG000DQLV23,Why AstraZeneca plc Stock Slumped in November,2016-12-07 16:57:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sPe4_7C_PzE/why-astrazeneca-plc-stock-slumped-in-november-cm718036,What happened According to data from S amp P Global Market Intelligence AstraZeneca s NYSE AZN shares fell by more than 8 last month The main culprit behind the drugmaker s poor showing in November was a disappointing third quarter earnings release Of particular
BMY,BMY:US,BBG000DQLV23,Why AstraZeneca plc Stock Slumped in November,2016-12-07 15:21:07 +0000,http://www.fool.com/investing/2016/12/07/why-astrazeneca-plc-stock-slumped-in-november.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why AstraZeneca plc Stock Slumped in November
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb To Present At Citi Conference; Webcast At 8:00 AM ET,2016-12-07 07:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9RvNS5GQqmc/bristolmyers-squibb-to-present-at-citi-conference-webcast-at-800-am-et-20161207-00213,Bristol-Myers Squibb To Present At Citi Conference; Webcast At 8:00 AM ET
BMY,BMY:US,BBG000DQLV23,EU clears Bristol-Myers immunotherapy drug for blood cancer,2016-12-07 00:01:01 +0000,http://finance.yahoo.com/news/eu-clears-bristol-myers-immunotherapy-000101832.html,"[Reuters] - Bristol-Myers Squibb's immunotherapy drug Opdivo has been approved in Europe for the treatment of classical Hodgkin lymphoma, a rare blood cancer, the U.S. company said on Wednesday. Opdivo is already ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Reports Data from Opdivo Combination Studies,2016-12-06 14:27:02 +0000,http://finance.yahoo.com/news/bristol-myers-reports-data-opdivo-142702369.html,Bristol-Myers Reports Data from Opdivo Combination Studies
BMY,BMY:US,BBG000DQLV23,"Opdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer, From Phase 1/2 Study CheckMate -032",2016-12-06 13:45:00 +0000,http://finance.yahoo.com/news/opdivo-nivolumab-alone-combined-yervoy-134500576.html,"[Business Wire] - Bristol-Myers Squibb Company announced today updated results for Opdivo monotherapy and in combination with Yervoy in previously treated small cell lung cancer patients, a cohort of the Phase 1/2 open-label CheckMate -032 trial."
BMY,BMY:US,BBG000DQLV23,U.S. 'Disappointed' by Japan's Plan to Cut Drug Costs,2016-12-06 02:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/poTbgndJTLE/us-disappointed-by-japans-plan-to-cut-drug-costs-20161206-00047,U.S. 'Disappointed' by Japan's Plan to Cut Drug Costs
BMY,BMY:US,BBG000DQLV23,Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting,2016-12-06 00:30:00 +0000,http://finance.yahoo.com/news/seattle-genetics-bristol-myers-squibb-003000062.html,"[Business Wire] - Seattle Genetics, Inc. and Bristol-Myers Squibb Company today highlighted the first reported data from an ongoing phase 1/2 clinical trial evaluating ADCETRIS in combination with Opdivo in relapsed or refractory classical Hodgkin lymphoma at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016."
BMY,BMY:US,BBG000DQLV23,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell,2016-12-05 20:55:28 +0000,http://finance.yahoo.com/news/pressure-biosciences-ceo-biological-samples-205528437.html,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
BMY,BMY:US,BBG000DQLV23,"D E Shaw Makes Massive Investments in Apple, Disney, More",2016-12-05 13:38:16 +0000,http://www.insidermonkey.com/blog/d-e-shaw-makes-massive-investments-in-apple-disney-more-489835/,"D E Shaw Makes Massive Investments in Apple, Disney, More"
BMY,BMY:US,BBG000DQLV23,Assessing Bristol-Myers Stock Valuation (BMY),2016-12-05 13:18:00 +0000,http://www.investopedia.com/news/assessing-bristolmyers-stock-valuation-bmy/?partner=YahooSA,Assessing Bristol-Myers Stock Valuation (BMY)
BMY,BMY:US,BBG000DQLV23,"Encouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up in First-line Advanced Non-small Cell Lung Cancer, in Updated Phase 1b CheckMate -012 Study",2016-12-05 10:00:00 +0000,http://uk.finance.yahoo.com/news/encouraging-survival-observed-opdivo-nivolumab-100000787.html,"Encouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up in First-line Advanced Non-small Cell Lung Cancer, in Updated Phase 1b CheckMate -012 Study"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Announces Updated Findings From Phase 1b Trial, CheckMate -012",2016-12-05 05:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Tthayea3L5s/bristolmyers-announces-updated-findings-from-phase-1b-trial-checkmate-012-20161205-00096,"Bristol-Myers Announces Updated Findings From Phase 1b Trial, CheckMate -012"
BMY,BMY:US,BBG000DQLV23,Why Bristol-Myers Squibb Co. Stock Surged in November,2016-12-03 14:43:06 +0000,http://www.fool.com/investing/2016/12/03/why-bristol-myers-squibb-co-stock-surged-in-novemb.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Bristol-Myers Squibb Co. Stock Surged in November
BMY,BMY:US,BBG000DQLV23,$50 Billion Quant Fund Is Making New Bets On These Stocks,2016-12-02 20:35:20 +0000,http://www.insidermonkey.com/blog/50-billion-quant-fund-is-making-new-bets-on-these-stocks-488040/,$50 Billion Quant Fund Is Making New Bets On These Stocks
BMY,BMY:US,BBG000DQLV23,What Do Analysts Recommend for Gilead Sciences Stock?,2016-12-02 13:04:05 +0000,http://marketrealist.com/2016/11/what-do-analysts-recommend-for-gilead-sciences-stock/?utm_source=yahoo&utm_medium=feed,What Do Analysts Recommend for Gilead Sciences Stock?
BMY,BMY:US,BBG000DQLV23,Heat Biologics Stock Falls on Negative Bladder Cancer Data,2016-12-01 17:21:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VtkRQQrUwss/heat-biologics-stock-falls-on-negative-bladder-cancer-data-cm716371,Heat Biologics Inc s HTBX shares plunged 56 1 during yesterday s after hours trading after the company presented disappointing top line data from a phase II study on its lead pipeline candidate HS 410 vesigenurtacel L for the treatment of non muscle invasive bladder cancer NMIBC
BMY,BMY:US,BBG000DQLV23,"Notable ETF Inflow Detected - IUSG, GOOG, ABBV, BMY",2016-12-01 17:17:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2dlfc2FaQ2A/notable-etf-inflow-detected-iusg-goog-abbv-bmy-cm716378,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Core Russell U S Growth ETF Symbol IUSG where we have detected an approximate 61 7 million dollar inflow that s a 5 9 increase week over week
BMY,BMY:US,BBG000DQLV23,"3 Ways Organovo Holdings, Inc. Plans to Grow Exponentially for Years to Come",2016-12-01 14:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E6HVPzLzglg/3-ways-organovo-holdings-inc-plans-to-grow-exponentially-for-years-to-come-cm716203,According to baseball legend Babe Ruth pointed to the center field bleachers in the third game of the 1932 World Series On the next pitch that s where he hit the ball making one of the greatest home runs in baseball history Organovo Holdings NASDAQ ONVO CEO Keith
BMY,BMY:US,BBG000DQLV23,"After Hours Most Active for Nov 30, 2016 :  FDC, INFO, MSFT, BAC, SFUN, BMY, AAPL, SIRI, INTC, NRG, EPD, SGEN",2016-11-30 22:05:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wDDkHgW8sU0/after-hours-most-active-for-nov-30-2016-fdc-info-msft-bac-sfun-bmy-aapl-siri-intc-nrg-epd-sgen-cm716039,The NASDAQ 100 After Hours Indicator is up 1 54 to 4 812 35 The total After hours volume is currently 93 435 420 shares traded The following are the most active stocks for the after hours session First Data Corporation FDC is unchanged at 14 57 with 11 101 653
BMY,BMY:US,BBG000DQLV23,ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.,2016-11-30 16:58:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z8cY7ZeXyuQ/ariads-leukemia-drug-iclusig-gets-full-approval-in-us-cm715746,ARIAD Pharmaceuticals Inc ARIA announced that the FDA has granted a full approval to its leukemia drug Iclusig ponatinib following its successful completion of the commitments made on the receipt of accelerated approval in Dec 2012 Iclusig is approved for the treatment of
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part at the Citi 2016 Global Healthcare Conference,2016-11-30 14:54:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-part-citi-145400321.html,"[Business Wire] - Bristol-Myers Squibb Company will take part in the Citi 2016 Global Healthcare Conference on Wednesday, December 7, 2016, in New York. Giovanni Caforio, M.D., chief executive officer, and Francis Cuss, MB, BChir, FRCP, chief scientific officer, will make formal remarks and answer questions about the company at 8:00 a.m."
BMY,BMY:US,BBG000DQLV23,Pharma Needs To Have A Sense Of Urgency,2016-11-30 13:00:00 +0000,http://www.forbes.com/sites/sciencebiz/2016/11/30/pharma-needs-to-have-a-sense-of-urgency/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Pharma Needs To Have A Sense Of Urgency
BMY,BMY:US,BBG000DQLV23,Hedge Funds Hate These 5 Huge Stocks -- Should You Sell Them?,2016-11-30 11:02:00 +0000,https://www.thestreet.com/story/13908383/1/hedge-funds-hate-these-5-huge-stocks-should-you-sell-them.html?puc=yahoo&cm_ven=YAHOO,Hedge Funds Hate These 5 Huge Stocks -- Should You Sell Them?
BMY,BMY:US,BBG000DQLV23,"The Zacks Analyst Blog Highlights: Bristol-Myers, Google, Deere, Halliburton and American Airlines",2016-11-29 16:58:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mihavD_0m08/the-zacks-analyst-blog-highlights-bristol-myers-google-deere-halliburton-and-american-airlines-cm715159,For Immediate Release Chicago IL November 29 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BMY,BMY:US,BBG000DQLV23,Is Bristol-Myers Feeling Better? Not Really,2016-11-29 16:31:00 +0000,http://realmoney.thestreet.com/articles/11/29/2016/bristol-myers-feeling-better-not-really?puc=yahoo&cm_ven=YAHOO,Is Bristol-Myers Feeling Better? Not Really
BMY,BMY:US,BBG000DQLV23,AVEO Partner Submits Response to Questions on Tivozanib,2016-11-29 15:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V94QVw-fioQ/aveo-partner-submits-response-to-questions-on-tivozanib-cm715062,AVEO Pharmaceuticals Inc AVEO announced that its development partner EUSA Pharma has submitted its response to the Day 120 List of Questions issued by the European Medicines Agency s EMA Committee for Medicinal Products for Human Use as part of the regulatory authority s centralized
BMY,BMY:US,BBG000DQLV23,How Was Bristol-Myers Squibb’s Profitability in 3Q16?,2016-11-29 15:04:14 +0000,http://marketrealist.com/2016/11/how-was-bristol-myers-squibbs-profitability-in-3q16/?utm_source=yahoo&utm_medium=feed,How Was Bristol-Myers Squibb’s Profitability in 3Q16?
BMY,BMY:US,BBG000DQLV23,"The Zacks Analyst Blog Highlights: Bristol-Myers, Google, Deere, Halliburton and American Airlines",2016-11-29 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-bristol-143002032.html,"The Zacks Analyst Blog Highlights: Bristol-Myers, Google, Deere, Halliburton and American Airlines"
BMY,BMY:US,BBG000DQLV23,"Top Research Reports for Alphabet, Deere & Bristol-Myers",2016-11-28 23:55:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F1vWyRhFVnE/top-research-reports-for-alphabet-deere-bristol-myers-cm714803,Monday November 28 2016 Today s Research Daily features new research reports on 16 major stocks including Bristol Myers BMY Google GOOGL and Deere DE Bristol Myers shares have underperformed the broader market as well as the large cap pharma group this year though the stock
BMY,BMY:US,BBG000DQLV23,3 Top Drug Stocks for Your Retirement Portfolio,2016-11-28 19:56:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0hozMTH8SI4/3-top-drug-stocks-for-your-retirement-portfolio-cm714673,What makes a stock a good fit for a retirement portfolio Most older investors want steady dividend payments for income but don t want to give up the potential for growth These three pharmaceutical stocks should be able to deliver both Here s why Bristol Myers Squibb NYSE
BMY,BMY:US,BBG000DQLV23,3 Top Drug Stocks for Your Retirement Portfolio,2016-11-28 16:02:32 +0000,http://www.fool.com/investing/2016/11/28/3-top-drug-stocks-for-your-retirement-portfolio.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Top Drug Stocks for Your Retirement Portfolio
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Lilly Alzheimer's Drug Fails, J&J in Acquisition Talks with ALIOF",2016-11-28 15:32:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jXY0HwZ0e7M/pharma-stock-roundup-lilly-alzheimers-drug-fails-jj-in-acquisition-talks-with-aliof-cm714418,The big news last week was the high profile failure of Lilly s LLY investigational Alzheimer s disease drug solanezumab While the news dented Lilly s shares with the stock touching a 52 week low other companies involved in developing Alzheimer s disease treatments were also not spared
BMY,BMY:US,BBG000DQLV23,How Did Bristol-Myers Squibb’s Blockbuster Oncology Drug Perform?,2016-11-28 13:04:29 +0000,http://marketrealist.com/2016/11/how-did-bristol-myers-squibbs-blockbuster-oncology-drug-perform/?utm_source=yahoo&utm_medium=feed,How Did Bristol-Myers Squibb’s Blockbuster Oncology Drug Perform?
BMY,BMY:US,BBG000DQLV23,A Look At Billionaire Julian Robertson’s Top Dividend Picks,2016-11-26 01:22:41 +0000,http://www.insidermonkey.com/blog/a-look-at-billionaire-julian-robertsons-top-dividend-picks-2-491917/,A Look At Billionaire Julian Robertson’s Top Dividend Picks
BMY,BMY:US,BBG000DQLV23,How Does Bristol-Myers Squibb’s Valuation Compare to Peers?,2016-11-25 14:40:33 +0000,http://marketrealist.com/2016/11/how-does-bristol-myers-squibbs-valuation-compare-to-peers-2/?utm_source=yahoo&utm_medium=feed,How Does Bristol-Myers Squibb’s Valuation Compare to Peers?
BMY,BMY:US,BBG000DQLV23,"Final Trade: GM, BMY & more",2016-11-23 22:59:00 +0000,http://finance.yahoo.com/video/final-trade-gm-bmy-more-225900790.html,"Final Trade: GM, BMY & more"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Hodgkin Lymphoma Drug OKed in EU (BMY),2016-11-23 20:50:00 +0000,http://www.investopedia.com/news/bristolmyers-opdivo-gets-eu-ok-lymphoma-bmy/?partner=YahooSA,Bristol-Myers Hodgkin Lymphoma Drug OKed in EU (BMY)
BMY,BMY:US,BBG000DQLV23,"Alzheimer's setback prompts rethink of Lilly, Biogen stock outlooks",2016-11-23 20:30:38 +0000,http://uk.finance.yahoo.com/news/alzheimers-setback-prompts-rethink-lilly-203038134.html,"Alzheimer's setback prompts rethink of Lilly, Biogen stock outlooks"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Opdivo Gets EU Approval for Label Expansion,2016-11-23 15:08:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gBuksYesV9E/bristol-myers-opdivo-gets-eu-approval-for-label-expansion-cm713203,Bristol Myers Squibb Company BMY announced that the European Commission has approved its immuno oncology drug Opdivo for an additional indication Opdivo has been approved for the treatment of adults with relapsed or refractory classical Hodgkin lymphoma cHL after autologous stem
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Opdivo Gets EU Approval for Label Expansion,2016-11-23 12:38:12 +0000,http://finance.yahoo.com/news/bristol-myers-opdivo-gets-eu-123812846.html,Bristol-Myers' Opdivo Gets EU Approval for Label Expansion
BMY,BMY:US,BBG000DQLV23,European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin,2016-11-22 22:25:26 +0000,http://www.publicnow.com/view/395BAF92EF9A6663EEC118C1F633D63C81A4DBAE,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced the European Commission approved Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory ..."
BMY,BMY:US,BBG000DQLV23,Where Does Eli Lilly’s Valuation Stand Next to Peers?,2016-11-22 16:54:12 +0000,http://marketrealist.com/2016/11/where-does-eli-lillys-valuation-stand-next-to-peers/?utm_source=yahoo&utm_medium=feed,Where Does Eli Lilly’s Valuation Stand Next to Peers?
BMY,BMY:US,BBG000DQLV23,AstraZeneca cleared to resume enrolment in cancer drug trials,2016-11-22 08:56:05 +0000,http://uk.finance.yahoo.com/news/astrazeneca-cleared-resume-enrolment-cancer-085605315.html,"[Reuters - UK Focus] - U.S. officials have given a green light for two clinical trials testing AstraZeneca's immunotherapy drug durvalumab in head and neck cancer to resume recruiting patients, lifting a hold imposed following cases of bleeding."
BMY,BMY:US,BBG000DQLV23,Cramer: Trump Rally is a FANG + FANG Affair,2016-11-22 00:01:00 +0000,http://realmoney.thestreet.com/articles/11/21/2016/cramer-trump-rally-fang-fang-affair?puc=yahoo&cm_ven=YAHOO,Cramer: Trump Rally is a FANG + FANG Affair
BMY,BMY:US,BBG000DQLV23,"Billionaire Julian Robertson Takes Out Huge SPY Hedge, Grows Bearish on Transportation Stocks",2016-11-21 21:35:10 +0000,http://www.insidermonkey.com/blog/billionaire-julian-robertson-takes-out-huge-spy-hedge-grows-bearish-on-transportation-stocks-488368/,"Billionaire Julian Robertson Takes Out Huge SPY Hedge, Grows Bearish on Transportation Stocks"
BMY,BMY:US,BBG000DQLV23,"Notable ETF Outflow Detected - PPH, SNY, BMY, PFE",2016-11-21 18:09:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y9dpIg15o70/notable-etf-outflow-detected-pph-sny-bmy-pfe-cm712104,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Pharmaceutical ETF Symbol PPH where we have detected an approximate 42 2 million dollar outflow that s a 14 1 decrease week over week from 5 688 138
BMY,BMY:US,BBG000DQLV23,"Why Is Lung Cancer so Attractive to Bristol, Merck, and Roche?",2016-11-21 16:04:23 +0000,http://marketrealist.com/2016/11/why-is-lung-cancer-so-attractive-to-bristol-merck-and-roche/?utm_source=yahoo&utm_medium=feed,"Why Is Lung Cancer so Attractive to Bristol, Merck, and Roche?"
BMY,BMY:US,BBG000DQLV23,Health Care Sector Update for 11/21/2016: ROSG,2016-11-21 14:50:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uL3baw-hTF4/health-care-sector-update-for-11212016-rosg-cm711870,Top Health care stocks Top Health care stocks JNJ flatJNJ flat PFE 0 3 PFE 0 3 ABT flatABT flat MRK flatMRK flat AMGN flatAMGN flat Health care shares were mainly unchanged in pre market trade on Monday Health care shares were mainly unchanged in pre market trade on Monday
BMY,BMY:US,BBG000DQLV23,Can Bristol-Myers Squibb's Dividend Even Survive?,2016-11-20 17:13:14 +0000,http://www.fool.com/investing/2016/11/19/can-bristol-myers-squibbs-dividend-even-survive.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Can Bristol-Myers Squibb's Dividend Even Survive?
BMY,BMY:US,BBG000DQLV23,Can Bristol-Myers Squibb's Dividend Even Survive?,2016-11-19 18:49:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dl6PhRdBQNc/can-bristol-myers-squibbs-dividend-even-survive-cm711630,Image source Getty Images The 21st century hasn t been easy for yield hungry Bristol Myers Squibb NYSE BMY shareholders The company froze its quarterly payout at 0 28 from 2001 through 2007 and the last four payments of 0 38 constitute a dismal growth rate of about 2 65
BMY,BMY:US,BBG000DQLV23,Better Buy: Celgene Corporation vs. Bristol-Myers Squibb,2016-11-19 17:05:52 +0000,http://www.fool.com/investing/2016/11/18/better-buy-celgene-corporation-vs-bristol-myers-sq.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Celgene Corporation vs. Bristol-Myers Squibb
BMY,BMY:US,BBG000DQLV23,Understanding Bristol’s Blockbuster: Opdivo’s Edge over Keytruda,2016-11-18 22:04:10 +0000,http://marketrealist.com/2016/11/understanding-bristols-blockbuster-opdivos-edge-over-keytruda/?utm_source=yahoo&utm_medium=feed,Understanding Bristol’s Blockbuster: Opdivo’s Edge over Keytruda
BMY,BMY:US,BBG000DQLV23,The 10 Best Pharma Stocks Under President Donald Trump,2016-11-18 21:50:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Rr-p2ujnig0/the-10-best-pharma-stocks-under-president-donald-trump-cm710889,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips It s been a little over a week yet the news has yet to fully sink in for many folks Donald Trump the mogul the mastermind the most interesting man in the world according to Donald Trump will be
BMY,BMY:US,BBG000DQLV23,Better Buy: Celgene Corporation vs. Bristol-Myers Squibb,2016-11-18 18:51:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-wA2EsLYRd8/better-buy-celgene-corporation-vs-bristol-myers-squibb-cm711370,Celgene NASDAQ CELG and Bristol Myers Squibb NYSE BMY have gained plenty of attention recently as great healthcare value plays My colleague Sean Williams included both stocks in his list of four top drug stocks that can be purchased on the cheap this fall David
BMY,BMY:US,BBG000DQLV23,What’s Bristol-Myers Squibb Stock Been Up To?,2016-11-18 18:39:21 +0000,http://marketrealist.com/2016/11/whats-bristol-myers-squibb-stock-been-up-to/?utm_source=yahoo&utm_medium=feed,What’s Bristol-Myers Squibb Stock Been Up To?
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Data Presented at ACR, Bristol-Myers Inks Immuno-Oncology Deal",2016-11-18 13:51:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rzqSEN84ZPw/pharma-stock-roundup-data-presented-at-acr-bristol-myers-inks-immuno-oncology-deal-cm711052,Several companies were present at the annual meeting of the American College of Rheumatology ACR presenting data on approved as well as pipeline candidates Meanwhile Bristol Myers BMY announced an immune oncology deal and also provided updates on some of its cancer treatments Recap of
BMY,BMY:US,BBG000DQLV23,"Pfizer’s Metabolic, Rare Disease Segments: Hope for the Future?",2016-11-18 13:04:47 +0000,http://marketrealist.com/2016/11/metabolic-rare-disease-segments-expected-boost-pfizers-revenues-future-years/?utm_source=yahoo&utm_medium=feed,"Pfizer’s Metabolic, Rare Disease Segments: Hope for the Future?"
BMY,BMY:US,BBG000DQLV23,Novartis’s Alcon Continues Its Falling Trend in 3Q16,2016-11-18 13:04:22 +0000,http://marketrealist.com/2016/11/novartiss-alcon-continues-its-falling-trend-in-3q16/?utm_source=yahoo&utm_medium=feed,Novartis’s Alcon Continues Its Falling Trend in 3Q16
BMY,BMY:US,BBG000DQLV23,Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma (164KB),2016-11-18 07:10:15 +0000,http://www.publicnow.com/view/E98DF640491C2B261038514B142441B2123D3754,"[at noodls] - November 18, 2016 Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma (PRINCETON, N.J., November 12, 2016) ..."
BMY,BMY:US,BBG000DQLV23,10 Pharma Stocks That Are Prescribed Under President Trump,2016-11-17 22:51:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w2zuywKHp48/10-pharma-stocks-that-are-prescribed-under-president-trump-cm710889,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips It s been a little over a week yet the news has yet to fully sink in for many folks Donald Trump the mogul the mastermind the most interesting man in the world according to Donald Trump will be
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Enterome Ink Immuno-Oncology Collaboration",2016-11-17 15:53:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GF6gcq9h1Io/bristol-myers-enterome-ink-immuno-oncology-collaboration-cm710586,Bristol Myers Squibb Company BMY announced an immuno oncology focused collaboration agreement with Enterome for the discovery and development of microbiome derived biomarkers drug targets and bioactive molecules as potential companion diagnostics and therapeutics for cancer The partnership
BMY,BMY:US,BBG000DQLV23,3 Things Exelixis Must Do to Survive and Thrive in 2017,2016-11-17 15:52:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FPpwwYqZXB8/3-things-exelixis-must-do-to-survive-and-thrive-in-2017-cm710577,Few stocks have performed as well as Exelixis NASDAQ EXEL has in 2016 The biotech s share price has nearly tripled this year Will Exelixis be able to carry this tremendous momentum in to 2017 Mike Morrissey Exelixis CEO spoke at the Stifel Healthcare Conference this week
BMY,BMY:US,BBG000DQLV23,3 Things Exelixis Must Do to Survive and Thrive in 2017,2016-11-17 14:29:41 +0000,http://www.fool.com/investing/2016/11/17/3-keys-for-exelixis-to-survive-and-thrive-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Things Exelixis Must Do to Survive and Thrive in 2017
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Enterome Ink Immuno-Oncology Collaboration",2016-11-17 13:17:01 +0000,http://finance.yahoo.com/news/bristol-myers-enterome-ink-immuno-131701115.html,"Bristol-Myers, Enterome Ink Immuno-Oncology Collaboration"
BMY,BMY:US,BBG000DQLV23,Japan sets 50 pct price cut for Opdivo cancer drug: Ono Pharma,2016-11-17 03:36:36 +0000,http://finance.yahoo.com/news/japan-sets-50-pct-price-033636882.html,Japan sets 50 pct price cut for Opdivo cancer drug: Ono Pharma
BMY,BMY:US,BBG000DQLV23,"Roche, Bristol-Myers cut cancer drug prices to win UK approval",2016-11-17 00:03:17 +0000,http://sg.finance.yahoo.com/news/roche-bristol-myers-cut-cancer-000317295.html,"Roche, Bristol-Myers cut cancer drug prices to win UK approval"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Presents New Data at IASLC 17th World Conference on Lung Cancer Underscoring Progress and Leadership in Broad Lung Development Program,2016-11-16 22:13:00 +0000,http://uk.finance.yahoo.com/news/bristol-myers-squibb-presents-data-221300124.html,Bristol-Myers Squibb Presents New Data at IASLC 17th World Conference on Lung Cancer Underscoring Progress and Leadership in Broad Lung Development Program
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-derived Biomarkers, Drug Targets and Bioactive Molecules",2016-11-16 09:04:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-enterome-sa-090400844.html,"[PR Newswire] - Bristol-Myers Squibb (BMY) and Enterome SA (Enterome), a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer. Additionally, the collaboration will seek to identify novel microbiome-derived biomarkers in an effort to improve clinical outcomes for patients treated with Bristol-Myers Squibb's Immuno-Oncology portfolio."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb To Present At Stifel Conference; Webcast At 9:30 AM ET,2016-11-16 08:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Uc0Bq6sYMog/bristolmyers-squibb-to-present-at-stifel-conference-webcast-at-930-am-et-20161116-00462,Bristol-Myers Squibb To Present At Stifel Conference; Webcast At 9:30 AM ET
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules",2016-11-16 08:00:00 +0000,http://uk.finance.yahoo.com/news/bristol-myers-squibb-enterome-announce-080000208.html,"Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb And Enterome Announce Immuno-Oncology Collaboration,2016-11-16 03:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pJQwMamx7dY/bristolmyers-squibb-and-enterome-announce-immunooncology-collaboration-20161116-00074,Bristol-Myers Squibb And Enterome Announce Immuno-Oncology Collaboration
BMY,BMY:US,BBG000DQLV23,AstraZeneca’s Other Products in 3Q16,2016-11-15 15:04:20 +0000,http://marketrealist.com/2016/11/astrazenecas-other-products-in-3q16/?utm_source=yahoo&utm_medium=feed,AstraZeneca’s Other Products in 3Q16
BMY,BMY:US,BBG000DQLV23,Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Efficacy and Safety in Previously Treated Patients With Advanced Form of Bladder Cancer (159KB),2016-11-15 04:07:05 +0000,http://www.publicnow.com/view/8B559E4E2B49C4D212652681FF67E31B9A51C8F5,"[at noodls] - November 15, 2016 Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Efficacy and Safety in Previously Treated Patients With Advanced Form of Bladder Cancer (PRINCETON, N.J., November 12, ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Offers Updates from Opdivo Combination Trials,2016-11-15 00:27:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_s8uJUUhoko/bristol-myers-offers-updates-from-opdivo-combination-trials-cm709050,Large cap pharma stock Bristol Myers Squibb Company BMY has come up with updates on its pipeline The company announced preliminary data from a phase I II open label study CheckMate 032 on Opdivo in combination with Yervoy for the treatment of locally advanced or metastatic
BMY,BMY:US,BBG000DQLV23,AstraZeneca's Symbicort Positive in Pediatric Asthma Study,2016-11-15 00:27:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W33ck9svw58/astrazenecas-symbicort-positive-in-pediatric-asthma-study-cm709049,AstraZeneca PLC AZN announced phase III study results for its well known product for asthma Symbicort The study showed that the drug improves lung function in pediatric asthma patients aged six to twelve years Results from CHASE 3 phase III study evaluated Symbicort budesonide
BMY,BMY:US,BBG000DQLV23,Investor Anticipating Bubble Julian Robertson Buys 2 Stocks in 3rd Quarter,2016-11-14 23:04:17 +0000,http://finance.yahoo.com/news/early-hedge-funder-julian-robertson-230417898.html,Investor Anticipating Bubble Julian Robertson Buys 2 Stocks in 3rd Quarter
BMY,BMY:US,BBG000DQLV23,AstraZeneca's Symbicort Positive in Pediatric Asthma Study,2016-11-14 22:41:10 +0000,http://finance.yahoo.com/news/astrazenecas-symbicort-positive-pediatric-asthma-224110777.html,AstraZeneca's Symbicort Positive in Pediatric Asthma Study
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Offers Updates from Opdivo Combination Trials,2016-11-14 22:39:10 +0000,http://finance.yahoo.com/news/bristol-myers-offers-updates-opdivo-223910485.html,Bristol-Myers Offers Updates from Opdivo Combination Trials
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Opdivo Drug Does Well in Study (BMY),2016-11-14 18:45:00 +0000,http://www.investopedia.com/news/bristolmyers-stomach-cancer-drug-shows-promise-bmy/?partner=YahooSA,Bristol-Myers Opdivo Drug Does Well in Study (BMY)
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Opdivo Nips at Keytruda's Heels (BMY),2016-11-14 16:55:00 +0000,http://www.investopedia.com/news/bristolmyers-opdivo-cancer-drug-gets-fda-ok-bmy/?partner=YahooSA,Bristol-Myers Opdivo Nips at Keytruda's Heels (BMY)
BMY,BMY:US,BBG000DQLV23,"Inside the Vanguard Health Care ETF: Bristol-Myers (BMY, VHT)",2016-11-14 14:58:00 +0000,http://www.investopedia.com/news/inside-vanguard-health-care-etf-bristolmyers-bmy-vht/?partner=YahooSA,"Inside the Vanguard Health Care ETF: Bristol-Myers (BMY, VHT)"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Showcases Rheumatoid Arthritis and Immunoscience Commitment with Depth of Research at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting,2016-11-14 11:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-showcases-rheumatoid-115900078.html,"[Business Wire] - Bristol-Myers Squibb Company today unveiled rheumatoid arthritis and autoimmune disease data being presented at the 2016 Annual Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals in Washington, D.C."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Sinks $100M in NASH, Fibrosis (BMY)",2016-11-14 10:50:00 +0000,http://www.investopedia.com/news/bristolmyers-nitto-ink-nash-fibrosis-deal-bmy/?partner=YahooSA,"Bristol-Myers Sinks $100M in NASH, Fibrosis (BMY)"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb's Opdivo® (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer (192KB),2016-11-14 06:07:06 +0000,http://www.publicnow.com/view/F55320AA6BB732AACC3B0934B5001B8945454453,"[at noodls] - November 14, 2016 Bristol-Myers Squibb's Opdivo® (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer (PRINCETON, NJ, November, 10, ..."
BMY,BMY:US,BBG000DQLV23,[$$] Big pharma is failing to do enough for poor countries,2016-11-14 00:34:40 +0000,"http://www.ft.com/cms/s/937eac86-a979-11e6-809d-c9f98a0cf216,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[$$] Big pharma is failing to do enough for poor countries
BMY,BMY:US,BBG000DQLV23,Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Efficacy and Safety in Previously Treated Patients With Advanced Form of Bladder Cancer,2016-11-12 16:37:13 +0000,http://www.publicnow.com/view/E06D4744C8BD1643C8D60C31ACFB12B17CDB43A2,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today additional results from the Phase 1/2 open-label CheckMate-032 trial investigating two combination schedules of ..."
BMY,BMY:US,BBG000DQLV23,Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck,2016-11-12 16:27:11 +0000,http://www.publicnow.com/view/A9633C898FCA30D4B100390302D7895D28E997B5,"[at noodls] - PRINCETON, N.J., & MARSEILLE, France--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Innate Pharma SA (Euronext Paris: FR0010331421 - IPH) today announced an interim efficacy analysis from ..."
BMY,BMY:US,BBG000DQLV23,Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma,2016-11-12 15:47:08 +0000,http://www.publicnow.com/view/9E7964F81DBD1B8682684C583FC12F45A7E98D36,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced safety and efficacy data from a Phase 1/2 study of urelumab in combination with Opdivo (nivolumab) in patients ..."
BMY,BMY:US,BBG000DQLV23,The Shot Heard ‘Round the World: First Inning of Global Reflation,2016-11-12 14:44:22 +0000,http://finance.yahoo.com/tumblr/blog-the-shot-heard-round-the-world-first-inning-of-144429291.html,The Shot Heard ‘Round the World: First Inning of Global Reflation
BMY,BMY:US,BBG000DQLV23,Infinity (INFI) Reports Narrower-than-Expected Loss in Q3,2016-11-11 22:28:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PNIRu5mrDDs/infinity-infi-reports-narrower-than-expected-loss-in-q3-cm708138,Infinity Pharmaceuticals Inc INFI reported a loss of 39 cents per share in third quarter 2016 much narrower than the Zacks Consensus Estimate of a loss of 84 cents In the year ago quarter the company had reported earnings of 84 cents Since Infinity does not have any approved product
BMY,BMY:US,BBG000DQLV23,Why You Should (and Shouldn't) Buy Merck,2016-11-11 17:30:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kgo4mR0q110/why-you-should-and-shouldnt-buy-merck-cm707929,Merck amp Co NYSE MRK 160 undoubtedly deserves its place among the pantheon of top big pharma stocks with its nearly 40 billion in annual sales 160 However the drugmaker has yet to put the so called patent cliff in the rearview mirror with top
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Pharma Stocks Rally on Trump Win, Pfizer to Divest Consumer Unit?",2016-11-11 16:16:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HGKETbDBVSU/pharma-stock-roundup-pharma-stocks-rally-on-trump-win-pfizer-to-divest-consumer-unit-cm707773,Although some big names like AstraZeneca AZN and Mylan MYL reported Q3 results this week earnings reports were overshadowed by the run up to the Presidential election and the surprise win of Donald Trump In fact the pharma sector responded favorably to Trump s victory on hopes that there
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. breached its 50 day moving average in a Bullish Manner : BMY-US : November 11, 2016",2016-11-11 12:19:00 +0000,http://www.capitalcube.com/blog/index.php/bristol-myers-squibb-co-breached-its-50-day-moving-average-in-a-bullish-manner-bmy-us-november-11-2016/,"Bristol-Myers Squibb Co. breached its 50 day moving average in a Bullish Manner : BMY-US : November 11, 2016"
BMY,BMY:US,BBG000DQLV23,Wall Street Points To Lower Opening,2016-11-11 06:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E1Eh6JLKVBQ/wall-street-points-to-lower-opening-20161111-00130,Wall Street Points To Lower Opening
BMY,BMY:US,BBG000DQLV23,"ANTH Plunges As Lupus Trial Fails, BMY''s Opdivo Is At It Again, FDA Nod For GILD",2016-11-11 04:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p9FyxiTIU2o/anth-plunges-as-lupus-trial-fails-bmys-opdivo-is-at-it-again-fda-nod-for-gild-20161111-00074,"ANTH Plunges As Lupus Trial Fails, BMY''s Opdivo Is At It Again, FDA Nod For GILD"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH,2016-11-10 22:21:06 +0000,http://www.publicnow.com/view/FA495E55241EB488D524DD609C91F7B6C0EE78A0,"[at noodls] - (NEW YORK and OSAKA - November 10, 2016) - Bristol-Myers Squibb Company (NYSE: BMY) and Nitto Denko Corporation (Nitto) (6988:Tokyo) today announced the companies have entered into an agreement granting ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Opdivo® (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer,2016-11-10 22:11:05 +0000,http://www.publicnow.com/view/9F8E86B80D57172767E37A3140BE3DCC7D4F3EDF,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Opdivo® (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer,2016-11-10 22:00:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-opdivo-nivolumab-220000543.html,"[Business Wire] - Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration has approved Opdivo injection, for intravenous use, for the tre"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Showcase New Data Spanning Rheumatoid Arthritis and Other Autoimmune Diseases at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting,2016-11-10 21:15:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-showcase-data-211500989.html,"[Business Wire] - Bristol-Myers Squibb Company today announced that 23 abstracts related to ORENCIA® and the company’s immunoscience pipeline will be presented at the 2016 annual meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals to be held November 11-16 in Washington, D.C."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers : FDA Oks Opdivo For Treatment Of Recurrent Or Metastatic SCCHN,2016-11-10 21:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tgmicN0cqos/bristolmyers--fda-oks-opdivo-for-treatment-of-recurrent-or-metastatic-scchn-20161110-01631,Bristol-Myers : FDA Oks Opdivo For Treatment Of Recurrent Or Metastatic SCCHN
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Enters into New Collaboration with Johns Hopkins Focused on Immuno-Oncology Research,2016-11-10 16:31:04 +0000,http://www.publicnow.com/view/5CC81C5F9E0C9523E2973C0572DBB9C90A0D9ED1,[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the company has entered into a five-year research collaboration with the Johns Hopkins University. The collaboration ...
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Company (BMY), Infinity Pharmaceuticals, Inc. (INFI) Team Up On Opdivo Combination Therapy",2016-11-10 14:50:30 +0000,http://www.insidermonkey.com/blog/bristol-myers-squibb-company-bmy-infinity-pharmaceuticals-inc-infi-team-up-on-opdivo-combination-therapy-486714/,"Bristol-Myers Squibb Company (BMY), Infinity Pharmaceuticals, Inc. (INFI) Team Up On Opdivo Combination Therapy"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Pfizer to Deliver 12 New Eliquis® (apixaban) Presentations at American Heart Association (AHA) Scientific Sessions 2016,2016-11-10 14:41:03 +0000,http://www.publicnow.com/view/23AD6D0DB39377393F4C063CB3405798DE0EB37F,"[at noodls] - Bristol-Myers Squibb Company(link is external) (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced today that 12 Eliquis abstracts will be presented at the AHA Scientific Sessions 2016, to be held November ..."
BMY,BMY:US,BBG000DQLV23,Blog Coverage Bristol-Myers Squibb and Infinity Pharma Collaborate for Clinical Trials to Test Combination Drugs,2016-11-10 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-bristol-myers-squibb-131500299.html,"[Accesswire] - LONDON, UK / ACCESSWIRE / November 10, 2016 / Active Wall St. blog coverage looks at the headline from Bristol-Myers Squibb Co. (NASDAQ: BMY ) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI ) (""Infinity"")as ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Opdivo succeeds in key stomach cancer study,2016-11-10 13:14:39 +0000,http://finance.yahoo.com/news/bristol-myers-opdivo-succeeds-key-124139841.html,Bristol-Myers' Opdivo succeeds in key stomach cancer study
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH,2016-11-10 12:11:08 +0000,http://www.publicnow.com/view/9AE4AADF4BC1CAE16ACAE329A9B32EB16E230B03,"[at noodls] - NEW YORK & OSAKA, Japan--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Nitto Denko Corporation (Nitto) (6988:Tokyo) today announced the companies have entered into an agreement granting ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Opdivo immunotherapy succeeds in key stomach cancer study,2016-11-10 12:10:26 +0000,http://finance.yahoo.com/news/bristol-myers-opdivo-immunotherapy-succeeds-121026551.html,Bristol-Myers' Opdivo immunotherapy succeeds in key stomach cancer study
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' deepens focus on fibrosis with Nitto deal,2016-11-10 12:01:16 +0000,http://finance.yahoo.com/news/bristol-myers-deepens-focus-fibrosis-120116270.html,Bristol-Myers' deepens focus on fibrosis with Nitto deal
BMY,BMY:US,BBG000DQLV23,Opdivo (nivolumab) Demonstrates Overall Survival Benefit in Patients With Unresectable Advanced or Recurrent Gastric Cancer in Phase 3 Study,2016-11-10 12:01:04 +0000,http://www.publicnow.com/view/286B7155466C7C4611965792AB60FA24C57DB17C,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that ONO-4538-12, a Phase 3, randomized, double-blind clinical trial evaluating the efficacy and safety of Opdivo ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb: Opdivo Meets Primary Endpoint Of Overall Survival,2016-11-10 07:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s13YgXhjDH8/bristolmyers-squibb-opdivo-meets-primary-endpoint-of-overall-survival-20161110-00377,Bristol-Myers Squibb: Opdivo Meets Primary Endpoint Of Overall Survival
BMY,BMY:US,BBG000DQLV23,"Celldex (CLDX) Q3 Loss Narrower than Expected, Sales Beat",2016-11-09 22:53:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AYRnb_MXI2k/celldex-cldx-q3-loss-narrower-than-expected-sales-beat-cm706815,Celldex Therapeutics Inc CLDX reported third quarter 2016 loss of 29 cents per share narrower than both the Zacks Consensus Estimate and the year ago loss of 32 cents FindTheCompany Graphiq Total revenue in the third quarter of 2016 surged 120 year over year to 2 2
BMY,BMY:US,BBG000DQLV23,Close Update: Stocks Rally as Wall Street Warms Up to Trump Presidency,2016-11-09 22:13:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LRiHqR5dmMo/close-update-stocks-rally-as-wall-street-warms-up-to-trump-presidency-cm706805,Wall Street orchestrated a stunning comeback Wednesday turning a 750 points loss in Dow futures into a 300 point gain as investors reconsidered Donald Trump s election victory and what his presidency could mean to Federal Reserve monetary policy and the U S economy Wall Street orchestrated
BMY,BMY:US,BBG000DQLV23,Midday Update: Stocks Snap Back as Financial and Healthcare Sectors Rally,2016-11-09 18:13:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CgwE0a-RIc4/midday-update-stocks-snap-back-as-financial-and-healthcare-sectors-rally-cm706630,Wall Street made an impressive comeback from Wednesday s ugly open with the major benchmark indices all solidly in the plus column led by gains in the financial healthcare and industrial sectors Wall Street made an impressive comeback from Wednesday s ugly open with the major benchmark indices
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part in Stifel 2016 Health Care Conference,2016-11-09 13:31:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-part-stifel-133100018.html,"[Business Wire] - Bristol-Myers Squibb Company will take part in the Stifel 2016 Health Care Conference on Wednesday, November 16, 2016, in New York. Charles Bancroft, Chief Financial Officer, will answer questions about the company at 9:30 a.m."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with IPI-549 in Advanced Solid Tumors,2016-11-09 12:09:14 +0000,http://www.publicnow.com/view/7727F54392662264D05B0FE92D843782F67569D9,"[at noodls] - CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration to evaluate Bristol-Myers ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Advanced Solid Tumors,2016-11-09 11:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-infinity-pharmaceuticals-115900337.html,"[PR Newswire] - CAMBRIDGE, Mass. and NEW YORK, Nov. 9, 2016 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration to ..."
BMY,BMY:US,BBG000DQLV23,Nektar (NKTR) Stock Up on Narrower-than-Expected Q3 Loss,2016-11-09 00:55:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lIaQkMf8O0M/nektar-nktr-stock-up-on-narrower-than-expected-q3-loss-cm706039,Nektar Therapeutics NKTR reported a loss of 32 cents per share in the third quarter of 2016 narrower than the Zacks Consensus Estimate of a loss of 34 cents The reported loss was however significantly wider than the year ago loss of 6 cents The company s shares are up 8 following
BMY,BMY:US,BBG000DQLV23,3 Stocks Set to Thrive in Pharma's New Price-Conscious World,2016-11-09 00:19:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UzXqjV9yn0E/3-stocks-set-to-thrive-in-pharmas-new-price-conscious-world-cm706017,Image source Getty Images With both presidential nominees pushing for 160 drug price reform investors need to start protecting themselves There s no need to dump all your pharma holdings you may want to pull away from those that lean on eye popping price increases on old drugs
BMY,BMY:US,BBG000DQLV23,3 Stocks Set to Thrive in Pharma's New Price-Conscious World,2016-11-08 21:50:03 +0000,http://www.fool.com/investing/2016/11/08/3-stocks-set-to-thrive-in-pharmas-new-price-consci.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Stocks Set to Thrive in Pharma's New Price-Conscious World
BMY,BMY:US,BBG000DQLV23,Nektar (NKTR) Stock Up on Narrower-than-Expected Q3 Loss,2016-11-08 21:26:09 +0000,http://finance.yahoo.com/news/nektar-nktr-stock-narrower-expected-212609749.html,Nektar (NKTR) Stock Up on Narrower-than-Expected Q3 Loss
BMY,BMY:US,BBG000DQLV23,Pfizer’s 3Q16 Earnings: Profitability and Financial Guidance,2016-11-08 15:04:29 +0000,http://marketrealist.com/2016/11/pfizers-3q16-earnings-profitability-and-financial-guidance/?utm_source=yahoo&utm_medium=feed,Pfizer’s 3Q16 Earnings: Profitability and Financial Guidance
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb To Present At Credit Suisse Conference; Webcast At 10:00 AM,2016-11-08 09:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bmDabMW1htE/bristolmyers-squibb-to-present-at-credit-suisse-conference-webcast-at-1000-am-20161108-00666,Bristol-Myers Squibb To Present At Credit Suisse Conference; Webcast At 10:00 AM
BMY,BMY:US,BBG000DQLV23,"Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals",2016-11-08 00:56:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G2GYMALdCpQ/zacks-industry-outlook-highlights-bristol-myers-biogen-merck-celgene-and-ariad-pharmaceuticals-cm705007,For Immediate Release Chicago IL November 07 2016 Today Zacks Equity Research discusses the Pharmaceuticals Part 2 including Bristol Myers NYSE BMY Free Report Biogen NASDAQ BIIB Free Report Merck amp Co Inc NYSE MRK Free Report
BMY,BMY:US,BBG000DQLV23,"Celldex Therapeutics, Inc. Watches Its Cash in Q3, Ready to Expand",2016-11-08 00:54:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y6ATJR-GD7o/celldex-therapeutics-inc-watches-its-cash-in-q3-ready-to-expand-cm705318,Image source Getty Images There hasn t been much good news for Celldex Therapeutics NASDAQ CLDX in 2016 Failure of Rintega in a late stage study resulted in a loss of roughly 80 of the biotech s market cap Celldex announced its third quarter results after the market closed
BMY,BMY:US,BBG000DQLV23,"Exelixis, Inc. Continues Its Solid Launch",2016-11-07 22:55:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3OyKhV8lWS0/exelixis-inc-continues-its-solid-launch-cm705291,Image source Getty Images Exelixis NASDAQ EXEL reported earnings after the bell on Thursday delighting investors with a continuation of the solid launch of its kidney cancer drug Cabometyx Exelixis results The raw numbers
BMY,BMY:US,BBG000DQLV23,AVEO Pharmaceuticals' (AVEO) Q3 Loss Lower than Expected,2016-11-07 22:53:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Cx8FZ9ZaKK0/aveo-pharmaceuticals-aveo-q3-loss-lower-than-expected-cm705275,AVEO Pharmaceuticals Inc AVEO reported a third quarter 2016 loss of 7 cents per share narrower than the Zacks Consensus Estimate of a loss of 12 cents The company had reported earnings of 14 cents per share in the year ago period FindTheCompany Graphiq AVEO does
BMY,BMY:US,BBG000DQLV23,AVEO Pharmaceuticals' (AVEO) Q3 Loss Lower than Expected,2016-11-07 20:59:08 +0000,http://finance.yahoo.com/news/aveo-pharmaceuticals-aveo-q3-loss-205908357.html,AVEO Pharmaceuticals' (AVEO) Q3 Loss Lower than Expected
BMY,BMY:US,BBG000DQLV23,"2 Reasons Exelixis, Inc. Dove 17% in October, and 1 Excuse to Be Excited",2016-11-07 19:15:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UyaOMP7ePR0/2-reasons-exelixis-inc-dove-17-in-october-and-1-excuse-to-be-excited-cm705153,Image source Getty Images What happened Shares of Exelixis NASDAQ EXEL a mid cap biopharmaceutical company focused on the development of oncology drugs dipped 17 in October based on data from S amp P Global Market Intelligence The reason for the drop can likely
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Pfizer, Allergan Q3 Results Fall Short, Insulin Drugmakers under Pricing Pressure",2016-11-07 16:02:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wGjCdid42RA/pharma-stock-roundup-pfizer-allergan-q3-results-fall-short-insulin-drugmakers-under-pricing-pressure-cm704894,This week key earnings updates came from companies like Pfizer PFE and Allergan AGN while pharma stocks remained under drug pricing pressure with lawmakers questioning the prices of insulin drugs Recap of the Week s Most Important Stories Pfizer Allergan Disappoint in
BMY,BMY:US,BBG000DQLV23,"Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals",2016-11-07 14:30:02 +0000,http://finance.yahoo.com/news/zacks-industry-outlook-highlights-bristol-143002199.html,"Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals"
BMY,BMY:US,BBG000DQLV23,The Path To Global Prosperity,2016-11-06 13:39:44 +0000,http://finance.yahoo.com/tumblr/blog-the-path-to-global-prosperity-133950829.html,The Path To Global Prosperity
BMY,BMY:US,BBG000DQLV23,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia",2016-11-04 20:26:46 +0000,http://biz.yahoo.com/e/161104/bmy8-k.html,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia"
BMY,BMY:US,BBG000DQLV23,Fundamentals Remain Strong in the Pharma Sector,2016-11-04 19:10:07 +0000,http://finance.yahoo.com/news/fundamentals-remain-strong-pharma-sector-191007373.html,Fundamentals Remain Strong in the Pharma Sector
BMY,BMY:US,BBG000DQLV23,52-Week Company Lows,2016-11-03 16:12:03 +0000,http://finance.yahoo.com/news/52-week-company-lows-161203241.html,52-Week Company Lows
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Present New Data at the 58th Annual Meeting & Exposition of the American Society of Hematology Demonstrating Research Advancements in Immuno-Oncology and Across Multiple Blood Cancers,2016-11-03 13:10:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-present-data-131000996.html,"[Business Wire] - Bristol-Myers Squibb Company announced today 17 presentations, including four oral presentations and 13 poster discussions, highlighting data from studies evaluating Opdivo , Sprycel and Empliciti , will be featured at the 58th Annual Meeting & Exposition of the American Society of Hematology in San Diego, Calif."
BMY,BMY:US,BBG000DQLV23,Pfizer Delivers Another Solid Quarter Of Organic Growth,2016-11-02 15:09:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bMfpSqVQl6A/pfizer-delivers-another-solid-quarter-of-organic-growth-cm702359,Image source Pfizer Inc Pfizer Inc s NYSE PFE third quarter performance shows that the company s finally overcoming the multiyear drag on sales caused by the patent expiration of Lipitor back in 2011 Pfizer s quarterly sales of 13 billion were up 8 year over year and
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Q3 Earnings Review: Opdivo Drives Strong Performance For the Quarter,2016-11-02 14:38:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GViEaEkooRE/bristol-myers-q3-earnings-review-opdivo-drives-strong-performance-for-the-quarter-cm702413,Bristol Myers Squibb 160 Bristol Myers BMY reported its Q3 16 earnings on October 27th The company posted strong sales and earnings growth Opdivo and Eliquis accounted for nearly 85 of the revenue increase for all the drugs which saw growth for the quarter and together added just
BMY,BMY:US,BBG000DQLV23,New Data Presentations at SITC 2016 Annual Meeting Highlight Bristol-Myers Squibb’s Leadership in Advancing the Science of Immuno-Oncology Combinations,2016-11-02 10:59:00 +0000,http://finance.yahoo.com/news/data-presentations-sitc-2016-annual-105900855.html,"[Business Wire] - Bristol-Myers Squibb Company today announced new data evaluating the combination of Opdivo plus Yervoy and Opdivo plus new investigational Immuno-Oncology assets, including lirilumab, will be presented at the 2016 Society for Immunotherapy of Cancer 31st Annual Meeting from November 9 – 11 in National Harbor, Maryland."
BMY,BMY:US,BBG000DQLV23,"Cramer: With the Election Coming, Valeant's Problem Is Increasing",2016-11-01 23:01:00 +0000,http://realmoney.thestreet.com/articles/11/01/2016/cramer-election-coming-valeants-problem-increasing?puc=yahoo&cm_ven=YAHOO,"Cramer: With the Election Coming, Valeant's Problem Is Increasing"
BMY,BMY:US,BBG000DQLV23,AVEO Pharmaceuticals (AVEO) Q3 Earnings: What's in Store?,2016-11-01 18:17:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nSig-uYNmV0/aveo-pharmaceuticals-aveo-q3-earnings-whats-in-store-cm701830,AVEO Pharmaceuticals Inc AVEO is expected to report third quarter 2016 results this month The company has an impressive track record for the last four reported quarters While it has beaten estimates on three occasions it met expectations in one with an average positive surprise of 57
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part in Credit Suisse 2016 Health Care Conference,2016-11-01 15:12:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-part-credit-151200417.html,"[Business Wire] - Bristol-Myers Squibb Company will take part in the Credit Suisse Annual Health Care Conference on Tuesday, November 8, 2016 in Scottsdale, Arizona. Fouad Namouni, senior vice president, Head Oncology Development, will answer questions about the company at 8 a.m."
BMY,BMY:US,BBG000DQLV23,The Election Can't Come Soon Enough For Biotechs,2016-11-01 14:39:49 +0000,http://finance.yahoo.com/news/election-cant-come-soon-enough-143949847.html,The Election Can't Come Soon Enough For Biotechs
BMY,BMY:US,BBG000DQLV23,Looking For a Sign That Bristol-Myers Squibb Has Bottomed,2016-11-01 14:25:00 +0000,http://realmoney.thestreet.com/articles/11/01/2016/looking-sign-bristol-myers-squibb-has-bottomed?puc=yahoo&cm_ven=YAHOO,Looking For a Sign That Bristol-Myers Squibb Has Bottomed
BMY,BMY:US,BBG000DQLV23,2 Beaten-Up Biotech Blue Chip Stocks on Sale Today,2016-10-31 22:15:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zw5RRK3rZhw/2-beaten-up-biotech-blue-chip-stocks-on-sale-today-cm701411,Image source 160 thebluediamondgallery This has been an overall rough year for biotech stocks With the iShares Biotechnology Nasdaq ETF 160 down more than 20 YTD investors have learned more than ever that betting on biotech is always a risky business However as is often
BMY,BMY:US,BBG000DQLV23,"5 Years After Adcetris Approval, Seattle Genetics, Inc. Still Focused on Pipeline",2016-10-31 21:15:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dShEf6dEcCY/5-years-after-adcetris-approval-seattle-genetics-inc-still-focused-on-pipeline-cm701365,Image source Getty Images Seattle Genetics NASDAQ SGEN reported third quarter earnings on Thursday but while the biotech s lead drug has been on the market for half a decade it still remains largely a pipeline story You have to skim down to the fourth subhead of the
BMY,BMY:US,BBG000DQLV23,2 Beaten-Up Biotech Blue Chip Stocks on Sale Today,2016-10-31 20:34:21 +0000,http://www.fool.com/investing/2016/10/31/2-beaten-up-biotech-blue-chip-stocks-on-sale-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,2 Beaten-Up Biotech Blue Chip Stocks on Sale Today
BMY,BMY:US,BBG000DQLV23,"ETF’s with exposure to Bristol-Myers Squibb Co. : October 31, 2016",2016-10-31 17:19:49 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-bristol-myers-squibb-co-october-31-2016/,"ETF’s with exposure to Bristol-Myers Squibb Co. : October 31, 2016"
BMY,BMY:US,BBG000DQLV23,What Analysts Are Recommending for Pfizer and Other Major Oncology Players in 2016,2016-10-31 15:04:05 +0000,http://marketrealist.com/2016/10/analysts-recommending-pfizer-major-oncology-players-2016/?utm_source=yahoo&utm_medium=feed,What Analysts Are Recommending for Pfizer and Other Major Oncology Players in 2016
BMY,BMY:US,BBG000DQLV23,Celldex (CLDX): Will the Stock Surprise in Q3 Earnings?,2016-10-31 14:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D6mVgeIRQho/celldex-cldx-will-the-stock-surprise-in-q3-earnings-cm701001,Celldex Therapeutics Inc CLDX is expected to report third quarter 2016 results on Nov 3 Celldex s performance has been encouraging with a three quarter average positive surprise of 4 85 In the last reported quarter the company recorded a positive surprise of 3 03 Let s see how things
BMY,BMY:US,BBG000DQLV23,New Bristol-Myers Squibb Research on Opdivo (nivolumab) Monotherapy and in Combination With Yervoy (ipilimumab) at SMR 2016 Congress Reinforces Immuno-Oncology Leadership and Scientific Expertise in Melanoma,2016-10-31 12:04:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-research-opdivo-120400697.html,"[Business Wire] - Bristol-Myers Squibb Company today announced new data presentations from studies evaluating Opdivo as monotherapy or in combination with Yervoy in the treatment of melanoma, including new research on the efficacy and safety of the combination in melanoma patients with high unmet need including those with elevated serum lactate dehydrogenase and brain metastases."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Announces New Data Presentations From Studies Evaluating Opdivo,2016-10-31 08:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fpZoBmjFmvc/bristolmyers-announces-new-data-presentations-from-studies-evaluating-opdivo-20161031-00525,Bristol-Myers Announces New Data Presentations From Studies Evaluating Opdivo
BMY,BMY:US,BBG000DQLV23,Reflation Alert!,2016-10-30 17:01:15 +0000,http://finance.yahoo.com/tumblr/blog-reflation-alert-170123613.html,Reflation Alert!
BMY,BMY:US,BBG000DQLV23,Can Keytruda Return Merck & Co. to Growth?,2016-10-28 21:33:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gMl4tkoyd4M/can-keytruda-return-merck-co-to-growth-cm700564,Image source Merck amp Co Following a speedy FDA approval Keytruda from Merck amp Co NYSE MRK became the first drug in its class to reach the front line in lung cancer Until recently it seemed Bristol Myers Squibb NYSE BMY would dominate this important field
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb (BMY) Shares Cross 3% Yield Mark,2016-10-28 20:32:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l-J60Nqbe58/bristol-myers-squibb-bmy-shares-cross-3-yield-mark-cm700503,Looking at the universe of stocks we cover at Dividend Channel in trading on Friday shares of Bristol Myers Squibb Co Symbol BMY were yielding above the 3 mark based on its quarterly dividend annualized to 1 52 with the stock changing hands as low as 50 66 on the day Dividends
BMY,BMY:US,BBG000DQLV23,Medivation Adds Leading Prostate Cancer Drug Xtandi to Pfizer’s Oncology Portfolio,2016-10-28 15:04:12 +0000,http://marketrealist.com/2016/10/medivation-adds-leading-prostate-cancer-drug-xtandi-pfizers-oncology-portfolio/?utm_source=yahoo&utm_medium=feed,Medivation Adds Leading Prostate Cancer Drug Xtandi to Pfizer’s Oncology Portfolio
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Bristol-Myers, Merck Top Estimates, Merck Wins Key FDA Nod",2016-10-28 14:34:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_mEm4L1No38/pharma-stock-roundup-bristol-myers-merck-top-estimates-merck-wins-key-fda-nod-cm700213,Third quarter earnings season is in full flow with several large cap pharma companies like Lilly LLY Merck MRK Bristol Myers BMY Novartis and others reporting results this week While companies like Merck and Bristol Myers surpassed expectations others like Lilly fell short Recap
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Yervoy (ipilimumab) Awarded Prix Galien USA Discovery of the Decade,2016-10-28 14:28:06 +0000,http://www.publicnow.com/view/E75DBCE70ED45BE2BEB94091EFC3FD3FF6B91D68,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that it received the Prix Galien USA Discovery of the Decade biotech award for Yervoy (ipilimumab), the Company's ..."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. :BMY-US: Earnings Analysis: Q3, 2016 By the Numbers : October 28, 2016",2016-10-28 13:26:50 +0000,http://www.capitalcube.com/blog/index.php/bristol-myers-squibb-co-bmy-us-earnings-analysis-q3-2016-by-the-numbers-october-28-2016/,"Bristol-Myers Squibb Co. :BMY-US: Earnings Analysis: Q3, 2016 By the Numbers : October 28, 2016"
BMY,BMY:US,BBG000DQLV23,"Why Bristol-Myers Squibb, CenturyLink, and Shutterfly Jumped Today",2016-10-27 22:43:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BE0gdIRDDuE/why-bristol-myers-squibb-centurylink-and-shutterfly-jumped-today-cm699884,The stock market was mostly lower on Thursday with major market benchmarks falling under the weight of downward pressure from some poor earnings performance among their components However for Bristol Myers Squibb NYSE BMY CenturyLink NYSE CTL and
BMY,BMY:US,BBG000DQLV23,"Thai Market: Resistance Likely At 1,500 Points",2016-10-27 22:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ucfu_PWkjp8/thai-market-resistance-likely-at-1500-points-20161027-01785,"Thai Market: Resistance Likely At 1,500 Points"
BMY,BMY:US,BBG000DQLV23,Win Streak May End For Indonesia Stock Market,2016-10-27 22:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uplYm8xE_W8/win-streak-may-end-for-indonesia-stock-market-20161027-02007,Win Streak May End For Indonesia Stock Market
BMY,BMY:US,BBG000DQLV23,Edited Transcript of BMY earnings conference call or presentation 27-Oct-16 2:30pm GMT,2016-10-27 21:24:29 +0000,http://finance.yahoo.com/news/edited-transcript-bmy-earnings-conference-212429858.html,Edited Transcript of BMY earnings conference call or presentation 27-Oct-16 2:30pm GMT
BMY,BMY:US,BBG000DQLV23,More Pain Expected For Hong Kong Shares,2016-10-27 21:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/87E-L2J8Qow/more-pain-expected-for-hong-kong-shares-20161027-02001,More Pain Expected For Hong Kong Shares
BMY,BMY:US,BBG000DQLV23,China Stock Market May Open In The Red,2016-10-27 21:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rLLFAMBlTfw/china-stock-market-may-open-in-the-red-20161027-01998,China Stock Market May Open In The Red
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Celgene Stocks Rocket After Sweeping Q3 Expectations",2016-10-27 20:56:03 +0000,http://www.investors.com/news/technology/bristol-myers-celgene-stocks-rocket-after-sweeping-q3-expectations/,"Bristol-Myers, Celgene Stocks Rocket After Sweeping Q3 Expectations"
BMY,BMY:US,BBG000DQLV23,"Why Bristol-Myers Squibb, CenturyLink, and Shutterfly Jumped Today",2016-10-27 20:56:00 +0000,http://www.fool.com/investing/2016/10/27/why-bristol-myers-squibb-centurylink-and-shutterfl.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,"Why Bristol-Myers Squibb, CenturyLink, and Shutterfly Jumped Today"
BMY,BMY:US,BBG000DQLV23,Taiwan Bourse May Extend Losing Streak,2016-10-27 20:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B2iZy-v3Q40/taiwan-bourse-may-extend-losing-streak-20161027-01992,Taiwan Bourse May Extend Losing Streak
BMY,BMY:US,BBG000DQLV23,Alexion Crushes Q3 Expectations; Stock Bounds On Drug Trial Plans,2016-10-27 20:19:18 +0000,http://www.investors.com/news/technology/alexion-crushes-q3-expectations-stock-bounds-on-drug-trial-plans/,Alexion Crushes Q3 Expectations; Stock Bounds On Drug Trial Plans
BMY,BMY:US,BBG000DQLV23,Singapore Shares May Reverse Thursday''s Gains,2016-10-27 20:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H1jESCC3388/singapore-shares-may-reverse-thursdays-gains-20161027-01776,Singapore Shares May Reverse Thursday''s Gains
BMY,BMY:US,BBG000DQLV23,Losing Streak May Continue For Malaysia Shares,2016-10-27 19:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w76bEN_FEOc/losing-streak-may-continue-for-malaysia-shares-20161027-01770,Losing Streak May Continue For Malaysia Shares
BMY,BMY:US,BBG000DQLV23,Renewed Selling Pressure Tipped For South Korea Shares,2016-10-27 19:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K5VkPRWRA9U/renewed-selling-pressure-tipped-for-south-korea-shares-20161027-01989,Renewed Selling Pressure Tipped For South Korea Shares
BMY,BMY:US,BBG000DQLV23,Thursday's ETF with Unusual Volume: DSI,2016-10-27 18:41:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rtpLSB1eB-c/thursdays-etf-with-unusual-volume-dsi-cm699636,The iShares MSCI KLD 400 Social ETF DSI is seeing unusually high volume in afternoon trading Thursday with over 62 000 shares traded versus three month average volume of about 29 000 Shares of DSI were off about 0 2 on the day Components of that ETF with the highest volume
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers (BMY) Beats on Q3 Earnings, Ups 2016 View",2016-10-27 17:44:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-eBxuF7vS0k/bristol-myers-bmy-beats-on-q3-earnings-ups-2016-view-cm699608,Bristol Myers Squibb Company s BMY third quarter 2016 earnings of 77 cents per share beat the Zacks Consensus Estimate of 65 cents and surged 97 from the year ago period FindTheCompany Graphiq Total revenue of 4 92 billion was also above the Zacks Consensus Estimate
BMY,BMY:US,BBG000DQLV23,Bristol-Myers CEO: Confident about promise of our portfol...,2016-10-27 17:36:00 +0000,http://finance.yahoo.com/video/bristol-myers-ceo-confident-promise-173600815.html,Bristol-Myers CEO: Confident about promise of our portfol...
BMY,BMY:US,BBG000DQLV23,"Bristol hikes 2016 profit forecast as top drugs deliver, shares jump",2016-10-27 17:25:20 +0000,http://finance.yahoo.com/news/bristol-hikes-2016-profit-forecast-114215502.html,"Bristol hikes 2016 profit forecast as top drugs deliver, shares jump"
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Squibb Makes Moves to Reassure Investors,2016-10-27 16:56:06 +0000,http://www.wsj.com/articles/bristol-myers-squibb-plans-organizational-revamp-unveils-3-billion-share-buyback-1477568382?mod=yahoo_hs,[$$] Bristol-Myers Squibb Makes Moves to Reassure Investors
BMY,BMY:US,BBG000DQLV23,Scout Daily Update: Core Durable Goods Down 21 Straight Months,2016-10-27 16:55:16 +0000,http://www.insidermonkey.com/blog/scout-daily-update-core-durable-goods-down-21-straight-months-483605/,Scout Daily Update: Core Durable Goods Down 21 Straight Months
BMY,BMY:US,BBG000DQLV23,3 Things You Really Need to Know About Bristol-Myers Squibb's Q3 Results,2016-10-27 16:44:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aW0J5icRmvw/3-things-you-really-need-to-know-about-bristol-myers-squibbs-q3-results-cm699480,Bristol Myers Squibb NYSE BMY is no stranger to exceeding expectations with its quarterly results Now the big drugmaker has done it again Bristol reported its third quarter financial results before the market opened on Thursday and shares popped over 6 on the company s
BMY,BMY:US,BBG000DQLV23,Stocks Close Mostly Lower Following Slew Of Earnings - U.S. Commentary,2016-10-27 16:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IH47xPitN_o/stocks-close-mostly-lower-following-slew-of-earnings--us-commentary-20161027-01488,Stocks Close Mostly Lower Following Slew Of Earnings - U.S. Commentary
BMY,BMY:US,BBG000DQLV23,Jim Cramer Addresses the Biggest Earnings Surprises,2016-10-27 16:14:00 +0000,http://www.thestreet.com/video/13870197/jim-cramer-addresses-the-biggest-earnings-surprises.html?puc=yahoov&cm_ven=YAHOOV,Jim Cramer Addresses the Biggest Earnings Surprises
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers (BMY) Stock Climbs on Q3 Beat, Guidance",2016-10-27 15:30:00 +0000,https://www.thestreet.com/story/13870198/1/bristol-myers-bmy-stock-climbs-on-q3-beat-guidance.html?puc=yahoo&cm_ven=YAHOO,"Bristol-Myers (BMY) Stock Climbs on Q3 Beat, Guidance"
BMY,BMY:US,BBG000DQLV23,3 Things You Really Need to Know About Bristol-Myers Squibb's Q3 Results,2016-10-27 15:22:37 +0000,http://www.fool.com/investing/2016/10/27/3-things-you-really-need-to-know-about-bristol-mye.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Things You Really Need to Know About Bristol-Myers Squibb's Q3 Results
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers (BMY) Beats on Q3 Earnings, Ups 2016 View",2016-10-27 15:22:03 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-beats-q3-152203873.html,"Bristol-Myers (BMY) Beats on Q3 Earnings, Ups 2016 View"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Rising Sharply On Upbeat Q3 Results, Guidance",2016-10-27 13:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/__JwP6d_A4o/bristolmyers-rising-sharply-on-upbeat-q3-results-guidance-20161027-01160,"Bristol-Myers Rising Sharply On Upbeat Q3 Results, Guidance"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Beats on Q3 Earnings and Revenues,2016-10-27 13:44:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CNijweUcypI/bristol-myers-bmy-beats-on-q3-earnings-and-revenues-cm699280,New York based Bristol Myers Squibb Company BMY is a major producer and distributor of pharmaceuticals and other healthcare related products The company s key oncology products include Opdivo Sprycel Yervoy and the recently launched Empliciti Beyond oncology the company remains focused
BMY,BMY:US,BBG000DQLV23,"Stock Futures Point to Higher Open on Strong Earnings, M&A in Tech Sector",2016-10-27 13:41:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ceHcvY3puVI/stock-futures-point-to-higher-open-on-strong-earnings-ma-in-tech-sector-cm699204,Stock futures were higher ahead of Thursday s open buoyed by better than expected third quarter earnings from Twitter TWTR Tesla TSLA Dow Chemical DOW and Bristol Myers Squibb BMY higher oil futures and another large merger deal in the technology sector Qualcomm
BMY,BMY:US,BBG000DQLV23,Pisani: Two serious problems the market is dealing with,2016-10-27 13:38:00 +0000,http://finance.yahoo.com/video/pisani-two-serious-problems-market-133800927.html,Pisani: Two serious problems the market is dealing with
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Makes Moves to Reassure Investors,2016-10-27 13:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c9QzbbvsMpI/bristolmyers-squibb-makes-moves-to-reassure-investors-20161027-01147,Bristol-Myers Squibb Makes Moves to Reassure Investors
BMY,BMY:US,BBG000DQLV23,Stocks Futures Gain on Upbeat Q3 Results,2016-10-27 13:01:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HQghatYwOA4/stocks-futures-gain-on-upbeat-q3-results-cm699132,Stock futures were higher ahead of Thursday s open buoyed by better than expected third quarter earnings from Twitter TWTR Tesla TSLA Dow Chemical DOW and Bristol Myers Squibb BMY higher oil futures and the expectation that this morning s round of economic data will
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Beats on Q3 Earnings and Revenues,2016-10-27 12:30:12 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-beats-q3-123012527.html,Bristol-Myers (BMY) Beats on Q3 Earnings and Revenues
BMY,BMY:US,BBG000DQLV23,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E",2016-10-27 12:16:25 +0000,http://biz.yahoo.com/e/161027/bmy8-k.html,"BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E"
BMY,BMY:US,BBG000DQLV23,Stocks Turning In Mixed Performance In Mid-Day Trading - U.S. Commentary,2016-10-27 12:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M7YbbxZaVHQ/stocks-turning-in-mixed-performance-in-midday-trading--us-commentary-20161027-01126,Stocks Turning In Mixed Performance In Mid-Day Trading - U.S. Commentary
BMY,BMY:US,BBG000DQLV23,Biotech Stocks Facing FDA Decision In November,2016-10-27 11:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yP8sYx6pvkQ/biotech-stocks-facing-fda-decision-in-november-20161027-01106,Biotech Stocks Facing FDA Decision In November
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Reports Third Quarter Financial Results,2016-10-27 11:36:07 +0000,http://www.publicnow.com/view/A70BC314ED0FA84DBEAC336FB843FD7AD78B51E7,"[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2016 which were highlighted by strong sales and operating performance, and continued growth ..."
BMY,BMY:US,BBG000DQLV23,"Investors Cheer Bristol-Myers' Q3 Results, Outlook",2016-10-27 11:35:25 +0000,http://finance.yahoo.com/news/investors-cheer-bristol-myers-q3-113525429.html,"Investors Cheer Bristol-Myers' Q3 Results, Outlook"
BMY,BMY:US,BBG000DQLV23,"Earnings Reaction History: Bristol Myers Squibb Co, 40.0% Follow-Through Indicator, 1.8% Sensitive",2016-10-27 11:09:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L0y8j99cUnw/earnings-reaction-history-bristol-myers-squibb-co-400-follow-through-indicator-18-sensitive-cm699099,Expected Earnings Release 10 27 2016 PremarketExpected Earnings Release 10 27 2016 Premarket Avg Extended Hours Dollar Volume 2 230 643Avg Extended Hours Dollar Volume 2 230 643 Bristol Myers Squibb Co BMY is due to issue its quarterly earnings report in the upcoming extended
BMY,BMY:US,BBG000DQLV23,Bristol-Myers tops Street 3Q forecasts,2016-10-27 11:09:06 +0000,http://sg.finance.yahoo.com/news/bristol-myers-tops-street-3q-110906132.html,Bristol-Myers tops Street 3Q forecasts
BMY,BMY:US,BBG000DQLV23,BMY posts big beat,2016-10-27 11:08:00 +0000,http://finance.yahoo.com/video/bmy-posts-big-beat-110800832.html,BMY posts big beat
BMY,BMY:US,BBG000DQLV23,Q3 2016 Bristol-Myers Squibb Co Earnings Release - Before Market Open,2016-10-27 11:07:07 +0000,http://biz.yahoo.com/research/earncal/20161027.html?t=bmy,Q3 2016 Bristol-Myers Squibb Co Earnings Release - Before Market Open
BMY,BMY:US,BBG000DQLV23,Bristol hikes 2016 forecast after top drugs deliver,2016-10-27 11:04:57 +0000,http://finance.yahoo.com/news/bristol-hikes-2016-forecast-top-110457333.html,Bristol hikes 2016 forecast after top drugs deliver
BMY,BMY:US,BBG000DQLV23,Stocks Turn Lower After Seeing Initial Strength - U.S. Commentary,2016-10-27 10:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h3IBk3_rnfc/stocks-turn-lower-after-seeing-initial-strength--us-commentary-20161027-01052,Stocks Turn Lower After Seeing Initial Strength - U.S. Commentary
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Q3 16 Earnings Conference Call At 10:30 AM ET,2016-10-27 09:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u1H7hQkHrdU/bristolmyers-squibb-q3-16-earnings-conference-call-at-1030-am-et-20161027-00758,Bristol-Myers Squibb Q3 16 Earnings Conference Call At 10:30 AM ET
BMY,BMY:US,BBG000DQLV23,Stocks May Move Higher Amid Slew Of Earnings News - U.S. Commentary,2016-10-27 08:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YAfyQwNfOxE/stocks-may-move-higher-amid-slew-of-earnings-news--us-commentary-20161027-00805,Stocks May Move Higher Amid Slew Of Earnings News - U.S. Commentary
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Plans Organizational Revamp,2016-10-27 08:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Tf9oHL5rfeE/bristolmyers-squibb-plans-organizational-revamp-20161027-00650,Bristol-Myers Squibb Plans Organizational Revamp
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Plans Organizational Revamp, Unveils $3 Billion Share Buyback",2016-10-27 07:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Sx-Q1ar143c/bristolmyers-squibb-plans-organizational-revamp-unveils-3-billion-share-buyback-20161027-00543,"Bristol-Myers Squibb Plans Organizational Revamp, Unveils $3 Billion Share Buyback"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Q3 Results Top View; Ups FY16 Forecast; To Buy Back $3 Bln Shares,2016-10-27 07:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CAYhCga7OXA/bristolmyers-q3-results-top-view-ups-fy16-forecast-to-buy-back-3-bln-shares-20161027-00534,Bristol-Myers Q3 Results Top View; Ups FY16 Forecast; To Buy Back $3 Bln Shares
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Co. Earnings Advance 99% In Q3,2016-10-27 07:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BH9QMPxDKOY/bristolmyers-squibb-co-earnings-advance-99-in-q3-20161027-00433,Bristol-Myers Squibb Co. Earnings Advance 99% In Q3
BMY,BMY:US,BBG000DQLV23,5 Stocks to Watch Before the Market Opens Tomorrow,2016-10-26 20:30:13 +0000,http://finance.yahoo.com/tumblr/blog-5-stocks-to-watch-before-the-market-opens-tomorrow-003008317.html,5 Stocks to Watch Before the Market Opens Tomorrow
BMY,BMY:US,BBG000DQLV23,"Pre-Market Earnings Report for October 27, 2016 :  MO, BMY, CELG, UPS, CL, DOW, TMO, EPD, COP, AMT, F, RTN",2016-10-26 20:19:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xj4Z5ZRKIRM/pre-market-earnings-report-for-october-27-2016-mo-bmy-celg-ups-cl-dow-tmo-epd-cop-amt-f-rtn-cm698924,The following companies are expected to report earnings prior to market open on 10 27 2016 Visit our Earnings Calendar for a full list of expected earnings releases Altria Group MO is reporting for the quarter ending September 30 2016 The tobacco company
BMY,BMY:US,BBG000DQLV23,What to Look For in Bristol-Myers Earnings,2016-10-26 19:27:03 +0000,http://finance.yahoo.com/news/look-bristol-myers-earnings-192703414.html,What to Look For in Bristol-Myers Earnings
BMY,BMY:US,BBG000DQLV23,"VUG, QCOM, AGN, BMY: Large Inflows Detected at ETF",2016-10-26 16:51:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FCpATBnPrVg/vug-qcom-agn-bmy-large-inflows-detected-at-etf-cm698650,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Growth ETF Symbol VUG where we have detected an approximate 86 0 million dollar inflow that s a 0 4 increase week over week in outstanding units
BMY,BMY:US,BBG000DQLV23,Gilead Sciences (GILD) Q3 Earnings: Stock to Disappoint?,2016-10-26 14:52:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7U4qS9tszv8/gilead-sciences-gild-q3-earnings-stock-to-disappoint-cm698565,Gilead Sciences Inc GILD is scheduled to report third quarter 2016 results on Nov 1 after the market closes Last quarter the company had surpassed expectations with a positive earnings surprise of 0 33 Gilead s track record has been encouraging so far with the company
BMY,BMY:US,BBG000DQLV23,"Inside Opdivo, Bristol-Myers Squibb’s Oncology Drug",2016-10-26 14:04:32 +0000,http://marketrealist.com/2016/10/inside-opdivo-bristol-myers-squibbs-oncology-drug/?utm_source=yahoo&utm_medium=feed,"Inside Opdivo, Bristol-Myers Squibb’s Oncology Drug"
BMY,BMY:US,BBG000DQLV23,"Drug Stock Q3 Earnings Roster for Oct 27: AMGN, BMY & More",2016-10-26 13:50:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oh1yETFMaVw/drug-stock-q3-earnings-roster-for-oct-27-amgn-bmy-more-cm698462,The Q3 earnings season has so far seen encouraging reports with 116 S amp P 500 companies having already released results as of Oct 21 Of the total 80 2 surpassed earnings estimates while 62 9 trumped revenue expectations The Q3 earnings cycle is on track to be the first quarter to
BMY,BMY:US,BBG000DQLV23,Why Earnings Season Could Be Great for Bristol-Myers (BMY),2016-10-26 13:50:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wzQ2KcKjGoA/why-earnings-season-could-be-great-for-bristol-myers-bmy-cm698459,Investors are always looking for stocks that are poised to beat at earnings season and Bristol Myers Squibb Company BMY may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because Bristol Myers is seeing
BMY,BMY:US,BBG000DQLV23,Can Xerox (XRX) Spring a Surprise this Earnings Season?,2016-10-26 13:50:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TNA8ntwQCUU/can-xerox-xrx-spring-a-surprise-this-earnings-season-cm698450,Xerox Corporation XRX is scheduled to report third quarter 2016 results before the opening bell on Oct 28 In the last reported quarter earnings beat the Zacks Consensus Estimate by 5 cents Over the trailing four quarters the company delivered a positive average earnings surprise of 8
BMY,BMY:US,BBG000DQLV23,Baron Funds Comments on Bristol-Myers Squibb Co.,2016-10-26 12:49:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Aep2gReg0qE/baron-funds-comments-on-bristol-myers-squibb-co-cm698390,Bristol Myers Squibb Company NYSE BMY is a large diversified pharmaceutical company that is one of the leaders in the development of immune system stimulating therapies to fight cancer These efforts are spearheaded by its product Opdivo now approved to treat several types of cancer
BMY,BMY:US,BBG000DQLV23,Why Earnings Season Could Be Great for Bristol-Myers (BMY),2016-10-26 12:49:12 +0000,http://finance.yahoo.com/news/why-earnings-season-could-great-124912582.html,Why Earnings Season Could Be Great for Bristol-Myers (BMY)
BMY,BMY:US,BBG000DQLV23,"Drug Stock Q3 Earnings Roster for Oct 27: AMGN, BMY & More",2016-10-26 12:45:12 +0000,http://finance.yahoo.com/news/drug-stock-q3-earnings-roster-124512439.html,"Drug Stock Q3 Earnings Roster for Oct 27: AMGN, BMY & More"
BMY,BMY:US,BBG000DQLV23,4 Top Drug Stocks That Can Be Purchased on the Cheap This Fall,2016-10-26 12:27:59 +0000,http://www.fool.com/investing/2016/10/25/4-top-drug-stocks-that-can-be-purchased-on-the-che.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,4 Top Drug Stocks That Can Be Purchased on the Cheap This Fall
BMY,BMY:US,BBG000DQLV23,'Mad Money' Lightning Round: Yum! Brands Split is a 'Great Idea',2016-10-26 10:00:00 +0000,https://www.thestreet.com/story/13741645/1/mad-money-lightning-round-yum-brands-split-is-a-great-idea.html?puc=yahoo&cm_ven=YAHOO,'Mad Money' Lightning Round: Yum! Brands Split is a 'Great Idea'
BMY,BMY:US,BBG000DQLV23,New Results Presented for Opdivo (nivolumab) Demonstrated Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients (177KB),2016-10-26 06:05:06 +0000,http://www.publicnow.com/view/9FDC90B2E31FAD5A6E70DCC63828939BE9E1FD72,"[at noodls] - October 26, 2016 New Results Presented for Opdivo (nivolumab) Demonstrated Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients (PRINCETON, N.J., ..."
BMY,BMY:US,BBG000DQLV23,Merck & Co.'s Keytruda Is &quot;Off to The Races&quot;,2016-10-25 21:26:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DpIE0RR9lC0/merck-cos-keytruda-is-off-to-the-races-cm698208,Since launching in late 2014 sales of Merck amp Co s NYSE MRK Keytruda a cancer fighting drug are already growing quickly However a new FDA approval of Keytruda as a first line therapy for metastatic non small cell lung cancer could make Keytruda s sales pace accelerate
BMY,BMY:US,BBG000DQLV23,Merck Crushes Q3 Expectations Following Lung Cancer Drug Win,2016-10-25 20:35:00 +0000,http://www.investors.com/news/technology/merck-crushes-q3-expectations-following-lung-cancer-drug-win/,Merck Crushes Q3 Expectations Following Lung Cancer Drug Win
BMY,BMY:US,BBG000DQLV23,What to Look for When Bristol-Myers (BMY) Posts Q3 Earnings,2016-10-25 19:59:00 +0000,https://www.thestreet.com/story/13866553/1/what-to-look-for-when-bristol-myers-bmy-posts-q3-earnings.html?puc=yahoo&cm_ven=YAHOO,What to Look for When Bristol-Myers (BMY) Posts Q3 Earnings
BMY,BMY:US,BBG000DQLV23,"Merck & Co.'s Keytruda Is ""Off to The Races""",2016-10-25 19:40:05 +0000,http://www.fool.com/investing/2016/10/25/merck-cos-keytruda-is-off-to-the-races.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Merck & Co.'s Keytruda Is ""Off to The Races"""
BMY,BMY:US,BBG000DQLV23,Baron Funds Comments on Bristol-Myers Squibb Co.,2016-10-25 17:29:01 +0000,http://finance.yahoo.com/news/baron-funds-comments-bristol-myers-172901298.html,Baron Funds Comments on Bristol-Myers Squibb Co.
BMY,BMY:US,BBG000DQLV23,Baron Opportunity Fund 3rd Quarter Commentary,2016-10-25 16:20:46 +0000,http://finance.yahoo.com/news/baron-opportunity-fund-3rd-quarter-162046797.html,Baron Opportunity Fund 3rd Quarter Commentary
BMY,BMY:US,BBG000DQLV23,Merck predicts lung cancer dominance for Keytruda immunotherapy,2016-10-25 16:11:30 +0000,http://finance.yahoo.com/news/merck-quarterly-revenue-beats-raises-111623742.html,"[Reuters] - Merck & Co on Tuesday declared its intention to dominate the large and lucrative lung cancer market, bolstered by a significant expansion of approved U.S. uses for its drug that helps the immune system attack tumors. Merck's optimistic comments came after it posted better-than-expected third quarter results, helped by growing sales of the cancer drug Keytruda. Keytruda on Monday became the first of the new immunotherapy drugs approved as an initial lung cancer treatment, when U.S. regulators cleared it for use in patients whose cancer cells express a high level of the PD-L1 protein that the medicine targets."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s 3Q16 Earnings: What’s Expected,2016-10-25 15:45:42 +0000,http://marketrealist.com/2016/10/bristol-myers-squibbs-3q16-earnings-whats-expected/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb’s 3Q16 Earnings: What’s Expected
BMY,BMY:US,BBG000DQLV23,4 Top Drug Stocks That Can Be Purchased on the Cheap This Fall,2016-10-25 14:25:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F3nBd9-FyfI/4-top-drug-stocks-that-can-be-purchased-on-the-cheap-this-fall-cm697683,Some great drug stocks could be hiding in plain view Image source Getty Images U S stocks have been taken for a wild ride in 2016 but at least most long term investors can relish the fact that despite the volatility the broader market indexes are all higher year to date The
BMY,BMY:US,BBG000DQLV23,New Results Presented for Opdivo (nivolumab) Demonstrate Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients,2016-10-25 12:21:04 +0000,http://www.publicnow.com/view/E03BF95E1A4BE74CE483E8445D1BAE6E323EC270,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced new results from CheckMate -205, a multi-cohort, single-arm, Phase 2 trial evaluating Opdivo (nivolumab) in patients ..."
BMY,BMY:US,BBG000DQLV23,Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment,2016-10-24 21:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FOwb-dUd8ZQ/merck-drug-gets-fda-approval-as-a-firstline-lung-cancer-treatment-20161024-01019,Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
BMY,BMY:US,BBG000DQLV23,Bristol-Myers's (BMY) Opdivo Under Priority Review by FDA,2016-10-24 16:27:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tEbTnB-ytRA/bristol-myerss-bmy-opdivo-under-priority-review-by-fda-cm697211,Bristol Myers Squibb Company BMY announced that its supplemental biologics license application sBLA for immuno oncology drug Opdivo has been accepted for priority review by the FDA The company is looking to expand Opdivo s label to include the treatment of locally advanced unresectable
BMY,BMY:US,BBG000DQLV23,Healthcare ETFs: Gain or Pain Ahead in Q3 Earnings?,2016-10-24 16:26:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lGd9FKvfjkU/healthcare-etfs-gain-or-pain-ahead-in-q3-earnings-cm697191,The Q3 earnings season is in full swing with the healthcare sector showing the third highest growth at this stage trailing materials and business services Earnings from 22 of the sector s market capitalization that have reported so far are up 15 9 with a beat ratio of 83 3 on revenue growth
BMY,BMY:US,BBG000DQLV23,Merck Gets FDA Approval for Investigational Drug Zinplava,2016-10-24 15:28:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ccoVG2UxxaU/merck-gets-fda-approval-for-investigational-drug-zinplava-cm697079,Merck amp Co Inc MRK announced that the FDA has approved its pipeline candidate Zinplava bezlotoxumab injection 25 mg mL for the prevention of Clostridium difficile C difficile infection recurrence Merck expects to launch Zinplava in the first quarter of 2017 Note that
BMY,BMY:US,BBG000DQLV23,What to Expect from Merck & Bristol-Myers' IO Drugs in Q3?,2016-10-24 14:26:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LLpxF4J6gGI/what-to-expect-from-merck-bristol-myers-io-drugs-in-q3-cm697125,Among the myriad diseases and therapeutic areas covered by pharma and biotech companies cancer will more often than not top the list of treatments being developed by most of these companies This is not surprising if you take into account the statistics surrounding cancer According to
BMY,BMY:US,BBG000DQLV23,Bristol-Myers's (BMY) Opdivo Under Priority Review by FDA,2016-10-24 14:21:02 +0000,http://finance.yahoo.com/news/bristol-myerss-bmy-opdivo-under-142102903.html,Bristol-Myers's (BMY) Opdivo Under Priority Review by FDA
BMY,BMY:US,BBG000DQLV23,What to Expect from Merck & Bristol-Myers' IO Drugs in Q3?,2016-10-24 13:02:01 +0000,http://finance.yahoo.com/news/expect-merck-bristol-myers-io-130201862.html,What to Expect from Merck & Bristol-Myers' IO Drugs in Q3?
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Coast 2 Coast 4 Cancer Ride Raises Over $1 Million for Cancer Research,2016-10-24 11:11:03 +0000,http://www.publicnow.com/view/35853EA951E09C8CA48E5B3345D1EAE591E5373E,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb's (NYSE:BMY) Coast 2 Coast 4 Cancerhas raised more than $1,050,000 to support Stand Up To Cancer's collaborative cancer research programs. In this ..."
BMY,BMY:US,BBG000DQLV23,"BMY''s Opdivo At The Altar Again, MRK Gets FDA Nod, Watch Out For OASM",2016-10-24 00:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q8vZp3CL2MA/bmys-opdivo-at-the-altar-again-mrk-gets-fda-nod-watch-out-for-oasm-20161024-00004,"BMY''s Opdivo At The Altar Again, MRK Gets FDA Nod, Watch Out For OASM"
BMY,BMY:US,BBG000DQLV23,It’s All About Positive Earnings Leverage,2016-10-23 15:19:28 +0000,http://finance.yahoo.com/tumblr/blog-its-all-about-positive-earnings-leverage-151935881.html,It’s All About Positive Earnings Leverage
BMY,BMY:US,BBG000DQLV23,"Stock Exchange: Charts For WB, DDD, DXCM And APD Deserve A Look",2016-10-22 09:29:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jvcH8kK2npE/stock-exchange-charts-for-wb-ddd-dxcm-and-apd-deserve-a-look-cm693298,By Jeff Miller ByJeff Miller Each week Felix and Oscar host a poker game We listen in on current trading ideas in the few minutes before the game starts They like to call this their Stock Exchange I am the only human present and the only one using fundamental analysis Their methods
BMY,BMY:US,BBG000DQLV23,U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients With Advanced Form of Bladder Cancer,2016-10-21 18:29:06 +0000,http://www.publicnow.com/view/3CC13A1C8144EB34F2CA263D4349AE884830A9C4,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA), ..."
BMY,BMY:US,BBG000DQLV23,Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments,2016-10-21 15:36:21 +0000,http://finance.yahoo.com/news/drugs-working-pharma-giants-eli-153621166.html,Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb (BMY) Q3 Earnings: What's in Store?,2016-10-21 15:27:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RMqSwE8I4l0/bristol-myers-squibb-bmy-q3-earnings-whats-in-store-cm696594,Bristol Myers Squibb Company BMY is scheduled to report third quarter 2016 results on Oct 27 before the market opens Last quarter the company posted a positive earnings surprise of 2 99 Bristol Myers has an impressive track record so far The company s earnings surpassed expectations
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Updates Conference Call Dial-in/ID for Third Quarter 2016 Results on October 27,2016-10-21 15:19:01 +0000,http://www.publicnow.com/view/259452A199B6E2EBBAF472CEECF33A544375C475,"[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2016 on Thursday, October 27, 2016. During a conference call at 10:30 a.m. EDT on October ..."
BMY,BMY:US,BBG000DQLV23,How Did Johnson & Johnson’s Pharmaceutical Segment Do in 3Q16?,2016-10-21 15:04:52 +0000,http://marketrealist.com/2016/10/how-did-johnson-johnsons-pharmaceutical-segment-do-in-3q16/?utm_source=yahoo&utm_medium=feed,How Did Johnson & Johnson’s Pharmaceutical Segment Do in 3Q16?
BMY,BMY:US,BBG000DQLV23,Will Merck Report Another Healthy Quarter?,2016-10-21 13:44:00 +0000,https://www.thestreet.com/story/13861951/1/will-merck-report-another-healthy-quarter.html?puc=yahoo&cm_ven=YAHOO,Will Merck Report Another Healthy Quarter?
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb (BMY) Q3 Earnings: What's in Store?,2016-10-21 13:26:01 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-bmy-q3-132601664.html,Bristol-Myers Squibb (BMY) Q3 Earnings: What's in Store?
BMY,BMY:US,BBG000DQLV23,"Nothing Can Stop Merck & Co., Inc. (MRK) Stock Now",2016-10-20 19:27:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nokB3QT7oC4/nothing-can-stop-merck-co-inc-mrk-stock-now-cm696156,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Shares of pharmaceutical giant Merck amp Co Inc NYSE MRK 160 have been on a roll lately MRK 160 stock jumped last week and reached its highest levels over the past year It also returned
BMY,BMY:US,BBG000DQLV23,Defining the True Value of Innovation in Cancer Treatment,2016-10-20 15:19:00 +0000,http://www.publicnow.com/view/D957353A4620FCF59AA2827D131E7DF2B6988134,[at noodls] - Bristol-Myers Squibb believes the current structure of the Institute for Clinical and Economic Review's (ICER) value assessment model takes a static approach to what is an incredibly dynamic environment. ...
BMY,BMY:US,BBG000DQLV23,Roche Sales Lifted by Cancer Drugs,2016-10-20 02:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nyE9T9sN6dQ/roche-sales-lifted-by-cancer-drugs-20161020-00063,Roche Sales Lifted by Cancer Drugs
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Co. : BMY-US: Dividend Analysis : October 07th, 2016 (record date) : By the numbers : October 19, 2016",2016-10-19 18:10:04 +0000,http://www.capitalcube.com/blog/index.php/bristol-myers-squibb-co-bmy-us-dividend-analysis-october-07th-2016-record-date-by-the-numbers-october-19-2016/,"Bristol-Myers Squibb Co. : BMY-US: Dividend Analysis : October 07th, 2016 (record date) : By the numbers : October 19, 2016"
BMY,BMY:US,BBG000DQLV23,3 Reasons Bristol-Myers Is a Buy,2016-10-19 17:47:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nlD07KYgnLc/3-reasons-bristol-myers-is-a-buy-cm695482,Image source Bristol Myers Squibb Fresh off a data release announcement providing full details of Opdivo s failure in its Phase 3 CheckMate 026 study Bristol Myers Squibb NYSE BMY shares dipped another 10 bringing shares off a whopping 35 since their July
BMY,BMY:US,BBG000DQLV23,3 Reasons Bristol-Myers Is a Buy,2016-10-19 16:23:40 +0000,http://www.fool.com/investing/2016/10/19/3-reasons-bristol-myers-is-a-buy.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Reasons Bristol-Myers Is a Buy
BMY,BMY:US,BBG000DQLV23,Can Eli Lilly (LLY) Pull a Surprise this Earnings Season?,2016-10-19 15:51:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/maogj0NV0yo/can-eli-lilly-lly-pull-a-surprise-this-earnings-season-cm695370,Eli Lilly and Company LLY is set to report third quarter 2016 results on Oct 25 before the market opens Last quarter the company posted a positive earnings surprise of 1 18 The company s performance has been pretty strong so far with earnings surpassing expectations in three of the
BMY,BMY:US,BBG000DQLV23,Can Merck (MRK) Keep the Earnings Streak Alive in Q3?,2016-10-19 14:49:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bDBwkEvGgR8/can-merck-mrk-keep-the-earnings-streak-alive-in-q3-cm695237,Merck amp Co Inc MRK is set to report third quarter 2016 results on Oct 25 before the market opens Last quarter the company delivered a positive earnings surprise of 1 09 Merck s performance has been pretty impressive with the company beating earnings expectations consistently
BMY,BMY:US,BBG000DQLV23,Roche's Tecentriq Wins FDA Nod for Additional Indication,2016-10-19 12:48:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ig-tM9FvOFQ/roches-tecentriq-wins-fda-nod-for-additional-indication-cm695170,Roche Holding AG RHHBY announced that the FDA has approved its immuno oncology drug Tecentriq atezolizumab for an additional indication Tecentriq has been approved for the treatment of metastatic non small cell lung cancer NSCLC in patients whose disease has progressed during or
BMY,BMY:US,BBG000DQLV23,Roche's lung cancer drug wins U.S. approval,2016-10-18 21:33:14 +0000,http://finance.yahoo.com/news/roches-lung-cancer-drug-wins-213314789.html,"[Reuters] - Swiss drugmaker Roche Holding AG's new immunotherapy, Tecentriq, won approval on Tuesday from U.S. health regulators as a second-line lung cancer treatment, a decision seen likely to erode Bristol-Myers Squibb's position in this hotly contested market. The U.S. Food and Drug Administration approved Tecentriq to be used in non-small cell lung cancer patients previously treated with chemotherapy, regardless of whether their tumours express a protein called PD-L1. People with high PD-L1 levels are generally more receptive to immunotherapy."
BMY,BMY:US,BBG000DQLV23,"Notable ETF Inflow Detected - VUG, BMY, AGN, QCOM",2016-10-18 16:47:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YUoa-Gr4c_I/notable-etf-inflow-detected-vug-bmy-agn-qcom-cm694829,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Growth ETF Symbol VUG where we have detected an approximate 104 6 million dollar inflow that s a 0 5 increase week over week in outstanding
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedot,2016-10-18 02:13:17 +0000,http://www.publicnow.com/view/6B4F903CE3578D2F132CA4BB0184D9713E6483EB,"[at noodls] - October 18, 2016 Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem ..."
BMY,BMY:US,BBG000DQLV23,Cramer Remix: The video game space is on fire. Here’s how...,2016-10-17 23:00:00 +0000,http://finance.yahoo.com/video/cramer-remix-video-game-space-230000502.html,Cramer Remix: The video game space is on fire. Here’s how...
BMY,BMY:US,BBG000DQLV23,"Nike, Bristol-Myers Drop into Monday’s 52-Week Low Club",2016-10-17 20:04:42 +0000,http://247wallst.com/investing/2016/10/17/nike-bristol-myers-drop-into-mondays-52-week-low-club/,"Nike, Bristol-Myers Drop into Monday’s 52-Week Low Club"
BMY,BMY:US,BBG000DQLV23,BMY Stock: Don’t Try to Catch This Falling Knife … Yet,2016-10-17 19:47:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CzUgvaEyfJU/bmy-stock-dont-try-to-catch-this-falling-knife-yet-cm694418,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Bristol Myers Squibb Co NYSE BMY stock has been an absolute mess the past few months down a staggering 33 from its early August high around 75 160 Still the company boasts solid
BMY,BMY:US,BBG000DQLV23,McDonald’s Corporation Shakes Up C-Suite to Revive Sales (MCD),2016-10-17 19:47:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PRBivM6QNrE/mcdonalds-corporation-shakes-up-c-suite-to-revive-sales-mcd-cm694416,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips The revival McDonald s Corporation NYSE MCD and McDonald s 160 stock have enjoyed since initiating All Day Breakfast has waned With second quarter same store sales growing at less than 2
BMY,BMY:US,BBG000DQLV23,The Time Is Right to Pick Up Bristol-Myers Squibb,2016-10-17 17:49:12 +0000,http://finance.yahoo.com/news/time-pick-bristol-myers-squibb-174912611.html,The Time Is Right to Pick Up Bristol-Myers Squibb
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Foundation Joins White House Cancer Moonshot,2016-10-17 16:23:07 +0000,http://www.publicnow.com/view/0FDA9968DF8CA931413993B64F634D738B31DADD,[at noodls] - NEW YORK--(BUSINESS WIRE)--Today the Bristol-Myers Squibb Foundation joins the White House Cancer Moonshot initiative through its commitment to addressing health disparities in cancer care. In response ...
BMY,BMY:US,BBG000DQLV23,"The Zacks Analyst Blog Highlights: Mylan, Pfizer, Roche, Merck and Bristol-Myers",2016-10-17 15:43:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k7mz-8RlIHc/the-zacks-analyst-blog-highlights-mylan-pfizer-roche-merck-and-bristol-myers-cm694137,For Immediate Release Chicago IL October 17 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BMY,BMY:US,BBG000DQLV23,Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis,2016-10-17 13:43:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jh4i_SRDlLc/pfizer-and-bristol-myers-squibb-could-face-a-big-threat-from-small-biotech-exelixis-cm694003,Image source Getty Images Only 12 of patients with advanced kidney cancer survive five years or more Exelixis NASDAQ EXEL hopes to increase that number and based on its latest clinical trial results the small biotech appears to be on the right track That s great news
BMY,BMY:US,BBG000DQLV23,What to Expect from J&J's (JNJ) Pharmaceutical Segment in Q3?,2016-10-17 13:42:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4nK4vBdrQpY/what-to-expect-from-jjs-jnj-pharmaceutical-segment-in-q3-cm694060,Healthcare giant Johnson amp Johnson JNJ will be reporting third quarter results tomorrow before the market opens The company has a pretty good earnings track record having surpassed expectations in each of the last four quarters While J amp J has three segments
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Wins CHMP Nod for Opdivo Label Expansion,2016-10-17 13:42:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_D2QW_2IhQ4/bristol-myers-wins-chmp-nod-for-opdivo-label-expansion-cm694051,Bristol Myers Squibb Company BMY announced that the European Medicines Agency s Committee for Medicinal Products for Human Use CHMP has recommended the approval of Opdivo for adults with relapsed or refractory classical Hodgkin lymphoma cHL after autologous stem cell transplant ASCT
BMY,BMY:US,BBG000DQLV23,"The Zacks Analyst Blog Highlights: Mylan, Pfizer, Roche, Merck and Bristol-Myers",2016-10-17 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-mylan-133001275.html,"The Zacks Analyst Blog Highlights: Mylan, Pfizer, Roche, Merck and Bristol-Myers"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Wins CHMP Nod for Opdivo Label Expansion,2016-10-17 12:44:12 +0000,http://finance.yahoo.com/news/bristol-myers-wins-chmp-nod-124412636.html,Bristol-Myers Wins CHMP Nod for Opdivo Label Expansion
BMY,BMY:US,BBG000DQLV23,Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis,2016-10-17 12:36:56 +0000,http://www.fool.com/investing/2016/10/17/pfizer-faces-a-big-threat-from-small-biotech-exeli.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis
BMY,BMY:US,BBG000DQLV23,“High Pressure Economy” Means Future-Focused Investing,2016-10-16 16:56:58 +0000,http://finance.yahoo.com/tumblr/blog-high-pressure-economy-means-future-focusing-165705066.html,“High Pressure Economy” Means Future-Focused Investing
BMY,BMY:US,BBG000DQLV23,3 Incredibly Cheap Big Pharma Stocks,2016-10-15 12:41:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RIX-fVuGge0/3-incredibly-cheap-big-pharma-stocks-cm693771,Image source Getty Images Not everything about Big Pharma is big Some stocks of the largest drugmakers in the world actually trade at relatively low valuations Here s why Mallinckrodt NYSE MNK Bayer AG NASDAQOTH BAYRY and Bristol Myers Squibb NYSE BMY look
BMY,BMY:US,BBG000DQLV23,3 Incredibly Cheap Big Pharma Stocks,2016-10-15 11:04:47 +0000,http://www.fool.com/investing/2016/10/15/3-incredibly-cheap-big-pharma-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Incredibly Cheap Big Pharma Stocks
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Mylan in EpiPen Medicaid Settlement, ESMO Data in Focus",2016-10-14 15:44:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f6ID7EEIvRU/pharma-stock-roundup-mylan-in-epipen-medicaid-settlement-esmo-data-in-focus-cm693441,Mylan MYL was in the news again with the company agreeing to a settlement related to Medicaid rebate classification for EpiPen Meanwhile several pharma companies were present at the congress of the European Society for Medical Oncology ESMO with data on their cancer treatments Recap
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedot,2016-10-14 11:10:09 +0000,http://www.publicnow.com/view/83633815D04B0855A10BF94381FB3F424F6D3762,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Asked to Seek Special Coverage for Opdivo in U.K.,2016-10-13 23:01:00 +0000,http://www.bloomberg.com/news/articles/2016-10-13/bristol-myers-asked-to-seek-special-coverage-for-opdivo-in-u-k?cmpid=yhoo.headline,Bristol-Myers Asked to Seek Special Coverage for Opdivo in U.K.
BMY,BMY:US,BBG000DQLV23,5 Dividend Stocks to Put on Your Shopping List,2016-10-13 22:41:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8XcgmSRUvew/5-dividend-stocks-to-put-on-your-shopping-list-cm693188,Image source Getty Images Dividend stocks are a wonderful way to grow your wealth and generate income The trick is finding companies with dividends that aren t at risk of getting slashed overnight and have prospects to increase payouts over time We asked five of our
BMY,BMY:US,BBG000DQLV23,5 Dividend Stocks to Put on Your Shopping List,2016-10-13 21:03:06 +0000,http://www.fool.com/retirement/2016/10/13/5-dividend-stocks-to-put-on-your-shopping-list.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Dividend Stocks to Put on Your Shopping List
BMY,BMY:US,BBG000DQLV23,Bristol-Myers (BMY) Stock Removed From Goldman's 'Conviction Buy' List,2016-10-13 18:59:00 +0000,https://www.thestreet.com/story/13852513/1/bristol-myers-bmy-stock-removed-from-goldman-s-conviction-buy-list.html?puc=yahoo&cm_ven=YAHOO,Bristol-Myers (BMY) Stock Removed From Goldman's 'Conviction Buy' List
BMY,BMY:US,BBG000DQLV23,3 Value Stocks Near 52-Week Lows Worth Buying,2016-10-13 16:44:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FPgTB13NjNU/3-value-stocks-near-52-week-lows-worth-buying-cm692942,Image source Getty Images While many companies shares are rising 160 past their fair values now others are trading at potentially bargain prices The difficulty with bargain shopping though is that you may be understandably hesitant to buy stocks wallowing near their 52 week
BMY,BMY:US,BBG000DQLV23,J&J (JNJ) Likely to Beat Earnings Estimates in Q3 Again,2016-10-13 16:43:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Cc2Kba6KROs/jj-jnj-likely-to-beat-earnings-estimates-in-q3-again-cm692874,Johnson amp Johnson JNJ the bellwether of healthcare companies is scheduled to report third quarter 2016 results on Oct 18 before the opening bell Last quarter the company reported a positive earnings surprise of 4 19 J amp J has consistently surpassed earnings expectations
BMY,BMY:US,BBG000DQLV23,Abbott Labs (ABT) Q3 Earnings: What's Ahead for the Stock?,2016-10-13 15:43:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zzLUTlC8kKw/abbott-labs-abt-q3-earnings-whats-ahead-for-the-stock-cm692803,Abbott Laboratories ABT is scheduled to report third quarter 2016 results before the opening bell on Oct 19 Last quarter Abbott Labs delivered a positive earnings surprise of 3 77 Let s see how things are shaping up for this quarter Factors at Play Abbott Labs operates
BMY,BMY:US,BBG000DQLV23,3 Value Stocks Near 52-Week Lows Worth Buying,2016-10-13 15:02:06 +0000,http://www.fool.com/investing/2016/10/13/3-value-stocks-near-52-week-lows-worth-buying.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Value Stocks Near 52-Week Lows Worth Buying
BMY,BMY:US,BBG000DQLV23,"S&P 500 Movers: FFIV, BBY",2016-10-12 17:41:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wt61nZmhumQ/sp-500-movers-ffiv-bby-cm692481,In early trading on Wednesday shares of Best Buy BBY topped the list of the day s best performing components of the S amp P 500 index trading up 3 7 Year to date Best Buy registers a 30 6 gain And the worst performing S amp P 500 component thus far on the day is F5 Networks
BMY,BMY:US,BBG000DQLV23,BMY’s Drug Treatments That Go beyond Immuno-Oncology,2016-10-12 14:04:25 +0000,http://marketrealist.com/2016/10/bmys-drug-treatments-that-go-beyond-immuno-oncology/?utm_source=yahoo&utm_medium=feed,BMY’s Drug Treatments That Go beyond Immuno-Oncology
BMY,BMY:US,BBG000DQLV23,How Large of a Role Does Opdivo Play in Bristol-Myers Squibb’s Success?,2016-10-12 12:04:33 +0000,http://marketrealist.com/2016/10/how-large-of-a-role-does-opdivo-play-in-bristol-myers-squibbs-success/?utm_source=yahoo&utm_medium=feed,How Large of a Role Does Opdivo Play in Bristol-Myers Squibb’s Success?
BMY,BMY:US,BBG000DQLV23,3 Additions to the Wide Moat Focus Index,2016-10-12 11:00:00 +0000,http://news.morningstar.com/articlenet/article.aspx?id=773764&SR=Yahoo,3 Additions to the Wide Moat Focus Index
BMY,BMY:US,BBG000DQLV23,BUZZ-AstraZeneca: investor survey sees 50:50 chance for cancer combo,2016-10-12 08:04:34 +0000,http://uk.finance.yahoo.com/news/buzz-astrazeneca-investor-survey-sees-080434671.html,BUZZ-AstraZeneca: investor survey sees 50:50 chance for cancer combo
BMY,BMY:US,BBG000DQLV23,"Tuesday’s Vital Data: Apple Inc. (AAPL), Twitter Inc (TWTR) and Bristol-Myers Squibb Co (BMY)",2016-10-11 15:19:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E5cQ0Qnr2CM/tuesdays-vital-data-apple-inc-aapl-twitter-inc-twtr-and-bristol-myers-squibb-co-bmy-cm691753,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Kicking off the trading week and much to the chagrin of autumnal volatility seekers the market offered up more of the same old and rather quiet price action though with a tinge of
BMY,BMY:US,BBG000DQLV23,BMY Waiting to Enter the First-Line Lung Cancer Space,2016-10-11 15:04:56 +0000,http://marketrealist.com/2016/10/bmy-waiting-to-enter-the-first-line-lung-cancer-space/?utm_source=yahoo&utm_medium=feed,BMY Waiting to Enter the First-Line Lung Cancer Space
BMY,BMY:US,BBG000DQLV23,How Bristol-Myers Squibb Is Expanding Its Lung Cancer Treatments,2016-10-11 14:06:23 +0000,http://marketrealist.com/2016/10/how-bristol-myers-squibb-is-expanding-its-lung-cancer-treatments/?utm_source=yahoo&utm_medium=feed,How Bristol-Myers Squibb Is Expanding Its Lung Cancer Treatments
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Strategies to Dominate Immuno-Oncology Market,2016-10-11 12:05:51 +0000,http://marketrealist.com/2016/10/bristol-myers-squibbs-strategies-to-dominate-immuno-oncology-market/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb’s Strategies to Dominate Immuno-Oncology Market
BMY,BMY:US,BBG000DQLV23,How a Merck cancer breakthrough caused Bristol-Myers’ stock to plunge,2016-10-11 11:03:41 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=11720CA4-8F18-11E6-94B4-A9EAC68D0F98&siteid=yhoof2,How a Merck cancer breakthrough caused Bristol-Myers’ stock to plunge
BMY,BMY:US,BBG000DQLV23,[$$] An Extended Trial for Bristol-Myers Squibb,2016-10-11 04:13:55 +0000,http://www.wsj.com/articles/an-extended-trial-for-bristol-myerssquibb-1476122276?ru=yahoo?mod=yahoo_itp,[at The Wall Street Journal] - Bristol-Myers Squibb’s disappointing clinical trial results may continue to weigh on the stock.
BMY,BMY:US,BBG000DQLV23,[$$] An Extended Trial for Bristol-MyersSquibb,2016-10-11 02:17:05 +0000,http://www.wsj.com/articles/an-extended-trial-for-bristol-myerssquibb-1476122276?mod=yahoo_hs,[at The Wall Street Journal] - Bristol-Myers Squibb’s disappointing clinical trial results may continue to weigh on the stock.
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer (165KB)",2016-10-11 01:57:05 +0000,http://www.publicnow.com/view/AF32EC1B88F8764683022DC5693621B9BAF843E6,"[at noodls] - October 11, 2016 Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Partner Ono Drops as Cancer Drug Data Disappoint,2016-10-11 01:09:32 +0000,http://www.bloomberg.com/news/articles/2016-10-11/bristol-myers-partner-ono-drops-as-cancer-drug-data-disappoint?cmpid=yhoo.headline,Bristol-Myers Partner Ono Drops as Cancer Drug Data Disappoint
BMY,BMY:US,BBG000DQLV23,"Why Bristol-Myers Squibb, Myriad Genetics, and Twilio Slumped Today",2016-10-11 00:18:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GONeZ2f2tyE/why-bristol-myers-squibb-myriad-genetics-and-twilio-slumped-today-cm691376,The stock market performed well on Monday with the Dow climbing 88 points and other major market benchmarks posting similar gains of roughly half a percent Many investors were pleased with the continued advances in the crude oil market where prices approached the 52 per barrel level
BMY,BMY:US,BBG000DQLV23,"Why Twitter Inc (TWTR), Bristol-Myers Squibb Co (BMY) and Twilio Inc (TWLO) Are 3 of Today’s Worst Stocks",2016-10-10 23:18:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TRHK6HogCO4/why-twitter-inc-twtr-bristol-myers-squibb-co-bmy-and-twilio-inc-twlo-are-3-of-todays-worst-stocks-cm691365,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Stocks started the new trading week with a bang largely celebrating the fact that Russia is finally starting to feel the burn of cheap oil and as such may crimp its output in an effort
BMY,BMY:US,BBG000DQLV23,"Why Bristol-Myers Squibb, Myriad Genetics, and Twilio Slumped Today",2016-10-10 22:42:00 +0000,http://www.fool.com/investing/2016/10/10/why-bristol-myers-squibb-myriad-genetics-and-twili.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,"Why Bristol-Myers Squibb, Myriad Genetics, and Twilio Slumped Today"
BMY,BMY:US,BBG000DQLV23,"Stocks Rise As Oil Rallies; Apple Up Amid Samsung Mess, Merck Pops",2016-10-10 22:21:01 +0000,http://finance.yahoo.com/video/stocks-rise-oil-rallies-apple-222101941.html,"Stocks Rise As Oil Rallies; Apple Up Amid Samsung Mess, Merck Pops"
BMY,BMY:US,BBG000DQLV23,CheckMate Again for Bristol-Myers Squibb Co. As Shares Dip 10%,2016-10-10 21:18:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6FHO_6vTjtQ/checkmate-again-for-bristol-myers-squibb-co-as-shares-dip-10-cm691321,Image source Bristol Myers Squibb What happened Shares of global drugmaker Bristol Myers Squibb NYSE BMY tumbled as much as 10 during Monday s trading session following the release of its primary data from the CheckMate 026 study involving its blockbuster cancer
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Co (BMY) Suffers Heavy Dose of Disappointment,2016-10-10 20:19:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CU-RN9Kf7fw/bristol-myers-squibb-co-bmy-suffers-heavy-dose-of-disappointment-cm691287,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Add the name Bristol Myers Squibb Co NYSE BMY to the list of volatile pharmaceutical stocks that have spooked investors into dumping their shares BMY stock is getting shellacked Monday down
BMY,BMY:US,BBG000DQLV23,"Health Care Sector Update for 10/10/2016: TSRO,MCUR,BMY",2016-10-10 20:18:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xgQ9QFKdi4I/health-care-sector-update-for-10102016-tsromcurbmy-cm691306,Top Health Care StocksTop Health Care Stocks JNJ 0 50 JNJ 0 50 PFE 0 13 PFE 0 13 MRK 1 28 MRK 1 28 ABT 1 66 ABT 1 66 AMGN 0 45 AMGN 0 45 Health care stocks were rising this afternoon with the NYSE Health Care Index climbing about 0 3 while shares of health care companies in
BMY,BMY:US,BBG000DQLV23,CheckMate Again for Bristol-Myers Squibb Co. As Shares Dip 10%,2016-10-10 20:14:12 +0000,http://www.fool.com/investing/2016/10/10/checkmate-again-for-bristol-myers-squibb-co-as-sha.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,CheckMate Again for Bristol-Myers Squibb Co. As Shares Dip 10%
BMY,BMY:US,BBG000DQLV23,"Health Care Sector Update for 10/10/2016: IPCI,MCUR,BMY, AZN",2016-10-10 18:18:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9KD4mHhbTys/health-care-sector-update-for-10102016-ipcimcurbmy-azn-cm691213,Top Health Care StocksTop Health Care Stocks JNJ 0 65 JNJ 0 65 PFE 0 40 PFE 0 40 MRK 1 28 MRK 1 28 ABT 1 62 ABT 1 62 AMGN 0 52 AMGN 0 52 Health care stocks were rising Monday afternoon with the NYSE Health Care Index climbing over 0 3 while shares of health care companies in
BMY,BMY:US,BBG000DQLV23,Analyst: Three things are pushing Mylan higher,2016-10-10 18:10:00 +0000,http://finance.yahoo.com/video/analyst-three-things-pushing-mylan-181000626.html,Analyst: Three things are pushing Mylan higher
BMY,BMY:US,BBG000DQLV23,Mylan soars on EpiPen settlement,2016-10-10 18:07:00 +0000,http://finance.yahoo.com/video/mylan-soars-epipen-settlement-180700797.html,Mylan soars on EpiPen settlement
BMY,BMY:US,BBG000DQLV23,"Here’s Why Bristol-Myers Squibb Co (BMY), Telefonica Brasil SA (ADR) (VIV) and Three Other Stocks Plunged on Monday",2016-10-10 17:52:44 +0000,http://www.insidermonkey.com/blog/heres-why-bristol-myers-squibb-co-bmy-telefonica-brasil-sa-adr-viv-and-three-other-stocks-plunged-on-monday-480027/,"Here’s Why Bristol-Myers Squibb Co (BMY), Telefonica Brasil SA (ADR) (VIV) and Three Other Stocks Plunged on Monday"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Enters Oversold Territory,2016-10-10 17:17:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iq3kaysSFK8/bristol-myers-squibb-enters-oversold-territory-cm691138,The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks according to a proprietary formula designed to identify those stocks that combine two important characteristics strong fundamentals and a valuation that looks inexpensive Bristol
BMY,BMY:US,BBG000DQLV23,Bristol-Myers: The Worst Case Scenario? This is It.,2016-10-10 17:14:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/10/bristol-myers-the-worst-case-scenario-this-is-it/?mod=yahoobarrons&ru=yahoo,Bristol-Myers: The Worst Case Scenario? This is It.
BMY,BMY:US,BBG000DQLV23,War on cancer,2016-10-10 16:35:00 +0000,http://finance.yahoo.com/video/war-cancer-163500595.html,War on cancer
BMY,BMY:US,BBG000DQLV23,"3 Stocks to Watch Monday: Mylan NV (MYL), Bristol-Myers Squibb Co (BMY) and Comcast Corporation (CMCSA)",2016-10-10 16:20:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kQJkYKo5q8c/3-stocks-to-watch-monday-mylan-nv-myl-bristol-myers-squibb-co-bmy-and-comcast-corporation-cmcsa-cm691101,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips The Mexican peso gained and Asian stocks surged slightly ahead of this week s action Meanwhile a report issued late last week revealed that the U S economy is garnering strength as 156
BMY,BMY:US,BBG000DQLV23,"Notable ETF Inflow Detected - VUG, BMY, AGN, CELG",2016-10-10 16:18:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JSGyh8XBM6Q/notable-etf-inflow-detected-vug-bmy-agn-celg-cm691056,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Growth ETF Symbol VUG where we have detected an approximate 80 8 million dollar inflow that s a 0 4 increase week over week in outstanding units
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb's Lost Ground,2016-10-10 16:00:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibbs-lost-ground-160000936.html,Bristol-Myers Squibb's Lost Ground
BMY,BMY:US,BBG000DQLV23,Mid-Morning Market Update: Markets Open Higher; Dover Lowers Full-Year Forecast,2016-10-10 15:37:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QbHgmsqD0IQ/mid-morning-market-update-markets-open-higher-dover-lowers-full-year-forecast-cm691134,Following the market opening Monday the Dow traded up 0 74 percent to 18 376 27 while the NASDAQ climbed 0 87 percent to 5 338 41 The S amp P also rose gaining 0 68 percent to 2 168 39 Leading and Lagging Sectors Monday morning energy shares climbed 1 70 percent Meanwhile
BMY,BMY:US,BBG000DQLV23,Monday’s 3 Major Biopharma Movers,2016-10-10 15:25:44 +0000,http://247wallst.com/healthcare-business/2016/10/10/mondays-3-major-biopharma-movers/,Monday’s 3 Major Biopharma Movers
BMY,BMY:US,BBG000DQLV23,"S&P 500 Movers: BMY, MYL",2016-10-10 15:18:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XLZpdRxsEok/sp-500-movers-bmy-myl-cm690967,In early trading on Monday shares of Mylan MYL topped the list of the day s best performing components of the S amp P 500 index trading up 8 8 Year to date Mylan has lost about 27 7 of its value And the worst performing S amp P 500 component thus far on the day is Bristol
BMY,BMY:US,BBG000DQLV23,Keytruda Leads over Opdivo in Head and Neck Cancer Treatment,2016-10-10 15:04:46 +0000,http://marketrealist.com/2016/10/keytruda-leads-over-opdivo-in-head-and-neck-cancer-treatment/?utm_source=yahoo&utm_medium=feed,Keytruda Leads over Opdivo in Head and Neck Cancer Treatment
BMY,BMY:US,BBG000DQLV23,"This Wasn't A Great ESMO For Bristol-Myers Squibb, But 2017 Could Be A Much Better Year",2016-10-10 14:56:33 +0000,http://finance.yahoo.com/news/wasnt-great-esmo-bristol-myers-145633844.html,"This Wasn't A Great ESMO For Bristol-Myers Squibb, But 2017 Could Be A Much Better Year"
BMY,BMY:US,BBG000DQLV23,"Dow, S&P 500 Retake 50-Day Line; Merck Rallies On Cancer Drug News",2016-10-10 14:28:42 +0000,http://www.investors.com/market-trend/stock-market-today/dow-s-merck-rallies-on-cancer-drug-trial-results/,"Dow, S&P 500 Retake 50-Day Line; Merck Rallies On Cancer Drug News"
BMY,BMY:US,BBG000DQLV23,Why Bristol-Myers (BMY) Stock Is Falling Today,2016-10-10 14:27:00 +0000,https://www.thestreet.com/story/13847307/1/why-bristol-myers-bmy-stock-is-falling-today.html?puc=yahoo&cm_ven=YAHOO,Why Bristol-Myers (BMY) Stock Is Falling Today
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Opdivo Vs. Merck's Keytruda In Front-Line Lung Treatment,2016-10-10 14:25:06 +0000,http://finance.yahoo.com/news/bristol-myers-opdivo-vs-mercks-142506704.html,Bristol-Myers' Opdivo Vs. Merck's Keytruda In Front-Line Lung Treatment
BMY,BMY:US,BBG000DQLV23,Bristol-Myers shares fall 9% after cancer treatment disappoints,2016-10-10 14:24:20 +0000,http://www.cnbc.com/id/104005838?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104005838,Bristol-Myers shares fall 9% after cancer treatment disappoints
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers shares tumble 10% on failed clinical trial,2016-10-10 14:18:00 +0000,"http://www.ft.com/cms/s/cab54424-8eeb-11e6-a72e-b428cb934b78,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[at Financial Times] - Investors dumped Bristol-Myers Squibb shares on Monday after the US drugmaker published the full results from a failed clinical trial of its new cancer immunotherapy. Bristol-Myers first announced the ...
BMY,BMY:US,BBG000DQLV23,Doctors grapple with best use of potent new cancer drugs,2016-10-10 14:06:23 +0000,http://finance.yahoo.com/news/doctors-grapple-best-potent-cancer-140623356.html,Doctors grapple with best use of potent new cancer drugs
BMY,BMY:US,BBG000DQLV23,A new kind of drug is working better than chemotherapy in some lung cancer patients,2016-10-10 13:48:00 +0000,http://finance.yahoo.com/news/kind-drug-working-better-chemotherapy-134800110.html,A new kind of drug is working better than chemotherapy in some lung cancer patients
BMY,BMY:US,BBG000DQLV23,Bristol-Myers stock drops nearly 9% after Merck announces positive lung cancer drug results,2016-10-10 13:23:42 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=0CE0806A-83AC-4AD6-AF3F-DCBE5C09060D&siteid=yhoof2,Bristol-Myers stock drops nearly 9% after Merck announces positive lung cancer drug results
BMY,BMY:US,BBG000DQLV23,Blog Coverage Bristol Myers Announces Positive Results for Yervoy,2016-10-10 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-bristol-myers-announces-131500799.html,"[Accesswire] - LONDON, UK / ACCESSWIRE / October 10, 2016 / Active Wall St. blog coverage looks at the headline from Bristol-Myers Squibb Co. (NYSE: BMY ) as the company announced the final primary analysis of CheckMate-026, ..."
BMY,BMY:US,BBG000DQLV23,"Pre-Market Most Active for Oct 10, 2016 :  TWTR, BCS, NOK, BMY, MYL, AAPL, AEG, TEF, TVIX, XIV, QQQ, TSRO",2016-10-10 12:57:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OgkrWMJ6M7c/pre-market-most-active-for-oct-10-2016-twtr-bcs-nok-bmy-myl-aapl-aeg-tef-tvix-xiv-qqq-tsro-cm690877,The NASDAQ 100 Pre Market Indicator is up 16 1 to 4 880 62 The total Pre Market volume is currently 12 169 666 shares traded The following are the most active stocks for the pre market session Twitter Inc TWTR is 2 59 at 17 26 with 5 621 579 shares traded TWTR
BMY,BMY:US,BBG000DQLV23,How Much Could Bristol-Myers Gain in 2016 and 2017?,2016-10-10 12:04:59 +0000,http://marketrealist.com/2016/10/how-much-could-bristol-myers-gain-in-2016-and-2017/?utm_source=yahoo&utm_medium=feed,How Much Could Bristol-Myers Gain in 2016 and 2017?
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Drops as Lung-Cancer Drug Disappoints Again,2016-10-10 11:57:54 +0000,http://finance.yahoo.com/news/bristol-myers-drops-lung-cancer-115754694.html,Bristol-Myers Drops as Lung-Cancer Drug Disappoints Again
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Drops to 2-Year Low as Cancer Drug Disappoints,2016-10-10 11:57:54 +0000,http://www.bloomberg.com/news/articles/2016-10-10/bristol-myers-drops-as-lung-cancer-drug-disappoints-again?cmpid=yhoo.headline,Bristol-Myers Drops to 2-Year Low as Cancer Drug Disappoints
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb (BMY) Has Dropped To A New Low On Study Results,2016-10-10 10:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4xODrQg8WIE/bristolmyers-squibb-bmy-has-dropped-to-a-new-low-on-study-results-20161010-00418,Bristol-Myers Squibb (BMY) Has Dropped To A New Low On Study Results
BMY,BMY:US,BBG000DQLV23,Wall Street Set For Strong Start After The Presidential Debate,2016-10-10 06:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MgjCxpjSTJA/wall-street-set-for-strong-start-after-the-presidential-debate-20161010-00133,Wall Street Set For Strong Start After The Presidential Debate
BMY,BMY:US,BBG000DQLV23,Merck Tops as Lung Cancer Treatment Moves Past Chemotherapy,2016-10-10 03:00:00 +0000,http://www.bloomberg.com/news/articles/2016-10-10/merck-leads-as-lung-cancer-treatment-moves-beyond-chemotherapy?cmpid=yhoo.headline,Merck Tops as Lung Cancer Treatment Moves Past Chemotherapy
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb: Phase 3 Studies Experienced Ongoing Responses With Opdivo,2016-10-09 21:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2WMEhwLMOwE/bristolmyers-squibb-phase-3-studies-experienced-ongoing-responses-with-opdivo-20161009-00063,Bristol-Myers Squibb: Phase 3 Studies Experienced Ongoing Responses With Opdivo
BMY,BMY:US,BBG000DQLV23,Mindset Shifts Take Time,2016-10-09 19:30:55 +0000,http://finance.yahoo.com/tumblr/blog-mindset-shifts-take-time-193102164.html,Mindset Shifts Take Time
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Lung-Cancer Drug Disappoints in Trial Analysis,2016-10-09 17:22:32 +0000,http://www.bloomberg.com/news/articles/2016-10-09/bristol-myers-lung-cancer-drug-disappoints-in-patient-trial?cmpid=yhoo.headline,Bristol-Myers Lung-Cancer Drug Disappoints in Trial Analysis
BMY,BMY:US,BBG000DQLV23,Which Big Pharma Is the Best Dividend Stock?,2016-10-09 17:18:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NGmWRS42cQ8/which-big-pharma-is-the-best-dividend-stock-cm690785,Image source Getty Images Big pharma stocks have historically been among investors favorite dividend stocks Which major drugmaker stock is the best of all I think turning to Charles Dickens can help answer the question Before you think I ve lost my mind let me explain
BMY,BMY:US,BBG000DQLV23,"AstraZeneca, Rivals Take Aim at Lung Cancer Combo Therapies",2016-10-09 16:31:21 +0000,http://www.bloomberg.com/news/articles/2016-10-09/astrazeneca-rivals-take-aim-at-lung-cancer-with-combo-therapies?cmpid=yhoo.headline,"AstraZeneca, Rivals Take Aim at Lung Cancer Combo Therapies"
BMY,BMY:US,BBG000DQLV23,Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer,2016-10-09 13:03:03 +0000,http://www.publicnow.com/view/A9D55F64254C25A97D59459280B18B55A34DC19A,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today updated results from two pivotal Phase 3 studies, CheckMate -057 and CheckMate -017, which showed more than one-third ..."
BMY,BMY:US,BBG000DQLV23,Updated Results Presented for the Opdivo (nivolumab) and Yervoy (ipilimumab) Combination in Metastatic Renal Cell Carcinoma From Phase 1 Study,2016-10-09 11:30:00 +0000,http://finance.yahoo.com/news/updated-results-presented-opdivo-nivolumab-113000887.html,"[Business Wire] - Bristol-Myers Squibb Company announced today updated results from the Phase 1 CheckMate -016 trial, which evaluated the safety and tolerability of Opdivo at different doses as part of a regimen with Yervoy, sunitinib or pazopanib in previously treated and treatment-naïve patients with metastatic renal cell carcinoma ."
BMY,BMY:US,BBG000DQLV23,Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress,2016-10-09 11:00:00 +0000,http://finance.yahoo.com/news/safety-data-lirilumab-combination-nivolumab-110000906.html,"[Business Wire] - Bristol-Myers Squibb Company and Innate Pharma SA today announced safety data for two Phase I studies conducted by Bristol-Myers Squibb, testing lirilumab in combination with nivolumab or ipilimumab, respectively, in patients with advanced refractory solid tumors."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer",2016-10-09 06:53:05 +0000,http://www.publicnow.com/view/F63EE613AE1A64B132C404E31D3742EECA24770C,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today the final primary analysis of CheckMate -026, a trial investigating the use of Opdivo (nivolumab) monotherapy as ..."
BMY,BMY:US,BBG000DQLV23,"Merck’s Drug Succeeds in Lung Cancer Test, Could Become Standard",2016-10-09 06:15:00 +0000,http://www.bloomberg.com/news/articles/2016-10-09/merck-s-drug-succeeds-in-lung-cancer-test-could-become-standard?cmpid=yhoo.headline,"Merck’s Drug Succeeds in Lung Cancer Test, Could Become Standard"
BMY,BMY:US,BBG000DQLV23,Opdivo (nivolumab) Stabilized Patient-reported Outcomes in Patients With Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck in Pivotal Phase 3 CheckMate -141 Study,2016-10-09 06:15:00 +0000,http://finance.yahoo.com/news/opdivo-nivolumab-stabilized-patient-reported-061500612.html,[Business Wire] - Bristol-Myers Squibb Company announced today new patient-reported quality-of-life data from an exploratory endpoint in the pivotal Phase 3 CheckMate -141 trial evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after platinum therapy compared to investigator’s choice of therapy .
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers lung cancer drug fails to meet immunotherapy hopes,2016-10-09 06:13:42 +0000,"http://www.ft.com/cms/s/8352f838-8ccf-11e6-8aa5-f79f5696c731,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - A new drug from Bristol-Myers Squibb that turns the body into a weapon against cancer failed to beat chemotherapy in a large head-to-head clinical trial, marking the biggest setback for the hot new field ..."
BMY,BMY:US,BBG000DQLV23,Study May Boost Use of Merck Lung-Cancer Drug,2016-10-09 02:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ddEOacQgBOU/study-may-boost-use-of-merck-lungcancer-drug-20161009-00007,Study May Boost Use of Merck Lung-Cancer Drug
BMY,BMY:US,BBG000DQLV23,Results From CheckMate-275 Validate Further Study of Opdivo (nivolumab) in Patients With Advanced Form of Bladder Cancer,2016-10-08 07:33:03 +0000,http://www.publicnow.com/view/9345428E955CF29069DC6AE781C92F668517B439,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today results from the CheckMate -275 trial, in which Opdivo had a confirmed objective response rate (ORR), the primary ..."
BMY,BMY:US,BBG000DQLV23,Yervoy (ipilimumab) Improves Overall Survival in Fully Resected Stage III Melanoma Patients From Phase 3 Study,2016-10-08 06:33:08 +0000,http://www.publicnow.com/view/21D189885D44BA741FED321A8BFAC4B3D9C2D0F9,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today superior efficacy with Yervoy 10 mg/kg versus placebo on all survival endpoints in the Phase 3 trial CA184-029 ..."
BMY,BMY:US,BBG000DQLV23,Incyte Could Stoke M&A Fire On 'Deep And Durable' Melanoma Drug Results,2016-10-07 20:23:53 +0000,http://www.investors.com/news/technology/incyte-could-stoke-ma-fire-on-deep-and-durable-melanoma-drug-results/,Incyte Could Stoke M&A Fire On 'Deep And Durable' Melanoma Drug Results
BMY,BMY:US,BBG000DQLV23,Understanding the Recent Fall in Bristol-Myers Squibb’s Valuation,2016-10-07 20:21:24 +0000,http://marketrealist.com/2016/10/understanding-the-recent-fall-in-bristol-myers-squibbs-valuation/?utm_source=yahoo&utm_medium=feed,Understanding the Recent Fall in Bristol-Myers Squibb’s Valuation
BMY,BMY:US,BBG000DQLV23,6 Healthcare Stocks Investors Can't Miss in Q3 Earnings,2016-10-07 18:43:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DZWZlJnc5pI/6-healthcare-stocks-investors-cant-miss-in-q3-earnings-cm690471,Controversies surrounding drug prices are again making it to the headlines this time spurred by the EpiPen price hike issue Generic drug maker Mylan N V drew flak from lawmakers for over pricing its epinephrine auto injector EpiPen severe allergic reactions around the end of Aug
BMY,BMY:US,BBG000DQLV23,"The Zacks Analyst Blog Highlights: Costco, ExxonMobil, Bristol-Myers, Shire and Darden",2016-10-07 15:47:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/21uXAAbNymw/the-zacks-analyst-blog-highlights-costco-exxonmobil-bristol-myers-shire-and-darden-cm690335,For Immediate Release Chicago IL October 07 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BMY,BMY:US,BBG000DQLV23,"The Zacks Analyst Blog Highlights: Costco, ExxonMobil, Bristol-Myers, Shire and Darden",2016-10-07 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-costco-133001973.html,"The Zacks Analyst Blog Highlights: Costco, ExxonMobil, Bristol-Myers, Shire and Darden"
BMY,BMY:US,BBG000DQLV23,Billions at stake for big pharma,2016-10-06 21:52:00 +0000,http://finance.yahoo.com/video/billions-stake-big-pharma-215200400.html,Billions at stake for big pharma
BMY,BMY:US,BBG000DQLV23,"Top Research Reports for Costco, Exxon & Bristol-Myers",2016-10-06 20:43:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QwNpt2Nhj8E/top-research-reports-for-costco-exxon-bristol-myers-cm690001,Thursday October 6 2016 Today s Research Daily features new research reports on 16 major stocks including Costco COST ExxonMobil XOM and Bristol Myers BMY Costco shares have been laggards lately as earnings performance has been weighed down by stiff competition and cautious
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Lilly Inks Animal Health Deal, J&J's Psoriasis Data Looks Good",2016-10-06 14:47:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k9ivxzZZw6s/pharma-stock-roundup-lilly-inks-animal-health-deal-jjs-psoriasis-data-looks-good-cm689700,Once again acquisitions and deals were in focus in the pharma sector with Lilly LLY announcing a deal to boost its animal health segment and Allergan AGN and AstraZeneca AZN announcing licensing agreements Meanwhile companies like Johnson amp Johnson JNJ and Novartis NVS presented data
BMY,BMY:US,BBG000DQLV23,4 Top Growth Stocks Priced at a Bargain This Fall,2016-10-06 12:45:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sPBpRyYQuCE/4-top-growth-stocks-priced-at-a-bargain-this-fall-cm689575,Image source Getty Images This year didn t exactly begin on the right foot and yet at the beginning of October the S amp P 500 sits a healthy 6 higher on a year to date basis For buy and hold investors the trading action this year has vindicated the strategy of
BMY,BMY:US,BBG000DQLV23,4 Top Growth Stocks Priced at a Bargain This Fall,2016-10-06 11:24:07 +0000,http://www.fool.com/retirement/2016/10/06/4-top-growth-stocks-priced-at-a-bargain-this-fall.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,4 Top Growth Stocks Priced at a Bargain This Fall
BMY,BMY:US,BBG000DQLV23,Tune In Sunday For More On Bristol-Myers's Cancer Drug,2016-10-05 18:52:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/05/tune-in-sunday-for-more-on-bristol-myerss-cancer-drug/?mod=yahoobarrons&ru=yahoo,Tune In Sunday For More On Bristol-Myers's Cancer Drug
BMY,BMY:US,BBG000DQLV23,How Much Return Could Gilead Offer in the Next Year?,2016-10-05 14:04:20 +0000,http://marketrealist.com/2016/09/how-much-return-could-gilead-offer-in-the-next-year/?utm_source=yahoo&utm_medium=feed,How Much Return Could Gilead Offer in the Next Year?
BMY,BMY:US,BBG000DQLV23,"CATB Data Pushed Back To Q1, SMMT At Peak, TRIB Pounded, OTIC Hits Right Notes",2016-10-05 01:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qCD762Mut_8/catb-data-pushed-back-to-q1-smmt-at-peak-trib-pounded-otic-hits-right-notes-20161005-00016,"CATB Data Pushed Back To Q1, SMMT At Peak, TRIB Pounded, OTIC Hits Right Notes"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for October 05, 2016",2016-10-04 13:14:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZI0umfBAeN4/bristol-myers-squibb-company-bmy-ex-dividend-date-scheduled-for-october-05-2016-cm688330,Bristol Myers Squibb Company BMY will begin trading ex dividend on October 05 2016 A cash dividend payment of 0 38 per share is scheduled to be paid on November 01 2016 Shareholders who purchased BMY prior to the ex dividend date are eligible for the cash dividend payment This marks
BMY,BMY:US,BBG000DQLV23,Samsung BioLogics IPO Could Value Firm at $8.2 Billion,2016-10-03 22:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qO4yZY97U7U/samsung-biologics-ipo-could-value-firm-at-82-billion-20161003-01301,Samsung BioLogics IPO Could Value Firm at $8.2 Billion
BMY,BMY:US,BBG000DQLV23,Samsung Affiliate Seeks European Approval for Herceptin Copy,2016-10-03 22:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ev-KibnLbHk/samsung-affiliate-seeks-european-approval-for-herceptin-copy-20161003-01293,Samsung Affiliate Seeks European Approval for Herceptin Copy
BMY,BMY:US,BBG000DQLV23,New Research From Bristol-Myers Squibb at ESMO 2016 Congress Reinforces Leadership in Immuno-Oncology and Differentiated Research Approach,2016-10-03 21:13:00 +0000,http://finance.yahoo.com/news/research-bristol-myers-squibb-esmo-211300984.html,"[Business Wire] - Bristol-Myers Squibb Company today announced new data across eight tumor types evaluating Opdivo and Yervoy , as monotherapy or in combination, as well as new assets, to be presented at the 2016 European Society for Medical Oncology Congress in Copenhagen, Denmark from October 7–11."
BMY,BMY:US,BBG000DQLV23,[$$] ConvaTec to Raise $1.8 Billion in London Float,2016-10-03 15:47:36 +0000,http://www.wsj.com/articles/convatec-to-raise-1-8-billion-in-london-float-1475509651?mod=yahoo_hs,[$$] ConvaTec to Raise $1.8 Billion in London Float
BMY,BMY:US,BBG000DQLV23,3 Growth Dividend Stocks to Buy in October,2016-10-03 09:54:26 +0000,http://www.fool.com/investing/2016/10/02/3-growth-dividend-stocks-to-buy-in-october.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Growth Dividend Stocks to Buy in October
BMY,BMY:US,BBG000DQLV23,Passing Inflection Point on Pricing and Profits,2016-10-02 16:44:49 +0000,http://finance.yahoo.com/tumblr/blog-passing-inflection-point-on-pricing-and-profits-164452728.html,Passing Inflection Point on Pricing and Profits
BMY,BMY:US,BBG000DQLV23,3 Growth Dividend Stocks to Buy in October,2016-10-02 16:42:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2fbtmVRkbTY/3-growth-dividend-stocks-to-buy-in-october-cm687536,Image source Getty Images Far too many people think the stock market is a great way to get rich quick But as many of the world s best investors will tell you there is no better method to predictably generate wealth than by doing so over long term And even then arguably the best
BMY,BMY:US,BBG000DQLV23,Understanding Merck’s Business Segments and Their Revenue Trends,2016-09-30 23:04:27 +0000,http://marketrealist.com/2016/09/understanding-mercks-business-segments-and-their-revenue-trends/?utm_source=yahoo&utm_medium=feed,Understanding Merck’s Business Segments and Their Revenue Trends
BMY,BMY:US,BBG000DQLV23,3 Top Healthcare Stocks to Buy Now,2016-09-30 20:22:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6aZIqzIYYEM/3-top-healthcare-stocks-to-buy-now-cm687338,Because of an aging global population an unprecedented amount of innovation and wider access to medical services in the United States the healthcare sector should continue to push higher in the coming years To take advantage of this rising tide investors may want to grab shares
BMY,BMY:US,BBG000DQLV23,3 Stocks to Own for the Next Decade,2016-09-30 17:22:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/m2MPvWcAGRM/3-stocks-to-own-for-the-next-decade-cm687235,Image source Getty Images Any investor that says they are buying and holding for the long term should be looking for investments that can hold up for a decade or more As Warren Buffett put it he buys companies on the assumption that they could close the market the next day and
BMY,BMY:US,BBG000DQLV23,"Exelixis, Inc. (EXEL) Crushed on CaboNivo Drug Trial Results",2016-09-30 16:24:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MCZ95b0VkVg/exelixis-inc-exel-crushed-on-cabonivo-drug-trial-results-cm687199,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Look up the term volatility and you re likely to find several biotech stocks that have posted wild price swings over the past several weeks Among them Exelixis Inc
BMY,BMY:US,BBG000DQLV23,"ETF’s with exposure to Bristol-Myers Squibb Co. : September 30, 2016",2016-09-30 13:41:35 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-bristol-myers-squibb-co-september-30-2016/,"ETF’s with exposure to Bristol-Myers Squibb Co. : September 30, 2016"
BMY,BMY:US,BBG000DQLV23,The Pfizer-Anacor Deal: A Review,2016-09-29 22:04:12 +0000,http://marketrealist.com/2016/09/the-pfizer-anacor-deal-a-review/?utm_source=yahoo&utm_medium=feed,The Pfizer-Anacor Deal: A Review
BMY,BMY:US,BBG000DQLV23,"IWB, MA, BMY, QCOM: Large Inflows Detected at ETF",2016-09-29 16:22:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bk7xaXUGDTk/iwb-ma-bmy-qcom-large-inflows-detected-at-etf-cm686587,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 1000 ETF Symbol IWB where we have detected an approximate 54 3 million dollar inflow that s a 0 3 increase week over week in outstanding
BMY,BMY:US,BBG000DQLV23,52-Week Company Lows,2016-09-29 15:51:44 +0000,http://finance.yahoo.com/news/52-week-company-lows-155144329.html,52-Week Company Lows
BMY,BMY:US,BBG000DQLV23,Two Stocks Teach a Lesson About Losses,2016-09-29 15:21:00 +0000,http://realmoney.thestreet.com/articles/09/29/2016/two-stocks-teach-lesson-about-losses?puc=yahoo&cm_ven=YAHOO,Two Stocks Teach a Lesson About Losses
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb To Present At Leerink Conference; Webcast At 3:00 PM ET,2016-09-29 14:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z0COiRDQXxY/bristolmyers-squibb-to-present-at-leerink-conference-webcast-at-300-pm-et-20160929-00819,Bristol-Myers Squibb To Present At Leerink Conference; Webcast At 3:00 PM ET
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Nektar Tie-Up for Opdivo/NKTR-214 Combo",2016-09-29 00:21:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FZOFMnefpe0/bristol-myers-nektar-tie-up-for-opdivonktr-214-combo-cm686300,Bristol Myers Squibb Company BMY announced a clinical collaboration agreement with Nektar Therapeutics NKTR under which Bristol Myers Opdivo will be evaluated in combination with Nektar s NKTR 214 across five tumor types and seven potential indications The collaboration will include
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Nektar Tie-Up for Opdivo/NKTR-214 Combo",2016-09-28 21:51:09 +0000,http://finance.yahoo.com/news/bristol-myers-nektar-tie-opdivo-215109623.html,"Bristol-Myers, Nektar Tie-Up for Opdivo/NKTR-214 Combo"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Abercrombie & Fitch Slide into Wednesday’s 52-Week Low Club",2016-09-28 20:04:36 +0000,http://finance.yahoo.com/news/bristol-myers-abercrombie-fitch-slide-200436247.html,"Bristol-Myers, Abercrombie & Fitch Slide into Wednesday’s 52-Week Low Club"
BMY,BMY:US,BBG000DQLV23,"Exxon, Chevron Dominate DJIA Wednesday",2016-09-28 20:01:28 +0000,http://finance.yahoo.com/news/exxon-chevron-dominate-djia-wednesday-200128133.html,"Exxon, Chevron Dominate DJIA Wednesday"
BMY,BMY:US,BBG000DQLV23,"Top trades for the 2nd half: BMY, CRM & more",2016-09-28 16:59:00 +0000,http://finance.yahoo.com/video/top-trades-2nd-half-bmy-165900297.html,"Top trades for the 2nd half: BMY, CRM & more"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Slides Into Value-Stock Territory,2016-09-28 15:00:00 +0000,http://realmoney.thestreet.com/articles/09/28/2016/bristol-myers-squibb-slides-value-stock-territory?puc=yahoo&cm_ven=YAHOO,Bristol-Myers Squibb Slides Into Value-Stock Territory
BMY,BMY:US,BBG000DQLV23,Cramer Remix: Why anyone would want to buy Twitter,2016-09-27 22:59:51 +0000,http://www.cnbc.com/id/103973781?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103973781,Cramer Remix: Why anyone would want to buy Twitter
BMY,BMY:US,BBG000DQLV23,Big Pharma partners with another Bay Area company in cancer immunotherapy quest,2016-09-27 20:04:52 +0000,http://www.bizjournals.com/sanfrancisco/blog/biotech/2016/09/cancer-immunotherapy-bmy-nktr-bristol-myers-nektar.html?ana=yahoo,Big Pharma partners with another Bay Area company in cancer immunotherapy quest
BMY,BMY:US,BBG000DQLV23,Bristol-Myers to test Opdivo with Nektar drug for several cancers,2016-09-27 11:29:11 +0000,http://finance.yahoo.com/news/bristol-myers-test-opdivo-nektar-112911352.html,Bristol-Myers to test Opdivo with Nektar drug for several cancers
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214,2016-09-27 11:09:03 +0000,http://www.publicnow.com/view/DB6B9A4ACBCAEF083E959519D7EE13294445E8EA,[at noodls] - SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) today announced a new clinical collaboration to evaluate Bristol-Myers Squibb's ...
BMY,BMY:US,BBG000DQLV23,"Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy",2016-09-27 11:00:00 +0000,https://www.thestreet.com/story/13752241/1/bristol-nektar-research-pact-aims-to-boost-efficacy-of-cancer-immunotherapy.html?puc=yahoo&cm_ven=YAHOO,"Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy"
BMY,BMY:US,BBG000DQLV23,How Mylan’s Profitability Has Changed,2016-09-26 15:05:05 +0000,http://marketrealist.com/2016/09/how-mylans-profitability-has-changed/?utm_source=yahoo&utm_medium=feed,How Mylan’s Profitability Has Changed
BMY,BMY:US,BBG000DQLV23,Generics or Specialty: Which Mylan Segment Is Growing Fastest?,2016-09-23 23:04:05 +0000,http://marketrealist.com/2016/09/generics-or-specialty-which-mylan-segment-is-growing-fastest/?utm_source=yahoo&utm_medium=feed,Generics or Specialty: Which Mylan Segment Is Growing Fastest?
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO",2016-09-23 14:24:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UDVTQGxu0qM/pharma-stock-roundup-allergan-acquisitions-in-focus-jj-to-buy-abbotts-amo-cm683695,Once again acquisitions and deals were in focus in the pharma sector with Allergan AGN announcing a couple of back to back deals including one worth up to 1 695 billion Meanwhile industry bellwether Johnson amp Johnson JNJ signed an agreement to acquire Abbott s ABT eye care segment
BMY,BMY:US,BBG000DQLV23,Gilead Sciences Focuses on a Strong Inorganic Growth Strategy,2016-09-23 12:08:09 +0000,http://marketrealist.com/2016/09/gilead-sciences-focuses-strong-inorganic-growth-strategy/?utm_source=yahoo&utm_medium=feed,Gilead Sciences Focuses on a Strong Inorganic Growth Strategy
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO",2016-09-23 12:00:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-allergan-acquisitions-120012919.html,"Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO"
BMY,BMY:US,BBG000DQLV23,"AVEO Collaborates With Bristol-Myers Squibb for RCC Drug (AVEO, BMY)",2016-09-23 00:20:00 +0000,http://www.investopedia.com/news/aveo-collaborates-bristolmyers-squibb-rcc-drug-aveo-bmy/?partner=YahooSA,"AVEO Collaborates With Bristol-Myers Squibb for RCC Drug (AVEO, BMY)"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Stock Is Down, but That Means You Should Buy",2016-09-22 18:03:00 +0000,https://www.thestreet.com/story/13748867/1/bristol-myers-squibb-stock-is-down-but-that-means-you-should-buy.html?puc=yahoo&cm_ven=YAHOO,"Bristol-Myers Squibb Stock Is Down, but That Means You Should Buy"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part in Leerink Partners Immuno-Oncology Roundtable Conference,2016-09-22 13:38:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-part-leerink-133800001.html,"[Business Wire] - Bristol-Myers Squibb Company will take part in Leerink Partners Immuno-Oncology Roundtable Conference on Thursday, September 29, 2016, in New York. Fouad Namouni, senior vice president, Head of Oncology, will answer questions about the company at 3:00 p.m."
BMY,BMY:US,BBG000DQLV23,Gilead to Stop GS-5745 Development for Ulcerative Colitis,2016-09-22 13:23:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-egF3JP4hIc/gilead-to-stop-gs-5745-development-for-ulcerative-colitis-cm683090,Gilead Sciences Inc GILD announced that it will discontinue the combined phase II III study on one of its pipeline candidates GS 5745 anti MMP9 antibody which was being developed for the treatment of patients suffering from moderate to severely active ulcerative colitis This decision
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Opdivo's Regulatory Application Validated in EU,2016-09-21 16:24:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FjwrHhZNX_0/bristol-myers-opdivos-regulatory-application-validated-in-eu-cm682695,Bristol Myers Squibb Company BMY announced that its type II variation application for Opdivo has been validated by the European Medicines Agency EMA The company is looking to expand Opdivo s label to include the treatment of locally advanced unresectable or metastatic urothelial
BMY,BMY:US,BBG000DQLV23,"IOO, PM, BMY, NKE: Large Outflows Detected at ETF",2016-09-21 16:20:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d-YinSmlvGg/ioo-pm-bmy-nke-large-outflows-detected-at-etf-cm682664,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Global 100 ETF Symbol IOO where we have detected an approximate 37 1 million dollar outflow that s a 2 3 decrease week over week from 21 850 000
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Opdivo's Regulatory Application Validated in EU,2016-09-21 14:29:02 +0000,http://finance.yahoo.com/news/bristol-myers-opdivos-regulatory-application-142902462.html,Bristol-Myers Opdivo's Regulatory Application Validated in EU
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Capitalizes on Japanese Markets for Its Cardio Drug,2016-09-21 12:04:13 +0000,http://marketrealist.com/2016/09/bristol-myers-squibbs-eliquis-considered-top-ranking-novel-anticoagulant-2016/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Capitalizes on Japanese Markets for Its Cardio Drug
BMY,BMY:US,BBG000DQLV23,European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer (189KB),2016-09-21 05:11:03 +0000,http://www.publicnow.com/view/9495E746D66DA3F4CB93C2011224F9B348BC5BBA,"[at noodls] - September 21, 2016‌ European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer (PRINCETON, NJ, September 20, 2016) ..."
BMY,BMY:US,BBG000DQLV23,How Multiple Research Programs in Lung Cancer Space Are Impacting Bristol-Myers Squibb,2016-09-20 14:04:29 +0000,http://marketrealist.com/2016/09/broad-registrational-program-expected-increase-opdivos-approved-labels-2016/?utm_source=yahoo&utm_medium=feed,How Multiple Research Programs in Lung Cancer Space Are Impacting Bristol-Myers Squibb
BMY,BMY:US,BBG000DQLV23,Multiple Segments of Lung Cancer Create Opportunity for Bristol-Myers Squibb’s,2016-09-20 12:04:32 +0000,http://marketrealist.com/2016/09/bristol-myers-squibb-continues-maintain-leadership-lung-cancer-segment-2016/?utm_source=yahoo&utm_medium=feed,Multiple Segments of Lung Cancer Create Opportunity for Bristol-Myers Squibb’s
BMY,BMY:US,BBG000DQLV23,European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer,2016-09-20 11:08:02 +0000,http://www.publicnow.com/view/E9FD2CF365A00E44AB25A8A21F65E1E142EAA1A6,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the European Medicines Agency (EMA) validated its type II variation application, which seeks to extend the ..."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Awards First “Golden Tickets” for LabCentral to PanTher, Suono Bio",2016-09-20 10:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-awards-first-105900252.html,"[Business Wire] - Bristol-Myers Squibb Company and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, today announced that PanTher and Suono Bio are the winners of Bristol-Myers Squibb’s Golden Tickets for LabCentral."
BMY,BMY:US,BBG000DQLV23,Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal,2016-09-20 09:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KICoivIhBEk/allergan-to-buy-tobira-therapeutics-in-17-billion-deal-20160920-00338,Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Type II Variation Application For Opdivo Validated By EMA,2016-09-20 07:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NOLE6T6RSko/bristolmyers-type-ii-variation-application-for-opdivo-validated-by-ema-20160920-00864,Bristol-Myers' Type II Variation Application For Opdivo Validated By EMA
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Strategic Focus on These Areas Could Boost Overall Growth,2016-09-19 15:04:47 +0000,http://marketrealist.com/2016/09/four-strategic-areas-expected-add-significant-value-bristol-myers-squibb-2016/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb’s Strategic Focus on These Areas Could Boost Overall Growth
BMY,BMY:US,BBG000DQLV23,What Could Drive Sales from Bristol-Myers Squibb’s Cancer Drug even Higher?,2016-09-19 14:05:40 +0000,http://marketrealist.com/2016/09/strong-demand-across-approved-indications-expected-boost-opdivos-sales-2016/?utm_source=yahoo&utm_medium=feed,What Could Drive Sales from Bristol-Myers Squibb’s Cancer Drug even Higher?
BMY,BMY:US,BBG000DQLV23,What Analysts Think about Bristol-Myers Squibb,2016-09-19 12:05:21 +0000,http://marketrealist.com/2016/09/inside-bristol-myers-squibb-analyst-recommendations-2016/?utm_source=yahoo&utm_medium=feed,What Analysts Think about Bristol-Myers Squibb
BMY,BMY:US,BBG000DQLV23,Roche Goes Up against Bristol-Myers Squibb in Oncology Drug Space,2016-09-19 12:04:40 +0000,http://marketrealist.com/2016/09/roche-goes-up-against-bristol-myers-squibb-in-oncology-drug-space/?utm_source=yahoo&utm_medium=feed,Roche Goes Up against Bristol-Myers Squibb in Oncology Drug Space
BMY,BMY:US,BBG000DQLV23,Trump Means Change Equals Major Inflection Point,2016-09-19 10:00:52 +0000,http://finance.yahoo.com/tumblr/blog-trump-means-change-equals-major-inflection-point-100058139.html,Trump Means Change Equals Major Inflection Point
BMY,BMY:US,BBG000DQLV23,Trump Means Change Equals a Major Inflection Point,2016-09-18 11:25:36 +0000,http://finance.yahoo.com/tumblr/blog-trump-means-change-equals-a-major-inflection-point-112541581.html,Trump Means Change Equals a Major Inflection Point
BMY,BMY:US,BBG000DQLV23,What Do 2016 Valuation Multiples Say about Bristol-Myers?,2016-09-16 22:27:33 +0000,http://marketrealist.com/2016/09/valuation-multiples-tell-bristol-myers-squibb-2016/?utm_source=yahoo&utm_medium=feed,What Do 2016 Valuation Multiples Say about Bristol-Myers?
BMY,BMY:US,BBG000DQLV23,Jim Cramer's 'Mad Money' Recap: Strong Demand Keeps Market From Cratering,2016-09-15 00:02:00 +0000,https://www.thestreet.com/story/13565597/1/jim-cramer-s-mad-money-recap-strong-demand-keeps-market-from-cratering.html?puc=yahoo&cm_ven=YAHOO,Jim Cramer's 'Mad Money' Recap: Strong Demand Keeps Market From Cratering
BMY,BMY:US,BBG000DQLV23,Cramer: Bristol-Myers is a screaming value buy,2016-09-14 22:15:00 +0000,http://finance.yahoo.com/video/cramer-bristol-myers-screaming-value-221500125.html,Cramer: Bristol-Myers is a screaming value buy
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb To Participate In BOA Merrill Lynch Conference At 8:00 AM,2016-09-14 07:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tD8KT1iiHDY/bristolmyers-squibb-to-participate-in-boa-merrill-lynch-conference-at-800-am-20160914-00232,Bristol-Myers Squibb To Participate In BOA Merrill Lynch Conference At 8:00 AM
BMY,BMY:US,BBG000DQLV23,European Commission Approves Bristol-Myers Squibb's ORENCIA® (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate (133KB),2016-09-14 06:08:03 +0000,http://www.publicnow.com/view/EA6A208D58DE2E22F04456F3E3538A3F2F7A304E,"[at noodls] - September 14, 2016 European Commission Approves Bristol-Myers Squibb's ORENCIA® (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb To Participate In Morgan Stanley Conference At 11:10 AM ET,2016-09-13 10:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IHcJWP3A0iw/bristolmyers-squibb-to-participate-in-morgan-stanley-conference-at-1110-am-et-20160913-00697,Bristol-Myers Squibb To Participate In Morgan Stanley Conference At 11:10 AM ET
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Response to ICER’s Call for Improvements to its Value Assessment Framework,2016-09-12 19:58:04 +0000,http://www.publicnow.com/view/9B477B95B52BCCFA359E692C32C0BD08207C347B,[at noodls] - Bristol-Myers Squibb (BMS) welcomes the opportunity to participate in the Institute for Clinical and Economic Review's (ICER) national call for suggestions on how to improve its value assessment framework. ...
BMY,BMY:US,BBG000DQLV23,"IYH, BMY, AGN, CELG: Large Outflows Detected at ETF",2016-09-12 16:32:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CLtDXwDt-so/iyh-bmy-agn-celg-large-outflows-detected-at-etf-cm678026,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares U S Healthcare ETF Symbol IYH where we have detected an approximate 29 7 million dollar outflow that s a 1 5 decrease week over week from 13 250
BMY,BMY:US,BBG000DQLV23,3 Great Dividend Stocks in the Bargain Bin for Retirees,2016-09-11 12:30:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HAhcZKqL41E/3-great-dividend-stocks-in-the-bargain-bin-for-retirees-cm677434,Image source Getty Images If you re looking for a long term winner as a retiree it s hard to beat a stock that not only pays growing dividends but whose shares are in the bargain bin because of short term disappointments Even the highest quality companies suffer setbacks which
BMY,BMY:US,BBG000DQLV23,3 Great Dividend Stocks in the Bargain Bin for Retirees,2016-09-11 11:39:07 +0000,http://www.fool.com/investing/2016/09/11/3-great-dividend-stocks-in-the-bargain-bin-for-ret.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Great Dividend Stocks in the Bargain Bin for Retirees
BMY,BMY:US,BBG000DQLV23,"Fed Members Should Talk Less, Guide Better and Think Globally",2016-09-11 11:36:35 +0000,http://finance.yahoo.com/tumblr/blog-fed-members-should-talk-less-guide-better-and-113640464.html,"Fed Members Should Talk Less, Guide Better and Think Globally"
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Drug Pricing Remains in Focus, Merck Drops Odanacatib",2016-09-09 14:34:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gg7G3Kk_UQY/pharma-stock-roundup-drug-pricing-remains-in-focus-merck-drops-odanacatib-cm676813,While drug pricing and Mylan MYL remained in the news this week as well companies like Merck MRK Bristol Myers BMY and Novo Nordisk NVO came out with regulatory pipeline updates Recap of the Week s Most Important Stories Mylan now Being Investigated by New York AG Allergan
BMY,BMY:US,BBG000DQLV23,The Biotech ETF With The Unusual Investment Strategy,2016-09-09 13:48:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LzdJHyilsgk/the-biotech-etf-with-the-unusual-investment-strategy-cm676816,"With most of the investable universe covered by an ETF in some form or another, fund providers are targeting increasingly narrow spaces for new product launches.     Management style tactics are also veering from the norm, as evidenced by the boom in smart beta products. While many of the ETFs are perfectly"
BMY,BMY:US,BBG000DQLV23,Is Bristol-Myers Squibb Presenting an Opportunity?,2016-09-08 17:09:11 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-presenting-opportunity-170911732.html,Is Bristol-Myers Squibb Presenting an Opportunity?
BMY,BMY:US,BBG000DQLV23,Celgene Carves Out More Share of This Cancer Treatment Market,2016-09-08 15:04:46 +0000,http://marketrealist.com/2016/09/celgene-carves-out-more-share-of-this-cancer-treatment-market/?utm_source=yahoo&utm_medium=feed,Celgene Carves Out More Share of This Cancer Treatment Market
BMY,BMY:US,BBG000DQLV23,This Crushing Blow Sent Bristol-Myers Squibb Co. Down 23% in August,2016-09-08 14:19:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6HKeFp4dtQI/this-crushing-blow-sent-bristol-myers-squibb-co-down-23-in-august-cm676130,Image source Getty Images What happened Shares of Bristol Myers Squibb NYSE BMY a global drug developer focused on the development cancer cardiovascular and genetic defined disease drugs plunged 23 in the month of August according to data from S amp P Global
BMY,BMY:US,BBG000DQLV23,Multi-Billion Dollar Cancer Treatment & Patient Care Industry Boosting Biotech Sector to New Highs,2016-09-08 12:30:00 +0000,http://finance.yahoo.com/news/multi-billion-dollar-cancer-treatment-123000511.html,[CNW Group] - Multi-Billion Dollar Cancer Treatment & Patient Care Industry Boosting Biotech Sector to New Highs
BMY,BMY:US,BBG000DQLV23,This Crushing Blow Sent Bristol-Myers Squibb Co. Down 23% in August,2016-09-08 12:23:06 +0000,http://www.fool.com/investing/2016/09/08/this-crushing-blow-sent-bristol-myers-squibb-co-do.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,This Crushing Blow Sent Bristol-Myers Squibb Co. Down 23% in August
BMY,BMY:US,BBG000DQLV23,3 Stocks to Help Fund Your Retirement,2016-09-07 23:17:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wC62MgHqxmI/3-stocks-to-help-fund-your-retirement-cm675935,Whether it s the freedom of the open road or something else entirely these stocks can help you fund the retirement you want Image source Getty Images Saving for retirement is one of the most important financial responsibilities people have but simply putting the money aside
BMY,BMY:US,BBG000DQLV23,3 Stocks to Help Fund Your Retirement,2016-09-07 21:45:04 +0000,http://www.fool.com/investing/2016/09/07/3-stocks-to-help-fund-your-retirement.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Stocks to Help Fund Your Retirement
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Orencia Gains EU Approval for Expanded Use,2016-09-07 17:17:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JDaiNWLTAxE/bristol-myers-orencia-gains-eu-approval-for-expanded-use-cm675717,Bristol Myers Squibb Company BMY announced that the European Commission has approved Orencia intravenous IV infusion and subcutaneous SC injection in combination with methotrexate MTX for the treatment of highly active and progressive disease in adult patients with rheumatoid
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Announce Results for Third Quarter 2016 on October 27,2016-09-07 15:29:04 +0000,http://www.publicnow.com/view/75248EE204166063390D70D1DCB9C17A8B92C3FC,"[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2016 on Thursday, October 27, 2016. During a conference call at 10:30 a.m. EDT on October ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Orencia Gains EU Approval for Expanded Use,2016-09-07 14:59:02 +0000,http://finance.yahoo.com/news/bristol-myers-orencia-gains-eu-145902474.html,Bristol-Myers' Orencia Gains EU Approval for Expanded Use
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference,2016-09-07 14:41:00 +0000,http://uk.finance.yahoo.com/news/bristol-myers-squibb-present-bank-144100892.html,Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Employees Cycle Coast to Coast to Raise Money and Awareness for Cancer Research,2016-09-07 10:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-employees-cycle-105900033.html,"[Business Wire] - Today, the first of six teams of Bristol-Myers Squibb Company oncology employees set out from Cannon Beach on the Oregon coast on the first leg of the 2016 Coast 2 Coast 4 Cancer Ride, a 21-day cycling ride that will bring together 80 riders to cover approximately 2,800 miles on a mission for cancer patients and their loved ones by raising money for Stand Up To Cancer’s innovative cancer research programs...."
BMY,BMY:US,BBG000DQLV23,"New Research Reports for September 6, 2016",2016-09-07 08:16:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q3oYdt2jdBw/new-research-reports-for-september-6-2016-cm675313,Tuesday September 6 2016 Today s must read reports are for Micron Technology MU Bristol Myers Squibb BMY and Delta Air Lines DAL Micron Technology shares are moving up strongly lately on the back of strong momentum for its key products DRAM and NAND chips The improving
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb (BMY) Stock Gains on EU Drug Approval,2016-09-06 16:20:00 +0000,https://www.thestreet.com/story/13695199/1/bristol-myers-squibb-bmy-stock-gains-on-eu-drug-approval.html?puc=yahoo&cm_ven=YAHOO,Bristol-Myers Squibb (BMY) Stock Gains on EU Drug Approval
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference,2016-09-06 16:14:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-part-morgan-161400706.html,"[Business Wire] - Bristol-Myers Squibb Company will take part in the Morgan Stanley 2016 Global Health Care Conference on Tuesday, September 13, 2016, in New York. Giovanni Caforio, M.D., chief executive officer will make formal remarks about the company and answer questions at 11:10 a.m."
BMY,BMY:US,BBG000DQLV23,European Commission Approves Bristol-Myers Squibb’s ORENCIA® (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate,2016-09-06 13:19:12 +0000,http://www.publicnow.com/view/C40DBE1A9B0F529165D0A6B075565C9CF24797B9,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission has approved ORENCIA(abatacept) intravenous (IV) infusion and subcutaneous (SC) injection, ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Gets EU Approval For Orencia For Rheumatoid Arthritis,2016-09-06 07:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QmRYy9Nzac8/bristolmyers-squibb-gets-eu-approval-for-orencia-for-rheumatoid-arthritis-20160906-00275,Bristol-Myers Squibb Gets EU Approval For Orencia For Rheumatoid Arthritis
BMY,BMY:US,BBG000DQLV23,How Are Eli Lilly’s New Products Performing?,2016-09-05 14:04:15 +0000,http://marketrealist.com/2016/09/eli-lillys-new-products-performing/?utm_source=yahoo&utm_medium=feed,How Are Eli Lilly’s New Products Performing?
BMY,BMY:US,BBG000DQLV23,"VeriFone (PAY), Gilead (GILD) Among 5 Stocks That Hit 52-Week Lows Last Week",2016-09-05 12:00:08 +0000,http://www.insidermonkey.com/blog/verifone-pay-gilead-gild-among-5-stocks-that-hit-52-week-lows-last-week-472266/,"VeriFone (PAY), Gilead (GILD) Among 5 Stocks That Hit 52-Week Lows Last Week"
BMY,BMY:US,BBG000DQLV23,Stop Fighting the Tape,2016-09-05 10:08:33 +0000,http://finance.yahoo.com/tumblr/blog-stop-fighting-the-tape-100837669.html,Stop Fighting the Tape
BMY,BMY:US,BBG000DQLV23,MRK: How Merck's Stock Price Rose 31.42% in 6 Months,2016-09-03 18:00:00 +0000,http://www.investopedia.com/articles/markets-economy/090316/mrk-how-mercks-stock-price-rose-3142-6-months.asp?partner=YahooSA,MRK: How Merck's Stock Price Rose 31.42% in 6 Months
BMY,BMY:US,BBG000DQLV23,This Well-Known Dividend Giant Is On Sale (BMY),2016-09-02 22:18:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7LLrUk1g1EU/this-well-known-dividend-giant-is-on-sale-bmy-cm674355,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips If a Blue Chip stock suddenly drops 16 in one day what do you do Do you rush to buy Do you step aside and wait for the dust to clear Or do you give up on the stock
BMY,BMY:US,BBG000DQLV23,"Notable Friday Option Activity: JPM, WDC, BMY",2016-09-02 20:17:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0wqJq59TaLU/notable-friday-option-activity-jpm-wdc-bmy-cm674291,Among the underlying components of the S amp P 500 index we saw noteworthy options trading volume today in JPMorgan Chase amp Co Symbol JPM where a total of 58 039 contracts have traded so far representing approximately 5 8 million underlying shares That amounts to about 51 of JPM
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers, Verifone Dive into Friday’s 52-Week Low Club",2016-09-02 20:04:24 +0000,http://247wallst.com/investing/2016/09/02/bristol-myers-verifone-dive-into-fridays-52-week-low-club/,"Bristol-Myers, Verifone Dive into Friday’s 52-Week Low Club"
BMY,BMY:US,BBG000DQLV23,Is Incyte Hurt by Having Only One FDA-Approved Drug?,2016-09-02 18:04:05 +0000,http://marketrealist.com/2016/09/incyte-hurt-one-fda-approved-drug/?utm_source=yahoo&utm_medium=feed,Is Incyte Hurt by Having Only One FDA-Approved Drug?
BMY,BMY:US,BBG000DQLV23,"Today's Fast Break: CMG, LULU, BMY",2016-09-02 17:11:00 +0000,http://finance.yahoo.com/video/todays-fast-break-cmg-lulu-171100148.html,"Today's Fast Break: CMG, LULU, BMY"
BMY,BMY:US,BBG000DQLV23,Unusual activity: Bristol-Myers,2016-09-02 16:56:00 +0000,http://finance.yahoo.com/video/unusual-activity-bristol-myers-165600321.html,Unusual activity: Bristol-Myers
BMY,BMY:US,BBG000DQLV23,Raymond James: Abbvie has value-enhancing catalysts,2016-09-02 16:30:00 +0000,http://finance.yahoo.com/video/raymond-james-abbvie-value-enhancing-163000340.html,Raymond James: Abbvie has value-enhancing catalysts
BMY,BMY:US,BBG000DQLV23,"Noteworthy ETF Outflows: IYH, BMY, AGN, CELG",2016-09-02 16:18:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nNDWzM9usNk/noteworthy-etf-outflows-iyh-bmy-agn-celg-cm674090,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares U S Healthcare ETF Symbol IYH where we have detected an approximate 60 3 million dollar outflow that s a 2 9 decrease week over week from 13 650
BMY,BMY:US,BBG000DQLV23,"Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar",2016-09-02 14:18:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pLG-q-y9fZ4/pharma-stock-roundup-mylan-epipen-pricing-in-focus-fda-nod-for-novartis-biosimilar-cm674021,It was a rough week for drug stocks with focus once again shifting to the pricing policies of pharma and biotech companies Mylan s MYL pricing policy for EpiPen raised a storm with lawmakers questioning the company s pricing actions Meanwhile companies like Novartis NVS and Roche RHHBY
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb (BMY) Has Dropped To A New Low For The Year,2016-09-02 09:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-Nr5p-bXvQQ/bristolmyers-squibb-bmy-has-dropped-to-a-new-low-for-the-year-20160902-00350,Bristol-Myers Squibb (BMY) Has Dropped To A New Low For The Year
BMY,BMY:US,BBG000DQLV23,This Well-Known Dividend Giant Is On Sale,2016-09-02 05:00:00 +0000,http://finance.yahoo.com/news/well-known-dividend-giant-sale-050000141.html,This Well-Known Dividend Giant Is On Sale
BMY,BMY:US,BBG000DQLV23,"Roche Drug Scores In Lung Cancer, Challenging Bristol-Myers",2016-09-01 20:35:47 +0000,http://www.investors.com/news/technology/roche-drug-scores-in-lung-cancer-challenging-bristol-myers/,"Roche Drug Scores In Lung Cancer, Challenging Bristol-Myers"
BMY,BMY:US,BBG000DQLV23,Options Activity Shows Traders are Betting on a Recovery for This Health Care ETF,2016-09-01 13:49:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UjNGVarUjXw/options-activity-shows-traders-are-betting-on-a-recovery-for-this-health-care-etf-cm673347,"Health Care stocks have gotten beaten up a bit in the latter part of August, with the benchmark Health Care SPDR ETF (   XLV  ) (Expense Ratio 0.15%) plunging below its 50 day MA five trading sessions ago, and failing to get back above this level.     Trading volume in the ETF has been about average lately, but"
BMY,BMY:US,BBG000DQLV23,Is Eli Lilly’s Valuation Higher than Its Peers?,2016-09-01 12:06:12 +0000,http://marketrealist.com/2016/09/eli-lillys-valuation-higher-peers/?utm_source=yahoo&utm_medium=feed,Is Eli Lilly’s Valuation Higher than Its Peers?
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESMO 2016 Congress Highlights,2016-08-31 23:13:02 +0000,http://www.publicnow.com/view/1A2C54B95C80CF42D264008F2990C38DF54E222F,"[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will host a teleconference on Sunday, October 9, 2016, at 7:30 p.m. CEST (1:30 p.m. EDT) to discuss data presented at the European Society ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESMO 2016 Congress Highlights,2016-08-31 23:05:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-hold-investor-230500037.html,"[Business Wire] - Bristol-Myers Squibb Company will host a teleconference on Sunday, October 9, 2016, at 7:30 p.m. CEST to discuss data presented at the European Society of Medical Oncology 2016 Congress in Copenhagen, Denmark."
BMY,BMY:US,BBG000DQLV23,"Merck: Lung Cancer Lead Depends On ""How Smart It Plays Its Hand""",2016-08-31 16:25:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/31/merck-lung-cancer-lead-depends-on-how-smart-it-plays-its-hand/?mod=yahoobarrons&ru=yahoo,"Merck: Lung Cancer Lead Depends On ""How Smart It Plays Its Hand"""
BMY,BMY:US,BBG000DQLV23,Why Do Hedge Funds Like Five Prime Therapeutics?,2016-08-31 15:36:09 +0000,http://www.insidermonkey.com/blog/why-do-hedge-funds-like-five-prime-therapeutics-471269/,Why Do Hedge Funds Like Five Prime Therapeutics?
BMY,BMY:US,BBG000DQLV23,Recent Developments at Johnson & Johnson,2016-08-31 15:04:48 +0000,http://marketrealist.com/2016/08/recent-developments-johnson-johnson/?utm_source=yahoo&utm_medium=feed,Recent Developments at Johnson & Johnson
BMY,BMY:US,BBG000DQLV23,Franchises that Drove Allergan’s International Sales in 2Q,2016-08-31 12:04:19 +0000,http://marketrealist.com/2016/08/franchises-that-drove-allergans-international-sales-in-2q/?utm_source=yahoo&utm_medium=feed,Franchises that Drove Allergan’s International Sales in 2Q
BMY,BMY:US,BBG000DQLV23,"After Hours Most Active for Aug 30, 2016 :  BAC, QQQ, BMY, TWTR, SOXX, FTR, WFC, MS, MSFT, PANW, ODP, INTC",2016-08-30 21:07:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zx_Jj2oGfk4/after-hours-most-active-for-aug-30-2016-bac-qqq-bmy-twtr-soxx-ftr-wfc-ms-msft-panw-odp-intc-cm672489,"The NASDAQ 100 After Hours Indicator is down .56 to 4,775.44. The total After hours volume is currently 20,222,492 shares traded. The following are the most active stocks for the after hours session Bank of America Corporation ( BAC"
BMY,BMY:US,BBG000DQLV23,Analyzing Johnson & Johnson’s Business Segments,2016-08-30 18:04:19 +0000,http://marketrealist.com/2016/08/analyzing-johnson-johnsons-business-segments/?utm_source=yahoo&utm_medium=feed,Analyzing Johnson & Johnson’s Business Segments
BMY,BMY:US,BBG000DQLV23,This Pharma Company Is Leading The Race For A Zika Vaccine,2016-08-30 17:30:00 +0000,http://finance.yahoo.com/news/pharma-company-leading-race-zika-173000684.html,This Pharma Company Is Leading The Race For A Zika Vaccine
BMY,BMY:US,BBG000DQLV23,These 3 Billionaires Dumped Johnson & Johnson Stock. Should You?,2016-08-30 13:14:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1FbV7oJEBls/these-3-billionaires-dumped-johnson-johnson-stock-should-you-cm672021,"Image source  Getty Images.  While I don't believe in blindly following billionaires into or out of specific equities, the fact that these so called ""super investors"" can have a sizable impact on the"
BMY,BMY:US,BBG000DQLV23,[$$] Bristol-Myers Squibb misses mark with cancer drug,2016-08-30 12:25:38 +0000,"http://www.ft.com/cms/s/1ee2402a-6dfd-11e6-a0c9-1365ce54b926,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Merck and Bristol-Myers Squibb have spent most of the past two years in a two-horse race to develop and sell immunotherapies, a new class of cancer drug that turns the body into a weapon against the disease. ..."
BMY,BMY:US,BBG000DQLV23,Healthcare's best bets following generic EpiPen,2016-08-29 16:26:00 +0000,http://finance.yahoo.com/video/healthcares-best-bets-following-generic-162600615.html,Healthcare's best bets following generic EpiPen
BMY,BMY:US,BBG000DQLV23,Time to Shift Your Focus,2016-08-28 11:07:40 +0000,http://finance.yahoo.com/tumblr/blog-time-to-shift-your-focus-110745912.html,Time to Shift Your Focus
BMY,BMY:US,BBG000DQLV23,Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo,2016-08-25 22:08:15 +0000,http://uk.finance.yahoo.com/news/lung-cancer-doctors-eye-mercks-220815057.html,Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo
BMY,BMY:US,BBG000DQLV23,"Notable ETF Outflow Detected - RXL, BMY, ABT, TMO",2016-08-25 16:41:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YgC3WB4y9as/notable-etf-outflow-detected-rxl-bmy-abt-tmo-cm670132,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra Health Care (Symbol RXL) where we have detected an approximate $40.1 million dollar outflow"
BMY,BMY:US,BBG000DQLV23,Tiffany Q2 16 Earnings Conference Call At 8:30 AM ET,2016-08-25 07:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IkKHPw18u9k/tiffany-q2-16-earnings-conference-call-at-830-am-et-20160825-00240,Tiffany Q2 16 Earnings Conference Call At 8:30 AM ET
BMY,BMY:US,BBG000DQLV23,How Did Bristol-Myers Squibb Fare in 2Q16?,2016-08-24 15:04:05 +0000,http://marketrealist.com/2016/08/how-did-bristol-myers-squibb-fare-in-2q16/?utm_source=yahoo&utm_medium=feed,How Did Bristol-Myers Squibb Fare in 2Q16?
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016,2016-08-23 12:08:04 +0000,http://www.publicnow.com/view/44D817B3D267775DA01C80533CC9D4FDB2189B7F,"[at noodls] - Bristol-Myers Squibb Company(link is external)(NYSE: BMY) and Pfizer Inc.(NYSE: PFE) announced today that 19 abstracts (late-breaking, rapid-fire, oral and poster presentations) will be presented at ESC ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016,2016-08-23 11:08:03 +0000,http://www.publicnow.com/view/C81A06B81A77A0FE6B9AC9DEA0FB3F377446D166,"[at noodls] - PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today that 19 abstracts (late-breaking, rapid-fire, oral and poster presentations) ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016,2016-08-23 10:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-pfizer-present-105900026.html,"[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. announced today that 19 abstracts will be presented at ESC Congress 2016, to be held August 27–31 in Rome, Italy."
BMY,BMY:US,BBG000DQLV23,"Allied Minds, Bristol-Myers Squibb to progress first drug to preclinical trials",2016-08-22 22:15:12 +0000,http://www.bizjournals.com/boston/blog/health-care/2016/08/allied-minds-bristol-myers-squibb-to-progress.html?ana=yahoo,"Allied Minds, Bristol-Myers Squibb to progress first drug to preclinical trials"
BMY,BMY:US,BBG000DQLV23,How Did Bristol-Myers Squibb’s Oncology Segment Perform in 2Q16?,2016-08-22 13:06:27 +0000,http://marketrealist.com/2016/08/how-did-bristol-myers-squibbs-oncology-segment-perform-in-2q16/?utm_source=yahoo&utm_medium=feed,How Did Bristol-Myers Squibb’s Oncology Segment Perform in 2Q16?
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Stock Will Bounce Back -- Here's How You Can Profit,2016-08-22 12:36:00 +0000,https://www.thestreet.com/story/13680812/1/bristol-myers-squibb-stock-will-bounce-back-here-s-how-you-can-profit.html?puc=yahoo&cm_ven=YAHOO,Bristol-Myers Squibb Stock Will Bounce Back -- Here's How You Can Profit
BMY,BMY:US,BBG000DQLV23,[$$] Pfizer agrees $14bn takeover of Medivation,2016-08-22 11:20:45 +0000,"http://www.ft.com/cms/s/0b556924-67e5-11e6-a0b1-d87a9fea034f,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Pfizer has reached a deal worth $14bn to acquire California biotechnology company Medivation, beating a handful of its biggest rivals to win the auction for the sought-after cancer drugmaker. Pfizer, the ..."
BMY,BMY:US,BBG000DQLV23,[$$] The Profit and Peril of Cancer Drugs,2016-08-22 04:35:12 +0000,http://www.wsj.com/articles/the-profit-and-peril-of-cancer-drugs-1471626673?ru=yahoo?mod=yahoo_itp,"[at The Wall Street Journal] - Cancer drugs have rightly generated significant investor excitement, but picking winners will be challenging."
BMY,BMY:US,BBG000DQLV23,"5 Trade Ideas for Monday: Bank of America, Bristol-Myers, DuPont, Halliburton and Mylan",2016-08-21 18:11:36 +0000,http://finance.yahoo.com/tumblr/blog-5-trade-ideas-for-monday-bank-of-america-181140343.html,"5 Trade Ideas for Monday: Bank of America, Bristol-Myers, DuPont, Halliburton and Mylan"
BMY,BMY:US,BBG000DQLV23,Curbing Excessive Exuberance May be Premature,2016-08-21 16:33:34 +0000,http://finance.yahoo.com/tumblr/blog-curbing-excessive-exuberance-may-be-premature-163340785.html,Curbing Excessive Exuberance May be Premature
BMY,BMY:US,BBG000DQLV23,These 3 Stocks Could Boost Their Dividends in the Next 12 Months,2016-08-20 13:45:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-7fy4L1ogB0/these-3-stocks-could-boost-their-dividends-in-the-next-12-months-cm668098,Image source  Getty Images.  Dividend stocks should always occupy prime real estate in any well balanced portfolio. And the best income generating equities to buy are those of companies with growing free cash flows that can
BMY,BMY:US,BBG000DQLV23,These 3 Stocks Could Boost Their Dividends in the Next 12 Months,2016-08-20 12:07:00 +0000,http://www.fool.com/investing/2016/08/20/these-3-stocks-could-boost-dividends-in-next-12-m.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,These 3 Stocks Could Boost Their Dividends in the Next 12 Months
BMY,BMY:US,BBG000DQLV23,How Does Bristol-Myers Squibb’s Valuation Compare to Peers?,2016-08-19 21:04:13 +0000,http://marketrealist.com/2016/08/how-does-bristol-myers-squibbs-valuation-compare-to-peers/?utm_source=yahoo&utm_medium=feed,How Does Bristol-Myers Squibb’s Valuation Compare to Peers?
BMY,BMY:US,BBG000DQLV23,[$$] The Profit and Peril of Cancer Drugs,2016-08-19 17:12:16 +0000,http://www.wsj.com/articles/the-profit-and-peril-of-cancer-drugs-1471626673?mod=yahoo_hs,[$$] The Profit and Peril of Cancer Drugs
BMY,BMY:US,BBG000DQLV23,"ETF’s with exposure to Bristol-Myers Squibb Co. : August 19, 2016",2016-08-19 16:41:59 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-bristol-myers-squibb-co-august-19-2016/,"ETF’s with exposure to Bristol-Myers Squibb Co. : August 19, 2016"
BMY,BMY:US,BBG000DQLV23,Is It &quot;Game Over&quot; After Portola's FDA Rejection?,2016-08-18 22:45:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6erSrWzjtyg/is-it-game-over-after-portolas-fda-rejection-cm667401,Image source  Getty Images.  Investors will have to wait to find out if Portola Pharmaceuticals '(NASDAQ  PTLA) first generation antidote to factor Xa anticoagulants will be as big of a hit as
BMY,BMY:US,BBG000DQLV23,What Caused Arrowhead Pharmaceuticals to Skyrocket 12.5% Today,2016-08-18 20:47:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YN6abzIIa0A/what-caused-arrowhead-pharmaceuticals-to-skyrocket-125-today-cm667331,"Image source  Getty Images.  What   After industry analysts at Cantor Fitzgerald began coverage with a buy rating, shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ  ARWR) shot 12.5% higher at 1 30 p.m."
BMY,BMY:US,BBG000DQLV23,"Is It ""Game Over"" After Portola's FDA Rejection?",2016-08-18 20:40:00 +0000,http://www.fool.com/investing/2016/08/18/is-it-game-over-after-portolas-fda-rejection.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Is It ""Game Over"" After Portola's FDA Rejection?"
BMY,BMY:US,BBG000DQLV23,Why Did We Update Our Price Estimate For Bristol-Myers Squibb?,2016-08-18 19:11:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DURxJpaZ6UA/why-did-we-update-our-price-estimate-for-bristol-myers-squibb-cm667299,"Bristol Myers Squibb ( BMY ) announced earlier this month that the Phase III trial for the use of its Opdivo as monotherapy for patients with non small cell lung cancer had failed to produce adequate results, despite its success treating"
BMY,BMY:US,BBG000DQLV23,Why Portola Pharmaceuticals Inc Is Plunging Today,2016-08-18 16:47:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kB9SkNhQNIo/why-portola-pharmaceuticals-inc-is-plunging-today-cm667189,"Image source  Getty Images.  What   Shares of Portola Pharmaceuticals (NASDAQ  PTLA) , a clinical stage biotech focused primarily on hematologic diseases, are down by more than 18% as of 10 40 a.m. EDT"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb attracts upside bets,2016-08-17 14:22:18 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-attracts-upside-142218478.html,Bristol-Myers Squibb attracts upside bets
BMY,BMY:US,BBG000DQLV23,Mirror Image: Bristol-Myers Loss Is Merck's Potential Gain,2016-08-16 14:11:58 +0000,http://finance.yahoo.com/news/mirror-image-bristol-myers-loss-141158016.html,Mirror Image: Bristol-Myers Loss Is Merck's Potential Gain
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb (BMY) Stock Falls, Bernstein: Failed Trial Impact to Persist",2016-08-15 19:53:00 +0000,https://www.thestreet.com/story/13675476/1/bristol-myers-squibb-bmy-stock-falls-bernstein-failed-trial-impact-to-persist.html?puc=yahoo&cm_ven=YAHOO,"Bristol-Myers Squibb (BMY) Stock Falls, Bernstein: Failed Trial Impact to Persist"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers to Reacquire Rights to Oncology Drug in Asia,2016-08-15 15:40:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vq7zcySJze0/bristol-myers-to-reacquire-rights-to-oncology-drug-in-asia-cm665322,"Bristol Myers Squibb CompanyBMY will reacquire the rights to ASLAN002 (BMS777607) from privately held biotech company, Aslan Pharmaceuticals, as announced by the latter. Reacquired rights cover the territories of China, Australia, Korea, Taiwan and other Asian countries. Aslan, an"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers to Reacquire Rights to Oncology Drug in Asia,2016-08-15 13:26:01 +0000,http://finance.yahoo.com/news/bristol-myers-reacquire-rights-oncology-132601994.html,Bristol-Myers to Reacquire Rights to Oncology Drug in Asia
BMY,BMY:US,BBG000DQLV23,Bavarian Nordic Announces Drug Supply Agreement with Bristol-Myers Squibb for NSCLC Clinical Study,2016-08-15 11:21:05 +0000,http://www.publicnow.com/view/5A913D3052E07C7AF2B05D5EC49F39401E774702,"[at noodls] - COPENHAGEN, Denmark, August 15, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the signature of a drug supply agreement with Bristol-Myers Squibb (BMS). Based on the agreement, BMS ..."
BMY,BMY:US,BBG000DQLV23,"Mark Your Calendar For Aug.17, TRIL To Report Data In Q4, FLML Launches Akova",2016-08-14 23:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gve17BIXunc/mark-your-calendar-for-aug17-tril-to-report-data-in-q4-flml-launches-akova-20160814-00049,"Mark Your Calendar For Aug.17, TRIL To Report Data In Q4, FLML Launches Akova"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Revolutionary Cancer Drug Suffers A Big Blow,2016-08-14 20:33:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DJnuQtNmmkY/bristol-myers-revolutionary-cancer-drug-suffers-a-big-blow-cm665108,"Bristol Myers Squibb 's  (NYSE  BMY) Opdivo is approved to treat some patients who see their lung cancer return following chemotherapy, but a key trial evaluating Opdivo's use in previously untreated patients recently came up"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers' Revolutionary Cancer Drug Suffers A Big Blow,2016-08-14 19:02:00 +0000,http://www.fool.com/investing/2016/08/14/bristol-myers-revolutionary-cancer-drug-suffers-a.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Bristol-Myers' Revolutionary Cancer Drug Suffers A Big Blow
BMY,BMY:US,BBG000DQLV23,Stay the Course,2016-08-14 13:56:45 +0000,http://finance.yahoo.com/tumblr/blog-stay-the-course-163144526.html,Stay the Course
BMY,BMY:US,BBG000DQLV23,3 Beaten-Up Big Pharma Stocks: Are They Bargains?,2016-08-14 12:34:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3WUTQUaKjvI/3-beaten-up-big-pharma-stocks-are-they-bargains-cm665074,"Image source  Getty Images.  On the whole, the pharmaceutical industry appears to be back in favor. The iShares US Pharmaceuticals ETF has gained about 12% over the past three months, after a nosedive"
BMY,BMY:US,BBG000DQLV23,3 Beaten-Up Big Pharma Stocks: Are They Bargains?,2016-08-14 11:18:00 +0000,http://www.fool.com/investing/2016/08/14/3-beaten-up-big-pharma-stocks-are-they-bargains.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Beaten-Up Big Pharma Stocks: Are They Bargains?
BMY,BMY:US,BBG000DQLV23,"How Risky Is Celldex Therapeutics, Inc.?",2016-08-12 18:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QqkX6ojECw4/how-risky-is-celldex-therapeutics-inc-cm664806,"Image source  Getty Images.  Tiny Celldex Therapeutics (NASDAQ  CLDX) is punching above its weight, as it develops one of the industry's more impressive clinical stage oncology pipelines. With five candidates in 13"
BMY,BMY:US,BBG000DQLV23,"How Risky Is Celldex Therapeutics, Inc.?",2016-08-12 17:42:00 +0000,http://www.fool.com/investing/2016/08/12/how-risky-is-celldex-therapeutics-inc.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"How Risky Is Celldex Therapeutics, Inc.?"
BMY,BMY:US,BBG000DQLV23,Strategy To YieldBoost Bristol-Myers Squibb Co. To 6.2% Using Options,2016-08-12 16:49:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FO7G54EqzHI/strategy-to-yieldboost-bristol-myers-squibb-co-to-62-using-options-cm664744,Shareholders of Bristol Myers Squibb Co. (Symbol BMY) looking to boost their income beyond the stock's 2.5% annualized dividend yield can sell the January 2018 covered call at the $70 strike and collect the premium based on the $3.20
BMY,BMY:US,BBG000DQLV23,See Which Of The Latest 13F Filers Holds Bristol-Myers Squibb,2016-08-12 16:48:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Klgg36efk3Y/see-which-of-the-latest-13f-filers-holds-bristol-myers-squibb-cm664717,"At Holdings Channel , we have reviewed the latest batch of the 23 most recent 13F filings for the 06 30 2016 reporting period, and noticed that Bristol Myers Squibb Co. (Symbol BMY) was held by 10 of these"
BMY,BMY:US,BBG000DQLV23,[$$] Samsung biopharma unit lines up South Korea IPO,2016-08-12 09:50:47 +0000,"http://www.ft.com/cms/s/24c04030-6062-11e6-ae3f-77baadeb1c93,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[at Financial Times] - Samsung Biologics is lining up a stock market debut that analysts say could raise Won2tn-Won3tn ($1.8bn-$2.7bn) in what would be South Korea's largest listing this year. The biopharmaceutical arm of the ...
BMY,BMY:US,BBG000DQLV23,"AstraZeneca Transcends Brexit Woes on Pound Slump, Rival’s Flop",2016-08-12 05:00:00 +0000,http://www.bloomberg.com/news/articles/2016-08-12/astrazeneca-rides-high-fueled-by-brexit-bristol-myers-failure?cmpid=yhoo.headline,"AstraZeneca Transcends Brexit Woes on Pound Slump, Rival’s Flop"
BMY,BMY:US,BBG000DQLV23,Will Bristol-Myers (BMY) Stock Be Hurt by Downgrade?,2016-08-11 19:53:00 +0000,https://www.thestreet.com/story/13673240/1/will-bristol-myers-bmy-stock-be-hurt-by-downgrade.html?puc=yahoo&cm_ven=YAHOO,Will Bristol-Myers (BMY) Stock Be Hurt by Downgrade?
BMY,BMY:US,BBG000DQLV23,iShares Russell 1000 Growth ETF Experiences Big Outflow,2016-08-11 16:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X7tEn-MnYC8/ishares-russell-1000-growth-etf-experiences-big-outflow-cm664116,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Growth ETF (Symbol IWF) where we have detected an approximate $199.5 million dollar"
BMY,BMY:US,BBG000DQLV23,"Berenberg Downgrades Bristol-Myers Squibb, Says Competitors Better Exposed For Near-Term Upside",2016-08-11 12:16:04 +0000,http://finance.yahoo.com/news/berenberg-downgrades-bristol-myers-squibb-121604928.html,"Berenberg Downgrades Bristol-Myers Squibb, Says Competitors Better Exposed For Near-Term Upside"
BMY,BMY:US,BBG000DQLV23,Cramer: Valeant Probe Is a Reminder of the Bristol-Myers Scandal,2016-08-11 11:38:00 +0000,http://realmoney.thestreet.com/articles/08/11/2016/cramer-valeant-probe-reminder-bristol-myers-scandal?puc=yahoo&cm_ven=YAHOO,Cramer: Valeant Probe Is a Reminder of the Bristol-Myers Scandal
BMY,BMY:US,BBG000DQLV23,Business Watch -- WSJ,2016-08-11 02:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HLOw0Y1FRuM/business-watch--wsj-20160811-00055,Business Watch -- WSJ
BMY,BMY:US,BBG000DQLV23,"After Opdivo's Failure, Is Merck a Better Buy Than Bristol-Myers?",2016-08-10 23:52:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vbRrVN8osOk/after-opdivos-failure-is-merck-a-better-buy-than-bristol-myers-cm663736,"Image source  Getty Images.  Bristol Myers Squibb 's(NYSE  BMY) Opdivo failed to deliver the goods in a key lung cancer trial, causing Bristol Myers' shares to plummet. The failure also prompted investors"
BMY,BMY:US,BBG000DQLV23,"After Opdivo's Failure, Is Merck a Better Buy Than Bristol-Myers?",2016-08-10 22:40:00 +0000,http://www.fool.com/investing/2016/08/10/is-merck-co-a-better-buy-than-bristol-myers-follow.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"After Opdivo's Failure, Is Merck a Better Buy Than Bristol-Myers?"
BMY,BMY:US,BBG000DQLV23,Big Caps Should Follow Smaller Stocks to New Highs,2016-08-10 17:48:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fu4t_-baKdQ/big-caps-should-follow-smaller-stocks-to-new-highs-cm663539,"Tuesday was another day of meandering trade, with the Dow Jones Industrial Average and S&P 500 closing unchanged, despite a new intraday high in the"
BMY,BMY:US,BBG000DQLV23,"Stock Market News for August 10, 2016",2016-08-10 16:54:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YkY2E8UcFbg/stock-market-news-for-august-10-2016-cm663526,Benchmarks closed narrowly in the green as drop in oil prices and disappointing productivity data offset some of the gains in healthcare and consumer staples stocks. Strong gains in Endo International following encouraging earnings results boosted the healthcare sector.
BMY,BMY:US,BBG000DQLV23,"Argus: Bristol-Myers Selloff Is Overdone, Reiterating $90 Target",2016-08-10 15:42:40 +0000,http://finance.yahoo.com/news/argus-bristol-myers-selloff-overdone-154240921.html,"Argus: Bristol-Myers Selloff Is Overdone, Reiterating $90 Target"
BMY,BMY:US,BBG000DQLV23,Samsung BioLogics Aims to Raise Up to $2.5 Billion From IPO,2016-08-10 03:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/47A9bAgPzUk/samsung-biologics-aims-to-raise-up-to-25-billion-from-ipo-20160810-00074,Samsung BioLogics Aims to Raise Up to $2.5 Billion From IPO
BMY,BMY:US,BBG000DQLV23,This Could Be August's Best Stock,2016-08-09 21:55:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n7jWZfgYtW8/this-could-be-augusts-best-stock-cm662867,"Image source  Getty Images.  Who said anything about selling in May and going away? Since May began, the broad based S&P 500  index has gained nearly 5%, with a post Brexit bounce and"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Co: The BMY Freefall Is Overdone,2016-08-09 18:33:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YfWsoLUDf38/bristol-myers-squibb-co-the-bmy-freefall-is-overdone-cm662677,Bristol Myers Squibb Co  (NYSE  BMY ) shares have dropped nearly 20% since Friday's open after the company said a trial for once promising
BMY,BMY:US,BBG000DQLV23,"Celldex Therapeutics, Inc.'s Q2 Results Hint at Another Stock Offering",2016-08-09 17:36:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aDHoSK2hsOQ/celldex-therapeutics-incs-q2-results-hint-at-another-stock-offering-cm662636,IMAGE SOURCE  GETTY IMAGES.  The big story for Celldex Therapeutics (NASDAQ  CLDX) this year has been the major setback from its canceled phase 3 study of Rintega. That bad news caused the
BMY,BMY:US,BBG000DQLV23,"Stock Market News for August 09, 2016",2016-08-09 16:38:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZG-8sKAiAGM/stock-market-news-for-august-09-2016-cm662605,"Despite strong crude rally, major benchmarks closed in the red on Monday on the back of declines in healthcare stocks. Declines in healthcare giants like Bristol Myers and Merck offset gains in energy stocks on the back of rising"
BMY,BMY:US,BBG000DQLV23,"Bernstein Says Merck's Lung Cancer Drug Will Lead The Market Near-Term, But Long-Term Market Share Harder To Predict",2016-08-09 15:49:42 +0000,http://finance.yahoo.com/news/bernstein-says-mercks-lung-cancer-154942679.html,"Bernstein Says Merck's Lung Cancer Drug Will Lead The Market Near-Term, But Long-Term Market Share Harder To Predict"
BMY,BMY:US,BBG000DQLV23,Don't Write Off Bristol-Myers After Opdivo Setback,2016-08-09 14:00:00 +0000,http://realmoney.thestreet.com/articles/08/09/2016/dont-write-bristol-myers-after-opdivo-setback?puc=yahoo&cm_ven=YAHOO,Don't Write Off Bristol-Myers After Opdivo Setback
BMY,BMY:US,BBG000DQLV23,"Celldex (CLDX) Posts Narrower Q2 Loss, Focus on Pipeline",2016-08-09 12:37:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pOLdrP8ss98/celldex-cldx-posts-narrower-q2-loss-focus-on-pipeline-cm662282,"Celldex Therapeutics, Inc.CLDX reported a second quarter 2016 loss of 32 cents per share, narrower than the Zacks Consensus Estimate and the year ago loss of 33 cents per share. Celldex Therapeutics Inc. (CLDX) Street Actual & Estimate EPS"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Hit With A Trio Of Analyst Price Target Cuts,2016-08-09 12:33:39 +0000,http://finance.yahoo.com/news/bristol-myers-hit-trio-analyst-123339251.html,Bristol-Myers Hit With A Trio Of Analyst Price Target Cuts
BMY,BMY:US,BBG000DQLV23,U.S. Stocks Down Despite Surge in Energy Sector,2016-08-09 04:09:30 +0000,http://www.wsj.com/articles/global-stocks-start-week-on-firm-footing-1470642026?ru=yahoo?mod=yahoo_itp,[at The Wall Street Journal] - Stocks started the week slightly firmer after Friday’s strong jobs report reassured investors that the U.S. economy remained on solid ground.
BMY,BMY:US,BBG000DQLV23,"Mattress Firm, Sotheby's, Horizon Pharma rise",2016-08-08 20:46:03 +0000,http://sg.finance.yahoo.com/news/mattress-firm-sothebys-horizon-pharma-204603539.html,"Mattress Firm, Sotheby's, Horizon Pharma rise"
BMY,BMY:US,BBG000DQLV23,Taking that next step forward in your trading with sizing,2016-08-08 20:38:51 +0000,http://finance.yahoo.com/tumblr/blog-taking-that-next-step-forward-in-your-trading-with-203856247.html,Taking that next step forward in your trading with sizing
BMY,BMY:US,BBG000DQLV23,The way you express yourself successfully in markets,2016-08-08 20:36:49 +0000,http://finance.yahoo.com/tumblr/blog-the-way-you-express-yourself-successfully-in-203653536.html,The way you express yourself successfully in markets
BMY,BMY:US,BBG000DQLV23,Stocks Retreat From Records as Health Care Slumps,2016-08-08 20:03:00 +0000,https://www.thestreet.com/story/13668399/1/stocks-retreat-from-records-as-health-care-slumps.html?puc=yahoo&cm_ven=YAHOO,Stocks Retreat From Records as Health Care Slumps
BMY,BMY:US,BBG000DQLV23,Stocks Lower In Afternoon Trade; Ski Resort Firm Leaps On Buyout,2016-08-08 19:29:44 +0000,http://www.investors.com/market-trend/stock-market-today/stocks-lower-in-afternoon-trade-ski-resort-firm-leaps-on-buyout/,Stocks Lower In Afternoon Trade; Ski Resort Firm Leaps On Buyout
BMY,BMY:US,BBG000DQLV23,Stocks Sag After Strong Recent Gains -- U.S. Commentary,2016-08-08 16:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TDEEP0oYBXQ/stocks-sag-after-strong-recent-gains--us-commentary-20160808-00955,Stocks Sag After Strong Recent Gains -- U.S. Commentary
BMY,BMY:US,BBG000DQLV23,Stocks Continue To See Modest Weakness In Mid-Day Trading - U.S. Commentary,2016-08-08 12:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pzOTNEjXBq4/stocks-continue-to-see-modest-weakness-in-midday-trading--us-commentary-20160808-00659,Stocks Continue To See Modest Weakness In Mid-Day Trading - U.S. Commentary
BMY,BMY:US,BBG000DQLV23,Stocks Continue To See Modest Weakness In Mid-Day Trading - U.S. Commentary,2016-08-08 12:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kgPeTFokrmw/stocks-continue-to-see-modest-weakness-in-midday-trading--us-commentary-20160808-00657,Stocks Continue To See Modest Weakness In Mid-Day Trading - U.S. Commentary
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Announces Top-Line Results from CheckMate-026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer (294KB)",2016-08-08 08:18:05 +0000,http://www.publicnow.com/view/D08B2CE7A1D434777C645A038CCBF59EF4CC107B,"[at noodls] - August 8, 2016 Bristol-Myers Squibb Announces Top-Line Results from CheckMate-026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer (PRINCETON, ..."
BMY,BMY:US,BBG000DQLV23,U.S. Stocks Slip Despite Surge in Energy Sector,2016-08-08 04:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SLIOEmnOGD4/us-stocks-slip-despite-surge-in-energy-sector-20160808-01111,U.S. Stocks Slip Despite Surge in Energy Sector
BMY,BMY:US,BBG000DQLV23,U.S. Stocks Slip But Oil Shares Gain,2016-08-08 04:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fXx3tD_JsZ0/us-stocks-slip-but-oil-shares-gain-20160808-00674,U.S. Stocks Slip But Oil Shares Gain
BMY,BMY:US,BBG000DQLV23,U.S. Stocks Slip But Energy Shares Gain,2016-08-08 04:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nXQwRFgfor0/us-stocks-slip-but-energy-shares-gain-20160808-00751,U.S. Stocks Slip But Energy Shares Gain
BMY,BMY:US,BBG000DQLV23,U.S. Stocks Down Despite Surge in Energy Sector,2016-08-08 04:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8oPXTJwJ7vk/us-stocks-down-despite-surge-in-energy-sector-20160808-00796,U.S. Stocks Down Despite Surge in Energy Sector
BMY,BMY:US,BBG000DQLV23,"DVAX To Face FDA Panel, BMY's Opdivo Disappoints, MRK Scores Big With FDA Nod",2016-08-07 21:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gyDgXustNhc/dvax-to-face-fda-panel-bmys-opdivo-disappoints-mrk-scores-big-with-fda-nod-20160807-00048,"DVAX To Face FDA Panel, BMY's Opdivo Disappoints, MRK Scores Big With FDA Nod"
BMY,BMY:US,BBG000DQLV23,Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer,2016-08-06 04:06:04 +0000,http://www.publicnow.com/view/6006B1EB749CB3450AEE242CCD02AEF31B247026,"[at noodls] - July 26, 2016 RARITAN, N.J., July 26, 2016 /PRNewswire/ -- Janssen Biotech, Inc. announced today it has entered into a clinical study collaboration agreement with Bristol-Myers Squibb Company to evaluate ..."
BMY,BMY:US,BBG000DQLV23,What's News: Business & Finance,2016-08-05 23:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mKJfAe9Qgxc/whats-news-business--finance-20160805-00729,What's News: Business & Finance
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers drug fails lung cancer study, shares plunge",2016-08-05 20:37:53 +0000,http://sg.finance.yahoo.com/news/bristol-myers-drug-fails-lung-132949747.html,"Bristol-Myers drug fails lung cancer study, shares plunge"
BMY,BMY:US,BBG000DQLV23,Nasdaq in Record Territory as Strong Jobs Fuel Stocks,2016-08-05 13:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QB_ZZTNkYVQ/nasdaq-in-record-territory-as-strong-jobs-fuel-stocks-20160805-00460,Nasdaq in Record Territory as Strong Jobs Fuel Stocks
BMY,BMY:US,BBG000DQLV23,Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study--4th Update,2016-08-05 12:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S1GDfmWF40o/bristol-myers-opdivo-failed-to-meet-endpoint-in-key-lung-cancer-study4th-update-20160805-00535,Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study--4th Update
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer",2016-08-05 12:34:07 +0000,http://www.publicnow.com/view/544A6230A6EA9CE9B2BFB40C8F115A625C6323CE,"[at noodls] - While today's news regarding CheckMate -026 is disappointing, Bristol-Myers Squibb is proud of all that the company has and aims to accomplish with Opdivo. We are indeed transforming cancer care, and remain ..."
BMY,BMY:US,BBG000DQLV23,The Swiss Stock Market Climbed After Better Than Expected U.S. Jobs Report,2016-08-05 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DWFYLWKfDag/the-swiss-stock-market-climbed-after-better-than-expected-us-jobs-report-20160805-00513,The Swiss Stock Market Climbed After Better Than Expected U.S. Jobs Report
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces Dividend,2016-08-03 20:22:21 +0000,http://www.publicnow.com/view/2084875957D1A9255AD009381D9F652D940C99AA,[at noodls] - NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-eight cents ($0.38) per share on the $.10 par value Common Stock ...
BMY,BMY:US,BBG000DQLV23,Pfizer beats Street 2Q forecasts despite big drop in profit,2016-08-02 17:02:35 +0000,http://sg.finance.yahoo.com/news/pfizer-beats-street-2q-forecasts-105923276.html,Pfizer beats Street 2Q forecasts despite big drop in profit
BMY,BMY:US,BBG000DQLV23,Bristol-Myers beats Street 2Q forecasts,2016-07-28 11:35:05 +0000,http://sg.finance.yahoo.com/news/bristol-myers-beats-street-2q-113056686.html,Bristol-Myers beats Street 2Q forecasts
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Reports Second Quarter Financial Results,2016-07-28 11:28:07 +0000,http://www.publicnow.com/view/44757BF1A3B91A0510D576F8564505EA37EF51EA,"[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the second quarter of 2016, which were highlighted by strong sales, key regulatory and clinical milestones ..."
BMY,BMY:US,BBG000DQLV23,ONO Submits Supplemental Application of OPDIVO® (Nivolumab) for Recurrent or Metastatic Head and Neck Cancer for a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan (49.5KB),2016-07-27 07:08:09 +0000,http://www.publicnow.com/view/30B8EC12756D84BACA4A9127C629C3053A1DE838,"[at noodls] - July 27, 2016 ONO Submits Supplemental Application of OPDIVO® (Nivolumab) for Recurrent or Metastatic Head and Neck Cancer for a Partial Change in Approved Items of Manufacturing and Marketing Approval ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces New Research Collaboration with Janssen in Immuno-Oncology Focused on Lung Cancer,2016-07-26 11:18:09 +0000,http://www.publicnow.com/view/55BE8067A15D548894E327D8F52414B93A4D1BB0,"[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate Bristol-Myers Squibb's Immuno-Oncology (I-O) ..."
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers Squibb Appoints Fouad Namouni, M.D., Oncology Development Head",2016-07-25 15:18:05 +0000,http://www.publicnow.com/view/66E7679EFEBEF34422C9D75DBCA706F03D9E2029,"[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that Fouad Namouni, M.D., has been appointed Oncology Development Head, effective July 25, 2016. Dr. Namouni will be responsible ..."
BMY,BMY:US,BBG000DQLV23,AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen,2016-07-25 11:38:07 +0000,http://www.publicnow.com/view/07128D8BBF71FD911B36CAD46D5D1465945E646A,"[at noodls] - NORTH CHICAGO, Ill. & NEW YORK--(BUSINESS WIRE)--AbbVie (NYSE:ABBV) and Bristol-Myers Squibb Company (NYSE:BMY) today announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy ..."
BMY,BMY:US,BBG000DQLV23,CHMP Issues Positive Opinion for ORENCIA® (abatacept) in the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis not Previously Treated with Methotrexate in the EU,2016-07-25 11:18:06 +0000,http://www.publicnow.com/view/7CCD1EEFBEB5E0978B739398F34C47F3B1C52B5B,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive ..."
BMY,BMY:US,BBG000DQLV23,UK cost agency rejects Bristol's Opdivo for kidney cancer,2016-07-05 13:51:04 +0000,http://uk.finance.yahoo.com/news/uk-cost-agency-rejects-bristols-135104756.html,UK cost agency rejects Bristol's Opdivo for kidney cancer
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals,2016-07-05 11:11:02 +0000,http://www.publicnow.com/view/9B27F8B701A6235E9380C552BAF1B01964826C40,[at noodls] - NEW YORK & STOCKHOLM--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock ...
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev,2016-06-30 11:21:03 +0000,http://www.publicnow.com/view/538F341FC86A0332496624DD4F65075FAA612FA2,"[at noodls] - NEW YORK & OXFORD, England--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev,2016-06-30 10:59:00 +0000,http://uk.finance.yahoo.com/news/bristol-myers-squibb-psioxus-therapeutics-105900477.html,Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev
BMY,BMY:US,BBG000DQLV23,MEDIA STATEMENT Bristol-Myers Squibb’s Response to ICER’s Draft Scoping Document “Treatment Options for Advanced Non-Small-Cell Lung Cancer”,2016-06-29 13:51:07 +0000,http://www.publicnow.com/view/800FDF2C174B7E80631DC11632261CFBD6836C92,"[at noodls] - At Bristol-Myers Squibb (BMS), it is our mission to continue to innovate the way cancer is treated by delivering clinically meaningful results―not just incremental improvements―across the entire spectrum ..."
BMY,BMY:US,BBG000DQLV23,FDA approves first pill to treat all forms of hepatitis C,2016-06-28 20:19:07 +0000,http://sg.finance.yahoo.com/news/fda-approves-first-pill-treat-151727935.html,FDA approves first pill to treat all forms of hepatitis C
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer,2016-06-27 11:11:02 +0000,http://www.publicnow.com/view/75AC74EF670CC4992F4C667E470937D20C7971E3,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Opdivo for the ..."
BMY,BMY:US,BBG000DQLV23,Murdo Gordon Appointed Executive Vice President and Chief Commercial Officer,2016-06-20 20:19:06 +0000,http://www.publicnow.com/view/958B6D542300A1C5D46675D8F9ABDD641A9111CF,"[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that Murdo Gordon has been appointed executive vice president and chief commercial officer, a newly created position, ..."
BMY,BMY:US,BBG000DQLV23,PeptiDream Achieves Milestone for Initiation of Clinical Development for Bristol-Myers Squibb’s First Collaboration Product Candidate,2016-06-15 10:57:00 +0000,http://au.finance.yahoo.com/news/peptidream-achieves-milestone-initiation-clinical-105700672.html,"[Business Wire] - TOKYO--(BUSINESSWIRE)-- PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”) (TOKYO:4587) announced today that it has earned a milestone for the dosing of a first patient in a clinical trial by its alliance partner, Bristol-Myers Squibb Company (BMS). This is the first program to enter clinical testing out of the discovery collaboration between the two companies. The molecule being advanced in clinical testing was discovered by Bristol-Myers Squibb starting from an active lead macrocyclic compound identified by Peptidream using its PDPS technology and provided to BMS for further optimization."
BMY,BMY:US,BBG000DQLV23,U.S. regulator says too many drugmakers chasing same cancer strategy,2016-06-14 20:44:09 +0000,http://uk.finance.yahoo.com/news/u-regulator-says-too-many-204549908.html,U.S. regulator says too many drugmakers chasing same cancer strategy
BMY,BMY:US,BBG000DQLV23,"New Data on Bristol-Myers Squibb’s Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial",2016-06-10 06:49:03 +0000,http://www.publicnow.com/view/95E7114D3EE999083F7E197FFE905FEE155670D3,"[at noodls] - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced results from CheckMate -205, a multi-cohort, non-comparative, single-arm, Phase 2 registrational trial evaluating Opdivo ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb to Announce Results for Second Quarter 2016 on July 28,2016-06-09 14:19:07 +0000,http://www.publicnow.com/view/DA7A41F75F855FFBFD097E2FF39E181DB2BA7A77,"[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter of 2016 on Thursday, July 28, 2016. During a conference call at 10:30 a.m. EDT on July 28, ..."
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology (EULAR 2016),2016-06-08 11:48:00 +0000,http://uk.finance.yahoo.com/news/bristol-myers-squibb-announces-rheumatoid-114800575.html,Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology (EULAR 2016)
BMY,BMY:US,BBG000DQLV23,FDA staff question dosing of Sanofi combination diabetes drug,2016-05-23 12:49:22 +0000,http://uk.finance.yahoo.com/news/fda-staff-dosing-sanofi-combination-124922805.html,FDA staff question dosing of Sanofi combination diabetes drug
BMY,BMY:US,BBG000DQLV23,Merck beats 1Q profit views with tight cost controls,2016-05-05 17:25:17 +0000,http://sg.finance.yahoo.com/news/merck-beats-1q-profit-forecasts-105531380.html,Merck beats 1Q profit views with tight cost controls
BMY,BMY:US,BBG000DQLV23,Bristol-Myers tops Street 1Q forecasts,2016-04-28 11:21:35 +0000,http://sg.finance.yahoo.com/news/bristol-myers-tops-street-1q-112135365.html,Bristol-Myers tops Street 1Q forecasts
BMY,BMY:US,BBG000DQLV23,Bristol-Myers 1Q sales jump but costs keep its profit flat,2016-04-28 11:00:45 +0000,http://sg.finance.yahoo.com/news/bristol-myers-1q-sales-jump-110045888.html,Bristol-Myers 1Q sales jump but costs keep its profit flat
BMY,BMY:US,BBG000DQLV23,New tests for choosing right hep C drug could save money,2016-04-14 21:45:03 +0000,http://sg.finance.yahoo.com/news/quest-diagnostics-launches-test-picking-190344752.html,New tests for choosing right hep C drug could save money
BMY,BMY:US,BBG000DQLV23,France wants medicine prices to be on agenda at G7 summit - source,2016-03-21 15:52:07 +0000,http://uk.finance.yahoo.com/news/france-wants-medicine-prices-agenda-155207876.html,France wants medicine prices to be on agenda at G7 summit - source
BMY,BMY:US,BBG000DQLV23,Bristol-Myers Squibb says stops some initiatives in China,2016-03-08 14:08:14 +0000,http://uk.finance.yahoo.com/news/bristol-myers-squibb-says-stops-140814200.html,Bristol-Myers Squibb says stops some initiatives in China
BMY,BMY:US,BBG000DQLV23,Pfizer earnings fall but tops Street 4Q forecasts,2016-02-02 18:44:48 +0000,http://sg.finance.yahoo.com/news/pfizer-tops-street-4q-forecasts-120256011.html,Pfizer earnings fall but tops Street 4Q forecasts
BMY,BMY:US,BBG000DQLV23,"FDA OKs Merck hepatitis C drug, adding to patient choices",2016-01-29 00:32:47 +0000,http://sg.finance.yahoo.com/news/fda-oks-merck-hepatitis-c-231031095.html,"FDA OKs Merck hepatitis C drug, adding to patient choices"
BMY,BMY:US,BBG000DQLV23,"Bristol-Myers posts 4Q loss, but beats views as sales rise",2016-01-28 12:52:55 +0000,http://sg.finance.yahoo.com/news/bristol-myers-posts-4q-loss-125255530.html,"Bristol-Myers posts 4Q loss, but beats views as sales rise"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers reports 4Q loss,2016-01-28 12:30:30 +0000,http://sg.finance.yahoo.com/news/bristol-myers-reports-4q-loss-121732907.html,Bristol-Myers reports 4Q loss
BMY,BMY:US,BBG000DQLV23,GlaxoSmithKline buys Bristol-Myers Squibb HIV assets for up to $1.46bn,2015-12-18 09:59:52 +0000,http://uk.finance.yahoo.com/news/glaxosmithkline-buys-bristol-myers-squibb-095952451.html,GlaxoSmithKline buys Bristol-Myers Squibb HIV assets for up to $1.46bn
BMY,BMY:US,BBG000DQLV23,GSK to buy HIV drugs from Bristol-Myers Squibb,2015-12-18 07:15:01 +0000,http://uk.finance.yahoo.com/news/gsk-buy-hiv-drugs-bristol-071501904.html,GSK to buy HIV drugs from Bristol-Myers Squibb
BMY,BMY:US,BBG000DQLV23,FDA approves blood cancer drug from Bristol-Myers and AbbVie,2015-11-30 21:30:51 +0000,http://sg.finance.yahoo.com/news/fda-approves-blood-cancer-drug-172731795.html,FDA approves blood cancer drug from Bristol-Myers and AbbVie
BMY,BMY:US,BBG000DQLV23,FDA approves Bristol-Myers drug for advanced skin cancer,2015-11-24 15:09:08 +0000,http://sg.finance.yahoo.com/news/fda-approves-bristol-myers-drug-150908466.html,FDA approves Bristol-Myers drug for advanced skin cancer
BMY,BMY:US,BBG000DQLV23,Bristol-Myers buying heart drug maker Cardioxyl for $2.1B,2015-11-02 17:27:25 +0000,http://sg.finance.yahoo.com/news/bristol-myers-buying-heart-drug-162851048.html,Bristol-Myers buying heart drug maker Cardioxyl for $2.1B
BMY,BMY:US,BBG000DQLV23,Bristol-Myers buys private drugmaker to boost heart treatment pipeline,2015-11-02 15:20:05 +0000,http://sg.finance.yahoo.com/news/bristol-myers-buy-private-drugmaker-121948466.html,Bristol-Myers buys private drugmaker to boost heart treatment pipeline
BMY,BMY:US,BBG000DQLV23,Reuters Business News Schedule at 1330 GMT/0830 AM ET,2015-11-02 13:46:34 +0000,http://uk.finance.yahoo.com/news/reuters-business-news-schedule-1330-134634331.html,Reuters Business News Schedule at 1330 GMT/0830 AM ET
BMY,BMY:US,BBG000DQLV23,Top U.S. drugmakers ride new products to strong results,2015-10-28 15:08:40 +0000,http://sg.finance.yahoo.com/news/top-u-drugmakers-ride-products-150840833.html,Top U.S. drugmakers ride new products to strong results
BMY,BMY:US,BBG000DQLV23,Merck tops 3Q profit forecasts,2015-10-27 12:09:17 +0000,http://sg.finance.yahoo.com/news/merck-tops-3q-profit-forecasts-105527824.html,Merck tops 3Q profit forecasts
BMY,BMY:US,BBG000DQLV23,"Tests for new cancer drugs not reliable enough, doctors say",2015-06-02 17:12:34 +0000,http://uk.finance.yahoo.com/news/tests-cancer-drugs-not-reliable-110000306.html,"Tests for new cancer drugs not reliable enough, doctors say"
BMY,BMY:US,BBG000DQLV23,MEDIA-Global annual spending on cancer drugs surges to $100 bln - FT,2015-05-05 04:21:33 +0000,http://uk.finance.yahoo.com/news/media-global-annual-spending-cancer-042133233.html,MEDIA-Global annual spending on cancer drugs surges to $100 bln - FT
BMY,BMY:US,BBG000DQLV23,EU regulators warn against combining hep C drugs with amiodarone,2015-04-24 11:55:08 +0000,http://uk.finance.yahoo.com/news/eu-regulators-warn-against-combining-115508130.html,EU regulators warn against combining hep C drugs with amiodarone
BMY,BMY:US,BBG000DQLV23,Bristol-Myers to invest in Dutch gene therapy company uniQure,2015-04-06 16:45:57 +0000,http://sg.finance.yahoo.com/news/bristol-myers-invest-dutch-gene-163914113.html,Bristol-Myers to invest in Dutch gene therapy company uniQure
BMY,BMY:US,BBG000DQLV23,Roche open to alliances in hunt for cancer drug combinations,2015-04-01 10:00:00 +0000,http://uk.finance.yahoo.com/news/roche-open-alliances-hunt-cancer-100000652.html,Roche open to alliances in hunt for cancer drug combinations
BMY,BMY:US,BBG000DQLV23,Europe pushes back verdict on Bristol immune system cancer drug,2015-03-27 15:14:14 +0000,http://uk.finance.yahoo.com/news/europe-pushes-back-verdict-bristol-151414247.html,Europe pushes back verdict on Bristol immune system cancer drug
BMY,BMY:US,BBG000DQLV23,"Bristol, Sanofi and Novartis drugs to shine among 2015 launches",2015-03-23 13:44:10 +0000,http://sg.finance.yahoo.com/news/bristol-sanofi-novartis-drugs-shine-040333286.html,"Bristol, Sanofi and Novartis drugs to shine among 2015 launches"
BMY,BMY:US,BBG000DQLV23,"BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Digital Ally, Home Loan Servicing",2015-02-23 15:13:25 +0000,http://uk.finance.yahoo.com/news/buzz-u-stocks-move-boeing-151325556.html,"BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Digital Ally, Home Loan Servicing"
BMY,BMY:US,BBG000DQLV23,"BUZZ-U.S. STOCKS ON THE MOVE-Rigel, oil stocks, Boeing",2015-02-23 14:30:57 +0000,http://uk.finance.yahoo.com/news/buzz-u-stocks-move-rigel-143057806.html,"BUZZ-U.S. STOCKS ON THE MOVE-Rigel, oil stocks, Boeing"
BMY,BMY:US,BBG000DQLV23,Bristol-Myers to buy private cancer drugmaker for up to $1.25 billion,2015-02-23 13:56:36 +0000,http://sg.finance.yahoo.com/news/bristol-myers-buy-private-cancer-135636220.html,Bristol-Myers to buy private cancer drugmaker for up to $1.25 billion
BMY,BMY:US,BBG000DQLV23,"Merck, Bristol heat up immunotherapy race in lung cancer",2015-01-12 20:34:08 +0000,http://uk.finance.yahoo.com/news/merck-bristol-heat-immunotherapy-race-203408650.html,"Merck, Bristol heat up immunotherapy race in lung cancer"
BMY,BMY:US,BBG000DQLV23,Prudential misses estimates as losses from derivatives soar,2014-11-05 22:59:20 +0000,http://sg.finance.yahoo.com/news/prudential-financial-profit-halves-u-212402060.html,Prudential misses estimates as losses from derivatives soar
BMY,BMY:US,BBG000DQLV23,AstraZeneca steps up push into cancer immunotherapy,2014-07-31 13:19:04 +0000,http://sg.finance.yahoo.com/news/astrazeneca-steps-push-cancer-immunotherapy-131904553.html,AstraZeneca steps up push into cancer immunotherapy
BMY,BMY:US,BBG000DQLV23,"Pfizer, Bristol clot drug wins EU green light for wider use",2014-06-27 11:10:54 +0000,http://sg.finance.yahoo.com/news/pfizer-bristol-clot-drug-wins-111054470.html,"Pfizer, Bristol clot drug wins EU green light for wider use"
BMY,BMY:US,BBG000DQLV23,"US slaps duties on steel pipes from Malaysia, Vietnam, Thailand",2014-06-24 18:56:37 +0000,http://sg.finance.yahoo.com/news/us-slaps-duties-steel-pipes-185637666.html,"US slaps duties on steel pipes from Malaysia, Vietnam, Thailand"
